AU2018200219B2

AU2018200219B2 - Inhibitors of Influenza Viruses Replication

Info

Publication number: AU2018200219B2
Application number: AU2018200219A
Authority: AU
Inventors: Upul K. Bandarage; Randy S. Bethiel; Randal Byrn; Paul Charifson; Michael P. Clark; John J. Court; Hongbo Deng; Ioana Drutu; John P. Duffy; Luc Farmer; Huai Gao; Ursula A. Germann; Wenxin Gu; Dylan H. Jacobs; Min Jiang; Steven Jones; Joseph M. Kennedy; Ann Dak-Yee Kwong; Mark W. Ledeboer; Brian Ledford
Original assignee: Vertex Pharmaceuticals Inc
Current assignee: Vertex Pharmaceuticals Inc
Priority date: 2009-06-17
Filing date: 2018-01-11
Publication date: 2019-09-26
Anticipated expiration: 2030-06-17
Also published as: AU2018200219A1; AU2016204286B2; AU2016204286A1

Abstract

2-(3H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-amine derivatives and their use in inhibiting influenza virus replication.

Description

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

RELATED APPLICATIONS [00100] This application claims priority to U.S. Provisional Application No. 61,187,713, filed on June 17, 2009, and to U.S. Provisional Application No. 61/287,781, filed on December 18, 2009. The entire teachings of these applications are incorporated herein by reference.

BACKGROUND OF THE INVENTION [00101] Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

[00101A] Influenza spreads around the world in seasonal epidemics, resulting in the deaths of hundreds of thousands annually - millions in pandemic years. For example, three influenza pandemics occurred in the 20th century and killed tens of millions of people, with each of these pandemics being caused by the appearance of a new strain of the virus in humans. Often, these new strains result from the spread of an existing influenza virus to humans from other animal species.

[00102] Influenza is primarily transmitted from person to person via large virus-laden droplets that are generated when infected persons cough or sneeze; these large droplets can then settle on the mucosal surfaces of the upper respiratory tracts of susceptible individuals who are near (e.g. within about 6 feet) infected persons. Transmission might also occur through direct contact or indirect contact with respiratory secretions, such as touching surfaces contaminated with influenza virus and then touching the eyes, nose or mouth. Adults might be able to spread influenza to others from 1 day before getting symptoms to approximately 5 days after symptoms start. Young children and persons with weakened immune systems might be infectious for 10 or more days after onset of symptoms.

[00103] Influenza viruses are RNA viruses of the family Orthomyxoviridae, which comprises five genera: Influenza virus A, Influenza virus B, Influenza virus C, Isavirus and Thogoto virus.

[00104] The Influenza virus A genus has one species, influenza A virus. Wild aquatic birds are the natural hosts for a large variety of influenza A. Occasionally, viruses are transmitted to other species and may then cause devastating outbreaks in domestic poultry or give rise to human influenza pandemics. The type A viruses are the most virulent human pathogens among the three influenza types and cause the most severe disease. The influenza A virus can be subdivided into different serotypes based on the antibody response to these

WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 viruses. The serotypes that have been confirmed in humans, ordered by the number of known human pandemic deaths, are: H1N1 (which caused Spanish influenza in 1918), H2N2 (which caused Asian Influenza in 1957), H3N2 (which caused Hong Kong Flu in 1968), H5N1 (a pandemic threat in the 2007-08 influenza season), H7N7 (which has unusual zoonotic potential), H1N2 (endemic in humans and pigs), H9N2, H7N2 , H7N3 and H10N7.

[00105] The Influenza virus B genus has one species, influenza B virus. Influenza B almost exclusively infects humans and is less common than influenza A. The only other animal known to be susceptible to influenza B infection is the seal. This type of influenza mutates at a rate 2-3 times slower than type A and consequently is less genetically diverse, with only one influenza B serotype. As a result of this lack of antigenic diversity, a degree of immunity to influenza B is usually acquired at an early age. However, influenza B mutates enough that lasting immunity is not possible. This reduced rate of antigenic change, combined with its limited host range (inhibiting cross species antigenic shift), ensures that pandemics of influenza B do not occur.

[00106] The Influenza vims C genus has one species, influenza C virus, which infects humans and pigs and can cause severe illness and local epidemics. However, influenza C is less common than the other types and usually seems to cause mild disease in children. [00107] Influenza A, B and C viruses are very similar in structure. The virus particle is 80-120 nanometers in diameter and usually roughly spherical, although filamentous forms can occur. Unusually for a virus, its genome is not a single piece of nucleic acid; instead, it contains seven or eight pieces of segmented negative-sense RNA. The Influenza A genome encodes 11 proteins: hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), Ml, M2, NS1, NS2(NEP), PA, PB1, PB1-F2 and PB2.

[00108] HA and NA are large glycoproteins on the outside of the viral particles. HA is a lectin that mediates binding of the vims to target cells and entry of the viral genome into the target cell, while NA is involved in the release of progeny virus from infected cells, by cleaving sugars that bind the mature viral particles. Thus, these proteins have been targets for antiviral drugs. Furthermore, they are antigens to which antibodies can be raised. Influenza A viruses are classified into subtypes based on antibody responses to HA and NA, forming the basis of the H and N distinctions (vide supra) in, for example, H5N1.

[00109] Influenza produces direct costs due to lost productivity and associated medical treatment, as well as indirect costs of preventative measures. In the United States, influenza is responsible for a total cost of over $10 billion per year, while it has been estimated that a future pandemic could cause hundreds of billions of dollars in direct and indirect costs.

-2WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Preventative costs are also high. Governments worldwide have spent billions of U.S. dollars preparing and planning for a potential H5N1 avian influenza pandemic, with costs associated with purchasing drugs and vaccines as well as developing disaster drills and strategies for improved border controls.

[00110] Current treatment options for influenza include vaccination, and chemotherapy or chemoprophylaxis with anti-viral medications. Vaccination against influenza with an influenza vaccine is often recommended for high-risk groups, such as children and the elderly, or in people that have asthma, diabetes, or heart disease. However, it is possible to get vaccinated and still get influenza. The vaccine is reformulated each season for a few specific influenza strains but cannot possibly include all the strains actively infecting people in the world for that season. It takes about six months for the manufacturers to formulate and produce the millions of doses required to deal with the seasonal epidemics; occasionally, a new or overlooked strain becomes prominent during that time and infects people although they have been vaccinated (as by the H3N2 Fujian flu in the 2003-2004 influenza season). It is also possible to get infected just before vaccination and get sick with the very strain that the vaccine is supposed to prevent, as the vaccine takes about two weeks to become effective. [00111] Further, the effectiveness of these influenza vaccines is variable. Due to the high mutation rate of the virus, a particular influenza vaccine usually confers protection for no more than a few years. A vaccine formulated for one year may be ineffective in the following year, since the influenza virus changes rapidly over time, and different strains become dominant.

[00112] Also, because of the absence of RNA proofreading enzymes, the RNAdependent RNA polymerase of influenza vRNA makes a single nucleotide insertion error roughly every 10 thousand nucleotides, which is the approximate length of the influenza vRNA. Hence, nearly every newly-manufactured influenza virus is a mutant—antigenic drift. The separation of the genome into eight separate segments of vRNA allows mixing or reassortment of vRNAs if more than one viral line has infected a single cell. The resulting rapid change in viral genetics produces antigenic shifts and allows the virus to infect new host species and quickly overcome protective immunity.

[00113] Antiviral drugs can also be used to treat influenza, with neuraminidase inhibitors being particularly effective, but viruses can develop resistance to the standard antiviral drugs.

[00114] Thus, there is still a need for drugs for treating influenza infections, such as for drugs with expanded treatment window, and/or reduced sensitivity to viral titer.

-32018200219 25 Mar 2019

SUMMARY OF THE INVENTION [00115] The present invention generally relates to methods of treating influenza, to methods of inhibiting the replication of influenza viruses, to methods of reducing the amount of influenza viruses, to compounds and compositions that can be employed for such methods.

[00116] In a particular aspect, the present invention provides a compound represented by the following Structural Formula (IA):

R¹ (IA), or a pharmaceutically acceptable salt thereof, wherein:

Z¹ is -R*, -F, -Cl, -CN, -OR*, -CO₂R*, -NO2, or -CON(R*)₂;

Z² is -R*, -OR*, -CO2R*, -NR*₂, or -CON(R*)₂;

Z³ is -H, -OH, halogen, -NH2; -NH(Ci-C4 alkyl); -N(Ci-C4 alkyl)2,-O(Ci-C4 alkyl), or CiCe alkyl that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C4 alkyl);

R¹ is -H or C1-C6 alkyl;

R² is -H, -F, -NH2, -NH(Ci-C4 alkyl),-N(Ci-C4 alkyl)2,-C=N-OH, cyclopropyl that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, -OCH3, and -CH3, or C1-C4 alkyl that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C4 alkyl);

R³ is -H, -Cl, -F, -OH, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C 4 alkyl), -N(Ci-C₄alkyl)2, -Br, -CN, or C1-C4 aliphatic that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO2H, -CO2(Ci-C4 alkyl), and C1-C4 alkoxy;

R⁴ is:

(followed by page 4a)

2018200219 29 Aug 2019

rings G3 and G4 are each independently a 5-10 membered non-aromatic bridged ring optionally further substituted with one or more instances of J^A;

ring G5 is a 5-10 membered non-aromatic bridged ring optionally further substituted with one or more instances of J^B;

X is -O-, -S-, or -NR^g-;

Q² is independently a bond, -O-, -S-, -NR-, -C(O)-, -C(=NR)-, -CO2-, -OC(O)-, -C(O)NR-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O-, -NRC(O)-, -NRC(O)NR-, -NRCO2-, -OC(O)NR-, -S(O)-, -SO2-,-N(R)SO2-, -SO2NR’-, -NRSO2NR’-, or-(CR⁶R⁷)P-Y'-;

each of J^A and J^B is independently selected from the group consisting of halogen, cyano, oxo, -NCO, and Q*-R⁵; or optionally two J^A and two J^B, respectively, together with the atom(s) to which they are attached, independently form a 4-8 membered ring that is optionally substituted with one or more instances of J^E1;

Q¹ is independently a bond, -0-, -S-, -NR’-, -C(O)-, -C(=NR)-, -C(=NR)NR-, -NRC(=NR)NR-, -CO2-, -OC(O)-, -C(O)NR’-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O-NRC(O)-, -NRC(O)NR’-, -NRCO2-, -OC(O)NR’-, -S(O)-, -SO2--SO2NR’-, -NRSO2-, or -NRSO2NR’-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)2O-, -CO2SO2-, or-(CR⁶R⁷)P-Y'-;

Y¹ is independently a bond, -0-, -S-, -NR’-, -C(O)-, -C(=NR)-, -C(=NR)NR-, -NRC(=NR)NR-, -CO2-, -OC(O)-, -C(O)NR’-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O-NRC(O)-, -NRC(O)NR’-, -NRCO2-, -OC(O)NR’-, -S(O)-, -SO2--SO2NR’-, -NRSO2--NRSO2NR’-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)₂O-, or-CChSCh-;

R⁵ is: i) -H; ii) a C1-C6 aliphatic group optionally substituted with one or more instances of J^C1; iii) a C3-C10 non-aromatic carbocycle, or a 6-10 membered aryl group, each optionally and independently substituted with one or more instances of J^C1; or iv) a 4-10 membered nonaromatic heterocycle, or a 5-10 membered heteroaryl group, each optionally and independently substituted with one or more instances of J^D1; or

4a (followed by page 4b)

2018200219 29 Aug 2019

R⁵, together with Q¹, optionally forms a 4-8 membered, non-aromatic ring optionally substituted with one or more instances of J^E1; and

R⁶ and R⁷ are each independently -H or Ci-Ce alkyl optionally substituted with one or more substitutents selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ce aminoalkoxy, Ci-Ce cyanoalkoxy, Ci-Ce hydroxyalkoxy and C2-C6 alkoxyalkoxy, or optionally R⁶ and R⁷, together with the carbon atom to which they are attached, form a cyclopropane ring optionally substituted with one or more instances of methyl;

R⁸ and R⁹ are each independently-H, halogen, cyano, hydroxy, amino, carboxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 cyanoalkyl, C2-C6 alkoxyalkyl, C1-C6 aminoalkyl, C1-C6 hydroxyalkyl, C1-C6 carboxyalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, Ci-G> aminoalkoxy, C1-C6 cyanoalkoxy, C1-C6 hydroxyalkoxy, or C2-C6 alkoxyalkoxy;

R¹³ and R¹⁴are each independently -H, halogen, or C1-C6 alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, C1-C6 alkoxy, C1-C6 haloalkoxy, G-G aminoalkoxy, CiCe cyanoalkoxy, C1-C6 hydroxyalkoxy, and C2-C6 alkoxyalkoxy;

Optionally, R¹³ and R¹⁴, together with the carbon atom to which they are attached, form a cyclopropane ring, optionally substituted with one or more instances of methyl;

R²¹, R²², R²³, R²⁴, and R²⁵ are each independently -H, halogen, -OH, Ci-G alkoxy, or CiG alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, Ci-G alkoxy, Ci-G haloalkoxy, Ci-Οό aminoalkoxy, Ci-Οό cyanoalkoxy, Ci-Οό hydroxyalkoxy, and C2-C6 alkoxyalkoxy;

R^g is -H or C1-C6 alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 aminoalkoxy, C1-C6 cyanoalkoxy, C1-C6 hydroxyalkoxy, and C2-C6 alkoxyalkoxy;

R and R’ are each independently -H or C1-C6 alkyl optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 aminoalkoxy, Ci-G cyanoalkoxy, Ci-G hydroxyalkoxy and C2-C6 alkoxyalkoxy; or optionally

4b (followed by page 4c)

2018200219 25 Mar 2019

R’, together with R⁵ and the nitrogen atom to which they are attached, forms a 5-7 membered non-aromatic heterocycle optionally substituted with one or more instances of J^D1;

R* is independently: i)-H; ii) a Ci-Ce alkyl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Cs-Cs non-aromatic carbocycle, 5-6 membered non-aromatic heterocycle, phenyl, 5-6 membered heteroaryl, -O(Ci-C6 alkyl), and -C(O)(Ci-C6-alkyl); wherein each of said alkyl groups in -O(Ci-C6 alkyl), and -C(O)(Ci-C6-alkyl) is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo,-NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -OCO(Ci-C4 alkyl), -CO(Ci-C4 alkyl), -CO2H, -CC>2(Ci-C4 alkyl), and C1-C4 alkoxy; and wherein each of said carbocycle, heterocycle, phenyl, and heteroaryl is independently and optionally substituted with one or more instances of J^E1; or iii) a C3-C8 non-aromatic carbocycle, or a 4-8 membered nonaromatic heterocycle, each of which is independently and optionally substituted with one or more instances of J^E1; and each of J^C1 and J^D1 is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a, -SO2R^a, -NR^bR^c, -C(O)R^b, -C(=NR)R^C, -C(=NR)NR^bR^c, -NRC(=NR)NR^bR^c, -C(O)OR^b, -OC(O)R^b, -NRC(O)R^b, -C(O)NR^bR^c, -NRC(O)NR^bR^c, -NRC(O)OR^b, -OCONR^bR^c, -C(O)NRCO2R^b, -NRC(O)NRC(O)OR^b, -C(O)NR(OR^b), -SO2NR^cR^b, -NRSO2R^b, -NRSO2NR^cR^b, -P(O)(OR^a)2, -OP(O)(OR^a)₂, -P(O)2OR^a and -GCESCER¹³, or optionally, two J^C1 and two J^D1, respectively, together with the atom(s) to which they are attached, independently form a 4-8 membered ring that is optionally substituted with one or more instances of J^E1;

each J^E1 is independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, amido, C1-C6 alkyl, -O(Ci-C6 alkyl), and -C(O)(Ci-C6-alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO2H, -CC>2(Ci-C4 alkyl), and C1-C4 alkoxy;

R^a is independently:

i) a C1-C6 aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino,

4c (followed by page 4d)

2018200219 25 Mar 2019 carboxy, amido, -O(Ci-C6 alkyl), -C(O)(Ci-C6-alkyl), C3-C8 non-aromatic carbocycle, 4-8 membered non-aromatic heterocycle, 5-10 membered heteroaryl group, and 6-10 membered carbocyclic aryl group; wherein each of said alkyl groups for the substituents of the C1-C6 aliphatic group represented by R^a is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy; and wherein each of said carbocycle, heterocycle, heteroaryl and carbocyclic aryl groups for the substituents of the C1-C6 aliphatic group represented by R^a is optionally and independently substituted with one or more instances ofJ^E1;

ii) a C3-C8 non-aromatic carbocycle, or a 4-8 membered non-aromatic heterocycle, each of which is optionally and independently substituted with one or more instances of J^E1; or iii) a 5-10 membered heteroaryl, or 6-10 membered carbocyclic aryl group, each of which is optionally and independently substituted with one or more instances of J^E1; and

R^b and R^c are each independently R^a or -H; or optionally, R^b and R^c, together with the nitrogen atom(s) to which they are attached, form a 5-7 membered non-aromatic heterocycle optionally substituted with one or more instances of J^E1;

p is independently 1, 2, 3 or 4;

q is 0, 1 or 2;

x is 0, 1 or 2; and r is 1 or 2;

provided that if Q² is a bond, then R⁵ is an optionally substituted C3-C8 non-aromatic carbocycle; an optionally substituted 6-10 membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted 5-10 membered heteroary group.

[00116A] In another aspect, the present invention provides a compound represented by

Structural Formula (II):

4d (followed by page 4e)

or a pharmaceutically acceptable salt thereof, wherein:

Z¹ is -F;

Z² is -H or Ci-C₆ alkyl;

R³ is -H, -F, -Cl, -CF₃, -NH₂, -NH(CH₃), or-N(CH₃)₂;

the group -[C(R¹³R¹⁴)]_x-ringA-Q²-R⁵ is independently selected from:

wherein

R⁵ is independently:

i) -H;

ii) a Ci-Ce-aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), -CO₂H, C₃-Cs non-aromatic carbocycle, phenyl, 4-8 membered non-aromatic heterocycle, and 5-6 membered heteroaryl;

iii) a C₃-C? non-aromatic carbocycle, a 4-7 membered non-aromatic heterocycle, a phenyl group, or a 5-6 membered heteroaryl, each of which is optionally and independently substituted with one or more substituents independently selected from the group consisting of

4e (followed by page 41)

2018200219 29 Aug 2019 halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C4 alkyl), -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), and -CO₂H;

wherein each of said alkyl groups for the substituents of R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy; and wherein each of said carbocycle, phenyl, heterocycle, and heteroaryl for the substituents of the Ci-Ce aliphatic group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -OCO(Ci-C4 alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy; and ring A is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C4 alkyl), -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄alkyl), -CO2H, and -CO2(Ci-C4 alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy;

provided that rings A21, and A26 are further substituted with one or more substituents other than -H.

[00116B] In a further aspect, the present invention provides a compound represented by Structural Formula (III):

(III)

4f (followed by page 4g)

2018200219 25 Mar 2019 or a pharmaceutically acceptable salt, wherein:

ring B is independently selected from:

wherein ring B is optionally and independently substituted;

each Q³ is independently -C(O)-, -CO2-, -C(O)NR’-, -SO2-,-SO2NR’-, -C(O)NRC(O)O-, or -(CR⁶R⁷)_p-Y'-;

Z¹ is -H, -F, -Cl, C1-C4 haloalkyl, C1-C4 alkyl, -O(Ci-C₄ alkyl), or-CN;

Z² is -H, C1-C6 alkyl, -O(Ci-C6 alkyl), -NH₂, -NH(Ci-C6 alkyl), or -N(Ci-C6 alkyl)₂, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy;

R³ is -H, -Cl, -F, -Br, -CN, -CF3, -O(Ci-C₄ alkyl), -OH, -NH₂, -NH(Ci-C₄ alkyl), or -N(Ci-C₄ alkyl)₂;

R⁵ is independently:

i) -H;

ii) a Ci-Ce aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), -CO₂H, C3-C8 non-aromatic carbocycle, phenyl, 4-8 membered non-aromatic heterocycle, and 5-6 membered heteroaryl; or iii) a C3-C7 non-aromatic carbocycle, a 4-7 membered non-aromatic heterocycle, a phenyl group, or a 5-6 membered heteroaryl ring, each of which is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl),

4g (followed by page 4h)

2018200219 29 Aug 2019

-N(C1-C₄ alkyl)2, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), and -CO₂H; wherein each of said alkyl groups for the substituents of R⁵is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy;

R⁶ and R⁷ are each independently -H or C1-C6 alkyl optionally substituted with one or more substitutents selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 aminoalkoxy, C1-C6 cyanoalkoxy, C1-C6 hydroxyalkoxy, and C2-C6 alkoxyalkoxy, or optionally R⁶ and R⁷, together with the carbon atom to which they are attached, form a cyclopropane ring optionally substituted with one or more instances of methyl;

R¹³ and R¹⁴are each independently -H, halogen, or C1-C6 alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, C1-C6 alkoxy, C1-C6 haloalkoxy, Ci-G> aminoalkoxy, CiCe cyanoalkoxy, C1-C6 hydroxyalkoxy, and C2-C6 alkoxyalkoxy, or, optionally, R¹³ and R¹⁴, together with the carbon atom to which they are attached, form a cyclopropane ring, optionally substituted with one or more instances of methyl;

each R and R’ is independently -H or Ci-C ealkyl;

Y¹ is independently a bond, -0-, -S-, -NR’-, -C(O)-, -C(=NR)-, -CO2-, -OC(O)-, -C(O)NR'-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O-, -NRC(O)-, -NRC(O)NR’-, -NRCO2-, -OC(O)NR’-, -S(O)-, -SO2--SO2NR’-, -NRSO2-, or-NRSO2NR’-;

p is 1, 2, 3, or 4; and y is 0 or 1;

provided that if Q³ is -C(O)-, then R⁵ is a substituted Ci-Ce aliphatic group; an optionally substituted C3-C7 non-aromatic carbocycle; a phenyl group; optionally substituted 4-7 membered non-aromatic heterocycle; or an optionally substituted 5-6 membered heteroaryl group;

provided that if Y¹ is a bond, then R⁵ is a substituted Ci-Ce aliphatic group; an optionally substituted C3-C7 non-aromatic carbocycle; a phenyl group; an optionally substituted 4-7 membered non-aromatic heterocycle; or an optionally substituted, 5-6 membered heteroaryl group; and

4h (followed by page 4i)

2018200219 29 Aug 2019 provided that the ring B-Q³-R⁵ moiety is not A-mcthyl-3-pyrrolidinyl (

[00116C] In a still further aspect, the present invention provides a compound represented by

Structural Formula (IV):

or a pharmaceutically acceptable salt, wherein:

ring C is independently selected from:

wherein each of rings C1-C5 is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -CO2H, and -CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more independently substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C6 alkyl), -N(Ci-C6 alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy.

Z¹ is -H, -F, -Cl, C1-C4 haloalkyl, C1-C4 alkyl, -O(Ci-C₄ alkyl), or-CN;

[FOLLOWED BY PAGE 4j]

4i

2018200219 25 Mar 2019

Z² is -H, Ci-C₆ alkyl, -O(Ci-C6 alkyl), -NH2, -NH(Ci-C6 alkyl), or -N(Ci-C6 alkyl)2, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO2H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy;

R³ is -H, -Cl, -F, -Br, -CN, -CF3, -O(Ci-C₄ alkyl), -OH, -NH₂, -NH(Ci-C₄ alkyl), or -N(Ci-C₄ alkyl)2; and

R¹⁰ is independently -H; or a Ci-Ce alkyl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, C1-C6 alkoxy, Ci-Ce haloalkoxy, Ci-Ceaminoalkoxy, C1-C6 cyanoalkoxy, Ci-Ce hydroxyalkoxy, C2-C6 alkoxyalkoxy, C3-C8 non-aromatic carbocycle, phenyl, a 4-8 membered non-aromatic heterocycle, and a 5-6 membered heteroaryl group; wherein each of said carbocycle, phenyl, heterocycle, and heteroaryl group for the substituents of the Ci-Ce alkyl group represented by R¹⁰ is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, C1-C6 alkyl, Ci-Ce haloalkyl, Ci-Ce cyanoalkyl, C2-C6 alkoxyalkyl, Ci-Ce aminoalkyl, Ci-Ce hydroxyalkyl, Ci-Ce alkoxy, C1-C6 haloalkoxy, Ci-Ce aminoalkoxy, Ci-Ce cyanoalkoxy, Ci-Ce hydroxyalkoxy, and Ci-Ce alkoxyalkoxy.

[00116D] In yet a further aspect, the present invention provides a compound represented by Structural Formula (V):

(V) or a pharmaceutically acceptable salt, wherein:

ring D is independently selected from one of the structures depicted below:

^Rd , and (followed by page 4k)

2018200219 29 Aug 2019 wherein each of rings D1-D7 is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄alkyl), -CO₂H and -CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C6 alkyl), -N(Ci-C6 alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy;

each R^d is independently -H, Ci-Ce alkyl or - C(O)(Ci-C6 alkyl), wherein each of said alkyl moiety is optionally and independently substituted with one or more groups selected from halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C6 alkyl), -N(Ci-C6 alkyl)₂, -OCO(Ci-C₄alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy;

Z¹ is -H, -F, -Cl, Ci-C₄ haloalkyl, Ci-C₄ alkyl, -O(Ci-C₄ alkyl), or -CN;

Z² is -H, Ci-C₆ alkyl, -O(Ci-C₆ alkyl), -NH₂, -NH(Ci-C₆ alkyl), or -N(Ci-C₆ alkyl)₂, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy;

R³ is -H, -Cl, -F, -Br, -CN, -CF₃, -O(Ci-C₄ alkyl), -OH, -NH₂, -NH(Ci-C₄ alkyl), or -N(Ci-C₄ alkyl)₂;

R¹³ and R¹⁴ are each independently -H, halogen, or C i-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-G> aminoalkoxy, CiCe cyanoalkoxy, Ci-Ce hydroxyalkoxy, and C₂-Ce alkoxyalkoxy, or, optionally, R¹³ and R¹⁴, together with the carbon atom to which they are attached, form a cyclopropane ring, optionally substituted with one or more instances of methyl; and z is 1 or 2.

[00116E] In one aspect, the present invention is directed to a method of inhibiting the replication of influenza viruses in a biological sample or in a patient. In one embodiment, the method comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (IA):

4k (followed by page 4L)

2018200219 25 Mar 2019

R¹ (IA), or a pharmaceutically acceptable salt thereof, wherein:

Z¹ is -R*, -F, -Cl, -CN, -OR*, -CO₂R*, -NO2, or -CON(R*)₂;

Z² is -R*, -OR*, -CO2R*, -NR*2, or -CON(R*)₂;

Z³ is -H, -OH, halogen (e.g., -Cl or -Br), -NH₂; -NH(Ci-C₄ alkyl); -N(Ci-C₄alkyl)2, -O(Ci-C₄ alkyl), or C1-C6 alkyl that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C₄ alkyl);

R¹ is -H or C1-C6 alkyl;

R² is -H; -F; -NH2; -NH(Ci-C₄ alkyl); -N(Ci-C₄ alkyl )₂; -C=N-OH; cyclopropyl that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, -OCH3, and -CH3; or Ci-C₄ alkyl that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C₄ alkyl); and

R³ is -H, -Cl, -F, -OH, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C ₄ alkyl), -N(Ci-C₄alkyl)2, -Br, -CN, or C1-C4 aliphatic that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO2H, -CO2(Ci-C₄ alkyl), and C1-C4 alkoxy;

R⁴ is:

[FOLLOWED BY PAGE 5]

4L

WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

i)

wherein ring T is a C3-C10 non-aromatic carbocycle optionally substituted with one or more instances of J^A, or a 3-10 membered non-aromatic heterocycle optionally substituted with one or more instances of J^B, or ring T and R⁹ optionally form a non-aromatic C5-C10 membered carbocycle optionally substituted with one or more instances of J^A or 5-10 membered non-aromatic heterocycle optionally substituted with one or more instances of J^B ;

ii) '—(CR¹³R¹⁴

wherein ring J is a 3-10 membered non-aromatic heterocycle optionally substituted with one or more instances of J^B; or

iii)

wherein ring D is a 4-10 membered non-aromatic heterocycle optionally substituted with one or more instances of J^D1; and each of J^A and J^B is independently selected from the group consisting of halogen, cyano, oxo, -NCO, and Q¹ —R^s; or optionally two J^A and two J^B, respectively, together with the atom(s) to which they are attached, independently form a 4-8 membered ring (e.g., spiro ring or fused ring) that is optionally substituted with one or more instances of J^E1;

Q¹ is independently a bond, -O-, -S-, -NR’-, -C(O)~, -C(=NR)-, -C(=NR)NR-,

-NRC(=NR)NR-, -CO2- -OC(O)- -C(O)NR’-, -C(O)NRC(O)O- -NRC(O)NRC(O)O

-NRC(O)-, -NRC(O)NR’-, -NRCO₂-, -OC(O)NR’-, -S(O)-, -SO₂- -SO₂NR’-, -NRSO2-, or -NRSO2NR’-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)2O-, -CO2SO2-t or -(CR⁶R⁷)p-Y‘-;

Y¹ is independently a bond, -O-, -S-, -NR’-, -C(O)-, -C(=NR)-, -C(=NR)NR-,

-NRC(=NR)NR-„ -CO2-, -OC(O)-, -C(O)NR’-, -C(O)NRC(O)O- -NRC(O)NRC(O)O-NRC(O)-, -NRC(O)NR’-, -NRCO₂- -OC(O)NR’~, -S(O)-, -SO₂- -SO₂NR’-, -NRSO2-, -NRSO2NR’-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)₂O-, or -CO2SO2-;

R⁵ is: i) -H; ii) a CrCe aliphatic group optionally substituted with one or more instances of J^CI; iii) a C3-C10 non-aromatic carbocycle, or a 6-10 membered carbocyclic aryl group, each optionally and independently substituted with one or more instances of J^C1; or iv) a 4-10 membered non-aromatic heterocycle, or a 5-10 membered heteroaryl group, each optionally and independently substituted with one or more instances of J^DI; or

-5WO 2010/148197

PCI7US2010/038988

2018200219 11 Jan 2018

R⁶ and R⁷ are each independently -H or Ci-Cc alkyl optionally substituted with one or more substitutents selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ci-Ce alkoxy, Ci-Cg haloalkoxy, Ci-Ce aminoalkoxy, Ci-Cecyanoalkoxy, Ci-Cghydroxyalkoxy and C2-C₆alkoxyalkoxy, or optionally R⁶ and R⁷, together with the carbon atom to which they are attached, form a cyclopropane ring optionally substituted with one or more instances of methyl;

R⁹ is independently -H, halogen, cyano, hydroxy, amino, carboxy, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Cc cyanoalkyl, C2-C6 alkoxyalkyl, Ci-Cg aminoalkyl, Ci-Ce hydroxyalkyl, QCe carboxyalkyl, Ci-Cg alkoxy, Ci-Ce haloalkoxy, Cj-Cgaminoalkoxy, Ci-Cgcyanoalkoxy, Ci-Ce hydroxy alkoxy and C2-C6 alkoxy alkoxy;

R¹³ and R¹⁴ are each independently -H, halogen, or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, oxo, amino, carboxy, Ci-Co alkoxy, Ci-Cg haloalkoxy, C[-Cg aminoalkoxy, Ci-C₆ cyanoalkoxy, Ci-Ce hydroxyalkoxy, and Cj-Ce alkoxy alkoxy;

optionally, R¹³ and Rⁱ⁴, together with the carbon atom to which they are attached, form a cyclopropane ring optionally substituted with one or more instances of methyl;

R and R’ are each independently -H or Ci-Ce alkyl optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ci-C<, alkoxy, Cj-Cg haloalkoxy, Ci-Cr aminoalkoxy, Ci-Ce cyanoalkoxy, Ci-Cg hydroxy alkoxy and C?-Cg alkoxyalkoxy; or optionally R’, together with R⁵ and the nitrogen atom to which they are attached, forms a 5-7 membered non-aromatic heterocycle optionally substituted with one or more instances of J^D1;

R* is independently: i)-H; ii) a Ci-Ce alkyl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ca-Cg non-aromatic carbocycle, 5-6 membered non-aromatic heterocycle, phenyl, 5-6 membered heteroaryl, -O(Ci-Ce alkyl), and -C(O)(Ci-C(5-alkyl); wherein each of said alkyl groups in -O(Ci-Cg alkyl), and -C(O)(Ci-C6-alkyl) is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)2, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO2(Ci-C₄ alkyl), and C_rC₄ alkoxy; and wherein each of said carbocyclc, heterocycle, phenyl, and hcteroaryl is independently and optionally substituted with one or more instances of J^E1; or iii) a Cs-Cs non-aromatic

-6WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 carbocycle, or a 4-8 membered non-aromatic heterocycle, each of which is independently and optionally substituted with one or more instances of J^E1; and each of J^C1 and J^DI is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a, -SO2R^a, -NR^bR^c, -C(O)R^b, -C(=NR)R^c, -C(=NR)NR^bR^c, -NRC(=NR)NR^bR^c, -C(O)OR^b, - OC(O)R^h, -NRC(O)R^b, -C(O)NR^bR^c, -NRC(O)NR^bR^c, -NRC(O)OR^b, -OCONR^bR^c, -C(O)NRCO2R^b, -NRC(O)NRC(O)OR^b, -C(O)NR(OR^b), -SO2NR^cR^b, -NRSO2R^b, -NRSO2NR^cR^b, -P(O)(OR^a)2, -OP(O)(OR^a)2, -P(O)2OR^a and -CO2SO₂R^b, or optionally, two J^CI and two J^D1, respectively, together with the atom(s) to which they are attached, independently form a 4-8-membered ring that is optionally substituted with one or more instances of J^E1;

each J^E1 is independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, amido, C|-Ce alkyl, -O(Ci-Cc alkyl), and -C(O)(Ci-C<5-alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(C_t-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy; and

R^a is independently: i) a Ci-Q aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, amido, O(Ci-Ce alkyl), -C(O)(Ci-Ce-alkyl), Ci-Cg non-aromatic carbocycle, 4-8 membered non-aromatic heterocycle, 5-10 membered heteroaryl group, and 6-10 membered carbocyclic aryl group; wherein each of said alkyl groups for the substituents of the Ci-Ce aliphatic group represented by R^a is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C[C₄ alkyl), -CO₂H, -CO₂(C[-C₄ alkyl), and C1-C4 alkoxy; and wherein each of said carbocycle, heterocycle, heteroaryl and carbocyclic aryl groups for the substituents of the Ct-Cg aliphatic group represented by R^a is optionally and independently substituted with one or more instances of J ;

ii) a C3-C8 non-aromatic carbocycle, or a 4-8 membered non-aromatic heterocycle, each of which is optionally and independently substituted with one or more instances of J^EI; or iii) a 5-10 membered heteroaryl, or 6-10 membered carbocyclic aryl group, each of which is optionally and independently substituted with one or more instances of J^EI; and

-7WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

R^b and R^c are each independently R^a or -H; or optionally, R^b and R^c, together with the nitrogen atom(s) to which they are attached, each independently form a 5-7 membered nonaromatic heterocycle optionally substituted with one or more instances of J^E1;

p is independently 1,2,3 or 4;

t is 0, 1 or 2;

j is 1 or 2; and z is 1 or 2.

[00117] In another embodiment, the method comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is -H;

R² is -H, -CH₃, -NH_2j -NH(C_rC₄ alkyl), or-N(Ci-C₄ alkyl)₂;

R⁴ is: i) a C3-C10 non-aromatic carbocycle optionally substituted with one or more instances of J^A; ii) a 4-10 membered non-aromatic heterocycle optionally substituted with one or more instances of J^B; or iii) a Ci-Ce aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of J^c; a Cj-Cs non-aromatic carbocycle, or a 6-10 membered carbocyclic aryl group, each optionally and independently substituted with one or more instances of J^A; and a 5-10 membered heteroaryl group, or a 410 membered non-aromatic heterocycle, each optionally and independently substituted with one or more instances of J^B;

each of J^A and J^B is independently selected from the group consisting of halogen, cyano, oxo, -NCO, andCri-R⁵; or optionally two J^A and two J^B, respectively, together with the atom(s) to which they are attached, independently form a 5-7 membered ring that is optionally substituted with one or more instanced of J^EI;

J^c is independently selected from the group consisting of halogen, cyano, oxo, -OR⁵, -SR⁵, -NR’R⁵, -C(O)R⁵, -CO2R⁵, -OC(O)R⁵, -C(O)NR’R⁵, -C(O)NRC(O)OR⁵, -NRC(O)NRC(O)OR⁵, -NRC(O)R⁵, -NRC(O)NR’R⁵, -NRCO2R⁵, -OC(O)NR’R⁵, -S(O)R⁵, -SO2R⁵, -SO2NR’R⁵, -NRSO2R⁵, and -NRSO2NR’R⁵;

-8WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Q¹ is independently a bond, -O- -S-, -NR’-, -C(O)-, -C(=NR)-, -CO?-, -OC(O)-, -C(O)NR’-, -C(O)NRC(O)O- -NRC(O)NRC(O)O- -NRC(O)-, -NRC(O)NR’-, -NRCO₃-, -OC(O)NR’-, -S(O)-, -SO₂-, -SO₂NR’- -NRSCl·-, or -NRSO2NR’-, or -(CR^R⁷),-Y¹-;

Y^! is independently a bond, -0- -S-, -NR’-, -C(O)-, -C(=NR)-, -CO₂-OC(O)- -C(O)NR’-, -C(O)NRC(0)O- -NRC(O)NRC(O)O- -NRC(O)-, -NRC(O)NR’- -NRCO2-, -OC(O)NR’-, -S(O)-, -SO₂- -SO₂NR’- -NRSO₂-, or -NRSO₂NR’-;

R⁵ is: i) -H; ii) a Cj-Cg aliphatic group optionally substituted with one or more instances of J^CI; iii) a C3-C8 non-aromatic carbocycle, or a 6-10 membered carbocyclic aryl group, each optionally and independently substituted with one or more instances of J^C1; or iv) a 4-8 membered non-aromatic heterocycle, or a 5-10 membered heteroaryl group, each optionally and independently substituted with one or more instances of J^D1. Optionally, R⁵, together with Q¹, optionally forms a 5-7 membered, non-aromatic ring optionally substituted with one or more instances of J^E1;

each of J^C1 and J^D1 is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a, -SO2R^a, -NR^bR^c, -C(O)R^b, -C(O)OR^b, -OC(O)R^b, -NRC(O)R^b, -C(O)NR^bR^c, -NRC(O)NR^bR'\ -NRC(O)OR^b, -0C0NR^bR^c, -C(O)NRCO2R^b, -NRC(O)NRC(O)OR^b, -C(O)NR(OR^b), -SO2NR^cR^b, -NRSO2R^b, -NRSO2NR^cR^b, and -P(O)(OR^a)2-, or optionally, two J^C1 and two J^D1, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^E1, and fused to the respective ring to which they are attached; and each of Z¹, Z², R³, R⁶, R⁷, R, R’, R*, J^E1, R^a, R^b, R^e and p is independently as described above for Structural Formula (IA).

[00118] hi another embodiment, the present invention is directed to a method of reducing the amount of influenza viruses in a biological sample or in a patient. The method comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (1) or Structural Formula (IA), each and independently as described above.

[00119] In yet another embodiment, the present invention is directed to a method of treating or preventing influenza in a patient, comprising administering to said patient an effective amount of a compound represented by Structural Formula (I) or Structural Formula (IA), each and independently as described above.

-9WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00120] In yet another embodiment, the present invention is directed to a compound represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof, wherein:

R¹ is -H, Ct-Ce alkyl, -S(O)₂-R”, or -C(O)OR”; or alternatively R¹ is -H or Ci-Ce alkyl;

R⁴ is:

or ; wherein:

ring A is a C3-C10 non-aromatic carbocycle optionally further substituted with one or more instances of J^A, or heterocyle optionally further substituted with one or more instances ofJ^B;

rings B and C are each independently a 4-10 membered, non-aromatic heterocycle optionally and independently further substituted with one or more instances of J^B;

ring D is a 4-10 membered, non-aromatic heterocycle optionally substituted with one or more instances of J^D1; or ring A and R⁸ optionally form a non-aromatic, 5-10 membered, bridged carbocycle or heterocycle, or ring A and R⁹ optionally form a non-aromatic, 5-10 membered, bridged carbocycle or heterocycle, or ring A and R¹¹ optionally form a non-aromatic, 5-10 membered, bridged carbocycle or heterocycle, wherein each carbocycle is optionally further substituted with one or more instances of J^A, and wherein each heteroocycle is optionally further substituted with one or more instances of J^B; and

Q² is independently a bond, -O-, -S-, -NR-, -C(O)- -C(=NR)-, -C(=NR)NR-, -NRC(=NR)NR-, -CO2-, -OC(O)-, -C(O)NR-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O-NRC(O)-, -NRC(O)NR- -NRC02-, -OC(O)NR- -S(O)-, -SO2-, -N(R)SO2-SO2N(R)-, -NRSO2NR-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)2O-, -CO₂SO₂-, or -(CR⁶R⁷)_P-Y-;

Q³ is independently a bond, -C(O)~, -C(=NR>, -C(=NR)NR-, -NRC(=NR)NR-, -CO2-, -C(O)NR-, -SO2-, -SO2N(R)-, -C(O)NRC(O)O- or -(CR⁶R⁷)P-Y'-;

-10WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

R” is independently: i) a Ci-Ce-alkyl optionally substituted with one or more substituents selected independently from the group consisting of halogen, cyano, hydroxyl, -NH₂, -NH(Ci-C6 alkyl), -N(Ci-Cs alkyl)₂, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ce aminoalkoxy, Ci-Cg cyanoalkoxy, Ci-Cg hydroxyalkoxy, and Cj-Cg alkoxyalkoxy; orii) aC₂Ce carbocyclic group, a 5-6 membered heteroaryl group, or a phenyl group, each optionally and independently being substituted with one ore more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, nitro, -NH₂, -NHfCi-Cg alkyl), -N(Ci-Ce alkyl)₂, Cj-Cg alkyl, Ci-Cehaloalky 1, Ci-C₆ cyanoalkyl, Ci-Ce-hydroxyalkyl, C₂Ce-alkoxyalkyl, CrCe-aminoalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ceaminoalkoxy, CiCg cyano alkoxy, Ci-Cg-hydroxy alkoxy, and C₂-Cs alkoxyalkoxy;

each of Z¹, Z², Z³, Q¹, Q², Q³, Y¹, R², R³, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R, R', R*, J^A, J^B, J^C1, J^D1, J^E1, R^a, R^b, R^c and p is independently as described above for Structural Formula (IA) for the method of inhibiting the replication of influenza viruses;

n and m are each independently 0 or 1 when rings A and B are 3-6-membered; or n and m are each independently 0,1 or 2 when rings A and B are 7-10-membered;

k is 0, 1 or 2;

x and y are each independently 0, 1 or 2;

z is 1 or 2; and provided that ifY¹ is a bond, then R⁵ is neither-H nor a Ci-Cg aliphatic group; and provided that if each Q² and Q³ independently is a bond, then R⁵ is neither -H nor a Ci-Cg aliphatic group.

[00121] In yet another embodiment, the present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein: the values of the variables of Structural Formula (I) are as described below:

R¹ is -H, Ci-Ce alkyl, -S(O)₂-R”, or-C(O)OR”; or alternatively R¹ is -H or Ci-Cg alkyl.

R⁴ is:

-11WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

_R11 R12 ring A is a C3-C8 non-aromatic carbocycle optionally further substituted with one or more instances of J^A, or heterocycle optionally further substituedd with one or more instances ofJ^B;

rings B and C are each independently a 4-8 membered, non-aromatic heterocycle optionally and independently further substituted with one or more instances of J^B;

ring D is a 4-8 membered, non-aromatic heterocycle optionally substituted with one or more instances of J^D1;

R” is independently: i) a Ci-Ce-alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxyl, “NH2, -NH(Ci-Cg alkyl), -N(Ci-C₆ alkyl)₂, Ci-C₆ alkoxy, Ci-Ce haloalkoxy, Ci-Ce aminoalkoxy, Cj-Cg cyanoalkoxy, Ci-Ce hydroxyalkoxy and C₂-Ce alkoxyalkoxy; or ii) a C3Q carbocyclic group, 5-6 membered heteroaryl group, or phenyl group, each optionally and independently being substituted with one ore more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, nitro, -NH2, -NH(Ci-C_c alkyl), “N(Ci-Ce alkyl)₂, Ci-C_s alkyl, Ci-Ce haloalkyl, Ci-C₆ cyanoalkyl, Ci-Ce-hydroxyalkyl, C>Cg-alkoxyalkyl, Cj-Ce-aminoalkyl, Cj-Cc alkoxy, Cj-Cs haloalkoxy, Ci-Cg amino alkoxy, CiCe cyanoalkoxy, Ci -Cfi-hydroxy alkoxy, and C₂-C6 alkoxy alkoxy;

each of Z¹, Z², Q^l, Q², Q³, Y^!, R², R³, R⁵, R^e, R⁷, R^s, R⁹, R¹⁰, R¹¹, R^!2, R¹³, R¹⁴, R, R’, R*, J^C1, J^DI, J^E1, R^a, R^b, R^c and p is independently as described above for Structural Formula (I) for the method of inhibiting the replication of influenza viruses;

n and m are each independently 0 or 1 when rings A and B are 4-6-membered; or n and m are each independently 0, 1 or 2 when rings A and B are 7-8 membered;

kisO, 1 or 2;

x and y are each independently 0, 1 or 2;

z is 1 or 2;

provided that if Y^l is a bond, then R⁵ is neither-H nor an unsubstituted Ci-Cg aliphatic group; and provided that if each Q^z and Q³ independently is a bond, then R⁵ is neither -H nor a Ci -Ce aliphatic group.

[00122] In yet another embodiment, the present invention is directed to a

-12WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 pharmaceutical composition comprising a compound represented by Structural Formula (I) or Structural Formula (IA), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle, wherein the values of the variable of Structural Formulae (I) and (IA) are each and independently as described above for the compounds of the invention.

[00123] The present invention also provides use of a compound described herein for inhibiting the replication of influenza viruses in a biological sample or patient, for reducing the amount of influenza viruses in a biological sample or patient, or for treating influenza in a patient.

[00124] Also provided herein is use of a compound described herein for the manufacture of a medicament for treating influenza in a patient, for reducing the amount of influenza viruses in a biological sample or in a patient, or for inhibiting the replication of influenza viruses in a biological sample or patient.

BRIEF DESCRIPTION OF THE DRAWINGS [00125] FIG. 1 is a graph showing percentages of survial of Balb/c mice (4-5 weeks of age) over time for a prophylaxis study in which an initial dose of Compound 514 (100 mg/kg) or vehicle only (0.5% Methylcellulose/0.5% Tween 80) were administered 2 hours prior to infection by oral gavage (10 mL/kg) and continued twice daily for 5 days.

[00126] FIG. 2 is a graph showing percentages of survial of Balb/c mice (4-5 weeks of age) over time for a therapeutic treatment study in which Compound 588 (200 mg/kg) or vehicle only were administered by oral gavage 24 hours post infection and continued twice daily for 10 days.

[00127] FIGs.3-8 are tables showing some specific compounds of the invention.

DETAILED DECRIPTION OF THE INVENTION

Uses of Disclosed Compounds [00128] One aspect of the present invention is generally related to the use of the compounds described herein or pharmaceutically acceptable salts, or pharmaceutically acceptable compositions comprising such a compound or a pharmaceutically acceptable salt thereof, for inhibiting the replication of influenza viruses in a biological sample or in a patient, for reducing the amount of influenza viruses (reducing viral titer) in a biological sample or in a patient, and for treating influenza in a patient.

-13WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00129] In one embodiment, the present invention is generally related to the use of compounds represented by Structural Formula (I) or Structural Formula (IA), or pharmaceutically acceptable salts thereof for any of the uses specified above:

(I)·

A first set of variables of Structural Formulae (I) and (IA) is independently as follows:

Z¹ is -R*, -F, -Cl, -CN, -OR*, -CO2R*, -NO2, or -CON(R*)2. Specifically, Z¹ is -H, Cs-C₆ alkyl, -O(Ci-C₆ alkyl), -F, -Cl, -CN, -CO₂H, -CO₂(C_t-C₆ alkyl), -CONH₂, -CONH(CiCg alkyl), or -CON(Ci-Ce alkyl)₂, wherein each of said alkyl groups (e.g., represented by CiC₆ alkyl, -O(Ci-C₆ alkyl), -CO₂(Ci-C₆ alkyl), -CONH(Ci-C₆ alkyl), and -CON(Ci-C₆ alkyl)₂) is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C4 alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C₁-C₄ alkyl), -CO₂H, -CO₂(C,-C₄ alkyl), and CiC₄ alkoxy. Specifically, Z^s is -H, -F, -Cl, Ci-C4 haloalkyl (e.g., -CF3), Ci-C4 alkyl, -CH2NH2, -C(O)NH2j -C(O)NH(CH3), -C(O)N(CH3)2, -O(Ci-C4 alkyl), or -CN. Specifically, Z¹ is -H, -F, -Cl, -CF3, C_rC₄ alkyl, or -CN. Specifically, Z^! is -H, -F, -Cl, -CF₃, -CH₃, or CN. Specifically, Z¹ is -H, -F, or-CN. Specifically, Z¹ is -H or -F.

Z² is -R* -OR*, -CO2R*, -NR*2j or -CON(R*)2. Specifically, Z² is -H, Ci-C6 alkyl, -O(Ci-Ce alkyl), -NH₂, -NH(Ci-Ce alkyl), or -N(Ci-Ce alkyl)₂, wherein each of said alkyl groups (e.g., represented by Ci-Ce alkyl, -O(Ci-Cc alkyl), -NH(Ci-Co alkyl), and -N(Ci-Ce alkyl)₂) is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(C_t-C₄ alkyl)₂, -OCO(C!-C₄ alkyl), -CO(C_rC₄ alkyl), -CO₂H, -CO₂(CiC₄ alkyl), and Ci-C₄ alkoxy. Specifically, Z² is -H, Cj-Ce alkyl, or -O(Ci-Ce alkyl), wherein each of the alkyl groups is optionally and independently substituted. Specifically, Z² is -H, or an optionally substituted Cj-Cc alkyl.

Z³ in Structural Formula (IA) is -H, -OH, halogen, -NH₂; -NH(Cj-C₄ alkyl); -N(Ci-C₄alkyl)_2i -0(C_s-C₄ alkyl), or Ci-Cc alkyl that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy,

-14WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 and -0(Ci-C4 alkyl). Specifically, Z³ is -H, -O(C]-C4 alkyl), or Ci-Ce alkyl that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C4 alkyl). Specifically, Z³ is -H or Ci-C₆ alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C4 alkyl). Specifically, Z³ is -H.

R¹ is -H or Ci .6 alkyl. Specifically, R¹ is -H.

R² is -H; -F; -NH2; -NH(Ci-C4 alkyl); -N(C|-C4 alkyl)2; -C=N-OH; cyclopropyl that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, -OCH3, and -CH3; or C1-C4 alkyl that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -0(^-C4 alkyl). Specifically, R² is -H, -CH3, -NH₂, -NH(CiC4 alkyl), or -N(Ci-C₄ alkyl)₂. Specifically, R² is -H, -F, -CH3, -CH?OH, or -NH2. Specifically, R² is -H or -CH3.

R³ is -H, -Cl, -F, -OH, -O(Ct-C4 alkyl), -NH2, -NH(CrC 4 alkyl), -N(Ci-C4 alkyl)2, -Br, -CN, or C1-C4 aliphatic that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C4 alkyl), -N(CrC4 alkyl)2, -OCO(Ct-C4 alkyl), -CO(Ci-C4 alkyl), -CO2H, -CO2(CiC4 alkyl), and C1-C4 alkoxy. Specifically, R³ is -H, -Cl, -F, -CF3, -OCH₃, -NH₂, -NH(C,-C ₄alkyl), -N(Ci-C4alkyl)₂, -Br, -O(Ci-C₄ alkyl), -CN, “C1-C4 haloalky 1, -OH, or-C!-C₄aliphatic. Specifically, R³ is -H, -Cl, -F, -CF3} -OCH3, -NH2, -NH(Ci-C 4alkyl), -N(Ci-C4 alkyl)2, -Br, -O(Ci-C4 alkyl), -CHCH(CH3), -CHCH2, -CN, -CH2CF3, -CH2F, -CHF2, -OH, or-Ci-C4 alkyl. Specifically, R³ is -H, -Cl, -F, -Br, -CN, -CF3, -O(Ci-C₄ alkyl), -OH, -NH₂, -NH(Ci-C₄ alley!), or -N(Ci-C₄ alkyl)₂. Specifically, R³ is -H, -F, -Cl, -CF3, -NH2, -NH(CH3), or -N(CHj)2, Specifically, R³ is -H, -Cl, or -F. Specifically, R³ is -Cl. Specifically, R³ is -H, -Cl, -F, -Br, -CN, -CF3, -CH₃, -C₂H₅, -O(CrC4 alkyl), -OH, -NH₂, -NH(Ci-C₄ alkyl), or -N(Ci-C₄ alkyl)₂. Specifically, R³ is -H, -F, -Cl, -CF₃, -CH₃, -C₂H₅, -NH₂, -NH(CH₃), or -N(CH₃₎2. Specifically, R³ is -F or-Cl.

R⁴ is: i) a C3-Cio non-aromatic carbocycle optionally substituted with one or more instances of J^A; ii) a Ci-Ce aliphatic group (e.g., Ci-C6 alkyl or C₂-C_e alkenyl group) optionally substituted with one or more substituents independently selected from the group consisting of J ; a C₃-C« non-aromatic carbocycle, or a 6-10 membered carbocyclic aryl group, each optionally and independently substituted with one or more instances of J^A; and a

5-10 membered heteroaryl group, or a 4-10 membered non-aromatic heterocycle, each optionally and independently substituted with one or more instances of J^B; or iii) a 4-10

-15WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 membered non-aromatic heterocycle optionally substituted with one or more instances of J^B. Specifically, R⁴ is i) an optionally substituted C3-C10 carbocyclic ring; ii) a Ci-Cg aliphatic group (e.g., CrCc alkyl or C2-C6 alkenyl group) that is substituted with one or more substituents independently selected from the group consisting of J^c, an optionally substituted Cj-Cs non-aromatic carbocycle, and an optionally substituted 4-10 membered non-aromatic heterocycle; or iii) an optionally substituted, 4-10 membered non-aromatic heterocycle. Specifically, the Ci-Cg aliphatic group represented by R⁴ is substituted with -OR⁵, -SR⁵, -NR’R⁵, -C(O)R⁵, -CO2R⁵, -OC(O)R⁵, -C(O)NR’R⁵, -C(O)NRC(O)OR⁵, -NRC(O)NRC(O)OR⁵, -NRC(O)R⁵, -NRC(O)NR’R⁵, -NRCO2R⁵, -OC(O)NR’R⁵, -SOR⁵, -SO2R⁵, -SO2NR’R⁵-, N(R)SO2R⁵, -NRSO2NR’R⁵, an optionally substituted C3-C8 non aromatic carbocycle, and an optionally substituted 4-10 membered non-aromatic heterocycle. More specifically, R⁴ is:

§---(CR¹³R¹⁴)_i—_/C T)

i) R⁹ wherein ring T (including rings A, B and C described below) is a C3-C10 non-aromatic carbocycle optionally substituted with one or more instances of J^A, or a 3-10 membered non-aromatic heterocycle optionally substituted with one or more instances of J^B, or ring T and R⁹ optionally form a non-aromatic C5-C10 membered carbocycle optionally substituted with one or more instances of J^A or 5-10 membered nonaromatic heterocycle optionally substituted with one or more instances of J^B ;

ii) ? X—' wherein ring J is a 3-10 membered non-aromatic heterocycle optionally substituted with one or more instances of J^B; or (CR¹³R¹⁴J^-^° iii) wherein ring D is a 4-10 membered non-aromatic heterocycle optionally substituted with one or more instances of J^Di. More specifically, R⁴ is:

(A)

(B)

-16WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

(C) (D).

R is: i) -H; ii) a Ci-C₆ aliphatic group optionally substituted with one or more instances of J ; iii) a C3-C10 non-aromatic carbocycle, or a 6-10 membered carbocyclic aryl group, each optionally and independently substituted with one or more instances of J^C1; or iv) a 4-10 membered non-aromatic heterocycle, or a 5-10 membered heteroaryl group, each optionally and independently substituted with one or more instances of J^D1. Specifically, R³is: i) -H; ii) a Ci-Ce aliphatic group (e.g., Ci-C₆ alkyl or C₂-Cs alkenyl group) optionally substituted with one or more instances of J^C1; iii) a C3-C3 non-aromatic carbocycle, or a 6-10 membered carbocyclic aryl group, each optionally and independently substituted with one or more instances of J^CI; or iv) a 4-8 membered non-aromatic heterocycle, or a 5-10 membered heteroaryl group, each optionally and independently substituted with one or more instances of J^D1. Optionally, R³, together with each of Q¹, Q² and Q³, optionally and independently forms a 4-8 membered, non-aromatic ring optionally substituted with one or more instances of J^EI. It is understood that the non-aromatic ring formed with R³ and Q¹ can employ a portion of Q¹. In some embodiments, R⁵, together with Q² and R⁸, optionally and independently forms a 5-7 membered, non-aromatic ring optionally substituted with one or more instances of J^Ei.

Specifically, R³ is independently i) -H; ii) a Ci-Ce-alkyl or C2-Ci,-alkenyl group optionally substituted with one or more instances of J^C1; iii) a C2-Cs non-aromatic carbocycle optionally substituted with one or more instances of J^Ci; iv) a phenyl group optionally substituted with one or more instances of J^C1; v) a 4-8 membered non-aromatic heterocycle optionally substituted with one or more instances of J^D1; or vi) a 5-6 membered heteroaryl ring optionally substituted with one or more instances of J^D1. Specifically, R⁵ is independently i) -H; ii) a Ci-Cg-alkyl or C2-C6-aIkenyl group optionally and independently substituted with one or more instances of J^C1; or iii) a 4-8 membered non-aromatic heterocycle optionally substituted with one or more instances of J^DI. Specifically, R³ is independently i) -H; or ii) a Ci-Ce-alkyl or C2-Ce-aIkenyl group optionally and independently substituted with one or more instances of J^Ci.

R⁶ and R⁷ are each independently -H or Ci-Ce alkyl optionally substituted with one or more substitutents selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ce aminoalkoxy, Ci-Cecyanoalkoxy,

-17WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Ci-Co hydroxy alkoxy, and C₂-Cg alkoxyalkoxy, or optionally R⁶ and R⁷, together with the carbon atom to which they are attached, form a cyclopropane ring optionally substituted with one or more instances of methyl. Alternatively, R⁶ and R⁷ are each independently -H or CjC₄ alkyl optionally substituted with one or more substitutents selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-Cg alkyl), -N(Ci-Ce alkyl)₂, -C(O)OH, -(CO)O(Ci-C₆ alkyl), -OC(O)(Ci-C₆ alkyl), Ci-Cg alkoxy, Ci-C₆ haloalkoxy, CiCg aminoalkoxy, Ci-Cg cyanoalkoxy, Ci-Ce hydroxy alkoxy, and C₂-Cg alkoxyalkoxy, or optionally R⁶ and R⁷, together with the carbon atom to which they are attached, form a cyclopropane ring optionally substituted with one or more instances of methyl. Specifically, R⁶ and R⁷ are each independently -H or -CH3, or, together with the carbon atoms to which they are attached, they form a cyclopropane ring.

Each R⁸ is independently -H, halogen, cyano, hydroxy, amino, carboxy, C_rCe alkyl, Ci-Cg haloalkyl, Ci-Cg cyanoalkyl, C₂-Cg alkoxyalkyl, Ci-Ce aminoalkyl, Ci-Cg hydroxyalkyl, Ci-Ce alkoxy, Ci-Cg haloalkoxy, Ci-Cg aminoalkoxy, Ci-Cg cyano alkoxy, CiCg hydroxy alkoxy, and C₂-Cg alkoxy alkoxy; or R⁸, together with Q² and R⁵, optionally and independently forms a 5-7 membered, non-aromatic ring optionally substituted with one or more instances of J^E1.

Each R⁹ is independently -H, halogen, cyano, hydroxy, amino, carboxy, Ci-Ce alkyl, Ci-Cg haloalkyl, Cj-Cg cyanoalkyl, C2-Cg alkoxyalkyl, Ci-Cg aminoalkyl, Ci-Cg hydroxyalkyl, Ci-Cg carboxyalkyl, Ci-Cg alkoxy, Ci-Cf, haloalkoxy, Ci-Cg aminoalkoxy, CiCg cyanoalkoxy, Ci-Cg hydroxyalkoxy, and C2-Cg alkoxyalkoxy; or R⁸, together with Q² and R⁵, optionally and independently forms a 5-7 membered, non-aromatic ring optionally substituted with one or more instances of J^E1. Specifically, each R⁹ is independently -H, halogen, cyano, hydroxy, amino, carboxy, Ci-Cg alkyl, Cj-Cg haloalkyl, Ci-Ce cyanoalkyl, C2-Cg alkoxyalkyl, Ci-Ce aminoalkyl, Ci-Cg hydroxyalkyl, Ci-Cg alkoxy, Ci-Cg haloalkoxy, Ci-Cgaminoalkoxy, Ci-Cgcyanoalkoxy, Ci-Cg hydroxyalkoxy, and C₂-Cgalkoxyalkoxy; or R⁸, together with Q² and R⁵, optionally and independently forms a 5-7 membered, nonaromatic ring optionally substituted with one or more instances of J^E1.

Optionally, R⁹ and ring T form a non-aromatic C5-C10 membered carbocycle optionally substituted with one or more instances of J^A or 5-10 membered non-aromatic heterocycle optionally substituted with one or more instances of J^B .

Specifically, each R⁸ is independently -H, halogen, cyano, hydroxy, C1-C4 alkyl, CiC₄ haloalkyl, C1-C4 hydroxyalkyl, C2-C4 alkoxyalkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C4

-18WO 2010/148197

PCT7US2010/038988

2018200219 11 Jan 2018 alkyl), or -N(Ci~C4 alkyl)₂; and each R⁹ is independently -H or C1-C4 alkyl, more specifically, -H, -CH₃, or-CH₂CH₃.

R¹⁰ is independently -H; or a Ci-Cg alkyl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ci-Cg alkoxy, Ct-Ce haloalkoxy, Ci-Cr>aminoalkoxy, Ci-Ce cyanoalkoxy, Ci-C<; hydroxyalkoxy, C2-C6 alkoxyalkoxy, C3-Cs non-aromatic carbocycle, phenyl, a 4-8 membered non-aromatic heterocycle, and a 5-6 membered heteroaryl group; wherein each of said carbocycle, phenyl, heterocycle, and heteroaryl group for the substituents of the CrCc alkyl group represented by R¹⁰ is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce cyanoalkyl, C2-Cc alkoxyalkyl, Ci-Cg aminoalkyl, Ci-Cg hydroxyalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ce aminoalkoxy, Ci-Cg cyanoalkoxy, Ci-Cc hydroxyalkoxy, and C₂-Ce alkoxyalkoxy. Specifically, R¹⁰ is independently -H, Ci-Cg alkyl, Ci-Cc haloalkyl, C2-C6alkoxyalkyl, Cj-Ce hydroxyalkyl, Ci-Ce aminoalkyl, or Cj-Ce cyanoalkyl. Specifically, R¹⁰ is -H or Ci-C<5-alkyI optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(C|-C4 alkyl), -N(CjC4 alkyl)₂, -OCO(Ci-C4 alkyl), -CO₂H, -CO₂(Ci-C4 alkyl), and C1-C4 alkoxy. Specifically, R¹⁰ is -H or Ci-Cs-alkyl.

R^u, R¹², R¹³ and R¹⁴ are each independently -H, halogen, or Ci-Cc alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, Ci-Ce alkoxy, C]-C6 haloalkoxy, Ci-Ce aminoalkoxy, Ci-Cg cyanoalkoxy, Ci-Ce hydroxyalkoxy, and C2-Cg alkoxyalkoxy; or optionally, R¹³ and R¹⁴ together with the carbon atom to which they are attached form a cyclopropane ring, optionally substituted with one or more instances of methyl. Specifically, R¹¹ and Rⁱ² are each independently -H or C1-C4 alkyl; and R¹³ and R¹⁴are each independently -H or C1-C4 alkyl, or together with the carbon atoms to which they are attached, they form a cyclopropane ring. Specifically, R¹¹ and R¹² are each independently -H or -CH3; and R¹³ and R¹⁴arc each independently -H, -CH₃, or -CH₂CH₃, or together with the carbon atoms to which they are attached, they form a cyclopropane ring.

Optionally R¹¹ and ring A form a bridged ring optionally further substituted with one or more instances of J^A.

Ring A is a C₃-Cjo non-aromatic carbocycle optionally further substituted with one or more instances of J^A, or 3-10 membered non-aromatic heterocycle optionally further

-19WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 substituted with one or more instances of J^B. Specifically, ring A is an optionally substituted CvCg non-aromatic carbocyclic or heterocyclic ring. Specifically, Ring A is a Cj-Cg nonaromatic carbocycle optionally further substituted with one or more instances of J^A. Specifically, Ring A is a non-aromatic, 4-7 or 5-7 membered, carbocyclic ring optionally further substituted with one or more instances of J^A. A specific example of Ring A is an optionally substituted, cyclohexyl or cyclopentyl ring.

Optionally, ring A and R⁸ form a non-aromatic, 5-10 membered, bridged carbocycle or heterocycle, or ring A and R⁹ optionally form a non-aromatic, 5-10 membered, bridged carbocycle or heterocycle, ring A and R¹¹ optionally form a non-aromatic, 5-10 membered, bridged carbocycle or heterocycle, wherein each carbocycle is optionally further substituted with one or more instances of J^A, and wherein each heteroocycle is optionally further substituted with one or more instances of J^B. In some embodiments, the bridged rings are

each of rings G1-G4 is independently a 5-10 membered non-aromatic bridged carbocycle optionally further substituted with one or more instances of J^A, and ring G5 is a 5-10 membered non-aromatic bridged heterocycle optionally further substituted with one or more instances of J^B; R^2t, R²², R²³, R²⁴, and R²⁵are each independently -H, halogen, -OH, Cj-Cg alkoxy, or Cj-Cq alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, oxo, amino, carboxy, CjCg alkoxy, Ci-Cg haloalkoxy, Cj-Cg aminoalkoxy, Cj-Cg cyano alkoxy, Cj-Cg hydroxyalkoxy, and C2-C6 alkoxyalkoxy; X is -O-, -S-, or-NR^s-; R^E is -H or Cj-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, Cj-Cg alkoxy, Cj-Cg haloalkoxy, Cj-Cg aminoalkoxy, Cj-Cg cyanoalkoxy, Cj-Cg hydroxy alkoxy, and C2-C6 alkoxyalkoxy; q is 0, 1 or

-20WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

2; x is 0, 1 or 2; r is 1 or 2. An additional example of the bridged rings includes an adamantyl ring.

Ring B is a 4-10 membered, non-aromatic, heterocyclic ring that is optionally further substituted with one or more instances of J^B Specifically, ring B is 4-8 membered. Specifically, ring B is 4-7 or 5-7 membered. Specific examples of Ring B include:

wherein each of rings B1-B9 is optionally substituted.

Ring C is a 4-10 membered, non-aromatic, heterocyclic ring that is optionally further substituted with one or more instances of J^B. Specifically, ring C is 4-8 membered. Specifically, ring C is 4-7 or 5-7 membered. Specific examples of Ring C include:

wherein each of rings C1-C5 is optionally and independently substituted.

Ring D is a 4-10 membered, non-aromatic, heterocyclic ring that is optionally substituted with one or more substituents instances of J^D1. Specifically, ring D is 4-8 membered. Specifically, ring D is 4-7 or 5-7 membered. Specific examples of ring D include:

wherein each of rings D1-D7 is optionally substituted.

Specifically, each of Rings A -D is independently and optionally substituted 4-8 or 47 membered ring.

-21WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Each Q¹ is independently a bond, -0-, -S-, -NR’-, -C(O)-, -C(=NR)-, -C(=NR)NR-, -NRC(=NR)NR-, -CO2-, -OC(O)-, -C(O)NR’-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O- -NRC(O)-, -NRC(O)NR’~, -NRCO2~, -OC(O)NR’-, -S(O)-, -SO2-SO2NR’-, -NRSO2-, or -NRSOjNR’-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)2O-, -CO₂SO₂-, or -(CR^jp-Y¹-. Specifically, each Q* is independently a bond, -O-, -S-, -NR’-C(O)-, -C(=NR)-, -CO2-, -OC(O)-, -C(O)NR’-, -C(O)NRC(O)O- -NRC(0)NRC(O)O, -NRC(O)-, -NRC(O)NR’-, -NRCO2-, -OC(O)NR’-, -S(O)-, -SO2- -NRSO2-SO2NR’-, NRSO2NR’-, or -(CR⁶R⁷)P-Y¹-. Specifically, each Q¹ is independently a bond, -0-, -S-, -NR’-, -C(O)~, -CO2-, -OC(O)-, -C(O)NR’-, -C(O)NHC(O)O-C(O)N(CH3)C(O)O, -NHC(O)NHC(O)O-, -N(CH3)C(O)NHC(O)O-, -NHC(O)-N(CH3)C(O)-, -NHC(O)NR’-, -N(CH3)C(O)NR’-, -NHCO2-,-N(CH3)CO2-OC(O)NR’-, -S(O)-, -SO2-, -NHSO2-, -N(CH3)SO2- -SO2NR’-, or -(CR⁶R⁷)P-Y‘-.

Each Q² is independently a bond, -0-, -S-, -NR-, -C(O)~, -C(=NR)-, -C(=NR)NR-, -NRC(=NR)NR-, -CO2-, -OC(O)~, -C(O)NR-, -C(O)NRC(O)O-NRC(O)NRC(O)O-, -NRC(O)-, -NRC(O)NR- -NRCO2- -OC(O)NR-, -S(O)-, -SO2-, -N(R)SO2-, -SO2N(R)-, -NRSO2NR-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)2O-, -CO2SO2-, or -(CR⁶R⁷)p-Y¹. Specifically each Q² is independently a bond, -0-, -S-, -NR’-, -C(O)-, -C(=NR)-, -CO2-, -OC(O)-, -C(O)NR’-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O-, -NRC(O)-, -NRC(0)NR’-, -NRCO2- -OC(O)NR’-, -S(O)-, -SO₂-, -NRSO₂-, -SO₂NR’“, NRSO2NR’-, or-(CR⁶R⁷)p-Y¹-. Specifically, each Q² is independently -0-, -NR’-, -C(O)-, -CO2-, -C(0)NR’-, -NRC(O)-, -NRC(0)NR’-, -NRCO2-, -OC(O)NR’-, -NRSO2-, -SO2NR’-, or -(CR⁶R⁷)P-Y‘-. Specifically, each Q² is independently -CO2-, -C(O)NR’-, -NRC(O)-, -NRC(O)NR’-, -NRCO2-, -OC(O)NR’-, NRSO2-, or -(CR⁶R⁷)P-Y^l- Specifically, each Q² is independently -NR’-, -C(O)NR’-, -NRC(O)-, -SO2NR’-, ~NRC(O)NR’~, -NRC02- -OCONR’-, or-(CR⁶R⁷)f-Y¹··-. Specifically, each Q² is independently -C(O)NR’-, -NRC(O)-, -NRC(0)NR’-, -NRCO2-, -OCONR’-, or -(CR⁶R')p-Y¹-. Specifically, each Q² is independently -0-, -NR’-, -C(0)-, -CO2-, -C(O)NR’-, -NHC(O)-, -N(CH3)C(O)~, -NHC(0)NR’-, -N(CH₃)C(O)NR’-, -NHCO₂- -N(CH₃)CO₂-, -OC(O)NR’-, -nhso₂-, -N(CH₃)SO2~, -SO₂NR’~, or-fCR^Vjp-Y¹-. Specifically, each Q² is independently -C0₂-, -C(O)NR’-, -NHC(O)-, -N(CH₃)C(O)-, -NHC(O)NR’-, -N(CH₃)C(O)NR’-, -NHC0₂-N(CH₃)CO₂- -OC(O)NR’-, -NHSO2-, -N(CH₃)SO₂-, -SO2NH-, -SO₂N(CH₃)-, or

-22WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

-(CR⁶R⁷)P-Y¹-. Specifically, each Q² is independently -NR’-, -C(O)NR’-, -NHC(O)-, -N(CH3)C(O)-, -NHC(O)NR’-, -N(CH₃)C(O)NR’-, -NHCO2-, -N(CH₃)CO₂~, -OCONR’- or-CCR^VY¹-. Specifically, each Q² is independently -C(O)NR’-NHC(O)-, -N(CH₃)C(O)-, -NHC(O)NR’-, -N(CH₃)C(O)NR’-, -NHCO2-, -N(CH₃)CO₂-, -OCONR’-, or-CCR^Qp-Y¹-.

Each Q³ is independently a bond, -C(O)-, -C(=NR)-, -C(=NR)NR-, -NRC(=NR)NR-, -CO2-, -C(O)NR- -SO2- -SO2N(R)- -C(O)NRC(O)O- or -(CR⁶R⁷)p-Y¹-. Specifically, each Q³ is independently is a bond, -C(O)-, -C(=NR)-, -CO?-, -C(O)NR’-, -SO2-, -SO2NR’-, -C(O)NRC(O)O- or -(CR⁶R⁷)P-Y'-. Specifically, each Q³is independently -C(O)-, -CO2-, -C(O)NR’-, -SO2- -SO2NR’-, -C(O)NRC(O)O-, or -(CR^jp-Y¹-. Specifically, each Q³ is independently -C(0)-, -CO2- -C(O)NH-, -C(O)N(CH₃)-, -SO₂-_;-SO₂NH-, -SO₂N(CH₃)-, -C(O)NHC(O)O- -C(O)N(CH₃)C(O)O-, or -(CR^’jp-Y¹- Specifically, each Q³ is independently -C(O)-, -CO2-, -C(O)NR’-, -C(O)NHC(O)O- or-(CR⁶R⁷)p-Y¹-. Specifically, each Q³ is independently -C(O)-, -CO2-~, -C(O)NR’~, or -(CR⁶R⁷)_P-Y¹-.

Optionally, Q² and Q³, together with R⁵, each and independently can form a 5-7 membered, non-aromatic ring optionally substituted with one or more instances of J^E1. Tt is understood that the non-aromatic ring formed with R⁵ and Q² can employ a portion of Q². It is also understood that the non-aromatic ring formed with R⁵ and Q³ can employ a portion of Q³Each Y¹ is independently a bond, -0-, -S-, -NR-, -C(O)-, -C(=NR)-, -C(=NR)NR-, -NRC(=NR)NR-, -CO2-, -OC(O)-, -C(O)NR-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O-NRC(O)-, -NRC(O)NR-, -NRCO2- -0C(O)NR-, -S(O)-, -SO2- -N(R)SO2-, -SO2N(R)-, -NRSO2NR-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)2O-, or -CO₂SO₂-. Specifically each Y¹ is independently a bond, -0-, -S-, -NR’-, -C(O)~, -C(=NR)-, -CO2-, -OC(O)-, -C(O)NR’-, -NRC(O)-, -NRC(O)NR’-, -NRCO2-, -OC(O)NR’-, -S(O)-, -SO2~, -SO2NR’-, -NRSO2-, -NRSO2NR’-, -NRC(O)NRC(O)O- or -C(O)NRC(O)O~. Specifically, each Y¹ is independently a bond, -0-, -NR’-, -C(0)NR’-, -NRC(O)-, -NRC(O)NR’-, -NRCO2-, -OC(O)NR’-, -NRC(O)NHC(O)O- or -C(0)NHC(0)0-. Specifically, each Y^l is independently a bond, -0-, -S-, -NR’-, -C(0)-, -CO2- -00(0)-, -C(O)NR’-, -NHC(O)-, -N(CH₃)C(O)-, -NHC(O)NR’-, -N(CH₃)C(O)NR’-, -NHCO2-, -N(CH₃)CO₂- -0C(0)NR’-, -S(0)-, -SO2-, -NHSO₂-, -N(CH₃)SO₂- -SO2NH-, SO₂N(CH₃)-, -NHSO2NH-, -N(CH₃)SO₂NH-> -N(CH3)SO₂N(CH₃)-, -C(O)NHC(O)O-,

-23WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

-C(0)N(CH₃)C(0)0-,.-NHC(0)NHC(0)0-, or-N(CH₃)C(O)NHC(O)O-. Specifically, each Y¹ is independently a bond, -0-, -NR’-, -C(O)NR’-, -NHC(O)-N(CH₃)C(O)-, -NHC(O)NR’-, -N(CH₃)C(O)NR’-, -NHCO2-, -N(CH₃)CO₂-, -OC(O)NR’-, -C(O)NHC(O)O- or -NHC(O)NHC(O)O-.

Each of J^A and J^B is independently selected from the group consisting of halogen, cyano, oxo, -NCO, andQ’-R⁵; or optionally two J^A and two J^B, respectively, together with the atom(s) to which they are attached, independently form a 4-8 membered ring (e.g., spiro ring or fused ring) that is optionally substituted with one or more instances of J^E1. Specifically each of J^A and J^B is independently selected from the group consisting of halogen, cyano, oxo, -NCO, andQ'-R⁵; or optionally two J^A and two J^B, respectively, together with the atom(s) to which they are attached, independently form a 5-7 membered ring that is optionally substituted with one or more instanced of J^E1. The 5-7-membered ring formed with J^A or J^B can be aromatic or non-aromatic. The 5-7-membered ring formed with J^A or J^Bcan optionally be fused to the ring to which they are attached. In some embodiments, the 57-membered ring can optionally be a spiro ring formed by two geminal J^A and two geminal J^B, respectively.

J^c is independently selected from the group consisting of halogen, cyano, oxo, -OR⁵, -SR⁵, -NR’R⁵, -C(O)R⁵, -CO2R⁵, -OC(O)R⁵, -C(O)NR’R^S, -C(O)NRC(O)OR⁵, -NRC(O)NRC(O)OR⁵, -NRC(O)R⁵, -NRC(O)NR’R⁵, -NRCO2R⁵, -OC(O)NR’R⁵, -S(O)R⁵, -SO2R⁵, -SO2NR’R⁵, -NRSO2R⁵, -NRSO2NR’R⁵, and -P(O)(OR^a)2- Specifically, J^c is independently selected from the group consisting of -OR⁵, -SR⁵, -NR’R⁵, -C(O)R⁵, -CO2R⁵, -OC(O)R⁵, -C(O)NR’R⁵, -C(O)NRC(O)OR⁵, -NRC(O)NRC(O)OR⁵, -NRC(O)R⁵, -NRC(O)NR’R⁵, -NRCO₂R⁵, -OC(O)NR’R⁵, -S(O)R⁵, -SO2R⁵, -SO2NR’R⁵, -NRSO2R⁵, and -NRSO2NR’R⁵. Specifically, J^c is selected from the group consisting of halogen, cyano, oxo, -OR⁵, -NR’R⁵, -C(O)R⁵, -CO₂R⁵, -OC(O)R⁵, -C(O)NR’R⁵, -C(O)NRC(O)OR⁵, -NRC(O)R⁵, -NRC(O)NR’R⁵, -NRCO2R⁵, and -OC(O)NR’R⁵. Specifically, J^c is selected from the group consisting of halogen, cyano, oxo, -OR⁵, -NR’R⁵, -C(O)R⁵, -CO2R⁵, -OC(O)R⁵, -C(O)NR’R⁵, and -NRC(O)R⁵. Specifically, J^c is selected from the group consisting of halogen, cyano, oxo, -OR⁵, -NR’R⁵, -C(O)NR’R⁵, and -NRC(O)R⁵. Specifically, J^c is selected from the group consisting of -OR⁵, -NR’R⁵, -C(O)NR’R⁵, and -NRC(O)R⁵.

Each of J^C1 and J^D1 is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a, -SO₂R^a, -NR^bR^c, -C(O)R^b, -C(=NR)R^C,

-24WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

-C(=NR)NR^bR^c, -NRC(=NR)NR^bR^c, -C(O)OR^b, -OC(O)R^b, ~NRC(O)R^b, -C(O)NR^bR^c, -NRC(O)NR^bR^c, -NRC(O)OR^b, -OCONR^bR^c, -C(O)NRCO₂R^b, -NRC(O)NRC(O)OR^b, -C(O)NR(OR^b), -SO2NR^cR^b, -NRSO2R^b, -NRSO₂NR^cR^b -P(O)(OR^a)2, -OP(O)(OR^a)2-, -P(O)₂(OR^a), and -CO2SO2R^b, or optionally, two J^C1 and two J^D1, respectively, together with the atom(s) to which they are attached, independently form a 4-8-membered ring that is optionally substituted with one or more instances of J^E1. Specifically, each of J^C1 and J^DI is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a, -SO2R^a, -NR^bR^c, -C(O)R^b, -C(O)OR^b, -OC(O)R^b, -NRC(O)R^b, -C(O)NR^bR^c, -NRC(O)NR^bR^c, -NRC(O)OR^b, -OCONR^bR^c, -C(O)NRCO₂R^b, -NRC(O)NRC(O)OR^b, -C(O)NR(OR^b), -SO2NR^cR^b, -NRSO2R^b, and -NRSO₂NR^cR^b.

Optionally, two J^C1 and two J^DI, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^E1, and fused to the respective ring to which they are attached. It is understood that selections of values of each J^C! and J^Dtare those that result in the formation of stable or chemically feasible compounds. For example, suitable values of each J^Ci and J^D1 on a carbon atom independently include halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a, “SO2R^a, -NR^bR^c, -C(O)R^b, -C(O)OR^b, -OC(O)R^b, -NR^bC(O)R^b, -C(O)NR^bR^c, -NRC(O)NR^bR^c, -NRC(O)OR^b, -OCONR^bR^c, -C(O)NRCO2R^b, -NRC(O)NRC(O)OR^b, -C(O)NR(OR^b), -SO2NR^cR^b, -NRSO2R^b, and -NRSO2NR^cR^b; and suitable values of J^D1 on a nitrogen atom include R^a, -SO2R^a, -SO2N(R)R^b, -C(O)R^b, -C(O)OR^b, -C(O)NR^bR^c, -C(O)NRCO2R^b, and -C(O)NR(OR^b). Specific examples of each J^C1 and J^D1 on a carbon atom independently include halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a, -SO2R^a, -NHR^C, -C(O)R^b, -C(O)OR^b, -OC(O)R^b, -NHC(O)R^b, -C(O)NHR^C, -NHC(O)NHR^C, -NHC(O)OR^b and -OCONHR^C, -N(CH3)R^C, -N(CH3)C(O)R^b, -C(O)N(CH3)R^C, -N(CH3)C(O)NHR^C, -N(CH3)C(O)OR^b, -OCON(CH3)R^c, -C(O)NHCO2R^b, -C(O)N(CH3)CO2R^b, -NHC(O)NHC(O)OR^b, -N(CH3)C(O)NHC(O)OR^b, -C(O)NH(OR^b)-, C(O)N(CH3)(OR^b), -NHSO2R^b, -SO2NHR^b, -SO2N(CH₃)R^b, and -N(CH3)SO2R^b. Specific examples of each J^D1on a nitrogen atom independently include R^a, -SO2R^a, -C(O)R^b, -C(O)OR^b, -C(O)NHR^C, -C(O)N(CH3)R^C, -C(O)NHCO2R^b, -C(O)N(CH3)CO2R^b, -C(O)NH(OR^b)-, and -C(O)N(CH3)(OR^b). More specific examples of each J^C1 and J^D1 on a carbon atom independently include halogen, cyano, hydroxy, oxo, C]-C₄ alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), C₃-Cg cycloalkyl, and -CO₂H, wherein each of said alkyl groups (e.g.,

-25WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 represented by C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH₂₎ -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), and C₃-C₆ cycloalkyl) is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(C,-C₄ alkyl), -OCO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy. More specific examples of each J^D1 on a nitrogen atom independently include halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -C(O)(C]-C₄ alkyl), -C(O)O(Ci~C₄ alkyl), and C₃-C₆ cyclo(alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, ~NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄alkyl), -OCO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C₍-C₄ alkoxy.

Each J^E1 is independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, amido, Ci-CG alkyl, -O(Ci-CG alkyl), and -C(O)(Ci-Ce-alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ct-C4 alkyl), -N(Ci-C4 alkyl)2, -OCO(Ci-C4 alkyl), -CO(Ct-C4 alkyl), -CO2H, -CO2(Ci-C4 alkyl), and Ci-C4 alkoxy. Specifically, each J^Ei is independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-CG alkyl, -O(Ci-C_Galkyl), -C(O)(Ci-C6-alkyl), -NH₂, -NH(C_rC6 alkyl), -N(C_f-C₆ alkyl)₂, -C(O)NH₂, C(O)NH(C_rC₆ alkyl), -C(O)N(C_S-C₆ alkyl)₂, -CfOXCi-Ce-alkyl), -C(O)O(C_rC₆ alkyl), OC(O)(C_rC₆ alkyl), -NHC(O)(C]-C₆ alkyl), -N(C,-C₆ alkyl)C(O)(Ci-C_G alkyl), and -CO₂H, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(C_t-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(C_t-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy. It is understood that selections of suitable J^E1 are those that result in the formation of stable or chemically feasible compounds. For example, suitable substituents on a carbon atom independently include halogen, cyano, hydroxy, oxo, Ci-C_G alkyl, -O(Ci-C_G alkyl), -C(O)(Ci-Ce-alkyl), -NH₂, -NH(Ci-C_g alkyl), -N(Ci-C₆ alkyl)₂, -C(O)NH₂, -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ci-C₆ alkyl)₂, -C(O)(Ci-C₆alkyl), -C(O)O(Ci-C6 alkyl), -OC(O)(Ci-C₆ alkyl), -NHC(O)(Ci-C₆ alkyl), -N(Ci-C₆alkyl)C(O)(Ci-C6 alkyl), and -CO₂H, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(C]-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy. For

-26WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 example, suitable substituents on a nitrogen atom independently include Cj-Cg alkyl, -C(O)NH(Ci-C₆ alkyl), -C(O)N(C_rC₆ alkyl)₂, -C(O)(Ci-C₆-alkyl), and -C(O)O(Ci-C₆ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(C₍-C₄ alkyl), -N(Cj-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Cj-C₄alkyl), -CO₂H, -CO₂(Cj-C₄ alkyl), and Cj-C₄ alkoxy.

R and R’ are each independently -H or Cj-Cg alkyl optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ci-Ce alkoxy, Cj-C₆ haloalkoxy, Ci-C₆aminoalkoxy, Cj-C₆ cyanoalkoxy, Ci-Ce hydroxyalkoxy, and C₂-Cg alkoxyalkoxy. Specifically, R and R’ are each independently -H or Cj-C₆ alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Cj-C₆ alkyl), -N(Cj-C₆ alkyl)₂, -C(O)O(Ci-C₆ alkyl), -OC(O)(CjCg alkyl), -CO₂H, Cj-Cg haloalkoxy, Cj-Cg aminoalkoxy, Cj-Cg cyanoalkoxy, Cj-Cg hydroxyalkoxy, and Cj-C₆alkoxyalkoxy. Specifically, R and R’ are each independently -H or Cj-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Cj-C_g alkyl), -N(CjCg alkyl)₂, and -O(Cj-Cg alkyl). Specifically, R and R’ are each independently -H or Cj-Cg alkyl (e.g., -CH₃ or -CH₂CH₃).

Optionally R’, together with R⁵ and the nitrogen atom to which they are attached, forms a 5-7 membered, non-aromatic, heterocyclic ring optionally substituted with one or more instances of J^DI. Specifically, the non-aromatic heterocycle is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Cj-Ce alkyl, C2-Cg alkenyl, -NH2, -NH(Ci-Ce alkyl), -N(Ci-Cg alkyl)2, -O(Ci.Cg alkyl), -C(O)NH2, -C(O)NH(Cj-C6 alkyl), -C(O)N(Cj-Cg alkyl)2> -C(O)(Cj-Cgalkyl), -OC(O)(Cj-Cg alkyl), -NHC(O)(Ci-C6 alkyl), -N(Cj-C6 alkyl)C(O)(Cj-C6 alkyl), and -CO2R^b; wherein each of said alkyl and alkenyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Cj-C₄ alkyl), -N(Cj-C₄ alkyl)₂, -OCO(Cj-C₄ alkyl), -C(O)(Cj-C₄ alkyl), -CO₂H, -CO₂(Cj-C₄ alkyl), and Cj-C₄ alkoxy. Specifically, the nonaromatic heterocycle is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, Cj-C₄ alkyl, -O(Ci-C₄alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Cj-C₄ alkyl)₂, -OCO(Cj-C₄ alkyl), -C(O)(Cj-C₄ alkyl), -CO₂H, and -“CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and

-27WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)?., -OCO(Ci-C₄ alkyl), -CO₂H, -CO2(Ci-C₄ alkyl), and Ci-C₄ alkoxy.

Each R* is independently: i) -H; ii) a Ci-C₆ alkyl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, C?-Cs non-aromatic carbocycle, 5-6 membered non-aromatic heterocycle, phenyl, 5-6 membered heteroaryl, -O(Ci-C₆ alkyl), and -C(O)(Ci-C6-alkyl); wherein each of said alkyl groups (e.g., represented by -O(Ci-Ce alkyl), and -C(O)(Ci-Cgalkyl)) is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(C!-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(CiC₄ alkyl), and C1-C4 alkoxy; and wherein each of said C3-C3 non-aromatic carbocycle, 5-6 membered non-aromatic heterocycle, phenyl, and 5-6 membered heteroaryl is independently and optionally substituted with one or more instances of J^E1; or iii) a Cj-Cg non-aromatic carbocycle, or a 4-8 membered non-aromatic heterocycle, each of which is independently and optionally substituted with one or more instances of J^E1. Specifically, each R* independently is: i)-H; ii) C₄-C₆ alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4aminoalkoxy, C1-C4 cyanoalkoxy, Ci-C₄ hydroxyalkoxy, and C2-C4 alkoxyalkoxy; or iii) a 3-7 membered carbocyclic ring optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, C4-C4 alkyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C₂-C₄alkoxyalkyl, C1-C4 aminoalkyl, C1-C4 hydroxyalkyl, Ci-C₄ alkoxy, C1-C4 haloalkoxy, Ci-C₄aminoalkoxy, Ci-C₄ cyanoalkoxy, C1-C4 hydroxyalkoxy, and C2-C4 alkoxy alkoxy. Specifically, each R* is i) -H, ii) Cj-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂₎ -NH(Ct-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy; or iii) a 3-7 membered carbocyclic ring optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(C[-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ct-C₄ alkyl), -CO₂H, -CO₂(C!-C₄ alkyl), C_t-C₄ alkoxy, and Ci-C₆alkyl, wherein each alkyl optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy,

-28WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(C]-C₄ alkyl), and C1-C4 alkoxy.

Each R^a is independently: i) a Ci-Cg aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, amido, -O(Ci-Cg alkyl), -C(O)(Ci-C6-alkyl), C3-C8 nonaromatic carbocycle, 4-8 membered non-aromatic heterocycle, 5-10 membered heteroaryl group, and 6-10 membered carbocyclic aryl group; wherein each of said alkyl groups for the substituents of the Ci-Ce aliphatic group represented by R^a is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2j -NH(Cj-C4 alkyl), -N(Ci-C4 alkyl)2, -OCO(Ci-C4 alkyl), -CCXC1-C4 alkyl), -CO2H, -CO2(Ci-C4 alkyl), and C1-C4 alkoxy; and wherein each of said carbocycle, heterocycle, heteroaryl and carbocyclic aiyl groups for the substituents of the CiCfi aliphatic group represented by R^a is optionally and independently substituted with one or more instances of J^E1; ii) a C3-C_s non-aromatic carbocycle, or a 4-8 membered non-aromatic heterocycle, each of which is optionally and independently substituted with one or more instances of J^El; iii) a 5-10 membered heteroaryl, or 6-10 membered carbocyclic aryl group, each of which is optionally and independently substituted with one or more instances of J^E1.

Alternatively, each R^a is independently: i) a Ci-Ce aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C6 alkyl), -N(Ci-Ce alkyl)2, -C(O)O(Ci-Cealkyl), -OC(O)(C,-C6-alkyl), -CO2H, -C(O)NH2, -C(O)NH(Ci-C6 alkyl), -C(O)N(Ci-C6 alkyl)2, -NHC(O)(Ci-C6 alkyl), -N(Ci-C6 alkyl)C(O)(Ci-C6 alkyl), -O(Ci-C6 alkyl), C(O)(Ci-C6-alkyl), C3-C8 non-aromatic carbocycle, 6-10 membered carbocyclic aryl, 4-8 membered non-aromatic heterocycle, and 5-10 membered heteroaryl; wherein each of said alkyl groups for the substituents of the C, -Cg aliphatic group represented by R^a is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C4 alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C4 alkyl), and CrC₄ alkoxy; and wherein each of said carbocycle, phenyl, non-aromatic heterocycle, and heteroaryl groups for the substituents of the Ci-Ce aliphatic group represented by R^a is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-Cg alkyl, -NH₂, -NH/Ci-Ce alkyl), N(Ci-C₆ alkyl)₂, -C(O)O(Ci-C₆-alkyl), -OC(O)(C_t-C₆-alkyl), -CO₂H, -C(O)NH₂, -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ct-C₆ alkyl)₂, -NHC(O)(Ct-Ce alkyl), -N(Ci-C₆

-29WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 alkyl)C(O)(Ci-C<> alkyl), -OfCi-Cg alkyl), and --C(O)(Ci-Cfi-alkyl), each said alkyl groups being optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C!-C₄ alkyl), -CO₂H, -CO₂(C_rC₄ alkyl), and C_rC₄ alkoxy; ii) a CvCg non-aromatic carbocyclic group, or a 4-8 membered, non-aromatic heterocyclic group, each of which is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₆ alkyl, -NH₂, -NH(Ci-Ce alkyl), -N(C_t-C₆ alkyl)₂, -C(O)O(C,-C₆-alkyl), -OC(O)(Ci-C₆-alkyl), -CO₂H, -C(O)NH₂, -C(O)NH(C_t-C_c alkyl), -C(O)N(Ci-C₆ alkyl)₂, NHC(O)(Ci-C₆ alkyl), -NCG-Q alkyl)C(O)(Ci-C6 alkyl), -O(Ci-C₆ alkyl), and-C(O)(Ci-C₆alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(C_rC₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_t-C₄allcyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy; or iii) a 5-10 membered heteroaryl group ora 6-10 membered carbocyclic aryl group, each of which is optionally and independently substituted with one or more instances of halogen, cyano, hydroxy, oxo, Ci-Ce alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(CrC₆ alkyl)₂, -C(O)O(C_rC₆-alkyl), -OC(O)(Ci-C₆alkyl), -CO₂H, -C(O)NH₂, -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ci-C6 alkyl)₂, -NHC(O)(Ci-C₆alkyl), -NiG-Ce alkyl)C(O)(C_t-C₆ alkyl), -O(Ci-C₆ alkyl), and -C(O)(Ci-C₆-alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Cj-C₄ alkyl), -N(Cj-C₄ alkyl)₂, -OCO(C]-C₄ alkyl), -CO(Cj-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy.

Specifically, R^J is independently: i) a Ci-Ce aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of halogen; cyano; hydroxy; oxo; -NH₂; -NH(C!-C₆ alkyl); -N(Ci-C₆ alkyl)₂; -C(O)O(Ci-C₆-alkyl); OC(O)(Ci-C₆-alkyl); -CO₂H; -O(Ci-C6 alkyl); -C(O)(Ci-C₆-alkyl); and a C3-C7 non-aromatic carbocyclic group, phenyl group, 4-7 membered non-aromatic heterocyclic group, or 5-6 membered heteroaryl group, each of which is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-Ce alkyl, -NH₂, -NH(Ci-Ce alkyl), -N(Ci-Ce alkyl)₂, -C(O)O(Ci-C₆-alkyl), -OC(O)(Ci-C₆-alkyl), -CO₂H, -O(Ci-C₆ alkyl), and -C(O)(C_rC₆-alkyl); ii) a C₃-C₇ nonaromatic carbocyclic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C6

-30WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 alkyl, -NH₂, -NH^-Cc alkyl), -N(Ci-C₆ alkyl)₂, -C(O)O(Ci-C₆-alkyl), -OC(0)(Ci-C₆alkyl), -CO₂H, -O(Ci-Cg alkyl), and-C(O)(Ci-Cfi-alkyl); iii) a 4-7 membered, non-aromatic heterocyclic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-Cg alkyl, -NH₂, NH(Ci-C₆ alkyl), -N(C]-C₆ alkyl)₂, -C(O)O(Ci-C₆-alkyl), -OC(O)(Ci-C₆-alkyl), -CO₂H, -O(Ci-Cfi alkyl), and -C(O)(Ci -Ce-alkyl); iv) a 5-6 membered heteroaryl group or a phenyl group, each of which is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₆ alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C_e alkyl)₂, -C(O)O(Ci-C₆-alkyl), OC(O)(Ci-C₆-alkyl), -CO₂H, -O(Ci-C₆ alkyl), and -C(O)(Ci-C₆-alkyl). Each of the alkyl groups referred to in the values of R^a, including substituents thereof, independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C4 alkyl)₂, -OCO(C!-C4 alkyl), -CO(Ci-C₄ alkyl), -C0₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy.

Specifically, the optionally substituted Ci-Cg aliphatic group represented by R^a is an optionally substituted Ci-Ce alkyl group.

R^b and R^c are each independently R^a or -H; or optionally, R^b and R^c, together with the nitrogen atom(s) to which they are attached (e.g., represented by -NR^bR^e, ~C(O)NR^bR^c, -NRC(O)NR^bR^c, or -OCONR^bR^c), each independently form a non-aromatic, 5-7 membered, heterocyclic ring that is optionally substituted with one or more instances of J^E1. Suitable specific substituents for the heterocyclic ring formed with R^b and R^c independently include halogen, cyano, hydroxy, oxo, amino, carboxy, amido, Ci-Cs alkyl, Cj-Ce haloalkyl, Ci-Ce cyanoalkyl, C2-Ce-alkoxy alkyl, Ci.-Cg aminoalkyl, Ci-Ce hydroxy alkyl, Ct-Cs alkoxy, Ci-Cs haloalkoxy, Ci-Cg aminoalkoxy, Ci-Cscyanoalkoxy, Ct-Cc> hydroxyalkoxy, C2-Ce alkoxy alkoxy, and -C(O)(C]-C6-alkyl). Specific suitable substituents for the heterocyclic ring formed with R^b and R^c independently include halogen, cyano, hydroxy, oxo, -NH2, -NH(CiC4 alkyl), -N(Ci-C₄ alkyl)₂, C1-C4 alkyl, C1-C4 haloalkyl, C]-C₄ hydroxyalkyl, C₂-C₄alkoxyalkyl, C1.C4 alkoxy, C1-C4 haloalkoxy, C1-C4 hydroxyalkoxy, C₂-C₄ alkoxyalkoxy, -CO₂(Ci-C₄ alkyl), -OC(O)(C_rC₄ alkyl), and -C0₂H.

It is understood that selections of suitable substituents for the heterocyclic ring formed with R^b and R^c are those that result in the formation of stable or chemically feasible compounds. For example, suitable substituents on a carbon atom independently include halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-Cs alkyl), -N(Ci-C₆ alkyl)₂, Cj-Cg alkyl, Ci-Cg haloalkyl, Ci-Cg hydroxyalkyl, C₂-Cg alkoxyalkyl, Ci-Cg aminoalkyl, Ci-Ce cyanoalkyl, Cj-31WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

C_G alkoxy, Ci-C_G haloalkoxy, Ci-C_G-aminoalkoxy, Ci-C_G-cyanoalkoxy, Ci-C_Ghydroxyalkoxy, C₂-C_G-alkoxyalkoxy, -C(O)(Ci-C_G-alkyl), -C(O)O(Ci-C_G-alkyl), -OC(O)(CiC6-alkyl), -CO₂H, -C(O)NH₂, -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ci-C₆ alkyl)₂, -NHC(O)(CiC_G alkyl), and -N(Ci-Ce alkyl)C(O)(Ci-C_G alkyl). In another example, suitable substituents on a carbon atom independently include halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄alkyl), -N(C|-C₄ alkyl)₂, C1-C4 alkyl, C1-C4 haloalkyl, Ci-C₄ hydroxyalkyl, C₂-C₄alkoxy alkyl, Ci_C₄ alkoxy, Ci-C₄ haloalkoxy, C₂-C₄ hydroxy alkoxy, C₂-C₄ alkoxy alkoxy, CO(Ci-C₄ alkyl), -CO₂(Ci-C₄ alkyl), and -CO₂H. For example, suitable substituents on a nitrogen atom independently include Ci-C_G alkyl, Ci-C_G haloalkyl, Ci-C_G hydroxyalkyl, C₂-C_Galkoxyalkyl, Ci-C_G aminoalkyl, Ci-C_G cyanoalkyl, -C(O)(Ci-C_G-alkyl), -C(O)O(Ci-C_G-alkyl), -OC(O)(Ci-C_G-alkyl), -CO₂H, -C(O)NH₂, -C(O)NH(Ci-C₆ alkyl), and -C(0)N(OC_G alkyl)₂. In another example, suitable substituents on a nitrogen atom independently include Ci-C₄alkyl, Ci-C₄ haloalkyl, C1-C4 hydroxyalkyl, C₂-C₄ alkoxyalkyl, Ci-C₄ alkoxy, C1-C4 haloalkoxy, C₂-C₄ hydroxy alkoxy, -CO(Ci-C₄ alkyl), -CO₂(Ct-C₄ alkyl), and -CO₂H. [00130] Each R^d is independently -H, C’i-CG alkyl or -C(O)(Ci-CG alkyl), wherein each of said alkyl moiety is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C4 alkyl), -N(CrC4 alkyl)2, -OCO(Ci-C4 alkyl), -CO(CrC4 alkyl), -CO2H, -CO2(Cr C4 alkyl), and Ci-C4 alkoxy. Specifically, each R^d is independently -H, or Cj-CG alkyl optionally substituted with one or more groups selected from halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(C_rC₄ alkyl)₂, -OCO(C_rC₄ alkyl), -CO(C_t-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy.

p is independently 1, 2, 3 or 4, Specifically, p is independently 1 or 2.

k, n and m are each independently 0, 1 or 2. Alternatively, when rings A and B are 3-

6-membered, n and m are each independently 0 or 1; and k is independently 0, 1 or 2; and when rings A and B are 7-8-membered, n and m, are each independently 0, 1 or 2; and k is independently 0,1 or 2.

x and y are each independently 0, 1 or 2.

z is 1 or 2.

[00131] A second set of variables of Structural Formulae (I) and (IA) is as follows: R² is -H or -CH₃.

R³ is -H, -Cl, -F, -Br, -CN, -CF₃, -O(Ci-C₄ alkyl), -OH, -NH₂, -NH(C_rC₄ alkyl), or -N(C!-C₄ alkyl)₂.

Values of the remaining variables of Structural Formulae (I) and (IA), including

-32WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 specific values, and provisos are each and independently as described above for the first set of variables of Structural Formulae (I) and (IA).

[00132] A third set of variables of Structural Formulae (I) and (IA) is as follows:

R² is -H or -CHj.

R⁴ is i) an optionally substituted C3-C10 carbocyclic ring; ii) a Ci-Ce aliphatic group (e.g., Cj-Cg alkyl or C₂-Cg alkenyl group) that is substituted with one or more substituents independently selected from the group consisting of J^c, an optionally substituted, Cs-Cs nonaromatic carbocycle, and an optionally substituted, 4-10 membered non-aromatic heterocycle; or iii) an optionally substituted, 4-10 membered non-aromatic heterocycle.

Values of the remaining variables of Structural Formulae (I) and (IA), including specific values, and provisos are each and independently as described above for the first set of variables of Structural Formulae (I) and (IA).

[00133] A fourth set of variables of Structural Formulae (I) and (IA) is as follows:

R² is -H or -CH3.

R³ is -H, -Cl, -F, -Br, -CN, -CF₃, -O(Ci-C₄ alkyl), -OH, -NH₂, -NH(Ci-C₄ alkyl), or -N(Ci-C₄ alkyl)₂.

R⁴ is selected from formulae A-D depicted above.

The remaining variables of Structural Formulae (I) and (IA), including specific values, are each and independently as described above for the first set of variables of Structural Formulae (I) and (IA).

[00134] A fifth set of variables of Structural Formulae (I) and (IA) is as follows:

R² is-H or-CH₃.

R³ is -H, ~F, -Cl, “CF3, -NH₂, -NHMe or -NMe₂,

R⁴ is i) an optionally substituted C3-C10 carbocyclic ring; ii) a Ci-Ce aliphatic group (e.g., Ci-Cg alkyl or C₂-Cg alkenyl group) that is substituted with one or more substituents independently selected from the group consisting of J^c, an optionally substituted, CrCg nonaromatic carbocycle, and an optionally substituted, 4-10 membered non-aromatic heterocycle; or iii) an optionally substituted, 4-10 membered non-aromatic heterocycle.

[00135] A sixth set of variables of Structural Formulae (I) and (IA) is as follows:

R² is -H or -CH3.

R³ is -H, -F, -Cl, -CF₃, -NH_2j -NH(CH₃), or -N(CH₃)2.

-33WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

R⁴ is selected from formulae A-D depicted above.

Values of the remaining variables of Structural Formulae (I) and (IA), including specific values, are each and independently as each and independently as described above for the first set of variables of Structural Formulae (I) and (IA).

[00136] A seventh set of variables of Structural Formulae (I) and (IA) is as follows:

R² is -H or -CH₃.

R³ is -H, -F, or -Cl.

R⁴ is i) an optionally substituted C3-Cio carbocyclic ring; ii) a Ci-Ce aliphatic group (e.g., Ci-Cf, alkyl or C2-Cc alkenyl group) that is substituted with one or more substituents independently selected from the group consisting of J^c, an optionally substituted, C3-Cs nonaromatic carbocycle, and an optionally substituted, 4-10 membered non-aromatic heterocycle; or iii) an optionally substituted, 4-10 membered non-aromatic heterocycle.

Values of the remaining variables of Structural Formulae (I) and (IA), including specific values, and provisos are each and independently as each and independently as described above for the first set of variables of Structural Formulae (I) and (IA).

[00137] An eighth set of variables of Structural Formula I is as follows:

R² is-H or-CH₃.

R³is-H,-F, or-Cl.

R⁴ is selected from formulae A-D depicted above.

[00138] A ninth set of variables of Structural Formulae (I) and (IA) is as follows:

R² is -H.

R³ is -H or -Cl.

R⁴ is i) an optionally substituted C3-Cio carbocyclic ring; ii) a C1-C7 aliphatic group (e.g., Ci-Ce alkyl or C2-Cc, alkenyl group) that is substituted with one or more substituents independently selected from the group consisting of J^c, an optionally substituted, C3-Cs nonaromatic carbocycle, and an optionally substituted, 4-10 membered non-aromatic heterocycle; or iii) an optionally substituted, 4-10 membered non-aromatic heterocycle.

[00139] A tenth set of variables of Structural Formulae (I) and (IA) is as follows:

-34WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

R² is -H.

R³ is ~H or -Cl.

R⁴ is selected from formulae A-D depicted above.

Values of the remaining variables of Structural Formulae (I) and (IA), including specific values, and provisos are each and independently as each and independently as described above for the first set of variables of Structural Formulae (I) and (IA). [00140] An eleventh set of variables of Structural Formulae (I) and (IA) is as follows:

Each of R², R³ and R⁴ is independently as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth set of variables of Structural Formulae (I) and (IA).

Z¹ is -H, Ci-Ce alkyl, -O(CrC6 alkyl), -F, -Cl, -CN, -CO2H, -CO2(Ci-C6 alkyl), -CONH2, -CONH(Ci-Ce alkyl), or -CON(Ci-Cg alkyl)2; and Z² is -H, Ci-C6 alkyl, -O(Ci-C₆alkyl), -NH₂, -NH(Ci-Cg alkyl), or -N(Ci-Cg alkyl)?; wherein each of said alkyl groups (e.g., represented by Ct-C₆ alkyl, -O(Ci-C₆ alkyl), -CO₂(Ci-C₆ alkyl), -NH(Ci-Cg alkyl), and -N(Ci-Cg alkyl)₂) is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(C_rC₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C|-C₄ alkyl), -CO₂H, -CO₂(CiC₄ alkyl), and C1-C4 alkoxy.

[00141] A twelfth set of variables of Structural Formulae (I) and (IA) is as follows:

Z¹ is ~H, -F, -Cl, C1-C4 haloalkyl (e.g, -CF₃), C;-C₄ alkyl, -O(C_rC₄ alkyl), or -CN.

Z² is -H, Ci-Ce alkyl, -O(Ci-C₆ alkyl), -NH₂, -NH(Ci-C₀ alkyl), or -N(C_s-Cg alkyl)₂; wherein each of said alkyl groups (e.g., represented by Ci-Ce alkyl, -O(Ci-Cg alkyl), -NH(C_rCg alkyl), and -N(Ci-Cg alkyl)₂) is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(C_t-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CC>2(Ci-C₄ alkyl), and C1-C4 alkoxy.

-35WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00142] A thirteenth set of variables of Structural Formulae (I) and (IA) is as follows:

Each of R², R³ and R⁴ is independently as described in the first set, second set, third set, fourth set, fifth set, sixth set, seventh set, eighth set, ninth set, or tenth set, of variables of Structural Formulae (I) and (IA).

Z¹ is -H, -F, -Cl, C1-C4 haloalkyl (e.g, -CF₃), C1-C4 alkyl, -O(Ci-C₄ alkyl), or -CN.

Z² is -H or a Ci-C_G alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NHz, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_rC₄ alkyl), -CO₂H, -CO₂(CiC₄ alkyl), and Ci-C₄ alkoxy.

[00143] A fourteenth set of variables of Structural Formulae (I) and (IA) is as follows:

Z¹ is -H, -F, -Cl, -CF₃, -CH_s, or-CN.

Z² is -H or a C|-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(C_rC₄ alkyl)₂, -OCO(C,-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(CiC₄ alkyl), and Ci-C₄ alkoxy.

[00144] In a fifteenth set of variables of Structural Formulae (I) and (IA), values of the the variables, except R*, R and R’, of Structural Formulae (I) and (IA), including specific values, and provisos are each and independently as described above in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth set of variables of Structural Formulae (I) and (IA); and, where applicable:

each R* independently is: i) -Η; n) Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano,

-36WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_rC₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy; or iii) a 3-7 membered carbocyclic ring optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), Ci-C₄ alkoxy, and Ci-Ce alkyl, wherein each alkyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(C_rC₄ alkyl)₂, -OCO(C_rC₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy; and

R and R’ are each independently -H or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-Ce alkyl), -N(Ci-Ce alkyl)₂, and -O(Ci-Ce alkyl); or optionally R’, together with R⁵ and the nitrogen atom to which they arc attached, forms a 5-7 membered, non-aromatic, heterocyclic ring optionally substituted with one or more instances ofJ^D1.

[00145] A sixteenth set of variables of Structural Formulae (I) and (IA) is as follows:

Each of J^A and J^B is independently selected from the group consisting of halogen, cyano, oxo, andQ^!-R⁵; or optionally two J^A and two J^B, respectively, together with the atom(s) to which they are attached, independently form a 5-7 membered ring that is optionally substituted with one or more instances of J^E1, and fused to the ring to which they are attached.

Q¹ is independently a bond, -0-, -S-, -NR’-, -C(O)-, -CO2-, -OC(O)-C(O)NR’-, -C(O)NRC(O)O- -NRC(O)NRC(O)O~, -NRC(O)-, -NRC(O)NR’-, -NRCO2-, -OC(O)NR’-, -S(O)-, -SO2- -SO2NR’-, -NRSO2~, or-NRSO2NR’-, or(CR⁶R⁷)P-Y¹-.

Each of J^C1 and J^D1 is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a, -SO2R^a, -NR^bR^c, -C(O)R^b, -C(O)OR^b, -OC(O)R^b, -NRC(O)R^b, -C(O)NR^bR^c, -NRC(O)NR^bR^c, -NRC(O)OR^b, -OCONR^bR°, -C(O)NRCO2R^b, -NRC(O)NRC(O)OR^b, -C(O)NR(OR^b), -SO2NR^cR^b, -NRSO2R^b, and -NRSO₂NR^cR^b, or optionally, two J^C1 and two J^D1, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^EI, and fused to the respective ring to which they are attached.

Values of the remaining variables of Structural Formulae (I) and (IA), including specific values, and provisos are each and independently as described above for the first,

-37WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth set of variables of Structural Formulae (I) and (IA).

[00146] A seventeenth set of variables of Structural Formulae (I) and (IA) is as follows:

R¹ is -H.

R² is -H, -CH3, -CH2OH, or -NH2. Alternatively R² is -H or -CH20H.

R³ is -H, -F, -Cl, Cm alkyl, or Ci_₄ haloalkyl. Alternatively, R³ is -H, -F, or -Cl.

Z¹ is -H, -F, or -Cl.

Z² is -H or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C₄alkyl).

Z³ is -H or Cj-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C₄alkyl).

The remaining variables are as decribed above in any set of variables for Structural Formulae (IA) and (I) as applicable.

[00147] An eighteenth set of variables of Structural Formulae (I) and (IA) is as follows:

R¹ is -H.

R² is -H or -CH₂OH.

R³ is -H, -F, or -Cl. Alternatively R³ is -F or -Cl.

Z¹ is-H,-F, or-Cl.

Z² and Z³ are -H.

The remaining variables are each and independently as decribed above in any set of variables for Structural Formulae (IA) and (I).

[00148] A nineteenth set of variables of Structural Formulae (I) and (IA) is as follows: R⁵ is; i) -H; ii) an optionally substituted Ci-CG alkyl group; iii) an optionally substituted, C3-C7 non-aromatic carbocycle; iv) an optionally substituted, 4-7 membered nonaromatic heterocycle; v) )an optionally substituted phenyl group; vi) an optionally substituted 5-6 membered heteroaryl ring; or optionally, together with R and the nitrogen atom to which it is attached, form a 5-7 membered, optionally substituted non-aromatic heterocycle; and said alkyl group represented by R⁵ is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C₄ alkyl), -N(C_t-C₄ alkyl)₂, -OCO(C_rC₄ alkyl), -CO(C_rC₄ alkyl),

-38WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

-CO₂H, -CO₂(C_i-C₄ alkyl), C1-C4 alkoxy, -NRCO(Ci-C₄ alkyl), -CONR(Ci-C₄ alkyl), -NRCO₂(Ci-C₄ alkyl), a C3-C7 non-aromatic carbocycle optionally substituted with one or more instances of J^E1, a 4-7 membered non-aromatic heterocycle optionally substituted with one or more instances of J^Ei; and a phenyl optionally substituted with one or more instances of J^E1; and wherein each of said carbocycle, heterocycle, phenyl and heteroary represented by R⁵is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -O(Ci-C₄alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄alkyl), -C(O)O(Ci-C₄ alkyl) and -CO₂H, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Cj-C₄ alkyl)₂, -OCO(C_t-C₄ alkyl), -CO(C_t-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C_rC₄ alkoxy.

R , R , R , Z , Z, and Z are each independently as described in the seventeenth or eighteenth set of variables above.

100149] In some embodiments, the variables of Structural Formulae (IA) and (I) are each and independently as described above in any set of variables, provided that: R⁴ is:

n and m are each independently 0 or 1 when rings A and B are 3-6-membered; or n and m are each independently 0,1 or 2 when rings A and B are 7-10-membered; and provided that ifY¹ is a bond, then R⁵ is neither-H nor a Ci-Ce aliphatic group; and provided that if each Q² and Q³ independently is a bond, then R⁵ is neither -H nor a Ci-Ce aliphatic group.

[00150] In another embodiment, the present invention is directed to the use of compounds represented by any one of the Structural Formulae II, III, IV, and V, depicted below, or pharmaceutically acceptable salts thereof, for any of the uses described above:

-39WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

(IV) (V).

[00151] The first set of variables of Structural Formulae II - V is as follows:

Z² is -H, Ci-C₆ alkyl, -O(Ci-C₆ alkyl), -NH₂, -NH(C]-C₆ alkyl), or -N(C_rC₆ alkyl)₂, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy.

R³ is -H, -Cl, -F, -Br, -CN, -CF3, -O(Ci-C4 alkyl), -OH, -NH2, -NH(Ci-C4 alkyl), or -N(Ci-C4 alkyl)2. Specifically, R³ is -H, -F, -Cl, -CF3, ~NH₂, -NH(CH₃), or -N(CH₃)₂. Specifically, R³ is -H, -Cl, or -F. Specifically, R³ is -Cl.

Each R and R’ are independently -H or Ci-C ealkyl.

Definitions of rings A-D of formulae II-V, including specific variables, are each and independently as described above for the first set of variables of Structural Formulae (I) and (IA), wherein each of rings A-D is independently an optionally substituted, 4-7 membered ring.

Values of the remaining variables of Structural Formulae II-V, including specific values, and provisos arc each and independently as described above for the first set of variables of Structural Formulae (I) and (IA).

[00152] A second set of variables of Structural Formulae II, III, IV and V is as follows:

-40WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Z¹ is -H, -F, -Cl, -CF₃, -CH₃, or-CN.

Z² is -H or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(C_£-C₄ alkyl), -N(C_rC₄ alkyl},, -OCO(C_rC₄ alkyl), -CO(C,-C₄ alkyl), -CO₂H, -CO₂(CiC₄ alkyl), and Ci-C₄ alkoxy.

Values of the remaining variables of Structural Formulae II-V, including specific values, and provisos are each and independently as described above for the first set of variables of Structural Formulae II-V.

[00153] A third set of variables of Structural Formulae II, III, IV and V is as follows: Z¹ is-H,-F or-CN.

Z² is -H or Ci-Cc alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(C_t-C₄ alkyl)₂, -OCO(C_t-C₄ alkyl), -CO(C_£-C₄ alkyl), -CO₂H, -CO₂(CiC₄ alkyl), and Ci-C₄ alkoxy.

[00154] A fourth set of variables of Structural Formulae II, III, IV and V is as follows: Z¹ is-H,-F or-CN.

Z² is -Η or Ct-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(C_£-C₄ alkyl), -C0(C_t-C₄ alkyl), -CO₂H, -CO₂(CiC₄ alkyl), and C1-C4 alkoxy.

R³ is -H, -Cl or -F.

[00155] A fifth set of variables of Structural Formulae II, III, IV and V is as follows:

Z^l is-H,-F or-CN.

Z² is -H or Ct-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(C_rC₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_t-C₄ alkyl), -CO₂H, -CO₂(C_rC₄ alkyl), and C_£-C₄ alkoxy.

R³ is -H, -Cl, -F, -CF₃,-NH₂, -NH(CH₃), or-N(CH₃)₂.

-41WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

R⁶ and R⁷ are each independently -H or -CH3, or together with the carbon atoms to which they are attached they form a cyclopropane ring.

Each R⁸ is independently -H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), or -N(Ci-C₄ alkyl)₂.

Each R⁹ is independently -H or -CH3.

R¹¹ and R¹² are each independently -H or -CH3.

R¹³ and R¹⁴ are each independently -H or -CH3, or together with the carbon atoms to which they are attached they form a cyclopropane ring.

[00156] A sixth set of variables of Structural Formulae II, III, IV and V is as follows:

Z¹ is-H, -F or-CN.

Z² is -H or an optionally substituted Ci-Cc alkyl.

R³ is-H,-Clor-F.

Each R⁸ is independently -H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl) or -N(Ci-C₄ alkyl)₂.

Each R⁹ is independently -H or -CH₃.

R¹¹ and R¹² are each independently -H or-CH3.

R¹³ and R¹⁴ are each independently -H or-CH₃, or together with the carbon atoms to which they are attached they form a cyclopropane ring.

[00157] In a seventh set of variables of Structural Formulae II-V, values for variables, except R⁶, R⁷, R⁸, R⁹, R¹¹, R¹², R¹³, and R¹⁴, of Structural Formulae II-V, including specific values, are each and independently as described above for the first, second, third, or fourth set of variables of Structural Formulae II-V; and

R⁶ and R⁷ arc each independently -H or -C1-C4 alkyl, or together with the carbon atoms to which they are attached they form a cyclopropane ring.

-42WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Each R^s is independently -H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(C!-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl) or -N(Ci-C₄ alkyl)₂.

Each R⁹ is independently -H or -Ci-C₄ alkyl.

R¹¹ and R¹² are each independently -H or-Ci-C₄ alkyl.

R¹³ and R¹⁴ are each independently -H or -C1-C4 alkyl, or together with the carbon atoms to which they are attached they form a cyclopropane ring.

[00158] In an eighth set of variables of Structural Formulae II-V, values for variables of Structural Formulae II-V, including specific values, are each and independently as described above for the first set of variables of Structural Formulae II-V.

It is provided that when Q²-R⁵ is -OR⁵ or -NR’R⁵, ring A is further substituted with one or more instances of J^A other than -H.

It is provided that if Q³ is -C(O)-, then R⁵ is a substituted Ci-Ce aliphatic group (e.g., Cj-Ce alkyl group or C2-Ce alkenyl group); an optionally substituted Cs-Cs non-aromatic carbocyclc; an optionally substituted, 6-10-membcred carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroaryl group. In one embodiment, the Ci-Ce aliphatic group is substituted with one or more instances of J^C1, wherein J^CI is independently selected from: an optionally substituted, C3-Cs non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aiyl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; an optionally substituted, 5-10 membered hetcroaryl group; -OR^b; -SR^b; -S(O)R^a; -SO2R^a; -NR^bR°; -C(O)R^b; -C(O)OR^b; -OC(O)R^b; -NRC(O)R^b; -C(O)NR^bR^c; -NRC(O)NR^bR^c; -NRC(O)OR^b; -OCONR^bR^c; -C(O)NRCO2R^b; -NRC(O)NRCO2R^b; -C(O)NR(OR^b); -SO2NR^cR^b; -NRSO2R^b; and -NRSO2NR^cR^b; or optionally two J^CI and two J^D1, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^E1, and fused to the respective ring to which they are attached.

[00159] In a ninth set of variables of Structural Formulae II-V, values for variables of Structural Formulae II-V, including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

[00160] A tenth set of variables of Structural Formulae II-V is as follows:

Each of J^A and J^B is independently selected from the group consisting of halogen, cyano, oxo, and Q^R⁵; or optionally two J^A and two J^B, respectively, together with the atom(s) to which they are attached, independently form a 5-7 membered ring that is

-43WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 optionally substituted with one or more instances of J^E1, and fused to the ring to which they are attached.

Q^! is independently a bond, -O-, -S-, -NR- -C(O)~, -CO2- -OC(O)-, -C(O)NR- -C(0)NRC(0)0- -NRC(0)NRC(0)0-, -NRC(O)-, -NRC(O)NR-NRCO2-, -OC(O)NR- -S(O)-, -SO2~, -N(R)SO2- -SO2N(R)-, -NRSO2NR-, or -(CR⁶R⁷)p-Y¹-.

Q² is independently a bond, -O-, -S-, -NR-, -0(0)-, -CO2-, -OC(O)-C(O)NR- -C(O)NRC(O)O~, -NRC(O)NRC(O)O-, -NRC(O)-, -NRC(0)NR-, -NRCO2-, -OC(O)NR- -S(O)-, -SO2- -N(R)SO2-, -SO2N(R)-, -NRSO2NR-, or -(CR^VY¹Q³ is independently a bond, -C(O)~, -CO2-, -C(0)NR-, -SO₂--S0₂N(R)-, -C(0)NRC(0)0- or -(CR⁶R⁷)p-Y-.

R⁵ is: i) -H; ii) a Ci-Cg aliphatic group optionally substituted with one or more instances of J^C1; iii) aC₃-Cs non-aromaticcarbocycle, or 6-10 membered carbocyclic aryl group, each optionally and independently substituted with one or more instances of J^CI; or iv) a 4-8 membered non-aromatic heterocycle, or a 5-10 membered heteroaryl group, each optionally and independently substituted with one or more instances of J^D1.

Each of J^CI and J^D1 is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a, -SO2R^a, -NR^bR^c, -C(O)R^b, -C(O)OR^b, -OC(O)R^b, -NRC(O)R^b, -C(O)NR^bR^c, -NRC(O)NR^bR^c, -NRC(O)OR^b, -OCONR^bR^c, -C(O)NRCO2R^b, -NRC(O)NRC(O)OR^b, -C(O)NR(OR^b), -SO2NR^cR^b, -NRSO2R^b, and -NRS0₂NR^cR^b, or optionally, two J^C1 and two J^D1, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of Jⁿ, and fused to the respective ring to which they are attached.

Ring A is a C₃-Cg non-aromatic carbocycle optionally and independently further substituted with one or more instances of J^A.

Values of the remaining variables of Structural Formulae II-V, including specific values, and provisos are each and independently as described above for the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth set of variables of Structural Formulae IIV.

[00161] In another embodiment, the present invention is directed to the use of compounds represented by the Structural Formula below XI(A) or XI(B), or a pharmaceutically acceptable salt thereof, for any of the uses described above.

-44WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

XI(A) XT{B)

A first set of variables of Structural formulae XI(A) and XI(B) is as follows:

Ring A is a 5-7 membered, non-aromatic carbocyclic ring optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C_G alkyl, C₂-C_G alkenyl, -NH₂, -NHfCi-Cfi alkyl), -N(Ci-Ce alkyl)₂, -O(Ci_C₆ alkyl), -C(O)NH₂, -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ci-C₆ alkyl)₂, C(O)(Ci-C₆-alkyl), ~OC(O)(Ci-C₆ alkyl), -NHC(O)(Ci-C₆ alkyl), -N(C_rC₆ alkyl)C(O)(C_rQ alkyl), and -CO2R^b; wherein each of said alkyl and alkenyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Cj-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy. Specifically, ring A is a 5-7 membered, non-aromatic carbocyclic ring optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(C]-C₄ alkyl), -NH2, -NH(C]-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(C_rC₄ alkyl), -OC(O)(Ci-C₄ alkyl), -CO₂H, and -CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and indepednently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(C,-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy. Specifically, ring A is a 5-7 membered carbocyclic ring optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₂ alkyl), --NH(Ci-C2 alkyl)₂, Ci-C₂ alkyl, C1-C2 haloalkyl, Ci-C₂ hydroxyalkyl, C₂-C₄ alkoxyalkyl, CiC₂ alkoxy, C1-C2 hydroxyalkoxy, Ci-C₂ haloalkoxy, C₂-C₄ alkoxy alkoxy, -CO₂H, and CO₂(Ci-C₄ alkyl).

R⁶ and R⁷ are each independently -H or -CH₃, or together with the carbon atoms to which they are attached they form a cyclopropane ring.

-45WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Each R⁸ is independently -H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C_rC₄ hydroxyalkyl, C2-C4 alkoxyalkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), or -N(Ci-C₄ alkyl)₂.

Each R⁹ is independently -H or -CH₃.

R¹¹ and R¹² are each independently -H or-CH₃.

R¹³ and R¹⁴ are each independently -H or -CH₃, or together with the carbon atoms to which they are attached they form a cyclopropane ring.

Each R and R’ are independently -H or Ci-Ce alkyl.

Values of the remaining variables of Structural formulae XI(A) and X1(B), including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

[00162] A second set of variables for Structural formulae XI(A) and XI(B) is as follows:

Values of Ring A, R, R’, R⁶, R⁷, R⁸, R⁹, R¹¹, R¹², R¹³ and R¹⁴, including specific values, arc each and independently as described above in the first set of variables of Structural formulae XI(A) and XI(B).

Variable x is 0 or 1 and variable n is 0 or 1.

Values of the remaining other variables of Structural formulae XI(A) and XI(B), including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

[00163] A third set of variables for Structural formulae XI(A) and XI(B) is as follows:

Values of Ring A, R, R’, R⁶, R⁷, R⁸, R⁹, Rⁿ, R¹², R¹³, R¹⁴, x and n, including specific values, are each and independently as described above in the second set of variables of Structural formulae XI(A) and XI(B).

Q² is -O-, -NR’-, -CO-, -CO2-, -C(O)NR’-, -NRC(O)-, -NRC(O)NR-NRCO2-, -OCONR’-, -NRSO2- -SO2NR’-, or -(CR⁶R⁷)p-Y‘-. Specifically, Q² is -O-, -NH-, -N(CH3)-, -C(O)-, -CO2-, -C(O)NH-, -C(O)N(CH3)-, -NHC(O)-, -N(CH3)C(O)-, -NHC(O)NR’-, -N(CH3)C(O)NR’-, -NHCO2-, -N(CH3)CO2-OC(O)NR’~, -NHSO2-, -N(CH3)SO2- -SO2NH-, -SO2N(CH3)-, or -(CR⁶R⁷)p-Y‘-.

Values of the remaining variables of Structural formulae XI(A) and XI(B), including specific values, and provisos arc each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

[00164] A fourth set of variables for Structural formulae XI(A) and XI(B) is as follows:

-46WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Values of Ring A, Q², R, R’, R⁶, R⁷, R^s, R⁹, Rⁿ,R¹², R¹³, R¹⁴, x and n, including specific values, are each and independently as described above in the third set of variables of Structural formulae XI(A) and XI(B).

R⁵ is independently i) -H; ii) a Ci-C6-aliphatic group (e.g., Ci-Ce-alkyl or C2-C6alkenyl group) optionally substituted with one or more instances of J⁰; iii) a C3-Cg nonaromatic carbocycle optionally substituted with one or more instances of J^CI; iv) a phenyl group optionally substituted with one or more instances of J^C1; v) a 4-8 membered nonaromatic heterocycle optionally substituted with one or more instances of J^Dt or vi) a 5-6 membered heteroaryl ring optionally substituted with one or more instances of J^D1.

Each of J^C1 and J^D1 is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a-, -SO2R^a, -NHR^C, -C(O)R^b, -C(O)OR^b, -OC(O)R^b, -NHC(O)R^b, -C(O)NHR^C, -NHC(O)NHR^C, -NHC(O)OR^b, ~OCONHR^C, -NHC(O)NHC(O)OR^b, -N(CH3)R^C, -N(CH3)C(O)R^b, -C(O)N(CH3)R^C, -N(CH3)C(O)NHR^C, -N(CH3)C(O)OR^b, -OCON(CH3)R^C, -C(O)NHCO2R^b, -C(O)N(CH3)CO2R^b, -N(CH3)C(O)NHC(O)OR^b, -NHSO₂R^b, -SO2NHR^b, -SO2N(CH₃)R^b, and -N(CH₃)SO2R^b.

Values of the remaining variables of Structural formulae XI(A) and XI(B), including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

[00165] A fifth set of variables for structure Structural formulae XI(A) and XI(B) is as follows:

Values of Q², R, R’, R⁵, R⁶, R⁷, R⁸, R⁹, Rⁿ,R¹², R¹³, R¹⁴, x and n, including specific values, are each and independently as described above in the fourth set of variables of Structural formulae XI(A) and XI(B).

Ring A is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄alkyl), ~NH₂, -NH(Ci-C₄ alkyl), -N(C_t-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -CO₂H, and CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(C_rC₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C_t-C₄ alkoxy.

[00166] A sixth set of variables for Structural formulae XI(A) and XI(B) is as follows:

-47WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Values of Q², R, R’, R⁵, R⁶, R⁷, R^s, R⁹, R¹¹, R¹², R¹³, R¹⁴, x and n, including specific values, are each and independently as described above in the fifth set of variables of Structural formulae XI(A) and XI(B).

The group ~[(C)o-iR^I3R¹⁴]-ringA-Q²-R⁵ is independently selected from one of the depicted below:

wherein each of rings A1-A27 is independently and optionally further substituted with one or more substituents. Suitable substituents are as described above for ring A in the first set of variables of Structural formulae XI(A) and XI(B).

Values of the remaining variables of Structural formulae XI(A) and XI(B), including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (1) and (IA).

[00167] A seventh set of variables of Structural formulae XI (A) and XI(B) is as follows:

Values of the group 4CR¹³R^t4]_x-ringA-Q²-R^s, Q², R, R’, R^e, R⁷, R⁸, R⁹, R¹¹, R¹², R¹³, R¹⁴, x and n, including specific values, are each and independently as described above in

-48WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 the sixth set of variables of Structural formulae XI(A) and XI(B).

Each R⁵ is independently: i) - H; ii) a Ci-Ce-aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Cj-C4 alkyl, -O(Ct-C4 alkyl), -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -C(O)(Ct-C4 alkyl), -OC(O)(Ct-C4 alkyl), -C(O)O(C!-C4 alkyl), -CO2H, C3-C8 nonaromatic carbocycle, phenyl, 4-8 membered non-aromatic heterocycle, and 5-6 membered heteroaryl; or iii) a C3-C? non-aromatic carbocycle, a 4-7 membered non-aromatic heterocycle, a phenyl group, or a 5-6 membered heteroaryl ring, each of which is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C4 alkyl, -O(Ci-C4 alkyl), -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -C(O)(Ci-C4 alkyl), -OC(O)(Ci~C4 alkyl), -C(O)O(Ci-C4 alkyl), and -CO2H; wherein each of said alkyl groups for the substituents of the aliphatic group, carbocycle, heterocycle, phenyl and heteroaryl group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_rC₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C,C₄ alkoxy; and wherein each of said carbocycle, phenyl, heterocycle, and heteroaryl for the substituents of the Ci-Ce-aliphatic group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C]-C₄ alkyl, -NH₂, -NH(Cj-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(C!-C₄ alkyl), -CO(C,-C₄ alkyl), -C0₂H, -CO₂(C,-C₄ alkyl), and C,-C₄ alkoxy.

Values of the remaining variables of Structural formulae XI(A) andXI(B), including specific values, and provisos are each and independently as described above in tire first set of variables of Structural Formulae (1) and (IA).

[00168] An eighth set of variables of Structural formulae XI(A) and XI(B) is as follows:

Values of Q², R, R’, R⁵, R⁶, R⁷, R⁸, R⁹, R¹¹, R¹², R¹³, R¹⁴, x and n, including specific values, are each and independently as described above in the seventh set of variables of Structural formulae XI(A) and XI(B).

The group -[(C)o-iR¹³R^I4]-ringA-Q²-R⁵ is independently selected from one of the depicted below

-49WO 2010/148197

PCI7US2010/038988

2018200219 11 Jan 2018

, wherein each of rings A6, A8, All, A14 and A15 is optionally and independently further substituted.

R⁸ independently is halogen, cyano, hydroxy, Ci-C₄ alkyl, Ci-C₄ haloalkyl, C1-C4 hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(Ci~C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), or -N(Ci~C₄ alky 1)₂.

[00169J A ninth set of variables of Structural formulae XI(A) and XI(B) is as follows:

Values of the group -[CR¹³R¹⁴]_x-ringA-Q²-R⁵, Q², R, R’, R⁶, R⁷, R⁸, R⁹, R¹¹, R¹², R¹³, R¹⁴, x and n, including specific values, are each and independently as described above in the eighth set of variables of Structural formulae XI(A) and XI(B).

R³ is: i) -H; ii) an optionally substituted Ci-Ce alkyl group; iii) an optionally substituted, C3-C7 non-aromatic carbocycle; or iv) an optionally substituted, 4-7 membered non-aromatic heterocycle. Each of said alkyl group represented by R³ is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -OCO(Ci-C4 alkyl), -CO(Ci-C4 alkyl), -CO2H, -CO2(Ci-C4 alkyl), C1-C4 alkoxy, optionally substituted, C3-C7 non-aromatic carbocycle, and optionally substituted, 4-7 membered non-aromatic heterocycle. Each of said carbocycles and heterocycles represented by R³, and referred to for the substituents of the Ci-Ce alkyl group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C4 alkyl), -NH₂₎ -NH(Ci“C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), and -CO₂H, wherein each of said alkyl groups (e.g,, represented by C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH(Ci-C₄ alkyl), -N(C!-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), and -C(O)O(Ci-C₄ alkyl)) is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy,

-50WO 2010/148197

PCI7US2010/038988 oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(C_rC₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy.

[00170] A tenth set of variables of Structural formulae XI(A) and XI(B) is as follows: Values of Q², R, R’, R⁵, R⁶, R⁷, R^s, R⁹, Rⁿ,R¹², R¹³, R¹⁴, x and n, including specific values, are each and independently as described above in the seventh set of variables of Structural formulae XI(A) and XI(B).

The group -[(C)o_iR¹³R¹⁴]-ringA~Q²-R⁵ is independently selected from one of the

wherein each of rings A1-A4, A7-A20, A22, A23, A25 and A27 is independently and optionally further substituted. Suitable substituents are as described above for ring A in the first set of variables of Structural formulae XI(A) and XI(B).

-51WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00171] An eleventh set of variables of Structural formulae XI(A) and XI(B) is as follows:

Values of Q², R, R’, R^s, R⁶, R⁷, R⁸, R⁹, R¹¹, R¹², R¹³, R¹⁴, x and n, including specific values, are each and independently as described above in the seventh set of variables of Structural formulae XI(A) and XI(B).

The group -[(C)o-iR¹³R¹⁴]-ringA-Q²-R⁵ is independently selected from one of the depicted below:

ORs

OR⁵

A21V-^ja· '''''OR⁵

NH

R⁵

wherein each of rings A5-A7, A21, A24 and A26 is independently and optionally further substituted. Suitable substituents are as described above for ring A in the first set of variables of Structure Formulae XI(A) and XI(B).

[00172] In a twelfth set of variables of Structural formulae XI(A) and XI(B), values of the variables for Structural formulae XI(A) and XI(B), including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

[00173] In a thirteenth set of variables of Structural Formulae XI(A) and XI(B), values of the variables for Structural Formulae XI(A) and XI(B), including specific values, are each and independently as described above in the sixteenth set of variables of Structural Formulae (I) and (IA), or in the tenth set of variables of Structural Formulae II-V.

[00174] In another embodiment, the present invention is directed to the use of compounds represented by Structural Formula below XII(A) or XII(B), or a pharmaceutically acceptable salt thereof, for any of the uses described above:

-52WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

(XIIA) (XIIB),

A first set of variables of Structural Formulae XII(A) and XII(B) is as follows:

Ring B is a 4-7 membered, non-aromatic, heterocyclic ring optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-Ccalkyl, Ci-Cgalkenyl, -NH₂, -NH(C|-Ce alkyl), -N(C_t-C₆alkyl)₂, -O(Ci.C₆ alkyl), -C(O)NH₂, -C(O)NH(C_t-C₆ alkyl), -Ο(Ο)Ν(Οι-Οδ alkyl)₂, C(O)(Ci-C₆-alkyl), -OC(O)(Ci-C_e alkyl), -NHC(O)(C_rC₆ alkyl), -N(C_rC₆ alky 1)C(O)(C iC₆ alkyl), and -CO₂R^b; wherein each of said alkyl and alkenyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C4 alkyl), -N(Ci-C₄ alkyl)₂, -OCO(C_rC₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(C_I-C₄ alkyl), and Ci-C₄ alkoxy. Specifically, Ring B is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(C,-C₄ alkyl), -CO₂H, and -CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ct-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -00₂(0[-0₄ alkyl), and C1-C4 alkoxy. Specifically, Ring B is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, NH(Ci-C₂ alkyl), -NH(C₍-C₂ alkyl)₂, C1-C2 alkyl, C1-C2 haloalkyl, C1-C2 hydroxyalkyl, C₂C₄ alkoxyalkyl, C1-C2 alkoxy, C1-C2 hydroxyalkoxy, Ci-C₂ haloalkoxy, C2-C4 alkoxyalkoxy, -CO2H, and -CO₂(Ci-C₄ alkyl).

R⁹ is -H or -CH₃.

R¹¹ and R¹² are each independently -H or-CH₃.

-53WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Each R and R’ are independently -H or Ci-C’g alkyl.

Values of the remaining variables of Structural Formulae XII(A) and XII(B), including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

[00175] A second set of variables of Structural Formulae XII(A) and XII(B) is as follows:

Values of Ring B, R, R’, R⁶, R⁷, R⁹, R¹¹, R¹², R¹³ and R¹⁴, including specific values, are each and independently as described above in the first set of variables of Structural Formulae XII(A) and XII(B).

Variable y = 0 or 1.

Values of the remaining variables of Structural Formulae ΧΠ(Α) and XI1(B), including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (I) and (IA), [00176] A third set of variables of Structural Formulae XII(A) and XII(B) is as follows:

Values of Ring B, R, R’, R⁶, R⁷, R⁹, R¹¹, R¹², R¹³ and Rⁱ⁴ and y, including specific values, are each and independently as described above in the second set of variables of Structural Formulae XII(A) and XII(B),

Q³ is independently -C(O)-, -CO₂- -C(O)NH- -C(O)N(CH₃)-, -C(O)NHC(O)O-C(O)N(CH₃)C(O)O- -SO₂-, -SO2NH-, -SO₂N(CH₃)-, or-fCR^jp-Y¹-.

[00177] A fourth set of variables of Structural Formulae XII(A) and XII(B) is as follows:

Values of Ring B, Q³, R, R’, R⁶, R⁷, R⁹, R, R¹², R¹³ and R¹⁴ and y, including specific values, are each and independently as described above in the third set of variables of Structural Formulae ΧΠ(Α) and XII(B).

R⁵ is independently i) -H; ii) Ci-Ci-aliphatic group (e.g., Ci-Cc-alkyl or C2-Csalkenyl group) optionally substituted with one or more instances of J^C1; iii) a C3-Cg nonaromatic carbocycle optionally substituted with one or more instances of J^CI; iv) a phenyl group optionally substituted with one or more instances of J^C1; v) a 4-8 membered non-54WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 aromatic heterocycle optionally substituted with one or more instances of J^D1 or vi) a 5-6 membered heteroaryl ring optionally substituted with one or more instances of J^D1.

Each of J^C1 and J^D1 is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -SOR^a, -SO2R^a, -NHR^C, -C(O)R^b, -C(O)OR^b, -OC(O)R^b, -NHC(O)R^b, -C(O)NHR^C, -NHC(O)NHR^c, -NHC(O)OR^b, -OCONHR^C, -NHC(O)NHC(O)OR^b, -N(CH3)R^C, -N(CH?.)C(O)R^b, -C(O)N(CH3)R^C, -N(CH3)C(O)NHR^C, -N(CH3)C(O)OR^b, -OCON(CH3)R^c, -C(O)NHCO2R^b, -C(O)N(CH3)CO2R^b, -N(CH3)C(O)NHC(O)OR^b, -NHSO₂R^b, -SO2NHR^b, -SO2N(CH₃)R^b, and -N(CH₃)SO₂R^b

Values of the remaining variables of Structural Formulae ΧΠ(Α) and XII(B), including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

[00178] A fifth set of variables of Structural Formulae ΧΠ(Α) and XII(B) is as follows:

Values of Ring B, Q³, R, R’, R⁵, R⁶, R⁷, R⁹, R^ll,R¹², R¹³, R¹⁴, and y, including specific values, are each and independently as described above in the fourth set of variables of Structural Formulae XII(A) and X1I(B).

Ring B is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -O(Ci-C₄alkyl), -NH₂, -NH(C_t-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -CO₂H, and CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -C0₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy.

[00179] A sixth set of variables of Structural Formulae XII(A) and XII(B) is as follows:

Values of Q³, R, R’, R⁵, R⁶, R⁷, R⁹, Rⁿ, R¹², R¹³, R¹⁴, and y, including specific values, are each and independently as described above in the fifth set of variables of Structural Formulae XII(A) and XII(B).

Ring B is independently selected from one of the structures depicted below:

-55WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

wherein each of rings B1-B9 is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, CrC₄ alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci~C₄ alkyl)₂, -C(O)(C_rC₄alkyl), -CO₂H and -CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(C_rC₄ alkyl), -CO(C_rC₄ alkyl), -C0₂H, -CO₂(Ci-C₄ alkyl), and C,-C₄ alkoxy. Specifically, each of rings Bl to B9 is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₂ alkyl), -NH(Ci-C₂ alkyl)₂, Ch-C.2 alkyl, Ci-C₂ haloalkyl, CjC₂ hydroxyalkyl, C₂-C₄ alkoxyalkyl, Ci-C₂ alkoxy, C|-C₂ hydroxyalkoxy, Ci-C₂ haloalkoxy, C₂-C₄ alkoxyalkoxy, -C0₂H, and -CO₂(Ci-C₄ alkyl).

[00180] A seventh set of variables of Structural Formulae X1I(A) and XII(B) is as follows:

Values of ring B, Q³, R, R’, R⁵, R⁶, R⁷, R⁹, Rⁿ,R¹², R¹³, R¹⁴, and y, including specific values, are each and independently as described above in the sixth set of variables of Structural Formulae XII(A) and XII(B).

Each R⁵ is independently: i) -H; ii) a Ci-Cc-aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄alkyl)₂, -C(O)(Ci~C₄ alkyl), -OC(O)(C_t-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), -CO₂H, C₃-C₈ nonaromatic carbocycle, phenyl, 4-8 membered non-aromatic heterocycle, and 5-6 membered heteroaryl; or iii) a C₃-C? non-aromatic carbocycle, a 4-7 membered non-aromatic heterocycle, a phenyl group, or a 5-6 membered heteroaryl ring, each of which is optionally and independently substituted with one or more substituents independently selected from the

-56WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci~C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(C|-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), -C(O)O(C_f-C₄ alkyl), and -CO2H; wherein each of said alkyl groups for the substituents of the aliphatic group, carbocycle, heterocycle, phenyl and heteroaryl group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ct-C4 alkyl), -N(Ci~C4 alkyl)2, -OCO(Ci-C4 alkyl), -00(0,-04 alkyl), -CO2H, -ΟΟ2(Ο,-Ο4 alkyl), and C1-C4 alkoxy; and wherein each of said carbocycle, phenyl, heterocycle, and heteroaryl for the substituents of the Ci-Ce-aliphatic group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C,-C4 alkyl, -NH₂, -NH(C,-C₄ allcyl), -N(C,-C₄ alkyl)₂, -OCO(C,-C₄ alkyl), -CO(C_rC₄ alkyl), -CO₂H, -00₂(0ι-0₄ alkyl), and 0,C₄ alkoxy.

Values of the remaining variables of Structural Formulae X1I(A) and Xll(B), including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

[00181] An eighth set of variables of Structural Formulae XII(A) and XII(B) is as follows:

Values of Q³, R, R’, R⁵, R⁶, R⁷, R⁹, R’^R¹², R¹³ and R¹⁴ and y, including specific values, are each and independently as described above in the seventh set of variables of Structural Formulae XII(A) and XII(B).

The group (ring B)-Q³-R³ is

Q3 wherein ring B2 is optionally and independently further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(C,-C₂ alkyl), -NH(C,-C₂ alkyl)₂, C,-C₂ alkyl, C1-C2 haloalkyl, C,-C₂hydroxyalkyl, C2-C4 alkoxyalkyl, C,-C₂ alkoxy, C,-C₂ hydroxyalkoxy, C,-C₂ haloalkoxy, C₂C₄ alkoxyalkoxy, -CO₂H, and -CO₂(Ci-C₄ alkyl).

Values of the remaining variables of Structural Formulae XII(A) and XIT(B), including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

-57WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00182] A ninth set of variables of Structural Formulae XII(A) and XII(B) is as follows:

Values of the group (ring B)-Q³-R⁵, Q³, R, R’, R⁶, R⁷, R⁹, Rⁿ,R¹², R¹³, R¹⁴, and y, including specific values, are each and independently as described above in the eighth set of variables of Structural Formulae XII(A) and XII(B).

R⁵ is: ί) -H; ii) an optionally substituted Cj-Cg alkyl group; iii) an optionally substituted, C3-C7 non-aromatic carbocycle; or iv) an optionally substituted, 4-7 membered non-aromatic heterocycle, wherein said alkyl group represented by R⁵ is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NHz, -NH(Cj-C4 alkyl), -N(Cj-C4 alkyl)2, -OCO(Cj-C4 alkyl), -CO(Ci-C4 alkyl), -COzH, -COz(Cj-C4 alkyl), C1-C4 alkoxy, optionally substituted, C3-C7 non-aromatic carbocycle, and optionally substituted, 4-7 membered non-aromatic heterocycle. Each of said carbocycles and heterocycles represented by R⁵, and referred to for the substituents of the Cj-Cg alkyl group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Cj-C4 alkyl, -O(Cj-C₄ alkyl), ~NH₂, -NH(Cj-C₄ alkyl), -N(Cj-C₄ alkyl)₂, -C(O)(Cj-C₄ alkyl), -OC(O)(Cj-C₄ alkyl), -C(O)O(Cj-C₄ alkyl) and -CO2H, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂₎ -NH(Cj-C₄ alkyl), -N(Cj-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Cj-C₄alkyl), -CO2H, -CO₂(Ci-C₄ alkyl), and Cj-C₄ alkoxy.

[00183] In a tenth set of variables of Structural Formulae XII(A) and XII(B), values of the variables for Structural Formulae XII(A) and XII(B), including specific values, are each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

[00184] In an eleventh set of variables of Structural Formulae XII(A) and XII(B), values of the variables for Structural Formulae XII(A) and XII(B), including specific values, are each and independently as described above in the sixteenth set of variables of Structural Formulae (I) and (IA), or in the tenth set of variables of Structural Formulae II-V.

[00185] In another embodiment, the present invention is generally directed to the use of compounds represented by Structural Formula below XIII, or a pharmaceutically

-58WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 acceptable salt thereof, for any of the uses described above.

(XIII).

A first set of variables of Structural Formula XIII is as follows:

Ring C is a 5-7 membered, non-aromatic, heterocyclic ring optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, Ci-Ce alkyl, C₂-Ce alkenyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆alkyl)₂, -O(Ci_C<5 alkyl), -C(O)NH₂, -C(O)NH(Ci-C₆ alkyl), -C(O)N(C_rC₆ alkyl)₂, C(O)(Ci-Cfi-alkyl), -OC(O)(Ci-C₆ alkyl), -NHC(O)(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)C(O)(Ci-C₆alkyl), and -CO₂R^b; wherein each of said alkyl and alkenyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and CiC₄ alkoxy. Specifically, ring C is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(C_t-C₄ alkyl), -CO₂H, and -CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy. Specifically, ring C is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, -NH₂, NH(C]-C₂ alkyl), -NH(Ci-C₂ alkyl)₂, Ci-C₂ alkyl, Cj-C₂ haloalkyl, Ci-C₂ hydroxyalkyl, C₂C₄ alkoxyalkyl, Ci-C₂ alkoxy, Ci-C₂ hydroxyalkoxy, Ci-C₂ haloalkoxy, C2-C4 alkoxyalkoxy, -CO₂H, and -CO₂(Ci-C₄ alkyl).

R⁹is-H or-CH₃.

-59WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

R^u and R¹² are each independently -H or -CHj.

Each R and R’ are independently -H or Cj-C_G alkyl.

Values of the remaining variables of Structural Formula XIII, including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

[00186] A second set of variables of Structural Formula XIII is as follows:

Values of Ring C, R, R’, R⁶, R⁷, R⁹, R^1! andR¹², including specific values, are each and independently as described above in the first set of variables of Structural Formula XIII.

R¹⁰ is -H or Ci-Ce-alkyl.

Values of the remaining variables of Structural Formula XIII, including specific values, and provisos arc each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

[00187] A third set of variables of Structural Formula XIII is as follows:

Values of R, R’, R⁶, R⁷, R⁹, R¹⁰, R¹¹ andR¹², including specific values, are each and independently as described above in the first set of variables of Structure Formula XIII.

Ring C is a 5-7 membered, non-aromatic, heterocyclic group optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH_2> -NH(Ci-C₄ alkyl), -N(Cj-C₄alkyl)₂, -C(O)(Ci-C₄ alkyl), -CO₂H and-CO₂(C_f-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_t-C₄ alkyl), -CO₂H, -CO2(Ci-C₄ alkyl), and Ci-C₄ alkoxy.

Values of the remaining variables of Structural Formula ΧΠΙ, including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (1) and (IA).

[00188] A fourth set of variables of Structural Formula XIII is as follows:

Values of R, R’, R⁶, R⁷, R⁹, R¹⁰, Rⁿ andR¹², including specific values, are each and independently as described above in the second set of variables of Structure Formula XIII.

Ring C is independently selected from:

-60WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 wherein each of rings C1-C5 is optionally and independently substituted. Suitable substituents are as described above for ring C in the first set of variables of Structural Formula XIV.

[00189] In a fifth set of variables of Structural Formula XIII, values of the variables for Structural Formula XIII, including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

[00190] In another embodiment, the present invention is generally directed to the use of compounds represented by Structural Formula below XIV, or a pharmaceutically acceptable salt thereof for any of the uses described above.

(Xiv).

A first set of variables of Structural Formula XIV is as follows:

Ring D is 4-7 membered, non-aromatic, heterocyclic ring optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C_rC₆ alkyl, C₂-C₆ alkenyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -O(Ci. C₆ alkyl), -C(O)NH₂, -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ci-C₆ alkyl)₂, -C(O)(Ci-C₆-alkyl), -OC(O)(C_rC₆ alkyl), -NHC(O)(C_t-C6 alkyl), -N(Ci-C₆ alkyl)C(O)(C,-C₆ alkyl), and -CO₂R^b; wherein each of said alkyl and alkenyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C_rC₄ alkoxy. Specifically, ring D is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl),

-61WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

-CO2H and -CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)_2j -OCO(Ci-C₄ alkyl), -CO(C_rC₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C_tC₄ alkoxy. Specifically, ring D is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, NH(Ci-C₂ alkyl), -NH(Ci-C₂ alkyl)₂, C_rC₂ alkyl, C_rC₂ haloalkyl, Ci-C₂ hydroxyalkyl, C₂C₄ alkoxyalkyl, Ci-C₂ alkoxy, Ci-C₂ hydroxyalkoxy, Ci-C₂ haloalkoxy, C₂-C₄ alkoxyalkoxy, -COoH, and-CO₂(Ci-C₄ alkyl).

R¹³ and R¹⁴ are each independently -H or-CH₂, or together with the carbon atoms to which they are attached they form a cyclopropane ring.

Each of R and R’ are independently -H or Ci-Ce alkyl.

Values of the remaining variables of Structural Formula XIV, including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (I) and (IA).

[00191] A second set of variables of Structural Formula XIV is as follows:

Values for Ring D, R, R’, R⁶, R⁷, R¹³ and R¹⁴, including specific values, are each and independently as described above in the first set of variables of Structural Formula XIV.

Value z is 1.

Values of the remaining variables of Structural Formula XIV, including specific values, and provisos are each and independently as described above for the first set of variables of Structural Formulae (I) and (IA).

[00192] A third set of variables of Structural Formula TV is as follows:

Values for z, R, R’, R⁶, R⁷, R¹³ and R¹⁴, including specific values, are each and independently as described above in the second set of variables of Structural Formula XIV.

Ring D is independently selected from the group consisting of

-62WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 wherein each of rings D1-D7 is optionally and independently substituted. Suitable substituents are as described above for ring D in the first set of variables of Structural Formula XIV.

Each R^d is independently -H, Ci-Cg alkyl or - C(O)(Ci-C6 alkyl), wherein each of said alkyl moiety is optionally and independently substituted with one or more groups selected from halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -OCO(Ci-C4 alkyl), -CO(Ci-C4 alkyl), -CO2H, -CO2(C,-C4 alkyl), and CiC4 alkoxy. Specifically, each R^d is independently -H or Ci-Ce alkyl optionally and independently substituted with one or more groups selected from halogen, cyano, hydroxy, oxo, Ci-C4 alkyl, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_rC₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy.

[00193] In a fourth set of variables of Structural Formula XTV, values of the variables for Structural Formula XIV, including specific values, and provisos are each and independently as described above in the first set of variables of Structural Formulae (I) and (ΪΑ).

[00194] In another embodiment, the compounds of Structural Formulae I-IV and XIXIV, and pharmaceutically acceptable salts thereof, are independently as described above; and provided that, where applicable, if Y¹ is a bond, then R⁵ is neither -H, nor an unsubstituted Ct-Cs aliphatic group. Specifically, if Y¹ is a bond, then R⁵ is a substituted CiCe aliphatic group; an optionally substituted C3-C8 non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; and an optionally substituted, 5-10 membered heteroary group. Specifically, the Ci-Ce aliphatic group represented by R⁵ is substituted with one or more instances of J^C1, wherein J^C1 is independently selected from: an optionally substituted, C3-Cs non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; an optionally substituted, 5-10 membered heteroaryl group; -OR^b; -SR^b; -S(O)R^a; -SO2R^a; -NR^bR^c; -C(O)R”; -C(O)OR^b; -OC(O)R^b; -NRC(0)R^b; -C(O)NR^bR^c; -NRC(O)NR^hR^e; -NRC(O)OR^b; -OCONR^bR^c; -C(O)NRCO₂R^b; -NRC(O)NRCO2R^b; -C(O)NR(OR^b); -SO2NR^cR^b;

-NRSO₂R^b; and -NRSO₂NR^cR^b; or optionally two J^C! and two J^D1, respectively, together with the atoms to which they are attached, independently form a 5-7-mcmbcred ring that is

-63WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 optionally substituted with one or more instances of J^E1, and fused to the respective ring to which they are attached.

[00195] In yet another embodiment, the compounds of Structural Formulae IA-IV and XI-XIV, and pharmaceutically acceptable salts thereof, are independently as described above; and provided that, where applicable, if Q² is a bond, then R⁵ is neither -H nor a Ci-Cg aliphatic group; and provided that if Q³ is a bond, then R⁵ is neither -H nor a Ci-Cg aliphatic group. Specifically, if Q² and Q³ are each and independently a bond, then R⁵ is an optionally substituted C3-C3 non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group. Specifically, if Q² and Q³ are each and independently a bond, then R⁵ is an optionally substituted Cj-Cg non-aromatic carbocycle; or an optionally substituted, 4-8 membered non-aromatic heterocycle.

[00196] In yet another embodiment, the compounds are represented by Structural

Structural Formula (I), or pharmaceutically acceptable salts thereof, wheren each variables of the formulae are independently as described above; and wherein:

R⁴ is:

Ring E is a C4-C8 non-aromatic carbocycle optionally further substituted with one or more instances of J^A.

Rings F is a 4-8 membered non-aromatic heterocycle optionally substituted with one or more instances of J^E1.

Each of rings G1 and G2 is independently a 5-10 membered non-aromatic bridged carbocycle optionally substituted with one or more instances of J^A.

Q² is independently bond, -O-, -S-, -NR- -C(O)-, -C(=NR)-, -CO₂- -OC(O)-C(O)NR_, -C(O)NRC(O)O- -NRC(O)NRC(O)O- -NRC(O)-, -NRC(0)NR-, -NRCO2- -OC(O)NR-, -S(O)-, -SO2-, -N(R)SO₂- -SO2NR’-, -NRSO2NR’-, or -(CR⁶R⁷)p“Y*-.

R⁵ is: i) -H; ii) an optionally substituted C1-C& alkyl group; iii) an optionally substituted, C3-C7 non-aromatic carbocycle; or iv) an optionally substituted, 4-7 membered non-aromatic heterocycle; or optionally, together with R and the nitrogen atom to which it is

-64WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 attached, form a 5-7 membered, optionally substituted non-aromatic heterocycle. The alkyl group represented by R⁵ is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(C|-C4 alkyl), -N(Ci-C4 alkyl)2, -OCO(CrC4 alkyl), -CO(Ci-C4 alkyl), -CO2H, -CO2(Ci-C4 alkyl), CrC4 alkoxy, an optionally substituted, C3-C7 non-aromatic carbocycle, and an optionally substituted, 4-7 membered non-aromatic heterocycle; wherein each of said carbocycles and heterocycles represented by R⁵, and referred to for the substituents of the Ci-Cg alkyl group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ct-C4 alkyl, -O(Ci-C₄ alkyl), -NH₂₎ -NH(Ci~C₄ alkyl), -N(C_t-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), OC(O)(Ci-C₄ alkyl), -C(O)O(Ci-C₄ alkyl) and -CO₂H, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and CiC₄ alkoxy.

Each of R⁸ and R⁹ is independently -H, halogen, cyano, hydroxy, Ci-C₄ alkyl, Ci-C₄haloalkyl, Ci-C₄ hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(C]-C₄ alkyl), -NH₂, -NH(Ci-C₄alkyl), or-N(C]-C₄ alkyl)₂.

Rⁿ, R¹², R¹³ and R¹⁴ are each independently -H, halogen, or Ci-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, oxo, amino, carboxy, Ci-Cg alkoxy, Ci-Cg haloalkoxy, Ci-Cg aminoalkoxy, Ci-Cg cyanoalkoxy, Ci-C₆hydroxyalkoxy, and C₂-Cg alkoxyalkoxy; or optionally, Rⁱ³ and R¹⁴, together with the carbon atom to which they are attached, form a cyclopropane ring, optionally substituted with one or more instances of methyl.

R²¹, R²², R²³ and R²⁴ are each independently -H, halogen, -OH, or Ci-C_e alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, oxo, amino, carboxy, Ci-Cg alkoxy, Ci-Ce haloalkoxy, Cj-Cg aminoalkoxy, Ci-Cg cyanoalkoxy, Ci-Cg hydroxy alkoxy, and C₂-Cg alkoxyalkoxy.

p and q are each independently 0, 1 or 2.

x is 0, 1 or 2.

r is 1 or 2.

-65WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Values of the remaining variables of Structural formula I, including specific values, and provisos are each and independently as described above in any one of the first through fifteenth sets of variables of Structural Formula I.

[00197] In yet another embodiment, the compounds represented by Structural Formula (I) or pharmaceutically acceptable salts thereof are independently as described above in the preceding paragraph; and ring F is selected from any one of rings F1-F6:

O

each of rings F1-F6 optionally and independently substituted; and each R^f is independently -H or Ci-Cc, alkyl optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ci-Ce alkoxy, Cj-Cs haloalkoxy, Ci-Ce aminoalkoxy, C i-Ce cyanoalkoxy, CrCe hydroxy alkoxy and C2-C6 alkoxyalkoxy.

[00198] In yet another embodiment, the compounds represented by Structural Formula (XIA) or (XIB), or pharmaceutically acceptable salts thereof are as described above; and the group -[C(R^l3R¹⁴)]_x-ringA-Q²-R⁵ is independently:

each of rings Al4 and A28 is optionally and independently further substituted; and values of the remaining variables of Structural Formulae (XIA) and (XIB), including specific values, and provisos are each and independently as described above in any one of the first through eleventh sets of variables of Structural Formulae (XIA) and (XIB).

[00199] In yet another embodiment, the compounds represented by Structural Formula (XIA) or (XIB), or pharmaceutically acceptable salts thereof are independently as described above in the preceding paragraph; and R⁵ is an optionally substituted Ci-Ce alkyl group; an optionally substituted, C3--C7 non-aromatic carbocycle; or an optionally substituted, 4-7 membered non-aromatic heterocycle; or optionally, together with R and the nitrogen atom to which it is attached, form a 5-7 membered, optionally substituted non-aromatic heterocycle. Specifically, R⁵ is an optionally substituted, 4-7 membered non-aromatic heterocycle; or optionally, together with R and the nitrogen atom to which it is attached, form a 5-7 membered, optionally substituted non-aromatic heterocycle.

[00200] In yet another embodiment, the compounds are represented by Structural

-66WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Formula (IA) or (I), or pharmaceutically acceptable salts, wherein:

Ring E is a C4-C10 non-aromatic carbocycle optionally further substituted with one or more instances of J^A.

Rings F is a 4-8 membered non-aromatic heterocycle optionally substituted with one or more instances of J^E1. Specific examples of ring F includes:

O

Additional example includes Each of rings F1-F7 optionally and independently substituted. Exemplary substituents for ring F (including rings F1-F7) include halogen, cyano, hydroxy, C4-C4 alkoxy, and C1-C4 alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, and -O(CiC₄ alkyl).

R^f is independently -H or Ci-Cf, alkyl optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ci-C₆ alkoxy, Ct-Cs haloalkoxy, Ci-Ce aminoalkoxy, Ci-Ce cyanoalkoxy, Ct-C<, hydroxy alkoxy and C2-C6 alkoxy alkoxy.

R⁹ is independently -H, halogen, cyano, hydroxy, amino, carboxy, Ci-Ce alkyl, Ci-Ce haloalkyl, Ct-Ce cyanoalkyl, C2-C6 alkoxyalkyl, Ci-Ce aminoalkyl, Ct-Cehydroxyalkyl, CiCe carboxyalkyl, Ct-Co alkoxy, Ci-Cs haloalkoxy, Ci-Ce amino alkoxy, Ci-Cecyanoalkoxy, Ci-Cg hydroxyalkoxy, or C2-C6 alkoxyalkoxy.

R¹¹, R¹², R¹³ and R¹⁴ are each independently -H, halogen, or Cj-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, oxo, amino, carboxy, Ct-Cgalkoxy, Ci-Ce haloalkoxy, Ct-Cg aminoalkoxy, Ci-Ce cyanoalkoxy, Ci-Cg hydroxyalkoxy, and C2-C6 alkoxyalkoxy.

Optionally, R¹³ and R¹⁴, together with the carbon atom to which they are attached, form a cyclopropane ring, optionally substituted with one or more instances of methyl.

s is 0, 1 or 2.

x is 0, 1 or 2.

-67WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

The remaining variables are each and independently as described above in any one of the sets of variables for Structural Formulae (IA) and (I).

[00201] In yet another embodiment, the compounds are represented by Structural Formula (I) or (IA), or pharmaceutically acceptable salts thereof, wherein:

R⁹ is independently -H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C2-C4 alkoxyalkyl, -O(Ci-C4 alkyl), -NH₂, -NH(Ci-C₄ alkyl), or-N(Ci-C₄alkyl)₂.

The other varibales are each and independently as described in the preceeding paragraph.

[00202] In yet another embodiment, the compounds are represented by Structural Formula (IA) or (I), or pharmaceutically acceptable salts, wherein:

R⁴ is:

Each of rings G1-G4 is independently a 5-10 membered non-aromatic bridged ring optionally further substituted with one or more instances of J^A.

Eing G5 is a 5-10 membered non-aromatic bridged ring optionally further substituted with one or more instances of J^B.

Xis -0-, -S-, or-NR^e-.

R⁸ and R⁹ are each independently -H, halogen, cyano, hydroxy, amino, carboxy, CiCg alkyl, Ci-Cg haloalkyl, Ci-Cg cyanoalkyl, C₂-Cg alkoxyalkyl, Ci-Cg aminoalkyl, Cj-Cg hydroxyalkyl, Ci-Cg carboxy alkyl, Ci-Cg alkoxy, Ci-Cg haloalkoxy, Ci-Cg aminoalkoxy, CtCg cyanoalkoxy, Ci-Cg hydroxyalkoxy, or C₂-Cg alkoxyalkoxy.

-68WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

R¹³ and R¹⁴ are each independently -H, halogen, or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, oxo, amino, carboxy, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ce aminoalkoxy, Ch-Ce cyanoalkoxy, Ci-Ce hydroxyalkoxy, and C₂-Ce alkoxyalkoxy.

Optionally, Rⁿ and R¹⁴, together with the carbon atom to which they are attached, form a cyclopropane ring, optionally substituted with one or more instances of methyl.

R²¹, R²², R²³, R²⁴, and R²⁵ are each independently -H, halogen, -OH, Ci-Ce alkoxy, or Ci-Cc alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, oxo, amino, carboxy, Ci-Cc alkoxy, CiCe haloalkoxy, Ci-Ce aminoalkoxy, Ci-Ce cyanoalkoxy, Ci-Ce hydroxyalkoxy, and C2-Ce alkoxyalkoxy. Specifically, R²¹, R²², R²³, R²⁴, and R²⁵ are each independently -H, halogen, -OH, Ci-Ce alkoxy, or Cj-Cc alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, Ci-C6 alkyl, -NHz, -NH(Ci-C₆ alkyl), -N(C_rC₆ alkyl)₂, -O(Ci.C₆ alkyl), -C(O)NH₂, -C(O)NH(Ci-C₆alkyl), -C(O)N(Ci-C₆ alkyl)₂, -C(O)(Ci-C₆-alkyl), -OC(O)(Ci-C₆ alkyl), -NHC(O)(Ci-C₆alkyl), -N(Ci-C₆ alkyl)C(O)(C_rCe alkyl).

R^s is -H or Ci-Cfi alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, Ci-Cealkoxy, Ci-Cs haloalkoxy, C|-Ceaminoalkoxy, CrG,cyanoalkoxy, Ci-Cr, hydroxy alkoxy, and C₂-Ce alkoxy alkoxy.

q is 0, 1 or 2; x is 0, 1 or 2; and r is 1 or 2.

The remaining variables are each and independently as described above in any set of variables for Structural Formulae (IA) and (I).

[00203] In yet another embodiment, the compounds are represented by Structural Formula (LA) or (I), pharmaceutically acceptable salts thereof, wherein:

R⁴ is:

wherein rings G1 and G2 are each and independently a 5-10 membered non-aromatic bridged ring optionally further substituted with one or more instances of J^A.

-69WO 2010/148197

PCI7US2010/038988

2018200219 11 Jan 2018

Each of R⁸ and R⁹ is independently -H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C2-C4 alkoxyalkyl, -O(Ci-C4 alkyl), -NH₂, -NH(Ci-C₄alkyl), or -N(Ci-C₄ alkyl)₂.

R²¹, R²², R²³, and R²⁴ are each independently -H, halogen, -OH, or Ci-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, oxo, amino, carboxy, Ci-Cg alkoxy, Ci-Ce haloalkoxy, Ci-Cg aminoalkoxy, Ci-Ce cyanoalkoxy, Cj-Cg hydroxyalkoxy, and C₂-Ce alkoxy alkoxy,

Q² is independently a bond, -O-, -S-, -NR-, -C(O)-, -C(=NR)-, -CO2-, -00(0)-, -C(O)NR- -C(O)NRC(O)O-, -NRC(0)NRC(0)0- -NRC(O)- -NRC(0)NR-, -NRCO2-, -OC(O)NR-, -S(O)-, -SO2-, -N(R)SO2- -SO2NR’-, -NRSO2NR’-, or -(CR^fiR⁷)p-Y^!-. Alternatively Q²is independently -0-, -CO2- -OC(O)-, -C(O)NR- -NRC(O)-, -NRC(0)NR- -NRC02-, -OC(O)NR- -CO2SO2-, -P(0)20-, or -(CR'jVjp-Y¹-. Alternatively Q² is independently -0- or -C02~.

[00204] In some embodiments, rings E and G (including G1-G5) are optionally and independently further substituted with one or more instances of J^A (for carbocycle) or J^B (for heterocycle), wherein each of J^A and J^B is independently selected from the group consisting of halogen, cyano, oxo, -NCO, andQ'-R⁵, and wherein:

Q¹ is independently a bond, -0-, -S-, -NR-, -C(O)-, -C(=NR)-, -CO2-, -00(0)-, -C(O)NR- -C(O)NRC(O)O- -NRC(O)NRC(O)O- -NRC(O)-, -NRC(O)NR-, -NRCO2-OC(O)NR- -S(O)-, -SO2-, -N(R)SO2-, -SO2NR’-, -NRSO2NR’-, or -(CR⁶R⁷)p-Y’-; and Y^l is independently a bond, -0-, -S-, -NR’-, -C(O)-, -C(=NR)-, -CO₂- -OC(O)-, -C(O)NR’-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O-, -NRC(O)-, -NRC(O)NR’~ -NRCO2-, -OC(0)NR’-, -S(O)-, -SO₂- -SO2NR’-, -NRSO₂-, or -NRS0₂NR’-.

Alternatively: Q¹ is independently a bond, -0-, -S-, -NR-, -C(O)-, -CO2-, -OC(O)-, -C(O)NR-, -C(O)NRC(O)O-, -NRC(0)NRC(0)0-, -NRC(O)-, -NRC(0)NR-, -NRCO2-, -OC(O)NR- -S(0)-, -S02- -N(R)S02- -S02NR’-, -NRSO2NR’-, or -(CR^GR⁷)P-Y'-; and Y¹ is independently -0-, -C0₂- -00(0)-, -C(O)NR- -NRC(0)-, -NRC(0)NR-, -NRCO₂- or -0C(0)NR[00205] In yet another embodiment, Q¹ and Y¹ are each independently as described above in the preceeding paragraph, and:

R⁵ is independently ί) -H; ii) a Ci-Cg-aliphatic group optionally substituted with one or more instances of J^C1; iii) a C3-C8 non-aromatic carbocycle optionally substituted with one

-70WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 or more instances of .f²¹; iv) a phenyl group optionally substituted with one or more instances of J^C1; v) a 4-8 membered non-aromatic heterocycle optionally substituted with one or more instances of J^D1 or vi) a 5-6 membered heteroaryl ring optionally substituted with one or more instances of J^D1; and each of J^C1 and J^Dl is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a, -SO2R^a, -NHR^C, -C(O)R^b, -C(O)OR^b, -OC(O)R^b, -NHC(O)R^b, -C(O)NHR^C, -NHC(O)NHR^C, -NHC(O)OR^b, -OCONHR^C, -NHC(O)NHC(O)OR^b, -N(CH3)R^C, -N(CH3)C(O)R^b , -C(O)N(CH3)R^C, -N(CH3)C(O)NHR^c, -N(CH3)C(O)OR^b, -OCON(CH3)R^C, -C(O)NHCO2R^b, -C(O)N(CH3)CO2R^b, -N(CH3)C(O)NHC(O)OR^b, -NHSO₂R^b, -SO2NHR^b, -SO2N(CH₃)R^b, and -N(CH₃)SO₂R^b.

[00206] In some specific embodiments, the compounds are represented by Stmctural Formula (IA) or (I), wherein:

R¹ is -H.

R² is -H, -CH3, -CH2OH, or -NH2. Specifically, R² is -H, or -CH2OH.

R³ is -H, -F, -Cl, Cm alkyl, or Cm haloalkyl. Alternatively, R³ is -H, -F, or -Cl.

Z¹ is -H, -F, or -Cl.

Z is -H or Ci-Cc alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(C[-C4 alkyl).

Z³ is -H or Ci-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C₄alkyl).

R⁵ is: i) -H; ii) an optionally substituted Ci-Ce alkyl group; iii) an optionally substituted, Cj-C₂ non-aromatic carbocycle; iv) an optionally substituted, 4-7 membered nonaromatic heterocycle; v) )an optionally substituted phenyl group; vi) an optionally substituted 5-6 membered heteroaryl ring; or optionally, together with R and the nitrogen atom to which it is attached, form a 5-7 membered, optionally substituted non-aromatic heterocycle; and said alkyl group represented by R⁵ is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(C_t-C₄ alkyl), -NCCt-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(C!-C₄ alkyl), C_rC₄ alkoxy, -NRCO(Ci-C₄ alkyl), -CONR(C_rC₄ alkyl), -NRCO₂(Ci-C₄ alkyl), a C₃-C? non-aromatic carbocycle optionally substituted with one or more instances of J^E1, a 4-7 membered non-aromatic heterocycle optionally substituted with

-71WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 one or more instances of J^E1; and a phenyl optionally substituted with one or more instances of J^Ei; and wherein each of said carbocycle, heterocycle, phenyl and heteroaiy represented by R⁵is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(C|-C₄alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ct-C₄ alkyl)₂, -C(O)(C_t-C₄ alkyl), -OC(O)(Ci-C₄alkyl), -C(O)O(C]-C₄ alkyl) and -CO₂H, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_t-C₄ alkyl), -CO₂H, -CO₂(C_rC₄ alkyl), and C_t-C₄ alkoxy.

The remaining variables, including R⁴ that includes a spiro ring represented by rings E and F, or a bridged ring represented by rings G1-G5, are each and independently as described in any one of the precceing four embodiments.

[00207] In yet another embodiment, the compounds are presented by Structural Formula (IA) or (I), wherein values of the variabels are each and independently as described in the preceeding embodiment, except:

Z² is -H;

Z³ is -H;

R⁵ is independently: i) -H or ii) a Ci-Ce-alkyl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(C,-C₄ alkyl), -NH₂, -NH(C,-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), -CO₂H, C₃-C_s nonaromatic carbocycle, 4-8 membered non-aromatic heterocycle, phenyl, and 5-6 membered heteroaryl;

wherein each of said alkyl groups referred to in the substituents of the Ct-Ce-alkyl group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy; and wherein each of said carbocycle, phenyl, heterocycle, and heteroaryl referred to in the substituents of the Ci-Ce-alkyl group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy.

-72WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00208]

In yet another embodiment, each of rings E, G1-G5 is independently and optionally substituted with onr or more substituents selected from the group consisting of halogen, cyano, hydroxy, Ci-C_G alkyl, -NH₂, -NH(Cj-Cq alkyl), -NfCi-Ce alkyl)₂, -O(Ci.Ce alkyl), -C(O)NH₂, -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ci-C₆ alkyl)₂, -C(O)(C_rC₆-alkyl), -OC(O)(Ci-C₆ alkyl), -NHC(O)(Ci-C₆ alkyl), -N(Ci-C_e alkyl)C(O)(Ci-C₆ alkyl), and -CO₂R^b; wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -0C0(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy. Specifically, each of rings E, G1-G5 is independently and optionally substituted with onr or more substituents selected from the group consisting of halogen, cyano, hydroxy, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(C|-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), C!-C₄ alkoxy, and C1-C4 alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C₄ alkyl), [00209] In yet another embodiment, the compounds are represented by Structural Formula (IA) or (I), or pharmaceutically acceptable salts thereof, wherein:

R⁴ is:

Ring A is a non-aromatic, 5-10 membered, bridged carbocylce or heterocycle, or ring A and R^s optionally form a non-aromatic, 5-10 membered, bridged carbocycle or heterocycle, or ring A and R⁹ optionally form a non-aromatic, 5-10 membered, bridged carbocycle or heterocycle, or ring A and R¹¹ optionally form a non-aromatic, 5-10 membered, bridged carbocycle or heterocycle, wherein each of said carbocycle is independently and optionally substituted with one or more instances of J^A and wherein each carbocycle is independently and optionally substituted with one or more instances of J^B.

R^! is -H.

R² is -H, -CH3, -CH2OH, or -NH2. Specifically, R² is -H, or -CH2OH.

R³ is -H, -F, -Cl, Cu alkyl (e.g., -CH₃ or -C₂H₅), or C_M haloalkyl (e.g., -CF₃). Alternatively, R³ is -H, -F, or -Cl.

Z¹ is -H, -F, or -Cl.

-73WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Z² is -H or C₅-C₆ alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C4 alkyl).

Z³ is -H or C_rC₆ alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(C]-C₄alkyl).

Q² is independently -O-, -CO2~, -00(0)- -C(O)NR’-, -C(O)NRC(O)O-NRC(O)-, -NRC(O)NR’- -NRCO2-, -OC(O)NR’- -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)2O-, -CO₂SO₂-, or-(CR⁶R⁷)p-Y’-.

Y¹ is -0-, -CO2- -OC(O)-, -C(0)NR’-, -C(0)NRC(O)O-,-NRC(O)-NRC(0)NR’-, -NRCO2-, -OC(O)NR’~, -P(O)(OR)O-, -0P(O)(OR^a)O-, -P(O)2O-, or -CO₂SO₂-.

R⁵ is: i) -H; ii) an optionally substituted Ci-Ce alkyl group; iii) an optionally substituted, C3-C7 non-aromatic carbocycle; iv) an optionally substituted, 4-7 membered nonaromatic heterocycle; v) )an optionally substituted phenyl group; vi) an optionally substituted 5-6 membered heteroaryl ring; or optionally, together with R and the nitrogen atom to which it is attached, form a 5-7 membered, optionally substituted non-aromatic heterocycle; and said alkyl group represented by R^s is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(C_rC₄ alkyl), -N(Ci-C₄ alkyl)₂, -0C0(C,-C₄ alkyl), -CO(C_rC₄ alkyl), -CO₂H, -CO₂(C_rC₄ alkyl), C1-C4 alkoxy, -NRC0(C_rC₄ alkyl), -CONR(Ci-C₄ alkyl), -NRCO₂(Ci-C₄ alkyl), a C3-C7 non-aromatic carbocycle optionally substituted with one or more instances of J^Ei, a 4-7 membered non-aromatic heterocycle optionally substituted with one or more instances of J^E1; and a phenyl optionally substituted with one or more instances ofJ^E1;

wherein each of said carbocycle, heterocycle, phenyl and heteroary represented by R⁵is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, CpC₄ alkyl, -O(Ci-C₄alkyl), -NH2, -NfffCj-Q alkyl), -N(C,-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄alkyl), -C(O)O(Ci~C₄ alkyl) and -CO₂H, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(C_rC₄ alkyl), -CO(Cj-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C_rC₄ alkoxy.

-74WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Each of R⁸ and R⁹ is independently -H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C_rC₄ hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄alkyl), or-N(Ci-C₄ alkyl)₂.

R¹¹, Rⁱ², R¹³, and R¹⁴ are each independently -H, halogen, or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and Ci-Ce alkoxy.

Each of J^A and J^B is independently selected from the group consisting of halogen, cyano, hydroxy, Ci-CG alkyl, -NH2, -NH(Ci-Cg alkyl), -N(Ci-Cg alkyl)2, -O(Ci.Cc alkyl), -C(O)NH2, -C(O)NH(Ci-C6 alkyl), -C(O)N(CrCe alkyl)2, -C(O)(Ci-C6-alkyI), -OC(O)(CtC6 alkyl), -NHC(O)(Ci-C6 alkyl), -N(Ci-C6 alkyl)C(O)(Ct-C6 alkyl), and -CO2R^b; wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -C0(C_t-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C_rC₄ alkoxy.

n is 0 or 1.

x is 0 or I.

[00210] In yet another embodiment, the compounds are represented by Structural Formula (IA) or (I), or pharmaceutically acceptable salts, wherein;

_R23

Each of rings G1-G4 is independently a 5-10 membered non-aromatic bridged carbocycle optionally further substituted with one or more instances of J^A, and ring G5 is a 510 membered non-aromatic bridged heterocycle optionally further substituted with one or more instances of J^B.

X is -O-, -S-, or -NR^g-.

-75WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

R²¹, R²², R²³, R²⁴, and R²³are each independently -H, halogen, -OH, Ci-Cs alkoxy, or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, Ci-Cs alkyl, -NH₂, -NH(Ci-Ce alkyl), -N(Ci-C₆ alkyl)₂, -O(Ci-C₆ alkyl), -C(O)NH₂, -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ci-C₆ alkyl)₂, -C(O)(Ci-C₆-alkyl)_} -OC(O)(C_rC_e alkyl), -NHC(O)(Ci-C₆ alkyl), -N(Ci-C₆ a!kyl)C(O)(CiCe alkyl).

R^s is -H or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, Ct-Cr,alkoxy, Ci-Cc haloalkoxy, Ci-Ce aminoalkoxy, Ci-Cecyanoalkoxy, Ci-Ce hydroxyalkoxy, and C₂-Ce alkoxy alkoxy.

q is 0, 1 or 2.

ris 1 or 2.

The remaining variables are each and independently as described above in the proceeding paragraph.

100211] In yet another embodiment, the compounds are represented by Structural Formula (IA) or (I), or pharmaceutically acceptable salts thereof, wherein the variables are each and independently as described above in the proceeding paragraph except those described below:

R¹ is -H.

R² is -H.

Z¹ is-H,-F, or-Cl.

Z² is -H.

Z³ is -H.

X is -O-.

R⁵ is -H, an optionally substituted Ci-Cc alkyl, or optionally substituted phenyl.

Each R⁸ is independently -H, halogen, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C2-C4 alkoxyalkyl, or-O(Ci-C4 alkyl).

Each of R⁹, R¹³, and R^l4is independently -H or Ci-C4 alkyl.

R²¹, R²², R²³, R²⁴, and R²⁵ are each independently -H, halogen, -OH, Ci-Cc alkoxy, or Ci -Cfi alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, Ci-Cs alkyl, and -O(Ci.Ce alkyl). Specifically R²¹, R²², R²³, R²⁴, and R²⁵ are each independently -H, Cm alkyl, or Cm haloalkyl.

-76WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Each rings G1-G5 are independently and optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, -NH?, -NH(CiCg alkyl), -N(Ci-Cg alkyl)₂, -O(Ci_Cg alkyl), C1-C4 alkyl that is optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, and C1-C4 alkoxy.

[00212] In yet another embodiment, the compounds are represented by any one of Structural Formulae I-V (hereinafter reference to Structural Formulae I-IV includes Structural Formulae I, ΙΑ, II, III, IV, V, and VI) and XI(A)-XIV (hereinafter reference to Structural Formulae XI(A)-XIV includes Structural Formulae XIA, XIB, XIIA, ΧΊΙΒ, XIII, and XIV), wherein values of the variables therein are independently as described above in any embodiments except that R³ is Ci_6 alkyl, such as methyl or ethyl.

[00213] In yet another embodiment, the compounds are represented by any one of Structural Formulae I-V and XI(A)-XIV, wherein values of the variables therein are independently as described above in any embodiments described above, except that x is 0. [00214] In yet another embodiment, the compounds are represented by any one of Structural Formulae I, I A, II, VI, XI(A), and XI(B), wherein values of the variables therein are independently as described above in any embodiments described above, except that ring A is bridged.

100215] In yet another embodiment, the compounds are represented by any one of Structural Formulae I, ΙΑ, Π, VI, XI(A), and XI(B), wherein values of the variables therein are independently as described above in any embodiments described above, except that Q² is independently -C(=NR)-, -C(=NR)NR-, -NRC(=NR)NR-, -CO2- -OC(O)-, -C(O)NR-, -C(O)NRC(O)O- -NRC(O)NRC(O)O-, -NRC(O)-, -NRC(O)NR- -NRCO2-, -OC(O)NR- -S(O)-, -SO2- -N(R)SO2- -SO2N(R)-, -NRSO2NR-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)2O-, -CO2SO2-, or -(CR⁶R⁷)P-Y-; or alternatively, Q² is independently -CO2- -OC(O)-, -C(O)NR- -C(O)NRC(O)O-, -NRC(O)NRC(O)O-NRC(O)-, -NRC(O)NR- -NRCO₂- -OC(O)NR~, -S(O)-, -SO₂~, -N(R)SO₂-SO₂N(R)-, -NRSO₂NR-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)2O-, -CO2SO2-, or -(CR⁶R⁷)P-Y¹-.

[00216] In yet another embodiment, the compounds are represented by any one of Structural Formulae I-V and XI(A)-XIV, wherein values of the variables therein are independently as described above in any embodiments described above, provided that when Q² is -O- or -NR-, then ring A is further substituted with J^A other than -H; and provided that if Q³ is -0(0)-, then R⁵ is a substituted Ci-Cg aliphatic group; an optionally substituted C.i-Cs _77_

WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted 5-10 membered heteroaryl group. In a specific embodiment, when Q² is -O- or -NR.-, then ring A is further substituted with J^A other than -H at the geminal position to -Q²R⁵.

|00217] In yet another embodiment, the present invention is directed to the use of any compound selected from the compounds depicted in FIGs. 3, 4, 5, 6, 7, and 8, or a pharmaceutically acceptable salt thereof, for any of the uses described above.

[00218] In some embodiments, the compounds are represented by any one of Structural Formulae I-V and XI(A)-XIV, and the variables are each independently as depicted in the compounds of FIGs. 1-8.

[00219] In yet another embodiment, the present invention is directed to the use of a compound described in any one of the embodiments, including various sets of variables, for Structural Formulae I-V and XI(A)-XIV described above, or a pharmaceutically acceptable salt thereof, for any of the uses described above, provided that when R³ is -Cl, Z¹ is -F, and Z² is -H, then R⁴ is not Z-NHi-cyclohexyl.

[00220] In yet another embodiment, the compounds described herein or pharmaceutically acceptable salts thereof can be used to reduce viral titre in a biological sample (e.g. an infected cell culture) or in humans (e.g. lung viral titre in a patient).

|00221] The terms “influenza virus mediated condition”, “influenza infection”, or “Influenza”, as used herein, are used interchangeable to mean the disease caused by an infection with an influenza virus.

[00222] Influenza is an infectious disease that affects birds and mammals caused by influenza viruses. Influenza viruses are RNA viruses of the family Orthomyxoviridae, which comprises five genera: Influenzavirus A, Influenzavirus B, Influenzavirus C, Isavirus and Thogotovirus. Influenzavirus A genus has one species, influenza A virus which can be subdivided into different serotypes based on the antibody response to these viruses: H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2 , H7N3 and H10N7. Influenzavirus B genus has one species, influenza B virus. Influenza B almost exclusively infects humans and is less common than influenza A. Influenzavirus C genus has one species, Influenzavirus C virus, which infects humans and pigs and can cause severe illness and local epidemics. However, Influenzavirus C is less common than the other types and usually seems to cause mild disease in children.

[00223] In some embodiments of the invention, influenza or influenza viruses are associated with Influenzavirus A or B. In some embodiments of the invention, influenza or

-78WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 influenza viruses are associated with Influenzavirus A. In some specific embodiments of the invention, Influenzavirus A is H1NI, H2N2, H3N2 or H5N1.

[00224] In humans, common symptoms of influenza are chills, fever, pharyngitis, muscle pains, severe headache, coughing, weakness, and general discomfort. In more serious cases, influenza causes pneumonia, which can be fatal, particularly in young children and the elderly. Although it is often confused with the common cold, influenza is a much more severe disease and is caused by a different type of virus. Influenza can produce nausea and vomiting, especially in children, but these symptoms are more characteristic of the unrelated gastroenteritis, which is sometimes called stomach flu or 24-hour flu.

[00225] Symptoms of influenza can start quite suddenly one to two days after infection. Usually the first symptoms arc chills or a chilly sensation, but fever is also common early in the infection, with body temperatures ranging from 38-39 °C (approximately 100-103 °F). Many people are so ill that they are confined to bed for several days, with aches and pains throughout their bodies, which are worse in their backs and legs. Symptoms of influenza may include: body aches, especially joints and throat, extreme coldness and fever, fatigue, Headache, irritated watering eyes, reddened eyes, skin (especially face), mouth, throat and nose, abdominal pain (in children with influenza B). Symptoms of influenza are non-specific, overlapping with many pathogens (“influenza-like illness). Usually, laboratory data is needed in order to confirm the diagnosis.

[00226] The terms, “disease”, “disorder”, and “condition” may be used interchangeably here to refer to an influenza virus mediated medical or pathological condition.

[00227] As used herein, the terms “subject” and “patient” are used interchangeably. The terms “subject” and “patient” refer to an animal (e.g., a bird such as a chicken, quail or turkey, or a mammal), specifically a “mammal” including a non-primate (e.g., a cow, pig, horse, sheep, rabbit, guinea pig, rat, cat, dog, and mouse) and a primate (e.g., a monkey, chimpanzee and a human), and more specifically a human. In one embodiment, the subject is a non-human animal such as a farm animal (e.g., a horse, cow, pig or sheep), or a pet (e.g., a dog, cat, guinea pig or rabbit). In a preferred embodiment, the subject is a “human”.

[00228] The term “biological sample”, as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.

[00229] As used herein, “multiplicity of infection” or “MOI” is the ratio of infectious agents (e.g, phage or virus) to infection targets (e.g. cell). For example, when referring to a

-79WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 group of cells inoculated with infectious virus particles, the multiplicity of infection or MOI is the ratio defined by the number of infectious virus particles deposited in a well divided by the number of target cells present in that well.

[00230] As used herein the term “inhibition of the replication of influenza viruses” includes both the reduction in the amount of virus replication (e.g. the reduction by at least 10 %) and the complete arrest of virus replication (i.e., 100% reduction in the amount of virus replication). In some embodiments, the replication of influenza viruses are inhibited by at least 50%, at least 65%, at least 75%, at least 85%, at least 90%, or at least 95%.

[00231] Influenza virus replication can be measured by any suitable method known in the art. For example, influenza viral titre in a biological sample (e.g. an infected cell culture) or in humans (e.g. lung viral titre in a patient) can be measured. More specifically, for cell based assays, in each case cells are cultured in vitro, virus is added to the culture in the presence or absence of a test agent, and after a suitable length of time a virus-dependent endpoint is evaluated. For typical assays, the Madin-Darby canine kidney cells (MDCK) and the standard tissue culture adapted influenza strain, A/Puerto Rico/8/34 can be used. A first type of cell assay that can be used in the invention depends on death of the infected target cells, a process called cytopathic effect (CPE), where virus infection causes exhaustion of the cell resources and eventual lysis of the cell. In the first type of cell assay, a low fraction of cells in the wells of a microtiter plate are infected (typically 1/10 to 1/1000), the virus is allowed to go through several rounds of replication over 48-72 hours, then the amount of cell death is measured using a decrease in cellular ATP content compared to uninfected controls. A second type of cell assay that can be employed in the invention depends on the multiplication of virus-specific RNA molecules in the infected cells, with RNA levels being directly measured using the branched-chain DNA hybridization method (bDNA). In the second type of cell assay, a low number of cells are initially infected in wells of a microtiter plate, the virus is allowed to replicate in the infected cells and spread to additional rounds of cells, then the cells are lysed and viral RNA content is measured. This assay is stopped early, usually after 18-36 hours, while all the target cells are still viable. Viral RNA is quantitated by hybridization to specific oligonucleotide probes fixed to wells of an assay plate, then amplification of the signal by hybridization with additional probes linked to a reporter enzyme.

[00232] As used herein a “viral titer (or titre)” is a measure of virus concentration. Titer testing can employ serial dilution to obtain approximate quantitative information from an analytical procedure that inherently only evaluates as positive or negative. The titer

-80WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 corresponds to the highest dilution factor that still yields a positive reading; for example, positive readings in the first 8 serial twofold dilutions translate into a titer of 1:256. A specific example is viral titer. To determine the titer, several dilutions will be prepared, such as 10'¹, 10'², IO'³,...,IO’⁸. The lowest concentration of virus that still infects cells is the viral titer.

[00233] As used herein, the terms “treat”, “treatment” and “treating” refer to both therapeutic and prophylactic treatments. For example, therapeutic treatments includes the reduction or amelioration of the progression, severity and/or duration of influenza viruses mediated conditions, or the amelioration of one or more symptoms (specifically, one or more discernible symptoms) of influenza viruses mediated conditions, resulting from the administration of one or more therapies (e.g., one or more therapeutic agents such as a compound or composition of the invention). In specific embodiments, the therapeutic treatment includes the amelioration of at least one measurable physical parameter of an influenza virus mediated condition. In other embodiments the therapeutic treatment includes the inhibition of the progression of an influenza virus mediated condition, either physically by, e.g,, stabilization of a discernible symptom, physiologically by, e.g., stabilization of a physical parameter, or both. In other embodiments the therapeutic treatment includes the reduction or stabilization of influenza viruses mediated infections. Antiviral drugs can be used in the community setting to treat people who already have influenza to reduce the severity of symptoms and reduce the number of days that they are sick.

[00234] The term “chemotherapy” refers to the use of medications, e.g. small molecule drugs (rather than “vaccines”) for treating a disorder or disease.

[00235] The terms “prophylaxis” or “prophylactic use” and “prophylactic treatment” as used herein, refer to any medical or public health procedure whose purpose is to prevent, rather than treat or cure a disease. As used herein, the terms “prevent”, “prevention” and “preventing” refer to the reduction in the risk of acquiring or developing a given condition, or the reduction or inhibition of the recurrence or said condition in a subject who is not ill, but who has been or may be near a person with the disease. The term “chemoprophylaxis” refers to the use of medications, e.g. small molecule drugs (rather than “vaccines”) for the prevention of a disorder or disease.

[00236] As used herein, prophylactic use includes the use in situations in which an outbreak has been detected, to prevent contagion or spread of the infection in places where a lot of people that are at high risk of serious influenza complications live in close contact with each other (e.g. in a hospital ward, daycare center, prison, nursing home, etc). It also includes

-81WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 the use among populations who require protection from the influenza but who either do not get protection after vaccination (e.g. due to weak immunse system), or when the vaccine is unavailable to them, or when they cannot get the vaccine because of side effects. It also includes use during the two weeks following vaccination, since during that time the vaccine is still ineffective. Prophylactic use may also include treating a person who is not ill with the influenza or not considered at high risk for complications, in order to reduce the chances of getting infected with the influenza and passing it on to a high-risk person in close contact with him (for instance, healthcare workers, nursing home workers, etc).

[00237] According to the US CDC, an influenza “outbreak” is defined as a sudden increase of acute febrile respiratory illness (AFRI) occurring within a 48 to 72 hour period, in a group of people who arc in close proximity to each other (e.g. in the same area of an assisted living facility, in the same household, etc) over the normal background rate or when any subject in the population being analyzed tests positive for influenza. One case of confirmed influenza by any testing method is considered an outbreak.

[00238] A “cluster” is defined as a group of three or more cases of AFRI occurring within a 48 to 72 hour period, in a group of people who are in close proximity to each other (e.g. in the same area of an assisted living facility, in the same household, etc).

[00239] As used herein, the “index case”, “primary case” or “patient zero” is the initial patient in the population sample of an epidemiological investigation. When used in general to refer to such patients in epidemiological investigations, the term is not capitalized. When the term is used to refer to a specific person in place of that person's name within a report on a specific investigation, the term is capitalized as Patient Zero. Often scientists search for the index case to determine how the disease spread and what reservoir holds the disease in between outbreaks. Note that the index case is the first patient that indicates the existence of an outbreak. Earlier cases may be found and are labeled primary, secondary, tertiary, etc. [00240] In one embodiment, the methods of the invention are a preventative or “preemptive” measure to a patient, specifically a human, having a predisposition to complications resulting from infection by an influenza virus. The term “pre-emptive” as used herein as for example in pre-emptive use, “pre-emptively”, etc, is the prophylactic use in situations in which an “index case” or an “outbreak” has been confirmed, in order to prevent the spread of infection in the rest of the community or population group.

[00241 ] In another embodiment, the methods of the invention arc applied as a “preemptive” measure to members of a community or population group, specifically humans, in order to prevent the spread of infection.

-82WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00242] As used herein, an “effective amount” refers to an amount sufficient to elicit the desired biological response. In the present invention the desired biological response is to inhibit the replication of influenza virus, to reduce the amount of influenza viruses or to ;

reduce or ameliorate the severity, duration, progression, or onset of a influenza virus| infection, prevent the advancement of an influenza viruses infection, prevent the recurrence,| development, onset or progression of a symptom associated with an influenza virus infection,| or enhance or improve the prophylactic or therapeutic effect(s) of another therapy used| against influenza infections. The precise amount of compound administered to a subject willI i depend on the mode of administration, the type and severity of the infection and on theI characteristics of the subject, such as general health, age, sex, body weight and tolerance toI dings. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. When co-administered with other anti viral agents, e.g., when co-I administered with an anti-influenza medication, an “effective amount” of the second agent will depend on the type of drug used. Suitable dosages are known for approved agents and can be adjusted by the skilled artisan according to the condition of the subject, the type ofI condition(s) being heated and the amount of a compound described herein being used. In| cases where no amount is expressly noted, an effective amount should be assumed. Forj example, compounds described herein can be administered to a subject in a dosage rangeI from between approximately 0.01 to 100 mg/kg body weight/day for therapeutic or| prophylactic treatment.| [00243] Generally, dosage regimens can be selected in accordance with a variety of| factors including the disorder being treated and the severity of the disorder; the activity of the| specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the renal and hepatic function of the subject; and the particular compound or salt thereof employed, the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The skilled artisan can readily determine and prescribe the effective amount of the compounds described herein required to treat, to prevent, inhibit (fully or partially) or arrest the progress of the disease.

[00244] Dosages of the compounds described herein can range from between about 0.01 to about 100 mg/kg body weight/day, about 0.01 to about 50 mg/kg body weight/day, about 0.1 to about 50 mg/kg body weight/day, or about 1 to about 25 mg/kg body weight/day. |

It is understood that the total amount per day can be administered in a single dose or can be I

-83WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 administered in multiple dosing, such as twice a day (e.g., every 12 hours), tree times a day (e.g., every 8 hours), or four times a day (e.g., every 6 hours).

[00245] For therapeutic treatment, the compounds described herein can be administered to a patient within, for example, 48 hours (or within 40 hours, or less than 2 days, or less than 1.5 days, or within 24 hours) of onset of symptoms (e.g., nasal congestion, sore throat, cough, aches, fatigue, headaches, and chills/sweats). The therapeutic treatment can last for any suitable duration, for example, for 5 days, 7 days, 10 days, 14 days, etc. For prophylactic treatment during a community outbreak, the compounds described herein can be administered to a patient within, for example, 2 days of onset of symptoms in the index case, and can be continued for any suitable duration, for example, for 7 days, 10 days, 14 days, 20 days, 28 days, 35 days, 42 days, etc.

[00246] Various types of administration methods can be employed in the invention, and are described in detail below under the section entitled “Administration Methods.”

Combination Therapy [00247] An effective amount can be achieved in the method or pharmaceutical composition of the invention employing a compound of any one of Structural Formulae I-V (e.g., Structural Formulae I, ΙΑ, II, III, IV and V) and XI(A)-XIV (e.g., Structural Formulae XIA, X1B, XIIA, XIIB, XIII, and XIV) or a pharmaceutically acceptable salt or solvate (e.g., hydrate) thereof alone or in combination with an additional suitable therapeutic agent, for example, an antiviral agent or a vaccine. When “combination therapy” is employed, an effective amount can be achieved using a first amount of a compound of any one of Structural Formulae I-V and XI(A)-XIV, or a pharmaceutically acceptable salt or solvate (e.g., hydrate) thereof, and a second amount of an additional suitable therapeutic agent (e.g. an antiviral agent or vaccine).

[00248] In another embodiment of this invention, the compound of any one of Structural Formulae I-V and XI(A)-XIV, and the additional therapeutic agent, are each administered in an effective amount (i.e., each in an amount which would be therapeutically effective if administered alone). In another embodiment, the compound of any one of Structural Formulae I-V and XI(A)-XIV, and the additional therapeutic agent, are each administered in an amount which alone does not provide a therapeutic effect (a subtherapeutic dose). In yet another embodiment, the compound of any one of Structural Formulae I-V and XI(A)-XIV can be administered in an effective amount, while the additional therapeutic agent is administered in a sub-therapeutic dose. In still another

-84WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 embodiment, the compound of any one of Structural Formulae I-V and XI(A)-XIV can be administered in a sub-therapeutic dose, while the additional therapeutic agent, for example, a suitable cancer-therapeutic agent is administered in an effective amount.

[00249] As used herein, the terms “in combination” or “co-administration” can be used interchangeably to refer to the use of more than one therapy (e.g., one or more prophylactic and/or therapeutic agents). The use of the terms does not restrict the order in which therapies (e.g., prophylactic and/or therapeutic agents) are administered to a subject.

[00250] Coadministration encompasses administration of the first and second amounts of the compounds of the coadministration in an essentially simultaneous manner, such as in a single pharmaceutical composition, for example, capsule or tablet having a fixed ratio of first and second amounts, or in multiple, separate capsules or tablets for each. In addition, such coadministration also encompasses use of each compound in a sequential manner in either order.

[00251] In one embodiment, the present invention is directed to methods of combination therapy for inhibiting Flu viruses replication in biological samples or patients, or for treating or preventing Influenza virus infections in patients using the compounds or pharmaceutical compositions of the invention of any one of Structural Formulae I-V and XI(A)-XIV. Accordingly, pharmaceutical compositions of the invention also include those comprising an inhibitor of Flu virus replication of this invention in combination with an antiviral compound exhibiting anti-influenza virus activity.

[00252] Methods of use of the compounds and compositions of the invention also include combination of chemotherapy with a compound or composition of any one of Structural Formulae I-V and XI(A)-XIV or with a combination of a compound or composition of this invention with another anti-viral agent and vaccination with a Flu vaccine.

[00253] When co-administration involves the separate administration of the first amount of a compound of any of Structural Formulae I-V and XI(A)-XIV and a second amount of an additional therapeutic agent, the compounds are administered sufficiently close in time to have the desired therapeutic effect. For example, the period of time between each administration which can result in the desired therapeutic effect, can range from minutes to hours and can be determined taking into account the properties of each compound such as potency, solubility, bioavailability, plasma half-life and kinetic profile. For example, a compound of any one of Structural Formulae I-V and XI(A)-XTV and the second therapeutic agent can be administered in any order within about 24 hours of each other, within about 16

-85WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 hours of each other, within about 8 hours of each other, within about 4 hours of each other, within about 1 hour of each other or within about 30 minutes of each other.

[00254] More, specifically, a first therapy (e.g., a prophylactic or therapeutic agent such as a compound of the invention) can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapy (e.g., a prophylactic or therapeutic agent such as an anti-cancer agent) to a subject.

[00255] It is understood that the method of co-administration of a first amount of a compound of any one of Structural Formulae I-V and XI(A)-XIV and a second amount of an additional therapeutic agent can result in an enhanced or synergistic therapeutic effect, wherein the combined effect is greater than the additive effect that would result from separate administration of the first amount of the compound of any one of Structural Formulae I-V and XI(A)-XIV and the second amount of the additional therapeutic agent.

[00256] As used herein, the term “synergistic” refers to a combination of a compound of the invention and another therapy (e.g., a prophylactic or therapeutic agent), which is more effective than the additive effects of the therapies. A synergistic effect of a combination of therapies (e.g., a combination of prophylactic or therapeutic agents) can permit the use of lower dosages of one or more of the therapies and/or less frequent administration of said therapies to a subject. The ability to utilize lower dosages of a therapy (e.g., a prophylactic or therapeutic agent) and/or to administer said therapy less frequently can reduce the toxicity associated with the administration of said therapy to a subject without reducing the efficacy of said therapy in the prevention, management or treatment of a disorder. In addition, a synergistic effect can result in improved efficacy of agents in the prevention, management or treatment of a disorder. Finally, a synergistic effect of a combination of therapies (e.g., a combination of prophylactic or therapeutic agents) may avoid or reduce adverse or unwanted side effects associated with the use of either therapy alone.

[00257] When the combination therapy using compounds of the present invention of any one of Structural Formulae I-V and XI(A)-XIV is in combination with a Flu vaccine, both therapeutic agents can be administered so that the period of time between each administration can be longer (e.g. days, weeks or months).

-86WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00258] The presence of a synergistic effect can be determined using suitable methods for assessing drug interaction. Suitable methods include, for example, the Sigmoid-Emax equation (Holford, N.H.G. and Scheiner, L.B., Clin. Pharmacokinet. 6: 429-453 (1981)), the equation of Loewe additivity (Loewe, S. and Muischnek, H., Arch. Exp. Pathol Pharmacol. 114: 313-326 (1926)) and the median-effect equation (Chou, T.C. and Talalay, P., Adv. Enzyme Regul. 22: 27-55 (1984)). Each equation referred to above can be applied with experimental data to generate a corresponding graph to aid in assessing the effects of the drug combination. The corresponding graphs associated with the equations referred to above are the concentration-effect curve, isobologram curve and combination index curve, respectively. [00259] Specific examples that can be co-administered with a compound described herein include neuraminidase inhibitors, such as oseltamivir (Tamiflu®) and Zanamivir (Rlenza®), viral ion channel (M2 protein) blockers, such as amantadine (Symmetrel®) and rimantadine (Flumadine®), and antiviral drugs described in WO 2003/015798, including T705 under development by Toyama Chemical of Japan. (See alsoRuruta et al., Antiviral Reasearch, 82: 95-102 (2009), “T-705 (flavipiravir) and related compounds: Novel broadspectrum inhibitors of RNA viral infections.”) In some embodiments, the compounds described herein can be co-administerd with a traditional influenza vaccine.

Compounds of the Invention [00260] Another aspect of the present invention is generally related to compounds. In one embodiment, the present invention is generally related to compounds represented by Structural Formula (IA) or (I), or pharmaceutically acceptable salts thereof:

[00261] A first subset of variables of Structural Formulae (I) and (IA) for the compounds of the invention is as follows:

R‘ is -H, Ci-C₆ alkyl, -S(O)₂-R” or-C(O)OR”. Specifically, R¹ is -H or S(O)2-R”. Specifically, R¹ is -H or -S(O)2-(phenyl), wherein the phenyl is optionally substituted with one or more selected from the group consisting of Ci-C_G alkyl and Ci-Ce haloalkyl. More specifically, the phenyl is optionally substituted with one or more selected from the group

-87WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 consisting of -CH3 and -CF₃ (e.g., at its para position). Specifically, R¹ is -H or Cj_6 alkyl. Specifically, R¹ is -H.

R⁴ is:

R” is independently: i) a Cj-Ce-alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxyl, -NH₂, -NH(Ci-C6 alkyl), -N(Ci-Cg alkyl)₂, Cj-Cg alkoxy, Cj-Cg haloalkoxy, Cj-Cg aminoalkoxy, Cj-Cg cyanoalkoxy, Cj-Cg hydroxyalkoxy, and C₂-Cg alkoxyalkoxy; or ii) a CjCg carbocyclic group, a 5-6 membered heteroaryl group, or a phenyl group, each optionally and independently being substituted with one ore more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, nitro, -NH₂, -NH(Ci-Cg alkyl), -N(Cj-Cg alkyl)₂, Cj-Cg alkyl, Cj-Cg haloalkyl, Cj-Cg cyanoalkyl, Cj-C_G hydroxyalkyl, C₂-Cg alkoxyalkyl, Cj-Cg aminoalkyl, Cj-Cg alkoxy, Ci-Ce haloalkoxy, Cj-Cg aminoalkoxy, Cj-Cg cyanoalkoxy, Cj-Cg hydroxyalkoxy, and C₂-Cg alkoxyalkoxy. Specifically, R” is independently an optionally substituted, 5-6 membered heteroaryl group, or an optionally substituted phenyl group. Specifically, R” is independently a phenyl group optionally substituted with one or more substituents independently selected from the group consisting of Cj-Cg alkyl and Cj-Cg haloalkyl.

Values of Z¹, Z², Z³, Q¹, Q², Q³, Y¹, rings A-D, R*, R, R’, R², R³, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R^:I, R^b, R^c, R^d, J^A, J^B, J^C1, J^D1 and J^E1, including specific values and substituents therefor, are each and independently as described above in the first set of variables of Structural Formulae (IA) and (I) for the methods of the invention.

Value p is independently 1,2,3 or 4. Specifically, p is independently 1 or 2.

When rings A and B are 3-6-membered, n and m are each independently 0 or 1; and k

-88WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 is independently 0, 1 or 2. Alternatively, when rings A and B are 7-10-membered, n and m, are each independently 0, 1 or 2; and k is independently 0, 1 or 2,

Values x and y are each independently 0, 1 or 2.

Value z is 1 or 2.

It is provided that if Y¹ is a bond, then R⁵ is neither -H, nor an unsubstituted Ci-Ce aliphatic group. Specifically, if Y¹ is a bond, then R⁵ is a substituted Ci-Cs aliphatic group; an optionally substituted C3-Cs non-aromatic carbocycle; an optionally substituted 6-10membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group. Specifically, the Ci-Cg aliphatic group represented by R⁵ is substituted with one or more instances of J⁰, wherein J^C1 is independently selected from: an optionally substituted, C3-C8 non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; an optionally substituted, 5-10 membered heteroaryl group; -OR^b; -SR^b; -S(O)R^a; -SO2R^a; -NR^bR^c; -C(O)R^b; -C(O)OR^b; -OC(O)R^b; -NRC(O)R^b; -C(O)NR^bR^c; -NRC(O)NR^bR^c; -NRC(O)OR^b; -OCONR^bR^c; -C(O)NRCO2R^b; -NRC(0)NRC02R^b; -C(O)NR(OR^b); -SO2N(R)R^b; -NRSO2R^b; and -NRSO₂NRR^b; or optionally two J^C1 and two J^D1, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^E1, and fused to the respective ring to which they are attached.

It is provided that if Q² and Q³ are each and independently a bond, then R⁵ is an optionally substituted C3-C8 non-aromatic carbocycle; an optionally substituted 6-10membered carbocyclic aiyl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroaiy group. Specifically, if Q²and Q³ are each and independently a bond, then R⁵ is an optionally substituted C3-C8 nonaromatic carbocycle; or an optionally substituted, 4-8 membered non-aromatic heterocycle.

Alternatively, it is provided that if rings A and B each and independently 5- or 6membered, R¹ and R² are both -H, R³ is -Cl, Z² is -H, and Z¹ is -F, then Q²-R⁵ and Q³-R⁵, respectively, are not -H; and it is provided that the ring B-Q³-R⁵ moiety is not V-methyl-3pyrrolidinyl ( ).

[00262] A second subset of variables of Structural Formulae (TA) and (I) for the compounds of the invention is as follows:

R²is-Hor-CH3.

-89WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

R⁴ is selected from formulae A-D depicted above.

Values of the remaining variables of Structural Formulae (IA) and (I), including specific values, and provisos are each and independently as described above for the first subset of variables of Structural Formulae (IA) and (I).

[00263] A third subset of variables of Structural Formula I for the compounds of the invention is as follows:

R² is -H or -CH₃.

R³ is -H, -F, -Cl, -CF₃, -NH_2j -NH(CH₃), or -N(CH₃)₂.

R⁴ is selected from formulae A-D depicted above.

[00264] A fourth subset of variables of Structural Formulae (I A) and (I)for the compounds of the invention is as follows:

R² is-H or-CH₃.

R³ is-H,-F, or-CI.

R⁴ is selected from formulae A-D depicted above.

Values of the remaining variables of Structural Formulae (IA) and (I), including specific values, are each and independently as described above for the first subset of variables of Structural Formulae (IA) and (I).

[00265] A fifth subset of variables of Structural Formulae (IA) and (I) for the compounds of the invention is as follows:

R² is -H.

R³ is -H or -Cl.

R⁴ is selected from formulae A-D depicted above.

Values of the remaining variables of S tructural Formulae (IA) and (I), including specific values, and provisos are each and independently as described above for the first subset of variables of Structural Formulae (IA) and (I).

[00266] A sixth subset of variables of Structural Formulae (IA) and (I)for the compounds of the invention is as follows:

Each of R², R³ and R⁴ is independently as described in the first subset, second subset, third subset, fourth subset, or fifth subset, of variables of Structural Formulae (IA) and (I).

-90WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Z¹ is -H, Ci-C6 alkyl, -O(Ci-C6 alkyl), -F, -Cl, -CN, -CO2H, -CO2(Ci-C6 alkyl), -CONH2, -CONH(Ci-Cg alkyl), or -CON(Ci-C6 alkyl)2; and Z² is -H, CrC₆ alkyl, -O(Ci-C₆alkyl), -NH₂, -NH(CrCe alkyl), or -N(Ci-Ce alkyl)₂; wherein each of said alkyl groups (e.g., represented by CrC_G alkyl, -O(Ci-C_G alkyl), -CO₂(Ci-Ce alkyl), -NH(Ci-C_g alkyl), and -N(Ci-Ce alkyl)₂) is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-C₄ alkyl), -N(C]-C₄ alkyl)₂, -OCO(C_rC₄ alkyl), -CO(C!-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy.

[00267] A seventh subset of variables of Structural Formulae (IA) and (I) for the compounds of the invention is as follows:

Z¹ is -H, -F, -Cl, -CF3, Ci-C4 alkyl, -O(Ci-C4 alkyl), or -CN; and Z² is -H, Ci-C6 alkyl, -O(Ci-C_G alkyl), -NH₂, -NH(Ci-Ce alkyl), or -N(Ci-C_g alkyl)₂, wherein each of said alkyl groups (e.g., represented by Cj-Ce alkyl, -O(Ci-C_G alkyl), -NH(Ci-C_g alkyl), and -N(CiC_G alkyl)₂) is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C]-C₄alkyl, -NH₂, -NH(C,-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ct-C₄ alkyl), -CO(C!-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ct-C₄ alkoxy.

Values of the remaining variables of Structural Formulae (IA) and (I), including specific values, and provisos are each and independently as described above for the first subset of variables.

[00268] An eighth subset of variables of Structural Formulae (IA) and (I) for the compounds of the invention is as follows:

Z² is -H or a Ci-C_G alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(C_!-C₄ alkyl), and C1-C4 alkoxy.

-91WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Values of the remaining variables of Structural Formulae (IA) and (I), including specific values, and provios are each and independently as described above for the first subset of variables.

[00269] A ninth subset of variables of Structural Formulae (IA) and (I) for the compounds of the invention is as follows:

Z¹ is -H, -F, -Cl, -CF₃, -CH_3j or -CN.

Z² is -H or a Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄alkyl, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C_rC₄ alkoxy.

[00270] In a tenth subset of variables of Structural Formulae (IA) and (I) for the compounds of the invention, the variables of Structural Formulae (IA) and (I), including specific values, are each and independently as described above for the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth subset of variables of Structural Formulae (IA) and (I); and where applicable:

each R* independently is: i) -H; ii) Ci-Cealkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Cj-C₄ alkyl), and C1-C4 alkoxy; or iii) a 3-7 membered carbocyclic ring optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci~C₄ alkyl), -hl(Ct-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), C1-C4 alkoxy, and C]-C₆alkyl, wherein each alkyl is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Cj-C4 alkyl), -N(C_t-C₄ alkyl)₂, -OCO(C_f-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C4 alkyl), and C1-C4 alkoxy; and

R and R’ are each independently -H or Ci-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NHfCi-Ce alkyl), -N(Ci-Cg alkyl)₂, and -O(Ci-Ce alkyl); or optionally

-92WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

R’, together with R⁵ and the nitrogen atom to which they are attached, forms a 5-7 membered, non-aromatic, heterocyclic ring optionally substituted with one or more instances of J^D1; and

R’ ’ is independently a phenyl group optionally substituted with one or more substituents independently selected from the group consisting of Ci-Cc alkyl and Ci-Ce haloalkyl.

[00271] In an eleventh subset of variables of Structural Formulae (IA) and (I) for the compounds of the invention, tire variables of Structural Formulae (IA) and (I), including specific values, are each and independently as described above for the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth subset of variables of Structural Formulae (IA) and (I); and where applicable:

provided that if Y¹ is a bond, then R^s is a substituted Cj-Cg aliphatic group; an optionally substituted C₃-Cg non-aromatic carbocycle; an optionally substituted 6- 10membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group; and provided that if Q² and Q³ are each and independently a bond, then R⁵ is an optionally substituted C₃-Cs non-aromatic carbocycle; an optionally substituted 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group.

[00272] In a twlefth subset of variables of Structural Formulae (IA) and (I) for the compounds of the invention , the variables of Structural Formulae (IA) and (I), including specific values, are each and independently as described above for the eleventh subset of variables of Structural Formulae (IA) and (I); and the Ci-Cr, aliphatic group represented by R⁵, when Y¹ is a bond, is substituted with one or more instances of J^CI, wherein J^C1 is independently selected from: an optionally substituted, C3-Cg non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; an optionally substituted, 5-10 membered heteroaryl group; -OR^b; -SR^b; -S(O)R^a; -SO2R^a; -NR^bR^c; -C(O)R^b; -C(O)OR^b; -OC(O)R^b; -NRC(O)R^b; -C(O)NR^bR^c; -NRC(O)NR^bR^c; -NRC(O)OR^b; -OCONR^bR^c; -C(O)NRCO2R^b; -NRC(O)NRCO2R^b; -C(O)NR(OR^b); -S02NR^sR^b; -NRSO2R^b; and -NRSO₂NR^cR^b; or optionally two J^C1 and two J^D1, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^Ei, and fused to the respective ring to which they are attached.

[00273] A thirteenth subset of variables of Structural Formulae (IA) and (I) is as

-93WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 follows:

Each of J^A and J^B is independently selected from the group consisting of halogen, cyano, oxo, and (/-Η⁵; or optionally two J^A and two J^B, respectively, together with the atom(s) to which they are attached, independently form a 5-7 membered ring that is optionally substituted with one or more instances of J^E1, and fused to the ring to which they are attached.

Q¹ is independently a bond, -O-, -S~, -NR’-, -C(O)-, -CO2-, -OC(O)-, -C(O)NR’-, -C(O)NRC(O)O- -NRC(O)NRC(O)O-, -NRC(O)-, -NRC(O)NR’-NRCO2-, -OC(O)NR’-, -S(O)-, -SO2- -SO2NR’~, -NRSO2-, or-NRSO2NR’-, or(CR^<’R⁷)P-Y¹-.

Each of J^CI and J^D1 is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a, -SO2R^a, -NR^bR^c, -C(O)R^b, -C(O)OR^b, -OC(O)R^b, -NRC(O)R^b, -C(O)NR^bR^c, -NRC(O)NR^bR^c, -NRC(O)OR^b, -OCONR^bR^c, -C(O)NRCO2R^b, -NRC(O)NRC(O)OR^b, -C(O)NR(OR^b), -SO2NR^cR^b, -NRSO2R^b, and -NRSO₂NR^cR^b, or optionally, two J^C1 and two J^D1, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^E1, and fused to the respective ring to which they are attached.

Values of the remaining variables of Structural Formulae (IA) and (I), including specific values, and provisos are each and independently as described above for the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, or twelfth subset of variables of Structural Formulae (IA) and (I).

[00274] In a fourteenth subset of variables of Structural Formulae (IA) and (I), values of the variables are independently as described above in the seventeenth set of variables of Structural Formulae (IA) and (I).

[00275| In a fifteenth subset of variables of Structural Formulae (IA) and (I), values of the variables are independently as described above in the eighteenth set of variables of Structural Formulae (IA) and (I).

[00276] In a sixteenth subset of variables of Structural Formulae (IA) and (I), values of the variables are independently as described above in the nineteenth set of variables of Structural Formulae (IA) and (I).

[00277] In some embodiments, the compounds arc represented by Structural Formula (IA) or (I), or pharmaceutically acceptable salts thereof, wherein R¹ is -H or C1-6 alkyl, and wherein values of the remaining variables are independently as described above in any one of the subsets of variables of Structural Formulae (IA) and (I).

-94WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00278] In another embodiment, the present invention is generally related to compounds represented by Structural Formula VI, or pharmaceutically acceptable salts thereof.

[00279] A first subset of variables of Structural Formula VI for the compounds of this invention is as follows:

Z^! is -H, Ci-C₆ alkyl, -O(C,-C₆ alkyl), -F, -Cl, -CN, -CO₂H, -CO₂(Ci-C₆ alkyl), -CONH₂, -CONH(Ci-C6 alkyl), or -CON(Ci-Ce alkyl)₂, wherein each of said alkyl groups (e.g., representd by Ci-Cs alkyl, -O(C_f-C6 allcyl), -CO₂(Ci-C6 alkyl), -CONH(Ci-C6 alkyl), and -CON(Ci-C_g alkyl)₂) is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(C!-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy.

Z² is -H, Ci-Ce alkyl, -O(Ci-C₆ alkyl), -NH₂, -NH(Ci-C₆ alkyl), or -N(Ci-C₆ alkyl)₂, wherein each of said alkyl groups (e.g., represented by Ci-Ce alkyl, -O(Ci-C_G alkyl), -NH(CiC_G alkyl), and -N(Ci-Ce alkyl)₂) is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C_t-C₄ alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(C_t-C₄ alkyl), -CO(C_S-C₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy.

Values of the remaining variables of Structural Formula VI, including specific values, and provisos are each and independently as described above for the first subset of variables of Structural Formulae (IA) and (I).

[00280] A second subset of variables of Structural Formula VI for the compounds of this invention is as follows:

Z¹ is -H, Ci-C₆ alkyl, -O(C_rC₆ alkyl), -F, -Cl, -CN, -CO₂H, -CO₂(Ci-C₆ alkyl), -CONH_2t -CONHfCi-C), alkyl), or -CON(Ci-C_e alkyl)₂, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -NH₂,

-95WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

-NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_S-C₄ alkyl), -CO₂H, -CO₂(CiC₄ alkyl), and Ci-C₄ alkoxy.

Z² is -H, Ci-C₆ alkyl, -O(Ci-C₆ alkyl), -NH₂, -NH(Ci-C₆ alkyl), or-N(C_rC₆ alkyl)₂; wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂₎ -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C,-C₄ alkyl), -CO₂H, -CO₂(C_rC₄ alkyl), and C_t-C₄ alkoxy.

R³ is -H, -Cl, -F, -Br, -CN, -CF₃, -O(Ci-C₄ alkyl), -OH, -NH₂, -NH(Ci-C₄ alkyl), or -N(CrC₄ alkyl)₂.

[00281] A third subset of variables of Structural Formula VI for the compounds of this invention is as follows:

Z¹ is -Η, Ci-Ce alkyl, -O(Ci-C₆ alkyl), -F, -Cl, -CN, -CO₂H, -CO₂(C_t-C₆ alkyl), -CONH₂, -CONH(C|-Cg alkyl), or -CON(Ci-Ce alkyl)₂, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(CiC₄ alkyl), and C1-C4 alkoxy.

Z² is -H, Ci-C₆ alkyl, -O(C_rC₆ alkyl), -NH₂, -NH(Ci-C₆ alkyl), or -N(Ci-C₆ alkyl)₂; wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(C_S-C_fi alkyl), -N(C_rC₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C_rC₄ alkoxy.

R³ is -Η, -F, -Cl, -CF₃, -NH_2j -NH(CH₃), or -N(CH₃)₂. Specifically, R³ is -H, -Cl, or-F. Specifically, R³ is Cl.

[00282] In a fourth subset of variables of Structural Formula VI for the compounds of this invention, values of the variables for Structural Formula VI, including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae (IA) and (I).

-96WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00283] In a fifth subset of variables of Structural Formula VI for the compounds of this invention, values of the variables for Structural Formula VI, including specific values, and provisos are each and independently as described above in the first, second, third, or fourth subset of variables of Structural Formulae (IA) and (I); and where applicable: provided that if Q²-R³ is -OR⁵ or -NR’R⁵, then ring A is further substituted with one or more instances of J^A other than -H; and provided that if Q³ is -C(O)-, then R⁵ is a substituted Ci-Cg aliphatic group; an optionally substituted C₃-Cs non-aromatic carbocycle; an optionally substituted, 6-10membered carbocyclic aryl group; optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted 5-10 membered heteroaryl group.

[00284] In a sixth subset of variables of Structural Formula VI for the compounds of this invention, values of the variables for Structural Formula VI, including specific values, and provisos are each and independently as described above in the fifth subset; and the Ci-Cg aliphatic group represented by R⁵, when Q³ is -C(O)-, is substituted with one or more instances of J^C1, wherein J^C1 is independently selected from; an optionally substituted, C3-Cs non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; an optionally substituted, 5-10 membered heteroaryl group; -OR^b; -SR^b; -S(O)R^a; -SO2R^a; -NR^bR^c; -C(O)R^b; -C(O)OR^b; OC(O)R¹’; -NRC(O)R^b; -C(O)NR^bR^c; -NRC(0)NR^bR^c; -NRC(O)OR^b; -OCONR^bR^c; -C(O)NRCO₂R^b; -NRC(O)NRCO2R^b; -C(O)NR(OR^b); -SO2NR^cR^b;

-NRSO₂R^b; and -NRSO₂NR^cR^b; or optionally two J^C1 and two J^D1, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^E1, and fused to the respective ring to which they are attached.

[00285] In a seventh subset of variables of Structural Formula VI for the compounds of this invention, values of the variables for Structural Formula VI, including specific values, and provisos are each and independently as described above in the first, second, third, or fourth subset of variables of Structural Formulae (IA) and (I); and where applicable: provided that if Y¹ is a bond, then R⁵ is a substituted Cj-Cg aliphatic group; an optionally substituted C₃-Cs non-aromatic carbocycle; an optionally substituted 6-10membered carbocyclic aiyl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group; and provided that if Q² and Q³ are each and independently a bond, then R⁵ is an optionally substituted C₃-Cg non-aromatic carbocycle; an optionally substituted 6-10-membered

-97WO 2010/148197

PCT7US2010/038988

2018200219 11 Jan 2018 carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group.

[00286] In an eighth subset of variables of Structural Formula VI for the compounds of this invention, values of the variables for Structural Formula VI, including specific values, and provisos are each and independently as described above in the seventh subset of variables of Structural Formulae (IA) and (I); and the Ci-Ce aliphatic group represented by R⁵, when Y^! is a bond, is substituted with one or more instances of J⁰¹, wherein J^C1 is independently selected from: an optionally substituted, C3-Cg non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; an optionally substituted, 5-10 membered heteroaryl group; -OR^b; -SR^b; -S(O)R^a; -SO2R¹¹; -NR^bR^c; -C(O)R^b; -C(O)OR^b; -OC(O)R^b; -NRC(O)R^b; -C(O)NR^bR^c; -NRC(O)NR^bR^c; -NRC(O)OR^b; -OCONR^; -C(O)NRCO₂R^b; -NRC(O)NRCO2R^b; -C(O)NR(OR^b); -SO2NR^cR^b; -NRSO2R^b; and -NRSO2NR^cR^b; or optionally two J^C1 and two J^D1, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^El, and fused to the respective ring to which they are attached.

[00287] In a ninth subset of variables of Structural Formula VI for the compounds of this invention, values of the variables for Structural Formula VI, including specific values, and provisos are each and independently as described above in the first, second, third, or fourth subset of variables of Structural Formulae (IA) and (I); and where applicable: provided that if Q²-R⁵ is -OR⁵ or -NR’R³, then ring A is further substituted with one or more instances of J^A other than -H;

provided that if Q³ is -C(O)-, then R⁵ is a substituted Ci-Ce aliphatic group; an optionally substituted C₃-Cg non-aromatic carbocycle; an optionally substituted, 6-10membered carbocyclic aryl group; optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted 5-10 membered heteroaryl group;

provided that if Y¹ is a bond, then R⁵ is a substituted Cj-Ce aliphatic group; an optionally substituted C₃-Cg non-aromatic carbocycle; an optionally substituted 6-10membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group; and provided that if Q² and Q³ are each and independently a bond, then R⁵ is an optionally substituted C₃-Cs non-aromatic carbocyclc; an optionally substituted 6-10-mcmbcred

-98WO 2010/148197

PCT7US2010/038988

[00288] In a tenth subset of variables of Structural Formula VI for the compounds of this invention, values of the variables for Structural Formula VI, including specific values, and provisos are each and independently as described above in the ninth subset of variables of Structural Formulae (IA) and (I); and when Q³ is -C(O)-, or Y¹ is a bond, the Ci-Cg aliphatic group represented by R⁵ is substituted with one or more instances of J^C1, wherein J^C1 is independently selected from: an optionally substituted, C3-Cs non-aromatic carbocycle; an optionally substituted, 6-10membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; an optionally substituted, 5-10 membered heteroaryl group; -OR^b; -SR^b; -S(O)R^a; -SO2R^a; -NR^bR^c; -C(O)R^b; -C(O)OR^b; -OC(O)R^b; -NRC(O)R^b; -C(O)NR^bR^c; -NRC(O)NR^bR^c; -NRC(O)OR^b; -OCONR^bR^c; -C(O)NRCO₂R^b; -NRC(O)NRCO2R^b; -C(O)NR(OR^b); -SO2NR^cR^b; -NRSO2R^b; and -NRSO2NR^cR^b; or optionally two J^C1 and two J^Di, respectively, together with the atoms to which they are attached, independently form a 5-

7-mcmbered ring that is optionally substituted with one or more instances of J^E1, and fused to tire respective ring to which they are attached.

[00289] In an eleventh subset of variables of Structural Formula VI, values of the variables for Structural Formula VI, including specific values, are each and independently as described above in the thirteenth subset of variables of Structural Formulae (IA) and (I). [00290] In another embodiment, the present invention is generally related to compounds represented by any one of Structural Formulae II, III, IV and V, or pharmaceutically acceptable salts thereof:

(Π) (III)

-99WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00291] A first subset of variables of Structural Formulae II, III, IV and V for the compounds of the invention is as follows:

Each Q² is independently -0-, -S-, -NR’-, -C(O)-, -CO2- -OC(O)-, -C(O)NR’-C(O)NRC(O)O- -NRC(O)NRC(0)0- -NRC(O)- -NRC(O)NR’-, -NRCO2-OC(O)NR’~, -S(O)-, -SO2- -N(R)SO2-, -SO2NR’-, -NRSO2NR’-, or -(CR⁶R⁷)P-Y^!-.

Each Q³ is independently -C(O)-, -CO2-, -C(O)NR’-, -SCh-.-SChNR’-, -C(O)NRC(O)O- or-(CR⁶R⁷)P-Y-.

Z¹ is -H, -F, -Cl, C1-C4 haloalkyl (e.g., -CF₃), C_rC₄ alkyl, -O(C_rC₄ alkyl), or-CN.

Z² is -H, Ci-C₆ alkyl, -O(Ci-C₆ alkyl), -NH₂, -NH(Ci-C₆ alkyl), or -N(C_rC₆ alkyl)₂, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(CrC₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_S-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy.

R³ is -H, -Cl, -F, -Br, -CN, -CF3, -O(Ci-C4 alkyl), -OH, -NH2, -NH(Ci-C4 alkyl) or -N(Ci-C4 alkyl)2. Specifically, R³ is -H, -F, -Cl, -CF3, -NH₂, -NH(CH₃), or -N(CH₃)₂. Specifically, R³ is -H, -Cl, or -F. Specifically, R³ is -Cl.

Each R and R’ is independently -H or Cj-C calkyl.

Definitions of rings A-D of formulae II-V, including specific variables, are each and independently as described above for the first set of variables of Structural Formulae (IA) and (I), wherein each of rings A-D is independently an optionally substituted, 4-7 membered ring.

Values of the remaining variables of Structural Formulae II-V, including specific values, and provisos are each and independently as described above for the first subset of variables of Structural Formulae (IA) and (I).

[00292] A second subset of variables of Structural Formulae II, III, IV and V for the compounds of the invention is as follows:

Z¹ is -H, -F, -Cl, -CF₃, -CH₃, or-CN.

-100WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Z² is -H or Cj-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Cj-C₄alkyl, -NH₂, -NH(Ct-C₆ alkyl), -N(Cj-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Cj-C₄ alkyl), and Cj-C₄ alkoxy.

Values of the remaining variables of Structural Formulae Π-V, including specific values and provisos are each and independently as described above for the first subset of variables of Structural Formulae II-V.

[00293] A third subset of variables of Structural Formulae II, III, IV and V for the compounds of the invention is as follows:

Z¹ is-H,-F, or-CN.

Z² is -H or Cj-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Cj-C₄alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(C_rC₆ alkyl)₂, -OCO(Cj-C₄ alkyl), -CO(Cj-C₄ alkyl), -CO₂H, -CO₂(Cj-C₄ alkyl), and Cj-C₄ alkoxy.

Values of the remaining variables of Structural Formulae Il-V, including specific values, and provisos are each and independently as described above for the first subset of variables of Structural Formulae II-V.

[00294] A fourth subset of variables of Structural Formulae II, III, IV and V for the compounds of the invention is as follows:

Z¹ is —H, —F, or-CN.

Z² is -H or Cj-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Cj-C₄alkyl, -NH₂, -NH(Cj-Cg alkyl), -N(Cj-C₆ alkyl)₂, -OCO(Cj-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Cj-C₄ alkoxy.

R³ is -H, -Cl or -F.

Values of the remaining variables of Structural Formulae II-V, including specific values, and provisos are each and independently as described above for the first subset of variables of Structural Formulae II-V.

[00295] A fifth subset of variables of Structural Formulae II, III, IV and V for the compounds of the invention is as follows:

Z^! is-H,-F or-CN.

Z² is -H or Cj-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Cj-C₄

-101WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_rC₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy.

R³ is -H, -Cl, -F, -CF₃,-NH₂, -NH(CH₃), -N(CH₃)₂.

Each R⁸ is independently -H, halogen, cyano, hydroxy, Ci-C₄ alkyl, C]-C₄ haloalky 1, Ci-C₄ hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl) or -N(Ct-C₄ alkyl)₂.

Each R⁹ is independently -H or-CH₃.

R¹¹ and R¹² are each independently -H or-CH₃.

[00296] A sixth subset of variables of Structural Formulae II, III, IV and V for the compounds of the invention is as follows:

Z¹ is -H, -F or-CN.

Z² is -H or Ci-Cr, alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy.

R³is-H, -Cl or-F.

Each R⁸ is independently -H, halogen, cyano, hydroxy, C_rC₄ alkyl, Ci-C₄ haloalkyl, C1-C4 hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), or -N(Ci~C₄ alkyl)₂.

Each R⁹ is independently -H or -CH₃.

Rⁿ and R¹² are each independently -H or -CH₃.

Values of the remaining variables of Structural Formulae II-V, including specific values, and provisos are each and independently as described above for the first subset of

-102WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 variables of Structural Formulae II-V.

[00297] In a seventh subset of variables of Structural Formulae II-V for the compounds of the invention, values for variables, except for R⁶, R⁷, R⁸, R⁹, R¹¹, R¹², R¹³ and R¹⁴, of Structural Formulae Π-V, including specific values, and provisos are each and independently as described above in the first, second, third, or fourth subset of variables of Structural Formulae (IA) and (I).

R⁶ and R⁷ are each independently -H or -C1-C4 alkyl, or together with the carbon atoms to which they are attached they form a cyclopropane ring.

Each R⁸ is independently -H, halogen, cyano, hydroxy, C1-C4 alkyl, C4-C4 haloalkyl, C4-C4 hydroxyalkyl, C2-C4 alkoxyalkyl, -O(Ci-C₄ alkyl), -NH2, -~NH(Ci-C₄ alkyl) or -”N(Ci-C₄ alky 1)₂.

Each R⁹ is independently -H or -C1-C4 alkyl.

R¹¹ and R¹² are each independently -H or-Ci-C₄ alkyl.

R¹³ and R¹⁴ are each independently -H or-C]-C₄ alkyl, or together with the carbon atoms to which they arc attached they form a cyclopropane ring [00298] In an eighth subset of variables of Structural Formulae II-V for the compounds of the invention, values for variables of Structural Formulae II-V, including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae (IA) and (I).

[00299] In a ninth subset of variables of Structural Formulae II-V for the compounds of the invention, values for variables of Structural Formulae Π-V, including specific values, are each and independently as described above for the first, second, third, fourth, fifth, sixth, seventh, or eighth subset of variables of Structural Formulae II-V; and where applicable: provided that if Q²-R⁵ is -OR⁵ or -NR’R³, then ring A is further substituted with one or more instances of J^A other than -H; and provided that if Q³ is -C(O)-, then R⁵ is a substituted Ci-Cg aliphatic group; an optionally substituted C3-C8 non-aromatic carbocycle; an optionally substituted, 6- 10membered carbocyclic aryl group; optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted 5-10 membered heteroaryl group.

[00300] In a tenth subset of variables of Structural Formulae Π-V for the compounds of the invention, values for variables of Structural Formulae Π-V, including specific values, are each and independently as described above for the ninth subset of variables of Structural Formulae II-V; and where applicable:

-103WO 2010/148197

PCI7US2010/038988

2018200219 11 Jan 2018 when Q³ is -C(O)-, the Ci-CG aliphatic group represented by R⁵ is substituted with one or more instances of J^C1, wherein J^C1 is independently selected from: an optionally substituted, C3-C₈ non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; an optionally substituted, 5-10 membered heteroaryl group; -OR^b; -SR^b; -S(O)R^a; -SO2R^a; -NR^bR^c; -C(O)R^b; -C(O)OR^b; -OC(O)R^b; -NRC(O)R^b; -C(O)NR^bR^c; -NRC(O)NR^bR°; -NRC(O)OR^b; -OCONR^bR^c; -C(O)NRCO2R^b; -NRC(O)NRCO₂R^b; -C(O)NR(OR^b); -SO?NR^cR^b; -NRSO2R^b; and -NRSO2NR^cR^b; or optionally two J^C1 and two J^D!, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^Ei, and fused to the respective ring to which they are attached.

[00301] In an eleventh subset of variables of Structural Formulae Π-V for the compounds of the invention, values for variables of Structural Formulae II-V, including specific values, are each and independently as described above for the first, second, third, fourth, fifth, sixth, seventh, or eighth subset of variables of Structural Formulae II-V; and where applicable:

provided that ifY¹ is a bond, then R⁵ is a substituted Ci-Cg aliphatic group; an optionally substituted C₃-Cg non-aromatic carbocycle; an optionally substituted, 6-10membered carbocyclic aiyl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group; and provided that if Q² and Q³ are each and independently a bond, then R⁵ is an optionally substituted C₃-Cs non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group.

[00302] In a twlefth subset of variables of Structural Formulae II-V for the compounds of the invention, values for variables of Structural Formulae II-V, including specific values, are each and independently as described above for the eleventh subset of variables of Structural Formulae II-V; and where applicable:

when Y¹ is a bond, the Ci-CG aliphatic group represented by R⁵ is substituted with one or more instances of J^C1, wherein J^C1 is independently selected from: an optionally substituted, C3-Cg non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; an optionally substituted, 5-10 membered heteroaryl group; -OR^b; ~SR^b; -S(O)R^a; -SO₂R^a; -NR^bR^c; -C(O)R^b; -C(O)OR^b; -OC(O)R^b; -NRC(O)R^b; -C(O)NR^bR^q; -NRC(O)NR^bR^c;

-104WO 2010/148197

PCT7US2010/038988

2018200219 11 Jan 2018

-NRC(O)OR^b; -OCONR^bR^c; -C(O)NRCO₂R^b; -NRC(O)NRCO2R^b; -C(O)NR(OR^b); -SO2NR^cR^b; -NRSO2R^b; and -NRSO2NR^cR^b; or optionally two J^CI and two J^D1, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^Et, and fused to the respective ring to which they are attached.

[00303] In a thirteenth subset of variables of Structural Formulae II-V for the compounds of the invention, values for variables of Structural Formulae II-V, including specific values, arc each and independently as described above for the first, second, third, fourth, fifth, sixth, seventh, or eighth subset of variables of Structural Formulae II-V; and where applicable:

provided that if Q²-R⁵ is -OR⁵ or -NR’R⁵, then ring A is further substituted with one or more instances of J^A other than -H;

provided that if Q³ is -C(O)-, then R⁵ is a substituted Ci-Cg aliphatic group; an optionally substituted C₃-Cs non-aromatic carbocycle; an optionally substituted, 6-10membered carbocyclic aryl group; optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted 5-10 membered heteroaryl group.

provided that if Y¹ is a bond, then R⁵ is a substituted Cj-Ce aliphatic group; an optionally substituted C₃-C₈ non-aromatic carbocycle; an optionally substituted, 6-10membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group; and provided that if Q² and Q³ are each and independently a bond, then R⁵ is an optionally substituted Cj-Cg non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group.

[00304] In a fourteenth subset of variables of Structural Formulae Π-V for the compounds of the invention, values for variables of Structural Formulae II-V, including specific values, are each and independently as described above for the thirteenth subset of variables of Structural Formulae II-V; and where applicable:

when Q³ is -C(O)-, or Y¹ is a bond, the Ci-Ce aliphatic group represented by R⁵ is substituted with one or more instances of J^CI, wherein J^CI is independently selected from: an optionally substituted, C3-Cs non-aromatic carbocycle; an optionally substituted, 6-10membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; an optionally substituted, 5-10 membered heteroaryl group; -OR^b; -SR^b; -S(O)R^a; -SO2R^a; -NR^bR^c; -C(O)R^b; -C(O)OR^b; -OC(O)R^b; -NRC(O)R^b; -C(O)NR^bR^c;

-105WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

-NRC(O)NR^bR^c; -NRC(O)OR^b; -OCONR^bR^c; -C(O)NRCO₂R^b; -NRC(O)NRCO2R^b; -C(O)NR(OR^b); -SO2NR^cR^b; -NRSO2R^b; and -NRSO2NR^cR^b; or optionally two J^C1 and two J^D1, respectively, together with the atoms to which they are attached, independently form a 57-membered ring that is optionally substituted with one or more instances of J^E1, and fused to the respective ring to which they are attached.

[00305 ] A fifteenth subset of variables of Structural Formulae Π-V is as follows:

Each of J^A and J^B is independently selected from the group consisting of halogen, cyano, oxo, and Q’-R⁵; or optionally two J^A and two J^B, respectively, together with the atom(s) to which they are attached, independently form a 5-7 membered ring that is optionally substituted with one or more instances of J^E1, and fused to the ring to which they are attached.

Q¹ is independently a bond, -O-, -S-, -NR-, -C(O)-, -CO₂-, -00(0)-, -C(O)NR- -C(O)NRC(O)O- -NRC(O)NRC(O)O- -NRC(O)-, -NRC(0)NR~, -NRC0₂-> -OC(O)NR- -S(O)-, -SO2-, -N(R)SO₂- -SO₂N(R)-, -NRSO₂NR-, or -(CR⁶R⁷)p-Y’-.

Q² is independently a bond, -0-, -S-, -NR-, -C(O)-, -CO₂~, -OC(O)-, -C(O)NR-, -C(O)NRC(O)O- -NRC(O)NRC(O)O-, -NRC(O)-, -NRC(O)NR-NRCO₂-, -OC(O)NR-, -S(O)-, -SO₂- -N(R)SO₂- -SO₂N(R)-_s -NRSO₂NR-, or -(CR^fiR⁷)p-^y!-.

Q³ is independently a bond, -C(O)-, -CO₂-, -C(0)NR-, -SO₂- -SO₂N(R)-, -C(O)NRC(O)O- or -(CR^Jp-Y¹-.

R⁵ is: i) -H; ii) a Ci-Cs aliphatic group optionally substituted with one or more instances of J^C1; iii) a C3-C8 non-aromatic carbocycle, or 6-10 membered carbocyclic aryl group, each optionally and independently substituted with one or more instances of J^C1; or iv) a 4-8 membered non-aromatic heterocycle, or a 5-10 membered heteroaryl group, each optionally and independently substituted with one or more instances of J^D1.

Each of J^C1 and J^DI is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R“, -SO2R^il, -NR^bR^c, -C(O)R^b, -C(O)OR^b, -OC(O)R^b, -NRC(O)R^b, -C(O)NR^bR°, -NRC(O)NR^bR^c, -NRC(O)OR^b, -OCONR^bR^c, -C(O)NRCO2R^b, -NRC(O)NRC(O)OR^b, -C(O)NR(OR^b), -SO2NR^cR^b, -NRSO2R^b, and -NRSO₂NR^cR^b, or optionally, two J^C1 and two J^Di, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^E1, and fused to the respective ring to which they are attached.

-106WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Ring A is a C₃-Cs non-aromatic carbocycle optionally and independently further substituted with one or more instances of J^A.

Values of the remaining variables of Structural Formulae II-V, including specific values, and provisos are each and independently as described above for the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth subset of variables of Structural Formulae II-V.

[00306] In another embodiment, the present invention is generally related to compounds of Structural Formula XI(A) or XI(B), or pharmaceutically acceptable salts thereof.

(XIA) (XIB) [00307] A first subset of variables of Structural Formulae XI(A) and XI(B) for the compounds of the invention is as follows:

Each Q² is independently -0-, -S-, -NR’-, -C(O)- -CO2- -OC(O)-, -C(O)NR’-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O- -NRC(O)-, -NRC(O)NR’-, -NRCO2-OC(O)NR’-, -SO2- -N(R)SO2- -SO2NR’-, or -(CR^cR⁷)p-Y'-.

Ring A is a 5-7 membered, non-aromatic carbocyclic ring optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-Ccalkyl, C₂-Cealkenyl, -NH₂, -NH(Ci-Cg alkyl), -N(Ci-Cc alkyl)₂, -O(Ci_C₆ alkyl), -C(0)NH₂, -C(O)NH(Ci-C₆ alkyl), -C(O)N(C!-C₆ alkyl)₂, C(O)(Ci-C₆-alkyl), -OC(O)(Ci-C₆ alkyl), -NHC(O)(Ci-C₆ alkyl), -N(C_rC₆ alkyl)C(O)(CiCe alkyl), and -CO₂R^b; wherein each of said alkyl and alkenyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-Ce alkyl), N(Ci-C₆ alkyl)₂, -OCO(C_rC₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C4 alkyl), and alkoxy. Specifically, ring A is a 5-7 membered, non-aromatic carbocyclic ring optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(C]-C₄ alkyl), -NH_2> -NHfCi-Qi

-107WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -CO₂H, and -CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-Ce alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ct-C₄ alkoxy. Specifically, ring A is a 5-7 membered carbocyclic ring optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci~C₂alkyl), -NH(Ci-C₂ alkyl)₂, Ci-C₂ alkyl, Ci-C₂ haloalkyl, Ci-C₂ hydroxyalkyl, C₂-C₄alkoxyalkyl, Ci-C₂ alkoxy, Ci-C₂ hydroxyalkoxy, Ci-C₂ haloalkoxy, C₂-C₄ alkoxyalkoxy, CO₂H, and -CO₂(Ci-C₄ alkyl).

Each R⁸ is independently -H, halogen, cyano, hydroxy, Ci-C₄ alkyl, Ci-C₄ haloalkyl, Ci-C₄ hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(C]-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), or -N(Ci-C₄ alkyl)₂.

Each R⁹ is independently -H or-CH₃.

R¹¹ and R¹² are each independently -H or -CH₃.

R^t3 and R¹⁴ are each independently -H or -CH₃, or together with the carbon atoms to which they are attached they form a cyclopropane ring.

Each R and R’ is independently -H or Ci-Ce alkyl.

Provided that if Q²-R⁵ is -OR⁵ or -NR’R⁵, then ring A is further substituted with one or more instances of J^A other than -H.

Values of the remaining variables of Structural Formulae XI(A) and XI(B), including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae (I A) and (I).

(00308] A second subset of variables of Structural Formulae XI(A) and XI(B) for the compounds of the invention is as follows:

Values of Ring A, Q², R, R’, R⁵, R⁶, R⁷, R⁸, R⁹, Rⁿ, R¹², R¹³ and R¹⁴, including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae XI(A) and XI(B).

Variable x is 0 or 1 and variable n is 0 or 1.

Values of the remaining variables of Structural Formulae XI(A) or XI(B), including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae XI(A) and XI(B).

-108WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00309] A third subset of variables of Structural Formulae XI(A) and XI(B) for the compounds of the invention is as follows:

Values of Ring A, R, R’, R⁶, R⁷, R⁸, R⁹, R¹¹, R¹², R¹³, Rⁱ⁴, x and n, including specific values, and provisos are each and independently as described above in the second subset of variables of Structural Formulae XI(A) and XI(B).

Q² is -0-, -NR’-, -CO-, -CO2- -C(O)NR’-, -NRC(O)-, -NRC(O)NR~, -NRCO2-, -OCONR’-, -NRSO2- -SO2NR'-, or-(CR⁶R⁷)p-Y¹-. Specifically, Q² is-O-, -NH-, -N(CH3)-, -C(O)-, -CO2-, -C(O)NH- -C(O)N(CH₃)- -NHC(O)-, -N(CH₃)C(O)-, -NHC(O)NR’-, -N(CH₃)C(O)NR’-, -NHCO2-, -N(CH₃)CO₂-OC(O)NR’-, -NHSO₂-, -N(CH₃)SO₂- -SO₂NH-, -SO₂N(CH₃)-, or -(CR⁶R⁷)_P-Y‘-.

Values of the remaining variables of Structural Formulae XI(A) and XI(B), including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae (IA) and (I).

[00310] A fourth subset of variables of Structural Formulae XI(A) and XI(B) for the compounds of the invention is as follows:

Values of Ring A, Q², R, R’, R⁶, R⁷, R^s, R⁹, R¹¹, R¹², R¹³, R¹⁴, x and n, including specific values, and provisos are each and independently as described above in the third subset of variables of Structural Formulae XI(A) and XI(B)

R⁵ is independently i) -H; ii) a Cj-Cg aliphatic group (e.g,, Ci-Ce-alkyl or Cz-Cs alkenyl group) optionally substituted with one or more instances of J^C1; iii) a C₃-Cs nonaromatic carbocycle optionally substituted with one or more instances of J^C1; iv) a phenyl group optionally substituted with one or more instances of J^CI; v) a 4-8 membered nonaromatic heterocycle optionally substituted with one or more instances of J^D! or vi) a 5-6 membered heteroaryl ring optionally substituted with one or more instances of J^D1.

Each J^C1 and J^D1 is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a-, -SO2R^a, -NHR^C, -C(O)R^b, -C(O)OR^b, -OC(O)R^b, -NHC(O)R^b, -C(O)NHR^C, -NHC(O)NHR°, -NHC(O)OR^b, -OCONHR^C, -NHC(O)NHC(O)OR^b, -N(CH3)R^C, -N(CH3)C(O)R^b , -C(O)N(CH3)R^C, -N(CH3)C(O)NHR^c, -N(CH3)C(O)OR^b, -OCON(CH3)R^C, -C(O)NHCO2R^b, -C(O)N(CH3)CO2R^b, -N(CH3)C(O)NHC(O)OR^b, -NHSO₂R^b, -SO2NHR^b, -SO2N(CH₃)R^b, and -N(CH₃)SO₂R^b.

-109WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00311] A fifth subset of variables of Structural Formulae XI(A) and XI(B) for the compounds of the invention is as follows:

Values of Q², R, R’, R⁵, R⁶, R⁷, R^s, R⁹, R¹¹, R¹², R¹³, R¹⁴, x and n, including specific values, and provisos are each and independently as described above in the fourth subset of variables of Structural Formulae XI(A) and XI(B).

Ring A is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci~C₄ alkyl)₂, -C(O)(C_rC₄ alkyl), -CO₂H, and CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of h halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -NH₂, -NH(Ci-C6 alkyl), -N(Ci-Ce alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_t-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C_rC₄ alkoxy.

It is provided that if Q²-R⁵ is -OR⁵ or -NR’R⁵, then ring A is further substituted with one or more instances of J^A other than -H.

[00312] A sixth subset of variables of Structural Formulae XI(A) and XI(B) for the compounds of the invention is as follows:

Values of Q², R, R’, R⁵, R⁶, R⁷, R⁸, R⁹, R¹¹, R¹², R¹³, R¹⁴, x and n, including specific values, and provisos are each and independently as described above in the fifth subset of variables of Structural Formulae XI(A) and XI(B).

The group -[(C)o-iR^I3R¹⁴]-ringA-Q²-R⁵ is independently selected from one of the depicted below

-110WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

wherein each of rings A1-A27 is independently and optionally further substituted with one or more substituents. Specifically, rings A5, A6, A21, A24, and A26 are each independently further substituted with one or more instances of substituents other than -H. Suitable substituents are as described above for ring A in the first subset of variables of Structural Formulae XI(A) and XI(B).

[00313] A seventh subset of variables of Structural Formulae XI(A) and XI(B) for the compounds of the invention is as follows:

Values of the group -[CR^t3R¹⁴]_x-ringA-Q²-R⁵, ring A, Q², R, R’, R⁶, R⁷, R^s, R⁹, R¹¹, R¹², R¹³, Rⁱ⁴, x and n, including specific values, and provisos are each and independently as described above in the sixth subset of variables of Structural Formulae XI(A) and XI(B).

Each R⁵ is independently: i) -H; ii) a Ci-C’c-aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -O(Ci-C4 alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci~C₄

-111WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 alkyl)₂, -C(O)(C_t-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), -C(O)O(C!-C₄ alkyl), -CO₂H, C₃-C_s nonaromatic carbocycle, phenyl, 4-8 membered non-aromatic heterocycle, and 5-6 membered heteroaryl; or hi) a C3-C7 non-aromatic carbocycle, a 4-7 membered non-aromatic heterocycle, a phenyl group, or a 5-6 membered heteroaiyl ring, each of which is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), and -CO₂H; wherein each of said alkyl groups for the substituents of the aliphatic group, carbocycle, heterocycle, phenyl and heteroaiyl group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci~C4 alkyl), -N(Ci-C4 alkyl)2, -OCO(Ci-C4 alkyl), -CO(Ci-C4 alkyl), -CO2H, -CO2(Ct-C4 alkyl), and C1-C4 alkoxy; and wherein each of said carbocycle, phenyl, heterocycle, and heteroaiyl for the substituents of the Ci-Cc-aliphatic group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C£-C₄ alkyl, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -C0₂H, -CO₂(C_rC₄ alkyl), and C_rC₄ alkoxy.

[00314] An eighth subset of variables of Structural Formulae XI(A) and XI(B) for the compounds of the invention is as follows:

Values of Q², R, R’, R⁵, R⁶, R⁷, R⁸, R⁹, Rⁿ,R¹², R¹³, R¹⁴, x and n, including specific values, and provisos are each and independently as described above in the seventh subset of variables of Structural Formulae XI(A) and XI(B).

The group -[(C)₀.iR¹³R¹⁴]-ringA-Q²-R⁵ is independently selected from one of the depicted below

-112WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

O , wherein each of rings A6, A8, All, A14 and A15 is optionally and independently further substituted. Suitable substituents are as described above for ring A in the first subset of variables of Structural Formulae XI(A) and XI(B).

Each R⁸ independently is halogen, cyano, hydroxy, Ci-C₄ alkyl, C1-C4 haloalkyl, CtC₄ hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(Ci-C₄ alkyl), ~NH₂, -NH(Ci-C₄ alkyl) or -N(Ci-C₄alkyl)₂.

[00315] A ninth subset of variables of Structural Formulae XI(A) and XI(B) for the compounds of the invention is as follows:

Values of the group -[CR¹³R¹⁴]_K-ringA-Q²-R⁵, ring A, Q², R, R’, R⁶, R⁷, R⁸, R⁹, R¹¹, R¹², R¹³, R¹⁴, x and n, including specific values, and provisos are each and independently as described above in the eighth subset of variables of Structural Formulae XI(A) and XI(B).

Each R⁵ is independently: i) -H; ii) an optionally substituted Ci-CG alkyl group; iii) an optionally substituted, C3-C7 non-aromatic carbocycle; or iv) an optionally substituted, 47 membered non-aromatic heterocycle, wherein said alkyl group represented by R⁵ is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C₄ alkyl), -N(C_t-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), Ci-C₄ alkoxy, optionally substituted, C3-C7 non-aromatic carbocycle, and optionally substituted, 4-7 membered nonaromatic heterocycle. Each of said carbocycles and heterocycles represented by R⁵, and referred to for the substituents of the Cj-Ce alkyl group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(C!-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(C!-C₄ alkyl), -C(O)O(Ci-C₄ alkyl) and -CO₂H, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the

-113WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy.

[00316] A tenth subset of variables of Structural Formulae XI(A) and XI(B) for the compounds of the invention is as follows:

The group -[(C)o_iR¹³R¹⁴]-ringA“Q²-R⁵ is independently selected from one of the depicted below:

wherein each of rings A1-A4, A7-A20, A22, A23, A25 and A27 is independently and optionally further substituted. Suitable substituents are as described above for ring A in the

-114WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 first subset of variables of Structural Formulae XI( A) and XI(B).

[00317] An eleventh subset of variables of Structural Formulae XI(A) and XI(B) for the compounds of the invention is as follows:

Values of Q², R, R’, R^s, R⁶, R⁷, R⁸, R⁹, R¹¹, R¹², R¹³, R¹⁴, x, and n, including specific values, and provisos are each and independently as described above in the seventh subset of variables of Structural Formulae XI(A) and XI(B).

The group -[(C)o.iR¹³R¹⁴]--ringA-Q²-R⁵ is independently selected from one of the depicted below:

wherein each of rings A5-A7, A21, A24 and A26 is independently and optionally further substituted. Suitable substituents are as described above for ring A in the first subset of variables of Structural Formulae XI(A) and XI(B).

Each R⁸ independently is halogen, cyano, hydroxy, C1-C4 alkyl, Ci-C₄ haloalkyl, C_tC₄ hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), or -N(Ci-C₄ alkyl)₂.

[00318] In a twelfth subset of variables of Structural Formulae XI(A) and XI(B) for the compounds of the invention, values of the variables for Structural Formulae XI(A) and XI(B), including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae (IA) and (I).

[00319] In a thirteenth subset of variables of Structural Formulae XI(A) and XI(B)for the compounds of the invention, values of the variables for Structural Formulae XI(A) and XI(B), including specific values, and provisos are each and independently as described above in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or eleventh subset

-115WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 of variables of Structural Formulae XI(A) and XI(B); and where applicable:

provided that if Y¹ is a bond, then R⁵ is a substituted Cj-C'e aliphatic group; an optionally substituted C3-C8 non-aromatic carbocycle; an optionally substituted, 6-10membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group; and provided that if Q² is a bond, then R⁵ is an optionally substituted C3-C& non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group.

[00320] In a fourteenth subset of variables of Structural Formulae XI(A) and XI(B) for the compounds of the invention, values of the variables for Structural Formulae XI(A) and XI(B), including specific values, and provisos are each and independently as described above in the thirteenth subset of variables of Structural Formulae XI(A) and XI(B); and where applicable:

when Y¹ is a bond, the Ci-Cg aliphatic group represented by R⁵ is substituted with one or more instances of J^C1, wherein J^CI is independently selected from: an optionally substituted, C3-C8 non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; an optionally substituted, 5-10 membered heteroaryl group; -OR^b; -SR^b; -S(O)R^a; -SO2R^a; -NR^bR^c; -C(O)R^b; -C(O)OR^b; -OC(O)R^b; -NRC(O)R^b; -C(O)NR^bR^c; -NRC(0)NR^bR^c; -NRC(O)OR^b; -OCONR^bR^c; -C(O)NRCO2R^b; -NRC(O)NRCO2R^b; -C(O)NR(OR^b); -SO2NR^qR^b; -NRS02R^b; and -NRSO2NR^cR^b; or optionally two J^CI and two J^DI, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^Et, and fused to the respective ring to which they are attached.

[00321] In a fifteenth subset of variables of Structural Formulae XI(A) and XI(B), values of the variables for Structural Formulae XI(A) and XI(B), including specific values, are each and independently as described above in the thirteenth subset of variables of Structural Formulae (IA) and (I), in the eleventh subset of variables of Structural Formula (VI), or in the fifteenth subset of variables of Structural Formulae (II)-(V).

In another embodiment, the present invention generally relates to compounds of Structural Formula XII(A) or XII(B), or pharmaceutically acceptable salts thereof.

-116WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00322] A first subset of variables of Structural Formulae ΧΠ(Α) and XII(B) for the compounds of the invention is as follows:

Each Q³ is independently -C(O)-, -CO2- -C(O)NR’-, -SO₂-, -SO₂NR’-, -C(O)NRC(O)O- or -(CRV),

Ring B is a 4-7 membered, non-aromatic, heterocyclic ring optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-Ce alkyl, C₂-Cg alkenyl, -NH₂, -NH(Ci-Cg alkyl), -N(Ci-Cg alkyl)₂, -O(Ci.C₆ alkyl), -C(O)NH₂, -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ci-C₆ alkyl)₂, C(O)(Ci-C6-alkyl), -OC(O)(Ci-C₆ alkyl), -NHC(O)(Ci-C₆ alkyl), -NfCj-Ce alkyl)C(O)(C_rCe alley 1), and -CO₂R^b; wherein each of said alkyl and alkenyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-Cg alkyl), N(C_rC₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Cj-C₄alkoxy. Specifically, Ring B is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄alkyl, -O(Ci-C₄ alkyl), -NH_2> -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(C,-C₄ alkyl), -CO₂H, and -CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -NH₂, -NH(Ci-Cg alkyl), N(Ci-C₆ alkyl)₂, -OCO(C_rC₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C_rC₄alkoxy. Specifically, Ring B is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, NH(Ci-C₂ alkyl), -NH(Ci-C₂ alkyl)₂, Ci-C₂ alkyl, Ci-C₂ haloalkyl, Ci-C₂ hydroxyalkyl, C₂C₄ alkoxyalkyl, Ci-C₂ alkoxy, Ci-C₂ hydroxyalkoxy, Ci-C₂ haloalkoxy, C₂-C₄ alkoxyalkoxy, -CO₂H, and -CO₂(C,-C₄ alkyl).

R⁶ and R⁷ are each independently -H or ~CH₃, or together with the carbon atoms to which they are attached they form a cyclopropane ring.

-117WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

R⁹ is -H or -CH₃.

R¹¹ and R¹² are each independently -H or -CH₃.

Each R and R’ is independently -H or Ci-Cg alkyl.

Provided that if Q³ is -0(0)-, then R⁵ is a substituted Cj-Cg aliphatic group; an optionally substituted C3-Cg non-aromatic carbocycle; an optionally substituted, 6-10membered carbocyclic aiyl group; optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted 5-10 membered heteroaryl group. Specifically, the Ci-Cg aliphatic group is substituted with one or more instances of J^CI, wherein J^C1 is independently selected from: an optionally substituted, C3-Cg non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; an optionally substituted, 5-10 membered hetero aryl group; -OR^b; -SR^b; -S(O)R^a; -SO2R^a; -NR^bR^c; -C(O)R^b; -C(O)OR^b; -OC(O)R^b; -NRC(0)R^b; -C(O)NR^bR^c; -NRC(O)NR^bR^c; -NRC(O)OR^b; -0C0NR^bR^c; -C(O)NRCO2R^b; -NRC(O)NRCO2R^b; -C(O)NR(OR^b); -SO2NR^cR^b; -NRSO2R^b; and -NRSO2NR^cR^b; or optionally two J^C1 and two J^D1, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^E1, and fused to the respective ring to which they are attached.

Values of the remaining variables of Structural Formulae XII(A) and XII(B), including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae (IA) and (I).

[00323] A second subset of variables of Structural Formulae XII(A) and XII(B) for the compounds of the invention is as follows:

Values of Ring B, Q³, R, R^!, R⁶, R⁷, R⁹, Rⁿ,R^]2, R¹³, and R¹⁴, including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae XII(A) and XII(B).

Variable y = 0 or 1.

Values of the remaining variables of Structural Formulae XII(A) and XII(B), including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae (I A) and (I).

[00324] A third subset of variables of Structural Formulae XII(A) and XII(B) is as follows:

Values of Ring B, R, R’, R⁶, R⁷, R⁹, Rⁿ, R¹², R¹³, R¹⁴ and y, including specific values,

-118WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 and provisos are each and independently as described above in the second subset of variables of Structural Formulae XII(A) and XII(B).

Q³ is independently -C(O)-, -CO₂~, -C(O)NH- -C(O)N(CH₃)-, -C(O)NHC(O)O-, -C(O)N(CH₃)C(O)O-, -SO2-, -SO2NH-, -SO₂N(CH₃)-, or -(CR^jp-Y¹-.

[00325] A fourth subset of variables of Structural Formulae XII(A) and XII(B) for the compounds of the invention is as follows:

Values of Ring B, Q³, R, R’, R⁶, R⁷, R⁹, R¹¹, R¹², R¹³, R¹⁴, andy, including specific values, and provisos are each and independently as described above in the third subset of variables of Structural Formulae XII(A) and XII(B).

R⁵ is independently i) -H; ii) a Ci-Ce aliphatic group (e.g., Ci-Cs-alkyl or C2-Cealkenyl group) optionally substituted with one or more instances of J^cl; iii) a C3-Cs nonaromatic carbocycle optionally substituted with one or more instances of J^C1; iv) a phenyl group optionally substituted with one or more instances of J^C1; v) a 4-8 membered nonaromatic heterocycle optionally substituted with one or more instances of J^DI or vi) a 5-6 membered heteroaryl ring optionally substituted with one or more instances of J^D1.

Each of J^C1 and J^DI is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a, -SO2R^a, -NHR^C, -C(O)R^b, -C(O)OR^b, -OC(O)R^b, -NHC(O)R^b, -C(O)NHR^C, -NHC(O)NHR^C, -NHC(O)OR^b, -OCONHR^C, -NHC(O)NHC(O)OR^b, -N(CH3)R^C, -N(CH3)C(O)R^b, -C(O)N(CH3)R', -N(CH₃)C(O)NHR^C, -N(CH₃)C(O)OR^b, -OCON(CH3)R^c, -C(O)NHCO2R^b, -C(O)N(CH3)CO2R^b, -N(CH3)C(O)NHC(O)OR^b, -NHSO₂R^b, -SO2NHR^b, -SO2N(CH₃)R^b, and -N(CH₃)SO₂R^b.

[00326] A fifth subset of variables of Structural Formulae XII(A) and XII(B)for the compounds of the invention is as follows:

Values of Q³, R, R’, R⁵, R⁶, R⁷, R⁹, Rⁿ,R¹², Rⁱ³, R¹⁴, and y, including specific values, and provisos are each and independently as described above in the fourth subset of variables of Structural Formulae XII(A) and XII(B).

Ring B is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄

-119WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -CO₂H, and CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C6 alkyl), -N(Ci-Ce alkyl)₂, -OCO(Ci-C₄alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C_rC₄ alkoxy.

[00327] A sixth subset of variables of Structural Formulae XII(A) and XII(B) for the compounds of the invention is as follows:

Values of Q³, R, R’, R⁵, R⁶, R⁷, R⁹, R¹¹, R¹², R¹³, R¹⁴, and y, including specific values, and provisos are each and independently as described above in the fifth subset of variables of Structural Formulae XII(A) and XII(B).

Ring B is independently selected from one of the structures depicted below:

wherein each of rings Bl, B2 and B4-B9 is optionally and independently substituted. Suitable substituents are independently as described above for ring B in the first subset of variables of Structural Formulae (IA) and (I).

[00328] A seventh subset of variables of Structural Formulae XII (A) and XII(B) for the compounds of the invention is as follows:

Values of the ring B, Q³, R, R’, R°, R⁷, R⁹, R¹¹, R¹², R¹³, R.¹⁴, and y, including specific values, and provisos are each and independently as described above in the sixth subset of variables of Structural Formulae XII(A) and XII(B).

Each R⁵ is independently: i) -H; ii) a Ci-Ce-aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄

-120WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), -CO₂H, C₃-C₈ nonaromatic carbocycle, phenyl, 4-8 membered non-aromatic heterocycle, and 5-6 membered heteroaryl; or iii) a Cr-C? non-aromatic carbocycle, a 4-7 membered non-aromatic heterocycle, a phenyl group, or a 5-6 membered heteroaryl ring, each of which is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(C,-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(C!-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), and -CO₂H; wherein each of said alkyl groups for the substituents of the aliphatic group, carbocycle, heterocycle, phenyl and heteroaryl group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -OCO(C!-C4 alkyl), -CO(CrC4 alkyl), -CO2H, -CO2(Ci-C4 alkyl), and C1-C4 alkoxy; and wherein each of said carbocycle, phenyl, heterocycle, and heteroaryl for the substituents of the Ci-CG-aliphatic group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C4 alkyl, -NH₂, -NH(Ci~C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_rC₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and CiC₄ alkoxy.

Values of the remaining variables of Structural Formulae XII(A) and XII(B), including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae (IA) and (1).

[00329] An eighth subset of variables of Structural Formulae XII(A) and XII(B) for the compounds of the invention is as follows:

Values of Q³, R, R’, R⁵, R⁶, R⁷, R⁹, R¹¹, R¹², R¹³, R¹⁴, and y, including specific values, and provisos are each and independently as described above in the seventh subset of variables of Structural Formulae XII(A) and XH(B).

The group -[C(R¹³Rⁱ⁴)]_x-ringB-Q²-R⁵:

Q³

R⁵, wherein ring B2 is optionally and independently further substituted with one or more substituents independently selected from the group consisting of with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy,

-121WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 oxo, -NH₂, -NH(C1-C₂ alkyl), -NH(C_t-C₂ alkyl)₂, Ci-C₂ alkyl, C_rC₂ haloalkyl, Ci-C₂hydroxyalkyl, C₂-C₄ alkoxyalkyl, Ci-C₂ alkoxy, Ci-C₂ hydroxyalkoxy, Ci-C₂ halo alkoxy, C₂C₄ alkoxyalkoxy, -CO₂H, and -CO₂(Ci-C₄ alkyl).

Values of tire remaining variables of Structural Formulae XII(A) and XII(B), including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae (IA) and (I).

[00330] A ninth subset of variables of Structural Formulae XII(A) and XII(B) for the compounds of the invention is as follows:

Values of ring B, Q³, R, R’, R⁶, R⁷, R^y, Rⁿ,R¹², R¹³, R¹⁴, and y, including specific values, and provisos are each and independently as described above in the eighth subset of variables of Structural Formulae XII(A) and XII(B).

Each R⁵ is independently: i) -H; ii) an optionally substituted Ci-Cc alkyl group; iii) an optionally substituted, C3-C7 non-aromatic carbocycle; or iv) an optionally substituted, 47 membered non-aromatic heterocycle, wherein said alkyl group represented by R⁵ is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ct-C4 alkyl), -N(Ci-C4 alkyl)2, -OCO(Ci-C4 alkyl), -CO(Ci-C4 alkyl), -CO2H, -CO2(Ci-C4 alkyl), Ci-C4 alkoxy, optionally substituted, C3-C7 non-aromatic carbocycle, and optionally substituted, 4-7 membered nonaromatic heterocycle. Each of said carbocycles and heterocycles represented by R⁵, and referred to for the substituents of the Ci-Ce alkyl group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C4 alkyl, -O(Ci--C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -NfC^ alkyl)₂, -C(O)(C,-C₄ alkyl), -OC(O)(Cj-C₄ alkyl), -C(O)O(Ci-C₄ alkyl) and -CO₂H, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci~C₄ alkyl), -N(Ci-C₄alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(C|-C₄ alkyl), and Ci-C₄ alkoxy.

[00331] In a tenth set of variables of Structural Formulae XII(A) and XII(B) for the compounds of the invention, values of the variables for Structural Formulae XII(A) and XII(B), including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae (IA) and (I).

-122WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00332] In an eleventh subset of variables of Structural Formulae XII(A) and XII(B)for the compounds of the invention, values of the variables for Structural Formulae XH(A) and XII(B), including specific values, and provisos are each and independently as described above in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or eleventh subset of variables of Structural Formulae XII(A) and XII(B); and where applicable:

provided that if Y¹ is a bond, then R⁵ is a substituted Ci-Cg aliphatic group; an optionally substituted CvCg non-aromatic carbocycle; an optionally substituted, 6-10membered carbocyclic aiyl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group; and provided that if Q³ is a bond, then R⁵ is an optionally substituted Cs-Cg non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted, 5-10 membered heteroary group.

[00333] In a twelfth subset of variables of Structural Formulae XII(A) and XII(B)for the compounds of the invention, values of the variables for Structural Formulae XII(A) and XII(B), including specific values, and provisos are each and independently as described above in the eleventh subset of variables of Structural Formulae XII(A) and XII(B); and where applicable:

when Y¹ is a bond, the Ci-Cg aliphatic group represented by R⁵ is substituted with one or more instances of J^C1, wherein J^C1 is independently selected from: an optionally substituted, C?,-Cs non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; an optionally substituted, 5-10 membered heteroaryl group; -OR^b; -SR^b; -S(O)R^a; -SO2R^a; -NR^bR^c; -C(O)R^b; -C(O)OR^b; -OC(O)R^b; -NRC(O)R^b; -C(O)NR^bR^c; -NRC(O)NR^bR^c; -NRC(O)OR^b; -OCONR^bR^q; -C(O)NRCO2R^b; -NRC(O)NRCO2R^b; -C(O)NR(OR^b); -SO2NR^cR^b; -NRSO2R^b; and -NRSO2NR^cR^b; or optionally two J^C1 and two J^DI, respectively, together with the atoms to which they are attached, independently form a 5-7-membered ring that is optionally substituted with one or more instances of J^E1, and fused to the respective ring to which they are attached.

[00334] In a thirteenth subset of variables of Structural Formulae XII(A) and XII(B), values of the variables for Structural Formulae XII(A) and XII(B), including specific values, are each and independently as described above in the thirteenth subset of variables of Structural Formulae (IA) and (I), in the eleventh subset of variables of Structural Formula

-123WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

VI, or in the fifteenth subset of variables of Structural Formulae II-V.

[00335] In another embodiment, the present invention generally relates to compounds of Structural Formula XIII, or pharmaceutically acceptable salts thereof:

(XIII).

[00336] A first subset of variables of Structural Formula XIII for the compounds of the invention is as follows:

Ring C is a 5-7 membered, non-aromatic, heterocyclic ring optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, Ci-Ce alkyl, C₂-Ce alkenyl, -NH₂, -NH(Ci-Ce alkyl), -N(CrCe alkyl)₂, -O(Ci.C₆ alkyl), -C(O)NH₂, -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ci-C₆ alkyl)₂, C(O)(Ci-C₆-alkyl), -OC(O)(C_rC₆ alkyl), -NHC(O)(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)C(O)(Ci-C₆alkyl), and -CO₂R^b; wherein each of said alkyl and alkenyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-Ce alkyl), -N(Ci-Ce alkyl)₂, -OCO(C,-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(C)-C₄ alkyl), and Ci-C₄ alkoxy. Specifically, ring C is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, Ci-C₄ alkyl, -O(CrC₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -CO₂H and -CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-Ce alkyl), -N(Cj-C₆ alkyl)₂, -OCO(Ci-C₄alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy. Specifically, ring C is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, -NH₂, -NH(Ci-C₂ alkyl), -NH(Ci-C₂alkyl)₂, Ci-C₂ alkyl, Ci-C₂ haloalkyl, Ci-C₂ hydroxyalkyl, C₂-C₄ alkoxyalkyl, Ci-C₂ alkoxy, Ci-C₂ hydroxyalkoxy, C]-C₂ haloalkoxy, C₂-C₄ alkoxyalkoxy, -CO₂H, and -CO₂(Ci-C₄alkyl).

-124WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

R⁹ is -H or -CH₃.

R^{1 1} and R¹² are each independently -H or -CH₃.

Each R and R’ is independently -H or Cj-Cs alkyl.

Values of the remaining variables of Structural Formula XIII, including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae (IA) and (I).

[00337] A second subset of variables of Structural Formula XIII for the compounds of the invention is as follows:

Values of Ring C, R, R’, R⁶, R⁷, R⁹, R¹¹, andR¹², including specific values, are each and independently as described above in the first subset of variables of Structural Formula XIII.

R¹⁰ is -H or Ci-Ce-alkyl.

[00338] A third subset of variables of Structural Formula XIII for the compounds of the invention is as follows:

Values of R, R’, R⁶, R⁷, R⁹, R¹⁰, R¹¹, andR¹², including specific values, are each and independently as described above in the second subset of variables of Structure Formula XIII.

Ring C is a 5-7 membered, non-aromatic, heterocyclic group optionally further substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C_rC₄ alkyl, -O(C_rC₄ alkyl), -NH₂, -NH(C]-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -CO₂H, and -CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(C_t-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci04 alkoxy.

[00339] A fourth subset of variables of Structural Formula XIII for the compounds of

-125WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 the invention is as follows:

Values of R, R’, R⁶, R⁷, R⁹, R¹⁰, R¹¹, andR¹², including specific values, are each and independently as described above in the third subset of variables of Structure Formula XIII.

Ring C is independently selected from:

wherein each of rings C1-C5 is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, Ci-C₄ alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄alkyl), -CO₂H, and -CO₂(Ci-C4 alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more independently substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH_2> -NH(Ci-Cg alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_rC₄ alkyl), -CO₂H, -CO₂(C!-C4 alkyl), and C_rC4 alkoxy.

Specifically, each of rings C1-C5 is optionally and independently further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, -NH₂, -NH(Ci-C₂ alkyl), -NH(Ci-C₂ alkyl)₂, Ci-C₂ alkyl, C_rC₂ haloalkyl, Ci-C₂ hydroxyalkyl, C₂-C₄ alkoxyalkyl, C1-C2 alkoxy, Ci-C₂ hydroxy alkoxy, Ci-C₂haloalkoxy, C2-C4 alkoxyalkoxy, -CO₂H, and -CO₂(Ci-C₄ alkyl).

Values of the remaining variables of Structural Formula ΧΙΠ, including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae (IA) and (I).

[00340] In a fifth set of variables of Structural Formula XIII for the compounds of the invention, values of the variables for Structural Formula XIII, including specific values, are each and independently as described above in the first subset of variables of Structural Formulae (IA) and (I).

[00341] In another embodiment, the present invention generally relates to compounds represented by Structural Formula below XIV, or a pharmaceutically acceptable salt thereof:

-126WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

(XIV).

[00342] A first subset of variables of Structural Formula XIV for the compounds of the invention is as follows:

Ring D is 4-7 membered, non-aromatic, heterocyclic ring optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-Cg alkyl, C₂-Ce alkenyl, -NH₂, -NH(Ci-Cg alkyl), -N(Ci-Cg alkyl)₂, -O(CiC₆ alkyl), -C(O)NH₂, -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ci-C₆ alkyl)₂, -C(O)(C_rC₆-aIkyl), -OC(O)(Ci-C₆ alkyl), -NHC(O)(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)C(O)(Ci-C₆ alkyl), and -CO₂R^b; wherein each of said alkyl and alkenyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-Cfi alkyl), -N(Ci-Cg alkyl)₂, -OCO(Ci-C4 alkyl), -CO(C!-C₄ alkyl), -CO₂H, -CO₂(C|-C4 alkyl), and Ci-C4 alkoxy. Specifically, ring D is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C4 alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -CO₂H and -CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH^-Ce alkyl), -N(C]-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Ci-C4 alkyl), and Cj-C4 alkoxy. Specifically, ring D is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₂ alkyl), -NH(Ci-C₂ alkyl)₂, Ci-C₂ alkyl, C[-C₂ haloalkyl, Ci-C₂ hydroxyalkyl, C₂-C4 alkoxyalkyl, Ci-C₂ alkoxy, Ci-C₂hydroxyalkoxy, Ci-C^ haloalkoxy, C₂-C4 alkoxyalkoxy, -CO₂H, and-CO₂(Ci-C4 alkyl).

Rⁿ and R¹⁴ are each independently -H or-CHj, or together with the carbon atoms to which they are attached they form a cyclopropane ring.

-127WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Each of R and R’ is independently -H or Ci-Cg alkyl.

Vlaues of the remaining variables of Structural Formula XIV, including specific values, and provisos are each and independently as described above in the first subset of variables of Structural Formulae (IA) and (I).

[00343] A second subset of variables of Structural Formula XIV for the compounds of the invention is as follows:

Values for Ring D, R, R’, R⁶, R⁷, R¹³, and R¹⁴, including specific values, are each and independently as described above in the first subset of variables of Structural Formula XIV.

Variable z is 1.

All other variables of Structural Formula XIV, including specific values, and provisos are each and independently as described above for the first subset of variables of Structural Formulae (IA) and (I).

[00344] A third subset of variables of Structural Formula IV for the compounds of the invention is as follows:

Values for z, R, R’, R⁶, R⁷, R^!3, and R¹⁴, including specific values, are each and independently as described above in the second subset of variables of Structural Formula XIV.

Ring D is independently selected from the group consisting of

wherein each of rings D1-D7 is optionally and independently substituted one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -O(C]-C₄ alkyl), -NH₂, -NH(Ci~C₄ alkyl), -N(Ci-C₄ alkyl)_2s -C(O)(C_rC₄alkyl), -CO₂H and -CO₂(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-Ci, alkyl), -N(Ci-C6 alkyl)₂, -OCO(C_rC₄ alkyl), -CO(C,-C₄ alkyl), -CO₂H, -C0₂(C!-C₄ alkyl), and C1-C4 alkoxy.

Specifically, each of rings D1-D7 is optionally and independently further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₂ alkyl), -NH(C_t-C₂ alkyl)₂, Ci-C₂ alkyl, Cj-C₂

-128WO 2010/148197

PCT7US2010/038988

2018200219 11 Jan 2018 haloalkyl, Ci-C₂ hydroxyalkyl, C₂-C₄ alkoxyalkyl, C1-C2 alkoxy, Ci-C₂ hydroxyalkoxy, C[C₂ haloalkoxy, C2-C4 alkoxyalkoxy, -CO₂H, and -CO₂(Ci-C₄ alkyl).

Each R^d is independently -H, Ci-Ce alkyl or - C(O)(Ci-CG alkyl), wherein each of said alkyl moiety is optionally and independently substituted with one or more groups selected from halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-Ce alkyl), -N(Ci-Ce alkyl)2, -OCO(CrC4 alkyl), -CO(Ci-C4 alkyl), -CO2H, -CO2(Ci-C4 alkyl), and Ci-C4 alkoxy. Specifically, each R^d is independently -H or Ci-CG alkyl optionally and independently substituted with one or more groups selected from halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C_e alkyl), -N(Ci-C₀ alkyl)₂, -OCO(C_t-C₄ alkyl), -C0(C_rC₄ alkyl), -CO₂H, -CO₂(CiC₄ alkyl), and Cj-C₄ alkoxy.

Vlaues of the remaining variables of Structural Formula XTV, including specific values, and provisos are each and independently as described above for the first subset of variables of Structural Formulae (IA) and (I).

[00345] In a fourth subset of variables of Structural Formula XIV for the compounds of the invention, values of the variables for Structural Formula XIV, including specific values and provisos, are each and independently as described above in the first subset of variables of Structural Formulae (IA) and (I).

[00346] In yet another embodiment, the compounds are represented by Structural Structural Formula (I), or pharmaceutically acceptable salts thereof, wheren each variables of the formulae are independently as described above; and wherein:

R⁴ is:

Ring E is a C₄-Cs non-aromatic carbocycle optionally further substituted with one or more instances of J^A.

Q² is independently bond, -O-, -S-, -NR-, -C(O)-, -C(=NR)-, -CO₂-, -OC(O)-, -C(O)NR-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O-, -NRC(O)-, -NRC(O)NR-129WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

-NRCO2-, -OC(O)NR- -S(O)-, -SO2- -N(R)SO₂-, -SO₂NR’-, -NRSO₂NR’-, or -(CR⁶R⁷)_p-Y¹-.

R⁵ is: i) -H; ii) an optionally substituted Ci-Cg alkyl group; iii) an optionally substituted, C3-C7 non-aromatic carbocycle; or iv) an optionally substituted, 4-7 membered non-aromatic heterocycle; or optionally, together with R and the nitrogen atom to which it is attached, form a 5-7 membered, optionally substituted non-aromatic heterocycle. The alkyl group represented by R³ is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -OCO(Ci-C4 alkyl), -CO(Ci-C4 alkyl), -CO2H, -CO2(Ci-C4 alkyl), C1-C4 alkoxy, an optionally substituted, C3-C7 non-aromatic carbocycle, and an optionally substituted, 4-7 membered non-aromatic heterocycle; wherein each of said carbocycles and heterocycles represented by R⁵, and referred to for the substituents of the Ci-Cg alkyl group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(CS-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), OC(O)(Ci-C₄ alkyl), -C(O)0(Ci-C₄ alkyl) and -CO₂H, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(C_£-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C]-C₄ alkyl), -CO₂H, -CO₂(C_t-C₄ alkyl), and Ci04 alkoxy.

Each of R⁸ and R⁹ is independently -H, halogen, cyano, hydroxy, C|-C₄ alkyl, Ci-C₄haloalkyl, C_£-C₄ hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(Ct-C₄ alkyl), -NH₂, -NH(Cj-C₄alkyl), or -N(Ci-C₄ alkyl)₂.

R¹¹, R¹², R¹³ and R¹⁴ arc each independently -H, halogen, or Ci-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, oxo, amino, carboxy, Ci-Cg alkoxy, C_£-Cg haloalkoxy, Ci-Cg aminoalkoxy, Ci-Cg cyanoalkoxy, Ci-Cg hydroxy alkoxy, and C₂-Cg alkoxyalkoxy; or optionally, R¹³ and R¹⁴, together with the carbon atom to which they are attached, form a cyclopropane ring, optionally substituted with one or more instances of methyl.

R²¹, R²², R²³ and R²⁴ are each independently -H, halogen, -OH, or Ci-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, oxo, amino, carboxy, Ci-Cg alkoxy, Ci-Ce haloalkoxy, Ci-Cg aminoalkoxy, Ci-Cg cyanoalkoxy, Ci-Cg hydroxyalkoxy, and C₂-Cg alkoxy alkoxy.

-130WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 p and q are each independently 0, 1 or 2.

x is 0, 1 or 2.

r is 1 or 2.

[00347] In yet another embodiment, the compounds represented by Structural Formula (I) or pharmaceutically acceptable salts thereof are independently as described above in the preceding paragraph; and ring F is selected from any one of rings F1-F6:

O

each of rings F1-F6 optionally and independently substituted; and each R^f is independently -H or Ci-Ce alkyl optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ci-Cg alkoxy, Ci-Ce haloalkoxy, Ci-Cg aminoalkoxy, Ci-Cgcyanoalkoxy, Ci-Cg hydroxyalkoxy and Cz-Ce alkoxyalkoxy.

[00348] In yet another embodiment, the compounds represented by Structural Formula (XIA) or (XIB), or pharmaceutically acceptable salts thereof are as described above; and the group-[C(R^l3R¹⁴)]_x-ringA-Q²-R⁵ is independently:

each of rings A14 and A28 is optionally and independently further substituted; and values of the remaining variables of Structural Formulae (XIA) and (XIB), including specific values, and provisos are each and independently as described above in any one of the first through eleventh sets of variables of Structural Formulae (XIA) and (XIB).

[00349] In yet another embodiment, the compounds represented by Structural Formula (XIA) or (XIB), or pharmaceutically acceptable salts thereof are independently as described above in the preceding paragraph; and R^s is an optionally substituted Ci-Ce alkyl group; an optionally substituted, C3-C7 non-aromatic carbocycle; or an optionally substituted, 4-7 membered non-aromatic heterocycle; or optionally, together with R and the nitrogen atom to which it is attached, form a 5-7 membered, optionally substituted non-aromatic heterocycle. Specifically, R⁵ is an optionally substituted, 4-7 membered non-aromatic heterocycle; or

-131WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 optionally, together with R and the nitrogen atom to which it is attached, form a 5-7 membered, optionally substituted non-aromatic heterocycle, [00350] In yet another embodiment, the compounds are represented by Structural Formula (IA) or (I), or pharmaceutically acceptable salts, wherein:

Ύ,/ Ο

Additional example includes .. Each of rings F1-F7 optionally and independently substituted. Exemplary substituents for ring F (including rings F1-F7) include halogen, cyano, hydroxy, C1-C4 alkoxy, and C1-C4 alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, and -O(CiC₄ alkyl).

R^f is independently -H or Ci-Ce alkyl optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ce aminoalkoxy, Ci-Ce cyanoalkoxy, Cj-Cg hydroxy alkoxy and C2-C6 alkoxyalkoxy.

R⁹ is independently -H, halogen, cyano, hydroxy, amino, carboxy, Ci-Cq alkyl, Ci-Ce haloalkyl, Ci-Ce cyanoalkyl, C₂-Ce alkoxyalkyl, Ci-C₆ aminoalkyl, Ci-Ce hydroxyalkyl, CiCe carboxyalkyl, Ct-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ce amino alkoxy, Ci-Ce cyanoalkoxy, Ci-Cehydroxyalkoxy, or C₂-Ce alkoxyalkoxy.

R¹¹, R¹², R¹³ and R¹⁴ are each independently -H, halogen, or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, oxo, amino, carboxy, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ce aminoalkoxy, Ci-C₆ cyanoalkoxy, Ci-Ce hydroxy alkoxy, and C^-Ce alkoxyalkoxy.

-132WO 2010/148197

PCT/US2010/038988

Optionally, R¹³ and R⁵⁴, together with the carbon atom to which they are attached, form a cyclopropane ring, optionally substituted with one or more instances of methyl.

s is 0, 1 or 2.

x is 0,1 or 2.

[00351] In yet another embodiment, the compounds are represented by Structural Formula (I) or (IA), or pharmaceutically acceptable salts thereof, wherein:

Ring E is a C₄-C§ non-aromatic carbocycle optionally further substituted with one or more instances of J^A.

R⁹ is independently -H, halogen, cyano, hydroxy, Ci-C₄ alkyl, Ci-C₄ haloalkyl, Ci-C₄hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(C,-C₄ alkyl), -NH₂, -NH(Ci~C₄ alkyl), or -N(Ci-C₄alkyl)₂.

The other varibales are each and independently as described in the proceeding paragraph.

[00352] In yet another embodiment, the compounds are represented by Structural Formula (IA) or (I), or pharmaceutically acceptable salts, wherein:

R⁴ is:

X is -O-, -S-, or -NR^S-.

-133WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

R^s and R⁹ are each independently -H, halogen, cyano, hydroxy, amino, carboxy, CiCo alkyl, Ci-Cg haloalkyl, Ci-Cg cyanoalkyl, C₂-Cg alkoxyalkyl, Ci-Cg aminoalkyl, Ci-Cg hydroxyalkyl, Ci-Cg carboxyalkyl, Ci-Cealkoxy, Ci-Cg haloalkoxy, Ci-Cg aminoalkoxy, CiCg cyanoalkoxy, Ci-Cg hydroxyalkoxy, or C₂-C₆ alkoxyalkoxy.

R¹³ and R¹⁴ are each independently -H, halogen, or Ci-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, oxo, amino, carboxy, Ci-Cg alkoxy, Ci-Cg haloalkoxy, Ci-Cg aminoalkoxy, G-Cg cyanoalkoxy, Ci-C₆ hydroxyalkoxy, and C₂-Ce alkoxy alkoxy.

R²¹, R²², R²³, R²⁴, and R²⁵are each independently -H, halogen, -OH, Ci-Cg alkoxy, or Ci-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, oxo, amino, carboxy, Ci-Cg alkoxy, CiCg haloalkoxy, Ci-Cg aminoalkoxy, Cj-Cccyanoalkoxy, Ci-Cg hydroxyalkoxy, and C2-Cg alkoxyalkoxy. Specifically, R²¹, R²², R²³, R²⁴, and R²⁵ are each independently -H, halogen, -OH, Ci-Cg alkoxy, or Ci-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, Ci-Cg alkyl, -NH2, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -O(Ci-C₆ alkyl), -C(O)NH₂, -C(O)NH(Ci-C₆alkyl), -C(O)N(Ci-Cg alkyl)₂, -C(O)(Ci-C₆-alkyl), -OC(O)(Ci-Cg alkyl), -NHC(O)(Ci-C₆alkyl), -N(Ci-C₆ alkyl)C(O)(Ci-C6 alkyl).

R^s is -H or Ci-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, Ci-Ce alkoxy, Ci-Cg haloalkoxy, Ci-Cg amino alkoxy, Ci-Cg cyanoalkoxy, Ci-Cg hydroxyalkoxy, and C₂-Cg alkoxyalkoxy.

q is 0, 1 or 2; x is 0, 1 or 2; and r is 1 or 2.

[00353] In yet another embodiment, the compounds are represented by Structural Formula (IA) or (I), pharmaceutically acceptable salts thereof, wherein:

R⁴is:

-134WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Each of R^s and R⁹ is independently -H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(C_t-C₄ alkyl), -NH₂, -NH(Ci-C₄alkyl), or-N(Ci-C₄alkyl)₂.

R²¹, R²², R²³, and R²⁴ are each independently -H, halogen, -OH, or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, oxo, amino, carboxy, Cj-Cf, alkoxy, Ct-Ce haloalkoxy, Ci-Q aminoalkoxy, C]-C_c cyanoalkoxy, Ci-C₆ hydroxyalkoxy, and C₂-C₆alkoxy alkoxy.

Q² is independently a bond, -O-, -S-, -NR-, -C(O)-, -C(=NR)-, -CO2-, -OC(O)~, -C(O)NR- -C(O)NRC(O)O-, -NRC(O)NRC(O)O-, -NRC(O)-, -NRC(O)NR-, -NRCO2-OC(O)NR- -S(O)-, -SO2-, -N(R)SO2- -SO2NR’-, -NRSO2NR’-, or -(CRVjp-Y¹-. Alternatively Q² is independently -0-, -CO2-, -OC(O)-, -C(O)NR- -NRC(O)-, -NRC(O)NR- -NRCO2-, -OC(O)NR-, -CO₂SO₂-, -P(O)₂O-, or -(CR^cR⁷)r-Y'-. Alternatively Q² is independently -O- or -CO2-.

[00354] In some embodiments, rings E and G (including G1-G5) are optionally and independently further substituted with one or more instances of J^A (for carbocycle) or J^B (for heterocycle), wherein each of J^A and J^B is independently selected from the group consisting of halogen, cyano, oxo, -NCO, andQ^l-R⁵, and wherein:

Q¹ is independently a bond, -0-, -S-, -NR-, -C(O)-, -C(=NR)-, -CO2- -OC(O)-, -C(0)NR- -C(O)NRC(O)O-, -NRC(O)NRC(O)O-, -NRC(O)-, -NRC(O)NR-, -NRCO2-, -OC(O)NR- -S(O)-, -SO2-, -N(R)SO2-, -SO2NR’-, -NRSO2NR’-, or -(CR^'^-Y¹-; and Y¹ is independently a bond, -0-, -S-, -NR’-, -C(O)-, -C(=NR)-, -CO2-, -OC(O)-C(O)NR'-, -C(O)NRC(O)O- -NRC(O)NRC(O)O-, -NRC(O)-, -NRC(0)NR’-, -NRCO2-, -OC(O)NR’-, -S(O)-, -SO2-, -SO₂NR’-, -NRSO2-, or -NRSO₂NR’-.

Alternatively: Q¹ is independently a bond, -0-, -S-, -NR-, -C(O)-, -CO2-, -OC(O)-, -C(O)NR- -C(O)NRC(O)O- -NRC(0)NRC(0)0-, -NRC(O)-, -NRC(0)NR-135WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

-NRCO2-, -OC(O)NR-, -S(O)-, -SO2-, -N(R)SO₂“, ~SO₂NR’-, -NRSO₂NR’-, or -(CR⁶R⁷)p-Y^I-; and Y¹ is independently -O-, -CO₂-, -OC(O)-, -C(O)NR- -NRC(O)-NRC(O)NR- -NRCO2-, or -OC(O)NR[00355] In yet another embodiment, Q¹ and Y¹ are each independently as described above in the proceeding paragraph, and:

R⁵ is independently i) -H; ii) a Ci-Ce-aliphatic group optionally substituted with one or more instances of J^C1; iii) a C₃-Cs non-aromatic carbocycle optionally substituted with one or more instances of J^C1; iv) a phenyl group optionally substituted with one or more instances of J^C1; v) a 4-8 membered non-aromatic heterocycle optionally substituted with one or more instances of J^D1 or vi) a 5-6 membered heteroaryl ring optionally substituted with one or more instances of J^DI; and each of J^C1 and J^D1 is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a, -SO2R^a, -NHR^C, -C(O)R^b, -C(O)OR^b, -OC(O)R^b, -NHC(O)R^b, -C(O)NHR^C, -NHC(O)NHR^C, -NHC(O)OR^b, -OCONHR^C, -NHC(O)NHC(O)OR^b, -N(CH3)R^C, -N(CH3)C(O)R^b , -C(O)N(CH3)R^C, -N(CH3)C(O)NHR^C, -N(CH3)C(O)OR^b, -OCON(CH3)R^C, -C(O)NHCO2R^b, -C(O)hJ(CH3)CO2R^b, -N(CH3)C(O)NHC(O)OR^h, -NHSO₂R^b, -SO2NHR^b, -SO2N(CH₃)R^b, and -N(CH₃)SO₂R^b [00356] In some specific embodiments, the compounds are represented by Structural Formula (IA) or (I), wherein:

R¹ is -H.

R² is -H, -CH3, -CH2OH, or -NH2. Specifically, R² is -H, or -CH2OH.

R³ is -H, -F, -Cl, Ci .4 alkyl, or C1-4 haloalkyl. Alternatively, R³ is -H, -F, or -Cl.

Z^J is -H, -F, or -Cl.

Z³ is -H or C[-C(j alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C₄alkyl).

R⁵ is: i) -H; ii) an optionally substituted Cj-Ce alkyl group; iii) an optionally substituted, C5-C7 non-aromatic carbocycle; iv) an optionally substituted, 4-7 membered nonaromatic heterocycle; v) )an optionally substituted phenyl group; vi) an optionally substituted

-136WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

5-6 membered heteroaryl ring; or optionally, together with R and the nitrogen atom to which it is attached, form a 5-7 membered, optionally substituted non-aromatic heterocycle; and said alkyl group represented by R⁵ is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂₎ -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), C_t-C₄ alkoxy, -NRCO(Ci-C₄ alkyl), -CONR(C₅-C₄ alkyl), -NRCO₂(Ci-C₄ alkyl), a C3-C7 non-aromatic carbocycle optionally substituted with one or more instances of J^E1, a 4-7 membered non-aromatic heterocycle optionally substituted with one or more instances of J^E1; and a phenyl optionally substituted with one or more instances of J^EI; and wherein each of said carbocycle, heterocycle, phenyl and hetcroary represented by R⁵is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -O(Ci-C₄alkyl), -NH₂, -NH(C_t-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci~C₄ alkyl), -OC(O)(Ci~C₄alkyl), -C(O)O(C|-C₄ alkyl) and -CO₂H, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy.

The remaining variables, including R⁴ that includes a spiro ring represented by rings E and F, or a bridged ring represented by rings G1-G5, are each and independently as described in any one of the preceeing four embodiments.

[00357} In yet another embodiment, the compounds are presented by Structural Formula (I A) or (I), wherein values of the variabels are each and independently as described in the preceeding embodiment, except:

Z² is -H:

Z³ is -H;

R⁵ is independently: i) -H or ii) a Ci-Cg-alkyl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH_2> -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(C_t-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), -CO₂H, C₃-C₈ nonaromatic carbocycle, 4-8 membered non-aromatic heterocycle, phenyl, and 5-6 membered heteroaryl;

wherein each of said alkyl groups referred to in the substituents of the Ci-Cg-alkyl group represented by R^s is independently and optionally substituted with one or more

-137WO 2010/148197

PCI7US2010/038988

2018200219 11 Jan 2018 substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(C_rC₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy; and wherein each of said carbocycle, phenyl, heterocycle, and heteroaryl referred to in the substituents of the Ci-Ce-alkyl group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy.

[00358]

In yet another embodiment, each of rings E, G1-G5 is independently and optionally substituted with onr or more substituents selected from the group consisting of halogen, cyano, hydroxy, Ci-C₆ alkyl, -NH₂, -NH(C,-C₆ alkyl), -N(C_t-C₆ alkyl)₂, -O(Ci.C₆alkyl), -C(O)NH₂, -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ci-C₆ alkyl)₂, -C(O)(Ci-C₆-alkyl), -OC(O)(Ci-C₆ alkyl), -NHC(O)(Ci-C_e alkyl), -N(C_rC₆ alkyl)C(O)(Ci-C₆ alkyl), and -CO₂R^b; wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy. Specifically, each of rings E, G1-G5 is independently and optionally substituted with onr or more substituents selected from the group consisting of halogen, cyano, hydroxy, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), C1-C4 alkoxy, and C1-C4 alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C₄ alkyl).

[00359] In yet another embodiment, the compounds are represented by Structural Formula (IA) or (I), or pharmaceutically acceptable salts thereof, wherein:

Ring A is a non-aromatic, 5-10 membered, bridged carbocylce or heterocycle, or ring A and R⁸ optionally form a non-aromatic, 5-10 membered, bridged carbocycle or heterocycle, or ring A and R⁹ optionally form a non-aromatic, 5-10 membered, bridged carbocycle or heterocycle, or ring A and R¹¹ optionally form a non-aromatic, 5-10 membered, bridged carbocycle or heterocycle, wherein each of said carbocycle is independently and optionally

-138WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 substituted with one or more instances of J^A and wherein each carbocycle is independently and optionally substituted with one or more instances of J^B.

R¹ is -H.

R² is -H, -CH3, -CH2OH, or -NH2. Specifically, R² is -H, or -CH2OH.

R³ is -H, -F, -Cl, Cm alkyl (e.g., -CH₃ or -C₂H₅), or C_M haloalkyl (e.g., -CF₃). Alternatively, R³ is -H, -F, or -CI.

Z¹ is -H, -F, or -Cl.

Z² is -H or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C4 alkyl).

Q² is independently -O-, -CO2~, -OC(O)-, -C(O)NR’-, -C(O)NRC(O)O-NRC(O)-, -NRC(O)NR’-, -NRCO2- -OC(O)NR’-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)2O-, -CO₂SO₂-, or-fCR^jp-Y¹-.

Y^l is -O-, -CO2- -OC(O)- -C(0)NR’-, -C(O)NRC(O)O--NRC(O)-NRC(0)NR’-, -NRCO2-, -OC(O)NR’-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)2O-, or -CO₂SO₂-.

R is: i) -H; ii) an optionally substituted Ci-Ce alkyl group; iii) an optionally substituted, C3-C7 non-aromatic carbocycle; iv) an optionally substituted, 4-7 membered nonaromatic heterocycle; v) )an optionally substituted phenyl group; vi) an optionally substituted 5-6 membered heteroaryl ring; or optionally, together with R and the nitrogen atom to which it is attached, form a 5-7 membered, optionally substituted non-aromatic heterocycle; and said alkyl group represented by R⁵ is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(C_t-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_f-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), C1-C4 alkoxy, -NRCO(Ci-C₄ alkyl), -CONR(Ci-C₄ alkyl), -NRCO₂(Ci-C₄ alkyl), a C₃-C? non-aromatic carbocycle optionally substituted with one or more instances of J^El, a 4-7 membered non-aromatic heterocycle optionally substituted with one or more instances of J^E1; and a phenyl optionally substituted with one or more instances ofJ^E1;

wherein each of said carbocycle, heterocycle, phenyl and heteroary represented by R⁵is independently and optionally substituted with one or more substituents independently

-139WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Cs-C₄alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci~C₄ alkyl)₂, -C(OXCi-C₄ alkyl), -OC(O)(Ci-C₄alkyl), -C(O)O(Ci-C₄ alkyl) and -CO₂H, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(C_rC₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C_rC₄ alkoxy.

Each of R^s and R⁹ is independently -H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C₂-C₄ alkoxyalkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄alkyl), or-N(Ci-C₄alkyl)₂.

R¹¹, R¹², R¹³, and R¹⁴ are each independently -H, halogen, or C,-Cc alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and Ci-Ce alkoxy.

Each of J^A and J^B is independently selected from the group consisting of halogen, cyano, hydroxy, C1-C6 alkyl, -NH2, -NH(Ci-C6 alkyl), -N(Ci-C6 alkyl)2, -O(C|.C6 alkyl), -C(O)NH2, -C(O)NH(CrC6 alkyl), -C(O)N(CrC6 alkyl)2, -C(O)(CrC6-alkyl), -OC(O)(CiC6 alkyl), -NHC(O)(Ci-C6 alkyl), -N(Ci-C6 alkyl)C(O)(Ci-C6 alkyl), and -CO2R^b; wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(C_rC₄ alkyl), -N(C_rC₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_rC₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy.

n is 0 or 1.

x is 0 or 1.

The remaining variables are each and independently as described above in any set of variables for Structural Formulae (IA) and (1).

[00360] In yet another embodiment, the compounds are represented by Structural Formula (IA) or (I), or pharmaceutically acceptable salts, wherein:

R²³

-140WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Each of rings G1-G4 is independently a 5-10 membered non-aromatic bridged carbocycle optionally further substituted with one or more instances of J'\ and ring G5 is a 510 membered non-aromatic bridged heterocycle optionally further substituted with one or more instances of J^B.

X is -0-, -S-, or -NR®-.

R²¹, R²², R²³, R²⁴, and R²⁵are each independently -H, halogen, -OH, Cj-Ce alkoxy, or Cj-Cg alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, Cj-Cg alkyl, -NH₂, -NH(Cj-Cg alkyl), -N(Ci-C₆ alkyl)₂, -O(Cj.C₆ alkyl), -C(O)NH₂, -C(O)NH(Cj-Cg alkyl), -C(O)N(Cj-Ce alkyl)₂, -C(O)(Ci-C₆-alkyI), -OC(O)(Ci-C₆ alkyl), -NHC(O)(Cj-C₆ alkyl), -N(Cj-C₆ alkyl)C(O)(CjC_G alkyl).

R^fi is -H or Ci-Cr, alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, Cj-Cg alkoxy, Cj-Cg haloalkoxy, Cj-Cg aminoalkoxy, Cj-Cg cyanoalkoxy, Cj-Cg hydroxyalkoxy, and Cj-Cgalkoxyalkoxy.

q is 0, 1 or 2.

r is 1 or 2.

The remaining variables are each and independently as described above in the preceeding paragraph.

[00361] In yet another embodiment, the compounds are represented by Structural Formula (IA) or (I), or pharmaceutically acceptable salts thereof, wherein the variables are each and independently as described above in the preceeding paragraph except those described below:

R¹ is -H.

R² is -H.

R³ is -H, -F, -Cl, Cj.4 alkyl, or Cm haloalkyl. Alternatively, R³ is -H, -F, or -Cl.

Z¹ is -H, -F, or -Cl.

Z² is -H.

Z³ is -H.

-141WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

X is -O-.

R⁵ is -H, an optionally substituted Ci-Cg alkyl, or optionally substituted phenyl.

Each of R⁹, R¹³, and R¹⁴ is independently -H or C1-C4 alkyl.

R³¹, R²², R²³, R²⁴, and R^2Sare each independently -H, halogen, -OH, Ci-C₆ alkoxy, or Cj-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, Ci-Cg alkyl, and -O(Ci_Cg alkyl). Specifically R²¹, R²², R²³, R²⁴, and R²⁵ are each independently -H, Ci-6 alkyl, or Ci.g haloalkyl.

Each rings G1-G5 are independently and optionally substituted with one or more substituents selected from the group'consisting of halogen, cyano, hydroxy, -NH₂, -NH(CiCg alkyl), -N(Ci-Ce alkyl)₂, -O(Ci_Ce alkyl), C1-C4 alkyl that is optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, and C1-C4 alkoxy.

[00362] In yet another embodiment, the compounds are represented by any one of Structural Formulae I-VI (hereinafter reference to Structural Formulae I-VI includes Structural Formulae I, ΙΑ, II, III, IV, V, VI) and XI(A)-XIV (hereinafter reference to Structural Formulae XI(A)-XIV includes Structural Formulae XIA, ΧΙΒ, ΧΠΑ, XIIB, XIII, and XIV), wherein values of the variables therein are independently as described above in any embodiments for the compounds of the invention, except that R³ is Ci-g alkyl, such as methyl or ethyl.

[00363] In yet another embodiment, the compounds are represented by any one of Structural Formulae I-VI and XI(A)-XIV, wherein values of the variables therein are independently as described above in any embodiments for the compounds of the invention, except that x is 0.

[00364] In yet another embodiment, the compounds are represented by any one of Structural Formulae I, I A, II, VI, XI(A), and XI(B), wherein values of the variables therein are independently as described above in any embodiments for the compounds of the invention, except that ring A is bridged.

[00365] In yet another embodiment, the compounds are represented by any one of Structural Formulae I, I A, II, VI, XI(A), and XI(B), wherein values of the variables therein are independently as described above in any embodiments for the compounds of the invention, except that Q² is independently -C(=NR)-, -C(=NR)NR-, -NRC(=NR)NR-, -CO2-, -OC(O)-, -C(O)NR-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O- -NRC(O)-,

-142WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

-NRC(O)NR-, -NRCO2-, -OC(O)NR-, -S(O)-, -SO₂- -N(R)SO₂- -SO₂N(R)-, -NRSO2NR-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)2O-> -CO2SO2-, or -(CR⁶R⁷)p-Y‘-; or alternatively, Q² is independently -CO₂- -OC(O)-, -C(O)NR- -C(O)NRC(O)O-NRC(O)NRC(O)O-, -NRC(O)-, -NRC(O)NR- -NRCO₂-, -OC(O)NR-, -S(O)-, -SO₂-, -N(R)SO₂- -SO₂N(R)-, -NRSO2NR-, -P(O)(OR)G-, -OP(O)(OR^a)O-, -P(O)2O-, -CO2SO2-, or -(CR⁶R⁷)P-Y¹-.

[00366] In yet another embodiment, the compounds are represented by any one of Structural Formulae I-VI and XI(A)-XIV, wherein values of the variables therein are independently as described above in any embodiments for the compounds of the invention, provided that when Q² is -O- or -NR-, then ring A is further substituted with J^A other than -H; and provided that if Q³ is -C(O)-, then R⁵ is a substituted Ci-C_G aliphatic group; an optionally substituted C3-C8 non-aromatic carbocycle; an optionally substituted, 6-10-membered carbocyclic aiyl group; optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted 5-10 membered heteroaryl group. In a specific embodiment, when Q²is -O- or -NR-, then ring A is further substituted with J^A other than -H at the geminal position to -Q²R³.

[00367] In yet another embodiment, the present invention is directed to any one of the compounds depicted in FIGs. 3-5, or pharmaceutically acceptable salts thereof.

[00368] In yet another embodiment, the present invention is directed to any one of the compounds depicted in FIG. 6, or pharmaceutically acceptable salts thereof. In yet another embodiment, the present invention is directed to any one of the compounds depicted in FIG. 7, or pharmaceutically acceptable salts thereof. In yet another embodiment, the present invention is directed to any one of the compounds depicted in FIG. 8, or pharmaceutically acceptable salts thereof.

[00369] In some embodiments, the variables of Structural Formulae I-VI and XI(A)XIV are each and independently as depicted in the compounds of FIGs. 3-8.

[00370] Each and independently as described above for the methods of the invention, the aforementioned compounds of the invention can be useful as inhibitors of influenza virus replication in biological samples or in a patient. These compounds can also be useful in reducing the amount of influenza viruses (viral titer) in a biological sample or in a patient. They can also be useful for therapeutic and prophylactic treatment of infections caused by the influenza viruses in a biological sample or in a patient.

[00371] The present invention also provides methods of preparing a compound of the invention. In one embodiment, the methods are directed to prepare compounds represented

-143WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 by Structural Formula (IA) or pharmaceutically acceptable salts thereof. The methods

comprise a step of reacting reacting compound A: ci (^A) with compound B :

Ts to form a compound represented by Structural Formula (XX), as shown in

Scheme A below:

Scheme A

The variables of Structural Formulae (IA) and (XX), and compounds (A) and (B) are independently as defined in any one of the embodiments described above. Ts is tosyl. Any suitable reaction condition known in the art, for example, in WO 2005/095400 and WO 2007/084557 for the coupling of a dioxaboraolan with a chloro-pyrimidine can be employed for the reaction between compound (A) and (B). For example, the reaction between compound (A) and (B) can be performed in the presence of Pd(PPh₃)₄. Specific exemplary conditions are described in the Exemplification below (e.g., General Schemes 5A, 6A, 7,11, 14, 16, 31,32, 33,40, 44, 49, 51, 52, 58, 60, 61, 62, 63,64, 66,67, 68, 69, 70, 76). [00372] In another embodiment, the methods comprise a step of reacting reacting compound Cl or C2 with NH₂R⁴ to form a compound represented by Structural Formula (XX), as shown in Scheme B below:

-144WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Scheme B

Ts (C2)

The variables of Structural Formulae (IA) and (XX), compounds (Cl) and (C2), and R⁴ of NH2R⁴ are independently as defined in any one of the embodiments described above. Ts is tosyl. Any suitable reaction condition known in the art, for example, in WO 2005/095400 and WO 2007/084557 for the coupling of an amine with a sulfinyl group can be employed for the reaction of compounds (Cl) and (C2) with NH2R⁴. Specific exemplary conditions are described in the Exemplification below (e.g., General Schemes 13,15, 19, 20,23, 30, 39, 41,

42,44, 45, 50, 53, 54, 65, 72, 73, 74, and 77).

[00373] The methods described above with reference to Schemes A and B optionally and independently further comprises deprotecting the Ts group of the compound of Structural Formula (XX) to form the compound of Structural Formula (IA). Any suitable condition for deprotecting a Ts group known in the art can be employed in the invention. Specific exemplary conditions are described in the Exemplification below. The de-tosylation can generate the compounds of Structural Formula (IA) where R¹ is -H. If desired, the R¹position can be alkylated by any suitable method known in the art to from the compounds of Structural Formula (IA) where R¹ is Cue alkyl.

[00374] Compounds (A), (B), (Cl), (C2), and NH₂R⁴ can be prepared by any suitable method known in the art. Specific exemplaiy synthethic methods are described below in the Exemplification below. For example, compound (Cl) can be prepared as described in Scheme C: reaction between compounds (D) and (E), for example, in the presence of Pd(PPh₃)4 can produce compound (F). Compound (F) can then be oxidated under suitable conditions, for example, by treatment with meta-chloroperbenzoic acid to form compound (C). (See, for example, detailed experimental details described in the Exemplification for

-145WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

General Scheme 44,)

Scheme C

Definitions and General Terminology [00375] For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistiy and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausolito: 1999, and “March’s Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[00376] As described herein, compounds of the invention may optionally be substituted with one or more substituents, such as illustrated generally below, or as exemplified by particular classes, subclasses, and species of the invention. It will be appreciated that the phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.” In general, the term “substituted”, whether preceded by the term “optionally” or not, refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group. When more than one position in a given structure can be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at each position. When the term “optionally substituted” precedes a list, said term refers to all of the subsequent substitutable groups in that list. If a substituent radical or structure is not identified or defined as “optionally substituted”, the substituent radical or structure is unsubstituted. For example, if X is optionally substituted Ci.C₃alkyl or phenyl; X may be either optionally substituted Ci-C₃ alkyl or optionally substituted phenyl. Likewise, if the term “optionally substituted” follows a list, said term also refers to all of the

-146WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 substitutable groups in the prior list unless otherwise indicated. For example: if X is Ci_ Cjalkyl or phenyl wherein X is optionally and independently substituted by J^x, then both Ci_ C3alkyl and phenyl may be optionally substituted by J^x. As is apparent to one having ordinary skill in the art, groups such as H, halogen, NO2, CN, NH2, OH, or OCF₃ would not be substitutable groups.

[00377] The phrase up to, as used herein, refers to zero or any integer number that is equal or less than the number following the phrase. For example, up to 3 means any one of 0, 1,2, and 3. As described herein, a specified number range of atoms includes any integer therein. For example, a group having from 1-4 atoms could have 1,2, 3, or 4 atoms.

[00378] Selection of substituents and combinations of substituents envisioned by this invention are those that result in the formation of stable or chemically feasible compounds. The term “stable”, as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, specifically, their recoveiy, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week. Only those choices and combinations of substituents that result in a stable structure are contemplated. Such choices and combinations will be apparent to those of ordinary skill in the art and may be determined without undue experimentation.

|00379] The term “aliphatic” or “aliphatic group”, as used herein, means a straightchain (i.e., unbranched), or branched, hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation but is non-aromatic. Unless otherwise specified, aliphatic groups contain 1-20 aliphatic carbon atoms, hi some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. Aliphatic groups may be linear or branched, substituted or unsubstituted alkyl, alkenyl, or alkynyl groups. Specific examples include, but are not limited to, methyl, ethyl, isopropyl, n-propyl, sec-butyl, vinyl, n-butenyl, ethynyl, and tert-butyl and acetylene.

[00380] The term “alkyl” as used herein means a saturated straight or branched chain hydrocarbon. The term “alkenyl” as used herein means a straight or branched chain hydrocarbon comprising one or more double bonds. The term “alkynyl” as used herein means a straight or branched chain hydrocarbon comprising one or more triple bonds. Each

-147WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 of the “alkyl”, “alkenyl” or “alkynyl” as used herein can be optionally substituted as set forth below. In some embodiments, the “alkyl” is Ci-Ce alkyl or C1-C4 alkyl. In some embodiments, the “alkenyl” is C₂-Ce alkenyl or C₂-C₄ alkenyl. In some embodiments, the “alkynyl” is Cz-Ce alkynyl or C2-C4 alkynyl.

[00381] The term “cycloaliphatic” (or “carbocycle” or “carbocyclyl” or “carbocyclic”) refers to a non-aromatic carbon only containing ring system which can be saturated or contains one or more units of unsaturation, having three to fourteen ring carbon atoms. In some embodiments, the number of carbon atoms is 3 to 10. In other embodiments, the number of carbon atoms is 4 to 7. In yet other embodiments, the number of carbon atoms is 5 or 6. The term includes monocyclic, bicyclic or polycyclic, fused, spiro or bridged carbocyclic ring systems. The term also includes polycyclic ring systems in which the carbocyclic ring can be “fused” to one or more non-aromatic carbocyclic or heterocyclic rings or one or more aromatic rings or combination thereof, wherein the radical or point of attachment is on the carbocyclic ring. “Fused” bicyclic ring systems comprise two rings which share two adjoining ring atoms. Bridged bicyclic group comprise two rings which share three or four adjacent ring atoms. Spiro bicyclic ring systems share one ring atom. Examples of cycloaliphatic groups include, but are not limited to, cycloalkyl and cycloalkenyl groups. Specific examples include, but are not limited to, cyclohexyl, cyclopropenyl, and cyclobutyl.

[00382] The term “heterocycle” (or “heterocyclyl”, or “heterocyclic” or “non-aromatic heterocycle”) as used herein refers to a non-aromatic ring system which can be saturated or contain one or more units of unsaturation, having three to fourteen ring atoms in which one or more ring carbons is replaced by a heteroatom such as, N, S, or O and each ring in the system contains 3 to 7 members. In some embodiments, non-aromatic heterocyclic rings comprise up to three heteroatoms selected from N, S and O within the ring. Tn other embodiments, non-aromatic heterocyclic rings comprise up to two heteroatoms selected from N, S and O within the ring system. In yet other embodiments, non-aromatic heterocyclic rings comprise up to two hetero atoms selected from N and O within the ring system. The term includes monocyclic, bicyclic or polycyclic fused, spiro or bridged heterocyclic ring systems. The term also includes polycyclic ring systems in which the heterocyclic ring can be fused to one or more non-aromatic carbocyclic or heterocyclic rings or one or more aromatic rings or combination thereof, wherein the radical or point of attachment is on the heterocyclic ring. Examples of heterocycles include, but are not limited to, piperidinyl, piperizinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, azepanyl, diazepanyl, triazepanyl, azocanyl, diazocanyl,

-148WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 triazocanyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, oxazocanyl, oxazepanyl, thiazepanyl, thiazocanyl, benzimidazolonyl, tetrahydrofuranyl, tetrahydrofuranyl, tetrahydro thiophenyl, tetrahydrothiophenyl, morpholino, including, for example, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-tetrahydropiperazinyl, 2tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 1pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3piperidinyl, 4-piperidinyl, 2-thiazolidinyl, 3-thiazolidinyl, 4-thiazolidinyl, 1-imidazolidinyl,

2-imidazolidinyl, 4-imidazolidinyl, 5-imidazolidinyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzothiolanyl, benzodithianyl, 3-(l-alkyl)-benzimidazol-2-onyl, and 1,3-dihydro-imidazol-2-onyl.

[00383] The term “aryl” (or “aryl ring” or “aryl group”) used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, “aryloxyalkyl”, or “heteroaryl” refers to both carbocyclic or heterocyclic aromatic ring systems. The term “aryl” may be used interchangeably with the terms “aryl ring” or “aryl group”.

[00384] “Carbocyclic aromatic ring” groups have only carbon ring atoms (typically six to fourteen) and include monocyclic aromatic rings such as phenyl and fused polycyclic aromatic ring systems in which two or more carbocyclic aromatic rings are fused to one another. Examples include 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl. Also included within the scope of the term “carbocyclic aromatic ring” or “carbocyclic aromatic”, as it is used herein, is a group in which an aromatic ring is “fused” to one or more nonaromatic rings (carbocyclic or heterocyclic), such as in an indanyl, phthal imidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, where the radical or point of attachment is on the aromatic ring.

[00385] The terms “heteroaiyl”, “heteroaromatic”, “heteroaryl ring”, “heteroaryl group”, “aromatic heterocycle” or “heteroaromatic group”, used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refer to heteroaromatic ring groups having five to fourteen members, including monocyclic heteroaromatic rings and polycyclic aromatic rings in which a monocyclic aromatic ring is fused to one or more other aromatic ring. Heteroaryl groups have one or more ring heteroatoms. Also included within the scope of the term “heteroaryl”, as it is used herein, is a group in which an aromatic ring is “fused” to one or more non-aromatic rings (carbocyclic or heterocyclic), where the radical or point of attachment is on the aromatic ring. Bicyclic 6,5 heteroaromatic ring, as used herein, for example, is a six membered heteroaromatic ring fused to a second five membered ring,

-149WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 wherein the radical or point of attachment is on the six membered ring. Examples of heteroaryl groups include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl or thiadiazolyl including, for example, 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxadiazolyl, 5oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-pyrazolyl, 4-pyrazolyl, 1-pyrrolyl, 2pyiTolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5pyrimidinyl, 3-pyridazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-triazolyl, 5-triazolyl, tetrazolyl, 2-thienyl, 3-thienyl, carbazolyl, benzimidazolyl, benzothienyl, benzofiiranyl, indolyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, isoquinolinyl, indolyl, isoindolyl, acridinyl, bcnzisoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl,

1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, purinyl, pyrazinyl, 1,3,5-triazinyl, quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), and isoquinolinyl (e.g., 1-isoquinolinyl, 3-isoquinolinyl, or 4-isoquinolinyl).

[00386] As used herein, “cyclo”, “cyclic”, “cyclic group” or “cyclic moiety”, include mono-, bi-, and tri-cyclic ring systems including cycloaliphatic, heterocycloaliphatic, carbocyclic aryl, or heteroaryl, each of which has been previously defined.

[00387] As used herein, a “bicyclic ring system” includes 8-12 (e.g., 9, 10, or 11) membered structures that form two rings, wherein the two rings have at least one atom in common (e.g,, 2 atoms in common). Bicyclic ring systems include bicycloaliphatics (e.g., bicycloalkyl or bicycloalkenyl), bicycloheteroaliphatics, bicyclic carbocyclic aiyls, and bicyclic heteroaryls.

[00388] As used herein, a “bridged bicyclic ring system” refers to a bicyclic heterocycloalipahtic ring system or bicyclic cycloaliphatic ring system in which the rings are bridged. Examples of bridged bicyclic ring systems include, but are not limited to, adamantanyl, norbomanyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.2.3]nonyl, 2-oxa-bicyclo[2.2.2]octyl, l-aza-bicyclo[2.2.2]octyl, 3-azabicyclo[3.2.1]octyl, and 2,6-dioxa-tricyclo[3.3.1.03,7]nonyl. A bridged bicyclic ring system can be optionally substituted with one or more substituents such as alkyl (including carboxy alkyl, hydroxy alkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, carbocyclic aryl, hctcroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, (carbocyclic aryl)oxy, hctcroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino,

-150WO 2010/148197

PCT/US2010/038988 (cycloalky lalkyl)carbonylamino, (carbocyclic aryl)carbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.

[00389] As used herein, “bridge” refers to a bond or an atom or an unbranched chain of atoms connecting two different parts of a molecule. The two atoms that are connected through the bridge (usually but not always, two tertiary carbon atoms) are denotated as “bridgeheads”.

[00390] As used herein, the term “spiro” refers to ring systems having one atom (usually a quaternary carbon) as the only common atom between two rings.

[00391] The term “ring atom” is an atom such as C, N, O or S that is in the ring of an aromatic group, cycloalkyl group or non-aromatic heterocyclic ring.

[00392] A “substitutable ring atom” in an aromatic group is a ring carbon or nitrogen atom bonded to a hydrogen atom. The hydrogen can be optionally replaced with a suitable substituent group. Thus, the term “substitutable ring atom” does not include ring nitrogen or carbon atoms which are shared when two rings are fused. In addition, “substitutable ring atom” does not include ring carbon or nitrogen atoms when the structure depicts that they are already attached to a moiety other than hydrogen.

[00393] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quatemized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR¹ (as in N-substituted pyrrolidinyl)).

[00394] As used herein an optionally substituted aralkyl can be substituted on both the alkyl and the aryl portion. Unless otherwise indicated as used herein optionally substituted aralkyl is optionally substituted on the aryl portion.

[00395] In some embodiments, an aliphatic or heteroaliphatic group, or a non-aromatic heterocyclic ring may contain one or more substituents. Suitable substituents on the saturated carbon of an aliphatic or heteroaliphatic group, or of a non-aromatic heterocyclic ring are selected from those listed above, for example, in the definitions of J^A, J^B, J^C1, J^D1, and J^E1. Other suitable substitutents include those listed as suitable for the unsaturated carbon of a carbocyclic aryl or heteroaryl group and additionally include the following: =0, =S, =NNHR*, =NN(R*)2, =NNHC(O)R’, =NNHCO₂ (alkyl), =NNHSO₂(alkyI), or =NR’, wherein each R* is independently selected from hydrogen or an optionally substituted Ct-6 aliphatic.

-151WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Optional substituents on the aliphatic group of R’ are selected from NHj, NH(Ci_₄ aliphatic), N(Ci-4 aliphatic)₂, halogen, Cm aliphatic, OH, 0(Cm aliphatic), NO₂, CN, CO₂H, CO₂(Cm aliphatic), O(halo Cm aliphatic), or halo(CM aliphatic), wherein each of the foregoing Cj. ^aliphatic groups of R’ is unsubstituted.

[00396] In some embodiments, optional substituents on the nitrogen of a non-aromatic heterocyclic ring include those used above, for example, in the definitions of J^B, J^D1 and J^E1. Other suitable substituents include -R⁺, -N(R⁺)2, -C(O)R⁺, -CO2R', -C(O)C(O)R⁺, -C(O)CH2C(O)R⁺, -SO2Rj -SO₂N(RQ₂, -C(=S)N(R⁺)2j -C(=NH)-N(R⁺)2, or -NR⁺SO2R⁺; wherein R⁺ is hydrogen, an optionally substituted Cm aliphatic, optionally substituted phenyl, optionally substituted -O(Ph), optionally substituted -CH2(Ph), optionally substituted -(CH₂)i.₂(Ph); optionally substituted -CH=CH(Ph); or an unsubstituted 5-6 membered heteroaryl or heterocyclic ring having one to four heteroatoms independently selected from oxygen, nitrogen, or sulfur, or, two independent occurrences of R⁺, on the same substituent or different substituents, taken together with the atom(s) to which each R⁺ group is bound, form a 5-8-membered heterocyclyl, carbocyclic aryl, or heteroaryl ring or a 3-8-membered cycloalkyl ring, wherein said heteroaryl or heterocyclyl ring has 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Optional substituents on the aliphatic group or the phenyl ring of R⁷ arc selected from NH₂, NH(Cm aliphatic), N(Cm aliphatic)₂, halogen, Cm aliphatic, OH, O(Ci-₄ aliphatic), NO₂, CN, CO2H, C0₂(Cm aliphatic), O(halo Cm aliphatic), orhalo(CM aliphatic), wherein each of the foregoing C_s ^aliphatic groups of R¹ is unsubstituted.

[00397] In some embodiments, a carbocyclic aiyl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents. Suitable substituents on the unsaturated carbon atom of a carbocyclic aryl or heteroaryl group are selected from those listed above, for example, in the definitions of J^A, J^B, J^C1, J^D1 and J^E1. Other suitable substituents include: halogen; -R°; -OR⁰; -SR°; 1,2-methylenedioxy; 1,2-ethylenedioxy; phenyl (Ph) optionally substituted with R°; -O(Ph) optionally substituted with R°; -(CH2)i_2(Ph), optionally substituted with R°; -CH=CH(Ph), optionally substituted with R°; -NO2; -CN; -N(R°)2; -NR°C(O)R°; -NR°C(S)R°; -NR^oC(0)N(R^o)2; -NR^OC(S)N(R°)2; -NR°CO2R°; -NR°NR°C(O)R°; -NR°NR^oC(0)N(R^o)2; -NR°NR^oC0₂R⁰; -C(O)C(O)R°;

-C(O)CH₂C(O)R°; -CO₂R°; -C(O)R°; -C(S)R°; -C(O)N(R^o)2; -C(S)N(R^o)2; -OC(O)N(R°)₂; -OC(O)R°; -C(O)N(OR°) R°; -C(NOR°) R°; -S(O)₂R°; -S(O)₃R°; -SO₂N(R°)₂; -S(O)R°; NR°SO₂N(R°)₂; -NR°SO₂R°; -N(OR°)R°; -C(=NH)-N(R°)₂; or -(CH₂)o.₂NHC(0)R°; wherein

-152WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 each independent occurrence of R° is selected from hydrogen, optionally substituted Cm aliphatic, an unsubstituted 5-6 membered heteroaryl or heterocyclic ring, phenyl, -O(Ph), or -CH₂(Ph), or, two independent occurrences of R°, on the same substituent or different substituents, taken together with the atom(s) to which each R° group is bound, form a 5-8membered heterocyclyl, carbocyclic aryl, or heteroaryl ring or a 3-8-membered cycloalkyl ring, wherein said heteroaryl or heterocyclyl ring has 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Optional substituents on the aliphatic group of R° are selected from NH₂, NH(CMaliphatic), N(Ci_4aliphatic)2, halogen, Ci-4aliphatic, OH, O(Ci. ₄aliphatic), NO₂, CN, CO₂H, CO2(C₁.₄aliphatic), O(haloCM aliphatic), or haloCi ^aliphatic, CHO, N(C0)(Cm aliphatic), C(O)N(Ct-₄ aliphatic), wherein each of the foregoing Cj. 4aliphatic groups of R° is unsubstituted.

[00398] Non-aromatic nitrogen containing heterocyclic rings that are substituted on a ring nitrogen and attached to the remainder of the molecule at a ring carbon atom are said to be N substituted. For example, an N alkyl piperidinyl group is attached to the remainder of the molecule at the two, three or four position of the piperidinyl ring and substituted at the ring nitrogen with an alkyl group. Non-aromatic nitrogen containing heterocyclic rings such as pyrazinyl that are substituted on a ring nitrogen and attached to the remainder of the molecule at a second ring nitrogen atom are said to be N’ substituted-N-heterocycles. For example, an N’ acyl N-pyrazinyl group is attached to the remainder of the molecule at one ring nitrogen atom and substituted at the second ring nitrogen atom with an acyl group. [00399] The term unsaturated, as used herein, means that a moiety has one or more units of unsaturation.

[00400] As detailed above, in some embodiments, two independent occurrences of R° (or R’ , or any other variable similarly defined herein), may be taken together with the atom(s) to which each variable is bound to form a 5-8-membered heterocyclyl, carbocyclic aryl, or heteroaryl ring or a 3-8-membered cycloalkyl ring. Exemplary rings that are formed when two independent occurrences of R° (or R⁺, or any other variable similarly defined herein) are taken together with the atom(s) to which each variable is bound include, but are not limited to the following: a) two independent occurrences of R° (or R⁺, or any other variable similarly defined herein) that are bound to the same atom and are taken together with that atom to form a ring, for example, N(R°)₂, where both occurrences of R° are taken together with the nitrogen atom to form a piperidin-l-yl, piperazin-1-yl, or morpholin-4-yl group; and b) two independent occurrences of R° (or R⁺, or any other variable similarly defined herein) that are bound to different atoms and are taken together with both of those atoms to form a ring, for

-153WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 example where a phenyl group is substituted with two occurrences of OR¹’ these two occurrences of R° are taken together with the oxygen atoms to which they are bound to form a fused 6-membered oxygen containing ring: \ ⁰ . It will be appreciated that a variety of other rings can be formed when two independent occurrences of R° (or R⁺, or any other variable similarly defined herein) are taken together with the atom(s) to which each variable is bound and that the examples detailed above are not intended to be limiting.

[00401] In some embodiments, an alkyl or aliphatic chain can be optionally interrupted with another atom or group. This means that a methylene unit of the alkyl or aliphatic chain is optionally replaced with said other atom or group. Examples of such atoms or groups would include, but are not limited to those listed in the definitions of Q¹, Y¹, Q² and Q³. Further examples include -NR- -O-, -S-, -CO₂- -OC(O)-, -C(O)CO-, -C(O)-, -C(O)NR- -C(=N-CN)-, -NRCO-, -NRC(O)O-, -SO₂NR-, -NRSO₂- -NRC(O)NR-OC(O)NR-, -NRSO₂NR-, -SO-, or -SO₂-, wherein R is as defined above.

[00402] As used herein, an “amino” group refers to -NR^XR^Y wherein each of R^x and R^Y is independently -H, Ci-Cc aliphatic, a C3.7 non-aromatic carbocycle, a 5-6 membered carbocyclic aryl or heteroaryl, or a 4-7 membered non-aromatic heterocycle, each of which independently being defined herein and being optionally substituted. Suitable substituents for the carbocycle, carbocyclic aryl, heteroaryl, and heterocycl are each independently include halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-Ce alkyl), -N(Ci-Cg alkyl)₂, Ci-Ce alkyl, -O(CiC₆ alkyl), -C(O)OH, -C(O)O(Ci-C₆ alkyl), -OC(O)(Ci-C₆ alkyl), -NHC(O)(Ci-C₆ alkyl), -NHC(O)O(Ci-C₆ alkyl), -C(O)NH(Ci-Ce alkyl), and -C(O)N(Ci-Cg alkyl)₂, wherein each of said alkyl groups is optionally and independently substituted with one or more substitutents selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), and -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C]-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy. Suitable substituents for the Ci-Ce aliphatic (including Ci-Ce alkyl) include halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-Cg alkyl), -N(Ci-Ce alkyl)₂, -O(Ci-Cg alkyl), -C(O)OH, -C(O)O(C!-C₆ alkyl), -OC(O)(Ci-C₆ alkyl), -NHC(O)(Ci-C₆ alkyl), -NHC(O)O(Ci-C₆ alkyl), -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ci-Ce alkyl)₂, phenyl, a 5-6 membered heteroaryl, a 5-6 membered non-aromatic heterocycle, and a C3-C7 carbocycle, wherein each of said alkyl groups is optionally and independently substituted with one or

-154WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 more substitutents selected from the group consisting of halogen, cyano, hydroxy, oxo, -NHz, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C_t-C₄ alkyl), -CO₂H, -CO₂(CiC₄ alkyl), and Ci-C₄ alkoxy, and wherein each of said phenyl, heteroaiyl, heterocycle and carbocycle is optionally and independently substituted with one or more substitutents described above for the carbocycle, carbocyclic aryl, heteroaryl, and heterocycle represented by R^x and R^Y. In some embodiments, each of R^x and R^Y is independently -H, an optionally substituted Ci-β aliphatic group, or an optionally substituted C3.8 non-aromatic carbocycle. In some embodiments, each of R^x and R^Y is independently -H or an optionally substituted CG aliphatic group, In some embodiments, each of R^x and R^Y is independently -H or Cus alkyl optionally substituted with one or more substitutents selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -OCO(Ci-C4 alkyl), -CO(Ci-C4 alkyl), -CO2H, -CO2(Ci-C4 alkyl), and Ci-C4 alkoxy. Examples of amino groups include -NH2, aliphatic amino, alkylamino, dialkylamino, or arylamino. As used herein, an “aliphatic amino” group refers to -NR^XR^Y wherein R^x is a C1-6 aliphatic group optionally substituted as described above; and R^Y is -H or a Ci_6 aliphatic group optionally substituted as described above. As used herein, an “alkylamino” group refers to -NHR^X wherein R^x is a Che alkyl group optionally substituted as described above. As used herein, a “dialkylamino” group refers to -NR^XR^Y wherein each of R^x and R^Y is independently a Ci-β alkyl group optionally substituted as described above. As used herein, an “arylamino” group refers to -NR^XR^Y wherein R^x is 5-6 membered, carbocyclic aryl or heteroaryl, and R^Y is -H or 5-6 membered, carbocyclic aryl or heteroaryl, wherein each of said carbocyclic aryl and heteroaryl groups is independently and optionally substituted as described above. When the term “amino” is not the terminal group (e.g., alkylcarbonylamino), it is represented by -NR^X-. R^x has the same meaning as defined above. In one embodiment, the amino group is -NH2 or an aliphatic amino. In another embodiment, the amino group is ~NH₂, alkylamino or dialkylamino. In yet another embodiment, the amino group is -NH₂ or an arylamino. In yet another embodiment, the amino group is -NH₂, -NH(Ci-Ce alkyl) or -N(Ci-Cc alkyl)₂, wherein each of the alkyl groups is optionally and independently substituted with one or more substitutents selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(C_rC₄ alkyl),, -OCO(Ci-C₄ alkyl), -C0(Ci-C₄ alkyl), -CO₂H, -CO₂(CiC₄ alkyl), and Ci-C₄ alkoxy.

[00403] As used herein, an “amido” encompasses both “aminocarbonyl” and “carbonylamino”. These terms when used alone or in connection with another group refer to an amido group such as N(R^XR^Y)-C(O)- or R^YC(O)-N(R^X)- when used terminally and -C(O)-155WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

N(R^X)- or -N(R^X)-C(O)- when used internally, wherein R^x and R^Y are defined above. Examples of amido groups include alkylamido (such as alkylcarbonylamino or alkylcarbonylamino or alkylaminocarbonyl), (heterocycloaliphatic)amido, (heteroaralkyl) amido, (heteroaryl)amido, (heterocycloalkyl)alkylamido, arylamido, aralkylamido, (cycloalkyl)alkylamido, or cycloalkylamido. In some embodiments, the amido group is -NHC(O)(Ci-C₆ alkyl), -N(Ci-C₆ alkyI)C(O)(C_t-C₆ alkyl), -C(O)NH₂, -C(O)NH(Ci-Ce alkyl), or -C(O)NH(Ci-C₆ alkyl)₂, wherein each of said alkyl is optionally and independently substituted with one or more substitutents selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C6 alkyl), -N(Ci-Ce alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ct-C₄ alkyl), and C1-C4 alkoxy. In some embodiments, the amido group is -NHC(O)(Ci-C6 alkyl), -N(Ci-Ce alkyl)C(O)(Ci-C6 alkyl), -C(O)NH₂, -C(O)NH(Ci-Ce alkyl), or -C(O)NH(Ci-Ce alkyl)₂, wherein each of the alkyl groups is optionally and independently substituted with one or more substitutents selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-Ce alkyl), -N(C_rC₆ alkyl)₂, -OCO(C_rC₄ alkyl), -CO(C_rC₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C_rC₄ alkoxy.

[00404] As used herein, a “urea” group refers to the structure -NR^X-CO-NR^YR^Z and a “thiourea” group refers to the structure -NR^X-CS-NR^YR^Z when used terminally and -NR^XCO-NR^Y- or -NR^X-CS-NR^Y- when used internally, wherein R^x, R^Y, and R^z are each independently as defined above.

[00405] As used herein, an “acyl” group refers to a formyl group or R^X-C(O)- (such as -alkyl-C(O)-, also referred to as “alkylcarbonyl”) where R^x and “alkyl” have been defined previously. Acetyl and pivaloyl are examples of acyl groups.

[00406] As used herein, a “carboxy” group refers to -COOH, -COOR^X, -OC(O)H, OC(O)R^X when used as a terminal group; or -OC(O)- or -C(O)O- when used as an internal group, wherein R^x is as defined above.

[00407] The term “hydroxyl”or “hydroxy” or “alcohol moiety” refers to -OH.

[00408] As used herein, an “alkoxycarbonyl,” which is encompassed by the term carboxy, used alone or in connection with another group refers to a group such as (alkyl-O)-C(O)-.

[00409] As used herein, a “carbonyl” refers to -C(O)-.

[00410] As used herein, an “oxo” refers to =0.

[00411] As used herein, the term “alkoxy”, or “alkylthio”, as used herein, refers to an alkyl group, as previously defined, attached to the molecule through an oxygen (“alkoxy”

-156WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

e.g., -O-alkyl) or sulfur (“alkylthio” e.g., -S-alkyl) atom.

[00412] As used herein, the terms “halogen”, “halo”, and “hal” mean F, Cl, Br, or I.

[00413] As used herein, the term “cyano” or “nitrile” refer to -CN or -ON.

[00414] The terms “alkoxyalkyl”, “alkoxyalkenyl”, “alkoxyaliphatic”, and “alkoxyalkoxy” mean alkyl, alkenyl, aliphatic or alkoxy, as the case may be, substituted with one or more alkoxy groups.

[00415] The terms “haloalky 1”, “haloalkenyl”, “haloaliphatic”, and “haloalkoxy” mean alkyl, alkenyl, aliphatic or alkoxy, as the case may be, substituted with one or more halogen atoms. This term includes perfluorinated alkyl groups, such as -CF₃ and -CF₂CF₃.

[00416] The terms “cyanoalkyl”, “cyanoalkenyl”, “cyanoaliphatic”, and “cyanoalkoxy” mean alkyl, alkenyl, aliphatic or alkoxy, as the case may be, substituted with one or more cyano groups. In some embodiments, the cyanoalkyl is (NC)-alkyl-.

[00417] The terms “aminoalkyl”, “aminoalkenyl”, “aminoaliphatic”, and “aminoalkoxy” mean alkyl, alkenyl, aliphatic or alkoxy, as the case may be, substituted with one or more amino groups, wherein the amino group is as defined above. In some embodiments, the aminoaliphatic is a C1-C6 aliphatic group substituted with one or more -NH₂ groups. In some embodiments, the aminoalkyl refers to the structure (R^xR^Y)N-alkyl-, wherein each of R^x and R^Y independently is as defined above. In some specific embodiments, the aminoalkyl is C1-C6 alkyl substituted with one or more -NH₂ groups. In some specific embodiments, the aminoalkenyl is CI-C6 alkenyl substituted with one or more -NH₂ groups. In some embodiments, the aminoalkoxy is -O(C1-C6 alkyl) wherein the alkyl group is substituted with one or more -NH₂ groups.

[00418] The terms “hydroxyalkyl”, “hydroxyaliphatic”, and “hydroxyalkoxy” mean alkyl, aliphatic or alkoxy, as the case may be, substituted with one or more -OH groups. [00419] The terms “alkoxyalkyl”, “alkoxyaliphatic”, and “alkoxyalkoxy” mean alkyl, aliphatic or alkoxy, as the case may be, substituted with one or more alkoxy groups. For example, an “alkoxyalkyl” refers to an alkyl group such as (alkyl-O)-alkyl-, wherein alkyl is as defined above.

[00420] The term “carboxyalkyl” means alkyl substituted with one or more carboxy groups, wherein alkyl and carboxy are as defined above.

[00421] In some embodiments, each of the amino groups referred to in the descriptions for the variables of Structural Formulae I-VI and XI(A)-XIV (e.g., R⁶, R⁷, J^E1, R, R’, R”, R*, R^a, R^b and R°) above is independently -NH₂, -NH(Ci-Ce alkyl), -NH(C₃-Cc carbocylce), -N(Ci-C6 alkyl)₂, or-N(Ci-Ce alkyl)(C₃-Ce carbocycle), wherein said alkyl and carbocycle

-157WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 groups are each optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(C₁-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(CiC₄ alkyl), and Ci-C₄ alkoxy; each of the carboxy groups referred to in the descriptions for the variables of Structural Formulae I-VI and XI(A)-XIV (e.g., R^e, R⁷, J^E1, R, R’, R”, R*, R^a, R^band R^c) above is independently -C(O)O(Ci-C6 alkyl), -OC(O)(Ci-C6 alkyl), -C(O)O(C3-C6 carbocycle), -OC(O)(C3-C6 carbocycle), or -CO2H, wherein said alkyl and carbocylce groups are each optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C4 alkyl), -N(CrC4 alkyl)2, -OCO(Ci-C4 alkyl), -CO(Ci-C4 alkyl), -CO2H, -CO2(CiC4 alkyl), and C1-C4 alkoxy; each of the amido groups referred to in the descriptions for the variables of Structural Formulae 1-VI and XI(A)-XIV (e.g., R⁶, R⁷, J^Et, R, R’, R”, R*, R^a, R^band R^c) above is independently -NHC(O)(Ci-C6 alkyl), -N(Ci-C₆ alkyl)C(O)(C_t-C₆ alkyl), -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ci-C_e alkyl)₂, -NHC(O)(C₃-C₆ carbocycle), -N(Ci-C₆alkyl)C(O)(C₃-Ce carbocycle), -C(O)NH(C₃-C6 carbocycle), -C(O)N(Ci-Cg alkyl)(C₃-C₆carbocycle), or -C(O)NH₂, wherein said alkyl and carbocycle groups are each optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(C]-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy; each of the aminoalkyl groups referred to in the descriptions for the variables of Structural Formulae

I-VI and XI(A)-XIV (e.g., R^s, R⁹, and R”) above is independently a C1-C6 alkyl group substituted with one or more aminogroups independently selected from the group consisting of -NH2, -NH(Ci-C4 alkyl), and -N(Ci-C4 alkyl)2; and each of the aminoalkoxy groups referred to in the descriptions for the variables of Structural Formulae I-VI and XI(A)-XIV (e.g., R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², Rⁱ³, R¹⁴, R, R’, and R”) above is independently is a -O(C1-C6 alkyl) group wherein the alkyl group is substituted with one or more one or more aminogroups independently selected from the group consisting of -NH2, -NH(Ci-C₄ alkyl), and -N(Ci-C₄ alkyl)₂.

[00422] In some embodiments, each of the amino groups referred to in the descriptions for the variables of Structural Formulae I-VI and XI(A)-XIV (e.g., R⁶, R⁷, J^E1, R, R’, R”, R*, R^a, R^b and R^c) above is independently -NH₂, -NH(Ci-C_g alkyl), or -N(Ci-Cc alkyl)₂, wherein said alkyl groups are each optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl),

-158WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

-CO₂H, -CO2(Ci“C₄ alkyl), and C1-C4 alkoxy; each of the carboxy groups referred to in the descriptions for the variables of Structural Formulae I-VI and XI(A)-XIV (e.g., R⁶, R⁷, J^E1, R, R’, R”, R* R^a, R^b and R^c) above is independently -C(O)O(C,-Cfi alkyl), -OC(O)(Ci-C6 alkyl), or -CO2H, wherein said alkyl groups are each optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -OCO(Ci-C4 alkyl), -CO(CiC4 alkyl), -CO2H, -CO2(Ci-C4 alkyl), and C1-C4 alkoxy; each of the amido groups referred to in the descriptions for the variables of Structural Formulae I-VI and XI(A)-XIV (e.g., R⁶, R⁷, J^E1, R, R’, R”, R*, R^a, R^b and R^c) above is independently -NHC(O)(Ci-C6 alkyl), -N(Ci-C₆alkyl)C(O)(Ct-C₆ alkyl), -C(O)NH(CrC6 alkyl), -C(O)N(Ci-C₆ alkyl)₂, or-C(O)NH₂, wherein said alkyl groups are each optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(C_t-C₄ alkyl), -N(C]-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ct-C₄ alkoxy; each of the aminoalkyl groups referred to in the descriptions for the variables of Structural Formulae I-VI and XI(A)-XIV (e.g., R^s, R⁹, and R”) above is independently a C1-C6 alkyl group substituted with one or more aminogroups independently selected from the group consisting of -NH2, -NH(Ci-C4 alkyl), and -N(Ci-C4 alkyl)2; and each of the aminoalkoxy groups referred to in the descriptions for the variables of Structural Formulae I-VI and XI(A)-XIV (e.g., R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R, R’, and R”) above is independently is a -O(C1-C6 alkyl) group wherein the alkyl group is substituted with one or more one or more aminogroups independently selected from the group consisting of -NH2, -NH(Ci-C₄ alkyl), and -N(Ci-C₄ alkyl)₂.

[00423] The term “protecting group” and “protective group” as used herein, are interchangeable and refer to an agent used to temporarily block one or more desired functional groups in a compound with multiple reactive sites. In certain embodiments, a protecting group has one or more, or specifically all, of the following characteristics: a) is added selectively to a functional group in good yield to give a protected substrate that is b) stable to reactions occurring at one or more of the other reactive sites; and c) is selectively removable in good yield by reagents that do not attack the regenerated, deprotected functional group. As would be understood by one skilled in the art, in some cases, the reagents do not attack other reactive groups in the compound. In other cases, the reagents may also react with other reactive groups in the compound. Examples of protecting groups are detailed in Greene, T. W., Wuts, P. G in “Protective Groups in Organic Synthesis”, Third Edition, John Wiley & Sons, New York: 1999 (and other editions of the book), the entire contents of

-159WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 which are hereby incorporated by reference. The term “nitrogen protecting group”, as used herein, refers to an agent used to temporarily block one or more desired nitrogen reactive sites in a multifunctional compound. Preferred nitrogen protecting groups also possess the characteristics exemplified for a protecting group above, and certain exemplary nitrogen protecting groups are also detailed in Chapter 7 in Greene, T.W., Wuts, P. G in “Protective Groups in Organic Synthesis”, Third Edition, John Wiley & Sons, New York: 1999, the entire contents of which are hereby incorporated by reference.

[00424] As used herein, the term “displaceable moiety” or “leaving group” refers to a group that is associated with an aliphatic or aromatic group as defined herein and is subject to being displaced by nucleophilic attack by a nucleophile.

[00425] Unless otherwise indicated, structures depicted herein arc also meant to include all isomeric (e.g., enantiomeric, diastereomeric, cis-trans, conformational, and rotational) forms of the structure. For example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers are included in this invention, unless only one of the isomers is drawn specifically. As would be understood to one skilled in the art, a substituent can freely rotate around any rotatable bonds. For example, a substituent drawn as

also represents

[00426] Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, cis/trans, conformational, and rotational mixtures of the present compounds are within the scope of the invention.

[00427] Unless otherwise indicated, all tautomeric forms of the compounds of the invention are within the scope of the invention.

[00428] Additionally, unless otherwise indicated, structures depicted herein arc also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a ⁱ³C- or ¹⁴C-enriched carbon are within the scope of this invention. For example, compounds of Structural Formulae I-VI (e.g., Structural Formulae I, ΙΑ, Π, III, IV, V, and VI) and XI(A)XIV (e.g., Structural Formulae XIA, ΧΙΒ, ΧΠΑ, XIIB, XIII, and XIV) that have -D at the position corresponding to R² are also within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays. Such compounds, especially deuterium analogs, can also be therapeutically useful.

[00429] The terms “a bond” and “absent” are used interchangeably to indicate that a

-160WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 group is absent.

[00430] The compounds of the invention are defined herein by their chemical structures and/or chemical names. Where a compound is referred to by both a chemical structure and a chemical name, and the chemical structure and chemical name conflict, the chemical structure is determinative of the compound’s identity.

Pharmaceutically Acceptable Salts, Solvates, Chlatrates, Prodrugs and Other Derivatives [00431] The compounds described herein can exist in free form, or, where appropriate, as salts. Those salts that are pharmaceutically acceptable are of particular interest since they are useful in administering the compounds described below for medical purposes. Salts that are not pharmaceutically acceptable are useful in manufacturing processes, for isolation and purification purposes, and in some instances, for use in separating stereoisomeric forms of the compounds of the invention or intermediates thereof.

[00432] As used herein, the term pharmaceutically acceptable salt refers to salts of a compound which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue side effects, such as, toxicity, irritation, allergic response and the like, and arc commensurate with a reasonable benefit/risk ratio.

[00433] Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds described herein include those derived from suitable inorganic and organic acids and bases. These salts can be prepared in situ during the final isolation and purification of the compounds.

|00434] Where the compound described herein contains a basic group, or a sufficiently basic bioisostere, acid addition salts can be prepared by 1) reacting the purified compound in its free-base form with a suitable organic or inorganic acid and 2) isolating the salt thus formed. In practice, acid addition salts might be a more convenient form for use and use of the salt amounts to use of the free basic form.

[00435] Examples of pharmaceutically acceptable, non-toxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate,

-161WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, glycolate, gluconate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like, [00436] Where the compound described herein contains a carboxy group or a sufficiently acidic bioisostere, base addition salts can be prepared by I) reacting the purified compound in its acid form with a suitable organic or inorganic base and 2) isolating the salt thus formed. In practice, use of the base addition salt might be more convenient and use of the salt form inherently amounts to use of the free acid form. Salts derived from appropriate bases include alkali metal (e.g., sodium, lithium, and potassium), alkaline earth metal (e.g., magnesium and calcium), ammonium and N(Ci-4alkyl)4 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization. [00437] Basic addition salts include pharmaceutically acceptable metal and amine salts. Suitable metal salts include the sodium, potassium, calcium, barium, zinc, magnesium, and aluminium. The sodium and potassium salts are usually preferred. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternaiy ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate. Suitable inorganic base addition salts are prepared from metal bases which include sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide and the like. Suitable amine base addition salts are prepared from amines which are frequently used in medicinal chemistry because of their low toxicity and acceptability for medical use. Ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N’-dibenzylethylenediamine, chloroprocaine, dietanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenaminc, dchydroabictylaminc, N-ethylpipcridinc, benzylamine, tetramethylammonium, tetraethyl ammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, dicyclohexylamine and the like.

-162WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00438] Other acids and bases, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds described herein and their pharmaceutically acceptable acid or base addition salts.

[00439] It should be understood that this invention includes mixtures/combinations of different pharmaceutically acceptable salts and also mixtures/combinations of compounds in free form and pharmaceutically acceptable salts.

[00440] In addition to the compounds described herein, pharmaceutically acceptable solvates (e.g., hydrates) and clathrates of these compounds may also be employed in compositions to treat or prevent the herein identified disorders.

[00441] As used herein, the term “pharmaceutically acceptable solvate,” is a solvate formed from the association of one or more pharmaceutically acceptable solvent molecules to one of the compounds described herein. The term solvate includes hydrates (e.g., hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate, and the like).

[00442] As used herein, the term “hydrate” means a compound described herein or a salt thereof that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.

[00443] As used herein, he term “clathrate” means a compound described herein or a salt thereof in the form of a crystal lattice that contains spaces (e.g., channels) that have a guest molecule (e.g., a solvent or water) trapped within.

[00444] In addition to the compounds described herein, pharmaceutically acceptable derivatives or prodrugs of these compounds may also be employed in compositions to treat or prevent the herein identified disorders.

[00445] A “pharmaceutically acceptable derivative or prodrug” includes any pharmaceutically acceptable ester, salt of an ester or other derivative or salt thereof of a compound described herein which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound described herein or an inhibitorily active metabolite or residue thereof. Particularly favoured derivatives or prodrugs are those that increase the bioavailability of the compounds when such compounds are administered to a patient (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.

[00446] As used herein and unless otherwise indicated, the term “prodrug” means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological

-163WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 conditions (in vitro or in vivo) to provide a compound described herein. Prodrugs may become active upon such reaction under biological conditions, or they may have activity in their unreacted forms. Examples of prodrugs contemplated in this invention include, but are not limited to, analogs or derivatives of compounds of the invention that comprise biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues. Other examples of prodrugs include derivatives of compounds described herein that comprise -NO, -NO₂, -ONO, or -ONO₂ moieties. Prodrugs can typically be prepared using well-known methods, such as those described by BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY (1995) 172-178, 949-982 (Manfred E. Wolff cd., 5th ed).

[00447] A “pharmaceutically acceptable derivative” is an adduct or derivative which, upon administration to a patient in need, is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof. Examples of pharmaceutically acceptable derivatives include, but are not limited to, esters and salts of such esters.

[00448] Pharmaceutically acceptable prodrugs of the compounds described herein include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.

Pharmaceutical Compositions [00449] The compounds described herein can be formulated into pharmaceutical compositions that further comprise a pharmaceutically acceptable carrier, diluent, adjuvant or vehicle. In one embodiment, the present invention relates to a pharmaceutical composition comprising a compound of the invention described above, and a pharmaceutically acceptable carrier, diluent, adjuvant or vehicle. In one embodiment, the present invention is a pharmaceutical composition comprising an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, adjuvant or vehicle. Pharmaceutically acceptable carriers include, for example, pharmaceutical diluents, excipients or carriers suitably selected with respect to the intended form of administration, and consistent with conventional pharmaceutical practices. (00450] An “effective amount” includes a “therapeutically effective amount” and a “prophylactically effective amount”. The term “therapeutically effective amount” refers to an amount effective in treating and/or ameliorating an influenza virus infection in a patient infected with influenza. The term “prophylactically effective amount” refers to an amount

-164WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 effective in preventing and/or substantially lessening the chances or the size of influenza virus infection outbreak. Specific examples of effective amounts are described above in the section entitled Uses of Disclosed Compounds.

[00451] A pharmaceutically acceptable carrier may contain inert ingredients which do not unduly inhibit the biological activity of the compounds. The pharmaceutically acceptable carriers should be biocompatible, e.g., non-toxic, non-inflammatory, non-immunogenic or devoid of other undesired reactions or side-effects upon the administration to a subject. Standard pharmaceutical formulation techniques can be employed.

[00452] The pharmaceutically acceptable carrier, adjuvant, or vehicle, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds described herein, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention. As used herein, the phrase “side effects” encompasses unwanted and adverse effects of a therapy (e.g., a prophylactic or therapeutic agent). Side effects are always unwanted, but unwanted effects are not necessarily adverse. An adverse effect from a therapy (e.g., prophylactic or therapeutic agent) might be harmful or uncomfortable or risky. Side effects include, but are not limited to fever, chills, lethargy, gastrointestinal toxicities (including gastric and intestinal ulcerations and erosions), nausea, vomiting, neurotoxicities, nephrotoxicities, renal toxicities (including such conditions as papillary necrosis and chronic interstitial nephritis), hepatic toxicities (including elevated serum liver enzyme levels), myelotoxicities (including leukopenia, myelosuppression, thrombocytopenia and anemia), dry mouth, metallic taste, prolongation of gestation, weakness, somnolence, pain (including muscle pain, bone pain and headache), hair loss, asthenia, dizziness, extra-pyramidal symptoms, akathisia, cardiovascular disturbances and sexual dysfunction.

[00453] Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as twin 80,

-165WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 phosphates, glycine, sorbic acid, or potassium sorbate), partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, or zinc salts), colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, poly ethyl enepolyoxypropylene-block polymers, methylcellulose, hydroxypropyl methylcellulose, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.

A dministration Methods [00454] The compounds and pharmaceutically acceptable compositions described above can be administered to humans and other animals orally, rectally, parenterally, intraci eternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.

[00455) Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuiyl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

-166WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00456] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

[00457] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[00458] In order to prolong the effect of a compound described herein, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of ciystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon ciystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.

[00459] Compositions for rectal or vaginal administration are specifically suppositories which can be prepared by mixing the compounds described herein with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

[00460] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at

-167WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, 1) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[00461] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingrcdient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.

[00462] The active compounds can also be in microencapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also bo of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include

-168WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 polymeric substances and waxes.

[00463] Dosage forms for topical or transdermal administration of a compound described herein include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

[00464] The compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term parenteral as used herein includes, but is not limited to, subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrastemal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Specifically, the compositions arc administered orally, intraperitoneally or intravenously.

[0046S] Sterile injectable forms of the compositions described herein may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in

-169WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

[00466] The pharmaceutical compositions described herein may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include, but are not limited to, lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

[00467] Alternatively, the pharmaceutical compositions described herein may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols. [00468] The pharmaceutical compositions described herein may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[00469] Topical application for the lower intestinal tract can be effected in a rectal suppositoiy formulation (see above) or in a suitable enema formulation. Topicallytrans dermal patches may also be used.

[00470] For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2 octyldodecanol, benzyl alcohol and water.

[00471] For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, specifically, as solutions in

-170WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.

[00472] The pharmaceutical compositions may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

[00473] The compounds for use in the methods of the invention can be formulated in unit dosage form. The term “unit dosage form” refers to physically discrete units suitable as unitary dosage for subjects undergoing treatment, with each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, optionally in association with a suitable pharmaceutical carrier. The unit dosage form can be for a single daily dose or one of multiple daily doses (e.g., about 1 to 4 or more times per day). When multiple daily doses are used, the unit dosage form can be the same or different for each dose.

EXEMPLIFICATION

Preparation of Compounds

The compounds disclosed herein, including those of Structural Formulae I-VI (e.g., Structural Formulae I, ΙΑ, II, III, TV, V, and VI) and XI(A)-XIV (e.g., Structural Formulae XIA, XIB, XIIA, XIIB, XIII, and XIV) can be prepared by any suitble method known in the art, for example, WO 2005/095400 and WO 2007/084557. For example, the compounds depicted in FIGs. 3-8 can be prepared by any suitble method known in the art, for example, WO 2005/095400 and WO 2007/084557, and by the exemplary syntheses deserbied below. In particular, the compounds depicted in FIG. 8 can be prepared as described in WO 2005/095400 and WO 2007/084557. Syntheses of certain exemplary compounds of Structural Formulae I-VI and XI(A)-XIV are described below. Generally, the compounds of Structural Formulae I-VI and XI(A)-XIV can be prepared as shown in those syntheses optionally with any desired appropriate modification.

General Analytical Methods.

[00474] As used herein the term RT (min) refers to the LCMS retention time, in minutes, associated with the compound. Unless otherwise indicated, the method employed to obtain the reported retention times is as follows:

-171WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Column: YMC-Pack Pro Cig, 50 mm x 4.6 mm id

Gradient: 10-95 % mcthanol/HoO. Flow rate: 1.5 ml/min. UV-vis detection.

Methodology for Synthesis and Characterization of Compounds [00475] Syntheses of certain exemplary compounds of Structural Formulae I-VI (e.g., Structural Formulae I, ΙΑ, II, III, IV, V, and VI) and XI(A)-XIV (e.g., Structural Formulae XIA, XIB, XIIA, XIIB, XIII, and XTV) are described below. NMR and Mass Spectroscopy data of certain specific compounds are summarized in Tables 1-5.

General Scheme 1

(a) (S)-1 -Boc-3-aminopiperidine, 'Pr₂NEt, DMF, 90 °C; (b) TFA, CH₂CI₂ (c) 2(methoxymethyl)oxirane, EtOH, microwave, 140 °C (d) 1N LiOH, THF, microwave, 120 °C [00476] Formation of (5)-toi-butyl 3-(2-(5-chloro-l-tosyl-1ff-pyrrolo [2,3i]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)piperidine-l-carboxylate (lb).

To a solution of 5-chloro-3-(5-fluoro-4-methylsulfonyl-pyrimidin-2-yl)-l-(ptolylsulfonyl)pyrrolo[2,3-b]pyridine, la, (3.5 g, 7.5 mmol) and /<?rt-butyl (35)-3aminopiperidine-1-carboxylate (1.8 g, 9.0 mmol) in DMF (32 mL) was added diisopropylethylamine (2.6 mL, 15.1 mmol). The reaction mixture was heated at 90 °C for 75 minutes. The mixture was cooled to room temp and diluted into aqueous saturated NH4CI solution and extracted with EtOAc. The organic phase was washed with brine (3 times), dried (MgSCtj), filtered and concentrated under vacuo. The resulting residue was purified via silica gel chromatography (0%-10% MeOH/CILCh) to afford the desired product lb as a white solid.

LCMS RT = 4.6 (M+l) 601.5, (M-l) 599.6.

[00477] Formation of (S)-2-(5-chloro-l-tosyl-lZ7-pyrrolo[2,3-6]pyridin-3-yl)-5fluoro-/V-(piperidin-3-yl)pyrimidin-4-amine (1c).

To a solution of /ert-butyl (3S)-3-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[5,4b]pyridin-3-yl]-5-fluoiO-pyrimidin-4-yl]amino]piperidine-l-carboxylate, lb, (2.1 g, 3.5

-172WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 mmol) in CH2CI2 (30 mL) was added trifluoroacetic acid (20 mL). After stirring the reaction mixture at room temperature for 75 min, the mixture was concentrated under vacuo. The crude residue was diluted with EtOAc and neutralized with IN sodium hydroxide solution. The aqueous phase was separated and extracted again with EtOAc. The combined organic phases were dried (MgSOQ, filtered and concentrated under vacuo to afford the desired product (lc) as a light yellow solid.

NMR (300 MHz, 76-DMSO) δ 8.76 (d, J= 2.5, Hz, 1H), 8.50 (d, 7= 2.5 Hz, 1H),

8.44 (s, 1H), 8.27 (d, 7 = 4.0 Hz, 1H), 8.06 (d, J= 8.5 Hz, 2H), 7.66 (d, J= 6.9 Hz, 1H), 7.45 (d, J= 8.2 Hz, 2H), 4.17 (m, 1H), 3.17 (dd, 7 = 3.1, 11.8 Hz, 1H), 2.99 - 2.94 (m, 1H), 2.67 2.60 (m, 1H), 2.38 - 2.34 (m, 1H), 2.06 - 2.02 (m, 1H), 1.77 - 1.73 (m, 1H) and 1.63 - 1.50 (m, 2H) ppm. LCMS RT = 2.1 (M+l) 501.5, (M-l) 499.5.

[00478] Formation of l-((_iS')-3-(2-(5-chloro-l-tosyI-l£/-pyrrolo[2,3-/i]pyridm-3-yl)5-flu or opy rimid in-4-ylamino)piperidin-l -yl)-3-methoxypr opan-2-ol (Id).

To a solution of 2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[5,4-b]pyridin-3-yl]-5-fluoroN-[(3S)-3-piperidyl]pyrimidin-4-amine, lc, (0.20 g, 0.40 mmol) in ethanol was added 2(methoxymethyl)oxirane (0.04 mL, 0.40 mmol). The reaction mixture was heated in a microwave reactor at 140 C for 5 minutes. The reaction was evaporated to dryness and the resulting residue was purified via silica gel chromatography (0-10 % MeOH: CH2CI2) to afford the desired product (Id).

*H NMR (300 MHz, 76-DMSO) δ 8.78 (d, 7= 2.5 Hz, 1H), 8.49 (d, 7= 2.4 Hz, 1H), 8.43 (d, 7= 1.2 Hz, 1H), 8.26 (d, 7= 3.9 Hz, 1H), 8.07 (d, 7= 8.4 Hz, 2H), 7.60 (d, 7= 7.5 Hz, 1H), 7.45 (d, 7= 8.2 Hz, 2H), 4.54 - 4.50 (m, 1H), 4.20 (m, 1H), 3.35 - 3.17 (m, 1H),

3.33 (s, 3H), 3.25 (m, 1H), 3.19 (d, 2H), 3.00 (m, 1H), 2.75 (d, J = 11.8 Hz, 1H), 2.44 - 2.26 (m, 4H), 1.93 (m, 1H), 1.73 (m, 2H), 1.63 (m, 1H) and 1.23 (m, 1H) ppm.

LCMS RT = 2.4 (M+l) 589.6.

[00479] Formation of l-((S)-3-(2-(5-chloro-lIT-pyrrolo[2,3-A]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)piperidin-l-yl)-3-methoxypropan-2-ol (537).

To a solution of l-[(35)-3-[[2-[5-chloiO-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3yl]-5-fluoro-pyrimidin-4-yl]amino]-l-piperidyl]-3-methoxy-propan-2-ol, Id, (0.15 g, 0.24 mmol) in THF was added IN LiOH solution. The reaction mixture was heated in a microwave reactor at 120 °C for 5 minutes. The reaction mixture was diluted with water and the aqueous phase was extracted with EtOAc (twice). The combined organic phases were dried (MgSOQ, filtered and concentrated under vacuo. The resulting solid was purified by silica gel chromatography (5-20% MeOH: CH2CI2) to afford the desired product (537) as a white solid.

NMR (300 MHz, 76-DMSO DMSO) δ 12.35 (s, 1H), 8.73 (d, 7= 2.4 Hz, 1H),

8.29 (d, 7= 2.4 Hz, 1H), 8.19 - 8.09 (m, 2H), 7.36 (d, 7= 7.5 Hz, 1H), 4.53 (dd, J= 4.5, 8.0 Hz, 1H), 4.27 (s, 1H), 3.77 - 3.72 (m, 1H), 3.36 - 3.20 (m, 3H), 3.22 (s, 3H), 3.03 - 2.97 (m, 1H), 2.76 (d, 7= 10.6 Hz, 1H), 2.44 - 2.14 (m, 2H), 2.08 (m, 2H), 1.99 - 1.94 (m, 1H), 1.71 1.63 (m, 2H), 1.44 (m, lH)and 1.23 - 1.15 (m, IH)ppm.

LCMS RT= 1.6 (M+l) 435.5.

[00480] Other analogs that can be prepared in the same manner as 537 are described below:

-173WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

525

551 [00481] 3-((5)-3-(2-(5-chloro-U7-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)piperidin-l-yl)propane-l,2-diol (525) ^lH NMR (300 MHz, ί/6-DMSO) δ 12.31 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.20 (s, 1H), 8.17 (d, J= 4.0 Hz, 1H), 7.33 (d, J= 7.6 Hz, 1H), 4.51 (m, 1H),

4.37 (s, 1H), 4.25 (m, 1H), 3.64 (m, 1H), 3.35 (s, 2H), 3.08-2.95 (m, 1H), 2.80-2.70 (m, 1H),

2.47 - 2.25 (m, 2H), 2.22 - 2.12 (m, 2H), 1.99 - 1.90 (m, 1H), 1.70 - 1.60 (m, 2H) and 1.45 (m, 1H) ppm.

LCMS RT = 1.5 (M+l) 421.5.

[00482] 1-((5)-3-(2-(5-^1 loro-1ίΓ-py rr olo [ 2,3 -b ] py ridin-3-y l)-5-fluoropy rimidin-4ylamino)piperidin-l-yl)-3-isopropoxypropan-2-ol (551).

^!H NMR (300 MHz, ί/6-DMSO) δ 12.32 (s, 1H), 8.72 (d, J= 2.4 Hz, 1H), 8.28 (d, J=

2.4 Hz, IH), 8.19 - 8.16 (m, 2H), 7.32 (d, J= 8.0 Hz, 1H), 4.42 - 4.37 (m, 2H), 3.70 (s, 1H),

3.52 - 3.42 (m, 1H), 3.35 - 3.25 (m, 1H), 2.99 (m, 1H), 2.73 (m, 1H), 2.43 - 2.11 (m, 4H),

1.94 (m, 1H), 1.75 - 1.60 (m, 2H), 1.52 - 1.40 (Μ, 1H) and 1.10 - 0.99 (m, 6H).

LCMS RT = 1.7 (M+l) 463.4, (M-l) 461.5.

[00483] (5)-1 -((5)-3-(2-(5-chloro-17/-pyrr olo [2,3-b]pyridin-3-y 1)-5fluoropynmidin-4-ylamino)piperidin-l-yl)butan-2-ol (538).

‘H NMR (300 MHz, ί/6-DMSO) δ 12.53 (s, 1H), 10.32 (s, 1H), 8.69 (dd, J= 2.5, 5.2 Hz, 1H), 8.56 (d, J= 2.4 Hz, 1H), 8.31 (m, 2H), 7.97 (s, 1H), 4.76 (m, 1H), 3.92 (m, 2H), 3.84 - 3.55 (m, 2H), 3.40 - 2.80 (m, 3H), 2.14 - 1.90 (m, 3H), 1.80 - 1.74 (m, 2H), 1.65 (m, 1H), 1.43 - 1.23 (m, 2H) and 0.96 - 0.85 (m, 3H) ppm.

LCMS RT= 1.6 (M+l) 419.6.

[00484] (5)-l-(3-(2-(5-chIoro-IZ7-pyrroIo[2,3-6]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)piperidin-l-yl)-2-methylpropan-2-ol (546).

‘H NMR (300 MHz, CDCfi) δ 9.60 (s, 1H), 8.87 (d, J= 2.3 Hz, 1H), 8.33 (d, 2.3

Hz, IH), 8.17 (d, 2.7 Hz, 1H), 8.09 (d, J= 3.3 Hz, 1H), 5.34 (d, J= 11.5 Hz, 1H), 4.45 -

4.42 (m, 1H), 3.09 (d, J= 11.3 Hz, 1H), 2.75 - 2.59 (m, 4H), 2.40 (s, 2H), 1.94 - 1.70 (m, 4H) and 1.27 (s, 6H) ppm.

-174WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

LCMS RT = 1.6 (M+I) 419.5.

[00485] (i)-3-((5)-3-(2-(5-chloro-lZ/-pyrrolo[2,3-6]pyridin-3-yl)-5fluoropy rimidin-4-yla min o)piperidin-l-yl)p ropane-l,2-diol (588).

^lH NMR (300 MHz, DMSO) 8 12.31 (s, 1H), 8.72 (d, J= 2.4 Hz, 1H), 8.27 (d, J=

2.4 Hz, 1H), 8.19 (s, 1H), 8.16 (d, 7 = 4.0 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 4.47 - 4.44 (m, IH), 4.35 (d, 7 = 4.0 Hz, 1H), 4.28 - 4.17 (m, IH), 3.64 - 3.62 (m, 1H), 3.17 (d, 7= 5.2 Hz, 1H), 3.02 - 2.98 (m, IH), 2.78 - 2.73 (m, IH), 2.37 (ddd, 7= 12.8, 5.2, 5.2 Hz, 2H), 2.22 -

2.10 (m, 2H), 1.99 - 1.89 (m, IH), 1.73 - 1.63 (m, 2H) and 1.46 - 1.43 (m, IH) ppm. LCMS RT= 1.5 (M+l) 421.4. LCMS RT = 1.6 (M+I) 419.3.

[00486] (5)-3-((5)-3-(2-(5-chloro-l/Z-pyrrolo[2,3-/>]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)piperidin-l-yl)propane-l,2-diol (587).

^lH NMR (300 MHz, DMSO) 8 12.31 (s, IH), 8.72 (d, 7= 2.4 Hz, IH), 8.28 (d, 7 =

2.4 Hz, IH), 8.20 (s, IH), 8.16 (d, 7= 4.0 Hz, IH), 7.33 (d, 7= 7.5 Hz, IH), 4.34 (s, IH),

4.27 - 4.23 (m, IH), 3.62 (s, IH), 3.35 (d, 7= 5.5 Hz, IH), 3.06 - 3.03 (m, IH), 2.78 - 2.74 (m, IH), 2.44 (d, 7= 5.0 Hz, IH), 2.27 (dd, 7= 12.9, 6.9 Hz, IH), 2.20 - 2.07 (m, 2H), 2.05 1.90 (m, IH), 1.75 - 1.59 (m,2H)and 1.49- 1.39 (m, lH)ppm.

603 [00487] 1-((35,45)-3-(2-(5-chloro-l//-pyrrolo[2,3-Z>]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-4-methylpiperidin-l-yl)-3-methoxypropan-2-oI (550).

*HNMR (300 MHz, 76-DMSO) 8 12.33 (s, IH), 8.72 (d, 7= 2.5 Hz, IH), 8.28 (d,7=

2.4 Hz, IH), 8.22 - 8.20 (m, 2H), 6.72 - 6.62 (m, IH), 4.61 (dd, 7 = 4.2, 10.0 Hz, IH), 4.54 (m, IH), 3.75 - 3.71 (m, IH), 3.34 - 3.22 (m, IH), 3.22 (d, 3H), 2.88 - 2.42 (m, 4H), 2.41 -

2.25 (m, 4H), 1.93 (m, IH), 1.56 (m, 2H) and 0.90 (d, 7= 6.7 Hz, 3H). LCMS RT = 1.6 (M+l) 449.5.

[00488] 3-((5)-3-(2-(5-chloro-l#-pyrrolo[2,3-&]pyridin-3-yl)-5-fhioropyriinidm“4ylamino)piperidin-l-yl)-2-hydi*oxypropanamide (603).

^lH NMR (300 MHz, DMSO) 8 12.31 (s, IH), 8.71 (d, 7= 2.4 Hz, IH), 8.28 - 8.25 (m, IH), 8.19 - 8.16 (m, 2H), 7.34- 7.30 (m, IH), 7.19 (s, IH), 7.11 (s, IH), 4.24 (s, IH), 3.99 (dd, 7= 3.5, 7.6 Hz, IH), 3.01 (d, 7= 10.3 Hz, IH), 2.81 - 2.63 (m, 2H), 2.36 - 2.29 (m, 2H),

-175WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1.71 (s, 3H)and 1.51 -1.44 (m, 2H)ppm.

General Scheme 2

(a) tert-butylbromoacetate, Na₂CO₃, DMF (b) 1N LiOH, THF, microwave, 120 °C, 10 min (c) TFA, CH₂CI₂ [00489] Formation of (SJ-tcrt-butyl 3-(2-(5-chloro-l-tosyl-117-pyrrolo[2,36]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)piperidine-l-carboxylate (2a).

To a solution of 2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[5,4-b]pyridin-3~yl]-5-fluoro/V-JpSj-B-piperidyllpyrimidin-d-ainine, 1c, (0.25 g, 0.50 mmol) in DMF was added tertbutylbromoacetate (0.08 mL, 0.55 mmol) and Na₂COj (0.11 g, 0.99 mmol). The reaction mixture was stirred at room temperature for 6 h. The resulting thick white precipitate was diluted with aqueous saturated NaCl solution and washed with water. The white solid was dissolved in CH₂C1₂ and the solution was dried (MgSO₄), filtered and concentrated in vacuo. The crude was purified via silica gel chromatography (0%-5% MeOH/ CH₂C1₂) to afford the desired product, 2a, as a white solid.

Ή NMR (300 MHz, 76-DMSO) 6 8.76 (d, 7 = 2.4 Hz, 1H), 8.48 (d, J= 3.6 Hz, 1H),

8.44 (s, 1H), 8.26 (d, 7= 3.9 Hz, 2H), 8.07 (d, 7= 8.4 Hz, 2H), 7.59 (d, 7= 8.2 Hz, 1H), 7.44 (d, 7= 8.1 Hz, 2H), 4.18 (m, 1H), 3.19 (s, 2H), 3.03 - 2.99 (m, 1H), 2.78 - 2.73 (m, 1H), 2.45 - 2.30 (m, 2H), 2.37 (s, 3H), 1.99 - 1.93 (m, 1H), 1.80 - 1.60 (m, 2H), 1.46 - 1.40 (m, 1H) and

1.36 (s, 9H) ppm.

LCMS RT = 2.8 (M+l) 615.6, (M-l) 613.6.

[00490] Formation of (Sj-tort-butyl 2-(3-(2-(5-chloro-17/-pyrrolo[2,3-/>]pyridin-3yl)-5-fluoropyrimidin-4-ylamino)piperidin-l-yl)ethanoate (2b).

To a solution of tert-butyl 2-[(3y)-3-[[2-[5-chloro-l-(p-tolyisulfonyl)pyrrolo[2,3-b]pyridin-

3-yl]-5-fluoro-pyrimidin-4-yl]amino]-1-piperidyl]acetate, 2a, (0.27 g, 0.44 mmol) in THF was added IN LiOH solution. The reaction mixture was heated in microwave at 120 degrees for 10 minutes. The reaction mixture diluted with brine, extracted with EtOAc, then with 20% isopropanol/CH₂Cl₂. The combined organic phases were dried (MgSO₄), filtered and concentrated in vacuo. The resulting product, 2b, was used without further purification. LCMS RT = 2.0 (M+l) 461.5.

[00491] Formation of (5)-2-(3-(2-(5-chloro-ljH-pyrrolo[2,3-/>]pyridin-3-yl)-5fluoropyrimidin-4-ylainino)piperidin-l-yl)ethanoic acid (577).

-176WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

To a solution /eri-butyl 2-[(3S)-3-[[2-(5-chloro-lH-pyrroIo[2,3-b]pyridin-3-yl)-5-fluoropy rimidin-4-yl] amino]-1-piperidyl] acetate, 2b, (0.12 g, 0.26 mmol) in CH₂C1₂ (4 mL) was added trifluoroacetic acid (4 mL). The reaction mixture was stirred at room temperature for 18 h and concentrated in vacuo. The crude residue was diluted with 5%MeOH/ CH2CI2 and die resulting white precipitate was filtered and washed with CH₂C1₂ to afford the desired product, 577, as trifluoroacetic acid salt.

*H NMR (300 MHz, 76-DMSO) δ 12.46 (s, 1H), 8.70 (d, J= 2.4 Hz, 1H), 8.36 (d, J= 2.3 Hz, 1H), 8.31 (d, J = 2.4 Hz, 1H), 8.29 (d, 7 = 3.9 Hz, 1H), 7.79 (d, 7 = 7.0 Hz, 1H), 4.70 -

4.50 (m, 1H), 4.21 (s, 2H), 3.80 - 3.70 (m, 1H), 3.55 - 3.47 (m, 1H), 3.20 - 2.90 (m, 2H), 2.10 -1.95 (m, 3H) and 1.69 - 1.60 (m, 1H) ppm. LCMS RT = 1.9 (M+l) 405.4.

[00492] Other analogs that can be prepared in the same manner as 577:

583 [00493] (5)-2-(3-(2-(5-chloro-lJ¥-pyrrolo[2,3-i»]pyridm-3-yl)-5-fluoropyrimidin-4ylamino)piperidin-l-yl)ethanamide (567).

^lHNMR (300 MHz, 76-DMSO) δ 12.29 (s, 1H), 8.72 (d, J= 2.4 Hz, 1H), 8.28 (d, J =

2.4 Hz, 1H), 8.21 (s, 1H), 8.17 (d, 7= 4.0 Hz, 1H), 7.41 (d, 7= 7.7 Hz, 1H), 7.29 (s, 1H),

7.10 (s, 1H), 4.35 - 4.29 (m, 1H), 2.98 - 2.75 (m, 1H), 2.92 (d, J= 6.8 Hz, 2H), 2.68 (d, J =

10.8 Hz, 1H), 2.29 - 2.19 (m, 2H), 1.96 - 1.92 (m, 1H), 1.80 - 1.65 (m, 2H) and 1.53 - 1.42 (m, 1H) ppm. LCMS RT = 2.1 (M+l) 404.4, (M-l) 402.5.

[00494] 2-((<S)-3-(2-(5-chloro-ljH-pyrrolo[2,3-Z']pyr'idin-3-yl)-5-fluoropyrimidin-4ylamino)piperidin-l-yl)propanamide (583).

¹HNMR(300 MHz, 76-DMSO) δ 8.70 (d, 7=2.3 Hz, IH), 8.52 (d, J= 8.7 Hz, 1H),

8.35 (dd, J= 5.0, 6.5 Hz, 2H), 4.10 (dd, J= 2.7, 7.0 Hz, IH), 3.80-3.90 (m, IH), 3.60 - 3.80 (m, IH), 2.35-2.45 (m, IH), 2.15 - 2.35 (m, IH), 1.80 - 1.95 (m, IH), and 1.60 - 1.65 (m, 3H) ppm.

LCMS (M+l) 418.4.

654

620

-177WO 2010/148197

PCT/US2010/038988 [00495] (5)-2-(3-(2-(5-chloro-l//-pyrrolo|2,3-6]pyridin-3-yI)-5-cyanopyrimidin-4y la mino)pip eridin-l-yl)ethanamide (654).

LCMS RT = 2.9 (M+l) 411.4, (M-l) 409.4.

[00496] (5^T)-2-(3-(2-(5-chloro-1//-pyrrolo[2,3-0]pyridiri-3-yl)-5-nicthylpyrimjdin-4ylamino)piperidin-l-yl)ethanamide (620).

LCMS RT = 1.9 (M+l) 400.4, (M-l) 398.3.

[00497] 2-((5)-3 -(2-(5-ch loro-1 //-pyrrole [2,3 -6] py ridm-3-yl)-5-fluor opy r imidin-4ylamino)piperidin-l-yl)propanoic acid (573).

*Η NMR (300 MHz, t/6-DMSO) δ 12.51 (s, 1H), 10.28 - 10.00 (m, 1H), 8.70 (s, 1H),

8.38 (s, 1H), 8.31 (d, J= 2.4 Hz, 1H), 8.30 (d, J= 4.2 Hz, 1H), 7.89 - 7.75 (m, 1H), 4.70 -

4.50 (m, 1H), 4.33 - 4.29 (m, 1H), 3.79 - 3.45 (m, 2H), 3.20 - 2.80 (m, 2H), 2.12 - 1.95 (m, 3H), 1.72 - 1.60 (m, 1H) and 1.52 (d, J = 5.5 Hz, 3H) ppm.

[00498] 2-((5)-3-(2-(5-chloro-l//-pyrrolo[2,3-/;|pyridin-3-yl)-5-fluoropyrimidin-4ylamino)piperidin-l-yI)-/V-methylpropanamide (606).

‘HNMR (300 MHz, ί/6-DMSO) δ 8.69 (d, J= 12.7 Hz, 1H), 8.54 - 8.49 (m, 1H), 8.32 (dd, 4.8, 7.2 Hz, 2H), 4.83 - 4.76 (m, 1H), 4.02 (m, 1H), 3.95 - 3.71 (m, 2H), 3.31 - 3.10 (m, 1H), 2.86 (s, 3H), 2.33 (d, J= 9.9 Hz, 1H), 2.40 - 2.14 (m, 3H), 1.94 (s, 1H), 1.66 - 1.58 (m, 3H) and 1.10 (d, J= 6.5 Hz, 3H) ppm.

LCMS (M+l) 432.2.

[00499] (5)-2-(3-(2-(5-chIoro-l//-pyrrolo[2,3-/>]pyridin-3-yl)-5-fluoropyrimidin-4yIamino)piperidin-l-yl)-2-methylpropanoic acid (590).

Ή NMR (300 MHz, MeOD) δ 8.81 (d, J= 2.3 Hz, 1H), 8.19 (t, J= 2.5 Hz, 2H), 7.98 (d, J= 4.2 Hz, 1H), 4.48 (s, 1H), 2.90 (d, J= 10.1 Hz, 1H), 2.74 - 2.66 (m, 2H), 2.60 (d, J=

5.7 Hz, 1H), 1.89 - 1.83 (m, 2H), 1.67 (s, 1H), 1.25 (d, J= 4.9 Hz, 6H) ppm. LCMS (M+l)

433.4.

[00500] (5)-2-(3-(2-(5-chloro-l£/-pyrrolo[2,3-6]pyridin-3-yl)-5-fluoropyrimidin-4yIamino)piperidin-l-yI)-2-methylpropanamide (598).

-178WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00501J (₁S)-2-(3-(2-(5-chloro-l.ff-pyrrolo[2,3“A]pjTidin-3“yl)-5“fluoropyrimidin“4“ ylamino)piperidin-l-yl)-A',2-dimethyIpropanamide (599).

^lHNMR (300 MHz, MeOD) 5 8.86 (d, J= 2.4 Hz, 1H), 8.23 (d, J= 2.3 Hz, 1H), 8.17 (s, 1H), 8.03 (d, J= 4.1 Hz, 1H), 4.46 (dd, J= 4.7, 8.8 Hz, 1H), 4.10 (q, J=7.2 Hz, 1H), 3.05 (d, J= 12.8 Hz, 1H), 2.66 (s, 3H), 2.34 (dd, 7= 11.3, 20.6 Hz, 2H), 2.08 (d, J= 12.3 Hz, 1H), 1.89-1.71 (m, 2H), 1.66- 1.54 (m, lH)and 1.19 (s, 6H) ppm.

LCMS (M+l) 433.4.

[00502] (5)-2-(3 -(2-(5-chlor o-l/T-pyr r olo [2,3-6] py ridin-3-y l)-5-fluoropyrimidin-4yIamino)piperidin-l-yl)-AyV,2-trimethylpropanamide (600).

^[H NMR (300 MHz, MeOD) δ 8.81 (d, J= 2.4 Hz, 1H), 8.22 (d, J= 2.4 Hz, 1H), 8.14 (s, 1H), 8.02 (d, 7=4.0 Hz, 1H), 4.45 - 4.37 (m, 1H), 3.61 (s, 3H), 2.97 (d, 7= 8.8 Hz, 1H), 2.80 (s, 3H), 2.72 (s, 1H), 2.39 (1,7= 10.0 Hz, 2H), 2.15 (dd,7= 3.6, 12.7 Hz, 1H), 1.91 -

1.79 (m, 2H), 1.53 - 1.47 (m, 1H) and 1.28 (s, 6H) ppm.

LCMS (M+l) 460.5.

[00503] (5)-2-(3-(2-(5-chloro-17f-pyrrolo[2,3-6]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)piperidin-l-yI)-A^r-(2-methoxyethyl)-2-methylpropanamide (601).

'H NMR (300 MHz, MeOD) δ 8.88 (d, 7 = 2.3 Hz, 1H), 8.23 (d, 7 = 2.3 Hz, 1H), 8.17 (s, 1H), 8.02 (d, 7= 4.1 Hz, 1H), 4.47-4.41 (m, 1H), 3.38 (dd, 7= 1.6,4.8 Hz, 4H), 3.12 3.07 (m, 1H), 2.73 (d, 7= 10.8 Hz, 1H), 2.35 - 2.29 (m,2H), 2.19-2.15 (m, 1H), 1.91-1.80 (m, 2H), 1.55 (s, 1H), 1.37 (s, 1H) and 1.20 (s, 6H) ppm..

[00504] (5')-2-(3-(2-(5-chloro-l//-pyrrolo[2,3-6]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)pip erid in-l-yl)-/V-cyclopropyl-2-methylp ropana mide (602).

‘H NMR (300 MHz, MeOD) δ 8.82 (d, 7= 2.3 Hz, 1H), 8.23 (d, 7= 2.3 Hz, 1H), 8.15 (s, 1H), 8.01 (d, 7=4.0 Hz, 1H), 4.41 (m, 1H), 3.02 (d, 7= 10.0 Hz, 1H), 2.59 - 2.47 (m,

-179WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1H), 2.40 - 2.30 (m, 2H), 2.09 ··· 2.01 (m, 1H), 1.89 - 1.85 (m, 1H), 1.78 - 1.66 (m, 1H), 1.61 - 1.55 (m, 1H), 1.26 - 1.16 (m, 1H), 1.10 (d, J= 6.6 Hz, 6H), 0.68 - 0.63 (m, 2H) and 0.44 0.40 (m, 2H) ppm.

LCMS (M+l) 472.4.

General Scheme 3 ci

(a) CF₃CH₂SO₂CCI₃, 'Pr₂NEt, DMF (b) 1N LIOH, THF, microwave, 120 °C, 10 min [00505] Formation of fV)-2-(5-chloro-l-tosyl-l//-pyrrolo[2,3-/>]pyridin-3-yl)-5fluoro-7V-(l-(2,2,2-trifluoroethyl)piperidin-3-yl)pyrimidin-4-amine (3a).

To a solution of 2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[5,4-b]pyridin-3-yl]-5-fluoiON-[(3S)-3-piperidyl]pyrimidin-4-amine, 1c, (0.17 g, 0.34 mmol) in DMF (1.5 mL) was added

2,2,2-trifluoroethyl trichloromethanesulfonate (0.19 g, 0.68 mmol), followed by 'Pr₂NEt (0.24 mL, 1.36 mmol). The reaction mixture was stirred at room temperature for 18 h. The mixture was poured into brine and extracted twice with EtOAc. The combined organic phases were washed twice with brine, dried (MgSO₄), filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (0-10% MeOH/CH₂Ch) afforded the desired product, 3a, as a white solid.

Ή NMR (300 MHz, ί/6-DMSO) δ 8.77 (d, J= 2.4 Hz, 1H), 8.48 (d, J= 2.4 Hz, 1H),

8.42 (s, 1H), 8.27 (d, J= 3.9 Hz, 1H), 8.05 (d, J= 8.4 Hz, 2H), 7.62 (d, 7.5 Hz, 1H), 7.44 (d, J= 8.2 Hz, 2H), 4.17 (m, 1H), 3.30 - 3.18 (m, 3H), 2.90 (m, 1H), 2.44 - 2.32 (m, 2H),

2.35 (s, 3H), 1.95 (m, 1H), 1.72- 1.57 (m,2H)and 1.51 - 1.40 (m, lH)ppm.

LCMS RT = 4.6 (M+l) 583.4, (M-l) 581.4.

[00506] Formation of (5)-2-(5-chloro-177-pyrroIo[2,3-0]pyridin-3-yl)-5-fluoro-A(1-(2,2,2-trinuorocthyi)piperidin-3-yI)pyrimidin-4-amine (668).

To a solution of 2-[5-chloiO-l-(p-toIylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5-fluoroN-[(3S)-l-(2,2,2-trifluoroethyl)-3-piperidyl]pyrimidin-4-amine, 3a, (0.10 g, 0.18 mmol) in THF was added IM LiOH (0.90 mL, 0.90 mmol) solution. The reaction mixture was heated in microwave at 120 °C for 10 minutes. The reaction mixture was diluted with brine, extracted with EtOAc, then with 20% isopropanol/CHzCf. The combined organic phases were dried (MgSO₄), filtered and concentrated in vacuo. The resulting residue was purified via silica gel chromatography (0-10 % Με0ΗΌΗ₂Ο₂) to afford the desired product, 1339, as a white solid.

‘H NMR (300 MHz, t/6-DMSO) δ 12.32 (s, 1H), 8.71 (d, J= 2.4 Hz, 1H), 8.28 (d, J =

2.4 Hz, 1H), 8.18 - 8.16 (m, 2H), 7.38 (d, J= 7.7 Hz, 1H), 4.22 - 4.17 (m, 1H), 3.31 - 3.16 (m, 3H), 2.90 (m, 1H), 2.40 (t, J= 10.2 Hz, 2H), 2.00 - 1.95 (m, 1H), 1.77 - 1.60 (m, 2H) and 1.50- 1.38 (m, 1H) ppm.

LCMS RT = 3.5 (M+l) 429.4, (M-l) 427.4.

[00507] Other analogs that can be prepared in the same manner as 668:

-180WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

595 [00508] Synthesis of (5')-2-(5-chloro-l/f-pyrrolo[2,3-6]pyridin-3-yl)-_JV-(l-(2,2diiluoroethyl)piperidin-3-yl)-5-fluoropyrimidin-4-amine (1).

Ή NMR (300 MHz, 76-DMSO) δ 12.31 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.20 (s, 1H), 8.17 (d, J= 4.0 Hz, 1H), 7.33 (d, 7= 7.6 Hz, 1H), 4.51 (m, 1H),

2.47 - 2.25 (m, 2H), 2.22 - 2.12 (m, 2H), 1.99 - 1.90 (m, 1H), 1.70 - 1.60 (m, 2H) and 1.45 (m, lH)ppm.

LCMS RT = 2.7 (M+l) 411.4, (M-l) 409.4.

[00509] (5)-2-(5-chloro-l//-pyrrolo|2,3-/2]pyridin-3-yl)-A-(l-(2,2difluoroethyl)piper idin-3-yl)-5-flu oropy rim idin-4-am in e (595).

'HNMR (300 MHz, 76-DMSO) δ 12.32 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.28 (d, J =

2.4 Hz, 1H), 8.18-8.15 (m, 2H), 7.32 (d, J = 7.1 Hz, 1H), 4.20 (d, J = 7.1 Hz, 1H), 3.46 (t, J = 5.8 Hz, 2H), 3.19 (s, 3H), 3.10 - 3.06 (m, 1H), 2.82 - 2.78 (m, 1H), 2.57 - 2.50 (m, 2H), 2.11-1.95 (m, 3H), 1.71-1.63 (m, 2H)and 1.48- 1.35 (m, lH)ppm.

LCMS RT = 1.7 (M+l) 405.4, (M-l) 403.4.

Cl

669 [00510] (S)-2“(3-(2“(5“ChlorO“l//-pyrroIo[2,3“6]pyridin-3-yl)-5-fluoropyrimidm-4ylamino)piperidin-l -yl) ethanenitrile (669).

‘HNMR (300 MHz, 76-DMSO) δ 12.31 (s, 1H), 8.69 (d, J= 2.4 Hz, 1H), 8.28 (d, J=

2.4 Hz, 1H), 8.19 - 8.17 (m, 2H), 7.47 (d, 7= 7.7 Hz, 1H), 4.30 - 4.20 (m, 1H), 3.80 (s, 2H),

3.07 3.03 (m, 1H), 2.82 - 2.73 (m, 1H), 2.29 - 2.10 (m, 2H), 2.05 - 1.96 (m, 1H), 1.87 1.65 (m, 2H) and 1.49 - 1.40 (m, 1H) ppm.; LCMS RT = 2.3 (M+l) 386.1, (M-l) 384.2.

General Scheme 4

-181WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

(a) 1H-imidazole-2-carba!dehyde, Na(OAc)₃BH, HOAc, 1,2-dichloroethane, 60 °C (b) 1N LiOH, THF, microwave, 120 °C, 10 min [00511] Formation of (5)-'V-(l-((177-imidazol-2-y])methyl)piperidin-3-yI)-2-(5chloro-l-tosyl-117-pyrrolo[2,3-6]pyridin-3-yl)-5-fluoropyrimidin-4-amine (4a).

To a solution of 2-[5-chloro-l-(p-tolylsulfonyl)pynOlo[5,4-b]pyridin-3-yl]-5-fluoroN-[(3S)-3-piperidyl]pyrimidin-4-amine, 1c, (0,16 g, 0,32 mmol) in 1,2-dichloroethane (2 mL) was added 17f-imidazole-2-carbaldehyde (0.03 g, 0.36 mmol) followed by 2 drops of acetic acid and Na(OAc)₃BH (0.10 g, 0.49 mmol). The reaction mixture was heated at 60 °C for 18 h. The mixture was cooled to room temperature and diluted with aqueous saturated NaHCCh solution. The aqueous phase was extracted twice with EtOAc. The combined organic phases were dried (MgSO₄), filtered and concentrated in vacuo. The crude residue was purified via silica gel chromatography (0-20% MeOH/CHjCh) to afford the product, 4a.

^lH NMR (300 MHz, r/6-DMSO) δ 11.83 (s, 1H), 8.75 (d, ,7= 2.4 Hz, 1H), 8.48 (d, J=

2.4 Hz, 1H), 8.41 (s, 1H), 8.25 (d, J= 3.8 Hz, 1H), 8.07 (d, J= 8.3 Hz, 2H), 7.56 (d, .7 = 8.2 Hz, 1H), 7.44 (d, J= 8.2 Hz, 2H), 7,00 - 6.80 (m, 2H), 4.22 (m, 1H), 3.58 (dd, J= 18.9, 13.8 Hz, 2H), 2,95 (m, 1H), 2.75 - 2.72 (m, 1H), 2.36 (s, 3H), 2.16 - 2.04 (m, 2H), 1.99 - 1.93 (m, 1H), 1.78 - 1.55 (m, 2H) and 1.45 - 1.30 (m, lH)ppm.

[00512] Formation of (S)-A^r-.(l-((Lff-imidazol-2-yl)methyl)piperidin-3-yl)-2-(5chloro-l/7-py rrolo [ 2,3-61 pyridin-3-yl)-5-fluoropyrimidin-4-a mine (589).

To a solution of 2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yI]-5-fluoro7V-[(3S)-l-(177-imidazol-2-ylmethyl)-3-piperidyl]pyrimidin-4-amine, 4a, (0.08 g, 0.13 mmol) in THF (2.5 mL) was added IM LiOH (0.67 mL, 0.65 mmol) solution. The reaction mixture was heated in microwave at 120 °C for 10 minutes. The mixture was cooled to room temperature and diluted with brine. The aqueous phase was extracted with CH2CI2, then twice with 20% isopropanol/ CH2CI2. The combined organic phases were dried (MgSO₄), filtered and concentrated in vacuo to afford the desired product, 589, as a white solid.

'H NMR (300 MHz, dd-DMSO) δ 8,77 (d, J = 2.4 Hz, 1H), 8.48 (d, J= 2.4 Hz, 1H),

8.42 (s, 1H), 8.27 (d, .7- 3.9 Hz, 1H), 8.05 (d, J= 8,4 Hz, 2H), 7.62 (d, J= 7.5 Hz, 1H), 7.44 (d, J= 8.2 Hz, 2H), 4.17 (m, 1H), 3.30 - 3.18 (m, 3H), 2.90 (m, 1H), 2.44 - 2.32 (m, 2H),

2.35 (s,3H), 1.95 (m, 1H), 1.72- 1.57 (m, 2H) and 1.51 - 1.40 (m, lH)ppm, LCMS RT = 1.6 (M+l) 427.4.

[00513] Other analogs which can be prepared in the same manner as 589:

Cl

594

-182WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00514] N-(i_((iH-imidazol-5-yl)inethyl)piperidin-3-y])-2-(5-chloro-l//py r rolo [ 2,3-b ] py ridin-3-yl)-5-fluor opy rimidm-4-amine (594).

^lH NMR (300 MHz, 76-DMSO) δ 12.31 (s, 1H), 11.86 - 11.77 (m, 1H), 8.70 (d, J =

2.2 Hz, 1H), 8.28 (d, 7=2.4 Hz, 1H), 8.15 (d, 7 = 3.9 Hz, 1H), 8.10 (d, 7= 2.5 Hz, 1H), 7.54 (s, 1H), 7.31 (d, 7= 7.6 Hz, 1H), 6.87 (s, 1H), 4.19 (m, 1H), 3.57 (d, 7= 13.8 Hz, 1H), 3.48 (d,7= 13.8 Hz, 1H), 3.04 (d, 7= 8.3 Hz, 1H), 2.80 (d,7= 10.4 Hz, 1H), 2.10 - 1.90 (m, 3H), 1.72 - 1.62 (m, 2H) and 1.51 - 1.35 (m, 1H) ppm; LCMS RT = 1.6 (M+l) 427.4, (M-l) 425.4.

General Scheme 5A

(a) Zerf-butyl (3//)-3-aminopiperidine-1 -carboxylate, 'Pr₂NEt base, 2-propanol, 80 °C (b) 5-chloro-l -(ptolylsulfonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine, DME/HjO, K₂CO₂, tetrakis triphenylphosphinepalladinm(0), 90 °C (c) NaOMe / MeOH (d) isopropanol/HCl (e) methanesulfonyl chloride, ^!Pr₂NEt, CH₂C1₂/DMF [00515] Formation of tert-butyl (3S)-3-[(2-chloro-5-fluoro-pyrimidin-4yl)amin 0] pip eridi ne- 1-carb oxyl ate (5a).

To a solution of te/7-butyl (3 5)-3-aminopiperidine-1-carboxylate (8.1 g, 40.4 mmol) and 2,4-dichloiO-5-fluoro-pyrimidine (6.6 g, 39.8 mmol) in isopropanol (80 mL) was added yVjV-diisopropyl-vV-ethylamine (9.0 mL, 51.7 mmol). The reaction mixture was warmed to 80 C and stirred for 17 hours. All volatiles were removed at reduced pressure and the residue was dissolved in EtOAc. The organic layer was partitioned with water and the layers were separated. The organic phase was washed with brine, dried (MgSCU), filtered and concentrated in vacuo. The resulting residue was dissolved in CH₂C1₂ and purified by silica gel chromatography (0 - 50% EtOAc /Hexanes) to afford the desired product, 5a.

LCMS RT = 3.3 (M+l) 331.1.

[00516] Formation of tert-butyl (3S)-3-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[5,4b]pyridin-3-yl]-5-fluoro-pyrimidin-4-yl]amino]piperidine-l-carboxylate (lb).

To a solution of 5-chloro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine (1.8 g, 4,2 mmol) and zeri-butyl (3S)-3-[(2-chloro5-fluoro-pyrimidin-4-yl)amino]piperidine-1-carboxylate, 5a, (1.2 g, 3.7 mmol) in DME (15 mL) and H₂O (5 mL) was added K₂CO₃ (1.7 g, 12.1 mmol). The mixture was purged with nitrogen for 15 min. To the mixture was added tetrakis triphenylphosphine palladium(O) (0.2 g, 0.2 mmol) and the reaction mixture was heated at 90 °C for 3 days. The reaction was cooled down to room temperature and then diluted with EtOAc / H₂O. The layers were separated and the organic phase was washed with brine, dried (MgSO4), filtered and evaporated to dryness. The resulting residue was dissolved in CH₂C1₂ and purified by silica gel chromatography (0 - 100 % EtOAc /Hexanes) to afford the desired product, lb.

-183WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

LCMS RT = 4.6 (M+l) 601.2.

[00517] Formation of tert-butyl (30)-3-[[2-(5-chIoro-ljff-pyrrolo[5,4-b]pyridin-3yl)-5-fluoro-pyrimidin-4-yl]amino]piperidine-l-carboxylate (2b).

To a solution of tert -butyl (35)-3-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[5,4b]pyridin-3-yl]-5-fluoro-pyrimidin-4-yl]amino]piperidine-l-carboxylate, lb, (0.93 g, 1.55 mmol) in methanol (10 mL) was added sodium methoxide (10 mL of IM solution). The reaction mixture was warmed to 45 °C. After stirring for 30 minutes the reaction was to cooled to room temperature and quenched by additon into water. The mixture was diluted with EtOAc and the layers were separated. The organic phase was washed with brine, dried (MgSCfi), filtered and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (0 -100% EtOAc /Hexanes) to afford the desired product, 2 b.

LCMS RT = 2.8 (M+l) 447.2.

[00518] Formation of (S)-2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-W(piperidin-3-yl)pyrimidin-4-amine (5b).

To a suspension of tert-butyl (3S')-3-[[2-(5-chloro-177-pyrrolo[5,4-b]pyridin-3-yl)-5fluoro-py rimidin-4-yl] amino] piperidine-1-carboxylate, 2b, (0.45 g, 1.01 mmol) in isopropanol (3 mL) was added propan-2-ol hydrochloride (1.5 mL of 5M solution, 7.500 mmol). The reaction mixture was warmed to 80 °C and stirred for 3 hours. The mixture was cooled to room temperature and all volatiles were removed at reduced pressure. The resulting crude product, 5b, was used without further purification.

LCMS RT = 1.5 (M+l) 347.1.

[00519] Formation of (5)-2-(5-chloro-lEf-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-A(l-(methyIsuIfonyl)piperidin-3-yl)pyrimidin-4-amine (389).

To a solution of (5)-2-(5-chloro-lFf-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-iV(piperidin-3-yl)pyrimidin-4-amine hydrochloride, 5b, (0.04 g, 0.11 mmol ) in CH2CI2 (1.4 mL) and DMF (0.30 mL) was added VA-diisopropyl-A-ethylamine (0.30 mL, 1.70 mmol) followed by methanesulfonyl chloride (0.02 g. 0.20 mmol). The reaction mixture was allowed to stir at room temperature for 17 hours. The mixture was concentrated in vacuo, dissolved in 1 mL of DMSO and purified by preparatory HPLC (0.1% ammonium formateFLO/acetonitrile) to afford the desired product, 389.

LCMS RT= 1.8 (M+l) 425.3.

[00520] Other analogs that can be prepared in the same manner as 389:

[00521] GS)-2-(5-chIoro-lH-pyrrolo|2,3-/i|pyridin-3-yl)-A-(l(ethylsuIfonyl)piperidin-3-yl)-5-fluoropyrimidin-4-amine (393).

LCMS RT= 1.8 (M+l) 439.3.

[00522] (5)-/V-(l-(butylsulfonyl)piperidin-3-yl)-2-(5-chIoro-lH~pyrrolo[2,3-184WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 /?|pyri(lin-3-yl)-5-fluoropyrhmdin-4-aniine (390).

LCMS RT = 2.1 (M+l) 467.3.

[00523] (5)-2-(5-chloro-lH-pyrrolo[2,3-£]pyridm-3-yl)-lV-(l(cyclopropyIsulfonyl)piperidin-3-yl)-5-fluoropyrimidin-4-amme (391).

LCMSRT= 1.9 (M+l) 451.3.

[00524] (5)-2-(5-chloro-l_Jff-pyrrolo[2,3-/>]pyridin-3-yl)-5-fluoro-/V-(l(isopropylsulfonyl)-piperidin-3-yl)pyrimidin-4-amine (394).

LCMS RT = 1.9 (M+l) 453.3.

392 [00525] (5)-2-(5“Chloro-lZZ-pyrrolo[2,3-/>]pyridin-3-yl)-/V-(l(cy clopentylmethy Isulfony l)piperidin-3-yl)-5-fluoropyri midin-4-amine (392).

LCMS RT = 2.3 (M+l) 493.5.

General Scheme 5B

-185WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

5c

316 [00526] Formation of (R)-2-(5-chloro-l//-pyrrolo|2,3-/7]pyridin-3-yl)-5-iluoro-A(l-(propylsulfonyl)piperidin-3-yl)pyrimidin-4-amine (316).

To a solution of 2-(5-chloro-l/Z-pyrrolo[2,3“b]pyridin-3-yl)-5-fluoro-lV-(piperidin-3yl)pyrimidin-4-amine, 5c, (0.40 g, 1.15 mmol) in 10:1 mixture of CH₂C1₂/DMF (8 mL) was added ’Pr₂NEt (0.60 mL, 3.46 mmol) followed by 1-propanesulfonyl chloride (0.13 mL, 1.15 mmol). The reaction mixture was stirred at room temperature for 5 hours. The resulting residue was purified by preparatory HPLC (0.1%TFA-H₂O/acetonitrile) to afford the desired product, 316.

LCMS RT = 2.5 (M+l) 453.3.

[00527] Other analogs that can be prepared in the same manner as 316:

[00528] (jR)-2-(5-ch loro-1/7-pyrrolo [2,3-6] pyridi n-3-yl)-/V-(l(ethyIsulfonyl)piperidin-3-yl)-5-fluoropyrimidin-4-amine (321).

LCMS RT = 2.7 (M+l) 439.1.

[00529] (R)-2-(5-chloro-l#-pyrrolo[2,3-6]pyridin-3-yl)-5-fluoro-/V-(l(isopropylsulfonyl)-piperidin-3-yl)pyrimidin-4-amine (322).

LCMS RT = 2.9 (M+l) 453.1.

[00530] (₁S)-2-(5-chloro-lH-pyrrolo[2,3-6]pyridin-3-yl)-5-fluoro-7V-(l(propylsulfonyI)-piperidin-3-yl)pyrimidin-4-amine (306).

LCMS RT = 2.9 (M+l) 453.2.

General Scheme 5C

-186WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

(a) cyclobutanecarbonyl chloride, TrjNEt, CHjCL/DMF

[00531] Formation of (5)-(3-(2-(5-chloro-117-pyrrolo[2,3“b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)piperidin-l-yl)(cyclobutyl)methanone (395).

To a solution of (₁S)-2-(5-chloro-lELpyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-A^r(piperidin-3-yl)pyrimidin-4-amine hydrochloride, 5b, (0.04 g, 0.11 mmol) in CH₂C1₂ (1.40 mL) and DMF (300 μ was added A/TV-diisopropyl-TV-ethylamine (0.30 mL, 1.70 mmol) followed by cyclobutanecarbonyl chloride (0.01 g. 0.12 mmol). The reaction mixture was allowed to stir at room temperature for 17 hours. The mixture was concentrated in vacuo, dissolved in 1 mL of DMSO and purified by preparatory HPLC (0.1% ammonium formateFLO/acetonitrile) to afford the desired product, 395.

LCMS RT = 1.9 (M+l) 429.3.

[00532] Other analogs that can be prepared in the same manner as 395:

[00533] (S)-l-(3-(2-(5-chloro-lFf-pyrrolo[2,3-/'lpyridin-3-yI)-5-fluoropyrimidin-4ylaminojpiperidin-l-yljpropan-l-one (435).

LCMS RT = 1.8 (M+l) 403.4.

[00534] (5)-l-(3-(2-(5-chloro-l/f-pyrrolo[2,3-/>]pyridin-3-yl)-5-fluoropyrimidin-4yla mino)pip eridin-l-yl)-2-methylprop an-1 -0 ne (436)

LCMS RT= 1.9 (M+l) 417.4.

437

451

-187WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00535] (S)-l-(3-(2(5-chloro-ljF7-pyrrolo[2,3-A]pyridin-3-yl)-5-fluoropyrimidin-4~ ylamino)piperidin-l-yl)-2,2-dimethylpropan-l-one (437)

LCMS RT = 2.0 (M+l) 431.4.

[00536] (.y)-(3-(2-(5-chloro-lH-pyrro]o[2,3-Z>]pyridin-3-yl)-5-fluoropyrimidin~4ylamino)piperidin-l-yl)(cyclopropyl)methanone (451)

LCMS RT = 1.8 (M+l) 415.4.

[00537] (S)-l-(3“(2-(5-chloro-177-pyrrolo[2,3-/j]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)piperidin-l-yl)-3-methoxypropan-l-one (396)

LCMS RT = 1.7 (M+l) 433.3.

[00538] (5)-l-(3-(2“(5-chloro-l£r-pyrrolo[2,3-A]pyridiii“3“yl)-5-fluoropyrimidin-4ylamino)piperidin-l-yl)ethanone (434)

LCMS RT = 1.6 (M+l) 389.4.

Cl

318

[00539] (J?)-l-(3-(2-(5-chloro-l//-pyrro]o[2,3-6|pyridin-3-yl)-5-fluoropyriniidin-4ylamino)piperidin-l-yl)-3-methylbutan-l-one (318)

LCMS RT = 2.9 (M+l) 431.1.

[00540| (_JR)-(3-(2-(5-chloro-lif-pyrrolo[2,3-6|pyridin-3-yl)-5-fluoropyrimidin-4ylamino)piperidln-l-yl)(cyclopropyl)methanone (317)

LCMS RT = 2.7 (M+l) 415.1.

-188WO 2010/148197

PCT/US2010/038988

319 [00541] (_JR)-l-(3-(2-(5-chloro-lZf-pyrrolo[2,3-_J&]pyridin-3-yl)-5-fluoropyrimidin-4yIammo)piperidm-l-yl)-3-methoxypropan-l-one (320)

LCMS RT = 2.5 (M+l) 433.1.

[00542] (7i)-(3-(2-(5-chloro-L//-|)yrrolo[2,3-h]pyridin-3-yl)-5-fluoropyriniidin-4ylamino)pip erid in-l-yl) (cyclob utyl)methanone (319)

LCMS RT = 2.8 (M+l) 429.1.

332

485 [00543] (5)-l-(3-(2-(5~chloro-l.ff-pyrrolo[2,3-Alpyridin-3-yl)-5-fluoropyrimidin-4ylamino)piperidin-l-yl)“3“methylbutan“l“One (332)

LCMS RT = 2.0 (M+l) 431.2.

[00544] (5)-1-(3-(2-(5-cliloro-l//-pyrroIo[2,3-/>|pyridin-3-yl)pyrinijdin-4ylamino)piperidin-l-yl)ethanone (485)

LCMS RT = 1.9 (M+l) 371.5.

Cl

486

Cl

487 [00545] (5)-l-(3-(2-(5-chloro-lZf-pyrrolo[2,3/*Ipyridin-3-yl)-5-fluoropyrimidin-4ylamino)piperidin-l-yl)-2-methoxyethanone (486)

LCMS RT = 1.9 (M+l) 401.5.

[00546] (S)-methyl 4-(3-(2-(5-chloro-17/-pyrrolo[2,3-Z>]pyridin-3-yI)pyrimidin-4ylamino)piperidin-l“yl)-4“oxobutanoate (487)

LCMS RT = 2.0 (M+l) 443.9.

-189WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

|00547] (5)-l-(3-(2-(5-chloro-l/i^;-pyrrolo[2,3-_J&]pyridin-3-yl)-5-fluoropyriniidin-4ylamino)piperidin-l-yl)-3-methoxypropan-l-one (488)

LCMS RT= 1.9 (M+l) 415.5.

[00548] (S)-l-(3-(2-(5-chloro-17/-pyrro]o[2,3-ti]pyridin-3-yl)pyrimidin-4y!amino)piperidin-l-yl)-3-methylbutan-l-one (489)

LCMS RT = 2.1 (M+l) 413.5.

General Scheme 5D

(a) 1-tnethylcyclopropane-l-carboxylic acid, EDAC-HC1, HOBt, ’Pr₂NEt, Cl+CWDMF [00549] Formation of (5)-(3-(2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)piperidin-l-yl)(l-methylcyclopropyl)niethanone (445)

To a solution of (S)-2-(5-chloro-177-pyrrolo[2,3-b]pyridin-3-yI)-5-fluoro-/V(piperidin-3-yl)pyrimidin-4-amine hydrochloride, 5b, (0.04 g, 0.10 mmol) in CH2CI2 (1.4 mL) and DMF (0.3 mL) was added jV.A'-diisopropyl-A-ethylamine (0.3 mL, 1.72 mmol), followed by 3-(ethyliminomethyleneamino)-/V,A^r-dimethyl-propan-l-amine hydrochloride (0.02 g, 0.12 mmol), 1-hydroxybenzotriazole hydrate (0.02 g, 0.12 mmol) and 1methylcyclopropane-1-carboxylic acid (0.01 g, 0.12 mmol). The mixture was concentrated in vacuo, dissolved in 1 mL of DMSO and purified by preparatory HPLC (0.1% ammonium formate-FEO/acetonitrile) to afford the desired product, 445.

LCMS RT = 2.1 (M+l) 429.5.

[00550] Analogs that can be prepared in the same manner as 445:

[00551] (S)-(3-(2-(5-chloro-lf/-pyrrolo[2,3-/»]pyridin-3-yl)-5-fluoropyrimidin-4-190WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 ylamino)piperidin-l-yl)(3-methyloxetan-3-yl)methanone (444)

LCMS RT = 1.7 (M+l) 445.4.

General Scheme 5E

(a) isocyanatopropane, ’PnNEt, CELCL/DMF

[00552] Formation of (5)-3-(2-(5-chloro-1 if-pyrrolo [2,3-b]pyridin-3-y 1)-5fluoropyrimidin-4-ylamino)-N-isopropylpiperidine- 1-carboxamide (439).

To a solution of (S)-2-(5-chloro-l/?-pyiTolo[2,3-b]pyridin-3-yl)-5-fluoro-7V(piperidin-3-yl)pyrimidin-4-amine hydrochloride, 5b, (0.042 g, 0.100 mmol) in CH2CI2 (1.4 mL) and DMF (0.3 mL) was added N,/V-diisopropyl-Wethylamine (0.300 mL, 1.720 mmol) followed by isocyanatopropane (0.120 mmol). The reaction mixture was stirred at room temperature for 17 hours. The mixture was concentrated in vacuo, dissolved in 1 mL of DMSO and purified by preparatory HPLC (0.1% ammonium formate-H₂O/acetonitrile) to afford the desired product, 439.

LCMS RT = 1.8 (M+l) 432.4.

[00553] Other analogs that can be prepared in the same manner as 439:

[00554] (5)-3-(2-(5-chloro-lif-pyrrolo[2,3-0]pyridin-3-yl)-5-fluoropyrimidin-4ylaminoj-TV-ethylpiperidine-l-carboxamide (438).

LCMS RT = 1.7 (M+l) 418.4.

[00555] Formation of 3-(2-(5-chloro-l.ff-pyrrolo[2,3-£’]pyridin-3-yl)-5nuoropyrimidin-4-ylammo)-2V-propylpiperidine-l-carboxamide (196).

To a solution of 2-(5-chloro-l/7-pyrrolo[2,3-Z>]pyridin-3-yl)-5-fhioro-A-(piperidin-3yl)pyrimidin-4-amine, 5b, (0.020 g, 0.058 mmol) in 1:1 mixture of CH₂Cl₂/pyridine (2 mL) was added propylisocyanate (0.005 mL, 0.058 mmol). The reaction mixture was stirred at room temperature for 12 hours. The resulting residue was purified by preparatory HPLC (0.1%TFA-H₂O/acetonitrile) to afford the desired product, 196.

LCMS RT = 2.6 (M+l) 432.1, (M-l) 430.1.

-191WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

324

[00556] (5)-3-(2-(5-chloro-ljff-pyrrol0[2,3-6]pyridin-3-yl)-5-fluor(>pyriimdin-4ylamino)-/V-propyIpiperidine-l-carboxaniide (324).

LCMS RT = 2.6 (M+l) 432.2.

[00557] (5)-A'-butyl-3-(2-(5-chluro-lJ7-pyrrolo|2,3-/i]pyridin-3-yl)-5fluoropy rimidin-4-yla mino)piperidine-l -carboxa mide (323).

LCMS RT = 2.7 (M+l) 446.2.

[00558] (S)-3-(2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)piperidine-l-carboxamide (507).

LCMS (TFA buffer): Rt 1.69 min, ES⁺ 390.

Genera] Scheme 5F

(a) methylchloroformate, Tr₂NEt, CHjCL/DMF [00559J Formation of (S)-methyl 3-(2-(5-chloro-LH-pyrrolo|2,3-/>]pyridin-3-yl)-5fhio ropyrimid in-4-ylamino)piperidin e-1-carboxylate (440).

To a solution of (S)-2-(5-chloro-l/LpynOlo[2,3-b]pyridin-3-yl)-5-fluoro7V(piperidin-3-yl)pyrimidin-4-amine hydrochloride, 5b, (0.042 g, 0.100 mmol) in CH2CI2 (1.4 mL) and DMF (0.3 mL) was added A/JV-diisopropyl-TV-ethylamine (0.300 mL, 1.720 mmol) followed by methyl chloroformate (0.009 g, 0.120 mmol). The reaction mixture was stirred at room temperature for 17 hours. The mixture was concentrated in vacuo, dissolved in 1 mL of DMSO and purified by preparatory HPLC (0.1% ammonium formateHzO/acetonitrile) to afford the desired product, 440.

LCMS RT = 1.8 (M+l) 405.4.

[00560] Analogs that can be prepared in the same manner as 440:

-192WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00561] (S)-ethyl 3-(2-(5-chloro-17f-pyrroIo[2,3-6]pyridin-3-yl)-5-fluoropyrimidin4-ylamino)piperidine-l-carboxyIate (441).

LCMS RT = 1.9 (M+l) 419.4.

[00562] (5)-isopr opyl 3-(2-(5-chloro-l JT-py rrolo [2,3-6] py ridin-3-yl)-5fluoropyrimidin-4-ylamino)piperidine-l-carboxylate (442).

LCMS RT = 2.1 (M+l) 433.4.

General Scheme 5G

(a) (2,5-dioxopyrrolidin-l-yl) [(3S)-tetrahydrofi.iran-3-yl] carbonate, 'PtiNEt, CH2CI2/DMF [00563] Formation of (S)-((5)-tetrahydrofuran-3-yl) 3-(2-(5-chloro-l/7pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)piperidine-l-carboxylate (443).

To a solution of (S)-2-(5-chloro-li/-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-A^r(piperidin-3-yl)pyrimidin-4-amine hydrochloride, 5b, (0.042 g, 0.100 mmol) in CH₂C1₂(1.4 mL) and DMF (0.3 mL) was added Λ/Ν-diisopropyl-jV-ethylamine (0.300 mL, 1.720 mmol) followed by (2,5-dioxopyrrolidin-l-yl) [(3S)-tetrahydrofuran-3-yl] carbonate (0.028 g, 0.120 mmol). The reaction mixture was stirred at room temperature for 17 hours. The mixture was concentrated in vacuo, dissolved in 1 mL of DMSO and purified by preparatory HPLC (0.1% ammonium formate-H₂O/acetonitrile) to afford the desired product, 443.

LCMS RT = 1.8 (M+l) 463.3.

General Scheme 6A

-193WO 2010/148197

PCT/US2010/038988

Η,Ν

Boc

(a) 'Pr₂NEt, THF (b) Pd(PPh₃)₄, 2M Na₂CO₃ 80 C (c) 4N HCI/dioxane, MeOH, 80 C (d) (S)-2,5dioxopyrrolidin-1-yl tetrahydrofuran-3-yl carbonate, 'Pr₂NEt, THF (e) 25% NaOMe/MeOH or 1M LiOH, 150 °C, microwave, 10 min.

[00564] Formation of tert-butyl 3-(2-chloro-5-fluoropyrimidin-4-ylamino)cyclobutylcarbamate (6a).

A mixture of 2,4-dichloro-5-fluoro-pyrimidine (0.97 g, 5.81 mmol) and ‘Pr₂NEt (2.53 mL, 14.50 mmol) in THF (50 mL) was treated with tert-butyl 3-aminoazetidine-1carboxylate (1.00 g, 5.81 mmol) and stirred at room temperature until complete by LCMS. The mixture was concentrated to dryness then diluted with water and extracted with dichloromethane. The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo to afford an oil that was purified by silica gel chromatography (0-100% petroleum ether/EtOAc gradient). Removal of the solvent under reduced pressure afforded 3.36g (89% yield) of a white solid after vacuum drying.

LCMS: RT = 3.2 min, ES⁺ 303.

[00565] Formation of tert-butyl 3-(2-(5-chloro-l-tosyl-12f-pyrrolo[2,3-b]pyridin-3yl)-5-fluo r opy rimidin-4-yIamino)azetidin e-l-ca rboxylate (6b).

A solution of tert-butyl 3-(2-chloro-5-fluoropyrimidin-4-ylamino)cyclobutylcarbamate, 6a, (0.39 g, 1.28 mmol) and 5-chloro-3-(4,4,5,5-tetramethyl-I,3,2dioxaborolan-2-yl)-l-tosyl-17Z-pyrrolo[2,3-Z?]pyridine (0.60 g, 1.39 mmol) in DME (10 mL) and 2M Na₂CO₃ (5 mL) was degassed with argon (3x vacuum and back fill) then treated with catalytic Pd(PPh₃)₄ and the mixture heated at 80 °C under argon. After 3h the solvent was concentrated to a reduced volume then diluted with EtOAc and filtered through florisil (40 mL pad) and washed with EtOAc. The solvent was concentrated in vacuo and die resulting dark residue purified with silica-gel chromatography (0-100% petroleum ether/EtOAc gradient) to afford 230 mg (32% yield) of 6b, as white-pink solid.

LCMS: RT = 4.7 min, ES⁺ 573.

[00566] Formation of V-(azetidin-3-yl)-2-(5-chloro-l-tosyl-1£f-pyrrolo[2,3b]pyridin-3-yl)-5-fluoropyrimidin-4-anrine hydrochloride (6c).

A suspension of tert-butyl 3-(2-(5-chloro-l-tosyl-l/7-pyrrolo[2,3-b]pyridin-3-yl)-5fluoiOpyrimidin-4-ylamino)azctidinc-1-carboxylate, 6b, (0.23 g, 0.40 mmol) in methanol (10 mL) was treated with 4N HCI/dioxane (5 mL, 20 mmol) then heated at 80 °C for 30 minutes. The solvent was removed and the residue dried under vacuum to afford 240mg of a solid that was used without purification.

LCMS RT = 2.4 min, ES⁺ 473.

[00567] Formatio n of (S)-tetr a hyd rofu ran-3-y 13-(2-(5-chIo rο-1 rt-pyrrolo [2,3-194WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

b]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)azetidine-l-carboxylate (422).

A suspension of/V-(azetidin-3-yl)-2-(5-chloro-l-tosyl-12/-pynOlo[2,3-b]pyridin-3-yl)5-fluoropyrimidin-4-amine hydrochloride, 6c, (0.06 g, 0.11 mmol) in THF (1 mL) was treated with 'PnNEt (0.30 mL, 1.70 mmol) then solid (5)-2,S-dioxopyrrolidin-1-yl tetrahydrofuran-3-yl carbonate (0.03 g, 0.11 mmol) was added. The resulting mixture was stirred for 2 hours at room temperature and then quenched with 200 pL of morpholine and evaporated to dryness to afford (S)-tetrahydrofuran-3-yl 3-(2-(5-chloro-1-tosyl-177pyraolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)azetidine-l-carboxylate, 6d, which was used without purification.

LCMS RT = 3.8 min, ES⁺ 588.

(Sj-tetrahydrofuran-3 -yl 3 -(2-(5-chloro-1 -tosyl- 177-pyrrolo[2,3 -b]pyridin-3 -y 1)-5 fluoropyrimidin-4-ylamino)azetidine-l-carboxylate, 6d, was dissolved in methanol (2 mL) and then treated with of 25% sodium methoxide/methanol (0.5 mL) and heated at 60 C in sealed tube. LCMS showed complete reaction after 10 minutes. The resulting solution was quenched with aqueous saturated NH4CI solution (0.5mL) then evaporated to dryness and the residue dissolved in DMSO and purified by reverse phase HPLC (ammonium formate buffer) to afford 25.9mg (55% yield) of the desired product, 422, as a solid.

LCMS RT = 1.8 min, ES⁺433.

[00568] Formation of 2-(5-chloro-l-tosyl-l/f-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro7V-(1-(p r opylsulfonyl)azeti din-3-y l)pyrimidin-4-amine (423).

To a stirred suspension of 2V-(azetidin-3-yl)-2-(5-chloro-l-tosyl-177-pyrrolo[2,3b]pyridm-3-yl)-5-fluoropyrimidin-4-amine hydrochloride, 6c, (0.055 g, 0.110 mmol) in THF (1 mL) was added ‘PnNEt (0.300 mL, 1.720 mmol) followed by propane-1-sulfonyl chloride (0.012 mL, 0.108 mmol). The resulting homogenous light yellow solution mixture was heated at 50 C for one hour at which time LCMS showed complete reaction. Morpholine (0.20 mL) was added and the solution evaporated to dryness. The resulting residue was dissolved in methanol (2 mL) then treated with 25% sodium methoxide/methanol (0.5 mL) and heated at 60 C in sealed tube for 10 minutes. The resulting solution was quenched with aqueous saturated NH4CI solution (0.5mL) then evaporated to dryness. The resulting residue was dissolved in DMSO and purified by reverse phase HPLC (ammonium formate buffer) to afford 19.8 mg (43% yield) of the desired product, 423, as a solid.

LCMS RT = 2.6 min, ES⁺ 425.

[00569] Other analogs that can be prepared in a manner similar to 423:

-195WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00570] Formation of 2-(5-chloro-117-pyrrolo[2,3-b]pyridin~3-yl)-A-(l(cyclopentyl-methylsulfonyl)azetidin-3-yl)-5-fluoropyrimidin-4-amine (469).

To a stirred solution of /V-(azetidin-3-yl)-2-(5-chloro-1-tosyl-1 #-pyrrolo[2,3b]pyridin-3-yl)-5-fluoropyrimidin-4-amine hydrochloride, 6c, (0.03 g, 0.06 mmol) in dichloromethane (1 mL) was added 'PrjNEt (0.33 pL, 1.90 mmol) followed by cyclopentylmethanesulfonyl chloride (0.01 g, 0.06 mmol). The resulting mixture was stirred 30 minutes at room temperature at which time LCMS showed complete reaction. Morpholine (0.20 mL) was added and the solution evaporated to dryness. The resulting residue was dissolved in methanol (2 mL) then treated with 25% sodium methoxide/methanol (0.5 mL) and heated at 60 °C in sealed tube for 10 minutes. The solution was quenched with aqueous saturated NH4CI solution (0.5mL) then evaporated to dryness. The resulting residue was dissolved in DMSO and purified by reverse phase HPLC (ammonium formate buffer) to afford 27.4 mg (88% yield) of the desired product, 469, as a solid. LCMS RT = 3.1 min, ES¹465.

[00571] Formation of l-(3-(2-(5-chloro-177-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)azetidin-l-yl)-2-niethoxyethanone (468).

According to the procedure for compound 469 using methoxyacetyl chloride afforded

11.7 mg (51% yield) of 468, as a white solid.

LCMS RT = 1.6 min, ES⁺ 390.

[00572] Formation of 3-(2-(5-chIoro-l/f-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)azetidine-l -carboxamide (512).

According to the procedure for compound 469 using 61 mg (0.11 mmol) of 6c and isocyanatotrimethylsilane (15.14 pL, 0.11 mmol) afforded 87mg (79% yield) of 512, as a white solid:

LCMS RT = 2.4 min, ES⁺ 362.

-196WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

General Scheme 7

(a)2,4-dichloro-5-fluoropyrimidine, 'Pr₂NEt, THF (b) 5-chloro-3-(4,4,5,5-tetramethyl-1,3,2dloxaborolan-2-yl)-1-tosyl-1H-pyrrolo[2,3-£>]pyridine, Pd(PPh₃)₄, 2M Na₂CO₃90°C (c)4N HCI/dioxane, MeOH, 80 °C; (d) methanesulfonyl chloride, ^!Pr₂NEt, THF, RT (e) 25% NaOMe/MeOH or 1M LiOH, 150 C, microwave, 10 min.

[00573] Formation of (5)-tert-butyl 3-(2-chloro-5-fluoropyrimidin-4yla mino)py rrolidine-1 -ca rb oxy late (7 a).

To a mixture of 2,4-dichloro-5-fluoro-pyrimidine (1.75 g, 10.48 mmol) and 'PrjNEt (3.27 mL, 18.78 mmol) in THF (50 mL) was added ter/-butyl (3S)-3-aminopyrrolidinc~lcarboxylate (1.83 mL, 10.48 mmol) in THF (2 mL). The resulting solution was allowed to stir at room temperature for 2 hours. The mixture was concentrated to dryness, diluted with dichloromethane and washed with water. The organic layer was dried over Na₂SO4 and concentrated in vacuo to afford 3.41 g of 7a, as a white foamy solid.

LCMS RT = 3.0 min. ES⁺ 317.

[00574] Formation of (5)-tert-butyl 3-(2-(5-ch loro-1-tosyl-lJT-pyrrolo [2,3b]pyridin-3-yI)-5-fluoropyrimidin-4-ylamino)pyrrolidine-l-carboxylate (7b).

A solution of 5-chloro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-

2-yI)pyrrolo[2,3-b]pyridine (2.41 g, 5.60 mmol) and iert-butyl (3S)-3-[(2-chloro-5-fluoropyrimidin-4-yl)amino]pyrrolidine-l-carboxylate, 7a, (1.69 g, 5.30 mmol) in DME (34 mL) and 2M Na^COa (8.5 mL) was degassed with nitrogen (5 min) then treated with Pd(PPh₃)₄(0.31 g, 0.27 mmol) then heated at 90 °C overnight. The resulting dark solution was filtered through fiorisil, washed with EtOAc then concentrated in vacuo. The resulting residue was purified by silica-gel chromatography (0-100%) petroleum ether: EtOAc gradient. Removal of the solvent under reduced pressure afforded I.33g (42% yield) of a white solid after vacuum drying.

LCMS RT = 4.4 min. ES⁺ 588.

[00575] Formation of 2-[5-chloro-l-(p-toIylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5fluoro-/V-[(3S)-pyrrolidin-3-yl]pyrimidin-4-amine (7c).

A solution of tert-butyl (35)-3-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[5,4-b]pyridin-

3-yl]-5-fluoro-pyrimidin-4-yl]amino]pyrrolidine-l-carboxylate, 7b, (1.33 g, 2.27 mmol) in THF (25 mL) was treated with hydrogen chloride (12 mL of 4M solution in dioxane, 48.00 mmol) at room temperature. The reaction was then heated at 90 °C until LCMS showed reaction was complete. The mixture was concentrated to dryness then dried under vacuum to afford 1.04g (88% yield) of 7c, as a tan solid.

LCMS RT = 2.3 min. ES⁺ 487.

-197WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00576] Formation of (S^r)-2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-/V(l-(methylsulfonyl)pyrrolidin-3-yl)pyrimidin-4-amine (398).

To a stirred suspension of 2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]5-fluoro-zV-[(3S)-pyrrolidin-3-yl]pyrimidin-4-amine hydrochloride, 7c, (0.05 g, 0.10 mmol) in THF (1 mL) was added ‘Pi^NEt (0.10 mL, 0.57 mmol) followed by methanesulfonyl chloride (0.04 mL, 0.57 mmol). The resulting homogenous light yellow mixture was heated at 50 °C for one hour at which time LCMS showed complete reaction. Morpholine (0.20 mL) was added and the solution evaporated to dryness. The resulting residue was dissolved in methanol (2 mL) then treated with 25% sodium methoxide/mefhanol (0.5 mL) and heated at 60 °C in sealed tube until LCMS showed reaction was complete. The resulting solution was quenched with aqueous saturated NH4CI (0.5mL) then evaporated to dryness. The residue was dissolved in DMSO and purified by reverse phase HPLC (ammonium formate buffer) to afford 15.8 mg (37% yield) of 398, as a solid.

LCMS RT = 1.7 min. ES⁺4II.

[00577] Other analogs that can be prepared in a manner similar to 398:

[00578] Formation of (5)-2-(5-chloro-lZf-pyrrolo[2,3-b]pyridin-3-y 1)-2V-(1(etliylsulfonyl)pyrrolidjn-3-yI)-5-fluoropyrimidin-4-amine (399).

According to the procedure for compound 398 using 50 mg (O.lOmmol) of 7c and ethanesulfonyl chloride (54 pL, 0.57 mmol) afforded 21.7mg (49% yield) of 399, as a solid.

LCMS RT = 1.8 min. ES⁺ 425.

[00579] Formation of (S)-2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-A(l-(isop r opylsulfonyl)py r rolidin-3-yl)py rimidin-4-am ine (400).

According to the procedure for compound 398 using 2-propanesulfonyl chloride (82 mg, 0.57 mmol) afforded 17.9 mg (39% yield) of 400, as a solid.

LCMS RT = 1.9 min. ES⁺ 439.

-198WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00580] Formation of (S)-2-(5-chloro-l.H-pyrrolo[2,3-b]pyridin-3-yl)-.?V-(l(cyclopropyIsulfonyl)pyrrolidin-3-yl)-5-fluoropyrimidin-4-amine (401).

According to the procedure for compound 398 using cyclopropanesulfonyl chloride (81 mg, 0.57 mmol) afforded 17.1 mg (37% yield) of 401, as a solid.

LCMS RT = 1.9 min. ES⁺ 437.

[00581] Formation of (5)-.V-(l-(butylsulfonyl)pyrrolidin-3-yl)-2-(5-chloro-l/7pyrroIo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-amine (402).

According to the procedure for compound 398 using 1-butanesulfonyl chloride (90mg, 0.57 mmol) afforded 21mg (45% yield) of 402, as a solid.

LCMS RT = 2.1 min. ES* 453.

[00582] Formation of (5)-2-(5-chloro-lfZ-pyrrolo[2,3-b]pyridin-3-yl)“N-(l“ (cyclopentylsulfonyl)pyrrolidin-3-yl)-5-fluoropyrimidin-4-amine (403).

According to the procedure for compound 398 using cyclopentanesulfonyl chloride (97 mg, 0.57 mmol) afforded 9.7 mg (20% yield) of 403, as a solid.

LCMS RT = 2.1 min. ES⁺ 465.

[00583] Formation of (S)-2-(5-chloro-l£f-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-N(1 -(propylsulfonyl)pyr rolidin-3-y!)py rimid in-4-amin e (410).

-199WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

According to the procedure for compound 398 using propylsulfonyl chloride (20 mg, 0.14 mmol) afforded 15.5 mg (36% yield) of 410, as a solid.

LCMS RT = 2.0 min. ES⁺ 439.

[00584] Formation of (S)-2-(5-chloro-lJ/-pyrrolo[2,3-b]pyridin-3-yl)-N-(l(cyclopentylmethylsulfonyl)pyrrolidin-3-yl)-5-fluoropyrimidin-4-amine (479).

According to the procedure for compound 398 using cyclopentylmethyl sulfonyl chloride (30 mg, 0.16 mmol) afforded 26.7 mg (58% yield) of 479, as a solid.

LCMS RT = 2.3 min. ES⁺ 479.

[00585] Formation of (S)~methyl 3-(2-(5-chloro-lZ7-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)pyrrolidine-l-carboxylate (476).

According to the procedure for compound 398 using methylchloroformate (20 mg, 0.21 mmol) afforded 13.6 mg (52% yield) of 476, as a trifluoroacetic acid salt after preparatory HPLC purification.

LCMS (ammonium formate buffer) RT = 2.6 min. ES⁺ 391.

[00586] Formation of (SJ-isopropyl 3-(2-(5-chIoro-17/-pyrrolo[2,3“b]pyridin-3-yl)5-flu oropyrimidin-4-ylamino)pyrrolidine-1 -carboxylate (477).

According to the procedure for compound 476 using isopropyl chloroformate (20mg, 0.21 mmol) afforded U.3mg (42% yield) of 477, as a trifluoroacetic acid salt after preparatory HPLC purification.

LCMS (ammonium formate buffer) RT = 2.0 min. ES⁺ 419.

-200WO 2010/148197

PCT/US2010/038988

[00587] Formation of (35)-( tetrahydrofuran-3-yl)methyl 3-(2-(5-chloro-l//pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)pyrrolidine-l-carboxylate (484).

According to the procedure for compound 398 using 2,5-dioxopyrrolidin-l-yl (tetrahydrofuran-3-yl)methyl carbonate (0.023 g, 0.096 mmol) afforded 5.7 mg (10% yield) of 484, as a trifluoroacetic acid salt after preparatory HPLC purification.

LCMS (ammonium formate buffer) RT = 2.6 min. ES⁺ 461.

[00588] Formation of ((5)-3-(2-(5-chlorO“lif-pyrrolo[2,3-b]pyridin-3“yl)-5fluor opy r imidin-4-ylam ino)pyrr olid in-1 -yl)(tetrahydrofu ran-3-yl) methanone (478).

According to the procedure for compound 398 using tetrahydrofuran-3-carboxylic acid (35 mg, 0.30 mmol) afforded 22.2mg (52% yield) of 478, as a solid.

LCMS (TFA buffer) RT = 1.6 min. ES⁺ 431.

F

[00589] Formation of (5)-l-(3-(2-(5-chloro-l£I-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)pyrrolidin-l-yl)ethanone (480).

According to the procedure for compound 398 using acetyl chloride (45 uL, 0.64 mmol) afforded 4.2 mg (18% yield) of 480, as a solid.

LCMS (TFA buffer) RT = 1.6 min, ES⁺ 375.

[00590] Formation of (5)-l-(3-(2-(5-chloro-12/-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)pyrrolidin-l-yl)-2-methoxyethanone (481).

-201WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

According to the procedure for compound 398 using methoxyacetyl chloride (50 mg, 0.46 mmol) afforded 8.6 mg (33% yield) of 481, as a solid.

LCMS (TFA buffer) RT = 1.6 min, ES⁺ 405.

F

^H 482 [00591] Formation of (S)-(3-(2-(5-chloro-17f-pyrrolo[2,3-/>]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)pyrrolidin-l-yl)(3-methyloxetan-3-yl)methanone (482).

According to the procedure for compound 398 using 3-methyloxetane-3-carboxylic acid (15 mg, 0.13 mmol) afforded 17.7 mg (42% yield) of 482, as a solid.

LCMS (TFA buffer) RT =1.6 min, ES⁺ 431.

|00592] Formation of ((5)-3-(2-(5-chioro-l//-pyrrolo[2,3-/>]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)pyrrolidin-l-yl)(morpholin-2-yl)methanone ¢483).

According to the procedure for compound 398 using morpholine 2-carboxyIic acid (25mg, 0.11 mmol) afforded 3,6mg (8% yield) of 483 as a solid.

LCMS (TFA buffer): Rt 1.4 min, ES* 446.

[00593] Using a procedure equivalent to that for the preparation of 7c, the other enantiomer (8a) can be obtained.

[00594] Analogs that can be prepared from compound 8a.

General Scheme 8

(a) (5)-2,5-dioxopynolidin-I-yl tetrahydrofuran-3-yl carbonate, 'PrzNEt, THF, RT (b) 25% NaOMe/MeOH or IM LiOH, 150°C, microwave, 10 min.

[00595] Formation of (R)-((5)-tetrahydrofuran-3-yl) 3-(2-(5-cliloro-l//pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)pyrrolidine-l-carboxylate (424).

-202WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

According to the procedure for compound 398 using (R)-te/7-butyl 3aminopyiTolidine-1-carboxylate and (5)-2,5-dioxopyrrolidin-l-yl tetrahydrofuran-3-yl carbonate afforded 19.8mg (47% yield) of424 as a solid.

LCMS (TFA buffer) RT = 1.8 min, ES⁺ 447.

[00596] Formation of (R)-(3-(2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)pyrrolidin-l-yl)(3-methyloxetan-3-yl)methanone (473).

According to the procedure for compound 482 using (2?)-2-(5-chloro-l-tosyl-l/7pyiTolo[2,3-h]pyridin-3-yl)-5-fluoro-/V-(pyrrolidin-3-yl)pyrimidin-4-amine hydrochloride, 8a, and 3-methyloxetane-3-carboxylic acid (50 mg, 0.46 mmol) afforded 18.6 mg (44% yield) of 473, as a solid.

LCMS (TFA buffer) RT = 1.6 min, ES⁺ 431.

F

[00597] Formation of (S)-2-(5-chloro-lK-pyrrolo[2,3-b]pyridin-3-yl)-N-(l(cy clop ropylm ethy l)py r r olidin-3-yl)-5-fluo ropyrimidin-4-a mine (415).

A solution of (S)-2-(5-chloro-l-tosyl-l#-pyrrolo[2,3-Z?]pyridin-3-yl)-5-fluoro-7V(pyrroIidin-3-yl)pyrimidin-4-amine hydrochloride, 7c, (0.05 g, 0.10 mmol) in methanol (3 mL) was treated with cyclopropane carboxaldehyde (0.30 mmol), sodium cyanoborohydride (0.30 mmol) and potassium acetate (0.04 g, 0.30 mmol) then stirred at 60 C until the reaction was complete. Aqueous workup afforded an oil that was dissolved in methanol (2 mL) then treated with of 25% sodium methoxide/methanol (0.5 mL) and heated at 60°C in sealed tube. LCMS showed complete reaction. The resulting solution was quenched with aqueous saturated NH4CI solution (0.5mL) then evaporated to dryness and the residue dissolved in DMSO and purified by reverse phase HPLC (ammonium formate buffer) to afford 6.2mg (17% yield) of415asasolid.

LCMS RT = 1.5 min, ES⁺ 387.

[00598] Formation of A-(2-(5-chloro-17/-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-yI)-l-(methylsulfonyl)azepan-4-amme (496).

-203WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

According to the procedure for compound 398 using methanesulfonyl chloride afforded the desired product, 496, as a solid.

LCMS RT = 1.8 min, ES⁺ 439.

[00599] Formation of l-(4-(2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5fIuoropyrimidin-4-ylamino)azepan-l-yl)ethanone (497).

According to the procedure for compound 398 using acetyl chloride afforded the desired product, 497, as a solid.

LCMS RT = 1.7 min, ES⁺ 403.

[00600] Formation of methyl 4-(2-(5-chloro-ll7-pyrroIo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)azepane-l-carboxylate (498).

According to the procedure for compound 398 using methyl chloroformate afforded the desired product, 498, as a solid.

LCMS RT = 1.9 min, ES⁺ 419.

[00601] Formation of 4-(2-(5-chloro-l/f-pyrrolo[2,3“b]pyridin-3-yl)-5fluoropyrinijdin-4-ylarnino)-ALV-dirnetlrylazepane-l-carboxamide (499).

According to the procedure for compound 398 using dimethyl carbamoyl chloride afforded desired product, 499, as a solid.

LCMS RT = 1.8 min, ES⁺ 432.

-204WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00602] Formation of 4-(2-(5-chloro-l//-pyrrolo[2,3-b|pyridin-3-yI)-5fluoropyrimidin-4-yla min o)azepane-l -ca rb oxamide (509).

According to the procedure for compound 398 using trimethylsilylisocyanate afforded desired product, 509, as a solid.

LCMS RT = 1.6 min, ES⁺ 404.

[00603] Formation of 4-(2-(5-chloro-lE?-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-JV-methylazepane-l-carboxamide (506).

According to the procedure for compound 398 using methyl isocyanate afforded the desired product, 506, as a hydrochloride salt after treating with HCI/dioxane.

LCMS RT = 2.1 min, ES⁺ 418.

General Scheme 11

ΕΊ

11c 327 (aj’PrjNEt, THF (b) 5-chloro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-

2- yl)pyiTolo[2,3-b]pyridine, Pd(Ph₃P)₄, Na₂CO₃, DME, 130 °C (c) HCI/dioxane, CH₂C1₂ (d)

3- methoxypropanoyI chloride, Pr₂NEt, CH₂C1₂/DMF [00604] Formation of (If)-teri-butyl 3-((2-chloro-5-fluoropyrimidin-4ylamino)methy l)-piperidine-l -ca rb oxy late (Ila).

To a solution of 2,4-dichloro-5-fluoropyrimidine (0.43 g, 2.59 mmol) and butyl 3-(aminomethyl)piperidinc-l -carboxylate (0.56 g, 2.59 mmol) in THF (50 mL) was

-205WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 added ‘Pr₂lSIEt (0.45 mL, 2.59 mmol). The reaction mixture was heated at 80 °C at for 8h. The solvent was concentrated under reduced pressure and the resulting residue was purified by silica gel chromatography (5-30% EtOAc/hexanes) to afford the desired product, 11a.

LCMS (M+l) 345.1.

[00605] Formation of (/^-tert-butyl 3-((2-(5-chloro-l//-pyrrolo[2,3-6]pyridin-3yl)-5-fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate (lib)

To a degassed solution of 5-chloro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyI-l,3,2dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine (0.71 g, 1.65 mmol), (R)-tert-butyl 3-((2-chloro-5fluoropyrimidin-4-ylamino)methyl)-piperidine-l-carboxylate, 11a, (1.19 g, 3.60 mmol) and aqueous K₂CO₃ (2.48 mL of 2 M solution, 4.97 mmol) in THE (30 mL) was added bis(triterZ-butylphosphine)palladium(0) (0.17 g, 0.33 mmol). The reaction mixture was degassed for an additional 15 min. The mixture was stirred at room temperature for 4 hours, concentrated in vacuo, and the resulting crude residue was purified by silica gel chromatography (10%-80% EtOAc/hexanes) to afford the desired product, lib.

LCMS (M+l) 461.4, (M-l) 460.7.

[00606] Formation of 2-(5-chloro-l-tosyl-l£f-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoroZV-(piperidin-3-ylmethyl)pyrimidin-4-amine (1 lc).

To a solution of (J?)-te/'t-butyl 3-((2-(5-chloro-l/?-pyrrolo[2,3-6]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate, lib, (0.13 g, 2.8 mmol) in 5% MeOH/CH₂Cl₂ was added 0.7 ml 4N solution of HCl/dioxane. The reaction mixture was stirred at room temperature for 12 hours. The resulting precipitate was filtered and used without further purification.

LCMS (M+l) 361.1.

[00607] For mation of (/? )-1 -(3 -((2-(5-ch loro-177-py r r olo [2,3-b] pyridin-3-y 1)-5fluoropyrimidin-4-ylamino)methyI)piperidin-l-yl)-3-methoxypropan-l“0ne (327).

To a solution of 2-(5-chloro-l-tosyl-l/7-pyrrolo[2,3-6]pyridin-3-yl)-5-fluoro-A^ir(piperidin-3-ylmethyl)pyrimidin-4-amine, 11c, (0.04 g, 0.11 mmol) in a 10:1 mixture of CH₂C1₂/DMF (1 mL) was added ‘Pr₂NEt (0.058 mL, 0.33 mmol) and 3-methoxypropanoyl chloride (0.02 g, 0.17 mmol). After 12 hours, the solvent was concentrated in vacuo and the resulting crude was and the crude was purified by preparatory HPLC (0.1%TFAH₂O/acetonitrile) to afford the desired product, 327.

LCMS (M+l) 447.3.

[00608] Other analogs that can be prepared in the same manner as 327:

113

104 [00609] (A)-(3-((2-(5-chloro-lAT-pyrrolo[2,3-6]pyridin-3-yI)-5-fluoropyrimidin-4ylamino)methyl)piperid in-l-yl)(2-methoxyp henyl)methanone(113).

LCMS RT = 2.9 (M+l) 479.4, (M-l) 477.6.

-206WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00610] (Λ)-1 -(3-((2-(5-chl or o-l /J-py rro I o 12,3-/>] py r idin-3 -y l)-5-fluor opy rimidin4-ylamino)methyl)piperidin-l-yl)-2-(thiophen-2-yl)ethanone (104).

LCMS RT = 2.8 (M+l) 485.3, (M-l) 483.4.

108 111 [00611] (R)-(3-((2-(5-ch]oro-1/7-pyrrolo[2,3-/;]pyridin-3-yI)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)(3,5-difluorophenyl)methanone (108).

LCMS RT = 2.1 (M+l) 501.3.

[00612] (ff)-l-(3-((2-(5-chloro-l//-pyrrolo[2,3-Z>]pyridin-3-yl)-5-fluoropyrimidin4-y la mino)m eth yl) pip eridin- l-yl)ethanone(lll).

LCMS RT == 2.5 (M+l) 403.4.

107 [00613] (ff)-benzo[Zi]thiophen-2-yl(3-((2-(5-chloro-l//-pyrrolo[2,3-/>]pyridin-3-yl)5-fiuoropyrimidin-4-ylamino)methyl)piperidin-l-yl)inethanone (107).

LCMS RT = 3.2 (M+l) 521.3.

[00614] (5)-l-(3-((2-(5-chIoro-lEf-pyrrolo[2,3-/’]pyridin-3-yl)-5-fluoropyriinidiii-4“ yla mino)methyl)piperidin-l-yl)ethan one (37).

LCMS RT = 2.5 (M+l) 403.3.

102 106 [00615] (7?)-(3-((2-(5-chloro-17Z-pyrrolo[2,3-b]pyridin-3“yl)“5-fluoropyriniidiii-4ylamino)methyl)piperidin-l-yl)(furan-2-yI)inethanone (102).

LCMS RT = 2.7 (M+l) 455.3, (M-l) 453.3.

-207WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00616] (/?)-2-(benzyloxy)-l-(3-((2-(5-chloro-l//-pyrroIo|2,3-/>jpyridin-3-yl)-5fluoropyriniidm-4-ylamino)niethyl)piperidin-l-yI)etiianone (106).

LCMS RT = 3.0 (M+l) 509.3, (M-l) 507.5.

126

[00617] (/?)-2-tluoroethyl 3-((2-(5-chloro-l//-pyrroIo[2,3-6]pyridin-3-yl)-5fluoropynmidin-4-ylamino)methyl)piperidine-l-carboxylate (126).

LCMS RT = 2.1 (M+l) 451.4.

[00618] (R)-(3-((2-(5-chloro-l/f-pyrrolo [2,3-6] pyndin-3-yl)-5-fluoropyrimidin-4yla mino)methy l)p ip eridin-l-yl)(thiophen-2-yl)m ethano ne (97).

LCMS RT = 2.9 (M+l) 471.2, (M-l) 469.6.

105

157 [00619] (li)-l-(3-((2-(5-chloro-l£Z-pyrrolo[2,3-6]pyridin-3-yl)-5-fluoropyrimidin4-ylamino)methyl)piperidin-l-yl)-2,2-dimethylpropan-l-one (105).

LCMS RT = 3.0 (M+l) 445.3, (M-l) 443.4.

[00620] (/?)-(3-((2-(5-chloro-lH-pyrrolo[2,3-6|pyridin-3-yl)-5-fluoropyrimidin-4ylamino) methy l)piperidin-l-yl) (2,3-dimethy lphenyl)meth anone(157).

LCMS RT = 2.0 (M+l) 493.1.

110

-208WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00621] (2?)-l-(3-((2-(5-chIoro-lif-pyrrolo[2,3-Z>]pyridin-3-yl)-5-fluoropyrimidin4-ylamino)methyl)piperidin-l-yl)-2-phenoxyethanone (94).

LCMS RT = 2.9 (M+l) 495.3, (M-l) 493.5.

[00622] (7?)-2-(3-((2-(5-chloro-l/+-pyrrolo|2,3-/?]pyridin-3-yI)-5-fluoropyrinijdin4-ylamino)methyl)piperidin-l-yl)-2-oxoethyl ethanoate (110).

LCMS RT = 2.5 (M+l) 461.3, (M-l) 459.4.

[00623] (5)-ethyl 3-((2-(5-chloro-lff-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate (33).

LCMS RT = 3.0 (M+l) 433.3, (M-l) 431.4.

[00624] (lf)-prop-l-en-2-yl3-((2-(5-chloro-lli-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylammo)methyl)piperidine-l-carboxylate (74).

LCMS RT = 3.1 (M+l) 445.2, (M-l) 443.4.

[00625] (J?)-3-(3-((2-(5-chloro-lfi-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin4-ylamino)methyl)piperidine-l-carbonyl)pyrazine-2-carboxylic acid (82).

LCMSRT= 1.6 (M+l) 511.3.

[00626] (lS,2R)-2-((R)-3-((2-(5-chloro-17f-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropy r imidin-4-yla min o)methyl)pip eridine-l-carb onyl) cyclop ropa necarboxylic a cid (83).

LCMS RT = 1.6 (M+l) 473.4.

-209WO 2010/148197

PCT/US2010/038988

[00627] (6)-1-(3-((2-(5-ch lo ro-l//-pyrr olo [2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylammo)methyl)piperidin-l-yl)-2-methoxyethanone (45).

LCMS RT = 2.4 (M+l) 433.3, (M-l) 431.4.

[00628] (5)-aIlyl 3-((2-(5-chloro-l/7-pyrrolo|2,3-b|pyridin-3-yl)-5fluoropyrimidin-4-ylaimno)methyl)piperidine-l-carboxylate (17).

LCMS RT = 3.1 (M+l) 445.3, (M-l) 443.4.

[00629] (jR)-prop-2-ynyl 3-((2-(5-chloro-l/7-pyrrolo [2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate (122).

LCMS RT = 2.9 (M+l) 443.3, (M-l) 441.5.

[00630] (S)-ethyl 5-(3-((2-(5-chloro-l£f-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidin-l-yl)-5-oxopentanoate (19).

LCMS RT = 2.8 (M+l) 503.4, (M-l) 501.5.

127

[00631] (jR)-but-2-ynyl 3-((2-(5-chloro-li7-pyrrolo[2,3-b]pyridin“3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate (127).

LCMS RT = 3.1 (M+l) 457.3, (M-l) 455.6.

100632 J (5)-m ethyl 3-((2-( 5-c hlor o-l//-py r r olo 12,3-b ]py ridin-3-y 1)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate (23).

LCMS RT = 2.8 (M+l) 419.3, (M-l) 417.3.

-210WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

119 30 [00633] (fl)-allyl 3-((2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate (119).

LCMS RT = 3.1 (M+l) 445.4, (M-l) 443.5.

[00634] (5)-but-2-ynyl 3-((2-(5-chloro-17f-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyI)piperidine-l -carboxylate (30).

LCMS RT = 3.1 (M+l) 457.3, (M-l) 455.6.

[00635] (R)-toi-butyl 3-((2-(5-chloro-l/Z-pyrrolo [2,3-A]pyridin-3-yI)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate (15).

LCMS RT = 2.7 (M+l) 461.3.

[00636] (5)-isobutyl 3-((2-(5-chloro-U7-pyi-rolo[2,3-/?]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate (28).

LCMS RT = 3.3 (M+l) 461.4.

[00637] (S)-l-(3-((2-(5-chloro-Lff-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4yla mino)methy l)p ip eridin-l-yl)prop an-1 -o ne (32).

LCMS RT = 1.9 (M+l) 417.2.

[00638] (5)-l-(3-((2-(5-chIoro-lzr-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l -yl)-2-methyIpropan-l -one (34).

LCMS RT = 3.2 (M+l) 447.4, (M-l) 445.5.

i

-211- I |

I

WO 2010/148197

PCT/US2010/038988

[00639] (5)-isopr opyl 3-((2-(5-chloro-llT-py r rolo [2,3-b ] pyridin-3-y 1)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate (35).

LCMS RT = 3.0 (M+l) 447.3, (M-l) 445.4.

[00640] (fl)-(3-((2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidiii-4ylamino)methyl)piperidin-l-yl)(cyclopentyl)methanone (99).

LCMS RT = 3.1 (M+l) 457.3, (M-l) 455.4Λ

[00641] (5)-l-(3-((2-(5-chloro-lfl-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperid in-l-yl)but-2-en-l -one (41)

LCMS RT = 2.7 (M+l) 429.3, (M-l) 427.4.

[00642] (5)-l-(3-((2-(5-chloro-ljH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)metliyl)piperidin-l-yl)-3,3-diinethylbutan-l-one(42)

LCMS RT = 3.1 (M+l) 459.3, (M-l) 457.4.

[00643] (5)-1 -(3-((2-(5-cbloro-l/7-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)-3,3,3-trifluoropropan-l-one (44)

LCMS RT = 2.8 (M+I) 471.3, (M-l) 469.4.

[00644] (5)-2-(3-((2-(5-chIoro-l/7-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyriniidin-4yiamino)niethyl)piperidin-l-yl)-A',A',A'-trimethyl-2-oxoethanaminium (43)

-212WO 2010/148197

PCT/US2010/038988

LCMS RT = 2.4 (M+l) 460.3, (M-l) 458.5.

[00645] (5)-1-(3-((2-(5-chloro-117-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyI)piperidin-l-yl)-2-(dimethylaniino)ethanone (46)

LCMS RT = 2.2 (M+l) 446.4, (M-l) 444.5.

[00646] (5)-l-(3-((2-(5-chIoro-117-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyriiiiidin-4ylaniino)methyl)piperidin-l-yl)-2-(pyridin-3-yl)ethanone (47)

LCMS RT = 2.4 (M+l) 480.3, (M-l) 478.6.

[00647 ] (5)-l-(3-((2-(5-c hlor o-l/7-py rrolo [2,3-b ] pyrid in-3-yl)-5-fluoropyr imidin-4ylamino)methyl)piperidin-l-yl)but-3-en-l-one (49)

LCMS RT = 2.7 (M+l) 429.3, (M-l) 427.4.

[00648] (5)-1 -(3-((2-(5-chloro-177-pyrroIo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4yIamino)methyl)piperidin-l-yl)-2-(lH-tetrazol-l-yl)ethanone (48)

LCMS RT = 2.4 (M+l) 471.3, (M-l) 469.4.

[00649] (R)-5-((S)-3-((2-(5-chlor ο-ΙίΓ-py rrolo [2,3-b ]pyridin-3-y 1)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carbonyl)dihydrofuran-2(3H)-one (51)

LCMS RT = 1.7 (M+l) 472.9.

[00650] (5)-l-(3-((2-(5-c hloro-l//-py r rolo [2,3-6] pyridin-3-yl)-5-flu or opy rimidin-4 yIamino)methyI)piperidin-l“yl)-2-(lJ7-imidazol-l-yl)ethanone (50)

-213WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

LCMS RT = 2.3 (M+l) 469.3, (M-l) 467.4.

[00651] (5)-l-(3-((2-(5-chloro-lZl'-pyrrolo[2,3-b]pyridin“3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)pent-4-yn-l-one (52)

LCMS RT= 1.9 (M+l) 441.3.

[00652] (jR)-5-(3-((2”(5-chlor o-l//-py rrolo [2,3-b] py ridin-3-yI)-5-fluoropyrimid in4-yIamino)methyl)piperidin-l-yl)-5-oxopentanoic acid (53)

LCMS RT = 1.8 (M+l) 475.3, (M-l) 473.4.

100653 ] (A)-2-(2-(3-((2~(5-c hloro-17/-py rrolo [2,3-b ] py r idin-3-y 1)-5fluoropyrimidin-4-ylamino)methyl)piperidin-l-yl)-2-oxoethoxy)ethanoic acid (54)

LCMS RT = 1.7 (M+l) 477.3, (M-l) 475.4.

[00654] (15,3/?)-3-((7/)-3-((2-(5-chloro-1//-pyrroIo[2,3-b]pyridin-3-yl)-5fhioropyrimidin-4-ylamino)methyl)piperidine-l-carbonyl)cycIopentanecarboxylic acid (55)

LCMS RT - 2.5 (M+l) 501.3, (M-l) 499.6.

[00655] (/?)-(3-((2-(5-chIoro-lZf-py rrolo [2,3-b ] py rid in-3-yl)~5-flu oropyrimid in-4ylamino)methyl)piperidin-l-yl)(2-fluorophenyl)niethanone (58)

-214WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

LCMS RT - 2.9 (M+l) 483.3, (M-l) 481.5.

[00656] (R)-5-(3-((2-(5-chloro-177-pyrrolo[2,3-b]pyridin-3-yI)-5-fluoropyrimidin4-ylamino)methyl)piperidin-l-yl)-3,3-dimethyl-5-oxopentanoic acid (80)

LCMS RT = 1.9 (M+l) 503.3.

[00657] 2-chloro-l-((R)-3-((2-(5-chIoro-1/7-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidin-l-yl)propan-l-one (93)

LCMS RT = 2.9 (M+l) 451.2, (M-l) 449.4.

[00658] (R)-(3-((2-(5-chIoro-17/-py rr olo [2,3-b] py rid in-3-yl)-5-flu oropy rimidin-4ylamino)methyl)piperidin-l-yl)(cyclohexyl)methanone (95)

LCMS RT = 3.2 (M+l) 471.3, (M-l) 449.4.

114 [00659] (□RJ-Zer/'-butyl 3-((2-(5-amin o-lZ6pyrrolo [2,3-Z>]pyridin-3-y 1)-5fluoropyriniidin-4-ylamino)methyl)piperidine-l-carboxylate (114)

LCMS RT = 2.7 (M+l) 461.3.

495

[00660] (J?)-ethyl3-((2-(5-chloro-177-pyrrolo[2,3-/>]pyridin-3-yl)pyrinndin-4ylamino)methyl)piperidine-l-carboxylate (495)

LCMS RT - 1.7 (M+l) 385.4.

[00661] (7?)-l-(3-((2-(5-chloro-l/^pyrrolo[2,3-A]pyridin-3-yl)pyrimidin-4ylamino)methyl)piperidin-l-yl)-2-methoxyeth anone (491)

-215WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

LCMS RT= 1.7 (M+l) 415.4.

[00662] (7!)-l-(3-((2-(5-chloro-ljfif-pyrrolo[2,3-/»]pyridin-3-yl)pyrimidin-4ylamino)methyl)piperidin-l-yl)-3-methoxypropan-l-one (493)

LCMS RT = 1.7 (M+l) 429.5.

100663 ] (20-l-(3-((2-(5-chloro-lZf-py r rolo 12,3- #]py ridin-3-yi)py rim idin-4ylamino)methyl)piperidin-l-yI)-3-methylbutan-l-one (494)

LCMS RT = 1.9 (M+l) 427.5.

[00664] (5)-2-m ethoxy ethyl 3-((2-(5-chloro-ljH^r-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l -carboxylate (24)

LCMS RT = 2.8 (M+l) 463.2, (M-l) 461.3.

[00665] (7f)-l-(3-((2-(5-chloro-li7-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin4-ylammo)methyl)piperidin-l-yl)-2-phenyiethanone (56)

LCMS RT = 2.9 (M+l) 479.3, (M-l) 477.4.

[00666] (Jf)-l-(3-((2-(5-chloro-Iff-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin4-ylamino)methyl)piperidin-l-yl)-3-methylbut-2-en-l-one (57)

LCMS RT = 2.8 (M+l) 443.3, (M-l) 441.4.

-216WO 2010/148197

PCT7US2010/038988

2018200219 11 Jan 2018 [00667] (jR)-4-(methoxycarbony!)phenyl 3-((2-(5-chloro-177-pyrrolo[2,3-b]pyridin-

3-yl)-5-fluoropyrimidin-4-ylaniino)methyl)piperidine-l-carboxylate (63)

LCMS RT = 3.2 (M+l) 539.3, (M-l) 537.4.

[00668] (fl)-phenyl 3-((2-(5-chloro-l /7-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate (68)

LCMS RT = 3.2 (M+l) 481.4, (M-l) 479.4.

[00669] (K)-2-chlorophenyl3-((2-(5-chloro-lff-pyrrolo[2,3-b]pyridiii-3-yl)-5fluoropyrimidm-4-ylamino)niethyl)piperidine-l-carboxylate (70)

LCMS RT = 3.3 (M+l) 515.3, (M-l) 513.3.

[00670] (/?)-2-methoxyphenyl 3-((2-(5-chloro-lZf-pyrrolo[2,3-6]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate (69)

LCMS RT = 3.2 (M+l) 511.3.

[00671] (jR)-p-tolyl 3-((2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l -carboxylate (71)

LCMS RT = 3.4 (M+l) 495.3, (M-l) 493.4.

[00672] (2f)-3-(trifluorometliyl)phenyl3-((2-(5-chloro-lZT-pyrrolo[2,3-b]pyridin-3yI)-5-fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate (72)

LCMS RT = 3.5 (M+l) 549.3, (M-l) 547.4.

-217WO 2010/148197

PCT/US2010/038988

[00673] (j?)-4-fluorophenyl 3-((2-(5-chIoro-l/f-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate (73)

LCMS RT = 3.3 (M+l) 499.3, (M-l) 497.4.

[00674] (/?)-2-(l-(2-(3-((2-(5-chIoro-lJ7-pyrroIo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-yIamino)methyl)piperidin-l“yl)-2-oxoethyl)cyclopentyl)ethanoic acid (81)

LCMS RT = 2.0 (M+l) 529.3.

[00675] (_JR)-(3-((2-(5-chloro-ljff“pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)(2-chlorophenyl)methanone (84)

LCMS RT = 2.0 (M+l) 499.4.

[00676] (/?)-(3-((2-(5-chloro-l/7-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)(3,4-difluorophenyl)methanone (85)

LCMS RT = 2.1 (M+l) 501.3.

[00677] (7?)-2-chloro-l-(3-((2-(5-chloro-l//-pyrroIo[2,3-b]pyridin-3-yl)-5flu oropy rimidin-4-y lam ino)methyl)piperid in-l-yl)ethano ne (92)

LCMS RT = 2.7 (M+l) 437.2, (M-l) 435.3.

-218WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00678] (R)-(3-((2-(5-chloro-l£F-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4yla mino)methyl)p ip eridin-l-yl)(2,6-dichlo rop henyl)methanone (96)

LCMS RT = 2.9 (M+l) 535.2, (M-l) 533.2.

[00679] (R)-l-(3-((2-(5-chIoro-lif-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-

4-ylamino)methyl)piperidin-l-yl)-2-(4-fluorophenyl)ethanone (98)

LCMS RT = 2.9 (M+l) 497.3, (M-l) 495.4.

[00680] (R)-l-(3-((2-(5-chloro-l/7-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyriinidin4-ylamino)methyl)piperidin-l-yI)-2-cyclopentylethanone (100)

LCMS RT = 3.1 (M+l) 471.3, (M-l) 469.5.

111

186 [006811 (R)-(3-((2-(5-chloro-l 17-py rrolo[2,3-b] pyridin-3-yl)-5-flu oropyrimidin-4yIannno)methyl)piperidin-l-yl)(pyrazin-2-yl)methanone (111)

LCMS RT = 2.5 (M+l) 467.2, (M-l) 465.4.

[00682] (fl)-(3-((2-(5-chIoro-l/Z-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)(furan“2-yl)methanone (186)

LCMS RT = 2.7 (M+l) 455.3, (M-l) 453.3.

152 [00683] (B)-benzo[d][l,3]dioxol-5-yl(3-((2-(5-chloro-lZf-pyrrolo[2,3-b]pyridin-3-219WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 yl)-5-fluoropyrimidin-4-ylamino)methyl)piperidin-l-yl)methanone (103)

LCMS RT = 2.8 (M+l) 509.3, (M-l) 507.5.

[00684] (i)-(3-((2-(5-chloro-UT-pyrrolo[2,3-b]pyridm-3-yl)-5-fluoropyrimidin-4ylamino)niethyl)piperidm-l-yl)(2,4-difluorophenyl)metlianone (152)

LCMS RT = 2.8 (M+l) 501.3, (M-l) 499.4.

[00685] (7?)-(3-((2-(5-chlorO“lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)(2-(methylamino)phenyl)methanone (112)

LCMS RT = 3.0 (M+l) 494.3, (M-l) 492.5.

[00686] (R)-(3-((2-(5-chlo ro-1 //-pyrrol o [2,3-b ] py ridm-3-yi)-5~fhior opy rimid in-4~ ylamino)methyl)piperidin-l-yl)(3,4-dimethoxyphenyl)methanone (109)

LCMS RT = 2.7 (M+l) 525.3, (M-l) 523.4.

[00687] (_JR)-(3-((2-(5-chloro-l_JH-pyrrolo[2,3-Z»]pyridin“3-yl)-5-fluoropyrimidin-4ylammo)methyl)piperidin-l-yl)(3,5-difluorophenyl)inetlian.one (86)

LCMS RT = 2.8 (M+l) 501, (M-l) 499.

[00688] (_JR)-(3-((2-(5-chloro-l_JH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyriniidin-4ylamino)methyI)piperidin-l-yI)(6“fluoro-4H-beiizo[d][l,3]dioxin-8-yl)methanone(142)

LCMS RT = 2.8 (M+l) 541.5.

[00689] (^)-(3-((2-(5-chloro-17/-pyrrolo|2,3-b]pyridin-3-yl)-5~fliioropyrimidin-4-220WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 ylamino)methyl)piperidin-l-yl)(o-tolyl)methanone (143)

LCMS RT = 2.9 (M+l) 479.4, (M-l) 477.6.

[00690] (^-(S-fiS-iS-chloro-lif-pyrroIolZ^-bjpyridin-S-ylj-S-fluoropyrimidin^ylamino)methyi)pip eridin-1-y I)(2-(trifluoromethyl)phenyl)methanone (146)

LCMS RT = 3.0 (M+l) 533.3, (M-l) 531.5.

[00691] (i?)-(3-((2-(5-chloro-17/-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methy l)piperidin-l-y 1)(2,3-dihydrobenzofuran-6-yl)methanone (145)

LCMS RT = 2.9 (M+l) 507.3, (M-l) 505.5.

[00692] (fi)-(3-((2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methy l)p iperidin-l-yl)(2,4-dichlo rop henyl) methanone (147)

LCMS RT = 3.2 (M+l) 533.3, (M-l) 531.4.

[00693] (l?)-(3-((2-(5-chIoro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)(2-ethoxyphenyl)methanone (158)

LCMS RT = 3.0 (M+l) 509.4, (M-l) 507.5.

[00694] (li)-(3-((2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)(2-methoxy-3-methylphenyl)methanone (148)

LCMS RT = 3.0 (M+l) 509.3, (M-l) 507.5.

151

150

-221WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00695] (J?)-(3-((2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)(2,5-difluorophenyl)inethanone (151)

LCMS RT = 2.9 (M+l) 501.2, (M-I) 499.5.

[00696] (fi)-(3-((2-(5-chloro-177-py rrolo [2,3-b] py ridin-3-yl)-5-flu oropy rimidin-4ylamino)methyl)piperidin-l-yl)(2-phenoxyphenyl)methanone (150)

LCMS RT = 3.2 (M+l) 557.3, (M-l) 555.6.

325 [00697] (Jf)-(3((2-(5-chloro-lFf-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)(2,4-dimethoxyphenyl)methanone (154)

LCMS RT = 2.3 (M+l) 525.3, (M-l) 523.2.

[00698] (jK)-(3-((2-(5-chloro-l/f-pyrrolo[2,3-b]pyridin-3-yl)5-fluoropyrimidin-4yla mino)methyl)piperid in-l-yl)(cyclopropyl)methan one (325)

LCMS RT = 2.7 (M+l) 429.2.

272

[00699] (J?)-(3-((5-iluoro-2-(lZ/-pyrrolo[2,3-i]pyridin-3~yl)pyrimidin-4ylamino)methyl)piperidin-l-yl)(2-niethoxyphenyl)methanone (272)

LCMS RT = 2.5 (M+l) 461.3.

[00700] (jR)-l-(3-((5-fluoro-2-(lJT-pyrrolo[2,3-i]pyridin-3-yl)pyrimidin-4ylamino)methyl)piperidin-l-yl)ethanone (268)

LCMS RT = 2.1 (M+l) 369.3.

-222WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00701] (R)-(3-((5-fluoro-2-(l.ff-pyrrolo[2,3-/>]pyridin-3-yl)pyrimidin-4ylamino)methyl)piperidin-l-yl)(phenyl)methanone (271)

LCMS RT = 2.5 (M+l) 431.4.

[00702] (R)-l-(3-((5-fluoro-2-(l#-pyrrolo[2,3-/>]pyridin-3-yl)pyrimidin-4ylamino)methyl)piperidin-l-yl)buta n-l-one (270)

LCMS RT = 2.4 (M+l) 397.3.

225 [00703] (jR)-(3-((5-fluoro-2-(117-pyrrolo[2,3-Zi]pyridin-3-yl)pyrimidin-4ylamino)methyl)piperidin-l-yl)(phenyl)propan-l“one (269)

LCMS RT = 2.3 (M+l) 383.3.

[00704] (5')-l-(3-((5-iluoro-2-(117-pyrrolo[2,3-i>]pyridin-3-yl)pyrimidin-4yla mino)methyl)p ip eridin-l-yl)b utan-l-one (225)

LCMS RT = 2.4 (M+l) 397.4.

[00705] In a manner analogous to that of the preparation of compound 327, compounds with the opposite absolute stereochemistry, were prepared as follows:

12a (a) fert-buty I isocyanate, pyridine, CH2CI2

[00706] Formation of (iS^r)-A^r-tert-butyl-3-((2-(5-chIoro-L/f-pyrroIo[2,3-b]pyridin-3yl)-5-fluo ropyrimidin-4-ylamino)methyl)p iperidine-1 -ca rboxamide (20).

To a solution of C/?)-2-(5-chloro-l/Y-pyiTolo[2,3-5]pyridin-3-yI)-5-fluoro-jV(piperidin-3-ylmethyl)pyrimidin-4-amine, 12a, (0.013 g, 0.036 mmol) in mixture of pyridine/CHjCh (1 mL of 1:1 mixture was added tort-butyl isocyanate (0.005 mL, 0.046 mmol). The reaction mixture was stirred at 40 °C for 12h. The solvent was concentrated under reduced pressure and the resulting residue was purified by preparatory HPLC (O.F/oTFA-HiO/acetonitrile) to afford die desired product, 20.

LCMS RT = 3.0 (M+l) 460.4, (M-l) 458.4.

-223WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00707] Other analogs that can be prepared in the same manner as 20:

[00708] (7?)-V-tert-butyl-3-((2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxamide (128)

LCMS RT = 3.0 (M+l) 460.4, (M-l) 458.4.

[00709] (S)-3-((2-(5-chloro-ljH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyriinidin-4ylannno)methyl)-/V-(thiophen-3-yl)piperidine-l-carboxaniide (22)

LCMS RT = 2.9 (M+l) 486.3, (M-l) 484.6.

[00710] (5)-ethyl 2-(3-((2-(5-chloro-17/-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxamido)ethanoate (25)

LCMS RT = 2.6 (M+l) 490.3, (M-l) 488.4.

[ 00711 ] (5)-ethyl 3-((2-(5-chloro-12/-pyrrolo [2,3-b ]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carbonylcarbamate (26)

LCMS RT = 2.5 (M+I) 476.3, (M-I) 474.5.

[00712] (₁S)-3-((2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidm-4yla mi n o)m ethyl)-A-isopr opy Ipiperidin e-l-ca rboxamide (27)

LCMS RT = 2.7 (M+l) 446.4, (M-l) 444.5.

[00713] (₁S)-3-((2-(5-chloro-li7-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)-jV-methylpiperidme-l-carboxamide (29)

-224WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

LCMS RT = 2.4 (M+l) 418.3, (M-l) 416.1.

[00714] (S)-/V-allyl-3-((2-(5-chloro-l£f-pyrrolo[2,3-b]pyridin-3-yl)-5~ fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxamide (39)

LCMS RT = 2.6 (M+l) 444.4, (M-l) 442.4.

[00715] (S)-3-((2-(5-chloro-lZl'-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)-/V-(pyridin-3-yl)piperidine-l-carboxaniide (40)

LCMS RT = 2.5 (M+l) 481.3, (M-l) 479.4.

[00716] (R)-3-((2-(5-chloro-lif-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyriniidin-4ylamino)methyl)-/V-(3-fluorophenyl)piperidine-l-carboxamide (75)

LCMS RT = 3.0 (M+l) 498.3, (M-I) 496.5.

[00717] (R)-3-((2-(5-chloro-l/Z-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4yla mino)m ethyl)-7V-(3-me th oxyphenyl)pip eridine-l-carboxamid e (76)

LCMS RT = 2.9 (M+l) 510.3, (M-l) 508.5.

[00718] (7?)-3 -((2-(5-chlor o-l JT-py rrolo [2,3-b] pyrid in-3-yl)-5-fluor opy rimidin-4ylamino)methyl)-/V-(3-ethanoylphenyl)piperidme-l-carboxamide (77)

LCMS RT = 2.8 (M+l) 522.3, (M-l) 520.4.

[00719] (R)-3~((2-(5-chloro-12/-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidm-4-225WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 ylaniino)metbyl)-A^!-m-t:olylpipendine-l-carboxarnide (78)

LCMS RT = 3.0 (M+l) 494.3, (M-l) 492.4.

[00720] (R)-3-((2-(5-chloro-lJ7-pyrroIo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylaniino)methyI)-A^r-(3-(trifluorornethyl)phenyl)piperidine-l--carboxarnide (79)

LCMS RT = 3.3 (M+l) 548.3, (M-l) 546.4.

[00721] (jR)-ethyl 3-(3-((2-(5-chloro-117-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxamido)propanoate (118)

LCMS RT = 2.6 (M+l) 504.2, (M-l) 502.5.

[00722] (jR)-3-((2-(5-chloro-lil-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin~4yIamino)methyl)-7V-(5-methyl-2-(trifluoromethyI)furan-3-yl)piperidine-l-carboxamide (120)

LCMS RT = 3.2 (M+l) 552.4, (M-l) 550.5.

[00723] (R)-methyl 2-(3-((2-(5-chloro-l.ff-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropy rimidin-4-yla min o)m ethyl)p iperidine-1 -ca rb oxamido)etha noate (125)

LCMS RT = 2.6 (M+l) 490.4, (M-l) 488.6.

[00724] (R)-A'-tert-butyl-3-((2-(5-chloro-17/-pyrrolo[2,3-bjpyridin-3-yl)-5fluoropyriinidin-4-ylamino)methyl)piperidine-l-carboxamide (117)

LCMS RT = 2.8 (M+l) 486.3, (M-l) 484.5.

-226WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00725] (jR)-3-((2-(5-chloro-lli-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4yiamino)methyl)-W-(thiophen-2-yl)piperidine-l-carboxamide (129)

LCMS RT = 2.8 (M+l) 486.3, (M-l) 484.5.

131

130 [00726] (R)-methyl 3-((2-(5-chloro-177-py rrolo [2,3-b]pyridin-3-yl)-5flu oropy rimidin-4-yIa mino)m ethy l)p iperidine-l-ca rb onylcarbamate (131)

LCMS RT = 1.6 (M+l) 462.7.

[00727] (fl)-3-((2-(5-chloro-lff-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4yla mino)m ethyl)-/V-(4-methylthiop hen-2-yl)piperidine-l -carb oxamide (130)

LCMS RT = 2.0 (M+l) 500.6.

228

274 [00728] (iS)-3-((5-fluoro-2-(l/Z-pyrrolo[2,3-Z>]pyridin-3-yl)pyrimidin~4ylamino)methyl)-A(A^r-dimethylpiperidine-l-carboxamide (228)

LCMS RT = 2.3 (M+l) 398.3.

[00729] (2?)-3-((5-fluoro-2-(lJ7-pyrrolo[2,3-6]pyridin-3-yl)pyriniidin-4ylammo)methyl)-/¥-methylpiperidine-l-carboxamide (274)

LCMS RT = 2.1 (M+l) 384.3.

275

[00730] (7?)-/V-etli y l-3-((5-flu o r 0-2-( 177-pyrrolo [ 2,3-6] py ridin-3-yl)py rimid in-4~ ylamino)methyl)piperidine-l-carboxamide (275)

LCMS RT = 2.2 (M+l) 398.4.

-227WO 2010/148197

PCT/US2010/038988 )00731] (77[-3-((5-fluoro-2-(lJ¥-pyrrolo[2,3-6]pyridin-3-yl)pyrimidin-4ylamino)methyl)-jV-propylpiperidine-l -carboxamide (276)

LCMS RT = 2.3 (M+l) 412.4.

General Scheme 12B

12a (b) propylisocyanate, 'Pr₂NEt, pyridine, CH₂CI₂ [00732] (5)-2-(5-chloro-ljff-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-A^r-((l(methylsulfonyl)-piperidin-3-yl)methyl)pyrimidin-4-amine (36).

To a solution of (R)-2-(5-chloro-177-pyrrolo[2,3-6]pyridin-3-yl)-5-fluoiO-2V(piperidin-3-ylmethyl)pyrimidin-4-amine, 12a, (0.018 g, 0.050 mmol) and pyridine (0.7 mL) in CH2CI2 (0.7 mL) was added methanesulfonyl chloride (0.004 mL, 0.050 mmol). The reaction mixture was stirred at room temperature for 24 hours. The solvent was concentrated under reduced pressure and the resulting residue was purified by preparatory HPLC (0.1%TFA-H₂O/acetonitrile) to afford the desired product, 36.

LCMS RT = 2.7 (M+l) 439.3, (M-l) 437.3.

[00733] Other analogs that can be prepared in the same manner as 36:

[00734] (R)-2-(5-chloro-lff-pyrrolo[2,3-b]pyridin-3-yl)-7V~((l(cyclopropylsulfonyl)piperidin-3-yl)methyI)-5-fIuoropyrimidin-4-amine (61)

LCMS RT = 2.8 (M+l) 465.3, (M-l) 463.3.

[00735] (J?,£)-2-(5-chloro-lif-pyrrolo|2,3-b]pyridin-3-yl)-5-fluoro-A^r-((l(styryIsulfonyl)piperidin-3-yl)methyl)pyrimidin-4-amine (60)

LCMS RT = 3.2 (M+l) 525.3.

-228WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00736] (2?)-2-(5-chloro-l//-pyrroIo[2,3-b]pyridin-3-yl)-5-fluoro-_JV-((l-(3methoxyphenylsulfonyl)piperidin-3-yI)methyl)pyrimidin-4-amine (62)

LCMS RT = 3.1 (M+l) 531.3, (M-l) 529.4.

[00737] (2?)-2-(5-chlorO“ljff-pyrrolo[2,3b]pyridin-3-yl)-5-fluoro-A^r-((l-(4fluorophenylsulfonyl)piperidin-3-yl)methyl)pyrimidiii-4-amine (64)

LCMS RT = 3.1 (M+l) 519.3, (M-l) 517.4

[00738] (R)-2-(5-chloro-lfZ-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-?V-((l-(3fluorophenyIsulfonyI)piperidin-3-yl)methyl)pyrimidin-4-amine (65)

LCMS RT = 3.1 (M+l) 519.2, (M-l) 517.4.

[00739] (7?)-2-(5-chloro-U7-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-/V-((l-(mtolyIsulfonyl)piperidin-3-yl)methyl)pyrimidin-4-amine (66)

LCMS RT = 3.2 (M+l) 515.3, (M-l) 513.4

[00740] (7?)-A-((l-(3-bronioplienylsulfonyl)piperidin-3-yl)methyl)-2-(5-chloro-l//pyrrolo[2,3“^]pyridin“3-yI)-5-fluoropyrimidin-4-amine (67)

LCMS RT = 3.3 (M+l) 579.2, (M-l) 577.2.

[00741] (7?)-2-(5-chloro-lif-pyrrolo[2,3-/»]pyridin-3-yl)-5-fluoro-yV-((l(phenylsulfonyl)piperidin-3-yl)methyl)pyrimidin-4-ainine (87)

-229WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

LCMS RT = 2.1 (M+l) 501.3.

[00742] (R)-/V-((l-(3-bromophenyIsulfonyI)piperidin-3-yl)methyl)-2-(5-chloro-l//pyrrolo[2,3-/>]pyridin-3-yl)-5-fluoropyrimidin-4-amine (88)

LCMS RT = 2.0 (M+l) 561.3.

[00743] (J?)-2-(5-chloro-l//-pyrrolo[2,3-/;]pyridin-3-yl)-5-fIuoro-A^r-((l(pbenylsuifonyl)piperidin-3-yI)inethyl)pyrimidin-4-aniine (89)

LCMS RT = 2.1 (M+l) 507.2.

[00744] (R)-2-(5-chloro-l£f-pyrrolo[2,3-Z»]pyridin-3-yl)-5-fluoro-/V-((l-(2fluorophenylsulfonyl)piperidin-3-yl)methyl)pyrimidin-4-amine (90)

LCMS RT = 2.1 (M+l) 519.2.

[00745] (/?)-2-(5-ch!oro-l//-pyrroIo[2,3-/>|pyrjdin-3-yl)-5-fluoro-A'-((l-(l-inetbyilZ/-imidazo]-4-ylsulfonyl)piperidin-3-yl)methyl)pyrimidin-4-aniine (91)

LCMS RT= 1.8 (M+l) 505.3.

General Scheme 12C

(a) (2?)-3-bromo-2-methylpropan-l-ol, ‘PgNEt, THF

-230WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00746] Formation of (5)-3-((5)-3-((2-(5-chloro-l£f-pyrrolo[2,3-b]pyridin-3-yI)-5fluoropyrimidm-4-ylaimno)methyl)piperidin-l-yl)-2-methylpropan-l-ol (135).

To a solution of (7?)-3-bromo-2-methylpropan-l-ol (0.006 mL, 0.055 mmol) and (/?)2-(5 -chloro - 177-py rrolo [2,3 -Z>]py ridin-3-y 1)-5-fluoro-Λ-(piperi din-3 -ylmethy 1) -pyrimidin-4amine, 12a, (0.020 g, 0.055 mmol) in CH₃CN (2 mL) was added K2CO3 (0.023 g, 0.165 mmol). The reaction mixture was heated at 80 °C at for 24h. The solvent was concentrated under reduced pressure and the resulting residue was purified by preparatory HPLC (0.1%TFA-H₂O/acetonitrile) to afford the desired product, 135.

LCMS RT = 2.5 (M+l) 433.4, (M-l) 431.6.

[00747] Other analogs that can be prepared in the same manner as 135:

140

141 [00748] (5)-l-(3-((2-(5-chloro-l//-py rrolo [2,3-b] pyridin-3-yl)-5-iluoropyrimidin-4ylamino)methyl)piperidin-l-yl)-3,3-dimethylbutan-2-one (140)

LCMS RT = 2.9 (M+l) 459.3, (M-l) 457.5.

[00749] (R)-3-((5)-3-((2-(5-chIor o-lfl-pyrrolo [2,3-b] pyridin-3-y 1)-5fluoropyrimidin-4-ylamino)methyl)piperidin-l-yl)-2-methylpropan-l-ol (141)

LCMS RT = 1.4 (M+l) 433.5.

139 137 [00750] (5)-2-(5-chloro-l/Z-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-/V-((l-(2~ methylb enzyl)p lperidin-3-yl)m ethyl)pyrimidin-4-amine (139)

LCMS RT = 3.2 (M+l) 465.3, (M-l) 463.4.

[00751] (5)-2-(5-chloro-lJT-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-A-((l-(3methy lb enzy I)piperid in-3-y I)m ethyl)py rimidin-4-amine (137)

LCMS RT = 3.1 (M+l) 465.4, (M-l) 463.6.

-231WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

134 133 [00752] (5)-2-(5-chIoro-l/f-pyrrolo[2,3-b]pyridin-3-yI>N-((l(cyclohexylmethyl)piperidin-3-yl)methyl)-5-fluoropyrimidin-4-amine (134)

LCMS RT = 3.1 (M+l) 457.3, (M-l) 455.5.

[00753] (5)-2-(3-((2-(5-chloro-lif-pyrroIo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methy])piperidin-l-yl)ethanol (133)

LCMS RT == 2.3 (M+l) 405.3, (M-l) 403.6.

132 138 [00754] (S)-2-(5-chloro-l/f-pyrrolo[2,3-b]pyridin-3-yl)-A^r-((l-(2,2dimethoxyethyl)piperidin-3-yl)methyl)-5-fluoropyrimidin-4-amine (132)

LCMS RT = 2.2 (M+l) 449.7.

[00755] (5,£)-methyl 4-(3-((2-(5-chloro-l//-pyrrolo[2,3-b]pyridm-3-yl)-5fluoropyrimidin-4-yJamino)methyl)piperidin-l-yl)but-2-enoate (138)

LCMS RT = 2.8 (M+l) 459.3, (M-l) 457.7.

666 [00756] (S)-4-(3-((2-(5-chloro-1//-pyrrolo[2,3-b]pyridin-3-yl)-5-nuoropyrimidin-4ylamino)methyl)piperidin-l-yl)butanenitrile (666)

LCMS RT = 2.6 (M+l) 428.3, (M-l) 426.5.

-232WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

667 124 [00757] (5)-3-(3-((2-(5-chloro-lJ7-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)propanenitrile (667)

LCMSRT = 1.4 (M+l) 414.5.

[00758] (jR)-2-(5-chloro-l/Z-pyrrolo[2,3-6]pyridin-3-yl)-5-fluoro-jV-((l-(pyrimidin-

2-yl)piperidin-3-yl)methyl)pyrimidin-4-amine (124)

LCMS RT = 3.1 (M+l) 439.3 (M-H) 437.4.

General Scheme 13

13f 13g 13h

(a) Benzyl chloroformate, triethylamine, CTI_;Cl₂; (b) dimethylsulfoxide, oxalyl chloride, triethylamine, Cl+Ch; (c) DAST, THF; (d) 10% Pd/C, MeOH, H,, di-tert-butyl dicarbonate (e) LiOH, THF/MeOH/Water; (f) Pyridine, di-tert-butyl dicarbonate, NH₄IICO₃₎ 1,4-Dioxane; (g) triethylamine, TFAA, CHjCl,; (h) Raney Ni, MeOH, H₃;

(i) 5-chloro-3-(5-fluoro-4-(melhylsulfinyl)pyrimidin-2-yl)-l-tosyl-17/-pyiTolo[2,3-b]pyridinc, 'PrjNEt, THF, microwave, 130 °C 15 min.; (j) NaOMe, MeOH (k) isoproponal/HCl, 45 °C; (1) 3-methoxy propanoyl chloride, 'Pr₂NEt, CH₂Ck, DMF.

[00759] (13b).

Formation of 1-benzyl 2-methyl 4-hydroxypiperidine-l,2-dicarboxylate

-233WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

To a cold (5 °C) solution of methyl 4-hydroxypiperidine-2-carboxylate, 13a, (5.17 g, 32.48 mmol) and triethylamine (6.00 mL, 43.05 mmol) in CH.2CI2 (135 mL) was added dropwise benzyl chloroformate (6.20 mL, 43.43 mmol) over 10 min. The resulting solution was stirred at 5 °C for 1 hour and then allowed to warm to room temperature. The reaction mixture was diluted with water and the layers were separated. The aqueous was re-extracted with CH2CI2 and the combined organics were dried over MgSO₄, filtered and evaporated to dryness. The crude was passed through a plug of silica gel, eluting with 30 - 80% EtOAc/Hexanes to afford the desired product, 13b.

Ή NMR (300 MHz, CDC1₃) δ 7.36 - 7.33 (m, 5H), 5.17 (s, 2H), 4.89 - 4.78 (m, 1H),

4.18 - 4.09 (m, 1H), 3.96 (s, 1H), 3.76 - 3.70 (m, 3H), 3.53 - 3.41 (m, 2H), 2.44 (s, 1H), 1.96 -1.91 (m, 1H) and 1.71 (s, 2H) ppm.

[00760] Formation of 1-benzyl 2-methyl 4-oxopiperidine-l,2-dicarb oxy late (13c).

To a 500 ml flask, flamed dry under N₂ was added CH₂C1₂ (65 mL) followed by oxalyl chloride (5.2 mL, 59.6 mmol). After cooling the reaction mixture to -78 °C, dimethyl sulfoxide (8.4 mL, 118.4 mmol) was added, followed by 1-benzyl 2-methyl 4hydroxypiperidine-l,2-dicarboxylate, 13b, (8.6 g, 29.2 mmol) in CH₂C1₂ (65 mL). The reaction was allowed to stir at -78 °C for 45 min. To the mixture was added triethylamine (24.4 mL, 175.1 mmol) and the mixture was allowed to warm to room temperature. The reaction mixture was diluted with CH₂C1₂ and IN HC1. The layers were separated and the aqueous phase was re-extracted with CH₂C12. The combined organic phases were washed with water, dried over MgSO₄, filtered and evaporated to dryness. The crude was purified by silica gel chromatography (30 -50% EtOAc/liexanes) to give the desired product, 13c.

Ή NMR (300 MHz, CDCh) 6 7.37 (s, 5H), 5.24 - 5.18 (m, 3H), 5.02 (s, 1H), 4.12 (q, J= 7.1 Hz, 1H), 3.74 - 3.65 (m, 3H), 2.79 (d, J= 7.0 Hz, 2H) and 2.53 (s, 2H) ppm.

[00761] Formation of 1-benzyl 2-methyl 4,4-difluoropiperidine-l,2-dicarboxylate (13d).

To a cold (0 °C) solution of 1-benzyl 2-methyl 4-oxopiperidine-l,2-dicarboxylate, 13c, (7.4 g, 25.4 mmol) in THF (75 mL) was added (diethylamino)sulfur trifluoride (25.0 mL, 189.2 mmol). After 2 hours at 0 °C, the reaction was quenched by the careful addition of water. The mixture was diluted with EtOAc and water. Solid NaHCOj was added to adjust the pH to neutral. The layers were separated and the organic was washed with water, brine, dried over MgSO₄, filtered and evaporated to dryness. The crude was passed through a plug of silica gel eluting with 15-20% EtOAc/hexanes to afford the desired product, 13d.

’H NMR (300 MHz, CDCh) δ 7.37 - 7.31 (m, 5H), 5.30 - 5.06 (m, 3H), 4.45 - 4.22 (m, 1H), 3.76 - 3.52 (m, 3H), 3.45 (d, 9.0 Hz, 1H), 2.76 (s, 1H) and 2.23 - 1.93 (m, 3H) ppm.

[00762] Formation of 1-terZ-butyl 2-methyl 4,4-difluoropiperidine-l,2dicarboxylate (13e).

To a PaiT flask (IL) was charged 10% palladium on carbon (0.57 g) and di-iert-butyl dicarbonate (4,47 g, 20.49 mmol). A solution of 1-benzyl 2-mcthyl-4,4-difluoropiperidine-

1,2-dicarboxylate, 13d, (4.28 g, 13.66 mmol) in methanol (150 mL) was added and hydrogen was introduced via parr shaker (46 PSI). The reaction mixture was shaken over weekend at room temperature. The mixture was filtered through Celite and washed throughly with CH₂C1₂. The filtrate was concentrated to dryness and redissolved in 10% EtOAc/hexanes. The crude was purified by silica gel chromatography (10-20% EtOAc/hexanes) to afford 5.1 g of a mixture of desired product, 13e, plus approximately 840 mg of contaminated product. The resulting crude mixture was used directly in next step without further purification.

-234WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 'H NMR (300 MHz, CDC1₃) δ 5.08 (s, IH), 4.89 (s, IH), 4.12 (q, 7= 7.2 Hz, IH), 3.76 (s, H), 3.74 (s, 3H), 3.34 (s, IH), 3.29 (t, 7= 7.2 Hz, IH), 2.77 (s, IH), 2.04 (m, IH) and

1.53 (s, 9H) ppm.

[00763] Formation of l-(tert-butoxycarbonyl)-4,4-difluoropiperidine-2-carboxylic acid (13f)

To a solution of 1-tert-butyl 2-methyI 4,4-difluoropiperidine-l,2-dicarboxylate, 13e, (4.6 g, 16.5 mmol) in THF (18 mL), methanol (18 mL) and H₂O (9 mL) was added lithium hydroxide (3.45 g, 82.22 mmol). The reaction mixture was stirred at room temperature for 1 hour. All volatiles were removed under reduced pressure. The residue was diluted with a slight amount of water and ether. The layers were separated and the organic phase was discarded. The aqueous phase was acidified to pH 3 with the addition of aqueous saturated KHSO4 solution. The product was extracted with EtOAc. The organic phase was washed with water, dried over MgSO₄, filtered and evaporated to dryness. The resulting product was used without further purification.

Ή NMR (300 MHz, CDClj) δ 5.14 (s, IH), 4.93 (s, IH), 4.12 (q, 7= 7.1 Hz, IH),

3.28 (d, 7= 6.3 Hz, IH), 2.75 (d, 7= 8.7 Hz, IH), 2.06 (d, 7= 8.5 Hz, IH), 1.99 -1.81 (m, IH) and 1.47 (s, 9H) ppm.

[00764] Formation of tert-butyl 2-carbamoyl-4_>4-difluoropiperidine-l-carboxylate (13g)

To a solution of l-zert-butoxycarbonyl-4,4-difluoiO-piperidine-2-carboxylic acid, 13f, (1.67 g, 6.30 mmol) in 1,4-dioxane (12 mL) was added pyridine (0.35 mL, 4.33 mmol), followed by di-tert-butyl dicarbonate (1.78 g, 8.17 mmol) and ammonium bicarbonate (0.63 g, 7.86 mmol). The reaction mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure and the residue was taken up in EtOAc. The organic phase was washed with water, aqueous saturated KHSO₄ solution, brine, dried over Na₂SO4, filtered and evaporated to dryness. The crude residue was used without further purification.

[00765] Formation of tert-butyl 2-cyano-4,4-difluoropiperidine-l-carboxylate (13h)

To a solution of tert-butyl 2-carbamoyl-4,4-difluoro-piperidine-l-carboxylate, 13g, (1.72 g, 6.51 mmol) in CH₂C1₂ (50 mL) was added was Λ/Λ'-triethylamine (2.03 mL, 14.61 mmol) followed by the dropwise addition of (2,2,2-trifluoiOacetyl)-2,2,2-trifluoroacctate (1.02 mL, 7.32 mmol). After 15 minutes, the mixture was diluted with aqueous saturated NaHCO₃ solution and the layers were separated. The organic phase was washed with water, dried over Na₂SO₄, filtered and evaporated to dryness. The crude residue was passed through a plug of silica gel and eluted with 10 - 30%EtOAc/hexanes to afford the desired product, 13h.

*H NMR (300 MHz, CDC1₃) δ 5.43 (s, IH), 4.19 (s, IH), 3.25 (s, IH), 2.36 (m, IH),

2.23 - 2.12 (m, IH), 1.83 (s, IH), 1.70 (s, IH) and 1.53 - 1.46 (m, 9H) ppm.

[00766] Formation of tert-butyl 2-(aminomethyl)-4,4-difluoropiperidine-lcarboxylate (13i)

Raney nickel (0.36 mL, 5.40 mmol) was washed with MeOH (2X) and charged into a parr shaker. A solution of tert-butyl 2-cyano-4,4-difluoro-piperidine-l -carboxylate, 13h, (1.33 g, 5.40 mmol) in methanol (50 mL). The reaction mixture was subject to hydrogenation conditions overnight on the parr shaker (46PSI). The mixture was filtered through celite and washed throughly with CH₂C1₂. All volatiles were removed at reduced pressure and the crude material was used without further purification.

-235WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00767] Formation of tert-butyl 2-((2-(5-chloro-l-tosyl-l/Z-pyrrolo[2,3-b]pyridin-

3-yl)-5-fluoropyrimidin-4-ylamino)methyl)-4,4-difluoropiperidine-l-carboxylate (13j)

To a solution of tert-butyl 2-(aminomethyl)-4,4-difluoro-piperidine-l-carboxylate, 13i, (0.10 g, 0.41 mmol) and 5-chloro-3-(5-fluoro-4-methylsulfmyl-pyrimidin-2-y 1)-1 -(ptolylsulfonyl)pyrrolo[2,3-b]pyridine (0.18 g, 0.38 mmol) in THF (2 mL) was added 'PrjNEt (0.20 mL, 1.15 mmol). The reaction mixture was heated in microwave at 130 °C for 15 minutes. The reaction was cooled to room temperature and the volatiles were removed under reduced pressure. The crude residue was purified via silica gel chromatography (0-100% EtOAc/hexanes) to afford the desired product, 13j.

LCMS (M-l) 649.52.

|00768] Formation of tert-butyl 2-((2-(5-ch!oro-l//-pyrroIo [2,3-b |pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)-4,4-difluoropiperidine-l-carboxylate (13k).

To a solution of zerz-butyl 2-[[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3yl]-5-fluoro-pyrimidin-4-yl]amino]methyl]-4,4-difluoro-piperidine-l-carboxylate, 13j, (0.23 g, 0.35 mmol) in methanol (4 mL) was added sodium methanolate (4 mL of 25 %w/v, 18.51 mmol). The reaction mixture was allowed to stir at room temperature for 15 minutes. All volatiles were removed at reduced pressure and the residue was quenched with water. EtOAc was added and the layers were separated. The organic phase was washed with brine, dried (MgSO₄), filtered and evaporated to dryness. The crude residue was pure enough to be used without further purification.

LCMS (M+l) 497.44, (M-l) 495.52.

[00769] Formation of 2-(5-chloro-lH-pyrrolo[2,3-bJpyridin-3-yl)-A'-((4,4difluoropiperidin-2-yl)methyl)-5-fluoropyrimidin-4-amine (13m)

To a solution of Zert-butyl 2-((2-(5-chloiO-17f-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)-4,4-difluoiOpiperidine-l-carboxylate, 13k, (0.09 g, 0.18 mmol) in 2-propanol (2 mL) was added propan-2-ol hydrochloride (2 mL of 6 M, 12.00 mmol). After stirring the reaction mixture at room temperature for 17 hours, an additional 1 mL of IPA/HC1 was added and the reaction mixture was heated at 45 °C for 1 hour. All volatiles were removed at reduced pressure and the residue was used directly in the next step without further purification.

LCMS (M+l) 397.40, (M-l) 395.44.

[00770] Formation of l-(2-((2-(5-chloro-liT-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)-4,4-difluoropiperidin-l-yl)-3-methoxypropan-l-one (584)

To a solution of 2-(5-chloiO-l/Z-pynOlo[2,3-b]pyridin-3-yl)-A-[(4,4-difluoro-2pipcridyl)methyl]-5-fluoro-pyrimidin-4-amine, 13k, (0.086 g, 0.198 mmol) in CH2CI2 (1 mL), DMF (0.5 mL) and ‘PrzNEt (0.10 mL, 0.57 mmol) was added 3-methoxypropanoyl chloride (2.43 g, 0.20 mmol). The reaction mixture was stirred at room temperature for 17 hours. All volatiles were removed at reduced pressure and the residue was purified via silica gel chromatography to give a mixture enriched in desired product, 13, which was repurified via preparatory HPLC.

’H NMR (300 MHz, 76-DMSO) 8 12.45 (m, 1H), 8.71 (d, 7= 8.5 Hz, 1H), 8.31 (m, 2H), 8.01 (m, 1H), 5.33 (s, IH), 4.62 - 4.43 (m, 2H), 4.39 - 3.72 (m, 5H), 3.68 (s, 2H), 3.43 -

3.40 (m, IH), 3.15 (s, IH), 3.07 (s, IH), 2.33 (s, 2H) and 2.08 (s, 2H) ppm: LCMS (M+l)

483.44, (M-l) 481.52.

[00771] Other analogs that may be prepared in the same manner as 584 are described

-236WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 below:

[00772] V-((4-benzylm orp h olin-2-yl)m ethy l)-2-(5-ch lo ro-1 //-py r rolo [2,3 b] pyridin-3-yl)-5-fluoropyrimidin-4-amine (388).

Ή NMR ¢300 MHz, CDCfi) δ 9.14 - 9.09 (m, 1H), 8.81 - 8.71 (m, 1H), 8.29 (d, J=

2.3 Hz, 1H), 8.07 (d, 7= 2.5 Hz, 1H), 7.34 (s, 5H), 5.58 - 5.41 (m, 1H), 3.92 - 3.43 (m, 4H), 2.83 - 2.72 (m, 2H), 2.38 - 2.28 (m, 2H) and 1.62 (m, 2H) ppm.

LCMS RT = 1.8 (M+l) 453.4.

[00773] 2-((2-(5-chloro-ljH-pyrrolo[2,3-b]pyridin“3-yl)-5-fluoropyi*imidin-4ylamino)methyl)-7V-isopropylmorpholine-4-carboxamide (446).

LCMS RT = 1.7 (M+l) 448.4

[00774] Isopropyl 2-((2-(5-chloro-117-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)niorpholine-4-carboxylate (447).

LCMS RT = 2.0 (M+l) 449.3

[00775] 2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-N-((4(isopropylsulfonyl)morpholin-2-yl)methyl)pyrimidin-4-ainine (448).

LCMS RT = 1.9 (M+l) 469.3

-237WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00776] l-(2-((2-(5-chloro-lZ7-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4yla mino)methyl)mo rpholino)p r opan-l-one (449).

LCMS RT = 1.7 (M+l) 419.4

[00777] (2-((2-(5-chloro-Lff-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)morpholino)(cyclopropyl)methanone (450).

LCMS RT = 1.7 (M+l) 431.4

[00778] teit-Butyl3-((2-(5-chloro-l£f-pyrrolo[2,3-b]pyridin-3“yl)-5fluoropyrimidin-4-ylamino)methyl)morpholine-4-carboxylate (515).

'H NMR (300 MHz, CDCh) 5 10.38 (s, IH), 8.81 (d, J = 2.0 Hz, IH), 8.49 (d, J = 2.3 Hz, IH), 8.38 (s, IH), 8.08 (d, J= 3.4 Hz, IH), 6.11 (d, J= 5.0 Hz, IH), 4.44 (d, J= 9.4 Hz, IH), 4.02 - 3.62 (m, 6H), 3.55 (dd, 7=2.4, 12.1 Hz, IH), 3.35 - 3.27 (m, IH) and 1.40 - 1.22 (m, 9H) ppm.

LCMS RT = 2.5 (M+l) 463.5.

[00779] l-(3-((2-(5-chloro-lZf-pyrrolo[2,3-b]pyridin-3-yl)-5-flu0ropyrimidin-4ylamino)methyl)morpholino)propan-l-one (516).

LCMS RT = 1.9 (M+l) 419.4

-238WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00780J 3-((2-(5-chloro-117-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)-A^r-propylmorpholine-4-carboxamide (517).

Ή NMR ¢300 MHz, t/6-DMSO) δ 12.54 (s, 1H), 8.76 (d, 7 = 2.0 Hz, 1H), 8.46 (s, 1H), 8.32 (d, 7= 2.1 Hz, 1H), 8.26 (d, 7= 3.9 Hz, 1H), 8.08 (d, 7= 7.5 Hz, 1H), 6.30 (s, 1H),

4.28 (s, 1H), 3.93 - 3.74 (m, 3H), 3.51 - 3.47 (m, 2H), 3.39 - 3.20 (m, 2H), 2.95 (dd, 7= 6.2, 13.1 Hz, 3H), 1.35 - 1.25 (m, 2H) and 0.76 (t, 7= 7.3 Hz, 3H) ppm.

LCMS RT = 2.3 (M+l) 448.54.

[00781] Methyl 3 -((2-(5-chloro- 177-pyr r olo [2,3-b] pyridi n-3-yl)-5-fluoropyrimidin-

4-yIamino)methyl)morpholine-4-carboxylate (526),

LCMS RT = 2.4 (M+l) 421.0.

H 527 [00782] Ethyl 3-((2-(5-chlorO”Lff-pyrrolo[2,3-b]pyridin-3-yl)-5-fliioropyrimidin-4ylamino)methyl)morpholine-4-carboxylate (527).

LCMS RT = 2.5 (M+l) 435.1.

[00783] Allyl 3-((2-(5-chloro-lif-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrjmidin-4yIamino)methyl)morpholine-4-carboxylate (528).

LCMS RT = 2.6 (M+l) 447.1.

-239WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00784] l-(3-((2-(5-cbloro-l/L-pyrrolo|2,3-b]pyridin-3-yl)-5-fluoropyriniidin-4ylamino)methyl)morpholino)-2-methylpropan-l-one ¢529).

LCMS RT= 2.5 (M+l) 433.1.

[00785] l-(3-((2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yI)-5-fluoropyrirnidin-4ylamino)methyl)morpholino)-2,2-dimethylpropan-l-one (530).

LCMS RT= 1.9 (M+l) 447.1.

[00786] (3-((2-(5-chloro-ljH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyriniidin-4ylamino)methyl)morpholino)(cyclobutyl)methanone (531).

LCMS RT - 2.6 (M+l) 445.1.

[00787] 2-(5-chloro-lif--pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-/V-((4(methyIsulfonyl)morpholin-3-yl)methyl)pyrimidin“4-aniine (532).

LCMS RT = 2.4 (M+l) 441.0.

-240WO 2010/148197

PCT/US2010/038988

Η [00788] 2-(5-cldoro-l//-pyrrolo[2,3-b]pyridin-3-yl)-/V-((4(cyclopropylsulfonyl)morpholin-3-yl)methyl)-5-fluoropyrimidin-4-ainine (533).

LCMS RT = 2.4 (M+l) 467.0.

100789 ] 3-((2-(5-chloro- l//-pyr r olo 12,3 -b ]pyridin-3-y l)-5-fluoropy rimidin-4ylamino)methyl)morpholine-4-carboxamide (534).

LCMS RT = 2.0 (M+l) 406.0.

[00790] 3-((2-(5-chloro-l //-pyrrolo [2,3-b] pyridin-3-yl)-5-fluoropyrimidiii-4ylamino)niethyl)--V-ethylmorpholine-4-carboxamide (535).

LCMS RT = 2.2 (M+l) 434.1.

[00791] 3-((2-(5-chloro-ll?-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyriinidin-4yIamino)metliyl)“?V“isopropylmorpholine-4-carboxamide (536).

LCMS RT = 2.3 (M+l) 448.1.

-241WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

161 [00792] (R)-2-fluoroethyl 2-((2-(5-chlor o-l jff-py rrolo [2,3-b ]py rid in-3-yl)-5fluoropy rimid in-4-ylamino)methyl)pip eridine-l-ca rb oxy late (180).

LCMS RT = 2.1 (M+l) 451.4.

[00793] (5)-2-m ethoxy ethyl 2-((2-(5-chloro-lJ?-pyrrolo[2,3“b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)piperidine-l-carboxylate (161).

LCMS RT = 2.8 (M+l) 463.4.

[00794] (S)-2-chloroethyl2-((2-(5-chloro-llZ-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropy rimidin-4-yla mino)methyl)p iperidine-l-ca rb oxy late (163).

LCMS RT = 3.1 (M+l) 467.4.

[00795] (S)-prop-2-ynyl 2-((2-(5-ehloro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5fluor opyr imidin-4-yla mino)ni ethyl)pip eridine-l-carboxy late (164).

LCMS RT = 3.0 (M+l) 443.5.

[00796] (S)-(2-((2-(5-chloro-lff-pyrrolo[2,3-b]pyridin-3-yl)“5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yI)(thiazoI-2-yI)methanone (165).

LCMS RT = 2.8 (M+l) 472.5.

[00797] (S)-(2-((2-(5-chlorO“Lff-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)(3-methoxyphenyl)methanone (174).

LCMS RT = 2.8 (M+l) 495.6.

-242WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00798] (y)-nietliyI2-((2-(5-chloro-17/-pyrrolo|2,3-A]pyridin-3-yI)-5fluoropyrimidin-4-ylamino)methyI)piperidine-l-carboxylate (166).

LCMS RT = 2.9 (M+l) 419.5.

[00799] (R)-l-(2-((2-(5-chloro-I//-pyrrolo[2,3“/>]pyridin-3-yl)-5-fluoropyrimidin4-yla mino)m ethyl)piperi din-l-yl)ethanone (179).

LCMS RT = 2.5 (M+l) 403.4.

[00800] (SJ-ethyl 2-((2-(5-chloro-17f-pyrrolo[2,3-h]pyridin-3-yl)-5fliioropyrimidin-4-ylamino)niethyl)piperidine“l-carboxylate (171).

LCMS RT = 3.0 (M+l) 433.3.

[00801] (7i’)-(2-((2-(5-chloro-l//-pyrroIo|2,3-/?]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)(3-methoxyphenyl)methanone (184).

LCMS RT = 2.7 (M+l) 495.5.

208 190 [00802] (Λ)-1 -(2-((2-(5-chloro-l//-py rrolo [2,3-Λ] py rid in-3-yl)-5-fluoropy rimidin4-ylaniino)inethyl)pip eridm-l-yl)propan-l -o ne (208).

LCMS RT == 1.9 (M+l) 417.2.

[00803] (Ji)-(2-((2-(5-chloro-l^r-pyrrolo[2,3-i]pyridin“3-yl)-5-fluoropyrimidin-4ylamino)methyl)piperidin-l-yl)(2-methoxyphenyl)methanone (190).

LCMS RT = 2.9 (M+l) 495.4.

-243WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00804] (_JB)-(2-((2-(5-chloro-lf?'-pyrrQlo[2,3-Z>]pyridin-3“yl)-5-fluoropyrimidiii~4ylamino)methyI)piperidinL-l-yl)(4-fluoroplienyI)niethanone (209).

LCMS RT = 2.0 (M+l) 483.1.

[00805] (A)-(2-((2-(5-chloro-l/7-pyrrolo[2,3-/>][)yridin-3-yl)-5-fluoropyriinidin-4ylamino)methyl)piperidin-l-yl)(3-(trifluoromethyl)phenyl)methanone (210).

LCMS RT = 2.2 (M+l) 533.1.

[00806] (7f)-4-chloro-l-(2-((2-(5-ch[oro-l/f-pynOio[2.3-/>]pyridin-3-yI)-5fluoropyrimidin-4-ylamino)methyl)piperidin-l-yl)butan-l-one (278).

LCMS RT = 2.4 (M+l) 465.1.

[00807] (/?)-!-(2-((2-(5-chloro-l/l-pyrrolo|2,3-/4pyridin-3-yl)-5-lJuoropyrimidin4-yIannno)methyl)piperidin-l-yI)pent-4-en-l-one (279).

LCMS RT = 2.1 (M+l) 443.2.

[00808] (R)-l-(2-((2-(5-chloro-lH-pyrrolo[2,3-Z>]pyridin-3-yl)-5-fluoropyrimidin4-ylamino)methyl)piperidin-l-yl)-3,3,3-ti'ifluoropropan-l-one (280).

LCMS RT = 2.1 (M+l) 471.2.

[00809] (2t)-l-(2“((2-(5-chloro-l//-pyrrolo[2_!3-6]pyridin-3-yl)-5-fluoropyrimidin4-ylamino)methyl)piperidin-l-yl)hex-5-yn-l-one (281).

LCMS (M+l) 454.2.

-244WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

293 294 [00810] (R)-1 -(2-((2-(5-chloro-l //-pyrrolo [2,3-6]py rid in-3-yl)-5-fluor opy rimidin4-ylamino)methyl)piperidin-l-yl)-3-phenylpropan-l-one (293).

LCMS RT = 3.1 (M+l) 493.2.

[00811] (ff )-1 -(2-((2-(5-chlor o-lrt-py rrolo [2,3-6] py ridin-3-y l)-5-fluoropy rimidin4-ylamino)methyl)piperidin-l-yl)-2-cyclohexylethanone (294).

LCMS RT = 3.3 (M+l) 485.2.

295 326 [00812] (R)-l-(2-((2-(5-chloro-l£f-py rrolo [2,3-6] pyridin-3-y l)-5-fluor opy rimidin4-ylamino)methyl)piperidin-l-yI)butan-l-one (295).

LCMS RT = 2.9 (M+l) 431.2.

[00813] (R)-l-(2-((2-(5-chloro-l#-py rrolo [2,3-6] pyridin-3-y l)-5-fluor opy rimidin4-ylamino)methyl)piperidin-l-yI)pentan-l-one (326).

LCMS RT = 3.0 (M+l) 445.2.

256 257 [00814] (0)-l-(2-((5-fluoro-2-(ljH-pyrrolo[2,3-6]pyridin-3-yl)pyrimidin-4ylamino)methyl)piperid in-1 -yl) ethan one (256).

LCMS RT = 2.2 (M+l) 369.3.

[00815] (5)-l-(2-((5-fluoro-2-(117-pyrrolo[2,3-6]pyridin-3-yl)pyriniidin-4ylamino)methyl)piperidin-l-yl)propan-l-one (257).

LCMS RT = 2.3(M+l) 383.3.

-245WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

259 [00816] (5)-l-(2-((5-fluoro-2-(ljFf-pyrrolo [2,3-6] pyridin-3-yl)pyrimidin-4 ylammo)methyl)piperidm-l-yl)butan-l-one (258).

LCMS RT = 2.5(M+1) 397.3.

[00817] (5)-(2-((5-fluoro-2-(l£r-pyrrolo[2,3-6]pyridm-3-yl)pyrimidin-4ylaimno)methyl)piperidin-l-yl)(phenyl)methanone (259).

LCMS RT = 2.4 (M+l) 431.3.

[00818] (S)-(2-((5-fluoro-2-(Lff-pyrr()lo[2,3-6]pyridiii“3-yl)pyrimidin-4ylamino)methyl)piperidin-l-yl)(2-methoxyphenyl)methanone (260).

LCMS RT = 2.4 (M+l) 461.3.

[00819] (/?)-2-(5-chloro-lff-pyrroIo[2,3-b]pyridin-3-yl)-5-fluoro-/V-((l(methylsuIfonyl)-piperidin-2-yl)methyl)pyrimidm-4-amine (381).

LCMS RT = 2.7 min, (M+H) 439.3 [00820] (jR)-2-(5-chloro-12/-pyrrolo[2,3-b|pyridin-3-yl)-5-fluoro-lV-((l(ethylsulfonyl)-piperidin-2-yl)methyl)pyriniidin-4-amine (382).

LCMS RT = 2.9 min, (M+H) 453.3.

-246WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00821] (ff )-2-(5-chloro-l.ff-pyrrolo [2,3-6] pyridin-3-yl)-5-fluoro-jV-((l(propylsuIfonyl)piperidin-2-yl)methyl)pyrimidin-4-amine (328).

LCMS RT = 2.2 min, (M+H) 467.1.

[00822] (R)-2-(5-chloro-l_JEr-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-/V-((l-(2,2,2trifluoro-ethylsulfonyl)-piperidin-2-yl)methyl)pyrimidin-4-amine (383).

LCMS RT = 3.0 min, (M+H) 507.3.

[00823] (5)-2-(5-chIoro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5-fIuoro-/V-((l(methy lsulfonyl)-p ip eridin-2-yl)m ethyl)py r imidin-4-am in e (384).

LCMS RT = 2.7 min, (M+H) 439.3.

[00824] CR)-7V-((l-(butylsulfonyl)piperidin-2-yl)methyl)-2-(5-chloro-l/Zpytrolo [2,3-6]pyridin-3-yl)-5-fluoropyrimidin-4-amine (329).

LCMS RT = 2.3 min, (M+H) 481.2.

[00825] (5)-2-(5-chloro-117-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-V-((l(cyclopropylsulfonyl)-piperidin-2-yl)methyl)pyrimidin-4-amine (386).

LCMS RT = 2.9 min, (M+H) 465.3.

[00826] (7?)-2-(5-chIoro-1//-pyrroIo[2,3-6]pyrjdin-3-yl)-A'-((l-(3chloropropylsulfonyl)piperidin-2-yl)methyl)-5-fluoropyrimidin-4-aniine (330).

LCMS RT = 2.2 min, (M+H) 501.1.

371

[00827] (ff)-2-((5-fhior o-2-( IH-py r rolo [2,3-b ] pyr id in-3-yl)py rimidin-4ylamino)methyI)-/V-isopropylpiperidine-l-carboxamide (371).

LCMS RT = 1.8 min, (M+H) 412.2.

[00828] 6R)/V-cyclopropyl-2-((5-fluoro-2-(lff-pyrrolo[2,3-b]pyridin-3yl)pyrimidin-4-ylamino)-methyl)piperidine-l-carboxamide (372).

-247WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

LCMS RT = 1.9 min, (M+H) 424.2.

[00829] (Ji)-A'-etliyl-2-((5-fluoro-2-(l//-pyrrolo[2,3-b|pyridin-3-yl)pyrimidin-4ylamino)-methyl)piperidine-l-carboxamide (373).

LCMS RT = 1.7 min, (M+H) 398.2.

[00830] (/C)-2-((5-fluoro-2-(]//-pyrrolo[2,3-b]pyridin-3-yI)pyrimidin-4ylamino)methyl)-N-methylpiperidine-l-carboxaniide (374).

LCMS RT = 1.6 min, (M+H) 384.2.

375 [00831] (K)-2-((5-fluoro-2-(lH-pyrrolo[2,3-b]pyridin-3-yl)pyriniidin-4ylamino)methyl)-N-propylpiperidine-l-carboxamide (375).

LCMS RT = 1.8 min, (M+H) 412.2.

General Scheme 14

Cl

F

(a)'Pr₂NEt, isopropanol, 80 °C (b) 5-chloro-3-(4,4,5₁5-tetramethyl-1,3_l2-dioxaborolan-2-yl)-1-tosyl-1Hpyrroloi2,3-b]pyridine, Pd(Ph₃P)₄, Na₂CO₃, DME, 130 °C (c) HCI/dioxane, CH₂CI₂ (d) propyirsocyanate, pyridine, CH₂Ci₂ [00832] Formation of l-((2-chloro-5-fluoropyrimidin-4-248WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 ylamino)methyl)cyclohexanol (14a).

To a solution of 2-(aminomethyl)cyclohexanol hydrochloride (0.09 g, 0.54 mmol) and

2,4-dichloro-5-fluoro-pyrimidine (0.10 g, 0.60 mmol) in isopropanol (2 mL) was added 'PrjNEt (0.21 mL, 1.20 mmol). The reaction mixture was heated at 80 °C for 12 hours. The reaction mixture was was concentrated under reduced pressure and the resulting residue was purified by silica gel chromatography (25%-75% EtOAc/hexancs) to afford desired product, 14a.

LCMS (M+l) 260.1, (M-l) 258.3.

[00833] Formation of 2-((2-(5-chloro-l“tosyl-i//-pyrrolo[2,3-b|pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)cyclohexanol (14b)

To a degassed solution of 5-chloro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine (0.15 g, 0.35 mmol), l-((2-chloro-5fluoropyrimidin-4-ylamino)methyl)cyclohexanol, 14a, (0.09 g, 0.35 mmol) and aqueous KOAc solution (1.04 mL of IM solution, 1.04 mmol) in dimethylacetamide was added palladium triphenylphosphine (0.04 g, 0.03 mmol). The reaction mixture was heated at 140 °C in microwave for 15 min and then cooled to room temperature. The reaction mixture was filtered through celite, concentrated in vacuo, and the resulting crude residue was purified by by preparatory HPLC (0. l%TFA-H₂O/acetonitri!e) to afford the desired product, 14b: LCMS RT = 2.6 (M+l) 530.3.

[00834] Formation of (2R)-2-((2-(5-chloro-lff-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-yIamino)methyl)cyclohexanol (12)

To a solution of 2-((2-(5-chloiO-l-tosyl-l/7'-pyrrolo[2,3-/2]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)cyclohexanol, 14b, (0.10 g, 0.19 mmol) in THF (3 mL) was added aqueous lithium hydroxide (1 mL of IN solution). The reaction mixture was stirred at room temperature for 12 hours. The resulting residue was purified by preparatoiy HPLC (0.1%TFA-H₂O/acetonitrile) to afford the desired product, 12.

LCMS FIA RT = 1.9 (M+l) 376.2.

[00835] 2-(2-(5-chloro-l£T-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidm-4ylamino)cyclohexanol (13)

-249WO 2010/148197

PCT/US2010/038988

LCMS FIA RT = 1.8 (M+l) 362.2.

[00836] 2-(2-(5-chloro-ljff'pyrrolo[2,3-Z»]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)cyclopentanol (14)

LCMS FIA RT = 1.0 (M+l) 348.3.

657 [00837] (12?, 2S, 32?, 5/?)-3-(2-(5-chloro-177-pyrrolo[2,3-0]pyridin-3-yl)-5fluoropyrimidin-4-yIamino)-5-(hydroxymethyl)cyclopentane-I,2-diol (657) 'H NMR (300 MHz, DMSO) δ 12.41 (s, 1H), 8.80 (d, J= 2.3 Hz, 1H), 8.28 (d, J=

2.4 Hz, 1H), 8.25 (s, 1H), 8.17 (d, J= 4.0 Hz, 1H), 7.64 (s, 1H), 4.80 - 4.50 (m, 3H), 4.47 (dd, J= 7.5, 14.8 Hz, 1H), 3.89 (dd, ,Z= 5.3, 6.3 Hz, 1H), 3.77 (dd, .7= 5.1, 5.0 Hz, 1H), 3.50 -3.37(m, 2H), 2.36-2.24 (m, 1H), 2.04 (dd, J= 8.3, 13.5 Hz, 1H), 1.99 (s, 1H), 1.27 (td, J=

8.4, 4.4 Hz, 1H) and 1.21 (s, 1H) ppm.

LCMS RT = 3.0 (M+l) 399.4.

(a) Raney-ΝΪ, H_a (50 PSI), EtOH (b) 15a, THF, 70 °C (c) TFA, CH₂CI₂ (d) 1N LiOH, THF, 120°C [00838] Formation of tert-butyl te«/is-2-(aminomethyi)cyclohexylcarbamate (14d)

A solution of tert-butyl i/w?.s'-2-cyanocyclohexylcarbamate and Raney-Ni in absolute EtOH was stirred under H₂ atmosphere (50 PSI) for 24 hours. Filtration and evaporation of the solvent followed by flash chromatography (SiO₂, 0-20% MeOH-CH₂Cl₂, gradient elution)

-250WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 provided the target compound, 14d, as a racemic mixture of trans isomers (286 mg, 66% yield): FIA (M+H) 229,33.

[00839] Formation of tert-butyl te«/zs'-2-((2-(5-chloro-l-tosyl-li7-pyrrolo[2,3Z>]pyridin-3-yl)-5-fluoro-pyrimidin-4-yI-amino)methyl)cyclohexylcarbamate (14e)

A mixture of 5-chloro-3-(5-fluoro-4-(mcthylsulfinyl)pyrimidiri-2-yl)-l-tosyl-lApyrrolo[2,3-0]pyridine, 15a, (0.42 g, 0.90 mmol) and tert-butyl trans-2-(aminomethyl) cyclohexylcarbamate (0.24 g, 1.06 mmol) were heated in THF (10 mL) to 70 °C. After 1.3 hours, the mixture was concentrated in vacuo. Flash chromatography (SiO₂, 0-60% EA/Hex, gradient elution) provided the desired intermediate, tert-butyl teaws-2-((2-(5-chloro-l-tosyl177-pyrrolo[2,3-ti]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)methyl)cyclohexylcarbamate, 14e, as a racemic mixture of trans isomers, which was taken into the next reaction without further purification (0.52g, 92% yield).

[00840] Formation of A-((/rau.v-2-aminocyclohexyI)methyl)-2-(5-chloro-l-tosyllF/-pyrrolo[2,3-£>]pyridin-3-yl)-5-fluoropyrimidin-4-amine (14f)

A solution of the tert-butyl zraHS-2-((2-(5-chloiO-l-tosyl-l/f-pyrrolo[2,3-/?]pyridin-3yl)-5-fluoropyrimidin-4-ylamino)methyl)cyclohexylcarbamate, 14e, (0.52g) in CH₂C1₂ (5mL) was treated with TFA (2.5 mL) for 30 min. the solution was concentrated in vacuo and the resulting crude material was taken up in CH₃CN and concentrated in vacuo several times to remove excess TFA and to provide the desired amine, 14f, as racemic mixture of trans isomers, as the TFA salt, which was sufficiently pure for use in the next reaction.

LCMS RT = 1.93 min, (M+H) 529.0

Cl

(+/-) [00841] Formation of /V-((teens-2-aminocyclohexyl)methyl)-2-(5-chloro-117pyrrolo [2,3 -b ]pyridin-3 -yl)-5-fluoropyrimidin-4-amine (555)

A solution of iV-((/raws-2-aminocyclohexyl)methyl)-2-(5-cliloro-1 -tosyl-1Hpyrrolo[2,3-Z>]pyridin-3-yl)-5-fluoropyrimidm-4-amine, 14f, (0.050g, 0.077 mmol) in THF was treated with LiOH (0.5 mL, 1.0M) at 60 °C. After 5 min, at 120 °C, the solution was diluted with EtOAc, and washed with brine, filtered and concentrated in vacuo. Preparative HPLC provided the desired compound, 555, as a racemic mixture of trans isomers (12 mg, 33% yield).

Ή NMR (300 MHz, MeOD) 6 8.75 (d, J= 2.4 Hz, 1H), 8.31 (d, J= 2.4 Hz, 1H), 8.29 (s, 1H), 8.24 (d, 7= 4.4 Hz, 1H), 3.96 (dd, J= 5.8, 14.4 Hz, 1H), 3.73 (dd, 7= 4.3, 14.3 Hz, 1H), 3.08 - 3.00 (m, 1H), 2.05 - 1.87 (m, 3H), 1.80 (m, 3H) and 1.48 - 1.39 (m, 4H) ppm; LCMS RT = 1.9 min, (M+H) 375.0.

General Scheme 14C

-251WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

(a) i: RCOCI, DIEA, CH_ZCI₂ ii: 1N LiOH, THF, 120°C.

[00842] Formation of A-(tr«;is-2-((2-(5-chloro-l/7--pyrrolo|2,3-/?|pyridin-3-yl)-5fluoropyrimidin-4-ylamino)methyl)cyclohexyl)-2-methoxyethanamide (556)

To a cooled mixture of .y-((iraMS-2-aminocyclohexyl)methyl)-2-(5-chloro-1-tosyl-1/7pyrrolo[2,3-Z?]pyridin-3-yl)-5-fluoropyrimidin-4-amine (0.060 g, 0.093 mmol) and ‘Pr₂NEt (0.057 mL, 0.330 mmol) in CH₂C1₂ (2mL) at 0 °C, was added 2-methoxyacetyl chloride (0.010 g, 0.098 mmol). After 5 min, the solution was allowed to warm to room temperature. After 3 hours, the mixture was concentrated in vacuo, taken up in THF (1 mL) and treated with LiOH (0.326 mL, 1.0 M solution) at 120 °C for 10 min. The resulting mixture was cooled to room temperature and partitioned and the aqueous layer extracted with EtOAc and the combined organics were concentrated in vacuo. Preparative HPLC provided the desired product, 556, as a racemic mixture of TFA salts (8.6 mg, 17% yield).

'H NMR (300 MHz, MeOD) δ 8.74 (d, J= 2.3 Hz, 1H), 8.42 (s, 1H), 8.38 (d, 7= 2.3 Hz, 1H), 8.27 (d, 7= 5.4 Hz, 1H), 3.85 - 3.81 (m, 2H), 3.75 (d, 7= 8.5 Hz, 2H), 3.26 (s, 3H),

1.97 - 1.77 (m, 5H) and 1.43 - 1.35 (m, 4H) ppm; LCMS RT = 2.8 min, (M+H) 446.8.

[00843] The following analogs can be prepared in same manner as 556.

[00844] Formation of 7V-(ifans-2-((2-(5-chloro-t7Z-pyrrolo[2,3-6]pyridin-3-yl)-5fhioropyrimidin-4-ylamino)methyl)cycIohexyl)niethanesulfonaimde (557)

Sulfonamide 557 was prepared according to the procedure for compound 36 (Scheme 12B) usingA'^r-((irani-2-aminocycloliexyl)methyl)-2-(5-chloro-l-tosyl-177-pyrrolo[2,3Z?]pyndin-3-yl)-5-fluoropyri mi din-4- amine, 14f, and methane sulfonyl chloride, afforded desired product, 557, as a racemic mixture of trans isomers.

*H NMR (300.0 MHz, MeOD) δ 8.78 (d, 7= 2.4 Hz, 1H), 8.45 (d, 7= 4.2 Hz, 1H),

8.37 (d, 7= 2.3 Hz, 1H), 8.26 (d, 7= 5.4 Hz, 1H), 4.12 (dd, 7= 4.5, 13.7 Hz, 1H), 3.89 (dd, J = ΊΛ, 13.8 Hz, 1H), 3.26 - 3.16 (m, 1H), 3.00 (s, 3H), 2.18 - 1.90 (m, 2H), 1.79 - 1.74 (m, 2H) and 1.50 - 1.25 (m, 4H) ppm; LCMS RT = 2.8 min, (M+H) 452.6.

[00845] Formation of 3-(/rans-2-((2~(5~chloro-177-pyrrolo[2,3-6]pyridin-3-y 1)-5fluoropyrimidin-4-ylamino)methyl)cyclohexyl)-l,l-dimethyIurea (564)

Urea 564 was prepared according to the procedure for compound 20 (Scheme 12A) using JV-((rraws-2-aminocyclohexyl)methyl)-2-(5-chIoro-l-tosyl-177-pyrrolo[2,3-/;]pyridin-3-252WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 yl)-5-fluoropyrimidin-4-amine, 14f, and dimethylcarbomoyl chloride, afforded desired product, 564, as a racemic mixture of trans isomers.

'H NMR (300.0 MHz, MeOD) δ 8.78 (d, 7= 2.4 Hz, 1H), 8.45 (d, 7= 4.2 Hz, 1H),

8.37 (d, 7 = 2.3 Hz, 1H), 8.26 (d, 7= 5.4 Hz, 1H), 4.12 (dd, 7= 4.5, 13.7 Hz, IH), 3.89 (dd, J = 7.1, 13.8 Hz, IH), 3.26 - 3.16 (m, IH), 3.00 (s, 3H), 2.18 - 1.90 (m, 2H), 1.79 - 1.74 (m, 2H) and 1.50 - 1.25 (m, 4H) ppm; LCMS RT = 1.9 min, (M+H) 445.7.

General Scheme 15

Ί 5a 15b 433 (a) (1S,2S)-cyclohexane-1,2-diamine, THF, 140 °C (b) AcCI, 'Pr₂NEt, CH₂CI₂ (c) 1M LiOH, DCE, 150 °C, microwave 20 min.

[00846] Formation of (15, 25)-AT-(2-(5-chloro-l-tosyl-l/f-pyrrolo[2,3-b]pyridin-3yl)-5-fluoropyrimidin-4-yl)cyclohexane-l,2-diamine (15b)

5-Chloro-3-(5-fluoro-4-methylsulfinyl-pyrimidin-2-yl)-l-(p-tolylsulfonyl)pyiTolo[2,3b]pyridine, 15a, (0.25 g, 0.53 mmol) and (1S,25)-cyclohexane-1,2-diamine (0.12 g, 1.08 mmol) were dissolved in THF (3.0 mL), and heated to 140 °C for 20 minutes in a sealed vial. The solvent was evaporated in vacuo and the residue was purified by silica gel chromatography (0%-15% MeOH/CHjCh) to provide product, 15b, as a white foamy solid (220 mg, 79% yield).

Ή NMR (300 MHz, CDC1₃) δ 8.85 (d, 7 =2.4 Hz, IH), 8.52 (s, IH), 8.40 (d, 7 =2.4 Hz, IH), 8.13 -8.09 (m,3H), 7.31 -7.28 (m, 2H), 5.14 (d, 7 =6.6 Hz, IH), 3.96 - 3.85 (m, IH), 2.69 (td, 7=10.2, 4.7 Hz, IH), 2,40 (s, 3H), 2.33 (d, 7=5.6 Hz, IH), 2.12 - 2.06 (m, IH), 1.88 - 1.84 (m, 2H) and 1.60 - 1.21 (m, 4H) ppm; LCMS RT = 2.33 (M+l) 515.2.

[00847] Formation of /V-[(1S, 2S)-2-[[2-(5-chloro-ljff-pyrrolo[2,3-b]pyridin-3~yl)5-fluor o-py rimidin-4-yl] amin o] cyclohexyl] aceta mide (433).

(lS,2S)-.V-[2-[5-chloro-l-(p-toly]sulfonyl)pyrrolo[5,4-b]pyridin-3-yl]-5-fluoropyrimidin-4-yl]cyclohexane-l,2-diamine, 15b, (0.100 g, 0.194 mmol) was dissolved in dichloromethane (2 mL) and treated with ‘Pr₂NEt (0.075 g, 0.101 mL, 0.583 mmol). Acetyl chloride (0.021 mL, 0.291 mmol) was added and the reaction was allowed to stir at room temperature for 30 minutes. The volatiles were evaporated under reduced pressure, and the residue was dissolved in dichloroethane (2 mL) and treated with LiOH (0.097 mL of 1 M solution, 0.971 mmol). The reaction mixture was heated in the microwave at 150 °C for 10 minutes. The reaction was diluted with EtOAc (5 mL) and water (5 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (2x5 mL), and the combined organic extracts were dried over Na₂SO₄ and concentrated in vacuo to provide the crude product, which was purified by silica gel chromatography (0%-15% MeOH/CH₂Cl₂) to provide N[(15, 2S)-2-[[2-(5-chloiO-lH-pyiTolo[2,3-b]pyridin-3-yl)-5-fluoro-pyrimidin-4yl]amino]cyclohexyl]acetamide, 433, (34 mg, 44% yield).

*HNMR (300 MHz, 76-DMSO) δ 13.03 (s, IH), 9.10 (s, IH), 9.05 (s, IH), 8.67 (d, 7 =2.1 Hz, IH), 8.48 (d, 7=5.4 Hz, IH), 8.43 (d, 7 =2.3 Hz, IH), 7.97 (d, 7 =7.7 Hz, IH), 4.15

-253WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

- 4.07 (m, 1H), 3.93 - 3.87 (m, 1H), 2.20 - 2.15 (m, 1H), 1.99 - 1.92 (m, 1H), 1.85 - 1.79 (m, 2H), 1.74 (s, 3H) and 1.52 - 1.36 (m, 4H) ppm; LCMS RT = 2.41 (M+l) 403.4.

General Scheme 16

(a) cyclohexane-cis-1,2-diamine, isopropanol, 'Pr₂NEt (b) 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)-1H-pyrrolo[2,3-h]pyridine, Pd(PPh₃)₄, Na₂CO₃, DME: DOE, 150 °C, microwave; (c) 1M LiOH 150 °C, microwave; (d) MeSO₂CI, 'Pr₂NEt, DMF:DCM.

[00848] Formation of Al-(2-chloro-5-fluoropyrimidin-4-yl)cyclohexane-c/s-l,2diamine (16a)

2,4-Dichloro-5-fluoropyrimidine (0.50 g, 2.99 mmol) was dissolved in isopropanol (7 mL) and treated with 'PrjNEt (1.50 mL, 8.98 mmol). Cyclohexane-m-l,2-diamine (0.46 g, 4.03 mmol) was added and the reaction was allowed to stir at room temperature overnight. The solvent was evaporated and the reaction mixture was diluted in EtOAc (15 mL) and washed with aqueous saturated NaHCO₃ solution. The aqueous layer was extracted with EtOAc (15 mL) and the combined organic layers were dried over Na₂SO₄ and concentrated in vacuo to provide the crude product. The resulting crude was purified by silica gel chromatography (5%-30% MeOH/CH₂Cl₂) to provide 16a (370 mg, 50% yield) as a white solid.

^lHNMR (300 MHz, CDC1₃) δ 7.83 (d, 7=2.8 Hz, 1H), 6.16 (s, 1H), 4.08 (s, 1H), 3.13 (d, 7=3.9 Hz, 1H) and 1.84 - 1.44 (m, 8H) ppm; LCMS RT = 0.8 (M+l) 245.1.

[00849] Formation of .Vl-(5-fluoro-2-(lH-pyrrolo[2,3-b|pyridin-3-yl)pyrimidin-4yl)cyclohexa ne-1,2-dia mine (16b)

3-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrrolo[2,3-b]pyridine (0.26 g, 0.65 mmol) was dissolved in DME (8 mL) and treated with M-(2-chloro-5-f1uoropyrimidin-

4-yl)cyclohexane-cis-l,2-diamine, 16a, (0.16 g, 0.65 mmol). Pd(PPh₃)₄ (0.10 mg, 0.08 mmol) and 2M aqueous Na₂CO3 (3.25 mL) were added and the suspension was heated in the microwave to 150 °C for 20 minutes. IM aqueous LiOH (5 mL) was added, and the reaction was heated in the microwave to 150 °C for an additional 15 minutes. The organic solvent was evaporated under reduced pressure and the aqueous phase was extracted with CH₂C1₂(2x20 mL). The combined organic phases were dried over Na₂SO4 and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (0%-100% CH₂Cl₂/EtOAc) to provide product 16b (140 mg, 66% yield) as a brown foam.

*HNMR (300 MHz, 76-DMSO) δ 12.14 (s, 1H), 8.66 (d, 7=8.0 Hz, 1H), 8.29 - 8.22 (m, 3H), 7.81 (s, 2H), 7.28 - 7.19 (m, 2H), 4.55 (s, 1H), 3.74 (s, 1H) and 1.92 - 1.49 (m, 8H) ppm; LCMS RT = 1.8 (M+l) 327.2.

[00850] Formation of 7V-[cis-2-[[5-fluoro-2-(lFf-pyrrolo[2,3-b]pyridin-3y l)py rim idi n -4-yl] amino] cycloh exyl] methanesulfonamide (337)

771-(5 -fhioro-2-( 1/7-py rrol o[2,3 -b]py ridin-3 -y l)pyrimidi n-4-y l)cyclohexane-1,2diamine, 16b, (0.009 g, 0.027 mmol) was dissolved in an 8:2 mixture of CH2CI2/DMF (1 mL) and treated with ‘Pr₂NEt (0.019 mL, 0.110 mmol) and methanesulfonyl chloride (0.006 mL,

-254WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

0.083 mmol). The reaction was stirred at room temperature overnight, concentrated in vacuo and the residue was purified by HPLC with 10%-90% acetonitrile/water with 0.03% TFA to provide compound 337.

Ή NMR (300 MHz, /6-DMSO) δ 12.47 (s, IH), 8.64 (d, J =7.8 Hz, 1H), 8.45 - 8.34 (m, 3H), 7.29 (dd, /=4.8, 7.8 Hz, IH), 7.06 (d, J =7.5 Hz, IH), 4.47 - 4.25 (m, IH), 4.05 3.89 (m, IH), 2.80 (s, 3H), 1.95 - 1.62 (m, 6H) and 1.49 - 1.24 (m, 2H) ppm.; LCMS RT =

2.3 (M+l) 405.3.

[00851] The following compounds can be prepared in a manner similar to the one described in either Scheme 15 or Scheme 16:

[00852] jV-[c/s-2-[ [5-flu oro-2-(l/7-py rrolo [2,3-b] pyridi n-3-yl)pyrimidin-4yl] amino] -cyclohexyl]propanamide (341)

Ή NMR (300 MHz, /6-DMSO) δ 12.47 (s, IH), 8.65 (d,/=8.1 Hz, IH), 8.49 - 8.23 (m, 3H), 7.61 (d, /=7.8 Hz, IH), 7.29 (dd, / =4.7, 8.0 Hz, IH), 4.39 (d, / = 19.5 Hz, 2H),

2.10 (q, /=7.6 Hz, 2H), 1.79 - 1.64 (m, 6H), 1.48 (d, /=6.4 Hz, 2H) and 0.91 (t, / =7.6 Hz, 3H) ppm; LCMS RT = 2.3 (M+l) 383.4.

[00853| jV-[cis-2-||5“fluoro-2-(l//-pyrrolo[2,3-b|pyridm-3-yl)pyrimidm-4yl]amino]cyclohexyl]butanamide (342)

LCMS RT = 2.5 (M+l) 397.4.

[00854] ZV-[cis-2-[[5-fluoro-2-(lH^r-pyrroio[2,3-b]pyridin-3-yl)pyrimidin-4yl]amino]cyclohexyl]cyclopentanecarboxamide (343)

LCMS RT = 2.7 (M+l) 423.4.

-255WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [00855] /V-[cis-2-[[5-fluoro-2-(lJT-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4yl] amino] cyclohexyl] b enza mide (344)

LCMS RT = 2.7 (M+l) 431.4.

[00856] 7V-[cis-2-[[5-fluoro-2-(lii^r-pyrrolo[2,3-b]pyridin-3“yl)pyriniidin-4yl]amino]cyclohexyl]propane-l-sulfonamide (346) *HNMR (300 MHz, /6-DMSO) δ 12.41 (s, IH), 8.65 (d, J =7.8 Hz, IH), 8.38 - 8.33 (m, 3H), 7.28 (dd, /=4.7, 7.9 Hz, IH), 7.06 (d, /=8.1 Hz, IH), 4.36 (s, IH), 3.88 (s, IH), 2.83 (t, / =7.7 Hz, 2H), 1.85 - 1.70 (m, 6H), 1.59 (q, / =7.8 Hz, 2H), 1.47 - 1.24 (m, 2H) and 0.82 (t, / =7.4 Hz, 3H) ppm; LCMS RT = 2.6 (M+l) 433.3.

347

346 [00857] l-|e7.s’-2-||5-fluoro-2-(l//-pyrrolo|2,3-b]pyridin-3-yl)pyrimidin-4yl] amino] cyclohexyl]-3-p ropyl-urea (347) ’H NMR (300 MHz, ί/6-DMSO) δ 12.47 (s, IH), 8.64 (d, J = 7.8 Hz, IH), 8.45 - 8.34 (m, 3H), 7.29 (dd, / = 4.8, 7.8 Hz, IH), 7.06 (d, / = 7.5 Hz, IH), 4.47 - 4.25 (m, IH), 4.05 3.89 (m, IH), 2.80 (s, 3H), 1.95 - 1.62 (m, 6H) and 1.49 - 1.24 (m, 2H) ppm; LCMS RT = 2.4 (M+I) 412.4.

[00858] Λ-[(1Λ, 2A)-2-|[5-fiuoro-2-(1//-pyrrolo[2,3-b|pyridin-3-yl)pyrimidin-4yl] amino] cyclohexyl] acetamide (348)

ΉNMR (300 MHz, /6-DMSO) δ 12.53 (s, IH), 8.66 (d,/=7.6 Hz, IH), 8.43 (s, IH), 8.39 - 8.36 (m, 2H), 7.91 (d, /=7.9 Hz, IH), 7.32 (dd, /=4.7, 7.9 Hz, IH), 4.08 - 3.94 (m, IH), 3.86 (d,/=8.4 Hz, IH), 2.13 (d,/=24.3 Hz, IH), 1.95 (d,/=10.2 Hz, IH), 1.81 1.73 (m, 2H), 1.73 (s, 3H) and 1.43-1.14 (m, 4H) ppm; LCMS RT = 2.2 (M+l) 369.4.

349

351 [00859] /V-[ir«7/s-2-[[2-(5-chIoro-lZI-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexyl]propanamide (349)

LCMS RT = 2.7 (M+l) 417.3.

[00860] 7V-[(1J?, 27f)-2-[[2-(5-chloro-lZ/-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl] am ino] cyclohexyl] cyclopenta necarboxa mide (351)

LCMS RT = 3.1 (M+l) 457.3.

-256WO 2010/148197

PCT/US2010/038988

353 [00861] Λ^Γ-[(1Λ, 2/?)-2-||2-(5-chloro-1//-pyrroIo|2,3-b|pyridin-3-yI)-5-fluoropyrimidin-4-yl] amino]cyclohexyl]benzamide (352)

LCMS RT = 3.0 (M+l) 465.3.

[00862] /V-[(1 Λ*, 2ff)-2-[[2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropy rimidin-4-yl] amino] cyclo hexyl] methanesulfonamide (353)

LCMS RT = 2.7 (M+l) 439.4.

[00863] 7V-[(li, 2/?)-2-[[2-(5-chloro-l//-pyrrolo[2,3-b[pyridin-3-yl)“5-fluoropyr imidin-4-yl] amin o] cyclohexyl] p r opane-l~sulfona mide (354)

LCMS RT = 3.0 (M+l) 467.3.

[00864] 1-[(17ϊ, 27?)-2-[[2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yI)-5-fluoropyrimidin-4-yl]amino]cyclohexyl]-3-propyl-urea (355)

LCMS RT = 2.8 (M+l) 446.3.

[00865] /V-[(l/?„ yl] amino] cyclohexyl] butanamide (358)

LCMS RT = 2.5 (M+l) 397.4.

21?)-2-[[5-fluoro-2-(127-pyrroIo[2,3-b]pyridin-3-yl)pyrimidm-4[00866] 7V-[(lfi, 2/Q-2-[[5-fluoro-2-(lZ7-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4yljamino] cyclohexyl]cyclopentanecarboxamide (359)

LCMS RT = 2.7 (M+l) 423.4.

-257WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00867| TV-[(1jK, 2fi)-2-[[5-fluoro-2-(lii-pyrrolo[2,3-b|pyridin-3-yl)pyrimidin-4yl] amino] cyclohexyl] b enza mid e (360)

LCMS RT = 2.63 (M+l) 431.4.

[00868] TV- [(1R, 2R)-2-[[ 5-flu or 0-2-( IH-py r rolo [2,3 -b] pyridin-3-yl)py rimidin-4yl]amino]cyclohexyl]methanesulfonamide (361) 'Η NMR (300 MHz, 76-DMSO) δ 12.54 (s, IH), 8.66 (d, J =8.0 Hz, IH), 8.43 - 8.36 (m, 3H), 7.32 (dd, ./=4.7, 7.9 Hz, IH), 7.21 (d, 7=8.3 Hz, IH), 4.16 (d, 7=9.3 Hz, IH), 3.35 (d, 7 =9.8 Hz, IH), 2.91 (d, 7 =8.9 Hz, 3H), 2.12 - 2.02 (m, 2H), 1.79 - 1.73 (m, 2H) and 1.64 - 1.15 (m, 4H) ppm; LCMS RT = 2.4 (M+l) 405.3.

[00869] ?V-[(l/i,21?)-2-[[5-fluoro-2-(lJ7-pyrrolo[2,3-b]pyridin-3-yl)pyriinidin-4yl]amino|cyclohexyl]propane-l-sulfonamide (362) 'H NMR (300 MHz, 76-DMSO) δ 12.43 (s, IH), 8.68 (d, J =7.9 Hz, IH), 8.38 - 8.33 (m, 3H), 7.29 (dd, 7 =4.7, 7.8 Hz, IH), 7.17 (d, 7 =8.6 Hz, IH), 4.14 (d, 7 =6.9 Hz, IH), 3.33 - 3.26 (m, IH), 3.07 - 2.89 (m, 2H), 2.07 (d, 7 = 12.6 Hz, 2H), 1.76 (d, 7=7.9 Hz, 2H), 1.61 -

1.33 (m, 6H) and 0.90 (t, 7=7.4 Hz, 3H) ppm; LCMS RT = 2.6 (M+l) 433.3.

[00870] yV-[//Y//Av-2-[J2-(5-ch]oro-1Z/-pyrro]o[2,3-b|pyridiii-3-yl)-5-fluoropyrimidin-4-yl] amino] cyclo hexyl] butanamide (363)

LCMS RT = 2.9 (M+l) 431.3.

[00871] /V-[(irans-2-[[2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexyl]cyclopentanecarboxamide (364)

LCMS RT = 3.1 (M+l) 457.3.

[00872] A-[i/wiS-2-[[2-(5-chloro-l/7-pyrroIo|2,3-b]pyridin-3-yl)-5-nuoropyrimidin-4-yl]amino]cyclohexyl]benzamide (365)

LCMS RT = 3.0 (M+l) 465.3.

-258WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00873] /V-[ft^,«/is-2-[[2-(5-chloro-lfi^r-pyrroIo[2,3“b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino] cyclohexyl]propane-l-sulfonamide (367)

LCMS RT = 3.0 (M+l) 467.3.

[00874] 1- [tra ns-2- [ [2-(5-ch loro-1 Z/-py rrolo [2,3-b] pyridin-3-y l)-5-fluo ropyrimidin-4-yl]amino]cyclohexyl]-3-propyl-urea (368)

LCMS RT = 2.8 (M+l) 446.3.

425 426 [00875] Methyl A-[(IS, 2S)-2-[[2-(5-chloro-l//-pyrrolo|2,3-bjpyridin-3-yl)-5fluoro-pyrimidin-4-yl]amino]cyclohexyl]carbamate (425)

Ή NMR (300 MHz, /6-DMSO) δ 13.02 (s, IH), 9.10 (s, 2H), 8.67 (s, IH), 8.44 -

8.40 (m, 2H), 7.26 (d, J =6.5 Hz, IH), 4.19 (s, IH), 3.66 (d, J =9.8 Hz, IH), 3.48 (s, 3H), 2.13 (s, IH), 2.02 (d, J =9.2 Hz, IH), 1.78 (d, J =9.6 Hz, 2H) and 1.47 - 1.34 (m, 4H) ppm; LCMS RT = 2.1 (M+l) 419.2.

[00876] 1-[(1S, 25)-2-[[2-(5-chloro-ljff-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidm-4-yl]amino]cyclohexyl]-3-methyl-urea (426) *H NMR (300 MHz, /6-DMSO) δ 12.56 (s, IH), 8.70 (d, J =2.2 Hz, IH), 8.35 (dd, J =2.4, 6.8 Hz, 2H), 8.28 (d, J =4.2 Hz, IH), 5.99 (d, /=7.0 Hz, IH), 5.80 - 5.63 (m, IH), 3.91 - 3.87 (m, IH), 3.66 - 3.45 (m, IH), 2.54 (s, 3H), 2.30 (d, / =13.0 Hz, IH), 2.04 (d, / =46.9 Hz, IH), 1.78 (d,/=8.5 Hz, 2H) and 1.56 - 1.23 (m, 4H) ppm; LCMS RT = 2.5 (M+l) 419.5.

[00877] 3-((15, 25)-2-[[2-(5-chloro-lH^|r-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexyl]-l,l-dimethyl-urea (427) *H NMR (300 MHz, /6-DMSO) δ 12.59 (s, IH), 8.72 (d, / =2.3 Hz, IH), 8.41 (d, / =2.7 Hz, IH), 8.35 (d, / =2.3 Hz, IH), 8.29 (d, / =4.4 Hz, IH), 8.23 (s, IH), 6.19 (d, / =7.8 Hz, IH), 4.04 - 3.97 (m, IH), 3.78 - 3.69 (m, IH), 2.68 (s, 6H), 2.31 (d, /=11.6 Hz, IH),

1.95 (d, / =9.8 Hz, IH), 1.79 (d, / =10.4 Hz, 2H) and 1.60 - 1.32 (m, 4H) ppm; LCMS RT =

2.7 (M+l) 432.4.

-259WO 2010/148197

PCT/US2010/038988 [00878] /V-[(1S, 2S)-2-[[2-(S-chloro-l.H-pyrrolo[2,3-b]pyridin-3-yl)-5”fluoropyrxmidin-4-yl]amino]cycIohexyl]methanesulfonamide (428)

NMR (300 MHz, ί/6-DMSO) δ 12.54 (s, 1H), 8.72 (d, J =2.3 Hz, 1H), 8.38 - 8.29 (m, 3H), 7.82 (s, 1H), 7.21 (d, J =8.3 Hz, 1H), 4.52 (brs, 1H), 4.12 - 4.05 (m, 1H), 2.92 (s, 3H), 2.09 (d, J =12.8 Hz, 2H), 1.78 (brs, 2H) and 1.49 - 1.39 (m, 4H) ppm; LCMS RT = 2.7 (M+l) 439.4.

[00879] 1- [as-2- [ [2-(5-chlor o-l/7-py r rolo [2,3 -b] py ridin-3-yl)-5-fluor o-py rimidin4-yl]amino] cycloh exyl] -3-methyl-urea (430) ‘H NMR (300 MHz, c/6-DMSO) δ 12.61 (s, 1H), 8.68 (d, J =2.2 Hz, 1H), 8.39 - 8.31 (m, 4H), 6.12 (d, J =6.7 Hz, 1H), 5.91 - 5.83 (m, 1H), 4.29 - 4.13 (m, 1H), 4.02 - 3.91 (m, 1H), 2.55 (s, 3H), 1.93 (d, J =12.8 Hz, 1H) and 1.74 - 1.53 (tn, 7H) ppm; LCMS RT = 2.6 (M+l) 418.5.

[00880] 3-[cis-2-[[2-(5-chloro-lir-pyrrolo[2,3-bJpyridin-3-yl)-5-fluoro-pyrimxdin4-yl]amino]cyclohexyl]-l,l-dinxethyl-xxrea (431) ^ΤΗ NMR (300 MHz, ί/6-DMSO) δ 12.54 (s, 1H), 8.68 (d, J =2.3 Hz, 1H), 8.33 - 8.29 (m, 3H), 7.96 (s, 1H), 5.72 (d, J =6.9 Hz, 1H), 4.36 (s, 1H), 4.10 (s, 1H), 2.76 (s, 6H), 1.96 -

1.87 (m, 2H), 1.74 - 1.63 (m, 4H) and 1.55 - 1.45 (m, 2H) ppm; LCMS RT = 2.8 (M+l)

432.4.

[00881] Methyl /V-[ri‘jf-2-[[2-(5-chloro-liT-pyrrolo[2,3-b]pyridin-3'-yl)-5-fluoropyrimidin-4-yl]amino] cycloh exyl] carbamate (432) ^]H NMR (300 MHz, ί/6-DMSO) δ 12.54 (s, 1H), 8.67 (d, J =2.2 Hz, 1H), 8.35 - 8.29 (m, 3H), 7.62 (s, 1H), 7.05 (d, J =7.2 Hz, 1H), 4.50 - 4.40 (m, 1H), 4.20 - 4.10 (m, 1H), 3.46 (s, 3H), 1.87 (d, J =10.9 Hz, 2H), 1.71 - 1.65 (m, 4H) and 1.43 (d, J -ΊΑ Hz, 2H) ppm; LCMS RT = 2.9 (M+l) 419.4.

[00882] /V-|5-fluoro-2-(l//-pyrrolo[5,4-b]pyridin-3-yl)pyrimidin-4-yl|cyclohexaneczs-l,2-diamine (206)

LCMS RT= 1.9 (M+l) 327.2.

207 ²⁷⁷

-260WO 2010/148197

PCT/US2010/038988 [00883] f/'«„s-2-[[5-fluoro-2-(12T-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4yl] amino | cyclohexanol (207)

LCMS RT = 2.2 (M+l) 328.2.

[00884] cis-2-[[5-fluoro-2-(177-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4yl]amino]cyclohexanol (277)

LCMS RT = 1.6 (M+l) 328.2.

[00885] A^r-[cis-2-[[2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)“5“fluoro-pyrimidin4-yl] amino] cyclohexyl] propanamide (333)

LCMS RT = 2.7 (M+l) 417.4.

[00886] 7V-[m-2-[[2-(5-chloro-lZ?-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-pyrimidin4-yl] amino] cycloh exyl]butanamide (334)

LCMS RT = 2.9 (M+l) 431.4.

[00887] ?V-[c/x-2-[[2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-pyrimidin4-yl]amino]cyclohexyl]cyclopentanecarboxamide (335)

LCMS RT = 3.1 (M+l) 457.3.

100888] A-| cis-2-[ |2-(5-chlor o-l//-py rrolo 12,3-b ] py ridin-3-yl)-5-fluoro-pyrimidin4-yl] amino] cyclohexyl]benzamide (336)

LCMS RT = 3.0 (M+l) 465.4.

[00889] TV-[<.7S'-2-[[2-(5-chIoro-liT-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-pyrimidin4-yl]amino]cyclohexyl]propane-l-sulfonamide(338)

LCMS RT = 2.9 (M+l) 467.3.

[00890] 1-[ cz\-2-| [2-(5-chloro-l/f-pyrrolo [ 2,3-b ]pyridin-3-yl)-5-fluoro-pyrimidin-261WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

4-yl]amino]cyclohexyl]-3-propyl-urea (339)

LCMS RT = 2.9 (M+l) 446.3.

350

[00891] l-[tr«Hs-2-[[2-(5-chloro-ljff-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yI]amino]cyclohexyl]-3-propyi-urea (350)

LCMS RT = 2.6 (M+l) 403.3.

[00892] A-[(1R, 2R)-2-[[5-fluoro-2-(lif-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4yl] amin o] cyclo hexyl]prop anamide (356)

LCMS RT = 2.3 (M+l) 383.4.

[00893] (1R,

2R)-2Vl-(2-(5-chloro-lJ7-pyrroIo[2,3-6]pyridin-3-yl)-5(trifluoromethyl)pyrimidin-4-yl)cyclohexane-l,2-diamine (31)

LCMS RT = 2.2 (M+l) 411.2.

[00894] M-(5-fluoro-2-(lfT-pyrrolo[2,3-6]pyridin-3~yl)pyrimidin-4yl)cyclohexane-l,2-diamine (4)

LCMS RT = 2.2 (M+l) 327.2.

(1Λ,

[00895] yl)py rimidin-4-yl)cyclo hexane-1,2-d iamine(115)

2/?)-AT-(5-chloro-2-(5-chloro-lH-pyrrolo[2,3-6]pyridin-3LCMS RT = 1.3 (M+l) 377.2.

[00896] A^rl-(2-(5-chloro-lH-pyrrolo[2,3-6]pyridin-3-yl)-5-methylpyrimidin-4yl)cyclohexane-l,2-diamine (116)

LCMS RT = 3.3 (M+l) 357.2.

-262WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00897] IV- [ (15, 2/2)-2- ] [2-(5-chIoro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl] amino] cyclohexyl]butanamide (369)

LCMS RT = 2.9 (M+l) 431.3.

[00898] 1-((122, 2R)-2-[[5-fiuoro-2-(lH-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4yljamino]cyclohexyl]-3-propyl-urea (370)

LCMS RT = 2.4 (M+l) 412.4.

412 [00899] 2-(5-chloro-l/Z-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-A^r-(2methoxycyclohexyl)-pyrimidin-4~amine (412)

LCMS RT = 3.5 (M+l) 376.4.

[00900] General Scheme 18

18a 18b 18c

18d 18e

Ϊ. DPPA, Et₃N, toluene, 110 °C; ii BnOH, 85 °C (b) LiOH, THF: H₂O (c) Boc₂O, pyridine, NH4HCO3, dioxane (d) BTIB, CH₃CN:H₂O.

[00901] Formation of (15, S^-S-fethoxycarbonyficyclohexanecarboxylic acid (18a)

(15, 37?)-3-(ethoxycarbonyl)cyclohexanecarboxylic acid can be prepared following the literature procedures described in : Barnett, C. J., Gu, R. L., Kobierski, Μ. E., WO2002024705, Stereoselective process for preparing cyclohexyl amine derivatives.

[00902] Formation of ethyl (17Ϊ, 35)-3benzyloxycarbonylaminocyclohexanecarboxylate (18b) (15, 3R)-3-(Ethoxycarbonyl)cyclohexanecarboxylic acid, 18a, (10.0 g, 49.9 mmol)

-263WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 was dissolved in toluene (100 mL) and treated with triethylamine (7.6 mL, 54.9 mmol) and DPPA (12.2 mL, 54.9 mmol). The resulting solution was heated to 110 °C and stirred for 1 hour. After cooling to 70 °C, benzyl alcohol (7.7 mL, 74.9 mmol) was added, and the mixture was heated to 85 °C overnight. The resulting solution was cooled to room temperature, poured into EtOAc (150 mL) and water (150 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (2x75 mL) and the combined organic extracts were washed with water (lOOmL) and brine (100 mL), dried over Na₂SO₄ and concentrated in vacuo. The crude material was purified by silica gel chromatography (0%-50% EtOAc/hexanes) to provide 18b (15.3 g, containing -25% benzyl alcohol), which was used for the next step without further purification.

|00903] Formation of (15, 35)-3-benzyloxycarbonylaminocyclohexanecarboxylic acid (18c)

Ethyl (15, 3S)-3-benzyloxycarbonylaminocyclohexanecarboxylate, 18b, (36 g, 117.9 mmol) was dissolved in THF (144.0 mL) and treated with a solution of LiOH (5.647 g, 235.8 mmol) in water (216.0 mL). After stirring overnight, the reaction mixture was diluted with water (100 mL), washed with methyl teri-butyl ether (150 mL) and brought to pH 3 by addition of 3N HC1. The acidic solution was extracted with EtOAc (3x100 mL), and the combined organic layers were washed with water and brine, dried on Na₂S04 and concentrated in vacuo.

The crude product was triturated with methyl ieri-butyl ether (30 mL) and filtered to provide a first crop of crystals. The filtrate was treated with heptane (20 mL), concentrated to 30 mL and allowed to stand at room temperature for 3 hours to provide a second crop of crystals that were collected by filtration for a total of 14.4 g (44%yield) 18c.

^XH NMR (300 MHz, CDC1₃) δ 7.38 - 7.33 (m, 5H), 5.11 (s, 2H), 4.68 (s, IH), 3.55 (s, IH), 2.44(d, /=11.0 Hz, IH), 2.32 (d, J =11.7 Hz, IH), 2.03 - 1.86 (m, 3H) and 1.48-0.88 (m, 4H) ppm.

[00904] Formation of benzyl 7V-[(15,35)-3-carbamoylcyclohexyl]carbamate (18d)

To a solution of (15, 35)-3-Benzyloxycarbonylaminocyclohexanecarboxylic acid, 18c, (10.0 g, 36.1 mmol) in 1,4-dioxane (300 mL) was added pyridine (2.9 mL, 36.1 mmol), followed by di-tert-butyl dicarbonate (10.7 mL, 46.9 mmol) and ammonium bicarbonate (10.1 g, 126.2 mmol). After 3 hours, another portion of di-zeri-butyl dicarbonate (1.5 g, 6.8 mmol) and ammonium bicarbonate (1.5 g, 6.8 mmol) was added and stirring was continued overnight. The reaction was quenched by addition of 2N HC1 (400 mL) and stirred for 1 hour. The resulting suspension was filtered under reduced pressure, washed with 2N HC1 (50mL), water (8x50mL) and hexanes (3x50mL) and vacuum dried to provide benzyl //-[(IS, 35)-3-carbamoylcyclohexyl]carbamate, 18d, (9.1 g, 91%) as a white solid.

^lH NMR (300 MHz, CDCI3) δ 7.40 - 7.24 (m, 5H), 5.08 (s, 2H), 3.58 - 3.44 (m, IH), 2.38-2.21 (m, IH), 2.17 (d,/ = 12.7, IH), 2.05- 1.78 (m, 8H), 1.54-0.97 (m, 5H).

[00905] Formation of benzyl A-[(15, 35)-3-aminocycIohexyl] carbamate (18e)

Benzyl 7V-[(IS, 35)-3-carbamoylcyclohexyl]carbamate, 18d, (9.1 g, 32.9 mmol) was suspended in a mixture of acetonitrile (100 mL) and water (100 mL) and treated with . bis(trifluoroacetoxy)iodobenzene (15.5 g, 36.1 mmol). The suspension was allowed to stir at room temperature overnight and was then quenched with IN HCI (lOOmL). After evaporation of the acetonitrile, the acidic aqueous solution was washed with EtOAc (2xl50mL). The pH was adjusted to basic by addition of solid KOH and the resulting emulsion was extracted with EtOAc (3x200 mL). The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo to provide product 18e (6.2 g, 75% yield).

^fH NMR (300 MHz, CDC1₃) δ 7.31 - 7.45 (m, 5H), 5.11 (s, 2H), 4.90 (br. s., IH),

-264WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

3.58 (br. s., IH), 2.72 - 2.97 (m, IH), 2.14 (d, J =11.90 Hz, IH), 1.87 - 2.02 (m, IH), 1.73 -

1.87 (m,2H), 1.21 - 1.46 (m, IH), 0.89- 1.18 (m,3H).

o

[00906] General Scheme 19

(a) MeOCOCI, EftN, THF (b) H₂, Pd/C, EtOH (c) 5-chloro-3-(5-fluoro-4-methylsulfinyl-pyrimidin-2-yl)1 -(p-toiy!su[fonyl)pyrrolo[2,3-b]pyridlne, THF, 130 °C, microwave (d) LiOH, 130 °C, microwave.

[00907] Formation of methyl /V-[(1A, 35)-3-benzyloxycarbonyIaminocyclohexyl] carbamate (19a)

Benzyl Α-[(15, 3I?)-3-ammocyclohexyl]carbamate, 18e, (0.99 g, 3.99 mmol) was dissolved in THF (20 mL) and treated with methyl chloroformate (0.62 mL, 7.97 mmol), followed by triethylamine (1.67 mL, 11.96 mmol). After stirring for 1 hour at room temperature, the solvent was evaporated under reduced pressure and the residue was diluted into 1:3 mixture of CH₂Cl₂:EtOAc (130 mL) and washed with IN HC1 (50 mL) and 2N Na₂CO₃ (50 mL). The organic layer was dried over Na₂SO₄ and concentrated under reduced pressure to afford the desired product, 19a, as a white solid (1.09g, 89% yield).

*H NMR (300 MHz, CDC1₃) δ 7.21 - 7.37 (m, 5H), 5.02 (s, 2H), 4.26 - 4.62 (m, IH),

3.58 (s, 3H), 3.34 - 3.54 (m, 2H), 2.24 (d, J =11.71 Hz, IH), 1.82 - 2.03 (m, 2H), 1.72 (dt, J =3.14, 13.93 Hz, IH), 1.23 - 1.44 (m, IH), 0.79 - 1.02 (m, 3H).

[00908] Formation of methyl TV-[(1 Ji, 3S)-3-aminocyclohexyl]carbamate (19b)

Methyl Α-[(1/?, 35)-3-benzyloxycarbonylaminocyclohexyl]carbamate, 19a, (1.09 g,

3.56 mmol) was dissolved in ethanol (100 mL) and treated with 10% Pd/C (0.38 g, 0.36 mmol). The flask was capped, degassed and fitted with a hydrogen balloon and allowed to stir overnight. The reaction mixture was filtered under nitrogen and concentrated in vacuo to provide the product, 19b, as a white solid.

^lH NMR (300 MHz, CDC1₃) δ 3.31 - 3.56 (m, IH), 3.03 (s, 4H), 2.81 (t, J =10.67 Hz, IH), 2.03 - 2.20 (m, IH), 1.71 - 2.01 (m, 3H), 1.27 - 1.49 (m, IH), 0.92 - 1.14 (m, 3H).

[00909] Formation of methyl 2V-[(lj?, 35)-3-[[2-(5-chloro-177-pyrrolo [2,3b]pyridin-3-yl)-5-fluoro-pyrimidin-4-yl]amino]cyclohexyl]carbamate (570)

5-chloro-3-(5-fluoro-4-methylsulfinyl-pyrimidm-2-yl)-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridine, 19b, (2.04 g, 4.39 mmol) and methyl /V-[(1I?, 35)-3-aminocyclohexyl]carbamate (0.60 g, 3.14 mmol) were suspended in THF (16 mL) and heated in the microwave to 130 °C for 20 minutes. Lithium hydroxide (15.67 mL of IM solution, 15.67 mmol) was added, and the resulting mixture was heated in the microwave for 20 min at 130 °C. The resulting solution was diluted with water (150 mL) and ethyl acetate (200 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (100 mL) and t organic layers were combined, dried over Na₂SO₄ and concentrated in vacuo. The crude product was purified by silica gel chromatography (40-100% EtOAc/hcxancs) followed by treatment of the pure fractions with 4N HC1 in dioxane to provide the hydrochloride of compound, 570, as an off white solid.

^!H NMR (300 MHz, MeOD) δ 8.81 (d, J =2.1 Hz, IH), 8.20 (d, 7=2.3 Hz, IH), 8.15 (s, IH), 7.97 (d, 7 =4.1 Hz, IH), 4.26 - 4.18 (m, IH), 3.71 - 3.52 (m, IH), 3.59 (s, 3H), 2.36

-265WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 (d, 7=10.5 Hz, 1H), 2.18 (d, 7 =10.7 Hz, 1H), 2.04 - 1.86 (m, 2H), 1.57 (s, 1H) and 1.43 -

1.15 (m, 3H) ppm; LCMS RT = 2.0 (M+l) 419.4 (M-l) 417.3.

[00910] General Scheme 20.

(a) 5-chloro-3-(5-fluoro-4-methylsulfinyl-pyrimidin-2-yl)-1-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridine, THF (b) CH₂CI₂, trifluoroacetic acid (c) acetyl chloride, EtsN, THF (d) LiOH, 130 °C, microwave.

[00911] Formation of tert-butyl 7V-[(11?, 35)-3-[[2-[5-chloro-l-(ptolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5-fluoro-pyrimidin-4y 1] amin o] cyclo hexyl] carba mate (20b) teri-Butyl N-[(1R, 3S)-3-amlnocyclohexyl]carbamate, 20a, (0.15 g, 0.70 mmol) and 5chloro-3-(5-fluoro-4-methylsulfinyl-pyrimidin-2-yl)-l-(p-tolylsulfonyl)pyiTolo[2,3b]pyridine, la, (0.49 g, 1.05 mmol) were dissolved in THF (30 mL) and allowed to stir at room temperature overnight. The solvent was evaporated under reduced pressure and the residue was purified by two rounds of silica gel chromatography - first with (0%-I0% MeOH/CH₂Cl₂) second with (10%-50% EtOAc/hexanes) to provide tert-butyl jV-[(1R, 35)-3[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5-fhioro-pyrimidin-4yl]amino]cyclohexyl]carbamate (20b) (330 mg, 38%).

^SH NMR (300 MHz, CDClj) δ 8.74 (d, 7= 2.4 Hz, 1H), 8.58 (s, 1H), 8.38 (d, 7= 2.4 Hz, 1H), 8.13 (s, 1H), 8.09 (t, 7 =3.3 Hz, 2H), 7.29 (d, 7= 8.1 Hz, 2H), 5.02 (d, 7= 7.1 Hz, 1H), 4.47 (d, 7= 7.7 Hz, 1H), 4.25-4.16 (m, 1H),3.68 (d, 7= 2.0 Hz, 1H), 2.48 (d, 7= 11.7 Hz, 1H), 2.38 (s, 3H), 2.26 (d, 7= 12.8 Hz, 1H), 2.11 (d, 7= 11.9 Hz, 1H), 1.95 - 1.89 (m, 1H), 1.69 - 1.56 (m, 1H), 1.44 (s, 9H) and 1.28 - 1.11 (m, 3H) ppm.

[00912] Formation of (1R, 3S)-7Vl-[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3b]pyridin-3-yl]-5-fluoro-pyrimidin-4-yl]cyclohexane-l,3-diamine (20c) tert-Butyl 7V-[(15, 3R)-3-[[2-[5-chloro-l-(p-tolylsulfonyl)pynOlo[2,3-b]pyridin-3-yl]5-fluoro-pyrimidin-4-yl]amino]cyclohexyl]carbamate, 20b, (0.33 g, 0.53 mmol) was dissolved in CH2CI2 (10 mL) and treated with trifluoroacetic acid (2 mL). After stirring for 2 hours, the solvent was evaporated under reduced pressure and the resulting residue was passed through a polymer supported carbonate column to provide the free base of (1R, 35)771 - [2- [5 -chloro-1 -(/?-tolylsulfonyl)pyrrolo[2,3 -b]pyridin-3 -yl] -5-fluoro-pyrimidin-4yl]cyclohexane-l,3-diamine , 20c, (0.25 g, 0.43 mmol, 81%).

^]H NMR (300 MHz, CDCL) δ 8.76 (dd, 7= 2.4, 6.3 Hz, 1H), 8.52 - 8.49 (m, 1H),

8.39 (d, J = 2.4 Hz, 1H), 8.14 - 8.04 (m, 3H), 7.29 (d, 7= 7.5 Hz, 2H), 5.61 (s, 1H), 4.28 -

4.16 (m, 1H), 3.19 - 3.10 (m, 1H), 2.39 (s, 3H), 2.39 - 2.31 (m, 1H), 2.08 - 1.90 (m, 3H), 1.63 - 1.50 (m, lH)and 1.40- 1.17 (m, 3H)ppm .

[00913] Formation of A-[(1R, 3S)-3-[[2-(5-chloro-L£f-pyrrolo[2,3-b]pyridin-3-yI)5-fluoro-pyrimidin-4-yl] amino]cyclohexyl]acetamide (547) (1R, 3S)-M-[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5-fluoiOpyrimidin-4-yl]cyclohexanc-l,3-diaminc, 20c, (0.050 g, 0.097 mmol) was dissolved in THF (1.0 mL) and treated with triethylamine (0.041 mL, 0.290 mmol) and acetyl chloride (0.013 mL, 0.190 mmol). After stirring overnight, the solvent was evaporated and the residue was

-266WO 2010/148197

PCT/US2010/038988 taken into THF (1.0 mL) and treated with IM LiOH (1.0 mL, 1.0 mmol) . The reaction mixture was heated in the microwave to 130 °C for 10 minutes. The solvent was evaporated under reduced pressure, and the residue was purified by HPLC, using 5%-70% HjO/acetonitrile with 0.1%TFA. The purified fractions were concentrated to dryness to provide the TFA salt of the product, which was dissolved in MeOH and passed through a polymer bound carbonate cartridge to provide the free base of product 547.

'H NMR (300 MHz, MeOD) δ 8.81 (s, 1H), 8.20 (s, 1H), 8.15 (s, 1H), 7.99 (d, 7=4.1, 1H), 4.23 (t, 7 =11.4, 1H), 3.90 (t, 7 =11.4, 1H), 2.35 (d, 7 =11.6, 1H), 2.20 (d, J = 12.5, 1H), 2.00 (d, 7 =15.9, 2H), 1.92 (s, 3H), 1.67 (dd, 7 = 26.3, 13.2, 1H), 1.53 -1.06 (m, 3H) ppm LCMS RT = 2.1 (M+l) 403.2.

100914] The following compounds can be prepared by methods similar to those described in Scheme 19 and Scheme 20:

542

[00915] (li?, 30)-ΛΊ -[2-(5-chloro- IH-py r rolo [2,3-b] py ridin-3-yl)-5”fluoropyrimidin-4-ylJcyclohexane-l ,3-diamine (542)

LCMS RT = 1.4 (M+l) 361.4.

[00916] _/V“[(lAf, 3>$)“3“[[2“(5-Ηι1θΓθ-1ίΓ-ργΓΓθ1ο[2,34)]ργΓίΰΐη-3·^1)-5-ΠηοΓθpy r imidin-4-yl] amino] cyclohexyl] a cetamide (576) 'HNMR (300 MHz, MeOD) δ 8.81 (s, 1H), 8.20 (s, 1H), 8.15 (s, 1H), 7.99 (d, 7=4.1, 1H), 4.23 (t, 7 =11.4, 1H), 3.90 (t, 7 = 11.4, 1H), 2.35 (d, J = 11.6, 1H), 2.20 (d, 7= 12.5, 1H), 2.00 (d, 7 = 15.9, 2H), 1.92 (s, 3H), 1.67 (dd, 7 = 26.3, 13.2, 1H), 1.53 -1.06 (m, 3H) ppm; LCMS RT = 1.8 (M+I) 403 (M-I) 401.4.

548 549 [00917] Methyl Λ-[(15, 3Jf)-3-[[2-(5-chloro-117-pyrrolo[2,3-b]pyridin-3-yl)-5fluoro-pyrimidin-4-yl]amino]cyclohexyl]carbamate (548).

LCMS RT = 2.8 (M+l) 419.5.

[00918] 3-[(lS,3tf)-3-[[2-(5-chloro-l#-pyrroIo[2,3-b]pyridin-3-yl)-5-fluoropyri midin-4-yl] am ino] cyclohexyl] -1,1-dimethyl-u rea (549).

LCMS RT = 2.6 (M+l) 432.5.

-267WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00919] Λ-|(1 R, 3S)-3-[[2-(S-chloro-l/7-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexyl]-2-methoxy-acetamide(591) ^lH NMR (300 MHz, MeOD) δ 8.82 (d, J = 2.4 Hz, IH), 8.21 (d, J = 2.3 Hz, IH),

8.16 (s, IH), 7.99 (d, J = 4.1 Hz, IH), 4.29 - 4.21 (m, IH), 4.04 - 3.96 (m, IH), 3.87 (s, 2H),

3.40 (s, 3H), 2.34 (d, J= 11.6 Hz, IH), 2.21 (d, J= 12.5 Hz, IH), 2.02- 1.93 (m, 2H), 1.741.62 (m, IH) and 1.54 - 1.28 (m, 3H) ppm.

LCMS RT = 2.6 (M+l) 433.4.

[00920] 2-methoxyethyl 7V-[(1jR, 3S)-3-[[2-(5-chloro-lZT-pyrrolo[2,3-b]pyridin-3yl)-5-flu or o-py rimidin-4-yl] amino] cyclo hexyl] carbamate (592) ^lH NMR (300 MHz, MeOD) δ 8.84 (s, IH), 8.21 (s, IH), 8.16 (s, IH), 7.99 (d, J =3.97 Hz, IH), 4.18 - 4.34 (m, IH), 4.14 (br. s., 2H), 3.49 - 3.74 (m, 3H), 3.3 (s, 3H) 2.38 (d, 7=9.06 Hz, IH), 2.19 (d, 7 =13.41 Hz, IH), 1.84-2.11 (m, 2H), 1.51 - 1.78 (m, IH), 1.12 -

1.47 (m, 3H) ppm.

LCMS RT = 2.5 (M+l) 463.4.

General Scheme 21:

20c a, b

(a) tetrahydrofuran-2-carboxylic acid, EDC, HOBt, DIPEA, CH2CI2, rt (b) LiOH, 130°C, microwave [00921] Formation of 7V-[(LR, 3S)-3-[[2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)5-fluoro-pyrimidin-4-yl] amino] cyclohexyl] tetra hyd rofuran-2-carboxamide hydrochloride (638).

To a solution of (IS, 37?)-7Vl-[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2₎3-b]pyridin-3yl]-5-fluoro-pyrimidin-4-yl]cyclohexane-l,3-diamine, 20c, (60 mg, 0.12 mmol) in CH2C1₂(3mL) was added tetrahydrofuran-2-carboxylic acid (20.3mg, 0.17 mmol), EDC (26.8 mg, 0.14 mmol), HOBt (17.8mg, 0.12 mmol) and DIPEA (60.2mg, 0.47 mmol), and the reaction mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the residue was dissolved in THF (4mL) and treated with IM aqueous lithium hydroxide (3.0 mL, 3.0 mmol). The reaction mixture was heated in the microwave to 130°C for 20 min. The solvent was evaporated under reduced pressure, and the residue was purified by HPLC, using 5-70% McOH//H₂O with 6mM HC1 over 15 minutes. The purified fractions were concentrated to provide the hydrochloride of 7V-[(12?, 3S)-3-[[2-(5-chloro-lHpyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-pyrimidin-4-yl]amino]cyclohexyl]tetrahydrofuran-2carboxamide, 638.

-268WO 2010/148197

PCT/US2010/038988 ‘H NMR (300 MHz, MeOD) δ 8.55 (d, 7= 1.0 Hz, IH), 8.46 - 8.45 (m, IH), 8.29 -

8.27 (m, 2H), 4.28 (d, 7= 6.1 Hz, 2H), 4.00 - 3.87 (m, 3H), 2.36 - 2.16 (m, 3H), 2.00 - 1.91 (m, 5H) and 1.75 -1.41 (m, 4H) ppm.

LCMS RT = 3.77 (M+l) 459.37, (M-l) 457.35.

[00922] The following compounds can be prepared by methods similar to those described in Scheme 19, Scheme 20 and Scheme 21:

542

576 [00923] (1R, 35^r)-.'Vl-[2-(5-chloro-l/f-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]cyclohexane-l,3-diamine (542)

LCMSRT= 1.4 (M+l) 361.4.

[00924] Λ-[(1Λ, 35)-3-( [2-(5-chloro-l.ff-pyrrolo [2,3-b]pyridin-3-y l)-5-fluoropyrimidin-4-yI]amino]cyclohexyl]acetamide (576)

Ή NMR (300 MHz, MeOD) δ 8.81 (s, IH), 8.20 (s, IH), 8.15 (s, IH), 7.99 (d, 7=4.1, IH), 4.23 (t, 7 =11.4, IH), 3.90 (t, 7 = 11.4, IH), 2.35 (d,7= 11.6, IH), 2.20 (d, 7 = 12.5, IH), 2.00 (d, 7= 15.9, 2H), 1.92 (s, 3H), 1.67 (dd, 7= 26.3, 13.2, IH), 1.53 -1.06 (m, 3H) ppm; LCMS RT = 1.8 (M+l) 403 (M-l) 401.4.

548 549 [00925] Methyl Λ-[(15,3R)-3-[[2-(5-chloro-I77-pyrrolo[2,3-b]pyridin-3-yl)-5fluoro-pyrimidin-4-yl]amino]cyclohexyl] carbamate (548).

LCMS RT = 2.8 (M+l) 419.5.

[00926] 3-((15,3Zf)-3-[[2-(5-chIoro-l.ff-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexyl]-l,l-dimethyl-urea (549).

LCMS RT = 2.6 (M+l) 432.5.

591 592 [00927] A-[(1R, 3S)-3-[[2-(5-chloro-l/i^f-pyrrolo[2,3“b]pyridin-3-yl)-5-fluoropyrimidin-4-yl] amino] cyclohexyl]-2-methoxy-acetamide (591)

-269WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

NMR (300 MHz, MeOD) δ 8.82 (d, J = 2.4 Hz, IH), 8.21 (d, J = 2.3 Hz, IH),

3.40 (s, 3H), 2.34 (d, J= 11.6 Hz, IH), 2.21 (d, J= 12.5 Hz, IH), 2.02 - 1.93 (m, 2H), 1.74 1.62 (m, IH) and 1.54 - 1.28 (tn, 3H) ppm.

LCMS RT = 2.6 (M+l) 433.4.

[00928] 2-methoxy ethyl JV-[(1R, 3S)-3-|[2-(5-chloro-l//-pyrrolo[2,3-b|pyridin-3yl)-5-fluor o-py r imidin-4-yl] amino] cyclohexyl] carba mate (592)

Ή NMR (300 MHz, MeOD) δ 8.84 (s, IH), 8.21 (s, IH), 8.16 (s, IH), 7.99 (d, J =3.97 Hz, IH), 4.18 - 4.34 (m, IH), 4.14 (br. s., 2H), 3.49 - 3.74 (m, 3H), 3.3 (s, 3H) 2.38 (d, /=9.06 Hz, IH), 2.19 (d,/=13.41 Hz, IH), 1.84-2.11 (m, 2H), 1.51 - 1.78 (m, IH), 1.12 -

1.47 (m, 3H)ppm.

LCMS RT = 2.5 (M+l) 463.4.

[00929] A'-[(IR, 35)-3-( [2-(5-chloro-l/T-pyrrolo [2,3-b] pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexyl]-3-hydroxy-2,2-dimethyl-propanamide hydrochloride (650)

NMR (300 MHz, MeOD) δ 8.56 - 8.54 (m, 2H), 8.34 (s, IH), 8.30 (t, /= 5.4 Hz, IH), 4.29 (t, / = 11.4 Hz, IH), 3.93 (t, / = 11.6 Hz, IH), 3.54 (s, 2H), 2.34 (d, / = 10.8 Hz, IH), 2.18 (d, /= 11.4 Hz, IH), 2.01 (d, /= 11.3 Hz, 2H), 1.73 - 1.37 (m, 4H) and 1.15 (s, 6H) ppm.

LCMS RT = 3.79 (M+l) 461.38, (M-l) 459.4.

[00930] ZV-[(1J?, 3S)-3-[[2-(5-chIoro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5-nuoropyrimidin-4-yl]amino]cyclohexyl]tetrahydropyran-3-carboxamide hydrochloride (633) *H NMR (300 MHz, MeOD) δ 8.64 (d, / = 2.2 Hz, IH), 8.51 (s, IH), 8.36 (d, /= 2.2 Hz, IH), 8.29 (d, /= 5.5 Hz, IH), 4.39 (t, /= 11.9 Hz, IH), 3.93 - 3.82 (m, 3H), 3.54 - 3.30 (m, 2H), 2.52 - 2.43 (m, IH), 2.37 - 2.33 (m, IH), 2.20 (d, /= 11.6 Hz, IH), 2.01 (d, /= 11.3 Hz, 2H), 1.90 - 1.88 (m, IH), 1.83 - 1.63 (m, 4H) and 1.59 - 1.26 (m, 3H) ppm.

LCMS RT = 3.25 (M+l) 473.42, (M-l) 471.1.

[00931] A-[(!/?, 35)-3-[[2-(5-chloro-l#-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexyI]-3-hydroxy-propanamide hydrochloride (634) ’HNMR (300 MHz, MeOD) δ 8.61 (d, /= 2.1 Hz, IH), 8.53 (s, IH), 8.35 (d, /= 2.0 Hz, IH), 8.29 (d, /= 5.5 Hz, IH), 4.37 (t, / = 11.2 Hz, IH), 3.95 (s, IH), 3.80 (s, 2H), 2.42

-270WO 2010/148197

PCT/US2010/038988 (t, 5.5 Hz, 3H), 2.20 (d, J = 11.5 Hz, 1H), 2.03 (d, J- 11.0 Hz, 2H) and 1.76 - 1.29 (m,

4H) ppm.

LCMS RT = 3.47 (M+l) 433.21, (M-l) 431.3.

[00932] TV-KIR, 35)-3-( [2-(5-chloro-U7-pyrrolo [2,3-b] pyridin-3-yl)-5-fliioropyrimidin-4-yl] amino] cyclohexyl] -3 -methyl-oxeta ne-3 -carboxamide hydrochloride (63 S) 'H NMR (300 MHz, MeOD) 8 8.48 - 8.45 (m, 2H), 8.29 - 8.23 (m, 2H), 4.84 (d, J = 6.0 Hz, 1H), 4.38 (d, 6.0 Hz, 1H), 4.26 - 4.23 (m, 1H), 3.96 (s, 1H), 3.77 - 3.62 (m, 2H),

2.36 (s, 1H), 2.18 (d, J= 11.5 Hz, 1H), 2.02 (d, 12.3 Hz, 2H), 1.70 - 1.25 (m, 4H) and

1.59 (s,3H) ppm.

LCMS RT = 3.12 (M+l) 459.38, (M-l) 457.4.

636 ®40 [00933] A^r-[(17?, 35)-3-[[2-(5-chloro-llZ-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexyl]tetrahydropyran-4-carboxamide hydrochloride (636) ‘H NMR (300 MHz, MeOD) 8 8.64 (d, J= 2.3 Hz, 1H), 8.51 (s, 1H), 8.36 (d, J= 2.3 Hz, 1H), 8.29 (d, J = 5.6 Hz, 1H), 4.44 - 4.36 (m, 1H), 3.96 - 3.87 (m, 3H), 3.47 - 3.37 (m, 2H), 2.49 - 2.35 (m, 2H), 2.21 (d, 7= 12.4 Hz, 1H), 2.02 (d, J= 11.9 Hz, 2H) and 1.83 - 1.23 (m, 8H) ppm. LCMS RT = 3.12 (M+1) 473.4, (Μ-1) 471.4.

[00934] _;V-[(l/?,35^r)-3-[[2-(5-chloro-l//-pyrrolo[2,3-b|pyridin-3-yl)-5-fluoropy rimidin-4-yl] amino] cyclo hexyl] -3-hydroxy-butanamide hydrochloride (640) 'H NMR (300 MHz, MeOD) 8 8.69 (d, J= 2.3 Hz, 1H), 8.51 (s, 1H), 8.37 (d, 7= 2.2 Hz, 1H), 8.29 (d, 7= 5.6 Hz, 1H), 4.43 (t, J= 11.9 Hz, 1H), 4.14 (q, J= 6.1 Hz, lH),3.94(t, J = 11.9 Hz, 1H), 2.40 - 2.19 (m, 4H), 2.03 (d, J= 8.2 Hz, 2H), 1.78 - 1.69 (m, 1H), 1.59 -

1.44 (m, 3H) and 1.18 (d, J= 6.1 Hz, 3H) ppm.

LCMS RT = 3.37 (M+l) 447.41, (M-l) 445.1.

642 651 [00935] 7V~[(1R, 35)-3-( [2-(5-chIoro-l£f-pyrrolo [2,3-b] pyridin-3-y l)-5-fluoropynmidin-4-yl]amino]cycIohexyl]-2-hydroxy-propanamide hydrochloride (642) ^]H NMR (300 MHz, MeOD) 8 8.68 (s, 1H), 8.56 (s, 1H), 8.39 (d, J= 1.5 Hz, 1H),

8.31 (d, 5.3 Hz, 1H), 4.47 - 4.40 (m, 1H), 4.15 (s, 1H), 3.98 (m, 1H), 2.41 (s, 1H), 2.23 (d, J= 10.6 Hz, 1H), 2.04 (d, J= 11.0 Hz, 2H) and 1.77 - 1.36 (m, 7H)ppm.

LCMS RT = 3.52 (M+I) 433.58, (M-l) 431.3.

[00936] /V-[(1R, 35)-3-[[2-(5-chloro-m-pyrrolo[2,3-b]pyridin-3-yI)-5-fluoropyrimidin-4-yl]amino]cyclohexyl]tetrahydropyran-2-carboxamide hydrochloride (651)

-271WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 ’H NMR (300 MHz, MeOD) δ 8.56 - 8.51 (m, 2H), 8.33 - 8.29 (m, 2H), 4.30 (d, J = 3.0 Hz, IH), 3.98 (dd, J= 11.5, 23.4 Hz, 2H), 3.83 - 3.79 (m, IH), 3.55 (t, J= 8.9 Hz, IH), 2.35 (d, J= 11.1 Hz, IH), 2.19 (d, J= 11.2 Hz, IH), 2.03 - 1.90 (m, 4H) and 1.73 - 1.37 (m, 8H)ppm. LCMS RT = 4.1 (M+l) 473.41, (M-l) 471.4.

[00937] 7V-[(1 R, 35)-3-( [2-(5-chloro-l 77-py r rolo [2,3-b] py r idin-3-yl)-5-fluo ropyrimidin-4-yl]amino]cyclohexyl]tetrahydrofuran-3-carboxaniide hydrochloride (652) ^]H NMR (300 MHz, MeOD) δ 8.72 (d, J= 2.3 Hz, IH), 8.56 (s, IH), 8.42 (d, J= 2.2 Hz, IH), 8.34 (d, J= 5.6 Hz, IH), 4.51 - 4.43 (m, IH), 4.02 - 3.88 (m, 3H), 3.86 - 3.78 (m, 2H), 3.07 - 3.02 (m, IH), 2.42 (d, J= 7.5 Hz, IH), 2.25 (d, J= 12.0 Hz, IH), 2.19 - 2.06 (m, 4H) and 1.79 - 1.35 (m, 4H) ppm.

LCMS RT = 3.9 (M+l) 459.41, (M-l) 457.4.

[00938] (5)-tetrahydrofuran-3-yl (15,35)-3-(2-(5-chIoro-l£i-pyrrolo[2,3Zi]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)cycIoliexyicarbamate (649)

LCMS RT = 3.3 (M+l) 475.37, (M-l) 473.35.

[00939] /V-((15,35)-3-(2-(5-chloro-l_JH^r-pyrrolo[2,3-Z>]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cyclohexyl)-3-methoxypropanamide (611)

LCMS RT = 2.0 (M+l) 447.4, (M-l) 445.4.

[00940] /V-[2-(5-chloro-17f-pyrroIo[5,4-b]pyridin-3-yI)-5-fluoro-pyrimidin-4yl]cyclohexane-cis-l,3-diamine (540)

LCMS RT= 1.4 (M+l) 361.5.

-272WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

457 [00941] /V-[<?is-3-[[2-(5-chloro-li5-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin4-yl] amino] cyclohexyl] acetamide (452) (prepared from cis/trans l,3diamino cyclohexane; separated by HPLC from trans diastereomer)

LCMS RT = 1.3 (M+l) 403.1 (M-l) 401.1.

[00942] /V-[fr«/is-3-[[2-(5-chloro-llT-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexyl]acetamide acetamide (457) (separated by HPLC from cis diastereomer)

LCMS RT= 1.6 (M+l) 403.2 (M-l) 401.1.

⁴⁵⁵ 458 [00943] l-[cz\-3-[[2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yI)-5-fluoro-pyriinidin4-yl] amino] cyclohexyl]-3-methyl-urea (455) (prepared from cis/trans l,3diamino cyclohexane; separated by HPLC from trans diastereomer)

LCMS RT = 1.7 (M+l) 416.2.

[00944] l-[trnns-3-[[2-(5-chloro-llT-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl] amino] cyclohexyl]-3-methyl-urea (458) (prepared from cis/trans 1,3-diamino cyclohexane; separated by HPLC from cis diastereomer)

LCMS RT = 0.8 (M+l) 418.2 (M-l) 416.1.

O

⁴⁵⁶ 459 [00945] 3-[cis'-3 - [ [2-(5-chloro-l£f-pyr rolo [2,3-b] py ridin-3-yl)“5-fluoro-py rimidin4-yI] amino] cyclohexyl] -1,1 -dimethyl-u rea (456) (prepared from cis/trans l,3diamino cyclohexane; separated by HPLC from trans diastereomer)

-273WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

LCMS RT = 1.5 (M+l) 432.2 (M-l) 430.2.

[00946] 3-[ir«iis’-3-[[2-(5-chIoro-l/I-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexyl]-l.,l-dimethyl-urea (459) (prepared from cis/trans l,3diamino cyclohexane; separated by HPLC from cis diastereomer) LCMS RT = 1.5 (M+l) 432.2 (M-l) 430.2.

[00947] Methyl-c/s-3-[[2-(5-chloro-lfi-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexylcarbamate (514) - (racemic cis mixture - prepared from cis-L3-diaminocyclohexane)

LCMS RT- 1.3 (M+l) 418.8.

[00948] 'V-((l/7, 35)-3-(2-(5-chloro-177-pyrrolo[2,3-6]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cyclohexyl)morpholine-4-carboxamide (647)

LCMS RT = 3.6 (M+l) 474.4 (M-l) 472.5.

[00949] jV-[3-[[2-(5-chIoro-lif-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-pyrimidin-4yl] amino] cyclohexyl] methanesulfonamide (454)

LCMS RT = 1.6 (M+l) 439.1 (M-l) 437.1.

[00950] (tetrahydrofuran-3-yl)methyl (l_ff,35)-3-(2-(5-chloro-l/Z-pyrrolo[2,36]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)cyclohexylcarbamate (648)

LCMS RT = 3.7 (M+l) 489.38, (M-l) 487.49.

General Scheme 22:

-274WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

20c 637 (a) 4-lerl-butoxycarbonyImorpholine-2-carboxylic acid, EDC, HOBt, 'PrjNEt, CH2CI2, rt (b) CH2CI2, TEA (c) LiOH, 13 0°C, microwave [00951] Formation /V-|(1Z?, 3S)-3-][2-(5-chloro-1//-pyrroIo[2,3-b|pyri(lin-3-yl)-5fluoro-pyrimidin-4-yl]amino]cyclohexyl]morpholine-2-carboxamide bishydrochloride (637)

To a solution of (IS, 3/?)-.Vl-[2-[5-ch]oro-J-(p-tolylsuIfonyI)pynOlo[2,3-b]pyridin-3yl]-5-fluoro-pyrimidin-4-yl]cyclohexane-l,3-diamine (0.06 g, 0.12 mmol) in CH₂C1₂ (3 mL) was added 4-te/^-i-butoxycarbonylmorpholine-2-carboxylic acid (40.4 mg, 0.17 mmol), EDC (0.03 g, 0.14 mmol), HOBt (0.02 g, 0.12 mmol) and ‘Pr₂NEt (0.06 g, 0.47 mmol), and the reaction mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the residue was dissolved in CH₂C1₂ (2 mL) and TFA (2 mL) and allowed to stir at room temperature for 2 hours. The resulting solution was concentrated in vacuo, dissolved in THF (4mL) and treated with IN aqueous lithium hydroxide (3.0 mL, 3.0 mmol). The reaction mixture was heated in the microwave to 130 °C for 20 min. The solvent was evaporated under reduced pressure, and the residue was purified by HPLC, using 5-70% MeOH/H₂O with 6mM HC1 over 15 minutes. The purified fractions were concentrated to provide the bis-hydrochloride of ΛΓ-[(1Λ, 35)-3-[[2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)5-fluoro-pyrimidin-4-yl]amino]cyclohexyl]morpholine-2-carboxamide.

^fH NMR (300 MHz, MeOD) δ 8.68 (s, IH), 8.62 (s, IH), 8.40 (s, IH), 8.33 (d, J= 4.7 Hz, IH), 4.44 - 4.35 (m, 2H), 4.21 (d, 7= 12.2 Hz, IH), 4.04 - 3.92 (m, 2H), 3.58 (d, J= 12.3 Hz, IH), 3.23 - 3.08 (m, 2H), 2.37 (d, 7 = 8.1 Hz, IH), 2.23 (d, 7= 11.1 Hz, IH), 2.05 (d, 7=

9.7 Hz, 2H), 1.72 (m, 2H) and 1.59 - 1.44 (m, 2H) ppm; LCMS RT = 2.4 (M+l) 474.43, (ΜΙ) 472.4.

[00952] Other analogs that can be prepared in the same manner as 637 are described below:

639 [00953] /V-[(lfi, 3S)-3-[[2-(5-chloro-17/-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin“4-yl]amino]cyclohexyl]piperidine-4-carboxamide bishydrochloride (639) ^lH NMR (300 MHz, MeOD) δ 8.66 (s, IH), 8.60 (s, IH), 8.38 (s, IH), 8.31 (d, 7= 4.7

Hz, IH), 4.43 - 4.36 (m, IH), 3.98 - 3.91 (m, IH), 3.43 (d, 7= 10.3 Hz, 2H), 3.03 (t, 7= 10.6

-275WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Hz, 2H), 2.60 (s, 1H), 2.38 (d, 7= 10.2 Hz, 1H), 2.21 (d, 7= 10.6 Hz, 1H), 2.07 - 1.92 (m, 6H) and 1.74 - 1.30 (m, 4H) ppm.

LCMS RT = 2.4 (M+l) 472.46, (M-l) 470.4.

ci

(a) (IS, 2S)-cyclohexane-i,2-diamine, THF, 120 °C microwave (b) methyl-chloroformate, 'PriNEt, CI+CL (c) L1AIH4, THF.

[00954] Formation of (15, 25)-/Vl-(2-(5-chIoro-l-tosyl-lH-pyrroIo[2,3-6]pyridin-3yl)-5-fluoropyrimidin-4-yl)cyclohexane-l,2-diamine (23b)

A solution of 5-chloro-3-(5-fluoro-4-methylsulfinyl-pyrimidin-2-yl)-l-(ptolylsulfonyl)pyrrolo[2,3-b]pyridine, 23a, (0.50 g, 1.08 mmol) in THF (4 mL) was treated with (15,25)-cyclohexane-l,2-diamine (0.27 g, 2.37 mmol) and ’Pr₂NEt (2.15 mmol) at 120 °C for 10 minutes. The mixture was concentrated in vacuo. The resulting residue was purified by silica gel chromatography (0-20% MeOH-CHaCL) to provide the desired intermediate as a white solid (410 mg).

LCMS RT = 2.2 (M+l) 515.5.

[00955] Formation of methyl (15, 25)-2-(2-(5-chloro-l-tosyl-l/f-pyrrolo[2,36]pyridin-3-yl)-5-fluoro-pyrimidin-4-ylamino)cyclohexylcarbamate (23c)

To a mixture of (15, 25)-/91 -(2-(5-chloro-l-tosyl-I/f-pyrrolo[2,3-i]pyridin-3-yl)-5fluoropyrimidin-4-yl)cyclohexane-l,2-diamine, 23b, (0.18 g, 0.35 mmol) in dichloromethane (4 mL) at room temperature was added 'Pr₂NEt (0.12 mL, 0.70 mmol) followed by methyl chloroformate (0.03 mL, 0.37 mmol). After 35 minutes, the mixture was diluted with EtOAc, washed successively with aqueous saturated NH4CI and aqueous saturated NaHCO₃ and brine, dried over Na₂SO4 filtered and concentrated in vacuo to provide the crude product sufficiently pure for use in the next reaction.

LCMS RT = 4.1 (M+l) 573.4.

[00956] Formation of (15, 25)-/Vl-(2-(5-chloro-l/Z-pyrrolo [2,3-6] pyridin-3-y 1)-5fluoropyrimidin-4-yl)-/V2-methylcyclohexane-l,2-diamine (522)

To astirred solution of methyl (15,2S)-2-(2-(5-chloro-l-tosyl-177-pyrrolo[2,36]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)cyclohexylcarbamate, 23c, (0.09 g, 0.16 mmol) in THF (3 mL) at room temperature was added LiA!H₄ (0.06 g, 1.66 mmol) and the mixture

-276WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 was stirred at room temperature for additional 2 hours. The reaction was quenched with 0.06 mL KOH (5% aq) followed by water (3 x 0.06 mL). Then, additional Et₂O (6 mL) was added and stirring was continued for 20 minutes. The milky white suspension was filtered and rinsed with EtOAc and the cake was rinsed with additional EtOAc. The combined organic phases were concentrated in vacuo and purified by preparative HPLC followed by preparative TLC to provide the desired product as the free base that was then converted to the HCI salt by treatment with HCI (4N in dioxane).

LCMSRT = 1.7 (M+l) 375.5.

General Scheme 24:

Cl

23b

(a) NaCNBH₃, (CH₂O)_n, HOAc, CH₃CN [00957] Formation of (IX, 2X)-A'1-(2-(5-chloro-l/7-pyrrolo[2,3-Z>]pyridin-3-yl)-5fluoropyrimidm~4-yl)-7V2,7V2-dimethy!cyclohexane-l ,2-di amine (523)

To a mixture of (IS, 25)-64-(2-(5-chloro-17f-pyrrolo[2,3-6]pyridin-3-yl)-5fluoropyrimidin-4-yl)cyclohexane-L2-diamine, 23b, (0.08 g, 0.22 mmol) in acetonitrile (1.6 mL) at room temperature was added formaldehyde (0.09 mL of 37 %w/v, 1.11 mmol) followed by NaCNBH₃ (0.04 g, 0.56 mmol). A gelatinous mix formed and after 4 min the mixture became fluid again. After 4 hours, the reaction was quenched with 5 mL of 2N NaOH and the mixture was stirred overnight. The mixture was diluted with EtOAc and stirred until all solid dissolved. The layer was extracted with EtOAc several times, dried over Na₂SO₄, filtered and concentrated in vacuo. Silica gel cliromatography (0-15% MeOHCH₂Cb) followed by prcparatoiy HPLC provided the desired product, which was converted to the corresponding HCI salt with HCI (4N in dioxane).

‘Η NMR (300 MHz, MeOD) δ 8.65 (d, J= 2.3 Hz, IH), 8.54 (s, IH), 8.43 (d, ./ = 5.1 Hz, IH), 8.40 (d, J= 2.3 Hz, IH), 4.82 - 4.72 (m, IH), 3.66 - 3.53 (m, IH), 2.96 (s, 3H), 2.77 (s, 3H), 2.33 (d, ./ = 12.3 Hz, 2H), 2.10 - 1.97 (m, 2H) and 1.75 - 1.48 (m, 4H) ppm; LCMS RT = 1.7 (M+l) 389.5.

General Scheme 25:

H₂N

(a) 2-(methoxymethyl)oxirane, methanol, 130°C, microwave (b) LiOH, 130°C, microwave [00958] Formation of l-[[(12?, 3X)-3-[[2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)-277WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

5-flu oro-pyrimidin-4-yI] amino] cyclohexyl] a mino]-3-methoxy-p ropan-2-ol (610)

To a solution of (15, 3R)-AT-[2-[5-chloro-l-(p-tolylsulfbnyl)pyrrolo[2,3-b]pyridin-3yl]-5-fluoro-pyrimidin-4-yl]cyclohexane-l,3-diamine, 20c, (50 mg, 0.09 mmol) in methanol (2 mL) was added 2-(methoxymethyl)oxirane (9.4 mg, 0.11 mmol) and the reaction mixture was heated in the microwave to 140°C for 10 min. IM aqueous LiOH (1.0 mL, 1.0 mmol) was added, and the reaction mixture was heated in the microwave to 130°C for 10 min.

The solvent was evaporated under reduced pressure, and the residue was purified by HPLC, using 5-70% CH₃CN//H₂O with 0.1% TFA over 15 minutes. The purified fractions were concentrated, redisolved in MeOH and passed through a carbonate-PS column to provide the free base of the desired product l-[[(lR,3S)-3-[[2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)5-fluoro-pyrimidin-4-yl]amino]cyclohexyl]amino]-3-methoxy-propan-2-ol, 610.

^!H NMR (300 MHz, MeOD) δ 8.85 (d, J= 2.3 Hz, IH), 8.22 (d, 7= 2.2 Hz, IH), 8.15 (s, IH), 7.98 (d, 7= 4.1 Hz, IH), 4.20 (m, IH), 3.82 (dd, 7= 3.9, 8.2 Hz, IH), 3.55 - 3.45 (m, IH), 3.30 (s, 3H), 3.23 - 3.07 (m, IH), 2.86 - 2.77 (m, 2H), 2.68 - 2.59 (m, IH), 2.44 (d, 7 =

10.9 Hz, IH), 2.15 (d, 7= 9.8 Hz, IH), 2.07 - 1.94 (m, 2H), 1.65 - 1.56 (m, IH) and 1.42 -

1.17 (m, 3H) ppm; LCMS RT = 1.52 (M+l) 449.42.

General Scheme 26:

(a) 2-bromoacetamide, Na₂CO₃, DMF, rt (b) LiOH, 130°C, microwave.

[00959] Formation of 2-[[LR, 35)-3-[2-(5-chloro-17/-pyrro]o[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-yl]amino]cyclohexylamino]-acetamide (593)

To a solution of (15, 3R)-iVl-[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3yl]-5-fluoro-pyrimidin-4-yl]cyclohexane-1,3-diamine, 20c, (0.050 g, 0.100 mmol) in DMF (2 mL) was added 2-bromoacetamide (0.015 g, 0.100 mmol) and Na₂CO₃ (0.021 g, 0.190 mmol) . The reaction mixture was stirred at room temperature overnight

IM aqueous lithium hydroxide (2.0 mL, 2.0 mmol) was added, and the reaction mixture was heated in the microwave to 130°C for 10 min. The solvent was evaporated under reduced pressure, and the residue was purified by HPLC, using 5-70% CH₃CN//H₂O with 0.1% TFA over 15 minutes. The purified fractions were concentrated, redisolved in MeOH and passed through a carbonate-PS column to provide the free base of the desired product 2-[[lR,3S)-3[2-(5-chloiO-lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4yl]amino]cyclohexylamino]-acetamide, 593.

^!H NMR (300 MHz, MeOD) δ 8.85 (d, 7= 2.3 Hz, IH), 8.22 (d, 7= 2.2 Hz, IH), 8.15 (s, IH), 7.99 (d, 7= 4.1 Hz, IH), 4.28 - 4.20 (m, IH), 2.82 - 2.73 (m, IH), 2.65 (s, 2H), 2.40 (d, 7= 10.2 Hz, IH), 2.15 (d, 7= 8.5 Hz, IH), 2.05 - 1.92 (m, 2H), 1.64 - 1.55 (m, IH) and

1.44 -1.12 (m, 3H) ppm; LCMS RT = 1.47 (M+l) 418.21.

General Scheme 27:

-278WO 2010/148197

PCT/US2010/038988

a) 3-Aminocyclohexanol, 'Pr₂NEt, THF, MW 130 °C; b) Ag₂O, CaSO_4i CH₃I, r.t.; c) sodium methoxide, THF.

[00960] Formation of (5)-3-(2-(5-chloro-l-tosyl-lI7-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cyclohexanol (27a).

To a solution of 5-chloro-3-(5-fluoro-4-(methylsulfonyl)pyrimidin-2-y 1)-1 -tosyl- 1/7pyrrolo[2_}3-Z>]pyridine, la, (1.09g, 2.34 mmol) and 3-aminocyclohexanol (0.32 g, 2.82 mmol) in THF was added DIEA (0.60 g, 4.69 mmol). The reaction mixture was heated at 130 °C in microwave for 10 min. The solvent was removed under reduced pressure and the resulting residue was purified by silica gel chromatography to afford 550 mg of the desired product, 27a.

Ή NMR (300 MHz, CDCI3) δ 8.88 (s, 1H), 8.56 (s, 1H), 8.40 (d, J = 2.4 Hz, 1H),

8.12 - 8.07 (m, 3H), 7.32 - 7.28 (m, 2H), 5.70 (m, 1H), 4.35 (m, 1H), 4.10 (m, 1H), 2.40 (s, 3H), 2.32 (d, 7= 12.3 Hz, 1H), 2.0 - 1.95 (m, 2H), 1.70-1.45 (m4H).

[00961] Formation of 2-(5-chloro-l-tosyl-117-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoroA-((lS)-3-methoxycyclohexyl)pyrimidin-4-amine (27b).

To a suspension of methyl iodide (0.20 g, 0.41 mmol) and 3-[[2-[5-chloro-l-(ptolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5-fluoro-pyrimidin-4-yl]amino]-cyclohexanol, 27a, (0.47 g, 2.04 mmol) was added silver oxide (0.578 g, 4.07 mmol and calcium sulfate (0.28 g, 2.04(mmol). The reaction mixture was stirred at room temperature for 18h. The mixture was filtered through celite and the resulting filtrate was concentrated in vacuo. The resulting crude mixture was purified by silica gel chromatography to afford 120 mg of the desired product, 27b.

*H NMR (300 MHz, CDCI3) δ 8.88 (s, 1H), 8.56 (s, 1H), 8.4 (d, 7= 2.4 Hz, 1H), 8.13 - 8.06 (m, 3H), 7.30 (d, 7 = 8.7 Hz, 2H), 6.00 (s, 1H), 4.42-4.32 (m, 1H), 3.60-3.50 (m, 1H),

3.4 (s, 3H), 2.4 (s, 3H), 2.25 (dd, 7= 3.4, 9.7 Hz, 1H), 2.00-1.84 (m 3H), 1.75-1.60 (m, 3H), 1.60-1.50 (m, 1H).

[00962] Formation of 2-(5-chIoro-Lff-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-N-((lS)3-methoxycyclohexyl)pyrimidin-4-amine (552).

To a solution of 2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5-fluoroW(3-methoxycyclohexyl)pyrimidin-4-aminc, 27b, (0.08 g, 0.15 mmol) in THF were added a few drops of NaOMe. The reaction mixture was stirred at room temperature for 20 min. To the reaction mixture was added ethyl acetate and brine. The organic phase was separated, dried (MgSOfl, filtered and concentrated in vacuo. The residue was dissolved in

-279WO 2010/148197

PCT/US2010/038988

CH3CN/H2O and the mixture was purified by preparatory HPLC to afford 23 mg of the desired product, 552.

‘H NMR (300 MHz, CD₃OD) 5 8.70 (d, J = 2.3 Hz, IH), 8.45 (s, IH), 8.35(d, J = 2.3 Hz, IH), 8.25(d, J= 5.4 Hz, IH), 4.35 (m, IH), 3.52 (m, IH), 3.4 (s, 3H), 2.53 (d, J= 12.1 Hz, IH), 2.18 (d, J= 11.4 Hz, 2H), 2.05-1.95 (m, IH), 1.65-1.4 (m, 3H), 1.38-1.25 (m, IH); LCMS RT = 2.22 min (M+l) 376.23

[00963] (35)-3-(2-(5-chloro-lH^r-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylammo)cyclo hexanol (524).

LCMS RT = 2.0 (M+l) 362.48.

[00964] 3-(2-(5-chloro-l//-pyrrolo|2,3-/)]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)cyclohexyl ethylcarbamate (608).

LCMS RT = 2.9 (M+l) 433.4.

General Scheme 28:

C!

571, 572

a) Dess-Martin periodinane, CH2CI2; b) CHsMgBr, THF; c) sodium methoxide, THF.

[00965] Formation of 3-(2-(5-chloro-l-(phenylsulfonyl)-li^l7-pyrrolo[2,3-b]pyridin3-yl)-5-fluoropyrimidin-4-ylamino)cyclohexanone(28a).

To a solution of3-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5fluoro-pyrimidin-4-yl]amino]cyclohexanol, 27a, (0.54 g. 1.05 mmol) in 20 ml CH2CI2 was added Dess-Martin periodinane (0.62 g, 1.47 mmol). The suspension was stirred at room temperature for 6h. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The resulting residue was purified by silica gel chromatography (45% ethyl acetate/hexanes gradient) to afford 430mg of the desired product.

-280WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 'HNMR (300MHz, CDC13) 6 8.66 (d, J = 2.4 Hz, IH), 8.42(slH), 8.31 (d, J = 2.3 Hz, IH), 8.05-8.02 (m, 3H), 7.24-7.19 (m, 2H), 2.99 (d, J= 5.2 Hz, IH), 4.56 (s, IH), 2.85 (dd, J= 4.7, 13.9 Hz, IH), 2.50-2.40 (m, 3H), 2.40 (s, 3H), 1.95-1.80 (m, 2H), 1.70-1.50 (m, 2H).

[00966] Formation of 3“(2“(5-chloro-l-(phenylsulfonyl)-lH-pyrrolo[2,3-b]pyridin3~yl)-5-fluoropyrimidin-4-ylamino)-l-methyIcycIohexanol (28b).

To a cold (0 °C) solution of 3-[[2-[5-chloro-l-(p-tolylsulfonyI)pyrrolo[2,3-b]pyridin3-yl]-5-fluoro-pyrimidin-4-yl]amino]cyclohexanone, 28a, (0.47 g, 0.92 mmol) in THF (5 mL) was added methylmagnesium bromide (3.30 ml of 1.4M solution, 4.58 mmol). The reaction mixture was stirred at 0 °C for Ih. The reaction mixture was diluted with ethyl acetate and aqueous saturated NH4CI solution. The organic phase was separated, dried (MgSO.'i), filtered and concentrated in vacuo. Tire products were purified by silica chromatography with DCM and methanol, two products were eluded with 95% DCM and 5% methanol no separation. The two diastereomers were taken on as a mixture without further purification.

LCMS (10-90% 3/5min(grad/run) w/FA) indicated 2 peaks for the desired products. Peak 1: retention time = 4.04 min (M + 1; 530.42); peak 2: retention time = 4.18min (M + 1: 530.45).

[00967] Formation of (35)“3-(2-(5-chloro-117-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-l-methylcycIohexanol (571 and 572).

To a solution of 3-(2-(5-chloro-l-(phenylsulfonyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-l-methylcyclohexanol, 28b, in THF was added a few drops of 25% sodium methoxide at room temperature. The reaction mixture was stirred at room temperature for 5 min. The reaction mixture was diluted with ethyl acetate and brine. The organic phase was separated, dried (MgSO₄), filtered and concentrated in vacuo. The product was purified by preparatoiy HPLC to afford two diastereomers.

Diastereomer 1 - 571.

Ή NMR (300MHz, CD3OD) δ 8.78 (d, J= 2.2 Hz, IH), 8.60 (s, IH), 8.36 (s, IH), 8.30 (dd, J = 5.6, 9.9 Hz, IH), 4.85 (m, IH) 2.25-1.95 (m, 3H), 1.86-1.6(m 4H), 1.40-1.3(m 2H), 1.3(s, 3H); LCMS RT 2.39 (M+l) 376.42.

Diastereomer 2 - 572.

Ή NMR (300 MHz, CD₃OD) 8.66 (d, J = 2.1 Hz, IH), 8.55 (d, 2.7 Hz, IH), 8.38 (s,

IH), 8.258 (dd, J= 5.6, 9.5 Hz, IH), 4.6(s, IH), 2.00-1.50 (m, 9H), 1.30 (s, 3H);

LCMS RT 1.97 (M+l) 376.41.

ci

617, 618

627, 628 [00968] 3-(2-(5-chlorO“177“pyn-oIo[2,3-6]pyridin-3-yl)-5-fluoropyrimidm-4ylamino)-l-ethynylcyclohexanol (617 and 618).

Diastereomer 1 - 617: LCMS RT = 3.6 (M+l) 386.4.

Diastereomer 2 - 618: LCMS RT = 3.2 (M+l) 386.3.

[00969] 3-(2-(5-chloro-lZ/-pyrrolo[2,3-/»]pyridin-3-yl)-5-fluoropyrimidin-4-281WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 ylamino)-l-vinylcyclohexanol (627 and 628).

Diastereomer 1 - 627: LCMS RT = 4.0 (M+l) 388.4.

Diastereomer 2 - 628: LCMS RT = 3.7 (M+l) 388.4.

[00970] 3-(2-(5-chloro-lif-pyrrolo[2,3-6]pyridin-3-yI)-5“fluoropyrimidin-4ylamino)-l-(hydroxymethyl)cyclohexanol (646).

LCMS RT = 3.4 (M+l) 392.4.

[00971] 3-(2-(5-chloro-1//-pyrrolo[2,3-/>]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)-l-ethylcyclohexanol (626).

LCMS RT = 4.1 (M+l) 390.4.

General Scheme 29

29a 29b 29c, 29d

Cl Cl

[00972] Formation of (3S)-3-(2-chloro-5-fluoropyrimidin-4-ylamino) cyclohexanol (29a).

The starting racemic alcohol, (3S)-3-aminocyclohexanol, was prepared following the procedure described by Bemardelli, P., Bladon, M., Lorthiois, E., Manage, A., Vergne, F. and Wrigglesworth, R., Tetrahedron Asymmetry 2Q04,15, 1451-1455.

(3S)-3-(2-chloro-5fluoropyrimidin-4-ylamino) cyclohexanol was prepared according to the procedure for compound 16a using (3S)-3-aminocyclohexanol, afforded desired product, 29a, as a solid.

[00973] Formation of (₁S)-3-(2-chloro-5-fluoropyrimidin-4-yIamino) cyclohexanone (29b).

To 700 ml DCM solution of 7.9g (32.16 mmol) (3S)-3-[(2-chloro-5-fluoiO-pyrimidin-

4-yl)amino]cyclohexanol, 29a, (7.90 g, 32.16 mmol) in CH2CI2 (700 mL) was added DessMartin reagent (17.73 g, 41.81 mmol). The reaction mixture was stirred at room temperature for 20 hours until TLC chromatography indicated reaction was complete. The reaction mixture was filtered through a pad of celite, and the resulting filtrate was washed with 200 mL of aqueous saturated NaHCOj solution and 200 mL brine. The organic phase was dried with MgSCfi, filtered and the solvent was removed under reduced pressure. The product was

-282WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 purified by silica gel chromatography (50% EtOAc/hexanes) to afford 7.3g of the desired product, 29b (93% yield).

‘H NMR (300MHz, CD₃OD) δ H NMR (300 MHz, CDC13) δ 7.96 - 7.93 (m, 1H),

7.28 (s, IH), 5.12 (s, IH), 4.57-4.48 (m, 1H), 2.87 (dd,7=4.8,14.0 Hz, 1H), 2.51 -2.23 (m, 4H), 2.12 - 2.02 (m, IH); LCMS RT = 2.97 (M+l) 244.26.

[00974] Formation of (35)-3-(2-chloro-5-fluoropyrimidin-4-yIamino)-lmethylcyclohexanol (29c, 29d).

To a solution of (3S)-3-[(2-chloro-5-fluoro-pyrimidin-4-yl)amino]cyclohexanone (1.83 g, 7.49 mmol) in THF (100 mL) was added methylmagnesium bromide (21.4 ml of 1.4M solution, 29.96 mmol) at room temperature. The reaction mixture was stirred at room temperature for 5 minutes. To the reaction mixture was added aqueous saturated NH4CI solution and EtOAc. The organic phase was washed with brine and dried with MgSCU, filtered and concentrated in vacuo. The two spots were separated by silica gel chromatography (120g silica gel column).

Fraction-1 (29c): ‘H NMR (300MHz, CD3OD) δ δ 7.81 (d, 7= 2.8 Hz, 1H), 7.28 (d, 7= 0.5 Hz, H), 4.47 (q, 7= 3.8 Hz, IH), 1.92 - 1.87 (m, 2H), 1.82 - 1.77 (m, 1H), 1.69 (dd, 7 = 4.2, 14.0 Hz, 2H) and 1.56 - 1.48 (m, 4H) ppm; LCMS RT = 3.43 (M+l) 260.3.

Fraction-2 (29d): ’H NMR (300MHz, CD3OD) δ 7.87 (d, J = 2.8 Hz, H), 7.28 (s, H),

4.95 (d, J = 5.0 Hz, 1H), 4.45-4.33 (m, 1H), 2,17 (s,H), 2.12-2.06 (m, 1H), 1.93 - 1.78 (m, 1H), 1.71 (dd, J = 3.1, 5.6 Hz, 2H), 1.39 - 1.25 (m, 4H) and 1.19 - 1.05 (m, 1H) ppm; LCMS RT = 3.10 (M+l) 260.29.

[00975] Formation of (35)-3-(2-(5-chloro-l-tosyl-l/f-pyrrolo[2,3-Z>|pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-l-methylcyclohexanol (29c, 29f).

Degassed a solution of 5-chIoro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-l,3,2dioxaboro!an-2-yl)pyrrolo[2,3-b]pyridine (1.46g, 3.37 mmol), (3S)-3-[(2-chloro-5-fluoropyrimidin-4-yl)amino]-l-methyl-cyclohexanol, 29c, (0.72g, 2.81 mmol) and Na₂CO₃ (4.21 mL of 2M solution, 8.433 mmol) in dimethoxyethane (15 mL) for 30 min with nitrogen. To the reaction mixture was added palladium tetrakis-triphenylphosphane (0.16 g, 0.14 mmol). The reaction mixture was heated at 130 °C in Q-tube apparatus for 45 minutes. The reaction mixture was filtered through a pad of 1 cm of silica gel and 2 cm celite. The product was purified by silica gel chromatography (hexanes/EtOAc) to afford the desired product, 29e (63% yield).

*H NMR (300MHz, CD₃OD) δ 8.81 (d, 7= 2.4 Hz, 1H), 8.50 (s, 1H), 8.38 (d, 7= 2.4 Hz, 1H), 8.10 (d, 7= 8.3 Hz, 2H), 8.04 (d, 7= 3.3 Hz, 1H), 7.29 (d, 7= 8.1 Hz, 2H), 6.85 (d, 7= 5.7 Hz, H), 4.58 (t, 7= 3.7 Hz, 1H), 2.39 (s, H), 1.98 - 1.93 (m, 2H), 1.86 (d, 7 = 4.0 Hz, 2H), 1.72- 1.56 (m, 5H), 1.36 (d, 1 = 3.8 Hz, 3H) and 1.30- 1.26 (m, 1H) ppm.

LCMS RT = 4.62 (M+l) 530.4.

The diastereomer, 29f, was made according to the same procedure as 29e, substituting 29d as the starting material for the Suzuki coupling procedure.

‘HNMR (300MHz, CD₃OD) δ 8.89 (d, 7= 2.4 Hz, IH), 8.55 (s, IH), 8.39 (d, 7= 2.4 Hz, IH), 8.09 (t, 7= 8.4 Hz, 2H), 8.08 (s, IH), 7.29 (d, 7= 8.2 Hz, 2H), 4.89 (d, 7= 6.6 Hz, IH), 4.55 (m, IH), 2.39 (s, 3H), 2.24 (t, 7= 1.8 Hz, 2H), 2.02 - 1.93 (m, IH), 1.77 (t, 7= 3.3 Hz, 2H), 1.46 - 1.33 (m, 5H) and 1.29 - 1.15 (m, lH)ppm.

LCMS RT = 4.36 (M+l) 530.3.

[00976] Formation of (35)-3-(2-(5-chloro-l-tosyl-127“pyrrolo[2,3-Z»]pyridin-3-yl)5-fluoropyrimidin-4-ylamino)-l-methylcycIohexanol (655, 656).

-283WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

To a solution of (3S)-3-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5fluoro-pyrimidin-4-yl]amino]-l-methyl-cyclohexanol, 29f, (2.85 g, 5.38 mmol) in THF (200 mL) was added 1.5 ml 25%W/W sodium methoxide solution at room temperature. The reaction mixture was immediately injected into LC/MS. LC/MS indicated the reaction was complete. The reaction mixture was diluted with 200 ml EtOAc and the organic phase was washed twice with aqueous saturated NaHCOj and then twice with brine. The organic phase was dried with MgSO₄, filtered and concentrated in vacuo. The product was purified by silica gel chromatography (80g silica, 5% MeOH/CHaCL) to afford 1.7 g of the desired product. The resulting product was dissolved in 70 ml THF, to it was added 1.8 ml 5M HC1/IPA. The resulting suspension was stirred for 1 hour at room temperature. The solvent was removed under reduced pressure to afford 1.7g of the desired product, 655 as an HC1 salt.

‘H NMR (300MHz, CD₃OD) δ 9.54 (s, IH), 8.86 (d, J= 2.3 Hz, IH), 8.31 (d, /= 2.4 Hz, IH), 8.15 (d, ,7= 2.7 Hz, IH), 8.04 (d, .7= 3.5 Hz, IH), 7.28 (s, H), 6.66 (s, IH), 4.62 -

4.59 (m, IH), 1.96 - 1.88 (m, 4H), 1.81 (dd, J= 4.5, 14.9 Hz, IH) and 1.68 - 1.57 (m, 6H) ppm; LCMS RT = 4.01 (M+l) 376.4.

[00977] The corresponding diastereomer, 656, can be prepared in the same fashion.

General Scheme 30

562, 563 (a) mCPBA, CH₂CI₂ (b) NH4OH, water, 50 °C, 72 h (c) 5-chloro-3-(5-fluoro-4-(niethylsiilfinyl)pyrimidin2-yl)-l-tosyl-lZ7-pyrrolo[2,3-b]pyridine,'Pr₂NEt, DMF, 90 °C, 17 h (d) 1N LiOH, THF, microwave, 120 °C, 10 min.

|00978| Formation of l-methyl-7-oxabicyclo[4.1.0|heptane (30a)

To a cold (0 °C) solution of 1-methylcyclohexene (3.0 g, 31.2 mmol) in CH2CI2 (150 mL) was added mCPBA (8.4 g, 48.7 mmol). The reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was diluted into aqueous saturated NaHCO₃ solution and extracted with ether. The organic phase was washed again with aqueous saturated NaHCOj solution, dried (MgSO₄), filtered and concentrated in vacuo to afford the desired product as anoil that was used without further purification.

[00979] Formation of 2-amino-l-methylcyclohexanol (30b)

To a solution of l-methyl-7-oxabicyclo[4.1.0]heptane, 30a, (1.0 g, 7.1 mmol) in water was added ammonium hydroxide (6.0 mL, 154.1 mmol). The mixture was heated to 50 °C for 48 hours. The mixture was diluted with water, extracted with EtOAc and then twice with 20%MeOH/CHCl₃. The organic phases were dried (MgSO₄), filtered and concentrated in vacuo to provide the desired product, 30b, as an amorphous white solid.

-284WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 ^lH NMR (300.0 MHz, DMSO) δ 2.44 (dd, 7= 3.4, 10.8 Hz, IH), 1.64 - 1.45 (m, 4H),

1.28 - 1.01 (m, 4H) and 0.97 (s, 3H) ppm.

[00980] Formation of 2-(2-(5-chIoro-l-tosyl-lH-pyrroIo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-l-methylcyclohexanol (30c)

To a solution of 5-chloro-3-(5-fluoro-4-methylsulfinyl-pyrimidin-2-yl)-l-(ptolylsulfonyl)pyrrolo[2,3-b]pyridine, la, (0.97 g, 2.09 mmol) and 2-amino-lmethylcyclohexanol, 30b, (0.40 g, 3.13 mmol) in DMF (10 mL) was added ’Pr₂NEt (0.73 mL,

4.17 mmol). The reaction mixture was heated at 90 C for 17 hours. The reaction mixture was cooled to room temperature and diluted into aqueous saturated NaCl solution. The aqueous phase was extracted twice with EtOAc. The organic phases were washed with twice with aqueous saturated NaCl solution, dried (MgSO₄), filtered and concentrated in vacuo. The crude residue was purified via silica gel chromatography (0-50% EtOAc/hexanes-loaded with CH₂C1₂) to afford the desired product, 30c, as a white solid.

^SH NMR (300.0 MHz, DMSO) δ 9.00 (d, 7= 2.4 Hz, IH), 8.49 (dd, 7 = 2.4, 10.3 Hz, IH), 8.42 (s, IH), 8.23 (d, 7= 4.1 Hz, IH), 8.10-8.01 (m, 2H), 7.52 - 7.43 (m, 2H), 7.21 (d, 7= 9.1 Hz, IH), 4.52 (s, IH), 4.28 (s, IH), 2.35 (s, 3H), 1.78 - 1.50 (m, 6H), 1.34 (m, 2H) and 1.15 (s, 3H).

LCMS RT = 4.1 (M+l) 530.6.

[00981] Formation of 2-(2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-yIammo)-l-methylcyclohexanol (562 and 563)

To a solution of 2-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5fluoro-pyrimidin-4-yl]amino]-l-methyl-cyclohexanol, 30c, (0.41 g, 0.77 mmol) in THF was added IM LiOH solution. The reaction mixture was heated in microwave at 120 °C for 5 minutes. The reaction mixture diluted with water, twice extracted with EtOAc and then twice with 10% MeOH/CH₂Cl₂. The combined organic phases were dried (MgSO₄), filtered and concentrated in vacuo. The crude residue was purified via silica gel chromatography (5-20% MeOH: CH2CI2) to afford a white solid as a mixture of trans-enantiomers. The two transenantiomers were separated by chiral preparatory HPLC to afford 562 and 563.

Enantiomer 1 - 563: *H NMR (300.0 MHz, DMSO) 612.32 (s, IH), 8.86 (d, 7= 2.4 Hz, IH), 8.28 (d, 7= 2.4 Hz, IH), 8.20 (d, IH), 8.15 (d, IH), 6.92 (d, 7= 8.2 Hz, IH), 4.56 (s, IH), 4.31 (dd, 7= 5.9, 8.6 Hz, IH), 1.89 - 1.35 (m, 8H) and 1.17 (s, 3H); LCMS RT = 2.5 (M+l) 376.4.

-285WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 (a) 2,4-dichloro-5-fluoropyrimidine, acetonitrile/isopropanol, reflux 1.5hrs. (b) 5-chloro-3-(4,4,5,5tetramethyl-i,3,2-dioxaborolan-2-yl)-l-tosyl-l/7-pyrrolo[2,3-/>]pyridine, Pd(PPh₃)₄,2M Na₂CO₃ , acetonitrile, 120 °C microwave 15 min., (c) TBAF, THF.

[00982] Formation of (1R, 2S, 35)-3-(2-chloro-S-fluoropyrimidin-4ylamino) cyclohexane-l,2-diol (31b).

The starting racemic diol, 31a, (1R, 25, 35)-3-aminocyclohexane-l,2-diol, was prepared following the procedure described in: Org. Bio. Chem. (2008) 6, 3751 and 3762, Davies, et. al. To a solution of racemic diol 31a (0.66 g, 5.00 mmol) in acetonitrile (5 mL) and isopropanol (5 mL) was added 2,4-dichloro-5-fhioro-pyrimidine (0.84 g, 5.03 mmol) and *Pr₂NEt (3.25 g, 4.38 mL, 25.20 mmol). The reaction mixture was sealed and heated to 100 °C for 90 minutes and then concentrated to dryness. The crude was purified via silica gel chromatography (40%-100% EtOAc/Hex) to afford a racemate, which was further purified via chiral HPLC separation to give compound 31b (0.26 g) as a white solid.

‘H NMR (300 MHz, MeOH-i/4) δ 7.80 (s, 1H), 4.60 (s, 6H), 4.10 (m, 1H), 3.80 (s, 1H), 3.60 (m, 1H), 3.20 (s, 1H), 3.15 (s, 2H), 1.50 - 1.70 (m, 5H), 1.20 (m, 1H) ppm.

LCMS RT = 2.8 (M+l) 262.0, (M-l) 260.1.

[00983] Formation of (1R, 2S, 35)-3-(2-(5-chloro-l-tosyIl£f-pyrrolo[2,3i] py ridin-3-yl)-5-fluo ropy r imidin-4-ylamin o)cy clohexane-1,2-diol (31 c).

To a deoxygenated solution of 5-chloro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)pynOlo[2,3-b]pyridine (0.22 g, 0.51 mmol) and (1R, 25, 35)-3-(2chloro-5-fluoropyrimidin-4-ylamino)cyclohexane-l,2-diol, 31b, (0.08 g, 0.24 mmol) in acetonitrile (6 ml) was added 2M sodium carbonate (0.45 mL of 2 M solution, 0.894 mmol) and Pd(PPh3)4 (34.5 mg, 0.030 mmol). The reaction was sealed and heated to 120°C for 15 minutes in the microwave. The rxn was diluted with EtOAc and filtered thru florisil. The solution was concentrated to crude and purified via silica gel chromatography (DCM to 20% MeOH/DCM) to give compound 31c (0.11 g) as a pink solid.

LCMS RT = 3.8 (M+l) 532.2, (M-l) 530.2.

[00984] Formation of (1R, 2S, 35)-3-(2-(5-chloro-ll/-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cyclohexane-l,2-diol (632).

To a solution of (1R, 25, 35)-3-(2-(5-chloro-l-tosyl-l/Lpyrrolo[2_J3-/?]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cyclohexane-l,2-dioI, 31c, (0.11 g, 0.21 mmol) in THF was added TBAF (0.23 g, 0.84 mmol). The reaction was aged at room temperature 1 hour, quenched with IN HC1 (1 ml), and purified via reverse phase chromatography (5-70% MeCN/H₂0 with 0.1% TFA). The product was desalted on an SPE bicarbonate cartridge, concentrated to dryness, and then triturated from MeOH to provide 18 mg of compound 632.

Ή NMR (300 MHz, MeOH-r/4) δ 8.42 (s, 1H), 7.90 (s, 1H), 7.82 (s, 1H), 7.70 (s, 1H), 4.15 (m, IH), 3.95 (m, 1H), 3.70 (m, 1H), 1.75 (m, 5H), 1.50 (m, 1H) ppm.

LCMS RT = 3.0 (M+l) 378.2, (M-l) 376.0.

General Scheme 32:

-286WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Ts

615 (a) 2,4-dichloro-5-fluoropyrimidine, acetonitrile, isopropanol, reflux 1.5 hours, (b) 5-chloro-3(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-tosyl-177-pyrrolo[2,3-6]pyridine, Pd(PPh₃)₄ , 2M Na₂CO₃ , acetonitrile, 120 °C microwave, 15 min., (c) TBAF, THF [00985] Formation of (15, 25, 35)-3-(2-chloro-5-fluoropyrimidin-4-ylamino) cyclohexane-l,2-diol (32b).

The starting racemic diol, 32a, (15, 25, 35)-3-aminocyclohexane-l,2-diol, was prepared following the procedure described in: Org. Bio. Chem. (2008) 6, 3751 and 3762, Davies, et. al.

According to the method for compound 632, except use the racemate of diol 32a (0.07 g, 0.53 mmol), to give compound 32b (0.03 g, 0.11 mmol) as a white solid.

*H NMR (300 MHz, MeOH-74) δ 7.90 (s, IH), 4.45 (m, IH), 3.80 (s, IH), 3.62 (s, IH), 1.40 - 1.80 (m, 6H), 0.85 (m, IH) ppm.

LCMS RT = 2.7 (M+l) 262.0.

[00986] Formation of (15, 25, 35)-3-(2-(5-chloro-l-tosyl-lH-pyrrolo [2,36]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)cyclohexane-l,2-diol (32c).

According to the method for compound 31c, except use compound 32b (0.03 g, 0.11 mmol), to give compound 32c (0.06 g, 0.11 mmol).

LCMS RT= 3.9 (M+l) 532.2, (M-l) 530.3.

[00987] Formation of (15, 25, 35)-3-(2-(5-chloro-177-pyrrolo [2,3-6]pyridin-3-y 1)5-fluoropyrimidin-4-ylamino)cyclohexane-l,2-diol (615).

According to the method for compound 624, except use compound 32c (0.06 g, 0.11 mmol) to give compound 615 (0.015 g, 0.035 mmol) as a white solid.

‘H NMR (300 MHz, MeOH-i/4) δ 8.83 (s, IH), 8.51 (s, IH), 8.40 (s, IH), 8.30 (s, IH), 4.00 (bs, 2H), 0.60 - 0.90 (m, 4H), 0.50 (m, 2H) ppm.

LCMS RT = 3.7 (M+l) 378.3, (M-l) 376.3.

General Scheme 33

-287WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

(a) 2,4-dichloro-5-fluoropyrimidine, acetonitrile, isopropanol, reflux 1.5 hours, (b) 5-cli loro-3-(4,4,5,5tetramethyl-l,3,2-dioxaborolan-2-yl)-l-tosyl-l/i-pyiTolof2,3-/>]pyridine, Pd(PPh₃)₄,2M Na^COj , acetonitrile, 120 °C microwave, 15 min., (c) TBAF, THF.

[00988] Formation of (1R, 2R, 35)-3-(2-chloro-5-fluoropyrimidin-4-ylamino) cyclohexane-l,2-diol (33b).

The starting racemic diol, 33a, (1Z?, 27?, 35)-3-aminocyclohexane-l,2-diol, was prepared following the procedure described in: Org. Lett. (2009) ό, 1333, Davies, et. al. According to the method for compound 632, except use the racemate of diol 33a (0.13 g, 1.01 mmol) to give compound 33b (0.14 g, 0.53 mmol) as a white solid.

NMR (300 MHz, MeOH-d4) δ 7.90 (s, IH), 4.05 (m, 2H), 3.70 - 3.80 (m, 0.6H),

1.95 (bs, 2.5H), 1.70 (m, 1.6H), 1.30 - 1.60 (m, 5.4H) ppm; ¹³C-APT NMR (300 MHz, MeOH-d4) δ 148.6, 145.2, 140.0, 139.8, 78.9, 75.2, 55.4, 49.15 (m, MeOH-d4), 33.9, 31.9,

22.4 ppm.

LCMS RT = 2.4 (M+l) 262.0, (M-l) 260.1.

[00989] Formation of (11?, 2R, 30)-3-(2-(5-chIoro-l-tosyHff-pyrrolo [2,36]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)cy clohexane-l,2-diol (33c).

According to the method for compound 31c, except use compound 33b (0.07 g, 0.26 mmol) to give compound 33c (0.008 g, 0.015 mmol). DME was used as solvent, not acetonitrile. LCMS RT = 4.2 (M+l) 532.3, (M-l) 530.3.

[00990] Formation of (12?, 21?, 35)-3-(2-(5-chIoro-17f-pyrrolo [2,3-6]pyridin-3-yl)5-fluor opyr imidin-4-yla mino)cy clohexane-1,2-d iol (625).

According to the method for compound 624, except use compound 33 c (0.008 g, 0.015 mmol to give compound 625 (0.005 g, 0.012 mmol).

Ή NMR (300 MHz, MeOH-d4) δ 8.80 (s, IH), 8.48 (s, IH), 8.40 (s, IH), 8.20 (s, IH), 4.5 (m, IH), 3.55 (m, 2H), 2.12 (m, 2H), 1.95(m, IH), 1.61 (m, 2H), 1.58 (m, IH) ppm.

LCMS RT = 2.4 (M+l) 378.2, (M-l) 376.2.

[00991] The following compounds, 631, 616 and 624, arc enantiomers of 632, 615 and 625 and can be prepared by isolation from chiral preparatory HPLC chromatography from their respective enantiomeric mixtures.

-288WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

General scheme 35

(a) (IS, 2S)-2-ami nocyclohexanecarboxylic acid, 'Pr₂NEt, Na₂CO₃, THF- CH₃CN (3:1), 135 °C microwave; (b) 1N LiOH, THF, microwave, 120 °C (c)4N HCI-dioxane, EtOH, 70 °C, [00992] Formation of (15, 25)-2-(2-(5-chloro-lff-pyrrolo[2,3-b]pyridin-3-yl)-5fhioropyrimidin-4-ylamino)cyclohexanecarboxylic acid (553).

A mixture of 5-chloro-3-(5-fluoro-4-methylsulfonyl-pyrimidin-2-yl)-l-(ptolylsulfonyl)pyn'olo[2,3-b]pyridine, la, (0.49 g, 1.05 mmol), (15,25)-2-aminocyclohexanecarboxylic acid (0.30 g, 2.10 mmol), freshly ground Na^COj (0.22 g, 2.10 mmol), and ‘Pr₂NEt (0.37 mL, 2.10 mmol) in THF (10 mL) and CI-LCN (2 mL) were heated in a sealed vessel to 130 °C for 30 minutes under microwave irradiation. The mixture was cooled to room temperature. A solution of IN LiOH (3.1 mL, 3.1 mmol) was added and the mixture was stirred at 120 °C for 10 minutes under microwave irradiation. The mixture was acidified with IN HC1 until pH 2 under vigorous stirring. The newly formed solid was collected by vacuum filtration. The solid was washed with small amounts of water and EtOAc. The solid was dried in vacuo to provide the desired product.

Ή NMR. (300 MHz, MeOD) δ 8.89 (d, J= 2.4 Hz, 1H), 8.44 (s, 1H), 8.38 (d, J= 2.3 Hz, 1H), 8.29 (d, J = 5.6 Hz, 1H), 4.75 (m, 1H), 2.75 - 2.66 (m, 1H), 2.25 - 2.16 (m, 2H), 1.99 - 1.89 (m, 2H), 1.71 - 1.29 (m, 4H) ppm; LCMS RT = 2.0 min, (M+H) 390.4.

[00993] Other analogs that can be prepared in the same manner as 553 are described below:

H

541 (+/.) [00994] z7Yi/ts-2-(2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yI)-5-fluoropyrimidin-4ylamino)cyclohexanecarboxylic acid (541)

LCMS RT = 2.4 min, (M+H) 390.5.

-289WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00995] (li?, 27?)-2-(2-(5-chloro-17/-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cyclohexanecarboxylic acid (554)

Ή NMR (300 MHz, MeOD) δ 8.89 (d, / = 2.4 Hz, IH), 8.44 (s, IH), 8.38 (d, / = 2.4 Hz, IH), 8.29 (d, / = 5.6 Hz, IH), 4.77 (m, IH), 2.75 - 2.66 (m, IH), 2.24 - 2.17 (m, 2H), 1.94 - 1.89 (m, 2H) and 1.74 - 1.36 (m, 4H) ppm.

LCMS RT = 2.3 min, (M+H) 390.4.

[00996] Cis-2-(2-(5-chloro-lJ/-pyrrolo[2,3“b]pyridin-3-yl)-5-fluoropyriniidin-4ylamino)cyclohexanecarboxylic acid (559) ^!H NMR (300 MHz, MeOD) δ 8.75 (d, J= 2.4 Hz, IH), 8.38 - 8.35 (m, 2H), 8.24 (d, J= 5.1 Hz, IH), 4.70 - 4.62 (m, IH), 3.25 - 3.17 (m, IH), 2.32 (m, IH), 2.14 - 1.80 (m, 4H) and 1.68 - 1.54 (m, 3H) ppm.

LCMS RT = 2.3 min, (M+H) 389.8.

[00997] (IS, 2R)-2-(2-(5-chloro-l//-pyrrolo[2,3-bjpyridin-3-yl)-5-fluoropyriinidin4-ylamino)cyclohexanecarboxylic acid (579)

Ή NMR (300 MHz, ί/6-DMSO) δ 12.52 (s, IH), 8.68 (d, / = 2.3 Hz, IH), 8.33 (d, J= 2.5 Hz, 2H), 8.30 (d, / = 4.4 Hz, IH), 7.57 (s, IH), 4.53 (m, IH), 3.05 (m, IH), 2.15 - 2.07 (m, IH), 1.96 (m, IH), 1.81 - 1.76 (m, 3H) and 1.51 (m, 3H) ppm.

LCMS RT = 2.9 min, (M+H) 390.4.

[00998] (IR, 2S)-2-(2-(5-chloro-l_JH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin4-ylamino)cyclohexanecarboxylic acid (578)

IH NMR (300 MHz, J6-DMSO) δ 12.51 (s, IH), 8.68 (d, / = 2.3 Hz, IH), 8.33 (d, / = 2.3 Hz, 2H), 8.29 (d, /= 4.3 Hz, IH), 7.55 (s, IH), 4.53 (s, IH), 3.05 (m, IH), 2.13 (m, IH), 1.96 (tn, IH), 1.79 (m, 3H) and 1.51 (m, 3H) ppm.

LCMS RT = 2.8 min, (M+H) 390.4.

-290WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[00999] Cz\-2-(2-(5-chloio-l//-pyrrolo[2,3-blpyridin-3-yl)-5-nuoropyriniidin-4ylamino)cyclopentanecarboxylic acid (558) ^!H NMR (300 MHz, MeOD) δ 8.78 (d, J= 2.4 Hz, IH), 8.38 (s, IH), 8.33 (d, J= 2.2 Hz, IH), 8.25 (d, J = 5.2 Hz, IH), 4.98 (dd, J= 7.2 Hz, IH), 2.27 - 2.03 (m, 5H) and 1.86 1.76 (m, IH) ppm.

LCMS RT = 2.5 min, (M+H) 376.2.

[001000] (1R, 3S)-3-(2-(5-chloro-177-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyriinidin4-ylamino)cyclopentanecarboxylic acid (566) 'H NMR (300 MHz, 76-DMSO) δ 12.42 (s, IH), 8.72 (d, J= 2.2 Hz, IH), 8.29 (m, 2H), 8.22 (d, J = 4.1 Hz, IH), 7.87 (s, IH), 4.56 - 4.49 (m, IH), 2.87 (dd, J = 8.4, 25.0 Hz, IH), 2.87 (s, IH), 2.42 - 2.33 (m, IH), 2.15 - 2.04 (m, IH), 2.00 - 1.85 (m, 3H) and 1.81 1.70 (m, IH) ppm.

LCMS RT = 2.3 min, (M+H) 376.4.

565

[001001] (IS, 3R)-3-(2-(5-chloro-l/Z-pyrrolo[2,3-b]pyridin-3“yl)-5“fluoropyriniidin4-ylamino)cyclopentanecarboxylic acid (565)

NMR (300 MHz, c/6-DMSO) δ 12.48 (s, IH), 8.71 (d, J = 2.3 Hz, IH), 8.35 - 8.31 (m, 2H), 8.26 (d, 7= 4.3 Hz, 2H), 8.02 (s, IH), 4.57 - 4.44 (m, IH), 2.87 (qn, 7= 8.3 Hz, IH), 2.39 - 2.32 (m, IH), 2.15 - 2.05 (m, IH), 2.00 - 1.86 (m, 3H) and 1.82 - 1.70 (m, IH) ppm.

LCMS RT = 2.4 min, (M+H) 376.4.

[001002] (11?, 3X)-3-(2-(5-chloro-lfi^r-pyrrolo[2,3-6]pyridin-3-yl)-5-fluoropyrimidin4-yIa min o)cyclohexan ecarb oxy lie acid (630)

Compound 630 was prepared in same fashion from intermediate 18c, by removal of Cbz-protecting group and reaction with intermediate la, followed by removal of tosyl protecting group.

LCMS RT = 3.2 min, (M+H) 390.4, (M-H) 388.1.

-291WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

585, 586 (+/-) [001003] 7^,/'«H5'-2-(2-(5“Chloro-117-pyrrolo[2,3-b]pyridin-3-yl)“5-fluoropyriniidin-4 ylamino)-l-methylcyclohexanecarboxylic acid (582) ^lH NMR (300.0 MHz, 76-DMSO) δ 12.46 (s, IH), 8.72 (d, /= 2.4 Hz, IH), 8.32 -

8.28 (m, 3H), 7.10 (d, /= 7.1 Hz, IH), 4.27 - 4.20 (m, IH), 2.26 (d, J = 10.1 Hz, IH), 1.93 (m, IH), 1.83 (m, IH), 1.68 - 1.59 (m, 3H), 1.36 (m, 2H) and 1.24 (s, 3H) ppm.

LCMS RT = 3.2 min, (M+H) 404.4.

[001004] Racemic n'«/w-2“(2-(5-chloro-l/f-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-l-ethylcyclohexanecarboxylic acid (586) 'Η NMR (300 MHz, MeOD) δ 8.93 (s, IH), 8.85 (m, 2H), 8.93 - 8.87 (m, IH), 8.31 (dd, /= 4.5, 1.2 Hz, 2H), 8.31 (dd, /= 4.5, 1.2 Hz, 2H), 8.30 (d, / = 2.3 Hz, IH), 8.19 (d, / = 5.0 Hz, IH), 5.26 - 5.20 (m, IH), 3.37 (dd, /= 3.3 Hz, 1.6, 2H), 3.33 (ddt, /= 6.6, 3.3, 1.6 Hz, 118H), 2.11 (dd, /= 8.0, 5.8 Hz, 2H), 1.80 (tdd, /= 21.2, 18.9, 11.6 Hz, 8H), 1.63 - 1.54 (m, 3H), 0.86 (q, /= 7.4 Hz, 4H) ppm.

LCMS RT = 2.9 min, (M+H) 418.4.

[001005] Racemic cN-2-(2-(5-cliloro-I//-pyrrolo[2,3-b]pyridin~3-yl)-5fluoropyrimidin-4-ylamino)-l-ethylcyclohexanecarboxylic acid (585)

NMR (300 MHz, MeOD) δ 8.80 - 8.76 (m, IH), 8.37 (s, IH), 8.35 (d, /= 2.3 Hz, IH), 8.27 - 8.23 (m, IH), 4.49 - 4.42 (m, IH), 2.43 - 2.34 (m, IH), 2.09 (d, /= 6.2 Hz, IH), 1.98- 1.36 (m, 12H),0.94 (dd,/= 11.3, 3.8 Hz, 3H)ppm.

LCMS RT = 3.2 min, (M+H) 418.4.

670 671 [001006] (35, 45, 55)-ethyl 3-(2-(5-chloro-l/Z-pyrrolo[2,3-6]pyridin-3-yl)-5fluo ropy rimidin-4-yla mino)-4-ethanamid o-5-(pentan-3-yloxy)cy clohex- 1-en ecarboxylate (670)

H NMR (300.0 MHz, MeOD) d 8.64 (d, J = 2.3 Hz, 1H), 8.40 (s, 1H), 8.32 (d, J = 2.3 Hz, IH), 8.29 (d, J = 5.0 Hz, IH), 6.96 (m, IH), 4.84 - 4.80 (m, IH), 4.34 (m, IH), 4.29 -

4.19 (m, 3H), 3.54 - 3.47 (m, IH), 3.15 - 3.07 (m, IH), 2.68 - 2.58 (m, IH), 1.92 (s, 3H), 1.59 - 1.51 (m, 4H), 1.26 (t, J = 7.1 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H) and 0.89 (t, J = 7.4 Hz, 3H) PPm

-292WO 2010/148197

PCT/US2010/038988

LCMS RT = 3.6 (M+l) 559.4.

[001007] (3S, 4R, 5ff)-3-(2-(5-chloro-lZf-pyrrolo[2,3-/»]pyridin-3--yl)-5fluoropyrimidin-4-ylamino)-4-ethanamido-5“(pentan-3-yloxy)cyclohex-l-enecarboxylic acid (671)

H NMR (300.0 MHz, McOD) d 8.66 (d, J = 2.3 Hz, IH), 8.39 (s, IH), 8.32 (d, J = 2.3 Hz, IH), 8.29 (d, J = 5.0 Hz, IH), 6.97 (m, IH), 4.82 - 4.79 (m, IH), 4.34 (m, IH), 4.25 (dd, J = 7.6, 10.1 Hz, IH), 3.54 - 3.47 (m, 2H), 3.11 - 3.04 (m, IH), 2.65-2.57 (m, IH), 1.91 (s, 3H), 1.59 (m, 4H), 0.95 (t, J = 7.4 Hz, 3H) and 0.89 (t, J = 7.4 Hz, 3H) ppm

LCMS RT = 3.1 (M+l) 531.4.

General Scheme 36

[001008] (15,2S)-ethyl 2-(2-(5-chloro-l/7-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cyclohexanecarboxylate (561)

To a mixed slurry of (IS, 2S)-2-[[2-(5-chloro-lH-pyriOlo[5,4-b]pyridin-3-yl)-5fluoro-pyrimidin-4-yl]amino]cyclohexane-l-carboxylic acid, 553, (0.090 g, 0.231 mmol), in ethanol (1.5 mL) at room temperature was added HC1 (0.577 mL of 4 M solution, 2.309 mmol). The solution was warmed to 50 °C. After 6 hours, the mixture was basified with IN NaOH, brine was added and the aqueous layer was and extracted repeatedly with EtOAc. The organic layer was dried over MgSO₄, and filtered through a short plug of silica gel and concentrated in vacuo to provide the desired product.

‘H NMR (300 MHz, MeOD) δ 8.95 (s, IH), 8.19 (m, 2H), 7.99 (s, IH), 4.61 (m, IH), 3.93 (m, 2H), 2.61 (m, IH), 2.17 - 2.05 (m, 2H), 1.89 - 1.32 (m, 7H) and 1.00 (m, 3H) ppm.

LCMS RT = 2.7 min, (M+H) 418.4.

[001009] The following compounds can also be prepared in a manner similar to the one described in Scheme 36.

575 [001010] (Iff, 2ff)-ethyl 2-(2-(5-chloro-lfl-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cyclohexanecarboxylate (560)

Ή NMR (300 MHz, MeOD) δ 8.95 (s, IH), 8.23 - 8.14 (m, 2H), 8.00 (m, IH), 4.61 (m, IH), 3.96 - 3.92 (m, 2H), 2.61 (m, IH), 2.14 - 2.04 (m, 2H), 1.89 - 1.35 (m, 7H) and 1.04 - 0.99 (m, 3H) ppm.

LCMS RT = 3.2 min, (M+H) 418.5.

-293WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [001011] (15, 25)-methyl 2-(2-(5-chloro-lif-pyrrolo[2,3-b]pyridin-3-yI)-5fluor opyrimidin-4-yla min o)cy clohexanecarb oxylate (575) 'H NMR (300 MHz, 76-DMSO) δ 8.76 (d, 7 = 2.5 Hz, 1H), 8.26 (d, 7= 2.4 Hz, 1H),

8.19 (s, 1H), 8.13 (d, 7= 4.0 Hz, 1H), 7.53 (d, 7= 8.5 Hz, 1H), 4.47 - 4.37 (m, 1H), 3.40 (s, 3H), 2.68 - 2.59 (m, 1H), 2.05 - 1.97 (m, 2H), 1.84 - 1.75 (m, 2H), 1.63 - 1.40 (m, 3H) and

1.31 - 1.23 (m, 1H) ppm.

LCMS RT = 3.1 min, (M+H) 404.4.

574

[001012] (15,25)-2-methoxyethyl 2-(2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cyclohexanecarboxylate (574) ^lH NMR (300 MHz, 76-DMSO) d 8.74 (d, J = 2.4 Hz, 1H), 8.24 (d, J = 2.4 Hz, 1H),

8.19 (s, 1H), 8.12 (d, J = 4.0 Hz, 1H), 7.55 (d, J = 8.6 Hz, 1H), 4.42 (m, 1H), 4.02 - 3.86 (m, 2H), 3.35 - 3.23 (m, 2H), 3.08 (s, 3H), 2.69 - 2.60 (m, 1H), 1.99 (m, 2H), 1.77 (m, 2H), 1.62 -

1.40 (m, 3H) and 1.27 (m, 1H) ppm.

LCMS RT = 3.0 min, (M+H) 448.4.

[001013] (1Λ, 2fi)-isopropyl 2-(2-(5-chloro-lJ7-pyr roio|2,3-b|py ridin-3-y 1)-5fluoropyrimidin-4-ylamino)cyclohexanecarboxylate (568) *H NMR (300 MHz, 76-DMSO) δ 8.80 (d, 7= 2.5 Hz, 1H), 8.27 (d, 7= 2.4 Hz, 1H), 8.19 (s, 1H), 8.13 (d, 7= 4.0 Hz, 1H), 7.60 (d, 7= 8.6 Hz, 1H), 4.72 (qn, 7= 6.2 Hz, 1H), 4.55 - 4.48 (m, 1H), 2.61 - 2.54 (m, 1H), 1.96 (m, 2H), 1.77 (m, 2H), 1.63 - 1.41 (m, 3H), 1.30 - 1.23 (m, 1H) and 0.93 (d, 7= 6.2 Hz, 6H) ppm.

LCMS RT = 3.08 min, (M+H) 432.46.

569 [001014] (15, 25)-isopropyl 2-(2-(5-chloro-lZf-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cycIohexanecarboxylate (569)

Ή NMR (300 MHz, 76-DMSO) δ 12.57 (s, 1H), 8.80 (d, 7= 2.4 Hz, 1H), 8.36 - 8.28 (m, 4H), 4.75 (td, 7= 12.5, 6.2 Hz, 1H), 4.52 (m, 1H), 2.65 - 2.56 (m, 1H), 2.00 (m, 2H), 1.83 - 1.76 (m, 2H), 1.57 - 1.42 (m, 3H), 1.32 - 1.24 (m, 1H) and 0.94 (d, J = 6.2 Hz, 6H) ppm.

LCMS RT = 2.7 min, (M+H) 432.5.

General Scheme 37:

Preparation of «s-Z-amino-l-methylcyclohexanecarboxylic acid (37c)

-294WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

nh₂

37a 37b 37c (+/-) (a) NaH, iodomethane DMF (b) NH₂OH- HCI, pyridine, EtOH (c) Ai (Hg), THF-H₂O (4:1).

[001015] Formation of ethyl l-methyl-2-oxocyclohexanecarboxylate (37a):

The title compound was prepared following the procedure described in: Tetrahedron Letters (2005) 46, 681-685 and JCS, Perkin Trans 1(2000) 3277-3289.

Sodium hydride (1.48 g, 37.14 mmol, 60% in oil) was rinsed twice with hexanes to remove oil and suspended in DMF (57 mL) at 0 °C. Then, ethyl 2oxocyclohexanecarboxylate (5.40 mL, 33.76 mmol) was added over 5 minutes. The mixture was stirred for 20 minutes and Mel (2.21 mL, 35.45 mmol) was added over 10 minutes. The mixture was warmed to room temperature and after 30 minutes, diluted with EtOAc (150 mL) and quenched with saturated NH4CI. The layers were separated and the aqueous layer was extracted twice more with EtOAc (2 x lOOmL). The organic layer was washed with brine (2 x) dried over MgSO₄, filtered through silica gel and concentrated to provide the desired product (37a).

[001016] Formation of 3a-methyl-4, 5, 6,7-tetrahydrobenzo[c]isoxazol-3(3a£i^,)-one (37b):

To a mixture of ethyl l-methyl-2-oxo-cyclohexanecarboxylate, 37a, (2.05 g, 11.10 mmol) in EtOH (20 mL) was added hydroxylamine hydrochloride (0.97 g, 13.96 mmol) and pyridine (0.99 mL, 12.20 mmol). The mixture was heated to 65 °C overnight. Tire solution was concentrated in vacuo and the crude material was partitioned between water and EtOAc. The aqueous layer was extracted with EtOAc twice more. The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was purified via silica gel chromatography (0-35% EtOAc/hexanes) to afford the desired product, 37b.

NMR (300 MHz, CDCI3) δ 2.72 - 2.65 (m, 1H), 2.29 (td, ,7 = 13.3, 6.3 Hz, 1H),

2.18 - 2.09 (m, 1H), 2.07 - 2.03 (m, 1H), 1.84 - 1.79 (m, 1H), 1.76 - 1.56 (m, 2H), 1.54 - 1.42 (m, 1H) and 1.40 (s, 3H) ppm.

[001017] Formation of ft-«ns-2-amino-l-methylcyclohexanecarboxyIic acid (37c):

To a solution of 3a-methyl-4,5,6,7-tetrahydro-2,l-benzoxazol-3-one, 37b, (0.075 g, 0.490 mmol) in THF-H₂O (2.5 mL of 4:1 mixture) at room temperature was added fresh Al(Hg) amalgam. Aluminum was amalgamated by dipping small strips of Aluminum foil in 2% HgCL solution, rinsing with water and EtOH. After 1 hour, an additional 65 mg Al(Hg) was added and the mixture was allowed to stir overnight. The thick gray emulsion that formed was filtered through celite and rinsed with water and THF. The clear solution was concentrated in vacuo, stripped with methanol and THF to remove residual water and concentrated in vacuo to provide the desired product as a glassy solid as mixture of trans and cis isomers (—9:1) with the trans isomer as the predominant isomer. The product was sufficiently pure for use in the next reaction.

^!H NMR (300 MHz, MeOD) δ 2.91 (dd, .7 = 3.9, 11.9 Hz, 1H), 2.25 (dd, J= 1.9, 13.4 Hz, 1H), 1.89 - 1.85 (m, 1H), 1.78 - 1.53 (m, 3H), 1.47 - 1.32 (m, 2H), 1.21 (s, 3H) and 1.09 0.99 (m, 1H) ppm.

FIA (M+H) 158.1, (M-H) 156.2.

-295WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [001018] Formation of 2-amino-l-ethylcyclohexanecarboxylic acid:

This compound was prepared by the methods described above as an inseparable mixture of cis and trans isomers (70:30) and was used without further purification.

General Scheme 38

Preparation of ci's-2-amino-l-alkyl-cyclohexanecarboxyIic acids:

(a) LDA, iodoethane, THF (b) H_z, Pd-C, MeOH

NH₂

38c

An alternative scheme for the preparation cA-2-amino-l-alkyl-cyclohexanecarboxylic acid is exemplified above. The method is described in: (a) Nemoto, T.; Fukuyama, T.; Yamamoto, E.; Tamura, S.; Fukuda, T.; Matsumoto, T.; Akimoto, Y.; Hamada, Y. Org. Lett. 2007, 9 (5), 927-930. (b) Seebach, D,; Estermann, H. Tetrahedron Lett. 1987, 28 (27), 31033106.

[001019] (IjR, 25)-methyl 2-(benzyloxycarbonylamino)-lethylcyclohexanecarboxylate (38b)

To a cold (-78 °C) solution of /V-isopropylpropan-2-amine (0.77 mL, 5.49 mmol) in THF (7 mL) was added, dropwise, n-butyllithium (3.43 mL of 1.6 M solution, 5.49 mmol). The mixture was stirred at -78 °C for 10 minutes. Then a solution of methyl (IS, 26)-2benzyloxycarbonylaminocyclohexanecarboxylate, 38a, (0.40 g, 1.37 mmol) in THF (2.5 mL) was added over a period of 3 minutes. After 15 minutes, the mixture was warmed slightly (40 °C) for 15 minutes and recooled to -78 °C for a further 10 minutes. Then, iodocthanc (0.86 g, 0.44 mL, 5.49 mmol) was added, dropwise over 3-5 minutes. The reaction mixture was maintained at -78 °C for 2 hours and allowed to warm to room temperature overnight. The reaction was quenched with 5 mL aqueous saturated NH4CI solution, extracted with EtOAc (3 x), washed successively with IN HC1 and brine. The combined organic layers were dried over Na₂SO4, filtered and concentrated in vacuo. Flash chromatography (SiO2, 0-20% EA/Hex slow gradient elution) provided 275 mg (63% yield) of the desired product (38b). NMR indicated a diastereomeric ratio greater than 10 to 1 (cis vs trans).

’HNMR (300.0 MHz, MeOD) 5 7.35 - 7.28 (m, 5H), 6.62 (d, J =9.2 Hz, 1H), 5.07 (dd, ,7= 12.5, 16.6 Hz, 2H), 3.67 (s, 3H), 3.59 (td, .7= 10.0, 4.6 Hz, IH), 2.14 (m, 1H), 1.76 -

1.29 (m, 9H) and 0.83 (t, J= 7.6 Hz, 3H) ppm.

[001020] (Iff, 25)-methyl 2-amino-l-ethylcyclohexanecarboxylate (38c)

A solution of methyl (LR, 2S)-2-benzyloxycarbonylamino-l-ethyl-cyclohexanecarboxylate, 38b, (0.27 g, 0.85 mmol) in MeOH (7.5 mL) was purged with nitrogen and a catalytic amount of Pd (5% Pd on carbon) was added. The solution was placed under H₂ atmosphere and stirred at room temperature. After 1 hour, the MeOH solution suspension was filtered through celite, and concentrated in vacuo to provide the desired product (138 mg, 88% yield). The material was diluted in acetonitrile and concentrated to remove residual methanol.

'HNMR (300.0 MHz, MeOD) δ 3.69 (s, 3H), 2.71 (m, IH), 2.07 - 2.01 (m, IH), 1.82 (m, 2H), 1.71 - 1.27 (m, H), 1.64 (m, 2H), 1.56 - 1.27 (m, 5H) and 0.85 (t, J= 7.5 Hz, 3H) ppm.

-296WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

General Scheme 39 preparation of rrans-2-amino-l-alkyl-cyclohexanecarboxylic acids:

39b 39c 39d

(a) Benzyl alcohol, toluene, 4 angstrom sieves, reflux (b) NaH, Mel, DMF (c) benzylamine, T1CI4, CH₂CI₂, then NaCNBH₃, MeOH, 0 oC (d) H₂, Pd-C, MeOH (e) 5-chloro-3-(5-fluoro-4-methylsulfinylpyrimidin-2-yl)-1-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridine, Na₂CO₃, THF/CH₃CN, microwave irradiation 135 °C (f) HCI, CH₃CN, dioxane, 80 °C,

39e (+/-) [001021] A general method for the synthesis of Zra«s-2-amino-l-alkylcyclohexanecarboxylic acids is shown in the scheme above.

[001022] Benzyl 2-oxocyclohexanecarboxylate (39b)

This compound was prepared following literature procedures described in: Matsuo, J. etal. Tetrahedon: Asymmetry 2007,18, 1906-1910.

[001023] Benzyl l-methyl-2-oxocyclohexanecar boxy late (39c)

This compound was prepared following the literature procedures described in: (a) Hayashi, Y.; Shoji, M.; Kishida, S. Tetrahedron Lett. 2005, 46, 681-685. (Winfield, C. J.; Al-Mahrizy, Z.; Gravestock, M.; Bugg, T. D. H. J. Chem. Soc., Perkin Trans. 1, 2000, 3277.

[001024] Trnns-Benzyl 2-(benzylamino)-l-methylcyclohexanecarboxylate (39d)(racemic trans)

To a solution of benzyl l-methyl-2-oxo-cyclohexanecarboxylate, 39c, (0.50 g, 2.03 mmol) and benzylamine (0.61 g, 0.63 mL, 5.75 mmol) in dichloromethane (10.0 mL), was added TiCl₄ (1.93 mL of 1 M solution, 1.93 mmol) dropwise, at room temperature. The mixture was stirred for 2 hours. The mixture was cooled to 0 °C and a solution of NaBHjCN (0.21 g, 3.34 mmol) in MeOH was added dropwise over a period of 3 minutes. After 15 min, the solution was warmed to RT and stirred for an additional 45 min. Then, the mixture was diluted with EtOAc, quenched with 10 mL IM NaOH. The mixture was partitioned with Et₂O and the aqueous layer was extracted several times with Et₂O (2 x) and EtOAc (1 x). The combined organic phases were dried over MgSO₄, filtered and concentrated in vacuo. Flash chromatography (SiO₂, 0-50% EtOAc-Hexanes gradient elution) and isolation of the major component provided the desired product (320 mg) as a single racemic trans isomer.

Ή NMR (300.0 MHz, MeOD) δ 7.34 - 7.16 (m, 10H), 5.07 (dd, J= 12.4, 31.2 Hz, 2H), 3.78 (d, J= 13.0 Hz, IH), 3.57 (d, J= 13.0 Hz, IH), 2.96 (m, IH), 1.86 (m, IH), 1.74 -

1.57 (m, 3H), 1.52 - 1.25 (m, 4H) and 1.20 (s, 3H) ppm.

-297WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [001025] 7)wix-2-Amino-l-methylcyclohexanecarboxylic acid (39c)

To a solution of racemic Zrans-benzyl (IS, 2S)-2-(benzylamino)-l-ethylcyclohexanecarboxylate, 39d, (0.32 g, 0.91 mmol) in MeOH (12.8 mL), was added Pd (5% Pd on carbon, 0.07 g). The solution was degassed and placed under 50 PSI H₂ (Parr shaker) overnight. The mixture was filtered through celite and the filtrate was rinsed with MeOH. Concentration of the mother liquor followed by acetonitrile azeotrope (2 x) to remove residual MeOH provided the desired product (162 mg).

'HNMR (300.0 MHz, MeOD) δ 3.22 (m, IH), 1.93 (m, IH), 1.77 (m, 2H), 1.57 -

1.23 (m, 5H) and 1.17 (s, 3H) ppm.

[001026] Z/vm.s'-2-[[2-[5-chloro-l-(p-tolylsulfonyI)pyrrolo[2,3-b|pyridin-3-yl]-5fluor o-py rimidin-4-y I] amino]-l-methyl-cyclo hexan ecar boxy lie acid (39f)

To a vessel charged with 5-chloro-3-(5-fluoro-4-methylsulfinyl-pyrimidin-2-yl)-l-(ptolylsulfonyl)pyrrolo[2,3-b]pyridine, 15a, (0.27 g, 0.58 mmol) and iraws-2-amino-1 -methylcyclohexanecarboxylic acid, 39e, (0.08 g, 0.47 mmol) and freshly ground Na₂CO₃ (0.19 g, 1.75 mmol) was added anhydrous THF (4.5 mL) and CH₃CN (0.9 mL). The vessel was sealed and heated to 135 °C for 35 min (microwave irradiation). LC-MS indicated complete consumption of starting material. Next, the reaction mixture was slowly poured into a vigorously stirred solution of IN HC1 (13.5 mL). The pH of the final solution was 1-2. The mixture was extracted with EtOAc (3 x), dried over Na₂SO₄ and filtered through Celite and concentrated in vacuo. Flash chromatography (SiO₂, 0-10% MeOH-dichloromethane, gradient elution) provided a sticky yellow foam, which was suspended in acetonitrile. Sonication followed by evaporation of the solvent provided white amorphous solid (240mg, 74% yield) as a racemic mixture of trans stereoisomers.

’H NMR (300.0 MHz, MeOD) δ 9.02 (d, 7 = 2.4 Hz, IH), 8.52 (s, IH), 8.33 (d, 7 =

2.4 Hz, IH), 8.09 - 8.05 (m, 3H), 7.38 (d, 7= 8.1 Hz, 2H), 5.04 (dd, 7= 3.6, 9.5 Hz, IH), 2.38 (s, 3H), 2.09 (m, IH), 1.83 - 1.59 (m, 7H), 1.29 (s, 3H) and 1.23 (m, IH) ppm.

LCMS RT = 4.00 min, (M+H) 558.34.

[001027] 7/wix-2-[|2-(5-chloro-l_Jff-pyrrolo[2,3“b]pyridin-3-yl)-5-fluoro-pyrimidin4-yl]amino]-l-methyI-cyciohexanecarboxyIic acid (643)

To a slurry of racemic Zra«5-2-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin3-yl]-5-fluoro-pyrimidin-4-yl]amino]-l-methyl-cyclohexanecarboxylic acid, 39f, (0.047 g, 0.084 mmol) in CH₃CN (2.35 mL) was added HC1 (1.26 mL of 4 M solution, 5.05 mmol) in

-298WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 dioxane. The suspension became a clear solution. The vial was sealed and heated to 80 °C for 2 hours during which time a thick slurry formed. The slurry was allowed to cool to room temperature overnight. Additional CHjCN was added and the mixture was centrifuged. The organic layer was discarded and the solid was triturated with CH₃CN three times more to provide an amorphous white solid as racemic mixture of trans stereoisomers.

NMR (300.0 MHz, MeOD) δ 8.98 (d, J= 2.3 Hz, IH), 8.45 (s, IH), 8.38 (d, J =

2.3 Hz, IH), 8.30 (d, J= 5.7 Hz, IH), 5.26 - 5.22 (m, IH), 2.17 - 2.10 (m, IH), 1.87 - 1.82 (m, 4H), 1.68 - 1.59 (m, 3H) and 1.36 (s, 3H) ppm.

LCMS RT = 3.30 min, (M+H) 404.36.

629

a) terr-butylmagneslum chloride; I₂, Et₃N, THF, DME (b) 5-chloiO-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyll,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine, DME/ILO, Na₂CO_3> tetrakis triphenylphosphinepalladium(O), 130 °C, microwave (c) mCPBA, CTEC'E (d) (IS, 2S)-2-aminocyclohexanecarboxylic acid,Na₂CO₃, THFCHjCN (3:1), 150 °C microwave.

[001028] Formation of 4-tert-butyl-2-chloro-5-fluoro-6-(methyIthio)pyrimidine (40a)

To a cold (0 °C) solution of tert-butylmagnesium chloride (7.5 mL, IM solution in THF, 7.5 mmol) in THF (15 mL) was added slowly a solution of 2-chloro-5-fluoro-4(methylthio)pyrimidinc (0.9 g, 5.0 mmol) in 1,2-dimcthoxyethane (5 mL). The reaction mixture was stirred at 15 °C for 1 hour, then cooled to 0 °C and triethylamine (0.7 mL, 5.0 mmol) was added, followed by the addition of a solution of iodine (1.3 g, 5.0 mmol) in tetrahydrofuran (3 mL). Water (10 mL) was added to quench the reaction and pH was adjusted to 1 using 6N hydrochloric acid. Tire aqueous phase was extracted twice with ethyl acetate (2 x 15 mL). The combined organic phases were washed with aqueous sodium thiosulfate and then brine, dried over MgSO₄, filtered and concentrated in vacuo to give a brown solid which was used without further purification.

Ή NMR (300.0 MHz, CDC1₃) δ 2.52 (s, 3H), 1.30 (s, 9H) ppm.

LCMS (M+l) 233.0.

[001029] Formation of 3-(tert-butyl-5-fluoro-6-(niethylthio)pyrimidin-2-yl)-5chloro-lH^r-pyrrolo[2,3-6]pyridine (40b)

To a degassed solution of 5-chloro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine (0.22 g, 0.50 mmol), 4-teri-butyl-2-chloro-5-fluoiO6-thiomethoxypyrimidine, 40a, (0.12 g, 0.50 mmol) in 1,2-dimethoxyethane (3 mL) and

-299WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 aqueous Na₂CO₃ (0.75 mL of 2 M solution, 1.5 mmol) was added tetrakis(triphenylphosphine)palladium(0) (0.03 g, 0.03 mmol). The reaction mixture was degassed for an additional 15 minutes. The mixture was heated in a microwave at 150 °C for 20 minutes. Ethyl acetate (15 mL) was added. The organic layer was separated and washed with brine, dried over MgSCfi, filtered and concentrated in vacuo. The resulting crude residue was purified by silica gel chromatography (0%-100% EtOAc/hexanes) to afford the desired product, 40b (47 mg).

*H NMR (300 MHz, CDC1₃) δ 10.82 (br, IH), 8.81 (d, 7= 2.2 Hz, IH), 8.27 (d, 7 =

2.3 Hz, IH), 8.20 (dd, 7= 7.2, 2.2 Hz, IH), 7.18 (s, IH), 2.63 (s, 3H), 1.41 (s, 9H) ppm.

LCMS (M+l) 352.3.

[001030] Formation of 3-(terr-birtyl-5-fluoro-6-(methylsulfinyl)pyriinidin-2-yl)-5ch loro-1 /7-pyrrolo [2,3-6] pyridine (40 c)

To the solution of 3-(ter/-butyl-5-fluoro-6-(methylthio)pyrimidm-2-yl)-5-chloro-177pyrrolo[2,3-6]pyridine, 40b, (0.05 g, 0.11 mmol) in CH₂C1₂ (3.4 mL) was added mCPBA (0.02 g, 0.11 mmol). The reaction mixture was stirred for 1 h. The reaction mixture was diluted with CH2CI2 (10 mL) and saturated NaHCOj solution (5 mL). The aqueous layer was extracted with CH₂C1₂ (10 mL). The combined organic phases were washed again with aqueous saturated NaHCO₃ solution, dried over Na₂SO4, filtered and concentrated in vacuo to afford the desired product that was used without further purification.

Ή NMR (300 MHz, CDCh) δ 10.93 (br, IH), 8.79 (d, 7= 2.2 Hz, IH), 8.34 (s, IH),

8.25 (d, 7= 2.2 Hz, IH), 7.19 (s, IH), 2.98 (s, 3H), 1.47 (s, 9H) ppm.

LCMS (M+l) 368.3.

[001031] Formation of (75, 25)-2-(6- tert-butyl-2-(5-chloro-l/7-pyrrolo[2,36]pyridin-3-yl)-5-fluoropyrimidin-4-yIamino)cyclohexanecarboxylic acid (629).

A mixture of 3-(teri-butyl-5-fluoro-6-(methylsulfinyl)pyrimidin-2-yl)-5-chloro-l/7pynOlo[2,3-6]pyridine, 40c, (0.05 g, 0.14 mmol), (15, 25)-2-amino-cyclqhexanccarboxylic acid (0.04 g, 0.27 mmol), freshly ground Na₂COj (0.04 g, 0.41 mmol), and ‘Pr₂NEt (0.37 mL, 0.27 mmol) in THF (1 mL) and CH3CN (0.5 mL) was heated in a sealed vessel to 140 °C for 30 minutes under microwave irradiation. The mixture was cooled to room temperature. A solution of IN HC1 (0.5 mL, 0.5 mmol) was added and the mixture was concentrated to give a yellow solid, which was purified by reverse phase HPLC (0%-50% methanol in water) to afford the desired product, 629, as off-white solid.

*H NMR (300 MHz, DMSO) δ 12.26 (s, IH), 8.79 (d, 7 = 2.4 Hz, IH), 8.28 (d, 7 =

2.4 Hz, IH), 8.13 (d, J = 2.7 Hz, IH), 7.25 (d, J = 8.3 Hz, IH), 4.34 (m, IH), 2.62 (m, IH), 2.05 (m, 2H), 1.75 (m, 2H), 1.57 (m, 2H), 1.39 (s, 9H) and 1.26 - 1.17 (m, 2H) ppm.

LCMS (M+l) 446.23.

General Scheme 41

379

-300WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 (b) 3-amino-l-methylpynOlidin-2-one, DMA, 140 °C microwave; (b) i: LiOH, THF, microwave, 120 °C, or ii: NaOMe, MeOH.

[001032] Formation of 3-(2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yi)-5“ fluoropyrimidin-4-ylamino)-l-methylpyrrolidin-2-one (379)

A solution of 5-chloro-3-(5-fluoro-4-methylsuIfmyl-pyrimidin-2-yl)-l-(ptolylsulfonyl)pyrrolo[2,3-b]pyridine, 15a, (0.060 g, 0.129 mmol) in DMA (0.5 mL) was treated with 3-amino-l-methylpyrrolidin-2-one (0.030 g, 0.258 mmol) and the reaction was heated at 140 °C for 20 minutes. The reaction mixture was cooled to room temperature and then treated with 0.5 mL of 25% NaOMe in MeOH and heated at 50 °C for 15 min. The mixture was then partitioned between aqueous saturated Na₂CO₃ solution and EtOAc. The aqueous layer was extracted with EtOAc twice more and the combined organic phases were concentrated in vacuo. The crude material was purified by preparative HPLC. The isolated product was filtered through basic resin to remove residual TFA and provide the desired product.

^lH NMR (300 MHz, MeOD) δ 8.72 (d, 7= 2.3 Hz, IE), 8.21 (d, 7= 2.4 Hz, IH), 8.11 - 8.07 (m, 2H), 4.94 (t, 7= 9.3 Hz, IH), 3.64 - 3.51 (m, 2H), 2.97 (s, 3H), 2.68 - 2.54 (m, IH) and 2.37-2.23 (m, lH)ppm.

LCMS RT = 2.3 min, (M+H) 361.3.

[001033] The following compounds can also be prepared in a manner similar to the one described in Scheme 41.

Cl Cl

380 397 [001034] 3-(2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidm-4ylamino)pyrrolidin-2-one (380) 'HNMR (300 MHz, MeOD) δ 8.79 (d, 7= 2.4 Hz, IH), 8.20 (d, 7= 2.4 Hz, IH), 8.13 (s, IH), 8.07 (d, 7= 3.9 Hz, IH), 4.91 (dd, 7= 8.7, 10.6 Hz, IH), 3.61 - 3.46 (m, 2H), 2.68 -

2.58 (m, 2H) and 2.48 - 2.31 (m, IH) ppm.

LCMS RT = 2.3 min, (M+H) 347.3.

[001035] (S)-3-(2-(5-chloro-177-pyrroIo[2,3-0]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)-l-methylpiperidin-2-one (397)

Ή NMR (300.0 MHz, DMSO) δ 8.65 (d, 7= 2.5 Hz, IH), 8.27 (d, 7= 2.4 Hz, IH),

8.20 - 8.19 (m, 2H), 7.63 (d, 7= 7.8 Hz, IH), 4.78 - 4.74 (m, IH), 3.41 (t, J= 5.4 Hz, 2H), 3.17 (MeOH), 2.89 (s, 3H), 2.50 (DMSO), 2.18 - 2.15 (m, IH) and 1.99 (d, 7= 7.4 Hz, 2H) ppm.

LCMS RT = 2.2 min, (M+H) 375.4.

-301WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

[001036] (S)-3-(2-(5-chIor o-l //-pyrrole [2,3-b] py ridin-3-yl)-5-flu or opy rimidin-4ylamino)piperidin-2-one (416)

LCMS RT = 1.6 min, (M+H) 361.3.

[001037] (5)-3-(2-(5-chloro-ljff-pyrrolo[2,3-b]pyridin-3-yI)-5-fluoropyrimidin-4ylamino)azepan-2-one (417) *H NMR (300 MHz, DMSO) δ 12.33 (s, 1H), 8.74 (d, ./= 2.3 Hz, 1H), 8.28 (d, J =

2.4 Hz, 1H), 8.21 (t, 7= 3.7 Hz, 2H), 8.02 - 7.98 (m, 1H), 7.21 (d, 7= 5.8 Hz, 1H), 4.86 (dd, 7= 6.3, 10.5 Hz, 1H), 3.51 - 3.41 (m, 1H), 3.25 - 3.16 (m, 1H), 2.13 - 1.85 (m, 4H), 1.66 1.52 (m, 1H) and 1.40 - 1.20 (m, 1H) ppm.

LCMS RT = 1.7 min, (M+H) 375.4.

460

[001038] (5)-3-(2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4yla mino)-l -ethylpip eridin-2-one (460)

LCMS RT = 2.0 min, (M+H) 389.1.

[001039] (5)-3-(2-(5-chl oro-1 Z/-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4yla mino)-l -m ethyIazepan-2-on e (461)

LCMS RT = 2.0 min, (M+H) 389.1.

[001040] (5)-3-(2-(5-chloro-l/f-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4yla mino)- l-ethylazepan-2-o ne (462) ^NMRpOO MHz, 76-DMSO) δ 12.35 (s, 1H), 8.68 (d,7= 1.7 Hz, 1H), 8.27 (d,7= 2.0 Hz, 1H), 8.21 (m, 2H), 7.28 (d, 7= 6.0 Hz, 1H), 4.98 (dd, 7= 6.9, 10.7 Hz, 1H), 3.88 -

3.79 (m, 1H), 3.84 (dd,7=11.4, 15.5 Hz, 1H), 3.49 - 3.17 (m, 5H),2.08 (d,7= 13.1 Hz, 1H),

1.95 - 1.88 (m, 3H), 1.65 - 1.58 (m, 1H), 1.42 (m, 1H) and 1.04 (t, 7= 7.0 Hz, 3H) ppm.

LCMS RT = 3.3 min, (M+H) 403.4.

-302WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1001041 ] (R)-5-((2-(5-chlo r o-lH-py rrolo [2,3-b ] py rid in-3-yl)-5-fluoropy rimidin-4y la mino)methyl)py rr olid in-2-one (503)

LCMS RT = 2.2 min, (M+H) 361.2.

Cl

505 [001042] (5)-3-(5-fluor o-2-(5-(trifluoromethy 1)-1 TZ-py rrolo [2,3-b] py r idin-3yl)pyrimidin-4-ylamino)azepan-2-one (502).

LCMS RT = 2.3 min, (M+H) 409.

[001043] (5)-6-(2-(5-chloro-l/T-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)-4-(4-methoxyb en zy 1)-1,4-oxazepa n-5-o ne (505)

LCMS RT = 3.1 min, (M+H) 497.7.

The starting amine for this compound was prepared following established procedures as described in: Blizzard, Timothy A.; Chen, Helen Y.; Wu, Jane Yang; Kim, Seongkon; Ha, Sookhee; Mortko, Christopher J.; Variankaval, Narayan; Chiu, Anna. 7-Oxo-2,6Diazabicyclo[3.2.0]heptane-6-sulfimic acid derivatives as h -lactamase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of bacterial infections. PCT Int. Appl. (2008), 101pp. W02008039420.

[001044] (5)-3-(2-(5-chloro-l Zf-py rrolo [2,3-Z>] pyridin-3-y I)py rimidin-4ylamino)azepan-2-one (500).

LCMS RT = 1.6 min, (M+H) 357.6.

[001045] (5)-3-(2-(5-fluoro-l^Fpyrrolo[2,3-Z>]pyridin-3-yl)pyrimidin-4y!amino)azepan-2-one (501)

LCMS RT = 1.6 min, (M+H) 341.4.

Cl

504

-303WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [001046] 3-(2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)-7,7-dimethylazepan-2-one (504)

LCMS RT = 3.2 min, (M+H) 403.6.

The amine for this compound was prepared following procedures as described in: J. A. Robl, E. Sieber-McMaster, R. Sulsky Synthetic routes for the generation of 7,7-dialkyl-2azepinones. Tetrahedron Letters (1996), 3 7(50), 8985-8988

General Scheme 42

ci

(a) 3-amino-l-methylpyiTolidin-2-one, DMA, 140 °C microwave; (b) LiOH, THF, microwave, 120 °C (c) EDCI, HOAt, Tr₂NEt, DCM-DMF (2:1).

Cl

[001047] 6-(2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)-l,4-oxazepan-5-one (513)

A mixture of 5-chloro-3-(5-fluoro-4-methylsulfinyl-pyrimidin-2-yl)-l-(ptolylsulfonyl)pyrrolo[2,3-b]pyridine, 15a, (0.17 g, 0.36 mmol) and (6S)-6-amino-I,4oxazepan-5-one (0.06 g, 0.43 mmol) in DMF (2 mL) with 'Pr₂NEt (0.10 mL, 0.57 mmol) was heated to 90 °C. After 1 hour, the temperature was raised to 100 °C. After 24 hours, the mixture was heated to 140 °C for 15 min (microwave). The mixture was partitioned between water and EtOAc and the aqueous layer was extracted with EtOAc twice more. The combined organic phases were dried organic over Na₂SO₄, filtered and concentrated in vacuo.

The resulting crude material (0.16 g) was treated with LiOH (IN solution, ImL) in THF (3mL) overnight. LC-MS indicates hydrolysis of amide along with detosylation. The mixture was concentrated in vacuo and purified by preparative HPLC to provide semi pure product (23mg). This material was subjected to cyclization conditions without further purification.

To a flask was charged with the crude material (0.020 g, 0.051 mmol), EDCf (0.010 g, 0.056 mmol) and HOAt (0.002 g, 0.015 mmol) and DCM (1 mL) was added 'Pr₂NEt (0.018 mL, 0.100 mmol) and DMF (0.5 mL). After 1 hour, additional EDCI was added (0.7 eq). After

-304WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

3.5 hour, the reaction was complete and the mixture was concentrated in vacuo. Purification by preparative HPLC followed by removal of TFA salt by filtration through basic resin provided the desired product: LCMS RT = 1.9 min, (M+H) 377.5.

The starting amine for this compound was prepared following the established procedures as described in: J, A. Robl, E. Sieber-McMaster, R. Sulsky Synthetic routes for the generation of 7,7-dialkyl-2-azepinones. Tetrahedron Letters (1996), 37(50), 8985-8988.

General Scheme 43 [001048] The following are general procedures for conversion of the cyclohexane carboxylic acids, 553 or 35a, to carboxamides of type 43a:

(a) Amine, HATU, DMF (b) BOCjO, NH₄CO₃H, pyridine, DMF; (c) i: Amine, HATU, DMF; then li: 1N LiOH.

521 [001049] Formation of (15, 2>S^T)-2-(2-(5-chloro-l/f-pyrrolo|2,3-£>|pyridin-3-yl)-5fluoropyriniidin-4~ylaminf»)-.V-ethylcycloliexanecarboxamide (521)

To a mixture of (IS, 2S)-2-[[2-(5-chIoro-lj^F7-pyrrolo[5,4-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexane-l-carboxylic acid, 553, (0.049 g, 0.126 mmol) and HATU (0.056 g, 0.147 mmol) in DMF (1.0 mL) at room temperature was added ethylamine (0.189 mL of 2 M solution, 0.377 mmol). The mixture was stirred at room temperature until all starting material had been converted as judged by HPLC. After 45 minutes, the mixture was partitioned between aqueous K.2CO3 and EtOAc and the organic layer was separated and dried over Na₂SO4 and concentrated in vacuo. Preparative HPLC provide the desired product as the TFA salt, which was converted to the parent compound by elution through a basic PSA cartridge with MeOH followed by concentration in vacuo. (14 mg, 30% yield).

'H NMR (300 MHz, MeOD) δ 8.93 (d, /= 2.4 Hz, IH), 8.22 (d, J= 2.3 Hz, IH), 8.18 (s, IH), 7.99 (d,/= 4.0 Hz, IH), 4.53 (ddd,/=7.1, 11.1 Hz, IH), 3.15 - 3.02 (m, 2H), 2.43 -305WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

2.34 (m, IH), 2.30 - 2.26 (m, IH), 1.97 - 1.82 (m, 3H), 1.77 - 1.65 (m, 2H), 1.47 - 1.35 (m, 2H) and 0.97 (t, J = 7.3 Hz, 3H) ppm.

LCMS RT = 2.0 min, (M+H) 417.5.

520 [001050] (15, 25)-2-(2-(5-chloro-l//-pyrrolo[2,3-A]pyridin-3-yl)-5-fluoropyrimidin4-ylamino)-7V,ZV-diethylcyclohexanecarboxamide

LCMS RT = 2.26 min, (M+H) 445.58.

(+/-)

1001051] Formation of C7s-2-(2-(5-chloro-lH'-pyri-olo[2,3-/;]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cyclohexanecarboxamide (544) and Cis-2-(2-(5-chIoro-Lf/~ pyrroloI2,3-/>]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)-A',TVdim ethyl cyclo hexanecarb oxamide (543)

To a mixture of czs-2-[[2-(5-chloiO-177-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexanecarboxylic acid, 554, (0.30 g, 0.77 mmol) in DMF (5 mL) at room temperature was added pyridine (0.61 g, 0.62 mL, 7.70 mmol) followed by di-zerzbutyl dicarbonate (0.50 g, 2.31 mmol), and NH4CO3H (0.33 g, 4.22 mmol). The mixture was stirred overnight at room temperature. LC-MS indicated the presence of the desired primary amide as well as the Λζ/V-dimethylamide product. A 1 mL aliquot of the reaction solution was acidified with HO Ac and diluted with DMSO. Preparative HPLC chromatography provided small amounts both products.

Primary amide, 544, racemic mixture - (8.6mg): LCMS RT = 1.94 min, (M+H)

389.42.

Dimethylamide, 543, racemic mixture - (3.7 mg): LCMS RT = 2.52 min, (M+H)

417.44.

[001052] Formation of (15, 25)-2-(2-(5-chloro-I77-pyrrolo[2,3-6]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-/V.JV-diethylcycIohexanecarboxamide (518)

-306WO 2010/148197

PCI7US2010/038988

To a mixture of (Iff, 2S)-2-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[5,4-b]pyridin-3yl]-5-fluoro-pyrimidin-4-yl]amino]cyclohexane-l-carboxylic acid (0.050 g, 0.092 mmol), and HATU (0.045 g, 0.120 mmol) in DMF (1 mL) at room temperature was added N,Ndiethylamine (0.138 mL of 2 M solution, 0.280 mmol). When the reaction appeared complete as judged by HPLC, LiOH (0.4 mL of 1 M solution, 0.4 mmol) in water was added. After 6 hours, LiOH (0.4 mL of 1 M, 0.4 mmol) was added again and the mixture was stirred overnight. The mixture was quenched with aqueous saturated NH4CI solution. Aqueous K2CO3 was added and the mixture was extracted with EtOAc (3 x), The combined organic phases were washed with aqueous saturated NH₄C1 solution, filtered and concentrated in vacuo. Preparative HPLC provided the desired product as the TFA salt which was converted to the HCI salt by treatment with HC1 in MeOH followed by evaporation of the solvents (12.9 mg, 28% yield).

³H NMR (300 MHz, MeOD) δ 8.67 (d, 7= 2.3 Hz, IH), 8.53 (s, IH), 8.41 (d, 7= 2.3 Hz, IH), 8.35 (d, 7= 5.5 Hz, IH), 4.75 - 4.73 (m, IH), 3.74 - 3.58 (m, IH), 3.42 (m, 2H),

3.29 - 3.22 (m, 2H), 2.57 (m, IH), 2.09 - 2.03 (m, IH), 1.96 - 1.76 (m, 4H), 1.06 (t, 7= 7.1 Hz, 3H) and 0.94 (t, 7= 7.1 Hz, 3H) ppm.

LCMS RT = 3.3 min, (M+H) 445.6.

	⁵¹⁹ 539 (- /-)
[001053]	(Iff, 25')-2-(2-(5-ch[oro-l/f-pyrrolo\|2,3-/?]pyridin-3-yl)-5-fiuoropyriinidin-

4-ylamino)-7V-ethylcyclohexanecarboxamide (519)

LCMS RT = 2.95 min, (M+H) 417.5.

[001054] C7s-2-(2-(5-chIoro-lH-pyrrolo[2,3-Z>]pyridin-3-yl)-5-fluoropyrimidin-4ylamino)-A-methylcyclohexanecarboxamide (539) - racemic mixture

LCMS RT = 2.13 min, (M+H) 403.44.

General Scheme 44

F

Ts Ts Te Ts

44a 44b 44c 44d

44o 44f ⁷⁰⁶ (a) Pd(PPh₃)₄, sodium carbonate, DME/water, reflux (b) meta-chloroperbenzoic acid, dichloromethane, rt. (c) 20a, tetrahydrofuran, 50“C (d) trifluoroacetic acid, dichloromethane, rt.

(e) morpholine-4-carbonyl chloride, dimethylformamide, rt (f) sodium methoxide, methanol, rt.

[001055] Formation of 5-fluoro-3-[5-fluoro-4-(methylthio)pyrimidin-2-yl]-l-tosyl-lH-307WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 pyrrolo[2,3-b]pyridine (44b)

2-Chloro-5-fluoro-4-methylsulfanyl-pyrimidine (34.1 g, 191.0 mmol), 5-fluoro-l-(ptolylsulfonyl)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine, 44a, (53.0 g, 127.3 mmol) andNa₂CO₃ (40.5 g, 381.9 mmol) were dissolved in a mixture of DME (795 mL) and water (159 mL). The mixture was purged with nitrogen for 20 minutes and treated with Pd(PPh₃)₄ (7.4 g, 6.6 mmol). After purging with nitrogen for another 20 minutes, the reaction was heated to reflux overnight, cooled to room temperature and diluted with water (600mL). The resulting suspension was stirred at room temperature for 30 minutes and the precipitate was then collected by filtration, washed with water and acetonitrile and dried at 50 °C to afford 48.2 g of 5-fluoro-3-[5-fluoro-4-(methylthio)pyrimidin-2-yl]-l-tosyl-lHpyrrolo[2,3-b]pyridine as a white solid.

'H NMR (300 MHz, DMSO-75) 5 8.70 - 8.58 (m, 2H), 8.54 - 8.41 (m, 2H), 8.09 (d, J = 8.4 Hz, 2H), 7.45 (d, 7 = 8.2 Hz, 2H), 2.76 (s, 3H), 2.36 (s, 3H).

[001056] Formation of 5-fluoro-3-[5-fluoro-4-(methylsulfinyI)pyrimidin-2-yl]-ltosyl-lH-pyrrolo[2,3-b]pyridine (44c)

5-fluoro-3-[5-fluoro-4-(methylthio)pyrimidin-2-yl]-l-tosyl-lH-pyrrolo[2,3b]pyridine, 44b, (48.2 g, 111.5 mmol) was dissolved in dichloromethane (2.3 L) and treated portionwise with m-CPBA (27.5 g, 122.6 mmol) while keeping the temperature below 20 °C. After addition was complete, the reaction was stirred at room temperature for 2 hours, then treated with another portion of m-CPBA (1.9 g) and stirred for another hour. The reaction mixture was washed with 12% aqueuous K₂CO₃ (2 x 1.0 L) and the organic layer was dried on Na₂SO₄ and concentrated in vacuo to provide 50 g of 5-fluoro-3-[5-fluoro-4(methylsulfinyl)pyrimidin-2-yl]-l-tosyl-lH-pyrrolo[2,3-b]pyridine as a yellow solid.

'H NMR (300 MHz, DMSO-76) δ 9.11 (d, 7= 1.5 Hz, 1H), 8.69 (s, 1H), 8.65 (dd, 7 = 9.0, 2.9 Hz, 1H), 8.52 (dd, 7= 2.8, 1.2 Hz, 1H), 8.11 (d, 7= 8.4 Hz, 2H), 7.46 (d, 7= 8.3 Hz, 2H), 3.05 (s, 3H), 2.36 (s, 3H).

[001057] Formation of tert-butyl ;V-[( 1/C, 35)-3-[[5-fluorO”2-[5-fluoro~l-(ptoIylsulfonyl)pyrrolo[2,3-b]pyridin-3yl]pyrimidin-4-yl]amino]cyclohexyl]carbamate (44d)

5-fluoro-3-(5-fluoro-4-methylsulfmyl-pyrimidin-2-yl)-l-(p-tolylsulfonyl)pyrrolo[2,3b]pyridine, 44c, (5.9 g, 10.5 mmol) and tert-butyl A-[(1R, 35)-3-aminocyclohexyl]carbamate (3 g, 12.60 mmol) were dissolved in THF (100 mL). The reaction mixture was heated to 50 °C for 6 hours, then cooled to room temperature. Celite was added and the solvent was removed under reduced pressure. The Celite-supported residue was purified by silica gel chromatography (20-80% EtOAc/hexanes gradient to provide 3.7 g of tert-butyl 79-[(lR, 35)3-[[5-fluoro-2-[5-fluoiO-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-4yl]amino]cyclohexyl]carbamate.

’H NMR (300 MHz, CDC1₃) δ 8.51 (s, 1H), 8.46 - 8.41 (m, 1H), 8.29 (d, 7= 1.6 Hz, 1H), 8.11 (s, 1H), 8.08 (s, 1H), 8.06 (d, 7= 3.2 Hz, 1H), 7.27 (d,7=8.4 Hz, 2H), 4.91 (d,7= 8.0 Hz, 1H), 4.41 (s, 1H), 4.29 - 4.01 (m, 1H), 3.64 (s, 1H), 2.47 (d, 7= 11.5 Hz, 1H), 2.36 (s, 3H), 2.24 (d, 7= 13.1 Hz, 1H), 2.08 (d, J= 10.9 Hz, 1H), 1.91 (d, 7= 13.8 Hz, 1H), 1.43 (s, 9H), 1.30- 1.03 (m, 4H).

[001058] Formation of (15, 3jR)-/Vl-[5-fluoro-2-[5-fluoro-l-(ptolylsulfonyl)pyrrolo [2,3-b] pyridin-3-yl] pyrimidin-4-y 1] cyclohexane-1,3-diamine (44e) tert-Butyl N-[(1R, 35)-3-[[5-fluoiO-2-[5-fluoro-l-(p-tolylsulfonyl)pyrrolo[2,3b]pyridin-3-yl]pyrimidin-4-yl]amino]cyclohexyl]carbamate, 44d, (3.7 g, 6.2 mmol) was dissolved in dichloromethane (105 mL) and treated with trifluoroacetic acid (31 mL). After 5 minutes, the volatiles were evaporated under reduced pressure, and the resulting residue was

-308WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 treated with IN NaOH (75 mL). The resulting precipitate was collected by filtration, washed with water (3 x 30 mL) and vacuum dried to provide 2.7 g of (15, 3R)-M-[5-fluoro-2-[5fluoro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-4-yl]cyclohexane-l,3-diamine as a white solid.

NMR (300 MHz, MeOD) d 8.56 (dd, .7= 8.0, 3.9 Hz, 2H), 8.35 - 8.26 (m, IH),

8.12 (dd, 7= 10.3, 6.1 Hz, 3H), 7.43 (d, 7= 8.4 Hz, 2H), 4.36 - 4.21 (m, IH), 3.28 - 3.13 (m, IH), 2.48 (d, 7= 12.3 Hz, IH), 2.46 (s, 3H), 2.25 - 1.97 (m, 7= 17.3, 10.6, 4.1 Hz, 4H), 1.76 - 1.28 (m, 3H).

[001059] Formation of 2V-[(11?, 35)-3-[[5-fluoro-2-[5-fluoro-l-(ptolylsulfonyl)pyr r olo [2,3 -b] pyridin-3-yl] pyrimidin-4-yl] amino] cycloh exyl] morpholine4-carboxamide (44f) (15, 3R')-N1 -[5-fluoro-2- [5-fluoro-1 -(p-tolylsulfony l)pyrrolo[2,3 -b]pyridin-3yl]pyrimidin-4-yl]cyclohexane-l,3-diamine, 44e, (2.3 g, 4.6 mmol) was dissolved in DMF (50mL) and treated with morpholine-4-carbonyl chloride (2.1 g, 13.8 mmol) and DIPEA (4.2 g, 5.6 mL, 32.3 mmol). After one hour, the resulting solution was diluted with water (400 mL) and stirred for an additional two hours. The resulting precipitate was collected by filtration, washed with water (3 x 50 mL) and dried to provide the crude product. This material was purified by flash chromatography on a 40g column using EtOAc/DCM 20100%, to provide 2.0 g of M[(1R, 3S)-3-[[5-fluoro-2-[5-fluoro-l-(ptolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-4-yl]amino]cyclohexyl]morpholine-4carboxamide as a white solid.

^lH NMR (300 MHz, DMSO-76) δ 8.53 - 8.43 (m, 7= 11.9, 2.7 Hz, 3H), 8.22 (d, 7 =

3.9 Hz, IH), 8.07 (d, 7= 8.4 Hz, 2H), 7.44 (d, 7= 8.3 Hz, 2H), 6.32 (d, 7= 7.5 Hz, IH), 4.05 (s, 7= 19.4 Hz, IH), 3.62 (s, IH), 3.58 - 3.45 (m, 4H), 3.27 - 3.18 (m, 4H), 2.36 (s, 3H), 2.12 (d, 7= 11.7 Hz, IH), 1.99 (d, 7= 9.5 Hz, IH), 1.83 (d, 7= 10.3 Hz, 2H), 1.53 - 1.11 (m, 7= 32.3,22.8, 10.9 Hz, 4H).

[001060] Formation of ΛΓ-[(1Λ, 35)-3-([5-fluoro-2-(5-fluoro-lH-pyrrolo[2,3b]pyridin-3-yl)pyrimidin-4-yl]amino]cyclohexyl]morpholine-4-carboxamide (706)

W-[(1R, 35)-3-[[5-fluoro-2-[5-fluoro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3yl]pyrimidin-4-yl]amino]cyclohexyl]morpholine-4-carboxamide, 44f, (2.0 g, 3.2 mmol) was suspended in methanol (50 mL) and treated with 25% sodium methoxide in methanol (19.9 mL, 92.3 mmol) . After stirring for 1 hour, the solvent was evaporated under reduced pressure, and the residue was partitioned between water (100 mL) and ethyl acetate (100 mL). The organic layer was collected, dried on Na₂SO4 and concentrated to provide the crude product as a yellow solid. This material was purified by silica gel chromatography on a 40g column, using DCM/MeOH 1-6%. The purified fractions were treated with 2N HC1 in ether and concentrated to provide 1.5 g of ;V-[(1R, 3S)-3-[[5-fluoro-2-(5-fluoro-lHpyrro lo [2,3 -b]py ridin-3 -yl)pyrimid in-4-y 1] aminojcyc lohexyl] -morpho line-4-carboxamide as a white solid.

-309WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

44e [001061] Formation of (15, 3R)-A'l-(2-fluoro-5-(5-fluoro-l//-py rrolo ] 2,3-6 |py rid in3-yl)phenyl)cyclohexane-l,3-diamine (44e)

To a solution of zert-butyl (IR, 3S)-3-(2-fluoro-5-(5-fluoro-l-tosyl-17i-pyrrolo-[2,3b]pyridin-3-yl)phenylamino)cyclohexylcarbamate, 44d, (0.65 g, 1.09 mmol) in methylene chloride (22 mL) was added hydrogen chloride (2.71 mL of 4M solution in 1,4-dioxane,

10.86 mmol). The reaction was heated to 50 °C and stirred for 6 hours. The mixture was cooled to room temperature and concentrated in vacuo, producing a yellow solid. The crude residue was purified via silica gel chromatography (25-50% Ethyl Acetate/hexanes gradient). Desired fractions were combined and concentrated in vacuo to produce 350 mg of 44e as a

HATU, Hunig'sBase

THF, r.t., 4 hours

F

871 [001062] Synthesis of l-cyano-A-((1 R, 35)-3-(2-fluoro-5-(5“fluoro-117-pyrrolo[2,36]pyridin-3-yl)phenylamino)cyclohexyl)cyclopropanecarboxamide (871)

To a solution of 1-cyano-1-cyclopropane-carboxylic acid (0.058 g, 0.527 mmol) in THF at room temperature was added HATU (0.200 g, 0.527 mmol) followed by N,Ndiisopropylethylamine (0.334 mL, 1.91 mmol). The solution was stirred for 10 minutes. (15, 3R)-Vl-(2-fluoro-5-(5-fluoro-l//-pyrrolo[2,3-6]pyridin-3-yl)phenyl)cyclohexane-l,3diamine, 44e, (0.200 g, 0.584 mmol) was then added and solution stirred at room temperature for 4 hours. The mixture was concentrated in vacuo and purified via silica gel chromatography (30-60% Ethyl Acetate/hexanes) to give 80 mg of 871 as off-white solid.

Ή NMR (300 MHz, DMSO) δ 12.80 (s, IH), 8.95 (s, IH), 8.78 (s, IH), 8.43 (d, J= 5.2 Hz, IH), 8.37 (d, J= 1.6 Hz, IH), 8.07 (d, J = 7.9 Hz, IH), 4.22 (s, 2H), 3.80 (s, IH), 2.17 - 1.94 (m, 2H), 1.90 - 1.71 (m, 2H), 1.71 - 1.06 (m, 8H).

General Scheme 45

-310WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 (a) 4-chlorobutanoyl chloride, Et₃N, CH₂CI₂; (b) KOtBu, THF; (c) H₂, Pd-C, MeOH; (d) 45c, Na₂CO₃, THF-CH₃CN, 135 °C; (e)4M HCI, dioxane-CH₃CN.

[001063] Formation of benzyl (15, 311)-3-(4chlorob utana mid o) cy ciohexylcarbamate (45a)

To a stirred slurry of benzyl jV-[(15, 37?)-3-aminocyclohexyl]carbamate, 18e, (0.97 g,

3,41 mmol) in CH2CI2 (34 mL), was added Et₃N (1.00 mL, 7.15 mmol) , followed by 4chlorobutanoyl chloride (0.40 mL, 3.58 mmol). After stirring at room temperature, the mixture was diluted with CH₂C1₂, washed with IN HCI (2 x), INNaOH (2x), and brine. The organic layer was dried overNa₂SO4, filtered and concentrated in vacuo to give 1.07 g of the desired product.

’H NMR (300 MHz, MeOD) δ 7.33 - 7.26 (m, 5H), 5.04 (s, 2H), 3.73 - 3.65 (m, IH), 3.56 (t, J= 6.5 Hz, 2H), 3.44 (dq, J == 3.9, 15.6 Hz, IH), 2.33 - 2.28 (m, 2H), 2.11 - 1.97 (m, 3H), 1.90 - 1.75 (m, 3H), 1.45 - 1.28 (m, IH) and 1.18 - 1.02 (m, 3H) ppm.

[001064] Formation of benzyl (15, 3jR)-3-(2-oxopyrrolidin-lyl)cyclohexylcarbamate (45b)

To a slurry of benzyl (15, 3/?)-3-(4-chlorobutanamido)cyclohexylcarbamate, 45a, (0.21 g, 0.58 mmol) in THF (8.2 mL) was added potassium zert-butoxide (0.08 g, 0.69 mmol) at room temperature. After stirring at room temperature for 25 h, the mixture was quenched with aqueous saturated NH₄C1 and extracted with Et₂O (3x). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. Flash chromatography (S1O2, 0-100% EtOAc-hexanes, gradient) provided a single fraction consisting of desired product and a small amount of starting material (168 mg). This material was immediately subjected to deprotection conditions.

³HNMR (300 MHz, MeOD) δ 7.33 - 7.27 (m, 5H), 5.04 (s, 2H), 3.95 - 3.88 (m, IH),

3.58 - 3.38 (m, 3H), 2.38 - 2.28 (m, 2H), 2.11 - 1.76 (m, 6H), 1.63 (d, 7= 2.7 Hz, IH), 1.46 -

1.34 (m, 3H) and 1.21 - 1.06 (m, 2H) ppm.

[001065] Formation of l-((Lff, 35)-3-aminocyclohexyl)pyrrolidin-2-one (45c)

A degassed solution of benzyl (15, 3/?)-3-(2-oxopyrrolidin-l-yl)cyclohexylcarbamate, 45b, (0.165 g, 0.522 mmol) and Pd on C (10% wet, Degussa, 0.050 g, 0.024 mmol) in MeOH (15 mL) was placed under H₂ atm (balloon). After 105 min, TLC (10% MeOH-DCM) indicated complete consumption of starting material. H₂ was removed and the solution filtered and concentrated in vacuo. The crude product was azeotroped with CH₃CN (2 x) to remove any residual MeOH and provided the desired product (96 mg): FIA (M + H⁺) 183.27 [001066] Formation of 1-((16(, 35)-3-(2-(5-chloro-l-tosyl-l//-pyrrolo[2,3-b]pyridin3-yl)-5-iluoropyrimidin-4-ylamino)cyclohexyl)pyrrolidin-2-one (45d)

A mixture of 5-chloro-3-(5-fluoro-4-methylsulfmyl-pyrimidin-2-yl)-l-(ptolylsulfonyl)-pyrrolo[2,3-b]pyridine, la, (0.14 g, 0.29 mmol) and 1-((17?, 35)-3aminocyclohexyl)pyrrolidin-2-one, 45c, (0.10 g, 0.53 mmol) and Na₂CO₃ (0.09 g, 0.88 mmol) freshly ground, in THF (2.25 mL) and CH₃CN (0.45 mL) and heat to 135 °C for 30 min. The mixture was slowly poured into 15 mL 1M HCI and extracted with EtOAc (5 x). The combined organic layers were washed with brine, dried over Na₂SO₄ and filtered and concentrated in vacuo. Flash chromatography (SiO₂, 0-20% MeOH-CH₂Cl₂ gradient) provided the final product as a sticky residue. Trituration with CH₃CN provided an off white powder (105 mg) which was impure, but which was taken directly to the final deprotection step.

LC/MS R, = 3.90 min, (M+H) 589.49.

[001067] Formation of 1 -((1R, 35)-3-(2-(5-chIoro-U7-pyrrolo[2,3-b]pyridin-3-yl)-5-311WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 fluoro-pyrimidin-4-ylamino)cyclohexyl)pyrrolidin-2-one (956)

A mixture of partially purified 1 -((12?, 3S)-3-(2-(5-chloro-l-tosyl-12/-pyrrolo[2,3b]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)cyclohexyl)pyrrolidin-2-one, 45d, (0.105 g, 0.180 mmol) in CH₃CN (5mL) was treated with HCI (2 mL of 4 M, 8.00 mmol) in dioxane at 70 °C. After 2H, the mixture was cooled to room temperature. Then CH₃CN was added and the solid that precipitated was triturated with more CH₃CN (3 x). Preparative HPLC provided the desired product as the HCI salt (35 mg).

ft-TNMR (300 MHz, MeOD) δ 8.72 (d, J= 22 Hz, IH), 8.49 (s, IH), 8.39 (d, J= 2.1 Hz, IH), 8.29 (d, 7= 5.5 Hz, IH), 4.54 - 4.47 (m, IH), 4.13 (t, 7= 11.8 Hz, IH), 3.57 - 3.45 (m, 2H), 2.42 - 2.36 (m, 2H), 2.25 (m, IH), 2.15 - 2.00 (m, 4H), 1.90 - 1.59 (m, 4H) and 1.53 -1.43 (m, IH) ppm; LC/MS RT = 3.15 min, (M+H) 429.53.

(a) 30% ammonium hydroxide, water, 50°C (b) Acetyl chloride, diisopropylethylamine, dichloromethane, rt. (c) 5-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1Hpyrrolo[2,3-b]pyridine, Pd(PPh₃)4.2M sodium carbonate, acetonitrile, 130 °C, microwave [001068] Formation of (15, 35)-l-(aminomethyl)-3-(2-chIoro-5-fluoropyrimidin“4ylamino)cyclohexanol (46b)

2-Chloro-5-fluoro-/V-[(3S, 5S)-l-oxaspiro[2.5]octan-5-yl]pyrimidin-4-amine, 46a, (0.19 g, 0.73 mmol) was dissolved in water (75 mL) and treated with 30% ammonium hydroxide (10 mL, 86.0 mmol) . The suspension was heated to 50 °C for 5 hrs then allowed to stir at room temperature overnight. The volatiles were evaporated under reduced pressure, and the residue, (IS, 3S)-l-(aminomethyl)-3-(2-chloro-5-fhioro-pyrimidin-4ylamino)cyclohexanol, was taken into the next step without further purification.

[001069] Formation of .V-{[(1S, 35)-3-(2-chloro-5-fluoropyrimidin-4-ylamino)-lhydroxycyclohexyl]methyl] acetamide (46c) (IS, 3S)-l-(aminomethyl)-3-(2-chloro-5-fluoropyrimidin-4-yIamino)cyclohexanol, 46b, (0.19 g, 0.69 mmol) was dissolved in dichloromethane (15 mL) and treated with DIPEA (1.20 mL, 6.91 mmol) and acetyl chloride (0.10 mL, 1.38 mmol). After 5 minutes, the reaction mixture was diluted into IN HCI (30 mL), and the aqueous layer was brought to a basic pH by addition of IN NaOH. The resulting suspension was extracted with dichloromethane (50 mL). The organic layer was dried on Na₂SO4 and concentrated in vacuo to provide the crude product, which was purified by silica gel chromatography (20-100% EtOAc/hexanes gradient) to afford 195 mg of //-{[(IS, 3S)-3-(2-chloro-5-fluoropyrimidin-4ylamino)-l-hydroxycyclo-hexyl]methyl]acetamide as a white foamy solid. LCMS RT = 2.82 (M+l) 317.33.

[001070] Formation of ZV-{[(15, 3S)-3-(2-(5-chloro-l//-pyrrolo|2,3-b|pyridin-3-yl)5-fluoropyrimidin-4-ylamino)-l-hydroxycycIohexyl]methyl] acetamide (857)

N- {[(1S, 3 S)-3 -(2-chloro-5 -fluoropyrimi din-4-y lamino) -1 -hydroxycyclohexyl] methyl]-acetamide, 46c, (0.2 g, 0.6 mmol) was dissolved in acetonitrile (6 mL) and treated

-312WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 with 5-chloro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pynOlo[2,3b]pyridine (0.5 g, 1.2 mmol) followed by Pd(PPh₃)₄ (0.07 g, 0.06 mmol). Aqueous 2M sodium carbonate (3.0 mL, 6.1 mmol) was added, and the vial was sealed and heated in the microwave to 130 °C for 30 min. The organic layer was collected and concentrated in vacuo to provide the crude product, which was dissolved in DMSO and purified by HPLC using 570% MeOH/HaO with 6mM HC1 over 15 minutes to provide after concentration 75 mg of N{[(15, 35)-3-(2-(5-chloro-l/f-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)-lhydroxycyclohexyljmethyl) acetamide hydrochloride as an off-white crystalline solid.

’H NMR (300 MHz, DMSO-76) δ 13.02 (s, IH), 9.22 (s, IH), 9.03 (d, 7= 2.4 Hz, IH), 8.71 (d, 7= 2.1 Hz, IH), 8.46 (d, 7= 5.5 Hz, IH), 8.41 (d, 7= 2.1 Hz, IH), 7.81 (t, 7 = 5.8 Hz, IH), 4.64 (d, 7= 8.0 Hz, IH), 3.16 - 2.99 (m, 2H), 2.09 - 1.73 (m, 3H), 1.85 (s, 3H), 1.73 - 1.42 (m, 3H), 1.28 (dd, 7= 27.5, 10.6 Hz, 2H).; LCMS RT = 3.47 (M+l) 433.37

General Scheme 47 (a) tert-butyl M-methyl-N-(2-oxoethyl)carbamate, diisopropylethylamine, THF/EtOH, 70 °C (b) HCI/dioxane, THF/MeOH (c) bis(4-nitrophenyl) carbonate, diisopropylethylamine, DMF.

[001071] Formation of tert-butyl 2-((17ζ 35)-3-(2-(5-chloro-l£T-pyrrolo[2,3b]pyridin-3-yl)-5-fluoropyrimidin-4-ylaniino)cyclohexyl-amino)ethyl(methyl)carbamate (47b)

In a flask containing (15, 35)-.Vl-(2-(5-chloro-l77-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-yl)cyclohexane-1,3-diamine, 47a, (0.14 g, 0.39 mmol) in THF/EtOH was added tert-butyl A^Lmethyl-/V-(2-oxoethyl)carbamate (0.10 g, 0.58 mmol) and diisopropylethylamine (0.13 mL, 0.77 mmol). The solution was heated at 70 °C for 30 min. Sodium triacetoxyborohydride (0.08 g, 0.39 mmol) was added. The solution was stirred at room temperature for 12 hrs. The solution was filtered and the solvent evaporated under reduced pressure. The resulting residue was purified by HPLC using 5-70% MeOH/H₂O with 6mM HC1 to provide the desired product.

[001072] Formation of (15, 3/f)-7Vl-(2-(5-chloro-17/-pyrroIo[2,3-b]pyridin-3-yl)-5fluoropyrinndin-4-yl)-7V3-(2-(methylamino)ethyl)cyclohexane-l,3-diamine (47c)

In a flask containing tert-butyl 2-((1 J?, 35)-3-(2-(5-chloro-l/f-pyiTolo[2,3-b]pyridin-3yl)-5-fluoropyrimidin-4-ylamino)cyclohexylamino)ethyl(methyl)carbamate, 47b, (0.02 g, 0.04 mmol) in dichloromethane/MeOH mixture was added HC1 in Dioxane (3.86 mL of 4 M solution, 15.44 mmol). The solution was stirred at room temperature for 12 hrs. The solvent was evaporated under reduced pressure and used without further purification.

[001073] Formation of 1-((1R, 35)-3-(2-(5-chIoro-lif-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cyclohexyl)-3-methylinndazolidm-2-one (958)

In a flask containing (15, 32?)-M-(2-(5-chloro-l/7-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-yl)-7V3-(2-(mcthylamino)ethyl)cyclohexane-l,3-diaminc, 47c, (0.020 g,

-313WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

0.048 mmol) in DMF was added diisopropylethylamine (0.025 mL, 0.144 mmol) and bis(4nitrophenyl) carbonate (0.016 g, 0.053 mmol). The reaction mixture was stirred at room temperature for 3 hrs. The resulting residue was purified by HPLC using 5-70% MeOH/H?O with 6mM HC1 to provide the desired product.

General Scheme 48

(a) 2-Methoxyethanamine, HATU, D1EA, CH₃CN, DMF [001074] Formation of (Iff, 35)-3-(2-(5~chloro-l£f-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-2V”(2-methoxyethyl)cyclohexanecarboxamide (789) (Iff, 3>S)-3-[[2-(5-chloro-lH-pynOlo[2,3-b]pyridin-3-yl)-5-fluoro-pyrimidin-4yl]amino]cyclohexanecarboxylic acid (HC1 salt)(0.05 g, 0.12 mmol), HATU (0.09 g, 0.24 mmol), diisopropylethylamine (0.06 g, 0.47mmol) and 2-methoxyethanamine (0.04 g, 0.47 mmol) were stirred together in 1 ml each of DMF and CH₃CN at room temperature overnight. All volatiles were removed with a stream of nitrogen and heat. The residue was dissolved in methanol and purification with phase preparatory HPLC with 10 - 90% MeOH/water (HC1 modifier) gave the desired product as the HC1 salt.

General Scheme 49

-314WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 (a) methyl(triphenyl)phosphonium bromide, (bis(trimethylsilyl)amino)lithium, THF (b) 3-chloroperoxybenzoic acid, MeOH, H2O. (c) methylsulfanylsodium, THF (d) 5chloro-1 - (p-toly Isulfony 1)-3-(4,4,5,5 -tetramethyl-1,3,2-dioxaborolan-2-y l)pyrrolo[2,3 b]pyridine, Na₂CO₃, tetrakis triphenylphosphinepalladium(O), CH₃CN (e) 3chloroperoxybenzoic acid, CH2CI2 (f) NaOMe, MeOH.

[001075] Formation of (5)-2-chloro-5-fluoro-lV-(3-methylenecyclohexyl)pyrimidin4-amine (49a)

To a suspension of methyl(triphenyl)phosphonium bromide (0.86 g, 2.40 mmol) in THF (100 mL) in a flamed dry flask was added (bis(trimethylsilyl)amino)lithium (2.40 mL of 1 M solution, 2.40 mmol) at room temperature. The reaction mixture was allowed to stir at room temperature for 1 hr. A solution of (5)-3-(2-chloro-5-fhioropyrimidin-4ylamino)cyclohexanone, 29b, (0.48 g, 2.00 mmol) in 20 mL of THF was added. The reaction was allowed to stir at room temperature for 2 hrs. The mixture was quenched by pouring into brine and the aqueous phase was extracted with EtOAc. The layers were separated and the organic was dried over MgSO₄, filtered and evaporated to dryness. The crude residue was purified via silica gel chromatography (0-100%EtOAc/hexanes gradient) to afford 270 mg of the desired product: LCMS RT: 3.83 min, (M+l): 242.2.

[001076] Formation of 2-chloro-5-fluoro-/V-((3J?, 55)-l-oxaspiro[2.5]octan-5yl)pyrimidin-4-amine (49b, 49c)

3-chloroperoxybenzoic acid (0.40 g, 1.79 mmol) was added to a solution of (5)-2chloro-5-fluoro-M-(3-methylenecyclohexyl)pyrimidin-4-amine, 49a, (0.27 g, 1.12 mmol) in water (0.6 mL) and MeOH (1.5 mL) at room temperature. The reaction mixture was allowed to stir at room temperature for 1 hr. The mixture was diluted with EtOAc and washed with aqueous saturated NaHCO₃ solution. The organic phase was dried (MgSO₄), filtered and evaporated to diyness. The crude residue was purified via silica gel chromatography (0100% EtOAc/hexanes gradient) which yielded both diastereomers, 49b and 49c. The isolated upper (less polar) spot, 49b, was carried forward: LCMS RT = 3.21 (M+l) 258.2.

[001077] Formation of (1R, 35)-3-(2-chloro-5-fluoropyrimidin-4-ylamino)-l-(methylthiomethyl)cyclohexanol (49d)

2-chloro-5-fluoro-i'V-((3R, 55)-l-oxaspiro[2.5]octan-5-yl)pyrimidin-4-amine, 49b, (0.10 g, 0.38 mmol) was dissolved in THF (2 mL). Methylsulfanylsodium (0.08 g, 1.15 mmol) was added to the reaction and the mixture was allowed to stir at room temperature for 3 hrs. An additional 36 mg portion of methylsulfanylsodium in THF (2 mL) was added and the reaction mixture was stirred overnight at room temperature. After LCMS showed starting material was still present, the reaction was warmed to 50 °C and stirred for 1 hr. The reaction was quenched with water and diluted with EtOAc. The layers were separated and the organic phase was washed with brine, dried (MgSO₄), filtered and evaporated to diyness. The crude residue was purified via silica gel chromatography (0-100%Etoac/hexanes gradient). The product (contaminated with small amount of staring material) was carried on to the next step without further purification. LCMS RT = 3.56 (M+l) 306.2.

[001078] Formation of (1Λ, 35)-3-(2-(5-chloro-l-tosyl-U7-pyrrolo[2,3-b]pyridin-3yl)-5-fluoropyrimidin-4-ylamino)-l-(methylthiomethyl)cyclohexanol (49e)

To a solution of (17?, 3S)-3-(2-chloro-5-fluoropyrimidin-4-ylamino)-l(methylthiomethyl)cyclohexanol, 49d, (0.09 g, 0.28 mmol) in CH₃CN (4 mL) was added 5chloro-l-(p-tolylsulfonyI)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrrolo[2,3-315WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 bjpyridine (0.14 g, 0.33 mmol) followed by aqueous Na₂CO₃ (0.42 mL of 2 M solution, 0.83 mmol). The reaction was degassed with nitrogen for 15 min and tetrakis triphenylphosphinepalladium(O) (0.02 g, 0.01 mmol) was added. The reaction was heated to 140 °C via microwave irradiation for 20 minutes. The mixture was cooled to room temperature and was diluted with water/EtOAc. The layers were separated and the organic phase was washed with brine, dried over MgSCq, filtered and evaporated to dryness. The crude residue was purified via silica gel chromatography (0-100% EtOAc/hexanes gradient).

IH NMR (300 MHz, DMSO) δ 8.76 (d, J= 1.8 Hz, IH), 8.47 (d, 8.1 Hz, IH),

8.30 (t, J= 26.7 Hz, IH), 8.05 (d, J= 8.1 Hz, 2H), 7.95 - 7.45 (m, 2H), 7.43 (s, IH), 4.81 (s, IH), 4.32 - 3.84 (m, IH), 2.70 (d, J= 19.5 Hz, 2H), 2.36 (s, 2H), 2.14 (s, IH), 2.13 (s, IH), 2.14 - 1.94 (m, 2H), 2.14 - 1.59 (m, 6H), 1.48-0.83 (m, 3H).

[001079] Formation of (15, 35)-3-(2-(5-chloro-l-tOsyl-U/-pyrrolo|2,3-b]pyridin-3y l)-5-fluor opy rimidin-4-ylamino)-l-(methylsulfonylmethyI) cy clohexan ol (49f)

To a cold (0 °C) solution of (15, 3S)-3-(2-(5-chloiO-l-tosyl-IELpyrrolo[2,3-b]pyridin3-yl)-5-fluoropyrimidin-4-ylamino)-l-(methylthiomethyl)cyclohexanol, 49e, (0.044 g, 0.077 mmol) in CH₂C1₂ (2 mL) was added 3-chloroperoxybenzoic acid (0.034 g, 0.155 mmol). After stirring for 1 hour at 0°C, the mixture was diluted with water and CH₂CI₂. The layers were separated and the organic was washed with aqueous saturated NaHCO₃ soln., dried over MgSCq, filtered and evaporated to dryness. The erode residue was purified via silica gel chromatography (0-100% EtOAc/hexanes gradient). LCMS RT = 4.20 (M+l) 608.3.

[001080] Formation of (15,35)-3-(2-(5-chIoro-llf-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-l-(niethylsulfonylmethyl)cyclohexanol (886)

To a solution of (15, 3S)-3-(2-(5-chloro-l-tosyl-lELpyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-l-(methylsulfonylmethyl)cyclohexanol, 49f, (0.045 g, 0.074 mmol) in MeOH (2 mL) was added NaOMe (2 mL of 25 %w/v, 9.255 mmol). The reaction mixture was allowed to stir at room temperature for 5 minutes, after which the mixture was quenched with the addition of aqueous saturated NH4CI solution and then diluted with EtOAc. The layers were separated and the organic was washed with brine, dried over MgSO₄, filtered and evaporated to dryness. The crude residue was purified via silica gel chromatography (0-10% MeOH/ CH₂C1₂ gradient).

General Scheme 50

(a) AIMe₃, [Rh₂(cod)₂CI₂], (S)-BINAP, THF, 0 °C (b) T8SCI, imidazole, DMAP, DMF (c) βοή loroperoxy benzoic acid, CH₂CI₂ (d) sodium azide, NH₄CI, MeOH, H₂O (e) H₂, Pd-C (10%), EtOAc (f) 5-chloro-3-(5-fluoro-4-(methylsulfinyl)pyrimidin-2-yl)-1-tosyl-1 H-pyrrolo[2,3b]pyridine, 'Pr₂NEt, microwave, 70 °C (g) TBAF, THF

[001081] Formation of (5)-l-methylcyclohex-2-enol (50a)

-316WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

In a 1000 mL flamed-dried round bottom flask, a mixture of (S)-BINAP (6.2 g, 10.0 mmol) and Rh₂(cod)₂C12 (2.1 g, 4.2 mmol) in anhydrous THF (350 mL), was stirred under nitrogen for 30 minutes at room temperature. The homogeneous red reaction mixture was then cooled to 0 °C and cyclohex-2-en-l-one (16.0 g, 166.4 mmol) was added followed by dropwise addition of neat trimethylaluminium (12.4 g, 16.5 mL, 166.4 mmol). The mixture was allowed to warm to room temperature for 30 min and then stirred for 1 hour. The reaction was monitored by NMR and a worked up aliquot indicated complete conversion to tertiary alcohol.

When the reaction was complete, its temperature was lowered to 0°C and quenched carefully with aqueous saturated NH4CI solution (500 mL). The layers were separated and the aqueous phase was further washed with ether (5 X 100 mL) and the combined organics were dried (MgSO₄) filtered over a celite pad and concentrated in vacuo to a yellow-brownish crude oil. Vacuum distillation (38 °C at 0.5-1 mm Hg), provided 13.9 g (72%) of light amber color oil.

[001082] Formation of (ff)-teri-butyldimetliyl(l-methylcyclohex-2-enyloxy)silane (50b)

To a solution of (ff)-l-methylcyclohex-2-enol, 50a, (1.00 g, 8.91 mmol) in 20 dry DMF at room temperature was added 477-imidazole (1.82 g, 26.74 mmol), ZerZbutyldimethylchloro silane (2.02 g, 13.33 mmol) and a catalytic amount of 4dimethylaminopyridine (0.11 g, 0.89 mmol). The resulting mixture was stirred at room temperature overnight. It was then diluted with ether, washed consecutively with water, citric acid and water. The organic phase was dried with MgSO₄₎ filtered and concentrated in vacuo. The colorless crude oil 1.98 g was used directly in the next step without further purification.

[001083] Formation of tert-butyldimethyl((12f, 2R, 6/?)-2-methyI-7oxabicyclo[4.1.0]heptan-2-yloxy)silane (50c)

3-chlorobenzenecarboperoxoic acid (2.47 g, 11.00 mmol) was added in one portion to a stirred solution of (7?)-ter/-butyldimethyl(l-methylcyclohex-2-enyloxy)silane, 50b, (1.98 g,

8.87 mmol) and sodium hydrogen carbonate in 30 mL of dry dichloromethane at room temperature under nitrogen. The resulting mixture was stirred for 20 hours. Then, 25% sodium sulfite solution (30 mL) was added and the resulting biphasic mixture was stirred for 15 minutes. The 2 layers were separated and the aqueous layer was extracted with dichloromethane (2X20 mL). The combined organic phases were washed with aqueous saturated NaHCCF, dried (Na₂SO₄) and concentrated in vacuo. The erode residue was purified by silica gel chromatography (0-10% EtOAc-hexanes gradient) to provide 647 mg of compound 50 c.

[001084] Formation of (1/i, 2R, 35)-3-azido-l-(tert-butyldimethylsilyloxy)-lmethylcyclo-hexan-2-ol (50d)

To a stirred solution of feri-butyl-dimethyl-[[( 1R, SR, 6R)-5-mcthyl-7oxabicyclo[4.1.0]heptan-5-yl]oxy] silane, 50c, (0.05 g, 2.15 mmol) in methanol (5 mL) and H₂O(0.6 mL) was added NH₄C1 (0.23 g, 0.15 mL, 4.30 mmol), followed by portion wise addition of sodium azide (0.42 g, 1.26 mL, 6.45 mmol). The resulting reaction mixture was warmed to 60 °C, stirred for 12 h, at which point TLC-analysis revealed traces of the starting material. The reaction mixture was cooled to ambient temperature, quenched with H₂O (2 mL), concentrated under reduced pressure to remove methanol, extracted with ethyl acetate (3 x 15 mL), washed with brine (10 mL), dried over MgSO₄, filter and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (2.5-10 %

-317WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 ethyl ether in hexanes gradient) to afford 254 mg of (JR, 2S, 6R)-2-azido-6-[tertbutyl(dimethyl)silyl]oxy-cyclohexanol, 50d, as a clear oil.

[001085] Formation of (1R, 2R, 35)-3-amino-l-(tert-butyldimethylsilyloxy)-lmethylcyclohexan-2-ol (50e)

A solution of azide, 50d, (0.25 g; 0.89 mmol) in 20 mL of ethyl acetate was hydrogenated with Degussa palladium (20 mole%) under 1 atmosphere of hydrogen overnight. The reaction mixture was filtered over celite and the celite was eluted with 2X10 mL of EtOAc. The filtrate was concentrated in vacuo to afford 230 mg of an oil that was used directly for the next step without further purification.

[001086] Formation of (1R, 2R, 65)-2-(tert-butyldimethylsilyloxy)-6-(2-(5-chloro-ltosyl-lff-pyrrolo[2,3-fr|pyridin-3-yl)-5-fluoropyrimidin-4-yIamino)-2methylcyclohexanol (501)

To a stirred suspension of (1R, 2R, 65)-6-amino-2-[zeri-butyl(dimethyl)silyl]oxy-2methyl-cyclohexanol, 50e, (0.16 g, 0.62 mmol) in THF (8 mL) in a microwave sealed tube vessel was added 5-chloro-3-(5-fluoro-4-(methylsulfiny l)pyrimidin-2-y 1)-1-tosyl-1Hpyrrolo[2,3-b]pyridine, la, (0.29 g, 0.63 mmol) followed by JV-ethyl4V-isopropyl-propan-2amine (0.13 mL, 0.74 mmol). The resulting reaction mixture was capped and warmed to 70 °C, stirred for 14 h. The reaction mixture was cooled to ambient temperature, added water (2 mL), concentrated under reduced pressure to remove THF. The crude product was diluted with ethyl acetate (25 mL), insoluble material (sulfone la) was removed by filtration. The organic layer was separated, washed with brine (2x5 mL), dried over Na₂SO4, filter and concentrated under reduced pressure. The crude product was purified by silica-gel plug using 10-30 % ethyl acetate in hexanes as eluant to afford 350 mg of (1R, 2R, 6S)-2-[tertbutyl(dimethyl)silyl]oxy-6-[[2-methyl[5-chloro-l-(p-tolylsulfonyl)-pyrrolo[2,3-b]pyridin-3yl]-5-fluoro-pyridin-4-yl] amino]cyclohexanol (50f).

[001087] Formation of (1R, 2R, 35>3-(2-(5Chloro-l£f-pyrrolo[2_>3-/’]pyri(lm-3-yl)5-fluoro-pyrimidin-4-ylamino)-l -methylcyclohexane-1,2-diol (860)

To a stirred solution of (1R, 2R, 6S)-2-[te/'Z-butyl(dimethyl)silyl]oxy-6-[[2-methyl[5chloro-l-(p-tolylsulfonyl)-pyrrolo[2,3-b]pyridin-3-yl]-5-fluoro-pyridin-4yl]amino]cyclohexanol, 50f, (0.11 g; 0.16 mmol) in THF (2 mL) at room temperature, was added tetrabutylammonium fluoride (1.5 equiv) and the reaction mixture stirred for 1.5 h, at which point HPLC-analysis revealed no starting material but the de-tosylated product was observed with minor desilylation. An additional equivalent of TBAF was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was suspended in ethyl acetate (10 mL), washed with H2O (2x4 mL), aqueous saturated NH4CI solution (2 mL) and brine (2 mL). The organic phase was dried (Na₂SO4) and concentrated in vacuo to provide 139 mg of crude. The crude residue was purified by reverse phase HPLC (5-95% MeOH/water w/ HC1 buffer over 15 minutes), to afford 15 mg of desired product, 860. LCMS M+l = 392.34

Genera] Scheme 51

-318WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

OBn

S1d

51o

511

(a) NaH, BnBr, THF, 60 °C (b) 3-chloroperoxybenzoic acid, CH₂CI₂, 0 °C (c) H₂SO₄, MeOH (d) TBSCI, imidazole, DMAP, DMF (e) H₂, Pd-C (10%), EtOAc (f) triphenylphosphine, diisopropylazadicarboxylate, diphenylphosphoryl azide, THF (g) H₂, Pd-C (10%), EtOAc (h) 2,4-dichloro-5-fluoropyrimidine, K₂CO₃, CH₃CN/!PA (i) TsOH, MeOH (j) 5-chloro-3-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine, aq Na₂CO₃, CH₃CN, microwave, 120 °C (k) LiOH, H₂O/THF, microwave, 120 °C.

[001088] Formation of ((cycIohex-2-enyloxy)methyl)benzene (51a)

A solution of cyclohex-2-en-l-ol (10.0 g, 101.9 mmol) in anhydrous THF (100 mL) was added to a stirred suspension containing sodium hydride (8.0 g, 199.7 mmol) (60% dispersion in oil) and benzyl bromide in anhydrous THF (250 mL) maintained at 50 °C. The resulting solution was stirred at 55-60 °C for 18 h. After cooling to ambient temperature, water was added to quench the reaction and the mixture was diluted with ether (500 mL). The organic phase was separated, dried (Na₂SO₄), filtered and concentrated in vacuo to an oil that was subjected to a short silica plug filtration to provide 16.1g of desired product 51a that was used directly in the next step without further purification.

[001089] Formation of racemic cis and imns-l-benzyloxy)-7oxabicyclo|4.1.0]heptane (51b and 51c)

A solution of benzyl ether 51a (16.10 g, 0.89 mol) in 500 mL of CH₂C1₂ at 0 °C was treated with 77% m-CPBA (21.08 g; 0.09 mol) portionwise. The reaction mixture was stirred at 0 °C for 2h then at room temperature for 12h. When the reaction is complete, it was quenched with sodium thiosulfate (100 mL) and the organic phase was further washed with another 100 mL of sodium thiosulfate, followed by aqueous NaHCOj solution, 5% NaOH (200 mL) and finally water. The organic phase was dried (Na₂SO₄) and concentrated in vacuo to afford an oil that was purified by silica gel chromatography (5% to 20% Et₂O/ hexanes) to afford 11.44 g of zraws-epoxide 51b and 3.95 g of cA-epoxide 51c were isolated (66:34 ratio).

[001090] Formation of racemic l-benzy!oxy-3-methoxycyclohexan-2-ol (51d)

A solution of cA-l-benzyloxy)-7-oxabicyclo[4.1.0]heptane, 51c, (2.0 g; 9.8 mmol) in 0.2N sulfuric acid (9.8 mmol) in 30 mL of anhydrous methanol was stirred at room temperature for 30 minutes. The reaction was diluted with water and extracted with ether. The organic phase was dried (Na₂SO₄) and concentrated in vacuo to afford 2.31 g of an oil that was used directly in the next step without further purification.

-319WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [001091] Formation of racemic [l-benzyloxy-3-methoxy-2-cyclohexanoxy]tertbutyl-dimethylsilane (51 e)

To a solution of l-benzyloxy-3-methoxy-cyclohexan-2-ol, 51 d, (2.31 g, 9.78 mmol), tert-butyl-chlorodimethyl-silane (2.21 g, 2.73 mL, 14.66 mmol) in 20 dry DMF at room temperature was added 4H-imidazole (1.997 g, 29.33 mmol) and a catalytic amount of 4dimetliylaminopyridine (0.12 g, 0.98 mmol). The resulting mixture was stirred at room temperature overnight. It was then diluted with ether, washed with water, aqueous saturated citric acid solution and water again. The organic phase was dried with MgSCfl. filtered and concentrated in vacuo. The colorless erode oil was used directly in the next step without further purification.

[001092] Formation of racemic [l-Hydroxy-3-methoxy-2-cyclohexanoxy]tert-butyldimethylsilane (51f)

A solution of racemic [l-benzyloxy-3-methoxy-2-cyclohexanoxy]tert-butyldimethylsilane, 51 e, (3.4 g, 9.7 mmol) was dissolved in ethyl acetate (50 mL) and hydrogenated under 45 PSI of hydrogen with Pd-C 10% for Ih. The reaction mixture was filtered over a nylon/fiberglass filter to provide, after concentration in vacuo 2.72 g of desired product 51 f. This material was used directly in the next step without further purification.

[001093] Formation of racemic [l-Azido-3-methoxy-2-cyclohexanoxy]tert-butyldimethylsilane (51 g)

To a solution of racemic [l-Hydroxy-3-methoxy-2-cyclohexanoxy]tert-butyldimethylsilane, 51f, (2.5 g; 9.6 mmol) in 60 mL of dry THF at room temperature was added, triphenylphosphine (5.0 g; 19.2 mmol), DIAD (3.9 g; 19.2 mmol) and diphenylphosphoryl azide (5.3 g; 19.2 mmol) and the reaction mixture was stirred at room temperature for 60h. The solvent was concentrated in vacuo and the resultant oil was purified by silica gel chromatography (10% EtoO-Hexane to ether gradient) to afford 2.57 g of the desired product 51 g.

[001094] Formation of racemic [l-Amino-3-methoxy-2-cyclohexanoxy]teri'-butyldimethylsilane (51h)

A solution of racemic [l-Azido-3-methoxy-2-cyclohexanoxy]/ert-butyldimethylsilane, 51g, (2.57 g; 6.3 mmol) in 20 mL of ethyl acetate was hydrogenated with PdC 10% (5 mole %; Degussa) at 45 PSI in a Pan^- hydrogenation apparatus for 1 h. The reaction mixture was filtered over a nylon and glass fiber filter and concentrated in vacuo to provide 2.32 g of the desired product 51h as a white solid.

[001095] Formation of racemic 7V-((l-2-(tert-butyIdimethy]silyloxy)-3m ethoxy cyclohexy l)-2-c hlo r o-5-fluoropy rim idin-4-amine (5 li)

In a flask was placed racemic [I-Amino-3-methoxy-2-cycIohexanoxy]/ert-butyldimethylsilane, 51h, (2.32 g; 6.26 mmol). To this was added MeCN and IPA (1.5:1 v/v) to a total volume of 125 mL. To the solution was added dipotassium carbonate (4.32 g, 31.30 mmol) and the mixt urc was allowed to stir 30 minutes at room temperature (to remove any water that might be present). To this mixture was added 2, 4-dicliloro-5-fluoro-pyrimidine (3.14 g, 18.78 mmol) and the mixture was stirred at room temperature for 60h. The reaction was filtered thru celite and concentrated in vacuo. The crude residue was purified by silica gel chromatography (20-100% Ether/hexanes gradient) to afford 2.27g pure racemate compound 51 i.

[001096] Formation of (Iff, 25, 6ff)-2-(2-chloro-5-fluoropyrimidin-4-ylainino)-6-320WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 methoxy-cyclohexanol (51 j)

To a solution of compound racemic 7/-(( 1 -2-(/ert-butyldimethylsilyloxy)-3methoxycyclohexyl)-2-ch!oro-5-fluoropyrimidin-4-amine, 51i, (1,96 g, 5,03 mmol) in 30 mL of MeOH was added p-TsOH (1.73 g; 10.06 mmol). The reaction mixture was stirred at room temperature for 3h and then was concentrated to diyness. The residue was dissolved in EtOAc (125 mL) and washed with aqueous potassium carbonate IM (2 X 50 mL), then brine. The organic phase was dried (Na₂SO₄), filtered and concentrated in vacuo to give, after SFC enantiomers separation (50% EtOH-50% CO₂; 10 mL/min; 100 bar) 635 mg of chiral alcohol 51J as a white solid.

[001097] Formation of (17?, 25, 62?)-2-(2-(5-chloro-l-tosyl-ljS-pyrrolo[2,36]py rid in-3-yl)-5-flu or opyr im idin-4-ylamino)-6-methoxy cycloh exan ol (51 k)

In a microwave tube was placed 5-chloro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine (0.10 g, 0.23 mmol). To this was added acetonitrile (0.61 mL) and the solution was deoxygenated with nitrogen. To the reaction was added (17?, 2S, 67?)-2-(2-chloro-5-fluoropyrimidin-4-ylamino)-6-methoxy-cyclohcxanol, 51j, (0.04 g, 0.14 mmol) and palladium catalyst (24 mg), and then aqueous sodium carbonate (0.21 mL of 2 M solution, 0.41 mmol). The reaction was sealed and heated to 120 C in the microwave reactor for 15 min. The reaction was diluted with ethyl acetate (40 mL), filtered thru florisil, and concentrated in vacuo to give crude as a green solid. This was purified by silica gel chromatography (20-75% EtOAc/hexanes gradient). Used resulting product directly in the next step.

LCMS (M+l) = 546.35.

[001098] Formation of (12?, 25, 62?)-2-(2-(5-chloro-12/-pyrrolo[2,3-Z>]pyridin-3-yl)-

5-fluoropyrimidin-4-ylamino)-6-methoxycyclohexanol (831)

In a microwave vial was placed azaindole 51k (0.050 g; 0.092 mmol). To this was added 3 mL of THF and 0.9 mL of 0.8 M LiOH. The vial was sealed and heated to 120 °C for 15 minutes in the microwave. When the reaction is complete, it was neutralized with 9 equivalents of IN HCI (0.704 mL), then aqueous saturated NaHCOj solution was added and the organic phase was separated and loaded onto silica gel for purification and eluted w/ 2% MeOH to 12% gradient over 10 minutes (4 g column) to provide 34.5 mg (91%) desired product 831.

General Scheme 52

-321WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

(a) LDA, iodomethane, THF, -78 °C (b) SOCI₂, DMF, CH₂CI₂, reflux, then NH₄OH (c) TMSOTf, iodine, Et₃N, pentane, CH₂CI₂ (d) Boc₂O, DMAP, CH₂CI₂ (e) 1,8-Diazabicyclo[5.4.0]undec-7ene, toluene, reflux (f) Cs₂CO₃, MeOH (g) H₂, Pd-C (5%), MeOH, 2 days (h) HCl, MeOH; 2,4dichloro-5-fluoropyrimidine, 'Pr₂NEt, DMF; SFC chiral separation (i) 5-chloro-3-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1 H-pyrro!o[2,3-b] pyridine, Pd(Ph₃P)₄, Na₂CO₃, THF/H₂O, reflux (j) NaH, MeOH (k) LiOH, H₂O/MeOH (I) benzotriazol-l-yl[bis(dimethylamino)methylene]oxonium hexafluorophosphate, 'Pr₂Net, THF, NH₄CI.

[001099] Formation of l-methylcyclohex-3-ene-l-carboxylic acid (52a)

ALisopropylpropan-2-amine (50.1 g, 69.5 mL, 495.5 mmol) was dissolved in 50 mL of THF. To the solution was added n-butyllithium (174.4 mL of 2.5 M solution in hexanes, 436.0 mmol) at -78 °C. The resulting solution was stirred for 30 minutes at -78 °C. To the reaction was then added cyclohex-3-ene-1 -carboxylic acid (25.0 g, 198.2 mmol) and the reaction was allowed to warm to 60 °C for 2 hrs. The reaction was cooled to room temp and iodomethane (29.5 g, 13.0 mL, 208.1 mmol) was added and the reaction was allowed to stir overnight and then quenched with 1 N HCl until the pH < 4. The crude product was extracted into CH2CI2 and water. The organic phase was concentrated in vacuo to a yellow oil (27 g) and used without further purification.

MS/RT; 141.09 (M+H)/1.65 [001100] Formation of l-methylcyclohex-3-ene-l-carboxamide (52b)

To a solution of 1-methylcyclohex-3-ene-1 -carboxylic acid, 52a, (54.0 g, 385.2 mmol) dissolved in CH2CI2 (200 mL) was added thionyl chloride (56.2 mL, 770.4 mmol) and I mL of DMF. The reaction was warmed to reflux for 3 hrs, then cooled and concentrated in vacuo. The residue was redissolved in 200 mL of CH2CI2. To the reaction was added ammonium hydroxide (148.2 mL of 13 M solution, 1.9 mol) slowly. The reaction was stirred

-322WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 overnight. The reaction was extracted into CH2CI2 and water. The organic phase was concentrated in vacuo and purified via flash silica gel chromatography (EtOAc), yielding 25 g of l-methylcyclohex-3-ene-l-carboxamide.

MS/RT: 139.96 (M+H)/2.66 [001101] Formation of 4-iodo-l-methyl-6-azabicyclo[3.2.1]octan-7-one (52c)

A solution of l-methylcyclohex-3-ene-l-carboxamide, 52b, (5.0 g, 35.9 mmol) dissolved in 100 mL of pentane and CH₂C1₂ was cooled to 0 °C and treated with triethylamine (11.0 mL, 79.0 mmol) and trimethylsilyl-triflate (14.3 mL, 79.0 mmol) sequentially. The resulting mixture was stirred for 1 hour at room temperature. The lower layer was removed via pipette. The upper pentane layer was concentrated in vacuo and the resulting residue was dissolved in THF (100 mL). To the stirred reaction was added iodine (20.1 g, 79.02 mmol) and the reaction was allowed to stir overnight at room temperature. After quenching with Na₂SO₃ and NaHCO₃, the reaction was partitioned between CH₂C1₂ and water. The organic layers were combined, dried over Na₂SC>4, concentrated in vacuo to a dark yellow oil (9.5 g) that was used without further purification.

MS/RT: 266.06(M+H)/2.39 [001102] Formation of tert butyl 4-iodo-l-methyl-7~oxo-6-azabicyclo[3.2.1]octane6-carboxylate (52d)

To a solution of 4-iodo-l-methyl-6-azabicyclo[3.2.1]octan-7-one, 52c, (9.5 g, 35.8 mmol) in CH₂C1₂ (100 mL) was added DMAP (0.2 g, 1.8 mmol), triethylamine (15.0 mL,

107.5 mmol) and teri-butoxycarbonyl /eri-butyl carbonate (7.8 g, 35.8 mmol). The reaction was stirred overnight at room temperature. The product was extracted into CH₂C1₂ and water. The organic layer was concentrated in vacuo and the residue was purified via silica gel chromatography (4:1 Hexanes:EtOAc), yielding 7.6 g.

MS/RT: 366.06 (M+H)/3.95 [001103] Formation of tert butyl 4-iodo-l-methyI-7-oxo-6-azabicyclo[3.2.1 ]oct-3ene-6-carboxylate (52e).

To a solution of tert-butyl 4-iodo-l-methyl-7-oxo-6-azabicyclo[3.2.1]octane-6carboxylate, 52d, (7.6 g, 20.8 mmol) in 100 mL of toluene was added 1,8diazabicyclo[5.4.0]undec-7-ene (6.2 mL, 41.6 mmol). The reaction was warmed to reflux and stirred overnight. The reaction was concentrated in vacuo and the resulting residue was purified by silica gel chromatography (4:1 Hexanes:EtOAc), yielding 4.9 g of the desired product, 52e.

MS/RT: 238.14 (M+H)/3.33 [001104] Formation of methyl 5-(tert-butoxycarbonylamino)-l-methylcyclohex-3enecarboxylate (52f)

To a solution of tert-butyl l-methyl-7-oxo-6-azabicyclo[3.2.1]oct-3-ene-6carboxylate, 52e, (4.93 g, 20.78 mmol) in MeOH (100 mL) was added cesium carbonate (13.54 g, 41.56 mmol). The reaction was stirred overnight and then concentrated in vacuo. The cesium salts were precipitated with Et₂O and filtered. The ether filtrate was evaporated to give 5.5 g of a yellow oil that was used without further purification.

MS/RT: 270.17 (M+H)/3.64 [001105] Formation of methyl 5-(tert-butoxycarbonylamino)-lmethylcyclohexanecarboxylate (52g)

Methyl 5-(/ert-butoxycarbonylamino)-l-methylcyclohex-3-enecarboxylate, 52f, (5.59 g, 20.75 mmol) was dissolved in 100 mL of MeOH. To the stirred solution was added 5%

-323WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 palladium on carbon (1.11 g, 10.38 mmol) and the reaction was stirred under a hydrogen balloon for 2 days. The reaction was filtered through celite, and the filtrate was concentrated in vacuo and used without further purification.

MS/RT: 272.24(M+H)/3.62 [001106] Isolation of (IR, 3S)-methyl 3-(2-chloro-5-fluoropyrimidin-4-ylamino)-l“ methyl-cyclohexanecarboxylate (52h).

A stirred solution of methyl 5-(tert-butoxycarbonylamino)-lmethylcyclohexanecarboxylate, 52g, (5.63 g, 20.75 mmol) in MeOH (20 mL) was treated with HC1 gas for 10 minutes. The resulting solution was stirred at room temperature for 1 hour, then concentrated to dryness and redissolved in THF (50 mL). To the reaction mixture was added 'PrjNEt (10.84 mL, 62.25 mmol) and 2, 4-dichloro-5-fluoro-pyrimidine (5.20 g,

31.12 mmol) sequentially. The reaction was stirred at reflux overnight, concentrated in vacuo and resulting residue was purified by silica gel chromatography (1:1 Hexane:EtOAc), yielding 2.2 g of the racemic product as a yellow oil. 300 mg of the racemic methyl 3-(2chloro-5-fluoropyrimidin-4-ylamino)-l -methylcyclohexanecarboxylate was submitted for SFC chiral separation, yielding 100 mg of the desired product, 52h, as a yellow oil.

MS/RT: 302.16 (M+H)/3.68 [001107] Formation of (IR, 35)-methyl 3-(2-(5-chloro-l-tosyl-l/7-pyrrolo[2,3/>]pyridin-3“yl)-5-fluoropyrimidin-4-ylamino)-l-methylcyclohexanecarboxylate (52i).

In a 25 mL round-bottomed flask were combined (IR, 3S)-methyl 3-(2-chloro-5fluoiOpyrimidin-4-ylamino)-l-methylcyclohexanecarboxylate, 52h, (0.061 g, 0.202 mmol) , 5-chloro- l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl) pyrrolo[2,3bjpyridine (0.096 g, 0.222 mmol) , disodium carbonate (0.064 g, 0.607 mmol) in 5 mL of THF and 1 ml of water. The reaction mixture was degassed via a stream of nitrogen. To the reaction was added tetrakis triphenyl phosphine palladium (0) (0.021 g, 0.202 mmol) and the reaction was stirred at reflux overnight. The reaction was concentrated in vacuo and purified by silica gel chromatography (4:1 Hexanes:EtOAc), yielding 85 mg of desired product, 52i. MS/RT: 572.33 (M+H)/6.27 [001108] Formation of (IR, 3A)-methyl 3-(2-(5-chloro-lH-pyrrolo[2,3-6]pyridin-3yl)-5-fluoropyrimidin-4“y]amino)-l-methylcyclohexanecarboxylate (52j)

To a stirred solution of (IR, 3S)-metbyl 3-(2-(5-chloro-l-tosyl-l/Z-pyrrolo[2,36]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)-l -methylcyclohexanecarboxylate, 52i, (0.085 g, 0.149 mmol) in 10 mL of MeOH was added NaH (0.004 g, 0.178 mmol) at room temperature. The resulting suspension was stirred for 2 hrs, quenched with solid NH₄C1. The mixture was concentrated in vacuo and purified via silica gel chromatography (3:1 Hexane:EtOAc), yielding 55 mg of the desired product, S2j.

MS/RT: 418.32 (M+H)/3.30 [001109] (IR, 35)-3-(2-(5-chloro-liT“pyrrolo[2,3-/>]pyridin-3-yl)-5-fluoropyrimidin4-yIamino)-l~methylcycIohexanecarboxyIic acid (826)

To a solution of (IR, 3S)-methyl 3-(2-(5-chloiO-17T-pyrrolo[2,3-/?]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-l-methylcyclohexanecarboxylate, 52j, (0.035 g, 0.083 mmol) dissolved in MeOH (5 mL) and water (1 mL) was added LiOH (0.004 g, 0.168 mmol). The reaction was allowed to stir for 2 days at room temperature and then concentrated to dryness. The residue was washed with ethanol. The combined ethanol washings were concentrated in vacuo, yielding 30 mg of desired product as an off white solid.

NMR: (300 MHz, DMSO) δ 12.34 (s, H), 8.74 (d, J= 2.3 Hz, H), 8.33 (d, J= 2.3 Hz, H), 8.28 (d, J= 1.6 Hz, H), 8.17 - 8.12 (m, H), 4.34 (s, H), 4.29 (s, H), 3.89 (s, H), 3.55

-324WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 (d, J= 6.3 Hz, H), 3.32 (s, H), 2.50 (s, H), 2.29 (s, H), 1.95 - 1.90 (m, H), 1.82 (d, 7= 6.6 Hz, H), 1.76 (s, 3 H), 1.67 (s, H), 1.55 (s, H), 1.44 - 1.42 (m, H), 1.31 (s, H), 1.23 (s, H), 1.17 (s, H), 1.07 (s, H), 0.84 (d, 7= 6.9 Hz, H) and -0.00 (d, 7 = 1.0 Hz, H) ppm; MS/RT: 404.24 (M+H)/3.39.

[001110] Formation of (1Λ, 3S)-3-[[2-(5-chloro-lfl-pyrrolo[2,3-b]pyridin-3-yl)-5fluoro-pyrimidin-4-yl]amino]-l-methyl-cyclohexanecarboxamide (924) (1Λ, 35)-3-[[2-(5-chloro-lJ7-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-pyrimidin-4yl]amino]-l-methyl-cyclohexanecarboxylic acid, 826, (0.050 g, 0.108 mmol), benzotriazol-1yl-[bis(dimethylamino)methylene]oxonium hexafluorophosphate (0.081 g, 0.216 mmol) and 7V-ethyl-N-isopropyl-propan-2-amine (0.075 mL, 0.432 mmol) were combined in 5 mL of THF. To the reaction was then added ammonia hydrochloride (0.002 g, 0.032 mmol) and the reaction was allowed to stir overnight at room temperature. After concentration under reduced pressure, the mixture was purified by reverse phase HPLC chromatography, yielding

3.3 mg of desired product.

NMR (300 MHz, MeOD) δ 8.85 (d, 7= 2.4 Hz, H), 8.22 (d, ./ = 2.3 Hz, H), 8.16 (s, H), 7.99 (d, 7= 4.1 Hz, H), 7.86 (s, H), 3.48 (d, 7= 7.0 Hz, H), 2.80 (s, H), 2.15 (s, H), 2.0 (s, H), 1.86 (qn, 7= 3.3 Hz, H), 1.80 (s, 3 H), 1.74 (m, 2 H), 1.44 (s, 6H); LC/MS: 403.34

[001111] Formation of 2-(5-chloro-lZ/-pyrrolo[2,3-6]pyridin-3-yl)-5-fluoro-JV-((15, 32?)-3-isocyanatO“3“methylcyclohexyl)pyrimidin-4-amine (52m).

To a solution of (IR, 3S)-3-[[2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl] amino]-1-methyl-cyclohexanecarboxylic acid, 826, (0.100 g, 0.216 mmol) and (azido(phenoxy)phosphoryl)oxybenzene (0.093 mL, 0.432 mmol) in 10 mL of toluene was added 1 mL of V-ethyl-6/-isopropyl-propan-2-amine. The reaction was warmed to reflux overnight. The mixture was concentrated to dryness and the residue was purified by silica gel chromatography (EtOAc), yielding 40 mg of desired product as a white foam.

MS/RT: 401.23 (M+H)/3.89

[001112] Formation of Λ-((1/?, 35)-3-(2-(5-chloro-l£Z-pyrrolo[2₅3-6]pyridin-3-yl)-5fluoropy rimidin-4-yla mino)-l -methylcy clohexyl)pyr r olidine-l-car boxa mide (926).

-325WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

A solution of 2-(5-chloro-17f-pyrrolo[2,3-/>]pyridin-3-yl)-5-fluoro-A^L((lS^, _> 32ϊ)-3isocyanato-3-methylcyclohexyl)pyrimidin-4-amine, 52m, (0.035 g, 0.087 mmol) in 3 mL of NMP with 0.5 mL of pyrrolidine was warmed to 200 °C in a microwave for 30 minutes. The reaction was then concentrated in vacuo and purified by reverse phase HPLC chromatography, yielding 8.7 mg of desired product as a tan solid.

NMR: (300.0 MHz, MeOD) δ 8.76 (d, J = 2.4 Hz, H), 8.44 - 8.38 (m, 2 H), 8.27 (d, 7 = 5.6 Hz, H), 4.87 (d, 7= 5.1 Hz, H), 4.64 - 4.56 (m, 4 H), 3.38 - 3.19 (m, 2 H), 2.65 (s, 2 H), 2.46 (m, H), 2.42 (s, 3 H), 2.16 (s, H), 2.07 (t, J= 12.0 Hz, H), 2.00 (s, H), 1.88 (q, 7 = 6.6 Hz, H), 1.88 (s, H), 1.70 (s, H) and 1.61 (d, 7= 12.8 Hz, H) ppm; MS/RT: 472.38.

General Scheme 53

O_ZN

53a

53b

(a) H₂, Pd-C, MeOH; (b) Na₂CO₃, THF-CH₃CN, 135 °C; (c) NaOMe, MeOH, DCM; (d) NaOH, MeOH, THF.

[001113] Formation of (+/-)-2, 3-Trans-methyl 3-nitrobicyclo[2.2.1Jhept-5-ene-2carboxylate (53a)

-326WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

This compound was prepared as a mixture of trans isomers (endo : exo = 84 : 16) following literature procedures described in: Chang, Linda L.; Truong, Quang; Doss, George A.; MacCoss, Malcolm; Lyons, Kathryn; McCauley, Ermengilda; Mumford, Richard; Forrest, Gail; Vincent, Stella; Schmidt, John A.; Hagmann, William K. Bioorg. Med. Chem. Lett. 2007,17(3), 597-601.

1001114] Formation of (+/-)-2,3-7rans-methyl 3-aminobicyclo[2.2.1|heptane-2carboxylate (53b)

A mixture of ¢+/-)-2, 3-trans-methyl 3-nitrobicyclo[2.2.1]hept-5-ene-2-carboxylate, 53a, (0.32 g, 1.62 mmol) and Pd-C (10%) in MeOH was purged and placed under H₂ atm (50 PSI) and shaken overnight. The mixture was filtered through celite, concentrated in vacuo and azeotroped twice with CH₃CN to remove traces of MeOH.

’Η NMR of the crude mixture indicated the presence of both the endo and exo products (84 :16 = endo : exo) which were taken directly into the next reaction without further purification.

[001115] Formation of (+/-)-2,3-7rn/is-m ethyl 3-(2-(5-chlo ro-l-tosy 1-1//pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-ylammo)bicyclo[2.2.1]heptane-2carboxylate (53 c)

A mixture of 5-chloro-3-(5-fluoro-4-(methylsulfinyl)pyrimidin-2-yl)-l-tosyl-lHpyrrolo[2,3-b]pyridine, la, (0.46 g, 1.00 mmol) and (+/-)-/ra»s-methyl 3aminobicyclo[2.2.1]heptane-2-carboxylate, 53b, (0.27 g, 1.60 mmol) (84 : 16 = endo : exo) and freshly ground Na₂CO₃ (0.32 g, 2.99 mmol in THF (3.7 mL) and CH₃CN (1.2 mL) was heated to 120 °C for 20 min in microwave. The reaction mixture was filtered and the solid was rinsed with Et₂O and THF. The organic layer was concentrated in vacuo to provide crude product which was purified by silica gel chromatography (0-40% EtOAc/hexanes, gradient) to provide the desired product (352 mg) as an inseparable mixture of trans-endo and trans-exo isomers (endo : exo = 85 : 15) as indicated by NMR.

LC/MS R, = 6.13 min, (M+H) 570.34.

[001116] (+/-)-2,3-trans-endo-methyi 3-(2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)~

5-fluoropyrimidin-4-ylamino)bicyclo[2.2.1]heptane-2-carboxylate (53d) & (+/-)-2,3-trans-exo-m ethyl 3-(2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5iluoropyrimidin-4-ylamino)bicyclo[2.2.1]heptane-2-carboxylate (53d)

To a solution of trans-endo- and iraws-exo-methyl 3-(2-(5-chloro-l-tosyl-lHpyirolo[2,3-b]pyridin-3-yl)-5-fluoiOpyrimidin-4-ylamino)bicyclo[2.2.1]heptane-2carboxylate, 53c, (0.18 g, 0.31 mmol) in MeOH (3mL) and CH₂C1₂ (ImL) was added NaOMe (3 mL of 25 %w/v, 13.88 mmol). After 90 sec, NH4CI solution (5 mL) was added to quench the reaction. The mixture was partitioned between aqueous NH4CI (half saturated) and EtOAc. The aqueous layer was extracted again and the combined organic layers were washed with brine, dried over Na₂SO4, filtered and concentrated in vacuo. Flash chromatography (SiO₂, 0-15% MeOH-DCM, gradient) gave the desired products as a mixture, (white solid): 112 mg ’H NMR indicated desired product existed as a mixture of endo and exo isomers (endo : exo = 84 : 16) which was taken forward into the hydrolysis step.

(+/-)-2,3-Trun.s-cxu-in ethyl 3-(2-(5-chIoro-lH-pyrrolo[2,3-b]pyridin-3-yI)-5nuoropyrimidin-4-ylamino)bicyclo[2.2.1]heptane-2-carboxylate (53d): minor isomer (exo): LC/MS (method: ml 17) R, = 3.17 min, (M+H) 416.27.

-327WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 (+/-)-2,3-7ri»ts'-e/irfo-methyl 3-(2-(5-chIoro-JH-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)bicyclo|2.2.1]heptane-2-carboxylate (53d): major isomer (endo): LC/MS (method: ml 17) R_; = 3.49 min, (M+H) 416.27.

947 (+/-) [001117] (946) (+/-)-2,3-ft‘«/is-e/i//o-3-(2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylam ino)bicyclo [2.2.1] heptane-2-carb oxylic acid &

(947) (+/-)-2,3-irans-exo-3-(2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5fIuoropynmidin-4-ylamino)bicyclo[2.2.1]heptane-2-carboxylic acid

To a stirred solution of starting methyl esters, 53d, (0.076 g, 0.183 mmol) (84 : 16 = endo : exo) in THF (0.60 mL) and MeOH (0.10 mL), was added NaOH (0.10 mL of 2 M, 0.201 mmol). The reaction progress was monitored by TLC. After 30 min, additional NaOH (0.18 mL of 2 M solution, 0.37 mmol) and MeOH (0.18 mL) was added. The mixture was stirred at room temperature for a further 16 hours. The mixture was neutralized with HC1 (IM) and concentrated in vacuo. Purification by preparative HPLC provided 52 mg of the major isomer (946) and 1 Img of the minor isomer (947) as the hydrochloric acid salts.

(946) major (endo) isomer: ’H NMR (300 MHz, MeOD) δ 8.82 (d, J= 2.2 Hz, 1H), 8.48 (s,

1H), 8.39 (d, 2.2 Hz, 1H), 8.31 (d, J= 5.6 Hz, 1H), 5.11 (m, 1H), 2.85 (br s, 1H), 2.68 (br s, 1H), 2.62 (d, J= 4.8 Hz, 1H), 1.92 (d, J= 10.1 Hz, 1H) and 1.77 - 1.51 (m, 5H) ppm; LC/MS R, = 3.51, (M+H) 402.32.

(947) minor (axo) isomer: ‘H NMR (300 MHz, MeOD) δ 8.87 (d, J - 2.1 Hz, 1H), 8.48 (s, 1H), 8.39 (d, J= 1.9 Hz, 1H), 8.30 (d, J = 5.7 Hz, 1H), 4.73 (d, J = 3.3 Hz, 1H), 3.12 (m, 1H), 2.76 (br s, 1H), 2.56 (d, J= 4.2 Hz, 1H), 1.86 (d, J= 9.5 Hz, 2H), 1.79 - 1.49 (complex m, 2H) and 1.51 (embedded d, J= 10.4 Hz, 2H) ppm; LC/MS R/ = 3.42, (M+H) 402.32.

[001118] (1184) (2S,3S)-3-((2-(5-chloro-lH-pyrroIo[2,3-b]pyridin-3-y 1)-5fluoropyrimidin-4-yl)amino)bicycIo[2.2.2]octane-2-carboxylic acid

Compound 1184 was made in a similar fashion as described above for compounds 946 and 947.

[001119] (1070) (2S,3S)-3-((2-(5-fluoro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-yi)amino)bicyclo[2.2.2]octane-2-carboxylic acid

-328WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Compound 1070 was made in a similar fashion as described above for compounds 946 and 947.

General Scheme 54

(a) Cyanogen Chloride, DMF, 0 °C , (b) Pd(OH)₂/Carbon, H₂; 5-chloro-3-(5-fluoro-4(methylsulfmyl)pyrimidin-2-yl)-l-tosyl-l#-pyrrolo[2,3-b]pyridine, ’Pr₂NEt/THF 45 °C, (c) Na/MeOH, (d) (n-Bu)₂SnO, TMSN₃, toluene, 110 °C.

[001120] Formation of benzyl (15, 35)-3-cyanocyclohexykarbamate (54a)

A suspension of benzyl Y-[(15, 35)-3-carbamoylcyclohexyl]carbamate, 18d, (0.69 g,

2.50 mmol) in DMF (10 mL) at 0 °C was treated with 2, 4, 6-trichloro-l, 3, 5-triazine (0.61 g,

3.29 mmol) and allowed to stir while slowly warming to room temperature. After 20 minutes, the solution became gold in color. After 1 hour a precipitate had formed. Stirred for an additional 3 hours then quenched with ice water (100 mL) and extracted with CH₂C1₂ (2 x 125 mL) then washed with IN HC1 (100 mL). The organic layer was concentrated in vacuo to afford an 730 mg of a residue that was purified using a pad of silica gel (45 mL) using 30% EtOAc/hexanes as eluent to afford 621 mg of a white solid after vacuum drying.

’HNMR (300 MHz, CDC13) 5 7.45 - 7.30 (m, 5H), 5.09 (s, 2H), 4.67 (s, IH), 3.49 (s, IH), 2.66 - 2.32 (m, 2H), 2.16 - 1.79 (m, 3H), 1.52 - 1.03 (m, 4H).

[001121] Preparation of (15, 35)-3-(2-(5-chloro-l-tosyl-lZ7-pyrrolo[2,3-b]pyridin-3yl)-5-fluoropyrimidin-4-ylamino)cyclohexanecarbonitrile (54b)

Benzyl N-[(15, 35)-3-cyanocyclohexyl]carbamate (0.26 g, 1.02 mmol) was dissolved in THF (15 mL) and treated with 0.13 g of 20% Pearlman's catalyst (50% wet by weight). The suspension was degassed with hydrogen for 2 min then placed under static hydrogen atmosphere. After 135 min, TLC showed no remaining starting material. The suspension was filtered through celite, washed with THF and degassed with nitrogen followed by the addition of‘Pr₂NEt (0.21 mL, 1.23 mmol) and 5-chloro-3-(5-fluoro-4-(methylsulfinyl)pyrimidm-2-yl)-

1-tosyl-l/f-pyrrolo[2,3-b]pyridine, la, (0.48 g, 1.02 mmol). The mixture was allowed to stir

-329WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 overnight at 45 °C then concentrated to dryness, absorbed on silica-gel and purified by silica gel chromatography using 0-60% EtOAc/hexanes gradient to afford 293 mg of a white solid.

’H NMR (300 MHz, CDC13) δ 8.74 (d, J= 2.4 Hz, 1H), 8.49 (s, 1H), 8.39 (d, J= 2.4 Hz, 1H), 8.15 - 8.05 (m, 3H), 7.37 - 7.23 (m, 2H), 5.01 (d, 7 = 6.2 Hz, 1H), 4.13 (s, 1H), 2.75 (d, J= 23.0 Hz, 1H), 2.58 (s, 1H), 2.38 (s, 3H), 2.20 (d, 7= 9.1 Hz, 2H), 2.03 (d, 7= 7.8 Hz, 1H), 1.78 - 1.43 (m, 4H), 1.26 (s, 1H).

[001122] Preparation of (1R, 35)-3-(2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5fluor opy r imidin-4-ylamino) cyclohexa neca rbo nitrile (54 c) (1R, 3S)-3-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5-fluoiOpyrimidin-4-yl]amino]cyclohexanecarbonitrile, 54b, (0.29 g, 0.55 mmol) was suspended in MeOH (15 mL) and sodium metal added and the mixture heated at 45 °C. The sodium dissolved in advance of the compound. The mixture was allowed to stir until complete by TLC and LCMS. Concentrated to reduced volume then quenched with 1:1 aqueous saturated NH4CI:water mixture (1 ml) then concentrated to dryness. The residue was diluted with EtOAc and washed with water and brine. The organic layer was concentrated in vacuo to give 0.3 g of a yellow solid that was adsorbed on silica-gel and purified using 40g isco column with the following gradient using 20% MeOH:DCM as the eluent: 0-25%/6 min hold 4 min; 25-50%/4 min hold 9 min to give 146 mg of a white solid. LCMS (10-90% MeOH:water with formic acid).LCMS RT 4.01 ES+ 371, ES- 369.

[001123] Preparation of (1R, 35)-3-(2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cyclohexanecarboxamide (847)

A sample of (1R, 35)-3-(2-(5-chloro-17f-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cyclohexanecarbonitrile was treated with 4N HCl/dioxane and heated at 78 °C overnight. Concentrated to dryness then quenched with aqueous saturated sodium bicarbonate and CH₂C1₂ were added to give a slurry. Filtered and extracted with CH2Q2. The organic phase was dried over Na2SO4 and concentrated in vacuo to give 189 mg of an orange residue that was purified by silica gel chromatography (0-10% MeOH:CH₂Cl₂gradient) to afford 9.9 mg of a solid: LCMS (10-90% MeOH:water with formic acid): RT

3.79 minES+ 389.

[001124] Preparation of A-((1S, 3R)-3-(lH-tetrazol-5-yl)cyclohexyl)-2-(5-chlorolZ7-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-amine (855)

A suspension of dibutyl(oxo)tin (0.016 g, 0.064 mmol) and (1R, 3<S)-3-[[2-(5-chlorolj^E7-pyiTolo[2,3-b]pyridin-3-yl)-5-fiuoro-pyrimidin-4-yl]amino]cyclohexane-carbonitrile (54c) (0.043 g, 0.107 mmol) in toluene (3 mL) was treated with azido(trimethyl)silane (0.200 mL, 1.507 mmol). The mixture was heated in a sealed tube at 120 °C overnight. The mixture was absorbed onto silica-gel and purified by silica gel chromatography (25-50% gradient of 20%MeOH:DCM containing 0.5% AcOH modifier). The combined fractions were concentrated to dryness to give a residue that was triturated with ether then dried under vacuum at 45 °C to afford 44mg of a yellow solid.

Ή NMR (300 MHz, DMSO) δ 12.33 (s, 1H), 8.74 (d, J = 2.4 Hz, 1H), 8.41 - 8.04 (m,3H), 7.62 (d, 7= 7.4 Hz, 1H),4.3O (s, 1H), 3.54-3.06 (m, 3H), 2.67-2.31 (m, 1H), 2.23 -1.33 (m,6H).

-330WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

55b + 55c (a) hydroxylamine-HCl, EtOH; (b) 5-ethyl-2-methyl-pyridinium borane, HCl, MeOH; (c)N(oxomethylene)carbamoyl chloride, THF; (d) NaOMe, MeOH.

[001125] Formation of CS>3-(2-(5-chloro-l-tosyl-l/7-pyrrolo|2,3-b]pyridin-3-yl)-5fluoro-pyrimidin-4-ylamino)cyclohexanone oxime (55a)

To solution of (35)-3-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5fluoro-pyrimidin-4-yl]amino]cyclohexanone (0.41 g, 0.81 mmol) in EtOH (8.2 mL) was added hydroxylamine hydrochloride (0.11 g, 1.61 mmol). The reaction mixture was stirred at room temperature overnight. Then the mixture was warmed to 70 °C for 15 min. The reaction mixture was concentrated in vacuo, suspended in EtOAc-DCM, washed with half saturated brine (2 x) and filtered through a SiO₂ plug. The resulting residue was azeotroped with CH3CN (2x) to provide an off white powder which was used without further purification.

^XH NMR (300 MHz, MeOD) δ 8.78 (d, 7 = 2.4 Hz, IH), 8.51 (d, 7= 10.8 Hz, IH),

8.32 (d, 7= 2.3 Hz, IH), 8.10 - 8.04 (m, 3H), 7.38 (d, J = 8.2 Hz, 2H), 4.29 - 4.15 (m, IH),

3.79 - 3.74 (m, 0.6H), 2.41 (m, IH), 2.38 (s, 3H), 2.30 - 2.16 (m, 2H), 2.06 - 1.84 (m, 4H) and 1.66 - 1.59 (m, 2H) ppm; LC/MS (method: ml20) R, = 3.90 min, (M+H) 529.44.

-331WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

(55c) [001126] 2-(5-chloro-l-tosyl-l H-py rrolo [2,3-b]py ridin-3-yl)-5-fluor o-N-((lS,3R)-3(hydroxyamino)cyclohexyl)pyrimidin-4-amine (55c) &

2-(5-chloro-l-tosyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-N-((lS,3S)-3(hydroxyamino)cyclohexyl)pyrimidin-4-amine (55b):

To a stirred solution of (S')-3-(2-(5-chloro-l-tosyl-177-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)cyclohexanone oxime (0.20 g, 0.38 mmol) and HC1 (0.19 mL of 6 M_s 1.134 mmol) in MeOH (10 mL) was added (5-ethyl-2-methyLpyridinium borane (0.12 mL, 0.76 mmol) at room temperature. After 30 min, the reaction was quenched with NaHCOj. The mixture was extracted successively with Et₂O, EtOAc, CH₂C1₂ and EtOAc. Each organic portion was washed with brine and the combined organic layers were dried over Na₂SO₄, filtered and concentrated in vacuo. Flash chromatography (SiO₂, 20-100% EtOAchexanes) provided the cis-4 (74 mg) and lrans-3 (64 mg) isomers.

[001127] 2-(5-chloro-l-tosyl-117-pyrrolo [2,3-b]pyridin-3-yI)-5-fluoro-7V-((lS,35)-3(hydroxyamino)cydohexyl)pyrimidin-4-amine (stereoisomer - 3) ¹H NMR (300 MHz, MeOD) δ 8.83 (d, J= 2.4 Hz, 1H), 8.50 (s, 1H), 8.33 (d, J= 2.4 Hz, 1H), 8.07 - 8.04 (m, 1H), 7.37 (d, J= 8.4 Hz, 1H), 4.24 - 4.17 (m, 1H), 3.07 - 3.00 (m, 1H), 2.34 (m, 1H), 2.14 - 2.08 (m, 1H), 1.93 (t, J= 3.5 Hz, 2H), 1.66 - 1.53 (m, 1H) and 1.44 - 1.12 (m, 3H) ppm; LC/MS RT = 3.64 min, (M+H) 531.47.

[001128] 2-(5-chlo ro-1 -tosyl- 1/7-py rrolo [2,3-b] pyridin-3-y])-5-fluoro-A-(( 1 S',37/)-3(hydroxyamino)cycIohexyl)pyrimidin-4-amine (stereoisomer - 4)

Ή NMR (300 MHz, MeOD) δ 8.84 (d, 7= 2.4 Hz, 1H), 8.53 (s, 1H), 8.32 (d, 7= 2.4 Hz, 1H), 8.07 - 8.04 (m, 1H), 7.37 (d, 7= 8.2 Hz, 1H), 4.58 - 4.54 (m, 1H), 3.26 - 3.23 (m, IH), 2.38 (s, 3H), 1.98 - 1.83 (m, 4H) and 1.69 - 1.60 (m, 4H) ppm; LC/MS RT = 3.67 min, (M+H) 531.47.

[001129] 2-((1//, 35)-3-(2-(5-chIoro-l//-pyrrolo[2,3-b]pyridin-3-yl)-5fluor opyrimidin-4-yl-amino) cy c!ohexyl)-l,2,4-oxadiazolidine-3,5-d io ne (796)

To a solution of 2-(5-chloro-1-tosyl-l//-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-jV-(( IS, 37/)-3-(hydroxyamino)cyclohexyl)pyrimidin-4-amine, 55b, (0.072 g, 0.136 mmol) in THF (2 mL) at 0 °C was added N-(oxometliylene)carbamoyl chloride (0.014 mL, 0.176 mmol). A white solid formed immediately. The slurry was shaken and sonicated to make an even suspension/slurry. Then, CH₂C12 (1 mL)) was added to help solvate the slurry. After 135 min, the mixture was treated with NaOMe (2 mL, 25% w/v). After 2 min, the mixture was quenched with saturated NH₄C1 and acidified with IM HC1. The mixture was extracted with EtOAc (3x) and the combined organic layers were dried over Na₂SO₄, filtered and concentrated in vacuo. Preparative HPLC provided the desired product (25mg).

-332WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

ΉNMR (300 MHz, MeOD) δ 8.73 (s, IH), 8.52 (s, IH), 8.38 (s, IH), 8.31 (br s, IH),

4.34 (m, IH), 2.60 - 2.56 (m, IH), 2.27 (m, IH), 2.08 (m, 3H) and 1.89 - 1.78 (m, 3H) ppm; LC/MS RT = 3.12 min, (M+H) 446.45.

[001130] 2-((15, 35)-3-(2-(5-chIoro-117-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylammo)cyclohexyl)-l, 2,4-oxadiazolidine-3,5-dione (798)

NMR (300 MHz, MeOD) δ 8.67 (s, IH), 8.56 (s, IH), 8.38 (s, IH), 8.31 (brs, IH),

4.47 (m, IH), 4.21 (m, IH), 2.41 (m, IH), 2.22 (m, IH), 2.10 - 1.90 (m, 3H), 1.72 (m, 2H) and 1.50 (m, IH) ppm; LC/MS RT = 3.37 min, (M+H) 446.34.

General Scheme 56

56a ggO (a) paraformaldehyde, methoxyphosphonoyloxymethane, 4A sieves, toluene, 90 °C , (b) NaOMe, MeOH.

[001131] Formation of (5)-dimethyl (3-(2-(5-chloro-l-tosyHH-pyrrolo[2,3b] py ridin-3-yl)-5-fluoropy rimidin-4-y lamino) piper idin-1 -y l)m ethy Ip hosp ho nate (56a)

To a solution of 2-[5-chloro-l-(/>-tolylsuIfonyl)pynOlo[5,4-b]pyridin-3-yl]-5-fluoro-?Z[(3S)-3-piperidyl]pyrimidin-4-amine, lc, (2.00 g, 3.99 mmol) in dry toluene was added 4 angstrom molecular sieves and methoxyphosphonoyloxymethane (0.97 g, 0.81 mL, 8.78 mmol). While stirring under nitrogen, paraformaldehyde (0.90 g, 9.98 mmol) was added portionwise. The mixture was heated at 90 °C for 90 minutes. The reaction was cooled to room temperature, diluted with aqueous saturated NaHCOj solution, extracted twice with EtOAc. The combined organic phases were dried (MgSO₄), filtered and concentrated in vacuo. The resulting residue was purified by silica gel chromatography using 0-10% MeOH/CH2C12 gradient to afford 2.0 g of desired product. LCMS RT = 4.47 (M+H) 623.3.

[001132] Formation of (5)-dimethyl (3-(2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-

5-fluoropyriimdm-4-ylamino)piperidm-l-yl)methylphosphonate (690)

To a solution of 2-[5-ch]oro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yi]-A/^;-[(35)-l(dimethoxyphosphorylmethyl)-3-piperidyl]-5-fluoro-pyrimidin-4-amine, 56a, (1.00 g, 1.61 mmol) in MeOH (40 mL) was added sodium methanolate (20 mL of 25 %w/v, 92.55 mmol) and the reaction mixture was stirred at room temperature for 30 minutes. All volatiles were removed at reduced pressure and the resulting residue was diluted with aqueous saturated NH4CI solution and extracted twice with CH₂C1₂. The combined organic phases were dried (MgSO₄), filtered and concentrated in vacuo. The resulting residue was purified via silica gel chromatography using 0-10% MeOH:CH₂Cl₂ gradient to provide 270 mg of a white solid.

’H NMR (300.0 MHz, DMSO) δ 12.33 (s, IH), 8.70 (d, 7= 2.4 Hz, IH), 8.28 (d, 7=

2.4 Hz, IH), 8.20 (d, 7= 2.6 Hz, IH), 8.17 (d, 7= 4.0 Hz, IH), 7.35 (d, 7= 7.8 Hz, 1H),4.27 - 4.17 (m, IH), 3.67 (s, 3H), 3.64 (s, 3H), 3.21 - 3.16 (m, IH), 2.96 - 2.90 (m, 3H), 2.33 -

2.20 (m, 2H), 1.99 - 1.94 (m, IH), 1.80 - 1.60 (m, 2H) and 1.47 - 1.35 (m, IH) ppm; LCMS RT = 3.84 (M+l) 469.47.

General Scheme 57

-333WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

(a) pyrazole-l-carboxamidine hydrochloride, ‘Pr₂NEt, 4A sieves, toluene, 90 °C (b) NaOMe, MeOH.

[001133] Formation of ((5)-3-(2-(5-chloro-l-tosyl-l/7-pyrrolo[2,3-I)]pyridin-3-yl)-5fluor o-py rimidin-4-y lamino)pip eridin e-1 -car boximida mide (57a)

To a solution of pyrazole-l-carboxamidine hydrochloride (0.12 g, 0.80 mmol) and 2[5-chloro-l-(p-tolylsulfonyl)pymrio[2,3-b]pyridin-3-yl]-5-fluoro-jV-[(3S)-3piperidyl]pyrimidin-4-amine, 1c, (0.40 g, 0.80 mmol) in DMF (0.9 mL) was added 'Pr₂NEt (0.14 mL, 0.80 mmol). The reaction mixture was stirred at room temperature for 4 hours. The mixture was diluted into water, filtered, washed with additional water, then ether. The filtrate was concentrated in vacuo. The resulting residue was purified by silica gel chromatography using 5-20% MeOH/CHaCl₂ gradient (product elutes with 20% MeOH) to afford 190 mg of the desired product.

NMR (300 MHz, DMSO) 8 8.73 (d, 7= 2.2 Hz, IH), 8.50 - 8.45 (m, 2H), 8.33 (d, J = 3.7 Hz, IH), 8.07 (d, 7= 8.2 Hz, 2H), 7.90 (d, 7= 7.0 Hz, IH), 7.53 - 7.42 (m, 7= 9.0 Hz, 6H), 3.87 (d, 7= 13.6 Hz, IH), 3.17 (d, 7= 5.2 Hz, IH), 3.03 (q, 7= 10.9 Hz, 2H), 2.36 (s, 3H), 2.11 (d, 7= 9.9 Hz, IH), 1.90 (d, 7 = 12.6 Hz, IH), 1.68 (dd, 7= 24.5, 13.9 Hz, 2H); LCMS RT = 3.07 (M+l) 543.34.

[001134] Formation of (S)-3-(2-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)piperidine-l-carboximidamide(881)

To a solution of (3S)-3-[[2-[5-chloiO-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5fluoro-pyrimidin-4-yl]amino]piperidine-l-carboxamidine, 57b, (0.18 g, 0.32 mmol) in MeOH (5 mL) was added sodium methanolate (3 mL of 25 %w/v, 13.88 mmol) and the reaction was stirred at room temperature. After 5 min, the mixture was concentrated in vacuo to light yellow solid. The crude residue was purified via preparatory HPLC (MeOH/1% aqueous HCI) to afford the desired product.

^JH NMR (300 MHz, DMSO) δ 12.79 (s, IH), 8.77 (s, IH), 8.60 (d, 7= 2.3 Hz, IH), 8.43 (d, 7= 4.8 Hz, IH), 8.37 (d, 7 = 2.3 Hz, IH), 7.52 (s, 3H), 4,29 (s, IH), 4.08 (d, 7= 12.6 Hz, IH), 3.90 (d, 7= 13.7 Hz, IH), 3.16 - 2.95 (m, 2H), 2.17 (d, J= 9.7 Hz, IH), 1.92 (d, 7=

8.5 Hz, IH), 1.81 - 1.57 (m, 2H); LCMS RT = 2.03 (M+l) 389.27.

General Scheme 58

(a) 3-bromoprop-l-ene, Zn dust, DMF (b) 5-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)-1-tosyl-1H-pyrrolo[2,3-bJpyridine, Pd(Ph₃P)₄, Na₂CO₃, acetonitrile, water, 120 °C, microwave, (c)

-334WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

OsO₄, pyridine, 4-methylmorpholineW-oxide, tert-butanol, water, THF, 120 °C (d) NaOMe, MeOH.

[001135] Formation of (35)-l-allyl-3-(2-cIiloro-5-fluoropyrimidin-4ylamino)cyclohexanol (58a)

To a solution of (3S)-3-[(2-chloiO-5-fluoro-pyrimidin-4-yl)amino]cyclohexanone, 29b, (0.60 g, 2.46 mmol) and 3-bromoprop-1-ene (0.43 mL, 4.92 mmol) in DMF was added Zn dust (0.32 g, 4.92 mmol). The reaction was stirred at room temperature for 3 days. The mixture was diluted into aqueous saturated NH₄C1 solution, extracted twice with EtOAc. The combined organic phases were washed twice with brine, dried (MgSO₄), filtered and concentrated in vacuo. The crude residue was purified by silica gel chromatography using 050% EtOAc/hexanes gradient to afford 553 mg of desired product, 58a, as an oil. LC/MS two peaks corresponding to two diastereomeric products: 286.4 (M+H), RT = 3.41 and 3.78.

[001136] Formation of (IR, 35)-l-allyl-3-(2-(5-chloro-l-tosyl-l_Jl7-pyrrolo[2,3b|pyridin-3-yl)-5-fluoropyrimidin-4-ylammo)cyclohexanol and (IA, 35)-l-allyl-3-(2-(5ch Io ro-1 -tosyl- 1/Z-py rrolo [2,3-b] pyridin-3-y l)-5-flu or opy rimidin-4ylamino)cyclohexanol (58b and 58c) hi a microwave tube was placed 5-chloro-l-(p-tolylsuIfony 1)-3-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine (0.57 g, 1.32 mmol) and (35)-l-allyl-3-[(2chloro-5-fluoro-pyrimidm-4-yl)amino]cyclohexanol, 58a, (0.32 g, 1.10 mmol) in acetonitrile (12 mL) and Na2CO₃ (1.65 mL of 2 M aqueous solution, 3.31 mmol). The mixture was deoxygenated with nitrogen for 15 min. To the mixture was added tetrakis triphenyl phosphine palladium (0) (0.03 g, 0.02 mmol). The reaction was sealed and heated to 120 °C for 20 min. The mixture was diluted with brine, extracted twice with CH2CI2. The combined organic phases were dried (MgSO₄), filtered and concentrated in vacuo. The resulting residue was purified via silica gel chromatography using a 10-60% EtOAc/hexanes gradient to afford two diastereomers:

Diastereomer 1 (more polar spot - 58c): LCMS RT = 4.45 min, (M+H) = 556.48 Diastereomer 2 (less polar spot - 58b): LCMS RT = 4.48 min (M+H) = 556.48 [001137] Formation of 3-((ll?, 35)-3-(2-(5-chloro-l-tosyI-l£f-pyrrolo [2,3-b]pyridin-

3-yl)-5-fluoropyrimidin-4-yIamino)-l-hydroxycyclohexyl)propane-l,2-diol (58d)

To a solution of (3S)-l-allyl-3-[[2-[5-chloro-l-(p-tolylsuIfonyl)pyrrolo[2,3-b]pyridin3-yl]-5-fluoro-pyrimidin-4-yl]amino]cycIohexanol, 58c, (0.30 g, 0.54 mmol) in 2-methyl-2propanol (9.23 mL), THF (3.69 mL) and water (1.85 mL) was added pyridine (0.09 mL, 1.08 mmol) and osmium tetroxide (0.27 mL of 2.5 %w/v, 0.03 mmol) and 4-methylmorpholine Noxide (0.07 mL, 0.65 mmol). The reaction mixture was heated to 80 °C for 20 hours. After cooling to room temperature, the mixture was diluted into aqueous saturated sodium bisulfite solution and extracted twice with 20% isopropanol/C^Ch. The combined organic phases were washed with more aqueous saturated sodium bisulfite solution, dried (MgSO₄), filtered and concentrated in vacuo. The crude residue was purified via silica gel chromatography using 5-10% MeOH/CH₂C12 gradient to afford 175 mg of the desired product as a racemic mixture, 58d.

'H NMR (d6-DMSO) δ 8.77 (t, J= 2.6 Hz, IH), 8.48 (d, J= 2.4 Hz, IH), 8.42 (d, J= 6.0 Hz, IH), 8.25 - 8.23 (m, IH), 8.07 (d, 7= 7.4 Hz, 2H), 7.74 (dd, J = 7.6, 13.5 Hz, IH),

7.44 (d, J = 8.3 Hz, 2H), 4.97 (d, J = 12.8 Hz, IH), 4.76 - 4.72 (m, IH), 4.54 - 4.51 (m, IH),

4.31 (m, IH), 3.83 (m, IH), 2.36 (s, 3H), 1.99 - 1.91 (m, 2H), 1.77 - 1.63 (m, 4H) and 1.57 1.46 (m, 4H) ppm; LCMS RT = 4.31 (M+H) 590.5.

[001138] Formation of 3-(( 17?, 35^T)-3-(2-(5-chloro-l//-pyrrolo[2,3-b]pyridin-3-yI)-5fluoropyrimidin-4-ylamino)-l-hydroxycyclohexyl)propane-l,2-diol (718)

-335WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

To a solution of 3-((lR, 35)-3-(2-(5-chloro-l-tosyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-l-hydroxycyclohexyl)propane-l,2-diol, 58d, (0.11 g, 0.18 mmol) in MeOH (5 mL) was added sodium methanolate (2 mL of 25 %w/v solution, 9.26 mmol) and the reaction mixture was stirred at room temperature. After 20 min, the reaction mixture was diluted with aqueous saturated NH4CI solution and extracted twice with 20% IPA/CH2CI2. The combined organic phases were dried (MgSO4), filtered and concentrated in vacuo. Purification via silica gel chromatography using 5-20% MeOH: CH₂C1₂ gradient to afford 56 mg of a white solid.

'H NMR (300 MHz, d6-DMSO) δ 12.29 (s, IH), 8.71 (t, J = 2.3 Hz, IH), 8.27 (d, J =

2.4 Hz, IH), 8.19 (dd, J = 2.8, 4.5 Hz, IH), 8.15 (t, J = 3.7 Hz, IH), 7.52 (t, J = 7.7 Hz, IH),

4.97 (d, J = 16.0 Hz, IH), 4.77 (dd, J = 3.8, 10.5 Hz, IH), 4.54 (t, J = 5.6 Hz, IH), 4.32 (m, IH), 3.86 (m, IH), 2.00 - 1.97 (m, 2H), 1.82 - 1.63 (m, 4H) and 1.59 - 1.45 (m, 4H) ppm; LCMS RT = 3.71 (M+l) 436.48.

General Scheme 59

(a) benzyloxyphosphonoyloxymethylbenzene, triethylamine, 95 °C, microwave, (b) NaOMe, MeOH.

[001139] Formation of dibenzyl (15, 35)-3-(2-(5-chioro-l-tosyl-177-pyrrolo[2,3b] pyridin-3-y l)-5-iluo ro py rimidin-4-ylamino)-l-hydroxycy clohexylp hosp hon a te and dibenzyl (1/Ϊ, 35)-3-(2-(5-chloro-l-tosyl-ljE/-pyrrolo[2,3-b]pyridm-3-yl)-5fluoropyrimidin-4-ylamino)-l-hydroxycyclohexyIphosphonate (59a and 59b)

To a solution of (3S)-3-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5fluoro-pyrimidin-4-yl]amino]cyclohexanone, 28a, (0.40 g, 0.78 mmol) in benzyloxyphosphonoyloxymethylbenzene (2.58 mL, 11.67 mmol) was added triethylamine (0.22 mL, 1,56 mmol). The reaction mixture was heated to 95 °C for 15 hours. The mixture was diluted with aqueous saturated NaHC0₃ solution, extracted with EtOAc, washed again with aqueous saturated NaHC0₃ solution. The organic phase was dried (MgSO4), filtered and concentrated in vacuo to white solid. The crude product was purified via silica gel chromatography using 0-10% MeOH/CH₂C12 gradient to afford 518 mg of a mixture of diastereomers, which contains somebenzyloxyphosphonoylmethylbenzene. The mixture was used without further purification in the next step. LCMS RT -4.6 (M+H) 776.32.

[001140] Formation of dimethyl (15, 35)-3-(2-(5-chloro-l.ff-pyrrolo[2,3-b]pyridin3-yl)-5-fluoropyrimidin-4-ylamino)-l-hydroxycyclohexylphosphonate and dimethyl (1R, 35)-3-(2-(5-chloro-lJ^l7-pyrro]o[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)-lhydroxycyclohexylphosphonate (741, 742)

-336WO 2010/148197

PCT/US2010/038988

To a solution of (17?, 35)-3-[[2-[5-chloro-l-(j9-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3yl]-5-fluoro-pyrimidin-4-yl]amino]-l-dibenzyloxyphosphoryl-cyclohexanol and (15, 35)-3[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5-fluoro-pyrimidin-4-yl]amino]-

1-dibenzyloxy in MeOH was added sodium methanolate and the reaction was stirred at room temperature. After 15 min, the reaction mixture was diluted with aqueous saturated NH4CI solution and extracted twice with 20% IPA/CH2CI2. The combined organic phases were dried (MgSOfi, filtered and concentrated in vacuo. The resulting residue was purified via silica gel chromatography using 0-5% MeOHiCHjCfi to elute impurity, 5%-10% to elute bottom two spots.

Diastereomer 1 [741]: 'H NMR (300 MHz, DMSO) δ 12.32 (s, 1H), 8.70 (d, J= 2.4 Hz, 1H),

8.27 (d, J= 2.4 Hz, 1H), 8.26 (d, J= 2.8 Hz, 1H), 8.18 (d, J = 3.9 Hz, 1H), 7.34 (d, 7= 7.1 Hz, 1H), 5.77 (d, 7= 2.9 Hz, 1H), 4.60 (s, 1H), 3.73 (dd, 7= 10.1, 6.3 Hz, 6H), 2.30 - 2.15 (m, 1H), 2.04 - 1.86 (m, 1H), 1.85 - 1.50 (m, 6H); LCMS RT = 3.82 (M+l) 470.5.

Diastereomer 2 [742]: 'H NMR (300 MHz, DMSO) δ 12.30 (s, 1H), 8.75 (d, 7= 2.4 Hz, 1H),

8.27 (d, 7=2.4 Hz, 1H), 8.18 (d, 7= 2.8 Hz, 1H), 8.14 (d, 7= 4.0 Hz, 1H), 7.44 (d, 7= 7.7 Hz, 1H), 5.38 (s, 1H), 4.55 - 4.36 (m, 1H), 3.71 (d, 7= 3.1 Hz, 3H), 3.68 (d, 7= 3.2 Hz, 3H), 2.16 - 2.01 (m, 2H), 2.00 - 1.72 (m, 3H), 1.71 - 1.41 (m, 2H), 1.39 - 1.18 (m, 1H); LCMS RT = 3.70 (M+l) 470.5.

General Scheme 60

-337WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [001141] Formation of Ethyl 2-((1 R, 3S)-3-(2-chloro-5-fluoropyrimidin-4-ylaniino)- l-hydroxy-cyclohexyl)ethanoate (60a)

Zinc dust (1.61 g, 24.62 mmol) was heated with a heat gun under N₂. THF (8.0 mL) was added, then a solution of chloro(trimethyl)silane (0.63 mL, 4.93 mmol) in THF (8.0 mL) was added and stirred for 15 min at room temperature then heated to reflux. After cooling to room temperature, a solution of ethyl 2-bromoacetate (2.73 mL, 24.62 mmol) in THF (6.0 mL) was added slowly to the zinc mixture. Then, a solution of (35)-3-[(2-chloro-5-fluoropyrimidin-4-yl)amino]cyclohexanone, 29b, (2.00 g, 8.21 mmol) in THF (6.0 mL) was added. The mixture was refluxed for 2 hours then concentrated in vacuo. EtOAc and aqueous saturated NaHCO₃ solution were added and the product was extracted with additional EtOAc (3x), dried (Na₂SO4) and concentrated in vacuo. Purification by silica gel chromatography (Hexanes:EtOAc) separated 2 products. The first peak was 60a (2.05 g, 6.18 mmol, 75%). LCMS+: 332.20 at 3.57 min (10-90% MeOH, 3/5 grad/run, Formic Acid).

[001142] Formation of Ethyl 2-((1Λ, 3S)-3-(2-(5-chloro-l-tosyl-lJ7-pyrroIo]2,3b ] py ndin-3-yl)-5-fluo ropy rim idin-4-ylamino)-l-hydr oxy cyclohexy l)ethanoate (6 0c)

To a solution of 5-chloro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine (0.31 g, 0.72 mmol) in acetonitrile (6.0 mL) was added ethyl 2-((LR, 35)-3-(2-chloro-5-fluoropyrimidin-4-ylamino)- 1-hydroxycyclohexyl)ethanoate, 60a, (0.20 g, 0.60 mmol) and degassed under N₂. Na₂CO₃ (0.90 mL of 2 M, 1.81 mmol) was added followed by Pd(PPh₃)₄ (0.10 g, 0.09 mmol). The reaction was sealed and microwaved at 120 °C for 30 min. The material was concentrated under reduced pressure then diluted in EtOAc and aqueous saturated NaHCO₃, then extracted with additional EtOAc (3x), dried (Na₂SO4) and concentrated in vacuo. The material was diluted in DCM and silica gel chromatography (Hexanes.’EtOAc) gave 217 mg of product 60c. LC MS+: 602.49 at 4.62 min (10-90% MeOH, 3/5 grad/run, Formic Acid).

[001143] Formation of 2-((121, 35)-3-(2-(5-chloro-lEf-pyrrolo[2,3-b]pyridin-3-yl)-5fluoro-pyrimidin-4-ylamino)-l-hydroxycyclohexyl)ethanoic acid (60d)

To a solution of ethyl 2-((1 R, 35)-3-(2-(5-chIoro-l-tosyl-177-pyrrolo[2,3-b]pyridin-3yl)-5-fluoropyrimidin-4-ylamino)-l-hydroxycyclohexyl)ethanoate, 60c, (0.14 g, 0.22 mmol) in THF (5.0 mL) was added LiOH (1.12 mL of 1 M aqueous solution, 1.12 mmol). The reaction was microwaved at 130 ° C for 30 min, neutralized with HC1 (0.56 mL of 2 M, 1.12 mmol) and concentrated under reduced pressure, diluted in toluene and concentrated (2x) to give 60d which was used without further purification. LC MS+: 420.30 at 3.05 min (10-90% MeOH, 3/5 grad/run, Formic Acid).

[001144] Formation of 2-((ll?, 35)-3-(2-(5-chloro-l#-pyrrolo[2,3-b]pyridin-3-yl)-5fluoro-pyrimidin-4-y la mino)-l-hyd r oxycy clohexyl)-N-methylethanamide (751)

To a solution of 2-((lR, 3S)-3-(2-(5-chloiO-l//-pyriOlo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-l-hydroxycyclohexyl)cthanoic acid, 60d, (0.032 g, 0.076 mmol) in MeCN (1.6 mL) and DMF (1.6 mL) was added HATU (0.058 g, 0.152 mmol), Methanamine (0.154 mL of 2 M solution, 0.305 mmol) and ‘Pr₂NEt (0.053 mL, 0.305 mmol). The reaction was heated to 60 °C overnight then concentrated in vacuo. The resulting residue was purified by reverse phase HPLC (Water/HCkMeOH). Pure fractions were combined and concentrated in vacuo to give 29 mg of 751 as the HC1 salt.

General Scheme 61

-338WO 2010/148197

PCT7US2010/038988

2018200219 11 Jan 2018

61a

c

[001145] Formation of Ethyl 2-((1 5, 35)-3-(2-cliloro-5-fluoropyrimidin-4-ylamino)l-hydroxycyclohexyl)propanoate (61b). (Step A):

Zinc dust (1.21 g, 18.47 mmol, 3 eq.) was heated with a heat gun under N₂. THF (6.0 mL) was added then a solution of chloro(trimethyl)silane (0.47 mL, 3.69 mmol) in THF (6.0 mL) was added and stirred for 15 min at room temperature then heated to reflux and cooled. A solution of ethyl 2-bromopropanoate (3.34 g, 18.47 mmol) and (3)S)-3-[(2-chloro-5-fluoropyrimidin-4-yl)amino]cyclohexanone (61a) (1.50 g, 6.16 mmol) in THF (6.0 mL) was added to the zinc mixture slowly. This mixture was refluxed for 2 hours then concentrated in vacuo. EtOAc and aqueous saturated NaHCCL were added and the product was extracted with EtOAc (3x), dried (Na₂SO4) and concentrated in vacuo. Purification by silica gel chromatography (Hexanes:EtOAc) separated 2 products. The first product eluted at 20-35% ethyl acetate and second product eluted at 35-40%. The fractions of the 2^nd product were concentrated in vacuo to give 760 mg of 61b. LCMS+: 346.23 at 3.35 min (10-90% MeOH, 3/5 grad/run, Formic Acid).

[001146] Formation of Ethyl 2-((15, 35)-3-(5-fluoro-2-(5-fluoro-l-tosyl-lirpyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-ylamino)-l-hydroxycyclohexyl)propanoate (61c).

To a solution of 5-fluoro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yI)pyriOlo[2,3-b]pyridine (0.21 g, 0.38 mmol) in acetonitrile (3.6 mL) was added ethyl 2-((15, 35)-3-(2-chloro-5-fluoropyrimidin-4-ylamino)- 1-hydroxycyclohexyl)propanoate (61b) (0.12 g, 0.35 mmol) and degassed under N₂. Na₂CO3 (0.52 mL of 2 M aqueous solution, 1.041 mmol) was added followed by Pd(PPh₃)₄ (0.06 g, 0.052 mmol). The reaction was sealed and heated in a microwave at 120 °C for 30 min. The material was concentrated under reduced pressure and then diluted in EtOAc and aqueous saturated NaHCOj, then extracted with additional EtOAc (3x). The combined organic phases were dried (NajSOq) and concentrated in vacuo, The material was diluted in CH₂C1₂ and silica gel chromatography (Hexanes:EtOAc) gave product 200 mg of 61c. LCMS+: 600.35 at 4,22 min (10-90% MeOH, 3/5 grad/run, Formic Acid).

[001147] Formation of 2-((15, 35)-3-(5-fluoro-2-(5-fluoro-lZ7-pyrrolo[2,3b]pyridin-3-yl)pyrimidin-4-ylamino)-l-hydroxycyclohexyl)propanoic acid (61d).

To a solution of ethyl 2-((15, 35)-3-(5-fluoro-2-(5-fluoro-l-tosyl-lJ7-pyrrolo[2,3b]pyridin-3~yl)pyrimidin-4-ylamino)-l-hydroxycyclohexyl)propanoate (61c) (0.20 g, 0.33 mmol) in THF (3 mL) was added LiOH (3 mL of 1 M aqueous solution, 3.0 mmol). The

-339WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 reaction was allowed to stir over 2 days at room temperature then neutralized with HC1 (1.5 mL of 2M, 3.0 mmol) and concentrated to dryness, diluted in toluene and concentrated again (2x) to give 6 Id which was used without further purification. LCMS+: 418.32 at 2.62 min (10-90% MeOH, 3/5 grad/run, Formic Acid).

[001148] Formation of (4R, 55, 75)-7-(5-fIuoro-2-(5-fluoro-l/7-pyrrolo [2,3b]pyridin-3-yI)pyrimidm-4-ylamino)-4-methyi-l-oxa-3-azaspiro|4.5]decan-2-one (967).

To a solution of 2-[(15, 3>S)-3-[[5-fluoro-2-(5-fluoro-lJ7-pyrrolo[2,3-b]pyridin-3“ yl)pyrimidin-4-yl]amino]-l-hydroxy-cyclohexyl]propanoic acid (61d) (0.095 g, 0.228 mmol) in toluene (5 mL) and triethylamine (0.048 mL, 0.341 mmol) was added (azido(phenoxy)phosphoryl)oxybenzene (0.059 mL, 0.273 mmol). The reaction was heated to 120 °C in a sealed tube overnight. The reaction was concentrated in vacuo and purified by reverse phase HPLC (Water/HCl.’MeOH) to separate the diastereomers. To remove a trace amount of leftover starting material, the first peak was diluted in MeOH (1 mL) and passed through a PL-HCO3 MP SPE cartridge to obtain the free base. This material was then salted (HC1 in water) and concentrated in vacuo to give 16 mg of 967 as the HC1 salt.

General Scheme 62

62c

[001149] Formation of (5)-ethyl 2-(3-(2-chloro-5-fluoropyrimidin-4ylamino)cyclohexylidene)ethanoate (62a).

To a solution of (35)-3-[(2-chloro-5-fluoro-pyrimidin-4-yl)amino]cyclohcxanonc (29b) (2.00 g, 8.21 mmol) in toluene (40 mL) was added ethyl 2triphenylphosphoranylideneacetate (4.29 g, 12.31 mmol). The reaction was refluxed overnight then concentrated in vacuo and purified by silica gel chromatography (Hexanes:EtOAc). The desired product eluted at 15% ethyl acetate. Clean fractions were combined and concentrated to give 2.57 g of 62a. LCMS+: 314.18 at 3.75 min (10-90% MeOH, 3/5 grad/run, Formic Acid).

[001150] Formation of Ethyl 2-((35)-3-(2-chloro-5-fluoropynmidin-4-ylamino)-l(nitromethyl)cyclohexyl)ethanoate (62b)

To a solution of (5)-ethyl 2-(3-(2-chloro-5-fluoropyrimidin-4ylamino)cyclohexylidene)ethanoate, 62a, (2.58 g, 8.22 mmol) in nitromethane (44.53 mL, 822.3 mmol) was added 1,1,3,3-tetramethylguanidine (1.55 mL, 12.33 mmol). The reaction was refluxed overnight then concentrated in vacuo and purified by silica gel chromatography (Hexanes :EtOAc) then a second chromatography (CH2CI2 :20% MeOH in CH2Q2). Fractions containing pure product were combined and concentrated to give 1.8 g of 62b LCMS+: 375.32 at 3.64 min (10-90% MeOH, 3/5 grad/run, Formic Acid).

-340WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 [001151] Formation of (75)-7-(2-chloro-5-fluoropyrimidin-4-ylamino)-2azaspiro[4.5]decan-3-one (62c)

To a solution of ethyl 2-((3 S)-3-(2-chloro-5-fluoropyrimidin-4-ylamino)-l(nitromethyl)cyclohexyl)ethanoate, 62b, (1.60 g, 4.27 mmol) in MeOH (20 mL) was added Raney Nickel (0.03 g, 0.43 mmol). The reaction was shaken on a Parr apparatus at 40 psi of H₂ overnight. The reaction was filtered, concentrated in vacuo and purified by silica gel chromatography (CH₂C1₂:2O% MeOH in CH₂C1₂) to give 155 mg of 62c. LCMS+: 299.13 at

2.87 min (10-90% MeOH, 3/5 grad/run, Formic Acid).

[001152] Formation of (75)-7-(2-(5-chloro-l-tosyl-117-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-ylamino)-2-azaspiro[4.5]decan-3-one (62d).

To a solution of 5-chloro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine (0.083 g, 0.195 mmol) in acetonitrile (1.6 mL) was added (7S)-7-(2-chloro-5-fluoropyrimidin-4-ylamino)-2-azaspiro[4.5]decan-3-one (62c) (0.053 g, 0.177 mmol) and degassed under N₂. Aqueous Na₂CO₃ (0.266 mL of 2 M solution, 0.5320 mmol) was added followed by Pd(PPha)₄ (0.031 g, 0.027 mmol). The reaction was sealed and heated in a microwave at 120 °C for 30 min then concentrated in vacuo. The material was diluted in CH₂C1₂ and silica gel chromatography using a gradient of Hexanes:EtOAc then 20% MeOH in CH₂C1₂. Pure fractions were combined and concentrated to give 91 mg of 62d. LCMS+: 569.26 at 4.20 min (10-90% MeOH, 3/5 grad/run, Formic Acid).

[001153] Formation of (7S)-7-(2-(5-chloro-lif-pyrrolo[2,3-b]pyridin-3-yl)-5fhioropyrimidin-4-ylamino)-2-azaspiro[4.5]decan-3-one (969).

To a solution of (75)-7-(2-chloro-5-fIuoiOpyrimidin-4-ylamino)-2-azaspiro[4.5]decan3-one, 62d, (0.091 g, 0.159 mmol) in MeOH (2 mL) was added NaOMe (2 mL of 25 %w/v, 9.255 mmol). The reaction was stirred for 0.5 hours then concentrated in vacuo. The material was purified by reverse phase HPLC (Water/HCl:MeOH) to give a mixture of diastereomers. The fractions containing pure product were combined and concentrated to give 50 mg of the HC1 salt of 969.

General Scheme 63

[001154] Formation of ethyl 2-((15,35)-3-(2-chloro-5-fluoropyrimidin-4-ylannno)1 -hydro xycyclo h exyl)ethanoate (63a)

Zinc dust (1.61 g, 24.62 mmol) was heated with a heat gun under N₂. THF (8.0 mL) was added, then a solution of chloro(trimethyl)silane (0.63 mL, 4.93 mmol) in THF (8.0 mL)

-341WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 was added and stirred for 15 min at room temperature then heated to reflux and cooled. A solution of ethyl 2-bromoacetate (2.73 mL, 24.62 mmol) in THF (6.0 mL) was added slowly to the zinc mixture, then a solution of (35)-3-[(2-chloro-5-fluoro-pyrimidin-4yl)amino]cyclohexanone, 29b, (2.00 g, 8.21 mmol) in THF (6.0 mL) was added. The mixture was refluxed for 2 hours then concentrated in vacuo. EtOAc and aqueous saturated NaHCOa solution were added and the product was extracted with additional EtOAc (3x), dried (Na₂SO₄) and concentrated in vacuo. Purification by silica gel chromatography (Hexanes:EtOAc) separated 2 products. Fractions containing the second (minor) peak were combined and concentrated to give 470 mg of 63a. LCMS+: 332.13 at 3.2 min (10-90% MeOH, 3/5 grad/run, Formic Acid).

(001155] Formation of (55,75)-7-(2-chloro-5-fluoropyrimidin-4-ylamino)-l-oxa-3azaspiro[4.5]decan-2-one (63b).

To a solution of ethyl 2-((15, 35)-3-(2-chloro-5-fluoropyrimidin-4-ylamino)-lhydroxycyclohexyl)ethanoate, 63a, (0.40 g, 1.20 mmol) in dry MeOH (6 mL) was added hydrazine (0.75 mL, 23.4 mmol). The reaction was stirred overnight at room temperature then concentrated under a stream of N₂. The reaction was diluted with HC1 (20 mL of a IM solution, 20 mmol) until acidic and cooled to 0° - 5° C. Then NaNO₂ (1.44 mL of a IM solution, 1.44 mmol) was added slowly. 1:1 Benzene :CHClj (20 mL) was added and the mixture was stirred. The organic layer was separated and added slowly to refluxing benzene. This was refluxed for 0.5h then concentrated. Silica gel chromatography (CH2C1₂:2O% MeOH in CH2CI2) gave 92 mg of pure product 63b. LCMS+: 301.15 at 2.76 min (10-90% MeOH, 3/5 grad/run, Formic Acid).

[001156] Formation of (55, 75)-7-(2-chloro-5-fluoropyrimidin-4-ylamino)-3methyl-l-oxa-3-azaspiro[4.5]decan-2-one (63c)

A solution of (55, 95)-9-[(2-chloro-5-fhioro-pyrimidin-4-yl)amino]-l-oxa-3azaspiro[4.5]decan-2-one, 63b, (0.049 g, 0.163 mmol) in DMF (8.2 mL) was cooled to 0 °C. NaH (0.010 mg, 0.244 mmol) was added followed by Mel (0.011 mL, 0.179 mmol). The reaction was allowed to warm to room temperature overnight. The reaction was quenched with water and concentrated in vacuo. Aqueous saturated NaHCCfi solution was added and the product was extracted with EtOAc (3x), washed with brine, dried (Na₂SO₄) and concentrated in vacuo. The material was purified using silica gel chromatography (CH₂C1₂:2O% MeOH in CH₂C1₂) to give 63b. LCMS+: 315.19 at 2.83 min (10-90% MeOH, 3/5 grad/run, Formic Acid).

[001157] Formation of (5S,7S)-7-(2-(5-chloro-l-tosyl-lH-pyrrolo[2,3-b]pyridin-3yl)-5-fluoropyrimidin-4-ylamino)-3-methyl-l-oxa-3-azaspiro[4.5]decan-2-one (63d)

To a solution of 5-chloiO-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine (0.031 g, 0.0724 mmol) in acetonitrile (0.570 mL) was added (55, 75)-7-(2-chloro-5-fluoropyrimidin-4-ylamino)-3-methyl-l-oxa-3azaspiro[4.5]decan-2-one, 63c, (0.019 g, 0.060 mmol) and degassed under N₂. Na₂CO3 (0.091 mL of 2 M, 0.1810 mmol) was added followed by Pd(PPh₃)₄ (0.010 g, 0.009 mmol). The reaction was sealed and heated in a microwave at 120 °C for 30 min. The mixture was then concentrated in vacuo. The material was diluted in CH₂C1₂ and silica gel chromatography (Hexanes :EtO Ac then 20% MeOH in CH₂C1₂) gave product 63d. LCMS+:

585.25 at 4.17 min (10-90% MeOH, 3/5 grad/run, Formic Acid).

[001158] (5S,7S)-7-(2-(5-chior ο-ΙΗ-py r rolo [2,3 -b] py ridin-3-yl)~5-fluoropy rimidin-

4-ylamino)-3-methyl-l-oxa-3-azaspiro[4.5]decan-2-one (971)

-342WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

To a solution of (55, 75)-7-(2-(5-chloro-l-tosyl-l/7-pyrrolo[2,3-b]pyridin-3-yl)-5fluoiOpyrimidin-4-ylamino)-3-methyl-l-oxa-3-azaspiro[4.5]dccan-2-one, 63d, (0.035 g, 0.060 mmol) in MeOH (2 mL) was added NaOMe (2 mL of 25 %w/v, 9.255 mmol). The mixture was stirred for 30 min then concentrated in vacuo and purified by reverse phase HPLC (Water/HCl:MeOH). Pure fractions were combined and concentrated in vacuo to afford product 971 as the HCI salt.

[001159] Formation of (35)-3-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3b] pyridin-3-yl] -5-fluoro-pyrimid in-4-yl] amino] cyclohexa no ne (64a)

A microwave tube was placed 5-chloro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tctramethyl- l,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridme (2,13 g, 4.93 mmol) and (35)-3-[(2-chloro-5fluoro-pyrimidin-4-yl)amino]cyclohexanone in DME (22.2 mL) and aqueous Na₂CO₃ (5.13 mL of 2 M solution, 10.26 mmol) solution. The mixture was deoxygenated with nitrogen for 20 min. To the reaction mixture was added tetrakis triphenylphosphane palladium (0.47 g, 0.41 mmol). The reaction was sealed and heated to 120 °C for 30 min. The reaction was diluted with ethyl acetate (40 mL), filtered through Celite. The filtrate was washed with brine, dried (MgSO₄), filtered and concentrated in vacuo. Purification via silica gel chromatography using 10-80% EtOAc/ hexanes gradient afforded (3S)-3-[[2-[5-chloro-l-(ptolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5-fluoro-pyrimidin-4-yl]amino]cyclohexanone, 64a.

[001160] Formation of (35)-3-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3b]pyridin-3-yl]-5-fluoro-pyriniidin-4-yl]amino]-l-trimethylsilyloxycyclohexanecarbonitrile (64b)

To a solution of (35)-3-[[2-[5-chloro-l-(p-toIylsulfonyl)pyrrolo[2_J3-b]pyridin-3-yl]-5fluoro-pyrimidin-4-yl]amino]cyclohexanone, 64a, (0.58 g, 1.13 mmol) in CH₂C1₂ (20 mL) was added diiodozinc (0.36 g, 1.13 mmol) and trimethylsilylformonitrile (0.30 mL, 2.26 mmol) at room temperature. The reaction was refluxed overnight. The mixture was purified by silica gel chromatography to afford 600 mg of (3S)-3-[[2-[5-chloro-l-(ptolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5-fluoro-pyrimidin-4-yl]amino]-l-trimethylsilyloxy-cyclohexanecarbonitrile, 64b.

[001161] Formation of (15, 35)-3-[[2-(5-chloro-lii^r-pyrrolo[2,3-b]pyridin-3-yl)-5fluoro-pyrimidin-4-yl]amino]-l-hydroxy-cyclohexanecarboxylic acid (64c) (3 5)-3 - [[2- [ 5-chl oro-1 -(p-tolylsulfony l)py rrolo[2,3 -b]py ridin-3 -y l]-5-fluoropyrimidin-4-yl]amino]-I-trimethylsilyloxy-cyclohexanecarbonitrile, 64b, (0.57 g, 0.93 mmol)

-343WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 was heated in HC1 (20 mL of 12 M solution, 240.0 mmol) at 80 °C in a sealed tube overnight. The solvent was evaporated and the crude product was purified by preparatoiy HPLC to provide 200 mg of (IS, 3S)-3-[[2-(5-chloro-l#-pynOlo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]- 1-hydroxy-cyclohexanecarboxylic acid, 64c.

*H NMR (300 MHz, MeOD) δ 8.70 (d, J= 22 Hz, 1H), 8.47 (s, 1H), 8.37 (d, J= 2.2 Hz, 1H), 8.28 (d, 7= 5.5 Hz, 1H), 5.37 - 4.57 (m, 49H), 3.38 - 3.26 (m, 26H), 2.42 (dd, 7 = 13.3, 4.2 Hz, 2H), 2.15 (d, 7= 10.4 Hz, 1H), 2.07 - 1.87 (m, 3H), 1.77 (dd, 7= 18.1, 8.6 Hz, 3H); LCMS: 406.35 (M+l).

[001162] Formation of (IS, 3S)-3-[[2-(5-chloro-lff-pyrrolo[2,3-b]pyridin-3-yi)-5fluoro-pyrimidin-4-yl] amino] -N-ethyl-l-hydroxy-cyclohexanecarb oxamide (779) (IS, 35)-3- [ [2-(5-chloro-1 ff-py rrolo [2,3 -b]pyridin-3 -yl)-5-fluoro-pyrimidin-4yl]amino]-l-hydroxy-cyclohexanecarboxylic acid, 64c, (0.040 g, 0.090 mmol) was dissolved in DMF (3 mL), then ’Pr₂NEt (0.047 mL, 0.271 mmol) and ethanamine (0.135 mL of 2 M solution, 0.271 mmol) was added, followed by HATU (0.080 g, 0.210 mmol). The reaction was stirred at room temperature for another 2 hours. The solution was evaporated and the product was purified by Preparatory HPLC to afford 10 mg of (IS, 3S)-3-[[2-(5-chloro-l//pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-pyrimidin-4-yl]amino]-lV-ethyl-l-hydroxycyclohexanecarboxamide, 779.

'H NMR (300 MHz, MeOD) d 8.72 (d, J = 2.2 Hz, 2H), 8.48 (s, 2H), 8.34 (dd, 7 = 23.7, 3.9 Hz, 3H), 4.99 (d, 7= 5.4 Hz, 3H), 4.88 (s, 1H), 4.85 - 4.67 (tn, 32H), 3.44 - 2.95 (m, 4H), 2.29 (dd, J = 13.5, 4.1 Hz, 3H), 2.11 (d, 7= 9.5 Hz, 2H), 2.04 - 1.80 (m, 7H), 1.76 (s, 3H), 1.13 (t, 7= 7.2 Hz, 4H); LCMS: 433.42 (M+l).

General Scheme 65

[001163] Formation of 3-amino-2-hydroxy-cyclohexanecarboxylic acid (65a)

2-Hydroxy-3-nitro-benzoic acid (5.0 g, 27.3 mmol) was mixed with HC1 (125 mL of 0.5 M, 62.5 mmol) and dioxoplatinum (1.0 g, 4.4 mmol) in a hydrogenation bottle. The mixture was placed on a Parr shaker (50 psi H₂) for 24 hours. The catalyst was filtered and washed with hot H₂O. The filtrate was evaporated to provide 3-amino-2-hydroxycyclohexanecarboxylic acid as a mixture of stereoisomers which was utilized to the next step without further purification.

[001164] Formation of 3-|[2-[5-chloro-l-(p-tolylsulfonyl)pyrroIo]2,3-b]pyridin-3yl]-5-fluoro-pyrimidin-4-yI]amino]-2-hydroxy-cyclohexanecarboxylic acid (65b)

-344WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

5-chloro-3-(5-fluoro-4-methylsulfinyl-pyrimidin-2-yl)-l-(p-toIylsulfonyl)pyrrolo[2,3-b]pyridine, 65a, (0.30 g, 0.64 mmol), 3-amino-2-hydroxy-cyclohexanecarboxylic acid (0.19 g, 0.97 mmol), ^lPr₂NEt (0.45 mL, 2.58 mmol) in DMF (23.2 mL) solution was heated in microwave at 130 °C for 10 min. The solvent of the reaction mixture was removed under reduced pressure and the residue was purified by preparatory HPLC to give 240 mg of

3-[[2-[5-chloiO-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5-fluoro-pyrimidin-4yl]amino]-2-hydroxy-cyclohexanecarboxylie acid, 65b, as a mixture of stereoisomers.

[001165] Formation of 3-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3yl]“5“fIuoro-pyrimidin-4-yl]amino]-/V-ethyl-2-hydroxy-cyclohexanecarboxamide (65c) 3-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5-fluoro-pyrimidin-4yl]amino]-2-hydroxy-cyclohexanecarboxylic acid, 65b, (0.100 g, 0.179 mmol) was dissolved in DMF (2 mL) and ‘Pr₂NEt (0.124 mL, 0.714 mmol) and ethanamine hydrochloride (0.029 g, 0.357 mmol) was added at room temperature. Then HATU (0.081 g, 0.214 mmol) was added to die solution at room temperature. After 30 min, EtOAc was added and the mixture was washed with 1 N HCl, aqueous saturated NH4CI solution, and brine. The organic phase was dried over Na₂SC>4, filtered and concentrated in vacuo. The crude product was used in the next step without further purification.

[001166] Formation of 3-[[2-(5-chloro-lH-pyrrolb[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl] amino]-N-ethyl-2-hydroxy-cycloh exaneca rb oxamide (815)

3-[[2-[5-chloro-l-(p-tolylsulfonyl)pyrroIo[2,3-b]pyridin-3-yl]-5-fluoiO-pyrimidin-4yl]amino]-/V-ethyl-2-hydroxy-cyclohexanecarboxamide, 65c, was treated with NaOMe in MeOH. The product was purified by preparatory HPLC to provide 3-[[2-(5-chloro-lHpyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-pyrimidin-4-yl]amino]-N-ethyl-2-hydroxycyclohexanecarboxamide as a mixture of stereoisomers. LCMS: 433.35 (M+l).

[001167] Formation of MethyLl-methylcyclohex-2-ene-l-carboxylate (66a)

To a cold (0 °C) solution of freshly distilled A-isopropylpropan-2-amine (4.20 mL, 29.96 mmol) in THF (150 mL) under argon was added dropwise nBuLi (12.65 mL of 2.2 M solution, 27.82 mmol). After 15 min the solution was cooled to -78 °C and dry HMPA (4.84 mL, 27.82 mmol) was added. The mixture was stirred for 30 min at -78 °C and methyl cyclohexene-1-carboxylate (3.00 g, 21.40 mmol) was then added. After stirring an additional 10 min, methyl iodide (2.00 mL, 32.10 mmol) was added. The solution was then allowed to warm to -5 °C over 2 h. An aqueous saturated solution of NH4CI was poured into the orange mixture. After dilution with hexanes and washing with brine, the organic layer was dried overNa₂SO4 and carefully evaporated to 3.3 g of generate methyl 1-methylcyclohex-2-ene-1carboxylate, 66a, which was used without further purification.

-345WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 *H NMR (300 MHz, CDC13) δ 5.77 (dt, J= 10.1, 3.5 Hz, 1H), 5.66 (s, 1H), 3.71 -

3.58 (m, 3H), 2.16 (ddd, J= 12.9, 7.0, 3.4 Hz, 1H), 2.03 - 1.88 (m, 2H), 1.72 - 1.53 (m, 2H), 1.49 - 1.37 (m, 1H), 1.32 - 1.14 (m, 3H).

[001168] Formation of racemic cis-methyl 5-methyI-7-oxabicyclo[4.1.0]heptane-5carboxylate (66b)

Methyl l-methylcyclohex-2-ene-l-carboxylate, 66a, (3.30 g, 21.40 mmol) was treated with 3-chloroperoxybenzoic acid (7.39 g, 42.80 mmol) in CH2CI2 (75 nlL) at room temperature for 2 hours. The solution was clear but white precipitate was observed after 1 hour. The resulting white solid was filtered and washed with hexanes, and the filtration was diluted with EtOAc and washed with aqueous saturated NaHCOj solution followed by brine. The organic phase was then dried over Na2SO4, concentrated in vacuo and the crude residue was purified by silica gel chromatography (Hexanes/Ethyl acetate 100/0 to 10/1 gradient) to provide two products. The less polar spot is a colorless oil, which is assigned by 1H NMR to be cis-methyl 5-methyl-7-oxabicyclo[4.1.0]heptane-5-carboxylate (1.2 g) and the second fraction is a white solid, which is irans-methyl -5-methyl-7-oxabicyclo[4.1,0]heptane-5carboxylate (2.2 g).

Racemic cis-isomer (66b): 'H NMR (300 MHz, CDC13) δ 3.67 (d, 7= 4.3 Hz, 3H),

3.23 -- 3.12 (m, 1H), 3.08 (d, 7= 3.8 Hz, 1H), 2.02 -1.78 (m, 2H), 1.68 (dtd, 7= 9.7, 6.8, 3.2 Hz, 1H), 1.49 - 1.27 (m, 2H), 1.25 - 1.15 (m, 3H), 1.06 (ddd, 7= 9.1,7.4, 3.2 Hz, 1H).

[001169] Formation of racemic methyl -3-azido-2-hydroxy-l-methyIcyclohexanecarboxylate (66c)

Racemic cis-methyl-5-methyl-7-oxabicyclo[4.1.0]heptane-5-carboxylate, 66b, (2.2 g, 12.93 mmol) was added to a flask containing MeOH (90 mL) and H₂O (10 mL) under nitrogen atmosphere. NH4CI (1.38 g, 0.90 mL, 25.86 mmol) and NaN₃ (2.52 g, 38.79 mmol) were then added to the reaction mixture. The mixture was heated to reflux for 16 hours. The solvent was evaporated under reduced pressure and the oil was taken up in H₂O and extracted with EtOAc. The combined organic phases were washed with brine and dried over Na2SO4. The crude product was purified by silica gel chromatography to afford 900 mg of racemic methyl-3-azido-2-hydroxy-l-methyl-cyclohexanecarboxylate.

'H NMR (300 MHz, CDC13) δ 3.74 (d, 7= 3.1 Hz, 3H), 3.64 - 3.43 (m, 2H), 3.25 3.05 (m, 1H), 2.25 -2.09 (m, 1H), 2.00 (ddd, 7= 9.7, 4.8, 2.9 Hz, 1H), 1.73 - 1.50 (m, 1H),

1.40 (d, J = 6.3 Hz, 3H), 1.32 - 1.03 (m, 3H).

[001170] Formation of racemic methyl-3-amino-2-hydroxy-l-methylcyclohexanecarboxylate (66d)

A solution of racemic methyl-3-azido-2-hydroxy-l-methyl-cyclohexane-carboxylate, 66c, (0.90 g, 4.22 mmol) in a mixture of MeOH (50 mL) and AcOH (10 mL) was stirred under a hydrogen atmosphere (balloon) with the presence of palladium (0.50 g, 0.47 mmol) overnight at room temperature. The mixture was filtered through a celite bed and washed with MeOH. The combined filtrates were evaporated to provide methyl-3-amino-2-hydroxy1-methyl-cyclohexanecarboxylate as a oil. Et₂O was added and the resulted acetic acid salt was stirred for 0.5 hour and was then filtered to give 1.0 g of racemic methy 1-3-aminoshydroxy-1-methyl-cyclohexanecarboxy late acetic acid salt as a white solid.

[001171] Formation of racemic Methyl-3-[(2-chloro-5-fluoro-pyrimidin-4yl)amino]-2-hydroxy-l-methyl-cyclohexanecarboxylate (66e)

To a solution of 2,4-dichloiO-5-fluoro-pyrimidine (0.43 g, 2.58 mmol) and racemic methy 1-3-amino-2-hydroxy-l-methyl-cyclohexanecarboxylate acetic acid salt, 66d, (0.58 g,

2.35 mmol) in THF (10 mL) and MeOH (8 mL) at room temperature was added ^lPr₂NEt (1.23

-346WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 mL, 7.04 mmol). After stirring the reaction overnight at room temperature, the solvent was evaporated under reduced pressure and the crude residue was purified by silica gel chromatography (Hexanes/EtOAc 100/0 to 0/100, R.f=0.7 in Hexanes/EtOAc 2/1) to provide 650 mg of racemic methyl-3-[(2-chloro-5-fluoro-pyrimidin-4-yl)annno]-2-hydroxy-l-methyL cyclohexanecarboxylate, 66e, as a white solid. LCMS: 318.16 (M+l).

[001172] Formation of racemic Methyi-3-] [2-[5-chloro-l-(ptolylsulfonyl)pyrrolo[2,3-b]pyridin~3-yl]-5-fluoro-pyrimidin-4-yl]amino]-2-hydroxy-lmethyl-cyclohexan ecarboxylate (66f)

To a solution of racemic methyl-3-[(2-chloro-5-fluoro-pyrimidin-4-yl)amino]-2hydroxy-l-methyl-cyclohexanecarboxylate, 66e, (0.65 g, 2.05 mmol) and 5-chloro-l-(ptolyIsu Ifony 1)-3 -(4,4,5,5-tetramethy 1-1,3,2-dioxaborolan-2-yl)pyrrol o [2,3-b]pyridine (1.3 2 g, 3.05 mmol) in THF (20 mL) was added aqueous Na₂CO₃ (3.52 mL of 2 M solution, 7.04 mmol). The solution was degassed with N₂ for 20 minutes, Tetrakis triphenylphosphane palladium (0) (0.14 g, 0.12 mmol) was added and the mixture was refluxed overnight. LCMS showed good conversion, but some starting materials remained. More degassed 2 N Na₂CO₃was added followed by another portion of Tetrakis triphenylphosphane palladium (0.14 g, 0.12 mmol). The reaction was refluxed for another 4 hours. The mixture was cooled to room temperature, extracted with EtOAc. The organic phase was washed by brine and dried over Na₂SO4. After evaporation of solvent the erode mixture was purified by silica gel chromatography (Hexanes/EtOAc 100/0 to 0/100) to provide 1.0 g of racemic methyl-3-[[2[5-chloro-l-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]-5-fluoro-pyrimidin-4-yl]amino]-2hydroxy-l-methyl-cyclohexanecarboxylate, 66f. LCMS: 588.26 (M+l).

[001173] Formation of (15,25, 35)-3-[[2-(5-chloro-l£T-pyrrolo[2,3-b]pyridin-3-yl)5-fluoro-pyrimidin-4-yl] amino]-2-hydroxy-l-methyl-cyclohexanecarboxylic acid (928)

Racemic methyl-3-[[2-[5-chIoro-l-(p-tolylsulfonyl)pyn'oio[2,3-b]pyridin-3-yl]-5fluoro-pyrimidin-4-yl]amino]-2-hydroxy-l-methyl-cyclohexanecarboxylate, 66f, (0.100 g, 0.170 mmol) was dissolved in MeOH (1 mL) and THF (1 mL) and treated with aqueous LiOH (0.24 mL of 1 M solution, 0.24 mmol) and the reaction was heated to reflux overnight. The reaction was cooled to room temperature and the resulting material directly purified by preparatory HPLC to afford 20 mg of racemic 3-[[2-(5-chloro-lJ7-pyrrolo[2,3-b]pyridin-3yl)-5-fluoro-pyrimidin-4-yl]amino]-2-hydroxy-l-methyl-cyclohexanecarboxylic acid. The enantiomers of the racemic material were separated by chiral SFC purification to afford 6 mg of (Iff, 2ff, 3ff)-3-[[2-(5-chloro-l.ff-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-pyrimidin-4yl]amino]-2-hydroxy-l-methyl-cyclohexanecarboxylic acid and 6 mg of (15, 25, 35)-3-[[2(5-chloro-l/7-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-pyrimidin-4-yl]amino]-2-hydroxy-lmethyl-cyclohexanecarboxylic acid. LCMS: 420.36 (M+I).

General Scheme 67

-347WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

18b

67b

(a) Pd/C (wet, Degussa), hydrogen, EtOH (b) 2,4-dichIoro-5-fluoropyrimidine, 'Pr₂NEt, THF, reflux (c) LiOH, THF/water, 50°C (d) DPPA, Et₃N, THF, 85 °C (e) 5-fluoro-3-(4,4,5,5-tetrametliyl-l,3,2-dioxaborolan-2-yl)-ltosyl-i/7-pyrrolo[2,3-6]pyridine, XPhos, Pd₂(dba)₃, K3PO4,2-methylTHF, water, 125 °C (f)

Formation (IR, 35)-ethyl 3-aminocyclohexanecarboxylate (67b)

To a solution of (IR, 35)-ethyl 3-(benzyloxycarbonylamino)cyclohexane-carboxylate, 18b, (14.0 g, 45.9 mmol) in ethanol (3 mL) was added Pd/C (wet, Degussa (2,4 g, 2.3 mmol). The mixture was evacuated and then stirred under atmosphere of nitrogen at room temperature overnight. The reaction mixture was filtered through a pad of celite and the resulting filtrate concentrated in vacuo to provide an oil that was used without further purification.

Formation (IR, 35)-ethyl 3-(2-chloro-5-fluoropyrimidin-4-ylammo)cyclohexanecarboxylate (67c)

To a solution of (IR, 35)-ethyl 3-aminocyclohexanecarboxylate, 67b, (5.1 g, 24.1 mmol) and 2,4-dichloro-5,-fluoropyrimidine (6.0 g, 36.0 mmol) in THF (60 mL) was added diisopropylcthylamine (9.6 mL, 55.4 mmol). The mixture was heated to reflux overnight. The reaction was cooled to room temperature and concentrated in vacuo. The residue was diluted with water and extracted twice with ethyl acetate. The combined organic phases were dried (MgSO₄), filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (0-40% EtOAc/hexanes gradient) to provide 6.7 g of (IR, 35)-ethyl 3-(2chloro-5-fluoropyrimidin-4-ylamino)cyclohexane-carboxylate as a white solid: LCMS RT = 3.1 (M+H) 302.2.

Formation (IR, 3S)-3-(2-chloro-5-fluoropyrimidin-4-ylamino)cyclohexanecarboxylic acid (67d)

To a solution of (IR, 3S)-ethyl 3-(2-chloro-5-fluoropyrimidin-4ylamino)cyclohexane-carboxylate, 67c, (20.0 g, 66.3 mmol) in THF (150 mL) was added added a solution of LiOH hydrate (8.3 g, 198.8 mmol) in 100ml water. The reaction mixture was stirred at 50 °C overnight, To the reaction mixture was added HC1 (16.6 mL of 12 M solution, 198.8 mmol) and EtOAc. The organic phase was washed with brine and dried over MgSO₄ and the solvent was removed under reduced pressure to afford 17.5 g of product that was used without further purification: ^lH NMR (300 MHz, CDC13) δ 7.91 (d, J = 2.7 Hz,

-348WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

2H), 5.24 (d, / = 7.3 Hz, 2H), 4.19 - 4.03 (m, 3H), 3.84 - 3.68 (m, 3H), 2.59 (ddd, J= 11.5, 8.2, 3.6 Hz, 2H), 2.38 (d, J = 12.4 Hz, 2H), 2.08 (d, / = 9.6 Hz, 6H), 1.99 - 1.76 (m, 5H), 1.63 - 1.34 (m, 6H), 1.32-1.15 (m, 4H).

Formation 2V-((15, 35)-3“(2“ChIoro-5-fluoropyrimidin-4-ylammo)cyclohexyl)pyrrolidine-l-carboxamide (67e)

A solution of (15, 3S)-3-(2-chloro-5-fluoropyrimidin-4-ylamino)cyclohexanecarboxylic acid, 67d, (8.2 g, 30.0 mmol), (azido(phenoxy)phosphoryl)oxybenzene (9.7 mL, 45.0 mmol) and triethylamine (5.8 mL, 42.0 mmol) in THF (200 mL) was degassed under nitrogen for 15 minutes. The reaction mixture was heated at 85 °C for 30 minutes until LC/MS indicated complete consumption of carboxylic acid, 67d. To the reaction mixture was added pyrrolidine (7.5 mL, 90.0 mmol) and the reaction was heated at 85 °C for an additional 15 min. The mixture was diluted into brine and extracted with EtOAc. The organic phase was separated, dried over MgSO₄. The product was isolated (6.25 g) by filtration after partial removal of solvent in vacuo: NMR (300 MHz, CDC13) δ 7.87 (d, J = 2.8 Hz, 2H), 5.04 (d, J = 8.1 Hz, 2H), 4.09 (ddd, J = 26.9, 13.4, 5.6 Hz, 4H), 3.91 - 3.71 (m, 2H), 3.32 (t, /= 6.5 Hz, 7H), 2.45 (d, J= 11.5 Hz, 2H), 2.08 (dd, J= 22.1, 12.0 Hz, 4H),

I. 96- 1.82 (m, 9H), 1.54 (dd, J= 18.6, 8.5 Hz, 2H), 1.22 - 1.01 (m, 6H).

Formation jV-((15, 35)-3-(5-fluoro-2-(5-fluoro-l-tosyl-177-pyrrolo|2,3“b]pyridin-3yl)pyrimidin-4-ylamino)eyclohexyl)pyrrolidine-l“Carboxamide (67f)

A solution of 7/-((15, 3S)-3-(2-chloro-5-fluoropyrimidin-4-ylamino)cyclohexyl)pyrrolidine-1 -carboxamide, 67e, ¢6.8 g, 20.0 mmol), 5-fluoro-l-(p-tolylsulfony 1)-3-(4,4,5,5tetramethyl-l,3,2-dioxaborolan-2-yl)pynOlo[2,3-b]pyridine, 44a, (12.5 g, 30.0 mmol) and K₃PO₄ (17.0 g, 80.0 mmol) in 2-methyl THF (180 mL) and water (20 mL) was degassed under nitrogen for 30 min. To the mixture was added dicyclohexyl-[2-(2,4,6triisopropylphenyl)phenyl]phosphane (XPhos) (1.1 g, 2.4 mmol) and Pd₂(dba)₃ (0.5 g, 0.5 mmol). The reaction mixture was heated in a pressure bottle at 125 °C for 2.5 hr. The reaction mixture was filtered through eelite, the solvent was removed under reduced pressure. The resulting residue was purified by silica gel chromatography (8%MeOH7CH₂Cl₂) to afford

II. 5 g of the desired product: ^!H NMR (300 MHz, CDC13) δ 8.54 (s, IH), 8.49 (dd, J = 9.0,

2.8 Hz, IH), 8.32 (d, /=2.1 Hz, IH), 8.13 (d, / = 8.3 Hz, 2H), 8.07 (d,/= 3.2 Hz, IH), 7.30 (d, /= 8.5 Hz, 2H), 4.98 (d, /= 6.3 Hz, IH), 4.37-4.16 (m, IH), 4.08 (d, /= 7.3 Hz, IH), 3.99 - 3.80 (m, IH), 3.33 (t, / = 6.5 Hz, 4H), 2.52 (d, /= 11.6 Hz, IH), 2.39 (s, 3H), 2.29 (d, /= 11.3 Hz, IH), 2.12 (d,/= 11.1 Hz, IH), 1.99-1.81 (m, 5H), 1.70- 1.55 (m, IH), 1.221.08 (m, 2H).

Formation 7V-((15, 35)-3-(5-fluoro-2-(5-fluoro-l.ff-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yIamino)cyclohexyl)pyrrolidine-l-carboxamide (895)

A solution of //-((15, 3S)-3-(5-fluoro-2-(5-fhioiO-l-tosyl-177-pyiToIo[2_t3-b]pyridin-3yI)pyrimidin-4-ylamino)cyclohexyl)pyrrolidine-l-carboxamide, 67f, (11.5 g, 19.3 mmol) in THF (150 mL) was added sodium methoxide (4.173 g, 19.31 mmol). After stirring the reaction mixture for 2 minutes, the mixture was poured into an aqueous saturated solution of NaHCO₃. The organic phase was washed with brine, dried over MgSO₄ and the solvent was removed under reduced pressure. The resulting residue was purified by silica gel chromatography (10%MeOH/CH₂Cl₂) to afford 6.5g of the desired product. The product was converted to an HCI salt by dissolving in MeOH (100 mL) and adding 2.4 mL of 12M HC1 solution at room temperature. The solution was stirred at for Ihour and the HCI salt precipitated out and filtered to provide 7.05g of the HCI salt: *H NMR (300 MHz, DMSO) δ

9.36 (s, 2H), 9.05 (d, /= 3.0 Hz, 2H), 8.49 (d, J= 5.6 Hz, 2H), 8.41 (dd, /= 2.6, 1.4 Hz, 2H),

-349WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

8.31 (d, J= 9.5 Hz, 2H), 5.92 (s, 3H), 4.24 (s, 3H), 3.64 (s, 2H), 3.18 (t, J= 6.6 Hz, 7H), 2.07 (dt, 7 = 22.7, 11.5 Hz, 4H), 1.87 (t, 7 = 12.6 Hz, 4H), 1.77 (dd, 7 = 8.0, 5.3 Hz, 7H), 1.65 1.13 (m,8H).

General Scheme 68

(a) TsCl, NaH, DMF, 45 °C (b) methyl iodide, IGCOj, DMF (c) bromine, CHC1₃, 0 °C to rt (d) bis(pinacol)diborane, palladium (II) dichloro bis(tricyclohexylphosphane), K.OAc, 2-methylTHF, 125 °C (e) (/?)//-((!/?, 3₁S)-3-((2-chloro-5-fluoropyrimidin-4-yl)amino)cyclohexyl)-3-fluoropyrrolidine-l-carboxamide, XPhos,

Pd₂(dba)₃, K5PO4, 2-methylTHF, water, 125 °C

Formation of 5-fluoro-l-tosyl-17/-pyrrolo|2,3-/?]pyridin-4-ol (68a)

To a solution of 5-fluoro-l#-pyriOlo[2,3-b]pyridin-4-ol (1.2 g, 7.9 mmol) in 80 mL DMF at 0 °C was added toluenesulfonyl chloride (1.8 g, 9.5 mmol) followed by NaH (0.8 g, 19.7 mmol, 60% w/w). The reaction was slowly warmed to 45 °C after 3 hours and stirred for an additional 3 hours. The mixture was then concentrated in vacuo. The crude oil was dissolved in 100 mL EtOAc and washed with water (2x50 mL) and brine. The organic phase was dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified via silica gel chromatography (10% EtOAc/Hexanes) to afford 1.5 g of the desired product.

Formation of 5-fluoro-4-methoxy-l“tosyl-l£/-pyrrolo|2,37]pyridine (68b)

To a solution of 5-fluoro-l-tosyl-lJ7-pyrrolo[2,3-Z/|pyridin-4-ol, 68a, (0.70 g, 2.29 mmol) in DMF (25 mL) was added methyliodide (0.14 mL, 2.29 mmol) and K2CO3 (0.32 g,

2.29 mmol). The reaction mixture was stirred for 3 hours at ambient temperature. The reaction was diluted with deionized water and EtOAc. The organic phase was washed with brine, dried over sodium sulfate and concentrated in vacuo to afford 720 mg of the desired product that was used in next step without further purification.

Formation of 5-fluoro-4-methoxy-3-bromo-l-tosyl-l//-pyrroloJ2,3-/?]pyridine (68c)

To a cold (0 °C) solution of 5-fluoro-4-methoxy-l-tosyl-l/7-pyrrolo[2,3-Z>]pyridine, 68b, (0.79 g, 2.45 mmol) in chloroform (50 mL) was added bromine (0.13 mL, 2.45 mmol). The reaction mixture was stirred at 0 °C for 3 hours and then slowly warmed to ambient temperature. The mixture was diluted with deionized water and quenched with aqueous sodium bicarbonate. The aqueous phase was extracted with methylene chloride and dried over sodium sulfate. The resulting solid was purified via silica gel chromatography (15-30% EtOAc/Hexanes) to give 170 mg of the desired product.

-350WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Formation of 5-fluoro-4-methoxy-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-ltosyl-lZ/-pyrrolo[2,3-/>jpyridme (68d)

To a solution of 5-fluoro-4-methoxy-3-bromo-l-tosyl-l/7-pyrrolo[2,3-I?]pyridine, 68c, (0.17 g, 0.43 mmol) in 2-Me-THF (9 mL) in a microwave vial was added bis(pinacol)diborane (0.16 g, 0.64 mmol), followed by potassium acetate (0.23 g, 1.06 mmol) and palladium (II) dichloro bis(tricyclohexylphosphane) (0.02 g, 0.02 mmol). Reaction vial was sealed and irradiated with microwaves at 125 °C for 90 minutes. The mixture was filtered and purified via silica gel chromatography (10-30% EtOAc/Hexanes) to afford 100 mg of the desired product.

Formation of (R)-3-fluoro-N-((lR, 35)-3-((5-fluoro-2-(5-fluoro-4-methoxy-l//pyrrolo[2,3-&]pyridin-3-yl)pyrimidin-4-yl)ammo)cyclohexy!)pyrrolidine-l-carboxamide (1104):

To a solution of 5-fluoro-4-methoxy-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)I-tosyl-I#-pyrrolo[2,3-/?]pyridine, 68d, (0.100 g, 0.220 mmol) in 2-Me-THF (2 mL) was added (7?)-jV-(( 1R, 3S)-3-((2-chloro-5-fluoropyrimidin-4-yl)amino)cyclohexyl)-3fluoropyrrolidine-l-carboxamide (0.060 g, 0.170 mmol). Potassium phosphate (0.130 g, 0.600 mmol) and deionized water (0.5 mL) were then added and solution was degassed under a flow of nitrogen for 10 minutes. 2-Dicyclohexylphosphino-2’,4’,6’-triisopropylbiphenyl (XPhos) (0.006 g, 0.012 mmol) and tris(dibenzylideneacetone)-dipalladium (0) (0.023 mg, 0.026 mmol) were then added and solution was again degassed under flow of nitrogen for 5 minutes. Vial was sealed and heated to 80 °C for 3 hours. Solution cooled to ambient temperature and was filtered and concentrated in vacuo. The crude oil was redissolved in anhydrous THF (5 mL) and a solution of 2N LiOH (2 mL) was added. The reaction mixture was heated to 80 °C for 2 hours. Solution was cooled to ambient temperature and concentrated in vacuo. Purification by preparative HPLC afforded 6 mg of the desired product.

General Scheme 69

N (a) NaCN, LiCiOj, CtfiCN (b) 5-fluoro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetrainethyl-l,3,2-dioxaborolan-2yl)pyrrolo[2,3-b]pyridine, Na₃CO₃, Pd(PPh₃)₄, dimethoxyethane, 120 °C (c) sodium methoxide, MeOH

-351WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Formation of 2-((15, 35)-3-(2-chloro-5-fluoropyrimidin-4-ylamino)-l-hydroxycyclohexyl)-ethanenitrile (69a)

A suspension of 2-chloro-5-fluoro-A^r-[(35)-l-oxaspiro[2.5]octan-7-yl]pyrimidin-4amine, 49c, (0.50 g, 1.94 mmol), NaCN (0.11 g, 2.33 mmol) and lithium perchlorate (0.25 g,

2.33 mmol) in CH₃CN was heated at 100 °C in a pressure tube for 3h. The mixture was diluted into EtOAc and the organic phase was washed with aqueous saturated NaHCO₃solution, dried with MgSO₄, filtered and the solvent was removed under reduced pressure. The resulting residue was purified by silica gel chromatography (EtOAc/hexanes) afforded the desired product: NMR (300.0 MHz, CDC13) δ 7.78 (d, / = 2.7 Hz, IH), 4.85 (d, / =

6.6 Hz, IH), 4.28 (qn, / = 4.0 Hz, IH), 2.45 (s, 2H), 2.16 (d, J = 13.0 Hz, IH), 2.05 (d, 7 = 11.7 Hz, IH), 1.80-1.71 (m, 3H), 1.46 - 1.28 (m, 2H) and 1.17-1.06 (m, IH) ppm; LCMS RT = 2.15 (M+H) 285.34.

Formation of 2-((15, 35)-3-(5-fluoro-2-(5-fluoro-l-tosyl-l//-pyrrolo|2,3-b]pyridin-3yl)pyrimidin-4-ylamino)-l-hydroxycyclohexyl)ethanenitrile (69b)

A solution of 5-fluoro-l-(p-tolylsulfbnyl)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-

2-yl)pyrrolo[2,3-b]pyridine, 44a, (0.23 g, 0.55 mmol), 2-((15, 35)-3-(2-chloro-5fluoropyrimidin-4-ylamino)-l-hydroxycyclohexyl)-ethanenitrile, 69a, (0.14 g, 0.50 mmol) and Na₂CO₃ (0.75 mL of 2M solution, 1.50 mmol) in dimethoxyethane (15 mL) was degassed with nitrogen for 30 min. To the reaction mixture was added palladium; triphenylphosphane (0.03 g, 0.03 mmol) and continued to degas the solution for 15 min. The reaction mixture was heated at 120 °C in a pressure tube for 45 min. The reaction mixture was filtered through celite and the filtrate was removed under reduced pressure. The resulting residue was purified by silica gel chromatography (40%EtOAc/Hexanes) to afford 150 mg of desired product: LCMS RT = 3.55 (M+H) 539.42.

2- ((15, 35)-3-(5-fluoro-2-(5-fluoro-17/-py rrolo [2,3-b] pyridin-3-yl)pyrimidin-4-ylamino)l-hydroxycyclohexyl)ethanenitrile (979)

To a solution of 2-((15, 35)-3-(5-fluoro-2-(5-fluoiO-l-tosyl-l/7-pyrrolo[2,3-b]pyridin-

3- yl)pyrimidin-4-ylamino)-l-hydroxycyclohexyI)ethanenitrile, 69b,(0.14 g, 0.26 mmol) in methanol (10 mL) was added sodium methoxide (0.06 g, 0.26 mmol). After stirring at room temperature for 2 minutes, the reaction mixture was diluted into EtOAc and brine. The separated organic phase was dried over MgSO₄, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (10%MeOH/CH₂Cl₂) to afford 46 mg of desired product: ^lH NMR (300.0 MHz, MeOD) δ 8.65 (dd, J= 2.8, 9.6 Hz, IH), 8.19 (s, IH), 8.14 (dd,/ = 2.0,2.5 Hz, IH), 7.98 (d,/ = 4.1 Hz, IH), 4.66 (dd,/=8.0, 15.8 Hz, IH), 2.64 (s, 2H), 2.20 (d, /= 12.6 Hz, 2H), 2.01 (dd, /= 3.4, 9.8 Hz, 2H), 1.84 - 1.75 (m, IH), 1.63 - 1.47 (m, 2H), 1.33 (dd, J = 3.6,12.4 Hz, IH) ppm; LCMS RT = 2.31 (M+H)

385.45.

General Scheme 70

-352WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Boc

1143

HN NHq (a) tert -butyl W-OV-tert-butoxycarbonyl-C-pyrazol-l-yl-carbonimidoyl)carbamate, CH2CI2 (b) 5-fluoro-l-(ptoly]sulfonyl)-3-(4,4,5,5-tetramethy!-l,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine, Na₂COj, Pd(PPh₃)4, dimethoxyethane, 120 °C (c) sodium methoxide, THF, MeOH

Formation of tert-butyl (tert-butoxycarbonylamino)((ljff, 35)-3-(2-chloro-5fluoropyrimidin-4-ylamino)cyclohexylamino)methylenecarbamate (70b)

To a solution of (15, 32?)-Vl-(2-chloro-5-fluoro-pyrimidin-4-yl)cyclohexane-l ,3diamine, 70a, (0,122 g, 0,500 mmol) in CH2CI2 (10 mL) was added tert-butyl N-(N-tertbutoxycarbonyl-C-pyrazol-l-yl-carbonimidoyl)carbamate (0.155 g, 0.500 mmol). The reaction mixture was stirred at room temperature for 2 days. The reaction mixture was concentrated in vacuo and used without further purification; ^[H NMR (300 MHz, CDC13) δ 11.51 (s, 3H), 8.29 (d, 7 = 8.3 Hz, 3H), 7.88 (d, 7 = 2.8 Hz, 3H), 5.01 (d, 7= 7.4 Hz, 3H),

4.28 - 4.18 (m, 4H), 2.48 (d, 7= 11.7 Hz, 3H), 2.12 (d, 7= 9.4 Hz, 3H), 1.87 (dd, 7= 10.3,

3.5 Hz, 3H), 1.52 (s, 24H), 1.50 (s, 25H), 1.24.....1.10 (m, 8H);

LCMS RT = 3.97 (M+H) 487.12.

Formation of tert-butyl 2V-pV-[(12?, 35)-3-[[5-fluoro-2-[5-fluoro-l-(p-tolylsulfonyI)pyrrolo [2,3-b] pyridin-3-yl] pyrimidin-4-yl] amino] cyclohexyl] carbaminndoylj-carbamate (70c)

Degassed a solution of (Z)-tert-butyl (tert-butoxycarbonylamino) ((IT?, 35)-3-(2chloiO-5-fluoropyrimidin-4-ylamino)cyclohexylamino) methylenecarbamate, 70b, (0.200 g, 0.411 mmol), 5-fluoro-l-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)pyrrolo[2,3-b]pyridine, 44a, (0.205 g, 0.493 mmol) and Na₂CO₃ (0.616 mL of 2M solution, 1.232 mmol) in dimethoxyethane (15 mL) for 30 min. To the mixture was added palladium triphenylphosphane (0.023 g, 0.021 mmol) and the reaction mixture was heated in a pressure tube at 120 °C for 45 min. The reaction mixture was filtered through a pad of celite and the filtrate concentrated in vacuo. Attempted purification of the resulting residue by silica gel chromatography (10% MeOH/CH₂Cl₂) yielded a mixture containing mostly desired product that was used without further purification: LCMS RT = 2.30 (M+H) 641.02.

Formation of l-((12f, 35)-3-(5-fluoro-2-(5-fluoro-17T-pyrrolo [2,3-b] py rid in-3yl)pyrimidin-4-ylamino)cyclohexyl)guanidine (1143)

To a solution of tert-butyl 1V-[TV-[(1T?, 35)-3-[[5-fluoro-2-[5 -fluoro- l-(ptolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yi]pyrimidin-4-yl]amino]cyclohexyl]

-353WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 carbamimidoyl]carbamate, 70c, (0.100 g, 0.156 mmol) in THF (20 mL) was added sodium methoxide (0.033 g, 0.156 mmol) at room temperature. After 1 minute, the reaction mixture was diluted into EtOAc and aqueous saturated NaHCO₃ solution. The organic phase was dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The resulting residue was purified by silica gel chromatography to afford 95mg of the desired product. To 10 ml MeOH solution of the product was added hydrochloride/IPA (0.031 mL of 5 M solution, 0.156 mmol). The reaction mixture was stirred at room temperature for 1 hour after which the solvent was removed under reduced pressure to afford the product, as hydrochloride salt: ^!H NMR (300 MHz, MeOD) δ 8.63 (s, 1H), 8.40 (dd,7 = 9.1, 2.7 Hz, 1H), 8.36 (s, 1H), 8.32 (d, J= 5.5 Hz, 1H), 4.46 (d, 7= 11.7 Hz, 1H), 3.78 - 3.53 (m, 1H),

2.41 (d, J =11.7 Hz, 1H), 2.28 (d, 7= 12.0 Hz, 1H), 2.18-1.98 (m, 2H), 1.69 (dd, 7= 23.6,

11.8 Hz, 2H), 1.56 - 1.28 (m, 2H); LCMS RT = 1.45 (M+H) 387.06.

General Scheme 71

(a) DBU, methyl 2-chlorooxazole-4-carboxylate, DMF, 75 °C (b) LiOH, THF

Formation of methyl 2-((12/, 35)-3-(5-fluoro-2-(5-fluoro-l-tosyl-l£6-pyrrolo[2,3b]pyridin-3-yl)pyrimidin-4-ylamino)cyclohexylaniino)oxazoIe-4-carboxylate (71a)

To a solution of (IS, 37/)-/71 -[5-fluoro-2-[5-fluoro-l-(p-tolylsulfonyl)pyrrolo[2,3b]pyridin-3-yl]pyrimidin-4-yl]cyclohexane-l,3-diamine, 44e, (0.089 g, 0.178 mmol) in DMF (1.5 mL) was added methyl 2-chlorooxazole-4-carboxylate (0.031 g, 0.195 mmol), followed by DBU (0.029 mL, 0.195 mmol). The reaction mixture was allowed to stir at room temperature overnight. The reaction was warmed to 75 °C and allowed to stir for 3 how’s. Added an additional 16 mg of the chlorooxazole ester and the reaction was heated at 75 °C overnight. The mixture was diluted into water and EtOAc. The layers were separated and the organic phase was washed with brine, dried over MgSO₄, filtered and evaporated to dryness. The crude residue was purified by silica gel chromatography (020%MeOH/CH₂Cl₂) to afford 28 mg of desired product: LCMS RT = 3.73 (M+l) 624.12.

Formation of 2-((1//, 3S)-3-(5-fluoro-2-(5-fluoro-17/-pyrrolo[2,3-b]pyriditi-3yl)py r imidin-4-ylamino)cy cloh exylamino) oxazole-4-ca r boxy lie acid (1144)

To a solution of methyl 2-(((12/, 3S)-3-[[5-fluoro-2-[5-fluoro-l-(p-tolylsulfonyl)pyiTolo[2,3-b]pyridin-3-yI]pyrimidm-4-yl]amino]cyclohexyl]-amino]oxazole-4-carboxylate, 71a, (0.028 g, 0.045 mmol) in THF (1 mL) was added LiOH (1 mL of 1 M solution, 1.000 mmol) and the reaction mixture was warmed to 130 °C via microwave irradiation. After heating and stirring for 20 minutes, the mixture was cooled to room temperature. All volatiles were removed under a stream of nitrogen and heat. The erode residue was suspended in MeOH and a few drops of trifluoroacetic acid were added to protonate molecule (solution occurs). The mixture was filtered and purified by reverse phase HPLC (5-95% CH3CN/H₂O) to afford 5 mg of the desired product as a TFA salt: *H NMR (300 MHz,

-354WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

MeOD) δ 8.83 (s, IH), 8.67 - 8.09 (m, 4H), 2.67 (s, 3H), 2.18 (m, 5H), 1.34 (d, J= 29.6 Hz, 3H); LCMS RT = 1.78 (M+l) 456.07.

General Scheme 72

(a) Nall CO-,, Br₂, H₂O (b) NaOH (c) TMSC1, MeOH (d) sodium methoxide, MeOH, 150 ^L'C (e) sodium borohydride, MeOH (f) ethyl 2-(tert-butoxycarbonylamino)-2-oxo-acetate, DEAD, PPh₃, 85 °C (g) NaOH, MeOH (h) trifluoroacetic acid, CH₂C1₂, IN HCl/ether(i) 5-fluoro-3-(5-fluoro-4-(methylsulfinyl)pyrimidin-2yl)-l-tosyl-lH-pyrrolo[2,3-b]pyridine, 'Pr+IEt, THF (j) lithium hydroxide, THF (k) DPPA, Et₃N, pyrrolidine

Formation of 6-bromohexahydro-2H-3,5-methanocyclopenta[b]furan-2-one (72a)

To a solution of bicyclo[2.2.1]hept-5-ene-3-carboxylic acid (25.0 mL, 204.3 mmol) in NaHCO₃ (51.5 g, 612.9 mmol) in water was added bromine (32.7 g, 204.3 mmol) dropwise at 0 °C. The solution was stirred for 1 hour and extracted with ether, and the organic phase was washed successively with 1 N Na₂S₂SO₃ solution and brine, and the organic phase was then dried (Na₂SO₄), filtered and concentrated in vacuo to afford 30 g of crude product that was used without further purification.

Formation of 6-oxonorbornane-2-carboxylic acid (72b)

6-bromohexahydro-2H'-3,5-methanocyclopenta[b]furan-2-one, 72a, (28.0 g, 129.0 mmol) was treated with NaOH (258.0 mL of 2 M solution, 516.0 mmol) in H₂O (350 mL) for 2 hour at room temperature. The reaction mixture was acidified with cone. HCl, extracted with Et₂O. The organic phase was dried (Na₂SO₄), filtered and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (0-20% MeOH/CH₂Cl₂ gradient) to provide 16 g of 6-oxonorbomane-2-carboxylic acid.

Formation of Endo methyl 6-oxonorbornane-2-carboxylate (72c)

A solution of 6-oxonorbomane-2-carboxylic acid, 72b, (16.0 g, 103.8 mmol) in methanol (350.0 mL) was treated with TMSC1 (42.04 g, 49.11 mL, 387.0 mmol). The reaction mixture was stirred at room temperature overnight. Solvent was evaporated under reduced pressure and the crude product was purified by silica gel chromatography (10% EtOAc/hexanes) to provide 12 g of Endo methyl 6-oxonorbornane-2-carboxylate.

-355WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Formation of Exo methyl 6-oxonorbornane-2-carboxylate (72d)

Endo methyl 6-oxonorbornane-2-carboxylate, 72c, (3.5 g, 20.8 mmol) was heated in a sealed tube in sodium methoxide (2.1 mL of 2 M solution in methanol, 4.2 mmol) at 150 °C for 17 hours. The solvent was evaporated and the crude product was purified by silica gel chromatography (0-16% EtOAc/hexanes gradient) to afford 3.3 g of starting endo methyl 6oxonorbomane-2-carboxylate as the first fraction (PMA staining) and 4.0 g of the desired exo product as the second spot. The recovered starting material was treated with the same conditions again to generate another 1.0 g desired exo-product.

Formation of methyl 6-hydroxynorbornane-2-carboxylate (72e)

To a solution of exo methyl 6-oxonorbornane-2-carboxylate, 72d, (4.7 g, 27.9 mmol) in MeOH (50 mL) was added sodium borohydride (1.6 g, 41.9 mmol) in five portions at 0 °C. TLC showed completed conversion after 2 hours. Aqueous saturated NH₄C1 solution was added to quench the reaction. The MeOH was evaporated under reduced pressure and then the aqueous phase was extracted with EtOAc. The combined organic phases were washed with brine, dried over Na₂SO4, filtered and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (0-100% EtOAc/hexanes, Rf = 0.5 in 50% EtOAc/hexanes) to afford 3.96 g of the desired product: *H NMR (300 MHz, CDC13) δ 4.23 - 4.06 (m, 1H), 3.56 (s, 3H), 3.37 (s, 1H), 3.03 (dd, 7 = 8.9, 5.5 Hz, 1H), 2.41 (d, 7= 3.9 Hz, 1H), 2.13 (s, 1H), 1.93 - 1.69 (m, 2H), 1.63 - 1.42 (m, 1H), 1.34 (ddt, 7= 10.3, 3.2, 1.6 Hz, 1H), 1.20 (dd, 7= 10.4, 0.7 Hz, 1H), 0.77 (dt, 7= 12.6, 3.4 Hz, 1H).

Formation of methyl 6-(?V-(tert-butoxycarbonyl)-2-ethoxy-2-oxoacetamido)bicycle [2.2.1] heptane-2-carboxylate (72f)

To a cold (0 °C) solution of methyl 6-hydroxynorbornane-2-carboxylate, 72e, (3.2 g,

18.8 mmol) in THF (150 mL) was added ethyl 2-(tert-butoxycarbonylamino)-2-oxo-acetate (4.9 g, 22.6 mmol) and triphenylphosphine (5.9 g, 22.6 mmol) followed by dropwise addition of diisopropyl azodicarboxylate (4.5 g, 22.6 mmol). The reaction was then heated to 85 °C and maintained at that temperature for 2 days. The solvent was evaporated under reduced pressure and the crude product was purified by silica gel chromatography (0-100% EtOAc/hexanes gradient) to provide 6 g of methyl 6-(A^r-(tert-butoxycarbonyl)-2-ethoxy-2oxoacetamido)bicyclo[2.2.1]heptane-2-carboxylate: LCMS 392.34 (M+Na’); 1H NMR (300 MHz, CDC13) δ 4.26 (q, 7= 7.2 Hz, 2H), 4.08 (dt, 7= 14.3, 7.2 Hz, 1H), 3.62 (d, 7= 2.1 Hz, 3H), 2.72 (s, 1H), 2.42-2.26 (m, 2H), 2.08 - 1.80 (m, 2H), 1.80 - 1.51 (m, 3H), 1.45 (s, 9H), 1.38- 1.25 (m, 3H).

Formation of 6-(teri-butoxycarbonylamino)norbornane-2-carboxylic acid (72g)

To a solution of methyl 6-[tert-butoxycarbonyl-(2-ethoxy-2-oxoacetyl)amino]norbomane-2-carb oxy late, 72f, (0.80 g, 2.17 mmol) in methanol (20 mL) was added NaOH (4.33 mL of 2N solution, 8.66 mmol) at room temperature. The reaction mixture was stirred overnight. The mixture was diluted into 0.5 N HC1 in ice, and extracted twice with EtOAc. The combined organic phases were dried (Na₂SO4), filtered and concentrated in vacuo to afford 600 mg of desired product that was used without further purification

Formation of 6-aminobicyclo[2.2.1]heptane-2-carboxylic acid (72h)

A solution of 6-(tert-butoxycarbonylamino)norbomane-2-carboxylic acid, 72g , in dichloromethane (5 mL) was treated with trifluoroacetic acid (5 mL) for 1 hour at room temperature. The solvent was evaporated under reduced pressure and the resulting product

-356WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 was dissolved in 2 mL TFA and added to a stirring IN HCI in Et₂O solution. After stirring the mixture for 0.5 hour, the resulting precipitate was filtered and washed with dry Et₂O to give 6-aminobicyclo[2.2.1]heptane-2-carboxylic acid.

Formation of 6-(5-fluoro-2-(5-fluoro-l£f-pyrrolo[2,3-b]pyridin-3-yl)pyrimidm-4ylamino)bicyclo[2.2.1]heptane-2~carboxylic acid (72j)

To a solution of 5-fluoro-3-(5-fluoro-4-methylsulfinyl-pyrimidin-2-yl)-l-(ptolylsulfoiiyl)pyrrolo [2,3-b]pyridine (0.187 g, 0.417 mmol) and 6-aminobicyclo[2.2.1]heptane-2-carboxylie acid, 72h, (0.080 g, 0.417 mmol) in THF (3 mL) was added di isopropylethylamine (0.291 mL, 1.670 mmol). The reaction mixture was heated at 80 °C overnight. Aqueous LiOH (3 mL of 2M solution, 6.000 mmol) was added and the mixture was heated for another 7 hours. The mixture was diluted with MeOH, neutralized with trifluoroacetic acid, filtered and the resulting filrate was purified by preparatoiy HPLC chromatography to afford 50 mg of desired product.

Formation of /V-[6-[[5-fluoro-2-(5-fluoro-liT“pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4yl] amino] norbornan-2-yl] pyrrolidine-l-carboxamide (1045)

To a solution of 6-[[5-fluoro-2-(5-fluoro-l#-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4yl]amino]norbornane-2-carboxylic acid, 72j, (0.030 g, 0.078 mmol) in THF (0.375 mL) was added triethylamine (0.032 mL, 0.234 mmol) and (azido(phenoxy)phosphoryl)oxybenzene (0.018 mL, 0.085 mmol). The reaction mixture was heated to 95 °C for 2.5 hours, cooled down to 5 °C, and treated with pyrrolidine (0.010 mL, 0.117 mmol). The reaction was stirred for 3 days at room temperature. The reaction mixture was injected directly into a preparatoiy HPLC system for purification to provide the product as a racemic mixture. The single enantiomers were obtained by separation using SFC chiral purification to afford 5.7 mg of the desired product as well as 1.4 mg of the enantiomer.

General Scheme 73 .

(a) 'Ργ,ΝΕΙ,THF, reflux (b) IN LiOH, THF/H₂O, 130 °C, microwave

Formation of (17?, 2Λ, 35)-3-((5-fluoro-2-(5-fluoro-l-tosyl-177-pyrrolo[2,3-b]pyridin“3yl)pyrimidin-4-yl)amino)cycloheptane-l,2-diol(73b)

Aminodiol, 73a, was synthesized by following the literature procedure (JOC 2009, 74, 6735). Aminodiol (0.040 mg), diisopropylethylamine (0.054 mL, 0.310 mmol) and 5fluoro-3-(5-fluoro-4-methylsulfinyl-pyrimidin-2-yl)-l-(p-tolylsulfonyl)pyiTolo[2,3-b]pyridine (0.139 g, 0.310 mmol) in THF was refluxed overnight. The solution was concentrated in vacuo and purified by silica gel chromatography (0-100% EtOAc/CH₂Cl₂) to give 43 mg of desired product as a white solid: *H NMR (300 MHz, CDC13) δ 8.40 (q, J = 2.8 Hz, 2H), 8.22 (d, J= 1.8 Hz, IH), 8.08 - 7.94 (m, 3H), 7.20 (d, 7 = 10.1 Hz, 3H), 5.26 (d, 7= 4.9 Hz, IH), 4.21 - 3.99 (m, IH), 3.84 (s, IH), 3.75 - 3.57 (m, IH), 3.43 (t, 7= 8.7 Hz, IH), 2.73 (s, IH), 2.30 (s, 3H), 2.11 - 1.85 (m, 2H), 1.84 - 1.36 (m, 8H), 1.18 (s, 2H), 0.79 (dd, 7= 15.0,

6.8 Hz, 2H). LCMS (+ Η): M/Z = 530.29

Formation of (II?, 2R, 3S)-3-((5-fluoro-2-(5-fluoro-177-pyrrolo[2,3-b]pyridin-3-357WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 yl)pyrimidin-4-yI)amino)cycloheptane-l,2-diol (984)

LiOH (0.5 mL of IN solution, 0.5 mmoL) was added to (1R, 2R, 35)-3-((5-fluoro-2-(5fluoro-1 -tosyl-1 ff-py rrol o [2,3 -b]py ridin-3 -y l)py ri midin-4-y l)amino)cy cloheptane-1,2-diol, 73a, in THF (3 mL). The reaction mixture was heated in microwave at 130 °C for 40 minutes. HC1 (0.5 mL of 1.25 N solution in MeOH) and MeOH was added to the mixture. The solution was purified by preparative HPLC (McCN/HiO 10-70%) to give desired product as TFA salt. Neutralization and re-acidification with hydrogen chloride (IN in MeOH) afforded the desired product (28 mg) as a white solid (HC1 salt): ^]H NMR (300 MHz, MeOD) 5 8.52 (s, IH), 8.48 (d, J= 2.8 Hz, IH), 8.34 (s, IH), 8.28 (d, J= 5.6 Hz, IH), 4.62 ·4.35 (m, IH), 3.65 (m, 2H), 2.11 - 1.43 (m, 8H); ¹⁹F NMR (282 MHz, MeOD) δ -137.38 - 137.51 (m, IH), -156.06 (d, J= 5.6 Hz, IH); LCMS (+ Η): M/Z = 376.28.

General Scheme 74

74a

Cbz''

(a) Cui, 2-(2- inctliylpropanoyl)cyclohexanone, DMF (b) H₂, Pd/C, MeOH (c) 5-fluoro-3-(5-fluoro-4-nietliylsulfinylpyriinidin-2-yl)-l-(p-tolylsuHbnyl)pyrrolo[2,3-bJpyridinc (d) IN LiOH, THF/H_:O, 130 “C microwave

Formation of benzyl ((15, 31?)-3-(pyrazin-2-ylamino)cyclohexyl)carbamate (74a)

A suspension of Cui (0.006 g, 0.030 mmol), benzyl jV-[(15, 3R)-3-aminocyclohexyl]carbamate, 18e, (0.075 g, 0.302 mmol) and cesium carbonate (0,197 g, 0.604 mmol) in DMF was evacuated and refilled with nitrogen multiple times. 2-iodopyrazine (0.036 mL, 0.362 mmol) and 2-(2- methylpropanoyl)cyclohexanone (0.020 mL g, 0.121 mmol) were then added and the reaction was stirred at room temperature overnight. The reaction was diluted into ethyl acetate and aqueous saturated sodium bicarbonate. The organic phase was separated, dried (MgSO₄), filtered and concentrated in vacuo. The crude residue was purified by silica gel chromatography (0-10% MeOH/CHiCL) to afford 40 mg of the desired product as yellow solid.

Formation of (11?, 35)-/Vl“(pyrazin-2-yl)cycIohexane-l,3-diamine (74b)

To a solution of benzyl 7/-((15, 3R)-3-(pyrazin-2-ylamino)cyclohexyl]carbamate, 74a, (0.040 g, 0.123 mmol) in methanol (10 mL) was added 10% Pd/C (0.043 g,

0.040 mmol) and the resulting suspension was stirred under an atmosphere of hydrogen for three hours until LCMS indicated completion of the reaction. The solution was filtered through a bed of celite and concentrated in vacuo to give a yellow solid, which was used without further purification.

Formation of (15, 3.ff)-/Vl-(5-fluoro-2-(5“fluoro-l-tosyl-lZ/-pyrrolo[2,3-b]pyridin~3“

-358WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 yl)py ri midin-4-yl)-A3-(py razin-2-yl) cyclohexane-1,3-diamine (74c)

A solution of (Iff, 35)vVl-pyrazin-2-ylcyclohcxanc-I,3-diaminc 74b, diisopropylethylamine (0.30 mmol) and 5-chloro-3-(5-fluoro-4-methyIsulfinyl-pyrimidin-2yl)-l-(p-tolylsulfonyl)-pyiTolo[2,3-b]pyridine (0.06 g, 0.13 mmol) in THF (3 mL) was refluxed overnight. The mixture was then concentrated in vacuo and the resulting residue was purified by silica gel chromatography (0-20% McOH/CHiCL gradient) to afford 39 mg of desired product: NMR (300 MHz, CDC13) δ 8.91 - 8.72 (m, IH), 8.50 (d, J= 11.8 Hz, IH), 8.38 (t, J= 7.5 Hz, IH), 8.06 (dd, 7= 14.8, 5.9 Hz, 3H), 7.88 (d, 7= 1.4 Hz, IH), 7.82 (s, IH), 7.62 (t, 7= 6.8 Hz, IH), 7.33 (dd, 7= 16.6, 7.1 Hz, 3H), 5.91 (s, IH), 4.27 (s, IH),

3.98 (t, 7= 11.3 Hz, IH), 2.59 (d, 7 = 12.0 Hz, IH), 2.39 (s, 3H), 2.34 - 2.09 (m, 2H), 1.99 (d, 7= 14.0 Hz, IH), 1.72 (dd, 7= 26.6, 13.1 Hz, IH), 1.48 - 1.08 (m, 4H).

LCMS (+H): M/Z = 593.25

Formation of (15, 3ff)-M-(5-fluoro-2-(5-fluoro-lff-pyrrolo[2,3-b]pyridin-3yl)pyrimidin-4-yl)-/V3-(pyrazin-2-yl)cyclohexane-l,3-diamine (985)

LiOH (0.3 mL of IN solution, 0.3 mmoL) was added to a solution of (15, 3ff)-7Vl-(5fluoro-2-(5-fluoiO-l-tosyl-177-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)-jV3-(pyrazin-2yl)cyclohexane-l,3-diamine, 74c, (35 mg) in THF (3 mL) and the reaction was heated in the microwave at 130 °C for 40 minutes. A solution of HC1 (0.5 mL of a 1.25N in MeOH) was added and the resulting solution was purified by Gilson HPLC (McCN/'HiO 10-70% in 8 mins) to give pure TFA salt product. Neutralization and re-acidification with hydrogen chloride (1.25N in MeOH) afforded 23 mg of the HC1 salt of the desired product as a light yellow solid: ^lH NMR (300 MHz, MeOD) δ 8.76 (d, 7 = 2.4 Hz, IH), 8.63 (s, IH), 8.41 (d, 7 = 2.3 Hz, IH), 8.36 (d, 7= 5.7 Hz, IH), 8.16 (s, IH), 7.96 (s, IH), 7.76 (s, IH), 4.51 (m, 7=

11.8 Hz, IH), 4.16-3.92 (m, IH), 2.35-2.14 (m, 2H), 2.09 (m,7= 13.8 Hz, IH), 1.63 (d,7 = 11.8 Hz, 4H); ⁱ⁹F NMR (282 MHz, MeOD) δ -155.25 (s, IH); LCMS ¢+ Η): M/Z = 439.24.

General Scheme 75

-359WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

(a) NaBH₃, MeOH (b) 5-fluoro-3-(4,4,5,5-telramethyl··! ,3,2-dioxaboiOlan-2-yl)-l-tosyl-lH-pynOlo|'2,3b]pyridine, 2-Mc-THF, water, K₃PO₄, Pd(PPh₃)4, XPhos, Tris(dibcnzylidcncacetone)dipalladiuin,reflux (c) bis(2,5-dioxopyrrolidin-l-yl) carbonate, 'Pr₂NEt, CH₃CN (d) (3/?)-3-fluoropyrrolidine,, “Pr₃NEt, CH₃CN (e) 2N LiOH, THF

Formation of (1R, 35)-3-((2-chloro-5-fluoropyrimidin-4-yl)amino)cyclohexanol (75a)

Mixed (35)-3-[(2-chloro-5-fluoro-pyrimidin-4-yl)amino]cyclohexanone, 18e, (1.05 g,

4.31 mmol) in MeOH (20 mL) and dichloromethane (10 mL) and cooled to -78 °C using an external dry-ice/acetone bath and monitored with an internal thermometer. After 30 minutes, NaBH₄ (0.16 g, 4,31 mmol) was added in one portion and continued to stir, (slight exotherm) and then cooled back down to -78°C. The reaction was monitored by HPLC for consumption of starting material as it was allowed to warm to room temperature overnight. The reaction was diluted with brine and EtOAc. The organic phase was dried (MgSO₄), filtered and concentrated in vacuo. The resulting residue was purified by silica gel chromatography to afford l.Og of a colorless foamy solid: LCMS method m201:10-90 CH₃CN/H2O, formic acid modifier, 5 minutes, (Cl8); RT = 2.08min, MH+ = 246.21.

Formation of (1R, 3S)-3-((5-fluorO“2-(5-fluoro-l-tosyl-lif-pyrrolo[2,3-b]pyridin”3yl)pyrimidin-4-yl)amino)cyclohexanol (75b)

K₃PO₄ (2.59 g, 12.21 mmol) in water (6 mL) and 2-Mc-THF (20 mL) was purged with a flow of nitrogen for 30 min. Added (1R,3 5)-3-((2-chloro-5-fluoro-pyrimidin-4yl)amino]cyclohexanol, 75a, (1.00 g, 4.07 mmol) and 5-fhioro-3-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)-l-tosyl-lH-pyrrolo[2,3-b]pyridine, 44a, (2.03 g, 4.88 mmol) and then purged with nitrogen for another 15 min. The reaction was then heated to 70 °C and then charged with Tris(dibenzylideneacetone)dipalladium (0.07 g, 0.08 mmol) and X-Phos (0.14 g, 0.28 mmol) under nitrogen. (Note Color changed from purple to hunter green). The reaction was heated to reflux for 1 h and 20 min. The reaction was cooled slowly to room

-360WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 temperature overnight. The mixture was treated with 100 mL of brine and 100 mL of ethyl acetate and separated the two layers. The aqueuous phase was extracted again with EtOAc (50 mL). Combined organic layers and passed through a plug of fluoracil, dried over NaoSOj, decanted and removed the solvent by rotoevaporation to give crude product which was then purified by silica gel chromatography (25-50% EtOAc/Hexanes) to afford the desired product.

2,5-dioxopyrrolidin-l-yl ((15, 32/)-3-((5-fluoro-2-(5-fluoro-l-tosyl-IH-py rrolo [2,32>]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl) carbonate (75c)

To a solution of (Iff, 35)-3-((5-fluoro-2-(5-fluoro-l-tosyl-l/7-pyrrolo[2_>3-Z?]pyridin-3yI)-pyrimidin-4-yI)amino)cyclohexanol, 75b, (0.50 g, 1.00 mmol) and N,Ndiisopropylethylamine (1.40 mL, 10.01 mmol) was added bis(2,5-dioxopyrrolidin-l-yl) carbonate (1.28 g, 5.01 mmol) in CH₃CN (4 mL) and stirred at room temperature overnight. Used reaction mixture as is in next reaction. Using LCMS method m201:10-90 CH3CN/H2O, formic acid modifier, 5 minutes, (Cl8); RT = 3.73min, MH+ = 641.43 (strong).

Formation of (1/)-(15, 3ff)-3“((5-fluoro-2-(5-fluoro-l-tosyl-177-pyrrolo[2,3-Z»]pyridin-3yl)pyrimidin-4-yl)amino) cyclohexyl 3-fluoropyrrolidine-l-carboxy late (75d)

To (2,5-dioxopyrrolidin-l-yl) [(Iff, 35)-3-[[5-fluoro-2-[5-fluoro-l-(ptolylsulfonyl)pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-4-yl]amino]cyclohexyl] carbonate, 75c, (0.125 g, 0.195 mmol) already in acetonitrile was added (3ff)-3-fluoropyrrolidine (0.445 g, 4.991 mmol) and the reaction mixture was stirred at room temperature for 20 hours; The reaction was monitored by HPLC until no more starting material was remaining. The reaction mixture was concentrated in vacuo and was earned on into the next reaction without further purification.

Formation of (5)-(15, 3ff)-3-((5-fluoro-2-(5-fiuoro-liZ-pyrrolo[2,3-/;]pyridin-3-yl)py rimidin-4-yl)a mino) cycloh exyl 3 -flu or opy r rolidine-l-ca rb oxylate (1151)

To a solution of erode (ff)-(lS, 3ff)-3-((5-fluoro-2-(5-fluoro-l-tosyl-l/Z-pyrrolo[2,3i>]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl 3-fluoropyrrolidine-1 -carboxylate, 75d, (0.119 g, 0.019mmol) in THF (2mL) was added 5mL 2N LiOH (10 mmol). The reaction mixture was heated at 50 °C for 2 hours. The mixture was diluted into aqueous saturated ammonium chloride (2mL), and extracted with EtOAc (2 x lOmL), dried over sodium sulfate, filtered and concentrated in vacuo. The resulting residue was purified on the semi-prep HPLC, 10-70% CH₃CN/H₂O; Three runs; homogeneous fractions were combined and the solvent removed under a stream of nitrogen and then removed residual solvent on rotoevaporator to afford 74 mg of the desired product: LCMS RT = 2.15 min (M+H) 461.51.

General Scheme 76

-361WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

76d

76c

(a) Rh/AI₂O₃, H₂O,10O 'C, 105 atm H₂, 19 hrs (b) 2,4-dichloro-5-fluoropyrimidine, IPA, MeCN, room temperature (c) GDI. ^!Pr₂NEt, (S)-3-fluoropyrro!idine, THF, RT, 2 days (d) 5-fluoro-3-(4,4,5,5tetramethyl-1_l3,2-dioxaboro!an-2-yl)-1-tosyl-1/-/-pyrrolo[2,3-ib]pyridine, MeTHF, K₃PO₄, X-Phos, Pd₂dba₃, H₂O, microwave, 120 °C, 20 minutes (e) 25% NaOMe in MeOH, RT, 30 min. (f) SFC separation

Formation of 5-methylcyclohexane-l,3-diamine (76a)

The 3-methyl-5-nitiOaniline (10.0 g, 65.7 mmol) was added to water (146 ml) and treated with 6N HCl (22.5 ml, 135.0 mmol) and 5% Rhodium on Alumina (1,9 g, 0.9 mmol). The mixture was charged to 105 atm of Hydrogen and heated to 100 °C for 19 hours. The reaction was cooled and filtered through celite and concentrated to dryness to give 5mcthylcyclohexane-l,3-diaminc dihydrochloride (12.9 g, 64.5 mmol) as a racemic mixture. The salt (6.5 g, 32,5 mmol) was dissolved in isopropyl alcohol (100 ml) and acetonitrile (100 ml) and treated with potassium carbonate (25.2 g, 182.0 mmol). The mixture was stirred at room temperature overnight, filtered thru celite, and concentrated in vacuo to afford 2.2 g of 5-methylcyclohexane-1,3-diamine as a racemic brown oil: LCMS RT = 0.41 (M+l) 128.9.

Formation of'V’-^-chloro-S-fluoropyriinidinM-ylJ-S-methylcyclohexane-lA-diamine (76b)

To a solution of 5-methylcyclohexane-l,3-diamine, 76a, (2.2 g, 17.2 mmol) in isopropyl alcohol (40 ml) and acetonitrile (40 ml) was added 2,4-dichloro-5-fluoropyrimidine (1.4 g, 8.6 mmol). The mixture was stirred at room temperature overnight, concentrated to dryness, and purified on silica gel eluted with 1-20% methanol/dichloromethane, to give 0.6 g of racemic A/¹-(2-chloro-5-fluoropyrimidin-4-yl)-5-methylcyclohexane-l,3-diamine: ^lH NMR (300 MHz, MeOD) δ 7.85 (d, 7= 3.5 Hz, IH), 4.07 (ddd, J = 11.9, 7.9, 4.1 Hz, IH),

3.54 (qd, J = 11.3, 4.2 Hz, IH), 2.82 (tt, J = 11.4, 3.7 Hz, IH), 2.16 (dd, 7= 15.0, 13.0 Hz, IH), 1.89 (t, 7= 13.4 Hz, 2H), 1.50 (dd, 7= 76.0, 21.9 Hz, 2H), 1.10 (dt, 7= 17.9, 9.0 Hz, IH), 0.99 (dd, 7= 8.5, 5.0 Hz, 3H), 0.81 (ddd, 7= 23.8, 12.0, 8.2 Hz, IH); LCMS RT =-- 1.24 (M+l) 259.1.

Formation of (35)-A^r-(3-((2-chloro-5-fluoropyrimidin-4-yl)amino)-5-methylcyclohexyl)-

3-fluoropyrrolidine-l-carboxamide (76c)

To a solution of N¹-(2-chloro-5-fluoropyrimidin-4-yl)-5-methylcyclohexane-l,3diamine, 76b, (0.14 g. 0.54 mmol) in THF (2.5 ml) was added carbonyldiimidazole (0.10 g, 0.60 mmol) and ‘Pr₂NEt (0.28 mL, 1.62 mmol). The reaction was aged 2 hours at room temp, and treated with (5)-3-fluoropyrrolidine hydrochloride (0.07 g, 0.54 mmol). The reaction was stirred at room temperature for 2 days and then concentrated to dryness to afford 202 mg of (35)-/V-(3-((2-chloro-5-fluoiOpyrimidin-4-yl)amino)-5-mcthylcyclohexyl)-3fluoropyrrolidine-l-carboxamide which was used without purification: LCMS RT = 2.46 (M+l) 374.2, (M-l) 372.

-362WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Formation of (35)~3-fluoro-/V-(3-((5-fluoro-2-(5-fluoro-l-tosyl-l/Z“pyrrolo[2,3-A]pyridin³-yl)py^rimidin-4-yl)amino)-5-methylcyclohexyl)pyrrolidine-l-carboxamide (76d)

To a solution of (35)-?/-(3-((2-chloiO-5-fluoropyrimidin-4-yl)amino)-5-methylcyclohexyI)-3-fluoropyrrolidine-1-carboxamide, XXc, (0.101 g, 0.270 mmol) in 2methyltetrahydrofuran (4 ml) was added potassium phophate (0.090 g, 0.950 mmol) in water (1.2 ml), x-phos (0.027 g, 0.057 mmol), and Pd₂dba₂ (0.015 g, 0.016 mmol). The reaction was heated in a microwave at 120 °C, for 20 minutes, and the organic phase was filtered thru a pad of florisil and the filtrate concentrated in vacuo. The crude was purified on silica gel eluted with EtOAc to afford 127 mg of racemic (3S)-3-fluoro-/V-(3-((5-fhioro-2-(5-fluoro-ltosyl-l//-pyrrolo[2,3-/j]pyridin-3-yl)pyrimidin-4-yl)amino)-5-methylcyclohexyl)pyrrolidine1-carboxamide: LCMS RT = 3.58 (M+l) 628.3, (M-l) 626.

Formation of (S)-3-iluoro-/V-((15, 3S, 55)-3-((5-fluoro-2-(5-fluoro-1//-pyrrole [2,30]pyridin-3-yl)pyrimidin-4-yl)amino)-5-methylcyclohexyl)pyrrolidine-l-carboxamide (76e)

To a solution of (3S)-3-fluoro-A-(3-((5-fluoro-2-(5-fluoro-l-tosyl-17i-pyrrolo[2,3Z?]pyridin-3-yl)pyrimidin-4-yl)amino)-5-methylcyclohexyl)pyrrolidine-l-carboxamide, 76d, (0.090 g, 0.143 mmol) in MeOH (2.5 ml) was added 25% sodium methoxide in methanol (2 ml). The reaction was stirred at room temperature for 30 minutes and quenched with aqueous saturated NH4CI. The methanol was removed in-vacuo and the residue was extracted with EtOAc and water. The organics were dried over sodium sulfate and concentrated to dryness. The resulting crude racemate was purified by SFC separation on a chiral column. The second peak was concentrated in vacuo to afford 32 mg of enantiomeric ally pure (5)-3-fluoro-A((15, 35, 55)-3-((5-fluoro-2-(5-fluoro-l//-pyrrolo[2,3-0]pyridin-3-yl)pyrimidin-4-yl)amino)5-methylcyclohexyl)pyrrolidine-l-carboxamide as a white solid: LCMS RT = 1.89 (M+l) 474.2, (M-l) 472.4; SFC RT = 3.2 min., 15% MeOH @ 5mL/min on an ODH (4.6*100), 100 bar, 35C, 220nm; ^!H NMR (300 MHz, DMSO) δ 12.26 (s, IH), 8.41 (dd, / = 9.9, 2.8 Hz, IH), 8.32 - 8.18 (m, 2H), 8.14 (d, .7= 4.0 Hz, IH), 7.53 (d, / = 7.6 Hz, IH), 6.02 (d, .7= 7.9 Hz, IH), 5.28 (d, / = 53.6 Hz, IH), 4.35 -4.00 (m, IH), 3.81 - 3.09 (m, 12H), 2.24 - 1.77 (m,/=41.2, 26.1, 10.6 Hz, 4H), 1.74- 1.51 (m, IH), 1.51 - 1.22 (m, IH), 1.14-0.70 (m, 4H).

General Scheme 77

(a) (/?)-nopinone, O-methylhydroxylamine hydrochloride, pyridine, EtOH (b) nBuLi, THF, -78 °C, ethylformate (c) NaBIL, MeOH (d) TBDPSC1, imidazole, DMF (e) BII3-THF, THF, 75 °C (f) 5-chloro-3(5-lluoro-4-(methyIsuliinyl)pyrimidin-2-yl)-l -tosyl-lH-pyrrolo[2,3-b]pyridine, 'Pr₂NEt, 75 °C (g) HCI, dioxane

-363WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

Formation of (IR, 55)-6,6-dimethylbicyclo[3.1.1]heptan-2-one O-methyl oxime (77a)

To a solution of (IS, 5R)-6,6-dimethylnorpinan-2-one (3.09 g, 22.35 mmol) in ethanol (70 mL) was added (9-methylhydroxylamine hydrochloride (2.05 g, 24.59 mmol) and pyridine (1.29 mL, 15.92 mmol). Heated reaction mixture to 80 °C for 4 hours. Removed solvent under reduced pressure. Diluted residue with IN HC1 and extracted twice with ether. The combined organic phases were washed with aqueous saturated NaHCOs, dried (MgSO₄), filtered, concentrated in vacuo to afford 3.36 g of a colorless oil (mixture of oxime isomers) that was used without further purification.

Formation of (IR, 35, 5R)-2-(methoxyimino)-6,6-dimethylbicyclo[3.1.1]heptane-3carbaldehyde (77b)

To a cold (-78 °C) solution of (IR, 5S)-6,6-dimethylbicyclo[3.1.1]heptan-2-one Omethyl oxime, 77a, (1.27 g, 7.59 mmol) in THF (33 mL) was added dropwise a solution of nbutyllithium (3.34 mL of 2.5 M solution in hexanes, 8.35 mmol). After stirring the mixture 20 min at -78 °C ethyl formate (0.61 mL, 7.59 mmol) was added dropwise. The reaction mixture was stirred at -78 °C for 3 hours and then quenched by pouring into aqueous saturated NaHCO₃ solution. The mixture was extracted with EtOAc. The organic phase was dried (MgSO4), filtered and concentrated in vacuo. The resulting residue was purified via silica gel chromatography (0-20% EtOAc/Hexanes gradient) to afford 810 mg yellow oil: LCMS RT = 3.54 (M+H) 196.28.

Formation of (IR, 35, 5R)-3-(hydroxymethyl)-6,6-dimethylbicyclo[3.1.1]heptan-2-one Omethyl oxime (77c)

To a solution of (IR, 35, 5R)-2-(methoxyimino)-6,6-dimethylbicyclo [3.1.1]heptane3-carbaldehyde, 77b, (0.70 g, 3.58 mmol) in methanol (15 mL) was added sodium borohydride (0.16 g, 4.30 mmol). After stirring at room temperature for 30 minutes, the reaction was diluted into aqueous saturated NaHCO₃ solution and extracted with EtOAc. The organic phase was dried (MgSO₄), filtered and concentrated in vacuo. The resulting residue was purified via silica gel chromatography (0-50% EtOAc/Hexanes gradient) to afford 330 mg of the desired alcohol as mixture of oxime isomers.

Formation of (IR, 35, 5R)-3-(((tert-butyldiphenylsiIyl)oxy)methyl)-6,6-dimethyIbicyclo[3.1.1]heptan-2-one O-methyl oxime (77d)

To a solution of (IR, 35, 5R)-3-(hydroxymethyl)-6,6-dimethylbicyclo[3.1.1]-heptan2-one O-methyl oxime, 77c, (0.32 g, 1.60 mmol) in DMF (6 mL) was added tertbutylchlorodiphenylsilane (0.55 g, 2.00 mmol) and imidazole (0.22 g, 3,20 mmol). The reaction mixture was stirred at room temperature for 18 hours. The reaction was diluted into aqueous saturated NH4CI solution and extracted twice with EtOAc. The combined organic phases were washed twice with brine, dried (MgSO₄), filtered and concentrated in vacuo. The resulting residue was purified via silica gel chromatography (0-15% EtOAc/Hexanes gradient) to afford 200 mg of one oxime isomer and 197 mg of second oxime isomer.

Formation of (IR, 35, 5R)-3-(((tert-butyldiphenylsilyI)oxy)methyl)-6,6-dimethylbicyclo[3.1 .l]heptan-2-amine (77e)

To a solution of (IR, 35, 5R)-3-(((tert-butyldiphenylsiIyl)oxy)methyl)-6,6-dimethylbicyclo[3.1.1]heptan-2-one O-methyl oxime, 77d, (0.20 g, 0.46 mmol) in THF (3 mL) was added borane-THF (1.38 mL of 1 M solution, 1,38 mmol). The reaction was heated to 75 °C for 18 hours. The mixture was diluted into IN NaOH (50 mL) and extracted twice with EtOAc. The combined organic phases were dried (MgSO₄), filtered and concentrated in

-364WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018 vacuo to afford 178 mg of a colorless oil that was used without further purification: LCMS RT = 2.53 (M+H) 408.54.

Formation of 7V-((12?, 25, 35, 55)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-6,6dimethylbicyclo[3.1.1]heptan-2-yl)-2-(5-chloro-l”tosyI-l/9-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-amine (77f)

To a solution of (17?, 35, 55)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-6,6-dimethylbicyclo[3.I.l]heptan-2-amine, 77e, (0.20 g, 0.46 mmol) and 5-chloro-3-(5-fluoro-4(methylsulfinyl)pyrimidin-2-yl)-l-tosyl-lH-pyrrolo[2,3-b]pyridine (0.14 g, 0.30 mmol) in DMF (1.5 mL) was added diisopropylethylamine (0.11 mL, 0.61 mmol). The reaction was heated to 75 °C for 18 hours. The mixture was diluted into aqueous saturated NH4CI solution and extracted twice with EtOAc. The combined organic phases were washed twice with brine, dried (MgSO4), filtered and concentrated in vacuo. The crude residue was purified via silica gel chromatography (0-5% MeOH/CH₂Cl₂ gradient) to afford 78 mg of the desired product.

Formation of ((15, 25, 35, 55)-2-((2-(5-chloro-l/f-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-yl)amino)-6,6-dimethylbicyclo[3.1.1]heptan-3-yl)methanol (1229)

To a solution of 79-((15, 25, 35, 55)-3-(((tert-butyldiphenyIsilyl)oxy)methyl)-6,6dimethylbicyclo[3.1.1]heptan-2-yl)-2-(5-chloro-l-tosyl-lif-pyrrolo[2,3-b]pyridin-3-yl)-5fluoropyrimidin-4-amine, 77f, (0.037 g, 0.046 mmol) in acetonitrile (1.1 mL) was added HC1 (0.221 mL of a 4 M solution in dioxane, 0.883 mmol). The mixture was heated to 70 °C for 18 h, during which a precipitate formed. The reaction was concentrated in vacuo and triturated three times with CH3CN to afford 4 mg of the desired product as a white solid: 'H NMR (300.0 MHz, MeOD) δ 8.72 - 8.64 (m, 1H), 8.39 (s, 1H), 8.32 (d, 7= 2.3 Hz, 1H), 8.21 (d, 7= 5.2 Hz, 1H), 4.71 (d, 7= 6.3 Hz, IH), 3.67 - 3.57 (m, 2H), 2.33 - 2.26 (m, 1H), 2.10 (m, IH), 1.78 - 1.70 (m, IH), 1.28 - 1.25 (m, 7H) and 1.19 (s, 3H) ppm; LCMS RT = 3.13 (M+H) 416.42.

Influenza Antiviral Assay [001174] Antiviral assays were performed using two cell-based methods:

A 384-well microtiter plate modification of the standard cytopathic effect (CPE) assay method was developed, similar to that of Noah, et al. (Antiviral Res. 73:50-60, 2006). Briefly, MDCK cells were incubated with test compounds and influenza A virus (A/PR/8/34), at a low multiplicity of infection (approximate MOI=0.005), for 72 hours at 37°C, and cell viability was measured using ATP detection (CellTiter Gio, Promega Inc.). Control wells containing cells and vims show cell death while wells containing cells, virus, and active antiviral compounds show cell survival (cell protection). Different concentrations of test compounds were evaluated, in quadruplicate, for example, over a range from approximately 20 μΜ to 1 nM. Dose-response curves were prepared using standard 4-parameter curve fitting methods, and the concentration of test compound resulting in 50% cell protection, or cell survival equivalent to 50% of the uninfected wells, was reported as the IC50.

-365WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

A second cell-based antiviral assay was developed that depends on the multiplication of virus-specific RNA molecules in the infected cells, with RNA levels being directly measured using the branched-chain DNA (bDNA), hybridization method (Wagaman et al, J. Virol Meth, 105:105-114,2002). In this assay, cells are initially infected in wells of a 96well microtiter plate, the virus is allowed to replicate in the infected cells and spread to additional rounds of cells, then the cells are lysed and viral RNA content is measured. This assay is stopped earlier that the CPE assay, usually after 18-36 hours, while all the target cells are still viable. Viral RNA is quantitated by hybridization of well lysates to specific oligonucleotide probes fixed to wells of an assay plate, then amplification of the signal by hybridization with additional probes linked to a reporter enzyme, according to the kit manufacturer’s instructions (Quantigene 1.0, Panomics, Inc.). Minus-strand viral RNA is measured using probes designed for the consensus type A hemagglutination gene. Control wells containing cells and virus were used to define the 100% viral replication level, and dose-response curves for antiviral test compounds were analyzed using 4-parameter curve fitting methods. The concentration of test compound resulting in viral RNA levels equal to that of 50% of the control wells were reported as EC50.

Virus and Cell culture methods: Madin-Darby Canine Kidney cells (CCL-34 American Type Culture Collection) were maintained in Dulbecco’s Modfied Eagle Medium (DMEM) supplemented with 2mM L-glutamine, l,000U/ml penicillin, 1,000 ug/ml streptomycin, 10 mM HEPES, and 10% fetal bovine medium. For the CPE assay, the day before the assay, cells were suspended by trypsinization and 10,000cells per well were distributed to wells of a 384 well plate in 50 μΐ. On the day of the assay, adherent cells were washed with three changes of DMEM containing lug/ml TPCK-treated trypsin, without fetal bovine serum. Assays were initiated with the addition of 30 TCIDso of virus and test compound, in medium containing 1 pg/ml TPCK-treated trypsin, in a final volume of 50 μΐ. Plates were incubated for 72 hours at 37°C in a humidified, 5% CO? atmosphere. Alternatively, cells were grown in DMEM + fetal bovine serum as above, but on the day of the assay they were trypsinized, washed 2 times and suspended in serum-free EX-Cell MDCK cell medium (SAFC Bioscienccs, Lenexa, KS) and plated into wells at 20,000 cells per well. These wells were then used for assay after 5 hours of incubation, without the need for washing.

Influenza virus, strain A/PR/8/34 (tissue culture adapted) was obtained from ATCC (VR-1469). Low-passage virus stocks were prepared in MDCK cells using standard methods (WHO Manual on Animal Influenza Diagnosis and Surveillance, 2002), and TCID50

-366WO 2010/148197

PCT7US2010/038988

2018200219 11 Jan 2018 measurements were performed by testing serial dilutions on MDCK. cells in the 3 84-well CPE assay format, above, and calculating results using the Karber method.

Mean IC50 values (mean all) for certain specific compounds are summarized in Tables 1-5:

A: ICsofmean all) < 5 μΜ;

B 5μΜ < IC50 (mean all) < 20 μΜ;

C ICsotmean all) > 10 μΜ;

D IC50 (mean all) > 20 μΜ;

E ICso(mean all) >3.3 μΜ.

Mean EC50 values (mean all) for certain compounds are also summarized in Tables 1-5:

A: EC50 (mean all) < 5 μΜ;

B 5μΜ < ECso(mean all) <10 μΜ;

C EC50 (mean all) > 3.3 μΜ;

D ECsofmean all) > 1θ μΜ.

As can be seen in Tables 1-5, a lot of compounds of the invention showed positive effect on the survial of the A/PR/8/34 infected cells, and inhibitory effect on the replication of A/PR/8/34 influenza virus. Exemplary IC50 and EC50 values are as follows: Compound 428 had 0.03 μΜ of IC50; Compound 895 had 0.0008 μΜ of IC50 and 0.001 μΜ of EC50; Compound 833 had 5.6 μΜ of ICsoand 3.5 μΜ of ECsoTable 1: IC50, ECso, NMR and LCMS Data of Compounds of FIG. 3:

Compound Nos.	IC50	EC50	LCMS Plus	LCMS_ RT	NMR
1		A	411.38	2.69	H NMR (300.0 MHz, DMSO) d 12.32 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.18 - 8.16 (m, 2H), 7,37 (d, J = 7.6 Hz, 1H), 6.33 (t, J =4.4 Hz, 0.25H), 6.15 (t, J = 4,3 Hz, 0.5H), 5.96 (t, J = 4.3 Hz, 0.25H), 4.22 (d, J = 7.6 Hz, 1H), 3.13 (d, J = 11.2 Hz, 1H), 2.88 (m, 1H), 2.81 (ddd, J = 15.5, 4.2, 4.2 Hz, 2H), 2.30 - 2.20 (m, 2H), 1.98 (m, 1H), 1.72 -1.61 (m, 2H) and 1.49 -1.36 (m, 1H) ppm
2			475	3.58	1H NMR (CD3OD): 1.1-1.3 (3H, m), 1.40-1.50 (3H, m), 1.55-2.10 (4H, m), 2.40-2.45 (1H, m), 3.3-3.5 (2H, m), 3.754.10 (4H. m). 5.4-5.5 (1H. m), 8.05-8.20 (3H, m), 8.70-8.80 (1H, m)
3			446.14	2.96	1H NMR (DMSO): 1.39 (4H, m), 1.542 (1H, m), 1.74 (2H, m), 2.33 (1H, m), 2.61 (1H, m), 2.88 (1H, m), 4.18 (1H, m), 4.37 (1H, m), 5.21 (1H, m), 6.84 (2H, d), 7.33 (2H, d), 7.60 (2H, m), 8.23 (3H, m), 8.63 (1H, d), 12.33 (1H, s)
4	D		327	1.2	500MHz, MeOD-d4: 8.83(dd,1H), 8.45(s,1H), 8.42(dd,1H), 8.32(d,1H),7.65(d,2H), 7.42(dd,1H), 7.18(d,2H), 4.55(m,1H), 3.4(m,1H), 2.3(s,3H),2.2(m,2H), 1.95(m,2H), 1.5(m,4H)
5			385.3	1.74
6			401.3	1.68

-367WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

7	D		371.1	1.63
8			421.1	1.82	H NMR (500 MHz, DMSO-d6) 12.98 (s, 1H), 9.24 (s, 1H), 8.80 (s, 1H), 8.60 (s, 1H), 8.38 (d, J = 1.9 Hz, 1H), 8.21 (d, J = 7.0 Hz, 1H), 6.65 (d, J = 6.7 Hz, 1H). 3.81 - 3.43 (m, 4H), 2.36 (t, J = 1.8 Hz, 1H), 2.19 (d, J = 10.1 Hz, 1H), 1.62 (s, 6H), 0,00 (TMS)
9			403.1	1.69	H NMR (500 MHz, DMS0-d6) 13.01 (s, 1H), 9.40 (s, 1H), 8.85 (d, J =6.9 Hz, 1H), 8.63 (s, 1H), 8.38 (d, J = 2.1 Hz, 1H), 8.18 (d, J = 7.0 Hz, 1H), 6.66 (s, 1H), 5.29-5.05 (m, 1H), 3.86 - 3.16 (m,4H), 1.65 (d, J = 10.6 Hz, 2H), 1.60 (s, 6H), 0.00 (TMS)
10			403.1	1.74	H NMR (500 MHz, DMS0-d6) 12.99 (d, J = 6.1 Hz, 1H), 9.39 (s, 1H), 8.84 (s, 1H), 8,62 (s, 1H), 8.38 (s, 1H), 8.18 (d, J = 7.0 Hz, 1H), 6.65 (s, 1H), 5.29 - 5.05 (m, 1H), 3.87 - 3.15 (m, 4H), 1.64 (d, J = 10.8 Hz, 2H), 1.59 (s, 6H), 0.00 (TMS)
11	A	A	362.2	1.8
12	D		376.2	1.9
13	A		362.2	1.8
14	B	A			(400 MHz, DMS0-d6): 12.80 (s, exchanged with D20,1H), 8.82 (d, J=2.4 Hz, 1H), 8.28 (d, J=2.4 Hz, 1H), 8.22 (d, J=2.8 Hz, 1H), 8.14 (d, J=4.0 Hz, 1H), 7.46 (br. d, J=6.4 Hz, exchanged with D20,1H),4.82 (d, J=3.6 Hz, 1H), 4.27 (quintet, J=6.4 Hz, 1H), 4.14 (quintet, J=5.6 Hz, 1H), 2.202.10 (m, 1H), 1.94-1.77 (m, 1H), 1.77-1.70 (m, 2H), 1.651.50 (m, 2H).
15	B	A	461.3	2.68	H NMR (300 MHz, DMSO-d6) 12.32 (s, 1 H), 8.72 (d, J = 2.5 Hz, 1 H), 8.28 (d, J = 2.4 Hz, 1 H), 8.19 - 8.15 (m, 1 H), 7.75 (d, J = 5.3 Hz, 1 H), 3.89 (s, 1 H), 3.69 (s, 1 H), 3.53 - 3.45 (m, 2 H), 3.45 (s, 1H), 2.89 - 2.49 (m, 2 H), 1.90-1.68 (m, 3 H), 1.28(01, 2H), 1.28 (s, 9 H)
16	D	A	461.3	2.63	H NMR ¢300 MHz, DMSO-d6) 12.31 (s, 1 H), 8.71 (d, J = 2.5 Hz, 1 H), 8.27 (d, J = 2.4 Hz, 1 H), 8.20 - 8.15 (m, 2 H), 7.74 (d, J = 5.9 Hz, 1 H), 3.88 (d, J = 3.8 Hz, 2 H), 3.71 (d, J = 11.3 Hz, 1 H), 3.53 - 3.35 (m, 3 H), 2.86 (t, J = 10.4 Hz, 1 H), 1.90 (s, 2 H), 1.68 (d, J = 9.1 Hz, 1 H), 1.41 (s, 2 H), 1.28 (s, 9 H),
17	B	A	445.3	3.1
18	B	A	443.3	2.9
19	D		503.4	2.8
20	B		460.4	3
21	A	A	451.3	2.9
22	A	A	486.3	2.9
23	A	A	419.3	2.8
24	D		463.2	2.8
25	A	A	490.3	2.6
26	A	A	476.3	2.5
27	A	A	446.4	2.7
28	D	A	461.4	3.3
29	B		418.3	2.4
30	B	A	457.3	3.1
31	A	A	411.2	2.22	(400 MHz, DMS0-d6): 12.73 (s, exchanged with D20, 1H), 8.85 (s, 1H), 8.65 (d, J= 5.6Hz, 1H), 8.37 (d, J=6.8 Hz, 1H), 8.03-7.89 (m, 4H, addition of D2O changed to d, J = 7.6Hz, 1H), 4.03 -3.98 (m, 1H), 3.60-3.50 (m, 1H), 2.18-1.95 (m, 2H), 1.77-1.23 (m, 6H).
32	A	A	417.4	2.6
33	A	vC	433.3	3
34	A		431.4	2.8

-368WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

35	D		447.4	3.2
36	A	A	439.3	2.7
37	A	A	403.3	2.4
38	A	A	457.4	3.1
39	A	A	444.4	2.6
40	D		481.3	2.5
41	A	A	429,3	2.7
42	D		459.3	3.1
43	D		460.3	2.4
44	A	A	471.3	2.8
45	A	A	433.3	2.4
46	D		446.3	2.5
47	A	A	480,3	2.4
48	D		471.3	2.4
49	A	A	429.3	2.7
50	D		469.3	2,3
51	A	A	472.9	1.7
52	A	A	441.3	1.9
53	B		475.3	1.8
54	B		477.3	1.7
55	A	A	501.3	2.5
56	A	A	479.3	2.9
57	A	A	443.3	2.8
58	A		483.3	2.9
59	A	A	429.3	2.7
60	A	A	527	3.2
61	A	A	465.3	2.8
62	A	A	531.3	3.1
63	D		539.3	3.2
64	B	A	519.3	3.1
65	A	A	519.2	3.1
66	A	A	515.3	3.2
67	A	A	579.2	3.3
68	B	A	481.4	3.2
69	A	A	511.3	3.2
70	A	A	515.3	3.3
71	B		495.3	3.4
72	B		549.3	3.5
73	B		499.3	3.3
74	A	A	445.2	3.1
75	A	A	498.3	3
76	A	A	510.3	2.9
77	B		522.3	2.8
78	A	A	494.3	3
79	B		548.3	3.3
80	A	A	503.3	1.9
81	A	A	529.3	2
82	D		511.3	1.6
83	D		473.4	1.6
84	A	A	499.4	2
85	B	A	501.3	2.1
86	A	A	501.3	2.1
87	A	A	501.3	2.1
88	A	A	561.3	2

-369WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

89	A	A	507.2	2.1
90	A	A	519.2	2.1
91	A	A	505.3	1.8
92	A	A	437.2	2.7
93	A	A	451.2	2.9
94	A	A	495.3	2.9
95	A	A	471.3	3.2
96	B		535.2	2.9
97	A	A	471.2	2.9
98	A	A	497.3	2.9
99	A	A	457.3	3.1
100	A	A	471.3	3.1
101	A	A	467.2	2.5
102	A	A	455.3	2.7
103	A		509.3	2.8
104	A	A	485,3	2.8
105	A	A	445.3	3
106	A	A	509.3	3
107	A	A	521.3	3.2
108	A	A	501.3	2.8
109	A	A	525.3	2.7
110	A	A	461.3	2.5
111	A	A	403.2	2.4
112	A	A	494.3	3
113	A	A	495.3	2.8
114	D		442.5	1.6
115	D		377.2	1.286	(400 MHz, DMS0-d6): 12.99 (m, exchanged with D20, 1H), 9.01 (m, exchanged with D20, 1H), 8.67 (s, 1H), 8.48 (s, 1H), 8.41 (s, 1H), 8.32 (overlapped s, 1H), 8.29 (overlapped br.s, exchanged with D2O,1 H), 7.50-7.20 (m, exchanged with D2O, 1H), 4.47 -4.40 (m, 1H), 3.53 -3.45 (m, 1H), 2.19 (br, d, J=10.0 Hz, 1H), 2.08 (br. d, J=10.4 Hz, 1H), 1.84 (br. d, J=10.4 Hz, 2H), 1.60-1.29 (m, 4H).
116	D		357.2	3.267	(400 MHz, DMSO-d6): 12.70 (br. hump, exchanged with D20,1H), 8.72 (s, 1H), 8.36 (s, 1H), 8.20-8.06 (overlapped hump, exchanged with D2O, 1H, + a s for an impurity), 7.47 (d, J=7.6 Hz, 1H), 7.35-7.0(overlapped m, exchanged with D2O, 2H), 7.10 (overlapped d, J=8.0 Hz, 1H), 4.39-4.35 (m, 1H), 3.16-3.10 (m, 1H), 2.28 (s, 3H), 2.18-1.35 (m, 8H).
117	A	A	486.3	2.8
118	B		504.2	2.6
119	A	A	445.4	3.1
120	A	A	552.4	3.2
121	D		446.4	2.2
122	A	A	443.3	2.9
123	B	A	461.5	3.4
124	A	A	439.3	3.1
125	A	A	490,4	2.6
126	A	A	451.3	2.9
127	A	A	457.3	3.1
128	A	A	460.4	3
129	A	A	486,4	2.9
130	A		500.6	2
131	A	A	462.7	1.6
132	D		449.7	2,2

-370WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

133	D		405.3	2.3
134	B		457.3	3.1
135	D		433.4	2.5
136	D		469.3	3.2
137	D		465.4	3.1
138	D		459.3	2.8
139	D		465.3	3.2
140	D		459.3	2.9
141	D		433.5	1.4
142	A	A	541.5	2.8
143	A	A	479.4	2.9
144	D	A	533.3	3
145	A	A	507.3	2.9
146	A	A	533.3	3
147	A	A	533.3	3.2
148	A	A	509.3	3
149	A	A	509.4	3
150	B		557.3	3.2
151	A	A	501.4	2.9
152	A	A	501.2	2.9
153	A	A	495.3	2.8
154	B	A	525.4	2.8
155	A	A	479.4	2.9
156	A	A	499,4	3
157	A	A	493.1	2
158	A		510	2
159	B	A	418.3	2.3
160	D	A	451.4	2.1
161	D	A	463.4	2.8
162	D	A	480.3	2.8
163	B	A	467.4	3.1
164	D	A	443.5	3
165	D		472.5	2.8
166	B	A	419.5	2.9
167	D	B	444.4	2.7
168	B	A	432.3	2.6
169	D	B	490.5	2.7
170	D	A	446.4	2.7
171	D	B	433.3	3
172	D		495.5	3.2
173	A	A	403.3	2.5
174	D		495.6	2.8
175	A	A	418.5	2.4
176	D	A	467.3	2.3
177	A	A	444.4	2.7
178	A	A	446.4	2.8
179	A	A	403.4	2.5
180	A	A	451.3	2.9
181	B	A		3
182	A	A	432.3	2.6
183	B	A	433.3	3
184	D		495.5	2.7
185	A	A	463.4	2.8
186	A	A	472.4	2.8

-371WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

187	A	A	480.3	2,8	NMR 1H (CDCI3): 8.7 (s, 1H), 8.6 (s, 1H), 8.3 (s, 1H). 8.1 (s, 1H), 4.7 (m, 1H), 4.2 (m, 1H), 1.3-3.7 (m, 15H).
188	A	A	419.4	2.9
189	A	A	490.5	2.7
190	B		495.4	3.1
191	A	A	446.3	2.7
192	A	A	460.4	2.9
193	B	A	474.4	3.1
194	A	A	431.2	2.9
195	B		513.2	2.5
196	A	A	432.1	2.6
197	A	A	446.2	2.7
198	A	A	453.1	2.9
199	A	A	439.1	2.8
200	A	A	453.1	2.9
201	D	A	481.1	2.6
202	A	A	478.2	2.7
203	A	A	458.2	2.8
204	A	A	462.2	2.5
205	A	A	476.2	2.6
206	A		327.2	1.85	H NMR (300.0 MHz, DMSO)d 12.14 (s, 1H), 8.66 (d, J = 8.0 Hz, 1H), 8.29 - 8.22 (m, 3H), 7.81 (s, 2H), 7.28 - 7.19 (m, 2H), 4.55 (s, 1H), 3.74 (s, 1H) and 1.92 -1.49 (m, 8H) ppm
207	A	A	328.2	2.22
208	A	A	417.2	1.9
209	A	A	483.1	2
210	D	B	533.1	2.2
211	B		369.3	2.27
212	A		383.3	2.42
213	D		417.3	2.45
214	D		447.3	2.35
215	D		384.3	2.27
216	D		355.3	2.08
217	B		355.3	1.93
218	A	A	369.4	2.08
219	D		383.3	2.23
220	A		384.3	2.12
221	B		417.3	2.34
222	D		447.3	2.25
223	B		369.3	2.12
224	B		383.3	2.27
225	B		397.4	2.38
226	A		431.3	2.49
227	B		461.3	2.49
228	B		398.3	2.31
229	D		370.3	2.05
230	D		384.3	2.23
231	D		398.3	2.35
232	B		432.3	2.6
233	B	A	370.3	1.9
234	B		384.3	2.04
235	B		398.3	2.2
236	B		432.4	2.38
237	B		384.3	2.05

-372WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

238	B		398.3	2.19
239	D		369.3	2.27
240	D		383.3	2.43
241	B		417.3	2.48
242	D		447.3	2.45
243	D		384.4	2.26
244	D		355.3	1.97
245	B		369.3	2.08
246	D		383.3	2.19
247	D		384.3	2.15
248	D		370.3	2.05
249	D		384.3	2.23
250	D		396.5	2.36
251	B		432.3	2.64
252	D		370.4	1.89
253	D		382.4	1.99
254	D		398.3	2.12
255	B		432.4	2.37
256	B		369.3	2.2
257	B		383.3	2.31
258	B		397.3	2.46
259	B		431.3	2.42
260	D		461.3	2.36
261	B		398.3	2.35
262	D		412.4	2.27
263	B		446.3	2.6
264	B		384.3	2.12
265	D		398.4	2.23
266	B		412.3	2.38
267	B		446.4	2.6
268	B		369.3	2.08
269	B		383.3	2.27
270	B		397.3	2.42
271	B		431.4	2.49
272	D		461.3	2.46
273	B		398.3	2.31
274	B		384.3	2.05
275	B		398.4	2.2
276	D		412.4	2.31
277	A	A	328.2	1.56
278	D		465.1	2.4
279	A	A	443.2	2.1
280	A	A	471.2	2.1
281	A	A	455.2	2.1
282	A	A	486.1	2
283	B		578.2	2.4
284	A	A	458.2	2
285	D		498.2	1.6
286	D		516.2	1.7
287	D		488.2	1.9
288	B		488.2	1.9
289	D		501.2	1.6
290	B		529.2	1.8
291	D		488,2	1.9

-373WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

292	D		481.2	1.6
293	A	A	493.2	3.1
294	D		485.2	3.3
295	A	A	431.2	2.9
296	B				(400 MHz, CDCI3): 8.85 (d, J = 2.0Hz, 1H), 8.80 ( br S, 1H), 8.29 ( d, J = 2.4Hz, 1H), 8.11 ( d, J = 2.8Hz, 1H), 8,07 (d, J = 3.2Hz, 1H), 6.19 ( br. hump, 1H), 5.16 (qunitet, J = 7.6Hz, 1H), 3.78-3.50 (series of m, 4H), 2.16-1.91( series of m, 4H), 1.58(d, J = 7.6Hz, 3H)
297	B				¢400 MHz, CDCI3): 8.95 ( br. hump, exchanged withy D2O, 1H), 8.83 ( d, J = 2.0Hz, 1H), 8.29 ( d, J = 2.4Hz, 1H), 8.11 ( d, J = 2.4 Hz, addtion of D2O changed to s,1H), 8.07 (d, J = 3.2Hz, 1H), 6.40( br. d, J = 5.6Hz, 1H), 5.16 (qunitet, J = 6.8Hz, addition of D2O changed to q, J - 6.8Hz, 1H), 3.073.50 ( series of m, 4H), 1.70-1.60 ( series of m, 6H), 1.55 (d, J = 6.4Hz, 3H)
298	D				(400 MHz, CDCI3): (400 MHz, CDCI3): 9.15 ( br. hump, exchanged with D20,1H), 8.83 (d, J = 2.4Hz, 1H), 8.30 ( d, J = 2.4Hz, 1H), 8.11 (d, J = 2.8Hz, 1H), 8.07 (d, J = 3.2Hz, 1H), 6.29 (d, J 6.4Hz, exchanged with D20,1H), 5.30 ( quintet, J - 6.8Hz, addtion of D2O changed wtih q, J = 6.8Hz, 1H), 3.90-3.80 ( m, 4H), 2.60-2.40 (m, 4H), 2.33 ( s, 3H), 1.57 (d, J= 7.2 Hz, 3H).
299	D				(400 MHz, CDCI3): 9.15 ( br. hump, exchanged with D2O, 1H), 8.83 (br.s, 1H), 8.30 ( br. s, 1H), 8.11-8.07 (m, 2H), 6.99 ( br. s, exchanged with D2O, 1H), 5.40-5.30 (m, 1H), 3.90-3.40 ( m, 8H), 2.14 (s, 3H), 1.57 (d overlapped with moisture, J= 7.2 Hz, 3H).
300	B				(400 MHz, CDCI3): 9.10 ( br. hump, exchanged with D2O, 1H), 8.83 ( br. s, 1H), 8.30 ( br. s, 1H), 8.11 (br. s, 1H), 8.09 ( d, J = 1.2Hz, 1H), 6.24 ( br. d, J = 5.2Hz, exchanged with D2O, 1H), 5.30 ( quintet, J = 7.2Hz, addtion of D2O changed wtih q, J = 6.8Hz, 1H), 3.90-3.80 ( m, 8H), 1.54 (overiaped d, J= 7.2 Hz, 3H).
301	B		460.4	1.712	(400 MHz, DMSO-d6, 7): 8,69 (d, J=2.4 Hz, 1H), 8.25 (d, J=2.8 Hz, 1H), 8.19 (d, J=3.6 Hz, 1H), 8.16 (br.s, 1H), 5.255.15 (m, 1H), 3.82-3.25 (m, 8H), 1.93 (br. s, 3H), 1.80-170 ( m, 2H), 1.43 (d, J=6.8 Hz, 3H).
302	B				(400 MHz, DMSO-d6): 8.56 (d, J=2.0 Hz, 1H), 8.31 (br. s, 1H), 8.13 (d, J=1.6 Hz, 1H), 8.07 (d, J=2.8 Hz, 1H), 5.17 (dq, J=7.6, 6.8 Hz, 1H), 3.77-3,70 ( m, 1H), 3.67-3.49 (m, 3H), 2.10-2.01 (m, 2H), 1.95-1.90 (m, 2H), 1.57 (d, J=6.8 Hz, 3H).
303	D				(400 MHz, DMSO-d6) :9.375 ( br. hump, exchanged with D20,1H), 8.84 (d, J=1.6 Hz, 1H), 8.31 (d, J=2.0 Hz, 1H), 8.13 (d, J=2.0 Hz, 1H), 8.07 (d, J-3.2 Hz, 1H), 6.36 ( br. d, J = 6.8Hz, 1H), 5.33 (q,J= 6.8 Hz, 1H), 3.71-3.61 (m, 4H), 1.71-1.61 (m, 6H), 1.56 (d, J=6.4 Hz, 3H).
304	D				(400 MHz, DMSO-d6): 9.09 (s, exchanged with D20,1H), 8.83 (d, J=2.0 Hz, 1H), 8.31 (br. s, 1H), 8.12 (d, J=2.8 Hz, 1H), 8.08 (d, J=3.6 Hz, 1H), 6.28 (d, J = 6.8Hz, exchanged with D2O, 1H), 5.31 (dq J=7.2, 6.8 Hz, 1H), 3.80-3.70 (m, 4H), 2.55-2.40 (m, 4H), 2.34 (s, 3H), 1.56 (d,J=7.2 Hz, 3H).
305	A	A	460.3	2.58
306	A	A	453.2	2.5
307	D		462.3	2.418	(400MHz, CDCI3): 8.90 (br. s, exchanged with D2O, 1H), 8.80 (d, J = 2.0Hz, 1H), 8.31 (d, J = 2.8Hz, 1H), 8.10 ( s, 1H), 8.08 (d, J = 3.6 Hz, 1H), 6.20 ( br. s, exchanged with D20,1H), 5.40-5.35( m, 1H), 3.74 (s, 3H), 3.90-3.40 ( series of m, 8H), 1.58 (d, J = 7.6Hz, 3H)
308	D				(400MHz, CDCI3): 9.11 (s, exchanged with D2O, 1H), 8.80

-374WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

					(s, 1H), 8.31 ( s, 1H), 8.10-8.08 ( m, 2H), 6.17 ( br. s, exchanged with D20,1H), 5.40-5.35 ( m, 1H), 3.90-3.40 ( series of m, 8H), 2.14 (s,3H), 1.59 ( overlapped d, J = 6.4Hz, 3H)
309	B				(400MHz, DMSO-d6): 12.07 (s, exchanged with D2O,1H), 8.69 (d, J = 2.4Hz, 1H), 8.25( d, J = 2.4Hz, 1H), 8.18 (d, J = 3.6Hz, 1H>, 8.17 (overlapped br. s, 1H), 7.16 (br.s, 1H), 5.20-5.05 ( m, 1H), 3.90-3.40 (series of m, 8H), 2.56 ( overlapped s with DMSO-d6 signal, 3H), 1.43( br. s, 3H), 1.40-1.20 (m, 2H)
310	D				(400MHz, CDCI3): 9.28 (s, exchanged with D2O, 1H), 8.81 (d, J = 2.0Hz, 1H), 8.29 (d, J = 2.0Hz, 1H), 8.11 (d, J = 3.3Hz, 1H), 8.10 (d, J = 2.4Hz, 1H), 6.22 ( br. d, J = 6.4Hz, 1H), 5.32 (quintet, 6.4Hz, addition of D2O changed to q, J = 6.4Hz, 1H), 3.74 ( s, 3H), 3.68- 3.49 (series of m, 8H), 1.57 (d, J = 6.4Hz, 3H)
311	D				(400MHz, CDCI3): 9.04 (s, exchanged with D20,1H), 8.81 (d, J = 2.0Hz, 1H), 8.29 (br.d, J = 2.0Hz, 1H), 8.11 (d, J = 2.4Hz, 1H), 8.09 (d, J = 3.2Hz, 1H), 6.23 ( br. d, J = 6.8Hz, 1H), 5.31 (quiniet, J = 6.8Hz, addition of D2O changed to q, J = 6.8Hz, 1H), 3.68- 3.49 (series of m, 8H), 1.57 (d, J = 6.8Hz, 3H)
312	A	A			(400MHz, CDCI3):9.72 ( s, exchanged with D20,1H), 8.83 ( d, J = 2.4Hz, 1H), 8.29 (d, J = 2.0Hz, 1H), 8.13 ( d, J = 2.0Hz, 1H), 8.08 (d, J = 4.4Hz, 1H), 6.07 (d, J = 7.6Hz, exchanged with D2O, 1H), 4.95 (qunitet, J = 7.2Hz, 1H), 4.68 (q, J = 7.6Hz, 1H), 4.36 (d, J = 8.4Hz, 1H), 4.18-4.07 ( m, 2H), 2.40-2.30 ( m, 2H), 1.54 (d, J = 7.2Hz, 3H).
313	B	A			(400MHz, DMSO-d6, 80oC): 12.07 ( s, exchanged with D20,1H), 8.71 (d, J = 2.4Hz, 1H), 8.26 (d, J = 2.0Hz, 1H), 8.21 (d, J = 2.0Hz, 1H), 8.17 ( br. s, 1H), 7.14 ( br. s , exchanged with D2O, 1H), 5.20-5.10 (m, 1H), 3.70-3.50 ( m, 8H), 1.54 (d, J = 7.2Hz, 3H), 1.95-1.80 (m, 2H)
314	B	B			(400MHz, CDC[3):9,80 (s, exchanged with D20,1H), 8.83 ( d, J = 2.4Hz, 1H), 8.30 (d, J = 2.0Hz, 1H), 8.13 (d, J = 2.0Hz, 1H), 8.08 ( d, J = 4.4Hz, 1H), 6,08 (d, J = 6.4Hz, exchanged with D2O, 1H), 4.95 (qunitet, J = 7.2Hz, 1H), 4.68 (q, J = 7.6Hz, 1H), 4.36 (d, J = 8.0Hz, 1H), 4.18-4.07 ( m, 2H), 2.40-2.30 ( m, 2H), 1.55 (d, J = 7.2Hz, 3H).
315	B	D			(400MHz, DMS0-d6, 80oC): 12.08 (s, exchanged with D2O, 1H), 8.69 (d, J = 2.4Hz, 1H), 8.24 (d, J = 2.0Hz, 1H), 8.18 (d, J = 2.0Hz, 1H), 8.16 ( br. s, 1H), 7.14 ( br. d , J = 7.2Hz, exchanged withD2O, 1H), 5,20-5.10 (m, 1H), 3.703.50 ( m, 8H), 1.46 (d, J = 7.2Hz, 3H), 1.95-1.80 (m, 2H)
316	B	A	453.3	2.48
317	B	A	415.1	2.7
318	D	A	431.1	2.9
319	D	A	429.1	2.8
320	B	B	433.1	2.5
321	B	A	439.1	2.7
322	D	A	453.1	2.9
323	D	A	446.2	2.7
324	B	A	432.2	2.6
325	B	A	429.2	2.7
326	B	A	445.2	3
327	A	A	447.2	1.8
328	D		467.1	2.2
329	D		481.2	2.3
330	A	A	501.1	2.2

-375WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

331	A	A	465.1	2.2	1H NMR (300.0 MHz, MeOD) d 8.83 (d, J = 2.3 Hz, 1H), 8.24 (s, 1H), 8,22 (d, J = 2.4 Hz, 1H), 8.01 (d, J = 3.9 Hz, 1H), 4.44 (m, 1H), 4.06 (dd, J = 9.2,13.8 Hz, 1H), 3.77 (dd, J =6.3, 13.8 Hz, 1H), 3.71 (m, 1H), 2.47 (m, 1H), 1.87-1.66 (m, 6H) and 1.00 - 0.92 (m, 4H) ppm
332	A	A	431.2	2
333	B		417.4	2.7
334	B		431.4	2.85
335	D		457.3	3.14
336	D		465.4	3.03
337	B	A	439.3	2.66
338	D		467.3	2.93
339	B		446.3	2.85
340	A	A	403.3	2.6
341	D		383.4	2.3	H NMR (300.0 MHz, DMSO) d 12.47 (s, 1H), 8.65 (d, J = 8.1 Hz, 1H), 8.49 - 8.23 (m, 3H), 7.61 (d, J = 7.8 Hz, 1H), 7.29 (dd, J = 4.7, 8.0 Hz, 1H), 4.39 (d, J = 19.5 Hz, 2H), 2.10 (q, J = 7.6 Hz, 2H), 1.79 -1.64 (m, 6H), 1.48 (d, J = 6.4 Hz, 2H) and 0.91 (t, J = 7.6 Hz, 3H) ppm
342	D		397.4	2.48
343	D		423.4	2.71
344	D		431.4	2.67
345	D		405.3	2.3	H NMR ¢300.0 MHz, DMSO)d 12.47 (s, 1H), 8.64 (d, J = 7.8 Hz, 1H), 8.45-8.34 (m, 3H), 7.29 (dd, J = 4.8, 7.8 Hz, 1H), 7.06 (d, J = 7.5 Hz, 1H), 4.47-4.25 (m, 1H), 4.05 - 3.89 (m, 1H), 2.80 (s, 3H), 1.95 - 1.62 (m, 6H) and 1.49 - 1.24 (m, 2H)ppm
346	D		433.3	2.56	H NMR (300.0 MHz, DMSO) d 12.41 (s, 1H), 8.65 (d, J = 7.8 Hz, 1H), 8.38 - 8.33 (m, 3H), 7.28 (dd, J = 4.7, 7.9 Hz, 1H), 7.06 (d, J = 8.1 Hz, 1H), 4.36 (s, 1H), 3.88 (s, 1H), 2.83 (t, J = 7.7 Hz, 2H), 1.85 -1.70 (m, 6H), 1.59 (q, J = 7.8 Hz, 2H), 1.47 -1.24 (m, 2H) and 0.82 (t, J = 7.4 Hz, 3H) ppm
347	D		412.4	2.41	H NMR (300.0 MHz, DMSO)d 12.47 (s, 1H), 8.64 (d, J = 7.8 Hz, 1H), 8.45 - 8.34 (m, 3H), 7.29 (dd, J = 4.8, 7.8 Hz, 1H), 7.06 (d, J = 7.5 Hz, 1H), 4.47-4.25 (m, 1H), 4.05-3.89 (m, 1H), 2.80 (s, 3H), 1.95 -1.62 (m, 6H) and 1.49 -1.24 (m, 2H)ppm
348	D		369.4	2.19	H NMR (300.0 MHz, DMSO)d 12.53 (s, 1H), 8.66 (d, J = 7.6 Hz, 1H), 8.43 (s, 1H), 8.39 - 8.36 (m, 2H), 7.91 (d, J = 7.9 Hz, 1H), 7.32 (dd, J = 4.7, 7.9 Hz, 1H), 4.08 - 3.94 (m, 1H), 3.86 (d, J = 8.4 Hz, 1H), 2.13 (d, J = 24.3 Hz, 1H), 1.95 (d, J = 10.2 Hz, 1H), 1.81 -1.73 (m, 2H), 1.73 (s, 3H)and 1.431.14 (m, 4H) ppm
349	D		417.3	2.74
350	B		417.3	2.74
351	D		457.3	3.11
352	D		465.3	3.03
353	D		439.4	2.74
354	D		467.3	3.04
355	D		446.3	2.81
356	D		383.4	2.33
357	D				(400 MHz, CDCI3, 75oC) : 12.07 (br. s exchanged with d2O, 1H), 8.69 (s, J=2.4 Hz, 1H), 8.25 (s, J-4.0 Hz, 1H), 8.19 (s, J=4.0 Hz, 1H), 8.15 (br. s, 1H), 7.15 ( br. s, exchanged with D2O, 1H), 5,20-5.10 (q, 1H), 3.62-3.55 (m, 8H), 3.03 (s, 3H), 1.76 (d, J=2.4 Hz, 2H), 1.43-1.41 (d, J=8.0Hz, 3H).
358	D		397.4	2.45
359	D		423.4	2.67

-376WO 2010/148197

PCT7US2010/038988

2018200219 11 Jan 2018

360	D		431.4	2.63
361	D		405.3	2.37	H NMR (300.0 MHz, DMSO) d 12.54 (s, 1H), 8.66 (d, J = 8.0 Hz, 1H), 8.43 - 8.36 (m, 3H), 7.32 (dd, J = 4.7, 7.9 Hz, 1H>, 7.21 (d, J = 8.3 Hz, 1H), 4.16 (d, J = 9.3 Hz, 1H), 3.35 (d, J = 9.8 Hz, 1H), 2.91 (d, J = 8.9 Hz, 3H), 2.12 - 2.02 (m, 2H), 1.79 -1.73 (m, 2H) and 1.64 -1.15 (m, 4H) ppm
362	D		433.3	2.63	H NMR (300.0 MHz, DMSO) d 12.43 (s, 1H), 8.68 (d, J = 7.9 Hz, 1H), 8.38 - 8.33 (m, 3H), 7.29 (dd, J = 4.7, 7.8 Hz, 1H), 7.17 (d, J = 8.6 Hz, 1H), 4.14 (d, J = 6.9 Hz, 1H), 3.33 - 3.26 (m, 1H), 3.07 - 2.89 (m, 2H), 2.07 (d, J = 12.6 Hz, 2H), 1.76 (d, J = 7.9 Hz, 2H), 1.61-1.33 (m, 6H) and 0.90 (t, J = 7.4 Hz, 3H) ppm
363	D		431.3	2.88
364	D		457.3	3.11
365	D		465.3	3.03
366	A	A	439.2	2.74
367	B		467.3	2.99
368	D		446.3	2.81
369	D		431.3	2.85
370	D		412.4	2.41
371	D		412.2	1.78
372	B	B	424.2	1.87
373	B	D	398.2	1.69
374	D		384.2	1.61
375	B	B	412.2	1.8
376	B		327.14	1.46
377	D		313.33	1.38
378	D				(300 MHz, DMSO-d6): 12.35 ( br. s, exchanged with D2O, 1H), 8.72 (d, J = 2.4Hz, 1H), 8.29 (d, J = 2.1 Hz, 1H), 8.21 (s, 1H), 8.17 (d, J=3.9 Hz, 1H), 7.80 (br. s, exchanged with D2O, 1H), 7.10 ( s, exchanged with D2O, 1H), 2.27-2.11 (m, 2H), 1.96 (m, 2H), 1.55 (m, 2H), 1.40-1.18 (m, 3H).
379	B	A	361.3	2.3	1H NMR (300.0 MHz, MeOD) d 8.72 (d, J = 2.3 Hz, 1H), 8.21 (d, J = 2.4 Hz, 1H), 8.11 - 8.07 (m, 2H), 4.94 (t, J = 9.3 Hz, 1H), 3.64 - 3.51 (m, 2H), 2.97 (s, 3H), 2.68 - 2.54 (m, 1H) and 2.37 - 2.23 (m, 1H) ppm
380	B		347.3	2.27	1H NMR (300.0 MHz, MeOD) d 8.79 (d, J = 2.4 Hz, 1H), 8.20 (d, J = 2.4 Hz, 1H), 8.13 (s, 1H), 8.07 (d, J = 3.9 Hz, 1H), 4.91 (dd, J = 8.7, 10.6 Hz, 1H), 3.61 -3.46 (m, 2H), 2.68 - 2.58 (m, 2H) and 2.48 - 2.31 (m, 1H) ppm
381	A	A	439.3	2.72
382	A	A	453.3	2.86
383	A	A	507.3	3.01
384	A		439.3	2.72
385	A		453.3	2.82
386	A		465.3	2.9
387	B		507.2	2.49
388	D		453.4	1.84
389	A	A	425.3	1.8
390	A	A	467.3	2.1
391	A	A	451.3	1.9
392	A	A	493.5	2.3
393	A	A	439.3	1.8
394	A	A	453.3	1.9
395	A	A	429.3	1.9
396	A	A	433.3	1.7
397	A	A	375.36	2.21	1H NMR (300.0 MHz, DMSO) d 8.65 (d, J = 2.5 Hz, 1H),

-377WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

					8.27 (d, J =2.4 Hz, 1H), 8.20-8.19 (m, 2H), 7.63 (d, J =7.8 Hz, 1H), 4.78 - 4.74 (m, 1H), 3.41 (t, J = 5.4 Hz, 2H), 3.17 (MeOH), 2.89 (s, 3H), 2.50 (DMSO), 2.18 - 2.15 (m, 1H) and 1.99 (d, J = 7.4 Hz, 2H) ppm
398	A	A	411	1.7
399	A		425	1.8
400	B		439	1.9
401	B		437	1.9
402	B		453	2.1
403	B		465	2.1
404	D		439	2
405	B		411	1.7
406	D		453	2.1
407	D		425	1.8
408	D		439	1.9
409	B		437	1.9
410	B		439	2
411	A	A	361,4	1.94
412	A	A	376.4	3.53
413	D		361.3	2.41
414	A	A	361.3	2.46
415	D		387	1.5
416	A	A	361.3	1.56
417	A	A	375.3	1.68	1H NMR (300.0 MHz, DMSO) d 12.33 (s, 1H), 8.74 (d, J = 2.3 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.21 (t, J = 3.7 Hz, 2H), 8.02 - 7.98 (m, 1H), 7.21 (d, J = 5.8 Hz, 1H), 4.86 (dd, J = 6.3,10.5 Hz, 1H), 3.51 -3.41 (m, 1H), 3.25-3.16 (m, 1H), 2.13 -1.85 (m, 4H), 1.66 -1.52 (m, 1H) and 1.40 -1.20 (m, 1H)ppm
418	A		421.37	1.79	1H NMR (300.0 MHz, DMSO) d 13.11 (d, J = 9.6 Hz, 1H), 13.05 (s, H), 9.30 (s, 1H), 8.72 (d, 1H), 8.62 (d, 1H), 8.49 (s, 1H), 8.18 (d, 1H), 6.83 (s, H), 6.72 (d, 1H), 4.30 (m, 1H), 3.88 (m, 1H), 3.76(m, 1H) 3.46 (m, 1H), 3.10 - 3.01 (m, 4H), 2.12 (m, 1H), 1.92 (m, 1H), 1.68 -1.61 (m, 2H), 1.20 (t, 3H), and -0.00 (TMS) ppm
419	A	A	449.39	2.08	1H NMR (300.0 MHz, DMSO) d 13.08 (s, 1H), 8.70 (d, 1H), 8.60 (d, 2H), 8.48 (s, 1H), 8.18 - 8.12 (m, 1H), 6.64 (d, 1H), 5.91 (s, H), 4.30 (m, 1H), 3.88 (m, 1H), 3.76(m, 1H) 3.46 (m, 1H), 3.10-3.01 (m, 4H), 2.08 (m,1H), 1.91 (m, 1H), 1.61 (dd, 4H), 1.47 (m, 2H), 0.86 (t, 3 H), and -0.00 (TMS)
420	D		461	2.83
421	B		447	1.8
4-22	D		433	1.8
423	D		425	2
424	D		447	1.8
425	A	A	419.21	2.13	H NMR (300.0 MHz, DMSO) d 13.02 (s, 1H), 9.10 (s, 2H), 8.67 (s, 1H), 8.44 - 8.40 (m, 2H), 7.26 (d, J = 6.5 Hz, 1H), 4.19 (s, 1H), 3.66 (d, J = 9.8 Hz, 1H), 3.48 (s, 3H), 2.13 (s, 1H), 2.02 (d, J = 9.2 Hz, 1H), 1.78 (d, J = 9.6 Hz, 2H) and 1.47 -1.34 (m, 4H) ppm
426	A	A	419.5	2.53	H NMR (300.0 MHz, DMSO) d 12.56 (s, 1H), 8.70 (d, J = 2.2 Hz, 1H), 8.35 (dd, J = 2.4, 6.8 Hz, 2H), 8.28 (d, J = 4.2 Hz, 1H), 5.99 (d, J = 7.0 Hz, 1H), 5.80-5.63 (m, 1H), 3.91 -3.87 (m, 1H), 3.66 - 3.45 (m, 1H), 2.54 (s, 3H), 2.30 (d, J = 13.0 Hz, 1H), 2.04 (d, J = 46.9 Hz, 1H), 1.78 (d, J = 8.5 Hz, 2H) and 1.56- 1.23 (m, 4H) ppm
427	D		432.4	2.69	H NMR (300.0 MHz, DMSO)d 12.59 (s, 1H), 8.72 (d, J = 2.3 Hz, 1H), 8.41 (d, J = 2.7 Hz, 1H), 8.35 (d, J = 2.3 Hz, 1H),

-378WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

					8.29 (d, J = 4.4 Hz, 1H), 8.23 (s, 1H), 6.19 (d, J = 7.8 Hz, 1H), 4.04 - 3.97 (m, 1H), 3.78 - 3.69 (m, 1H), 2.68 (s, 6H), 2.31 (d, J = 11.6 Hz, 1H), 1.95 (d, J = 9.8 Hz, 1H), 1.79 (d, J = 10.4 Hz, 2H) and 1.60 -1.32 (m, 4H) ppm
428	A	A	439.4	2.71	H NMR (300.0 MHz, DMSO) d 12.54 (s, 1H), 8.72 (d, J = 2.3 Hz, 1H), 8.38 - 8,29 (m, 3H), 7.82 (s, 1H), 7.21 (d, J = 8.3 Hz, 1H), 4.52 (brs, 1H), 4.12 -4.05 (m, 1H), 2.92 (s, 3H), 2.09 (d, J = 12.8 Hz, 2H), 1.78 (brs, 2H) and 1.49 -1.39 (m, 4H)ppm
429	B		403.4	2.57
430	A		418.5	2.57	H NMR (300.0 MHz, DMSO) d 12.61 (s, 1H), 8.68 (d, J = 2.2 Hz, 1H), 8.39-8.31 (m, 4H), 6.12 (d, J = 6.7 Hz, 1H), 5.91 5.83 (m, 1H), 4.29-4.13 (m, 1H), 4.02 - 3.91 (m, 1H), 2.55 (s, 3H), 1.93 (d, J = 12.8 Hz, 1H) and 1.74 -1.53 (m, 7H) PPm
431	A		432.4	2.77	H NMR (300.0 MHz, DMSO)d 12.54 (s, 1H), 8.68 (d, J = 2.3 Hz, 1H), 8.33 - 8.29 (m, 3H), 7.96 (s, 1H), 5.72 (d, J = 6.9 Hz, 1H), 4.36 (s, 1H), 4.10 (s, 1H), 2.76 (s, 6H), 1.96-1.87 (m, 2H), 1.74 -1.63 (m, 4H) and 1.55 - 1.45 (m, 2H) ppm
432	D		419.4	2.85	H NMR (300.0 MHz, DMSO)d 12.54 (s, 1H), 8.67 (d, J = 2.2 Hz, 1H), 8.35 - 8.29 (m, 3H), 7.62 (s, 1H), 7.05 (d, J = 7.2 Hz, 1H), 4.50 - 4.40 (m, 1H), 4.20 - 4.10 (m, 1H), 3.46 (s, 3H), 1.87 (d, J = 10.9 Hz, 2H), 1.71 -1.65 (m, 4H) and 1,43 (d, J = 7.4 Hz, 2H) ppm
433	A	A	403.4	2,41	H NMR (300.0 MHz, DMSO) d 13.03 (s, 1H), 9.10 (s, 1H), 9.05 (s, 1H), 8.67 (d, J = 2.1 Hz, 1H), 8.48 (d, J = 5.4 Hz, 1H), 8.43 (d, J = 2.3 Hz, 1H), 7.97 (d, J = 7.7 Hz, 1H), 4.154.07 (m, 1H), 3.93 - 3.87 (m, 1H), 2.20 - 2.15 (m, 1H), 1.99 1.92 (m, 1H), 1.85 -1.79 (m, 2H), 1.74 (s, 3H) and 1.52 1.36 (m, 4H) ppm
434	A	A	389.4	1.6
435	A	A	403.4	1.8
436	A		417.4	1.9
437	D		431.4	2
438	A	A	418.4	1.7
439	A	A	432.4	1.8
440	A	A	405.4	1.8
441	B		419.4	1.9
442	B		433.4	2.1
443	A	A	461.3	1.8
444	A	A	Α4·5,4	1.7
445	A		429.4	1.9
446	D		448.4	1.7
447	D		449.3	2
448	D		469.3	1.9
449	B		419.4	1.7
450	B		431.4	1.7
451	B		415.4	1.8
452	A	A	403.14	1.2619 75
453	A	A	419	1.1784 28
454	A	A	439.11	1.5486 67
455	A	A	418.16	1.6900 93
456	A	A	432.17	1.5181 83

-379WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

457	A	A	403.22	1.57
458	A	A	418.16	0.76
459	A	A	432.17	1.46
460	A	A	389.14	2.01
461	A	A	389.14	2.05
462	B	A	403.15	2.24	1H NMR (300.0 MHz, DMSO) d 12.35 (s, 1H), 8.68 (d, J = 1.7 Hz, 1H), 8.27 (d. J = 2.0 Hz, 1H), 8.21 (m, 2H), 7.28 (d, J = 6.0 Hz, 1H), 4.98 (dd, J = 6.9, 10.7 Hz, 1H), 3.88 - 3.79 (m, 1H), 3.84 (dd, J = 11.4, 15.5 Hz, 1H>, 3.49- 3.17 (m, 5H), 2.08 (d, J = 13.1 Hz, 1H), 1.95 -1.88 (m, 3H), 1.65 - 1.58 (m, 1H), 1.42 (m, 1H) and 1.04 (t, J = 7.0 Hz, 3H) ppm
463	D	A	475.2	2.26	DMSO d-6:13.21 (s, 1H), 9.29 (d, 1H), 8.76 (d, 1H), 8.60 (s, 1H), 8.47 (s, 1H), 8.17 (d, 1H), 6.67 (d, 1H), 4.29 (m, 1H), 3.75 (m, 1 H), 3.46 (m, 1H), 3.07 - 2.98 (m, 3H), 2.27 1.45 (m, 12H), 1.28 -1.24 (m, 2H), -0.00 (s, H) ppm
464	A	A	435.14	2.03	DMSO d-6:13.21 (s, 1H), 9.29 (d, 1H), 8.76 (d, 1H), 8.60 (s, 1H), 8.47 (s, 1H), 8.17 (d, 1H), 6.67 (d, 1H), 4.29 (m, 1H), 3.75 (m, 1 H), 3.46 (m, 1H), 3.07 - 2.98 (m, 3H),2.22.1(m, 1H), 1.85-2.0(m, 1H), 1.72-1.57(m, 4H), 0.95(t, 3H)
465	B		435.14	2	DMSO d-6: 13.21 (s, 1H), 9.29 (d, 1H), 8.76 (d, 1H), 8.60 (s, 1H), 8.47 (s, 1H), 8.17 (d, 1H), 6.67 (d, 1H), 4.25(m, 1H), 3.79(m, 1H), 3.53(m, 1H), 3.37(m, 1H), 3.17(m, 1H), 2.14(m, 1H), 1.90(m, 1H), 1.66-1,60(m, 1H), 1.21(d, 6H).
466	B		407.12	1.85	DMSO d-6:13.21 (s, 1H), 9.29 (d, 1H), 8.76 (d, 1H), 8.60 (s, 1H), 8.47 (s, 1H), 8.17 (d,1H), 6.67 (d,1H), 4.4(m, 1H), 3.75(d, 1H), 3.4(m, 1H), 3.1 (m, 1H), 2.9(s, H), 2.10-1.9(m, 2H), 1.8-1.65(m, 2H).
467	D		431.4	1.6
468	B		391.3	1.6
469	D		465.3	2.3
470	D		479.3	2.3
471	A		375.3	1.6
472	B		405.3	1.6
473	B		431.3	1.6
474	D		446.3	1.4
475	D		461.3	2.6
476	B		391.3	2.6
477	D		419.4	2
478	B		431.3	1.6
479	D		479.3	2.3
480	A		375.3	1.6
481	B		405.3	2.2
482	A		431.3	1.6
483	D		446.3	1.4
484	B		461.3	2.6
485	B		371.46	1.89	1H NMR (300.0 MHz, DMSO) d 13.09 (s, H), 9.3 (s, 1H), 8.74 (d, J = 2.8 Hz, 1H), 8.57 (d, 1H), 8.47 (s, 1H), 8.188.14 (m, 1H), 6.66 - 6.58 (m, 1H), 4.5(d, 1H), 4.43-4.05 (m, 1H), 4.29(s, H), 3.88 (d,2H), 3.34 - 3.08 (m, 2H), 2.13 (s, 1H), 2.07 (s, 1H), 1.91 1.56 (m, 3H), 0.00 (TMS)
486	B		401.48	1.87
487	B		443.9	1.97
488	D		415.5	1.9
489	A		413.51	2.12
490	A	A	385.43	1.7	1H NMR (300.0 MHz, DMSO) d 13.12 (s, 1H), 9.52 (s, 1H), 8.73 (d, 1H), 8.65 (d, 1H), 8.45 (d, 1H), 8.14 (d, 1H), 6.63 (d, 1H), 4.29 (d, 1 H), 4.04 (d, 1H), 3.80-3.32 (m, 3H), 3.10

-380WO 2010/148197

PCT/US2010/038988

					-3.02(m, 1H), 2.07 (s, 3H)_t 1.99 (m, 2H), 1.8-1.6 (m, 2H), 1.55 -1.24 (m. 2H) and -0.00 (TMS) ppm
491	A		415.43	1.7
492	B		457.49	1.79
493	A	A	429.46	1.74
494	B		427.52	1.92
495	B		401.48	1.83	1H NMR (300.0 MHz, DMSO) d 13.12 (s, 1H), 9.44 (d, 1H), 8.73 (d, 1H), 8.65 (d, 1H), 8.45 (d, 1H), 8.14 (d, J = 7.2 Hz, H), 6.80 (d, 1H), 6.63 (d, 1H), 3.9(dd, 1H) 3.76 (dd, 1H), 3.60 - 3.50 (m, 3H), 3.47 -(s, 3H), 3.05-2.8 (m, 2H), 1.93 (m, 2H), 1.83 (d, 2H), 1.42 -1.35 (m, 2H), and -0.00 (TMS) PPm...............
496	B		439.3	1.8
497	A	A	403.3	1.7
498	A		419.3	1.9
499	A	A	432.5	1.8
500	A	A	357.62	1.62	1H NMR (300.0 MHz, DMSO) d 13.02 (s, 1H), 8.73 (d, 1H), 8.66 (d, 1 H), 8.42 (d, 1H), 8.16 (d, 1H), 8.06 (t, 1H), 6.83 (d, 1H), 5.05 - 4.99 (m, 1H), 3.52 - 3.42 (m, 1H), 3.36 (d, H), 3.28 - 3.24 (m, 1H), 2.50 (qn, J = 1.8 Hz, H), 2.00 -1.80 (m, 4H), 1.77 -1.64 (m, 1H), 1.34 (m, 1H), 1.28 (s, H), 1.06 (t, J = 7.0 Hz, H) and 0.00 (TMS) ppm
501	B		341.38	1.56	1H NMR (300.0 MHz, DMSO) d 12.96 (s, 1H), 8.66 (d, 1H), 8.46 - 8.41 (m, 2H), 8.16 (d, 1H), 8.05 (d, 1H), 6.80 (d, 1H), 5.00 (dd, 1H), 3.54 - 3.40 (m, 1H), 3.26 - 3.21 (m, 1H), 2.50 (qn, J = 1.8 Hz, H), 2.03 -1.86 (m, 4H), 1.64 (t, 1H>, 1.36 (t, 1H) and -0.00 (TMS) ppm
502	A	A	409.3	2.6
503	A		361.2	2.17
504	B	A	403.3	2.85
505	B		497.72	3.05
506	A	A	418.5	2.09	1H NMR (300.0 MHz, DMSO) d 13.06 (s, 1H), 9.24 (s, 1H), 9.05 (d, J = 2.4 Hz, 1H), 8.66 (d, J = 2.3 Hz, 1H), 8.52 - 8.45 (m, 2H), 4.35 (d, J = 8.0 Hz, 1H), 3.81 (qn, J - 6.1 Hz, 1H), 3.59-3.39 (m, 2H), 3.18 (t, J = 11.6 Hz, 1H), 2.61 (d,J = 16 Hz, 3H) and 2.12 -1.67 (m, 6H) ppm
507	A	A	390.42	1.69
508	D		397.37	1.59
509	A	A	404.45	1.67
510	D		343.39	0.65
511	D		343.42	1.29
512	D	B	361.3	2.36
513	B	A	377.46	1.89
514	A	A	418.78	1.26	1H NMR (300.0 MHz, MeOD) d 8.83 (d, J = 2.3 Hz, 1H), 8.22 (d, J =2.3 Hz, 1H), 8.16 (s, 1H), 7.99 (d, J =4.1 Hz, 1H), 4.29 - 4.17 (m, 1H), 3.67 - 3.60 (m, 1H), 3.60 (s, 3H), 2.37 (m, 1H), 2.19 (m, 1H), 2.07 - 1.90 (m, 2H), 1.72 -1.60 (m, 1H), 1.40 -1.25 (m, 2H) and -0.00 (TMS) ppm
515	D		463.5	2.47	1H NMR (300.0 MHz, CDCI3) d 10.38 (s, 1H), 8.81 (d, J = 2.0 Hz, 1H), 8.49 (d, J = 2.3 Hz, 1H), 8.38 (s, 1H), 8,08 (d, J = 3.4 Hz, 1H), 7.26 (s, CDCI3), 6.11 (d, J = 5.0 Hz, 1H), 4,44 (d, J = 9.4 Hz, 1H), 4.02 - 3.62 (m, 6H), 3.55 (dd, J = 2.4, 12.1 Hz, 1H), 3.35-3.27 (m, 1H)and 1.40-1.22 (m, 9H) ppm
516	B		419.4	1.91
517	B		448.54	2.26	1H NMR (300.0 MHz, DMSO) d 12.54 (s, 1H), 8.76 (d, J = 2.0 Hz, 1H), 8.46 (s, 1H), 8.32 (d, J = 2.1 Hz, 1H), 8.26 (d, J = 3.9 Hz, 1H), 8.08 (d, J = 7.5 Hz, 1H), 6.30 (s, 1H), 4.28 (s,

-381WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

					1H), 3.93 - 3.74 (m, 3H), 3.51 - 3.47 (m, 2H), 3.39 - 3.20 (m, 2H), 2.95 (dd, J = 6.2,13.1 Hz, 3H), 1.35 -1.25 (m, 2H) and 0.76 (t, J = 7.3 Hz, 3H) ppm
518	D		445.6	3.3	1H NMR (300.0 MHz, MeOD) d 8.67 (d, J = 2.3 Hz, 1H), 8.53 (s, 1H), 8.41 (d, J = 2.3 Hz, 1H), 8.35 (d, J = 5.5 Hz, 1H), 4.75 - 4.73 (m, 1H), 3.74 - 3.58 (m, 1H), 3.42 (m, 2H), 3.29 - 3.22 (m, 2H), 2.57 (m, 1H), 2.09 - 2.03 (m, 1H), 1.96 1.76 (m, 4H), 1.06 (t, J = 7.1 Hz, 3H) and 0.94 (t, J = 7.1 Hz, 3H)ppm
519	B		417.49	2.95
520	D		445.58	2.26
521	B		417.53	2.34	1H NMR (300.0 MHz, MeOD) d 8.93 (d, J = 2.4 Hz, 1H), 8.22 (d, J = 2.3 Hz, 1H), 8.18 (s, 1H), 7.99 (d, J = 4.0 Hz, 1H), 4.53 (ddd, J = 7.1, 11.1 Hz, 1H), 3.15-3.02 (m, 2H), 2.43 - 2.34 (m, 1H), 2.30 - 2.26 (m, 1H), 1.97 -1.82 (m, 3H), 1.77 -1.65 (m, 2H), 1.47 -1.35 (m, 2H) and 0.97 (t, J = 7.3 Hz, 3H) ppm
522	D		375.46	1.68
523	D		389.54	1.72	1H NMR (300.0 MHz, MeOD) d 8.65 (d, J = 2.3 Hz, 1H), 8.54 (s, 1H), 8.43 (d, J = 5.1 Hz, 1H), 8.40 (d, J = 2.3 Hz, 1H), 4.82 - 4.72 (m, 1H), 3.66 - 3.53 (m, 1H), 2.96 (s, 3H), 2.77 (s, 3H), 2.33 (d, J = 12.3 Hz, 2H), 2.10-1.97 (m, 2H) and 1.75 -1.48 (m, 4H) ppm
524	A	A	362.48	1.95
525	A	A	421.52	1.48	1H NMR (300.0 MHz, DMSO) d 12.31 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.20 (d, J = 2.0 Hz, 1H), 8.17 (d, J = 4.0 Hz, 1H), 7.33 (d, J = 7.6 Hz, 1H), 4.54 (m, 1H), 4.44 (s, 1H), 4.36 (m, 1H), 3.64 (s, 1H), 3.40 (m, 1H), 3.03 (t, J = 11.0 Hz, 1H), 2.77 (m, 1H), 2.47-2.25 (m, 2H), 2.22-2.12 (m, 2H), 1.99-1.90 (m, 1H), 1.70-1.60 (m, 2H) and 1.45 (m, 1H) ppm
526	B	A	421	2.36
527	D	D	435.1	2.49
528	B	D	447.1	2.64
529	B	D	433.1	2.45
530	D	B	447.1	1.93
531	B	A	445.1	2.56
532	B	A	441	2.4
533	B	A	467	2.4
534	B	A	406	1.96
535	B	D	434.1	2.17
536	B	D	448.1	2.34
537	A	A	435.54	1.56	1H NMR (300.0 MHz, DMSO) d 12.35 (s, 1H), 8.73 (d, J = 2.4 Hz, 1H), 8.29 (d, J = 2.4 Hz, 1H), 8.19-8.09 (m, 2H), 7.36 (d, J = 7.5 Hz, 1H), 4.53 (dd, J = 4.5, 8.0 Hz, 1H), 4.27 (s, 1H), 3.77 - 3.72 (m, 1H), 3.36 - 3.20 (m, 3H), 3.22 (s, 3H), 3.03-2.97 (m, 1H), 2.76 (d, 4= 10.6 Hz, 1H), 2.442.14 (m, 2H), 2.08 (m, 2H), 1.99 -1.94 (m, 1H), 1.71 -1.63 (m, 2H), 1.44 (m, 1H) and 1.23 -1.15 (m, 1H) ppm
538	A	A	419.55	1.61	1H NMR (300.0 MHz, DMSO) d 12.53 (s, 1H), 10.32 (s, 1H), 8.69 (dd, J =2.5, 5.2 Hz, 1H), 8.56 (d, J = 2.4 Hz, 1H), 8.31 (m, 2H), 7.97 (s, 1H), 4.76 (m, 1H), 3.92 (m, 2H), 3.84 - 3.55 (m, 2H), 3.40 - 2.80 (m, 3H), 2.14 -1.90 (m, 3H), 1.80 -1.74 (m, 2H), 1.65 (m, 1H), 1.43 -1.23 (m, 2H) and 0.96 - 0.85 (m, 3H)ppm
539	B	A	403.44	2.13
540	A	A	361.5	1.43
541	A	A	390.46	2.43
542	B	B	361.37	1.42

-382WO 2010/148197

PCT/US2010/038988

543	A	A	417.44	2.52
544	D	A	389.42	1.94
545		A	376.46	375.13	1H NMR (300.0 MHz, DMSO) d 12.32 (s, 1H), 8.86 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.20 (d, 1H), 8.15 (d, 1H), 6.92 (d, J = 8.2 Hz, 1H), 4.56 (s, 1H), 4.31 (dd, J = 5.9, 8.6 Hz, 1H), 1.89 -1.35 (m, 8H), 1.17 (s, 3H) and 0.00 (TMS) ppm
546		A	419.49	418.17	1H NMR (300.0 MHz, CDCI3) d 9.60 (s, H), 8.87 (d, J = 2.3 Hz, H), 8.33 (d, J = 2.3 Hz, H), 8.17 (d, J = 2.7 Hz, H), 8.09 (d, J = 3.3 Hz, H), 8.04 (s, H), 7.28 (s, H), 5.34 (d, J = 11.5 Hz, H), 4.45 - 4.42 (m, H), 3.09 (d, J = 11.3 Hz, H), 2.98 (s, H), 2.90 (d, J = 0.5 Hz, H), 2.72 (d, J = 12.9 Hz, H), 2.62 (d, J = 6.3 Hz, H), 2.40 (s, H), 1.94 (d, J = 11.6 Hz, H), 1.86 1.72 (m, H), 1.62 (s, H), 1.27 (s, H) and 1.22 (s, H) ppm
547		A	403.22	3.99	1H NMR (300 MHz, MeOD) d 8.81 (s, 1H), 8.20 (s, 1H), 8.15 (s, 1H), 7.99 (d, J = 4.1,1H), 4.23 (t, J = 11.4, 1H), 3.90 (t, J = 11.4, 1H), 2.35 (d, J = 11.6, 1H), 2.20 (d, J = 12.5, 1H), 2.00 (d, J = 15.9, 2H), 1.92 (s, 3H), 1.67 (dd, J = 26.3,13.2, 1H), 1.53 -1.06 (m, 3H) ppm LCMS
548		A	419.46	2.82
549		A	432.5	2.6
550		A	449.48	448.18	1H NMR (300.0 MHz, DMSO) d 12.33 (s, 1H), 8.72 (d, J = 2.5 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.22 - 8.20 (m, 2H), 6.72-6.62 (m, 1H), 4.61 (dd, J =4.2,10.0 Hz, 1H),4.54(m, 1H), 3.75 - 3.71 (m, 1H), 3.34 - 3.22 (m, 1H), 3.22 (d, 3H), 2.88 - 2.42 (m, 4H), 2.41 - 2.25 (m, 4H), 1.93 (m, 1H), 1.56 (m, 2H), 0.90 (d, J = 6.7 Hz, 3H) and -0.00 (TMS) ppm
551		A	463.51	462.19	1H NMR (300.0 MHz, DMSO) d 12.32 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.19 - 8.16 (m, 2H), 7.32 (d, J =8.0 Hz, 1H), 4.42-4.37 (m, 2H), 3.70 (s, 1H), 3.52 - 3.42 (m, 1H), 3.35 - 3.25 (m, 1H), 2.99 (m, 1H), 2.73 (m, 1H), 2.43 - 2.11 (m, 4H), 1.94 (m, 1H), 1.75 -1,60 (m, 2H), 1.52 -1.40 (M, 1H), 1.10 - 0.99 (m, 6H) and 0.00 (TMS) ppm
552		A	376.23	2.22	CD3OD: 8.7(d, 1H), 8.45(s, 1H), 8.35(d, 1H), 8.25(d, 1H), 4.37(1, 1H), 3.58-3.48(m, 1H), 3.4(s, 3H), 2.55(dd, 1H), 2.232.1(m, 2H), 2.05-1.95(m, 1H), 1.7-1.4(m, 3H), 1.35-1.25(m, 1H), O.OO(TMS)
553	A	A	390.35	2.05	1H NMR (300.0 MHz, MeOD) d 8.89 (d, J = 2.4 Hz, 1H), 8.44 (s, 1H), 8.38 (d, J = 2.3 Hz, 1H), 8.29 (d, J = 5.6 Hz, 1H), 4,75 (m, 1H), 2.75-2.66 (m, 1H), 2.25- 2.16 (m, 2H), 1.99 -1.89 (m, 2H), 1.71-1.29 (m, 4H) and 1.37 (m, contaminant) ppm
554	C	B	390.41	2.3	1H NMR ¢300.0 MHz, MeOD) d 8.89 (d, J =2.4 Hz, 1H), 8.44 (s, 1H), 8.38 (d, J = 2.4 Hz, 1H), 8.29 (d, J = 5.6 Hz, 1H), 4.77 (m, 1H), 2.75 - 2.66 (m, 1H), 2.24 - 2.17 (m, 2H), 1.94 -1.89 (m, 2H) and 1.74-1.36 (m, 4H) ppm
555	C	A	375	1.93	1H NMR (300.0 MHz, MeOD) d 8.75 (d, J = 2.4 Hz, 1H), 8.31 (d, J = 2.4 Hz, 1H), 8.29 (s, 1H), 8.24 (d, J = 4.4 Hz, 1H), 3.96 (dd, J = 5.8, 14.4 Hz, 1H), 3.73 (dd, J =4.3, 14.3 Hz, 1H), 3.08 - 3.00 (m, 1H), 2.05 -1.87 (m, 3H), 1.80 (m, 3H) and 1.48 -1.39 (m, 4H) ppm
556	C	A	446.8	2.8	1H NMR (300.0 MHz, MeOD) d 8.74 (d, J = 2.3 Hz, 1H), 8.42 (s, 1H), 8.38 (d, J = 2.3 Hz, 1H), 8.27 (d, J = 5.4 Hz, 1H), 3.85 - 3.81 (m, 2H), 3.75 (d, J = 8.5 Hz, 2H), 3.26 (s, 3H), 1.97 -1.77 (m, 5H) and 1.43 -1.35 (m, 4H) ppm
557		A	452.6	2.8	1H NMR (300.0 MHz, MeOD) d 8.78 (d, J = 2.4 Hz, 1H), 8.45 (d, J = 4.2 Hz, 1H), 8.37 (d, J = 2.3 Hz, 1H), 8.26 (d, J = 5.4 Hz, 1H), 4.12 (dd, J = 4.5, 13.7 Hz, 1H), 3.89 (dd, J = 7.1, 13.8 Hz, 1H), 3.26-3.16 (m, 1H), 3.00 (s, 3H), 2.18- 1.90 (m, 2H), 1.79 -1.74 (m, 2H) and 1.50-1.25 (m, 4H)

-383WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

					ppm
558	A	A	376.2	2.49	1H NMR (300.0 MHz, MeOD) d 8.78 (d, J = 2.4 Hz, 1H), 8.38 (s, 1H), 8.33 (d, J = 2.2 Hz, 1H), 8.25 (d, J = 5.2 Hz, 1H), 4.98 (dd, J = 7.2 Hz, 1H), 2.27 - 2.03 (m, 5H) and 1.86 1.76 (m, 1H) ppm
559	A	A	389.8	2.27	1H NMR ¢300.0 MHz, MeOD) d 8.75 (d, J = 2.4 Hz, 1H), 8.38 - 8.35 (m, 2H), 8.24 (d, J = 5.1 Hz, 1H), 4.70 - 4.62 (m, 1H), 3.25 - 3.17 (m, 1H), 2.32 (m, 1H), 2.14 -1.80 (m, 4H) and 1.68 -1.54 (m, 3H) ppm
560	C	D	418.46	3.21	H NMR (300.0 MHz, MeOD) d 8.95 (s, 1H), 8.23 - 8.14 (m, 2H), 8.00 (m, 1H), 4.61 (m, 1H), 3.96 - 3.92 (m, 2H), 2.61 (m, 1H), 2.14 - 2.04 (m, 2H), 1.89 - 1.35 (m, 7H) and 1.04 0.99 (m, 3H) ppm
561	B	A	418.41	2.73	H NMR (300.0 MHz, MeOD) d 8.95 (s, 1H), 8.19 (m, 2H), 7.99 (s, 1H), 4.61 (m, 1H), 3.93 (m, 2H), 2.61 (m, 1H), 2.17 - 2.05 (m, 2H), 1.89-1.32 (m, 7H) and 1.00 (m. 3H) ppm
562 (enantiomer 1)	C	A	376.43	8.62	H NMR (300.0 MHz, DMSO) d 8.85 (d, J = 2.5 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.19(s, 1H), 8.14 (d, J =4.2 Hz, 1H), 6.88 (d, J = 8.7 Hz, 1H), 4.52 (s, 1H), 4.32-4.25 (m, 1H), 1.90 -1.33 (m, 8H) and 1.15 (s, 3H) ppm
563 (enantiomer 2)	A	A	376.43	11.16	H NMR (300.0 MHz, DMSO) d 12.31 (s, 1H), 8.86 (d, J = 2.4 Hz, 1H), 8,28 (d, J = 2.4 Hz, 1H), 8.19 (d, J = 2,4 Hz, 1H), 8.16 (d, J = 4.2 Hz, 1H), 6.89 (d, J = 9.6 Hz, 1H), 4.54 (s, 1H), 4.30 (t, J = 8.8 Hz, 1H), 1.86 -1.25 (m, 8H) and 1.16 (s, 3H)ppm
564	C	A	445.7	1.91
565	B	A	376.39	2.43	H NMR (300.0 MHz, DMSO)d 12.48 (s, 1H), 8.71 (d, J = 2.3 Hz, 1H), 8.35 - 8.31 (m, 2H), 8.26 (d, J = 4.3 Hz, 2H), 8.02 (s, 1H), 4.57 - 4.44 (m, 1H), 2.87 (qn, J = 8.3 Hz, 1H), 2.39 2.32 (m, 1H), 2.15 - 2.05 (m, 1H), 2.00 -1.86 (m, 3H) and 1.82-1.70 (m, 1H) ppm
566	A	A	376.4	2.34	H NMR (300.0 MHz, DMSO) d 12.42 (s, 1H), 8.72 (d, J = 2.2 Hz, 1H), 8.29 (m, 2H), 8.22 (d, J = 4.1 Hz, 1H), 7.87 (s, 1H), 4.56 - 4.49 (m, 1H), 2.87 (dd, J = 8.4, 25.0 Hz, 1H), 2.87 (s, 1H), 2.42-2.33 (m, 1H), 2.15-2.04 (m, 1H), 2.00-1.85 (m, 3H) and 1.81 -1.70 (m, 1H)ppm
567	A	A	404.42	2.13	H NMR (300.0 MHz, DMSO) d 12.29 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8,21 (s, 1H), 8.17 (d, J = 4.0 Hz, 1H), 7.41 (d, J = 7.7 Hz, 1H), 7.29 (s, 1H), 7.10 (s, 1H), 4.35 - 4.29 (m, 1H), 2.98 - 2.75 (m, 1H), 2.92 (d, J = 6.8 Hz, 2H), 2.68 (d, J = 10.8 Hz, 1H), 2.29 - 2.19 (m, 2H), 1.96 -1.92 (m, 1H), 1.80 -1.65 (m, 2H) and 1.53-1.42 (m, 1H) PPm
568	C	D	432.46	3.08	H NMR (300.0 MHz, DMSO) d 8.80 (d, J = 2.5 Hz, 1H), 8.27 (d, J = 2.4 Hz, 1H), 8.19(s, 1H), 8.13 (d, J =4.0 Hz, 1H), 7.60 (d, J = 8.6 Hz, 1H), 4.72 (qn, J = 6.2 Hz, 1H), 4.55 4.48 (m, 1H), 2.61 - 2.54 (m, 1H), 1.96 (m, 2H), 1.77 (m, 2H), 1.63 -1.41 (m, 3H), 1.30- 1.23 (m, 1H) and 0.93 (d, J = 6.2 Hz, 6H) ppm
569	C	D	432.48	2.69	H NMR (300.0 MHz, DMSO) d 12.57 (s, 1H), 8.80 (d, J = 2.4 Hz, 1H), 8.36 - 8.28 (m, 4H), 4.75 (td, J = 12.5, 6.2 Hz, 1H), 4.52 (m, 1H), 2.65-2.56 (m, 1H), 2.00 (m, 2H), 1.83-1.76 (m, 2H), 1.57 -1.42 (m, 3H), 1.32 -1.24 (m, 1H) and 0.94 (d, J = 6.2 Hz, 6H) ppm
570	A	A	419.42	2	H NMR (300.0 MHz, MeOD) d 8.81 (d, J = 2.1 Hz, 1H), 8.20 (d, J = 2.3 Hz, 1H), 8.15 (s, 1H), 7.97 (d, J = 4.1 Hz, 1H), 4.26- 4.18 (m, 1H), 3.71 - 3.52 (m, 1H), 3.59 (s, 3H), 2.36 (d, J = 10.5 Hz, 1H), 2.18 (d. J = 10.7 Hz, 1H), 2.04 -1.86 (m, 2H), 1.57 (s, 1H) and 1.43 -1.15 (m, 3H) ppm
571 (diastereomer	A	A	376.41	1.97	CD3OD: 8.69(d, 1H), 8.55(s, 1H), 8.38(d, 1H), 8.33(d, 1H), 4.62(m, 1H), 2.0-1.6(m, 8H), 1.35(s, 3H)

-384WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1)
572 (diasteroemer 2)	A	A	376.42	2.39	CD3OD: 8.78(d, 1H), 8.55(s, 1H), 8.35(s, 1H), 8.25(d, 1H), 4.8(m, 1H), 2.25-1.95(m 2H), 1.80-1.60(m, 4H), 1.45-1.3(m, 2H), 1.3(s, 3H)
573		A	419.42	1.87	H NMR (300.0 MHz, DMSO) d 12.51 (s, 1H), 10.28 -10.00 (m, 1H), 8.70 (s, 1H), 8.38 (s, 1H), 8.31 (d, J = 2.4 Hz, 1H), 8.30 (d. J = 4.2 Hz, 1H), 7.89 - 7.75 (m, 1H), 4.70 - 4.50 (m, 1H), 4.33 - 4.29 (m, 1H), 3.79 - 3.45 (m, 2H), 3.20 - 2.80 (m, 2H), 2.12-1.95 (m, 3H), 1,72 -1.60 (m, 1H) and 1,52 (d, J = 5.5 Hz, 3H) ppm
574		A	448.41	2.99	1H NMR (300.0 MHz, DMSO) d 8.74 (d, J = 2.4 Hz, 1H), 8.24 (d, J =2.4 Hz, 1H), 8.19 (s, 1H), 8.12 (d, J = 4.0 Hz, 1H), 7.55 (d, J = 8.6 Hz, 1H), 4.42 (m, 1H), 4.02 - 3.86 (m, 2H), 3.35 - 3.23 (m, 2H), 3.08 (s, 3H), 2.69 - 2.60 (m, 1H), 1.99 (m, 2H), 1.77 (m, 2H), 1.62 -1.40 (m, 3H) and 1.27 (m, 1H)ppm
575		A	404.38	3.12	1H NMR (300.0 MHz, DMSO) d 8.76 (d, J =2.5 Hz, 1H), 8.26 (d, J =2.4 Hz, 1H), 8.19 (s, 1H), 8.13 (d, J = 4.0 Hz, 1H), 7.53 (d, J = 8.5 Hz, 1H), 4.47 - 4.37 (m, 1H), 3.40 (s, 3H), 2.68 - 2.59 (m, 1H), 2.05 -1.97 (m, 2H), 1.84 - 1.75 (m, 2H), 1.63 -1.40 (m, 3H) and 1.31-1.23 (m, 1H) ppm
576		A	403.4	1.78	1H NMR (300 MHz, MeOD) d 8.81 (s, 1H), 8.20 (s, 1H), 8.15 (s, 1H), 7.99 (d, J = 4.1,1H), 4.23 (t, J= 11.4, 1H>, 3.90 (t, J = 11.4, 1H), 2.35 (d, J = 11.6, 1H), 2.20 (d, J = 12.5, 1H), 2.00 (d, J = 15.9, 2H), 1.92 (s, 3H), 1.67 (dd, J = 26.3,13.2, 1H), 1.53-1.06 (m, 3H).
577		A	405.4	1.95	1H NMR (300.0 MHz, DMSO) d 12.46 (s, 1H), 8.70 (d, J = 2.4 Hz, 1H), 8.36 (d, J = 2.3 Hz, 1H), 8.31 (d, J = 2.4 Hz, 1H), 8.29 (d, J = 3.9 Hz, 1H), 7.79 (d, J = 7.0 Hz, 1H), 4.70 4.50 (m, 1H), 4.21 (s, 2H), 3.80 - 3.70 (m, 1H), 3.55 - 3.47 (m, 1H), 3.20-2.90 (m, 2H), 2.10-1.95 (m, 3H) and 1.691.60 (m, 1H)ppm
578	A	A	390.41	2.82	1H NMR (300.0 MHz, DMSO) d 12.51 (s, 1H), 8.68 (d, J = 2.3 Hz, 1H), 8.33 (d, J = 2.3 Hz, 2H), 8.29 (d, J = 4.3 Hz, 1H), 7.55 (s, 1H), 4.53 (s, 1H), 3.05 (m, 1H), 2.13 (m, 1H), 1.96 (m, 1H), 1.79 (m, 3H) and 1.51 (m, 3H) ppm
579		A	390.36	2.92	1H NMR (300.0 MHz, DMSO) d 12.52 (s, 1H), 8.68 (d, J = 2.3 Hz, 1H), 8.33 (d, J = 2.5 Hz, 2H), 8.30 (d, J = 4.4 Hz, 1H), 7.57 (s, 1H), 4.53 (m, 1H), 3.05 (m, 1H), 2.15 - 2.07 (m, 1H), 1.96 (m, 1H), 1.81 -1.76 (m, 3H) and 1.51 (m, 3H) ppm
580		A	376.44	2.28	1H NMR ¢300.0 MHz, MeOD) d 8.88 (d, 1 H), 8.45 (s, 1H), 8,39 (d, J1H), 8.26 (d, H), 4.53 (t, 1H), 3.95 - 3.88 (m, 1H),2.03 -1.81 (m, 7H), 1.69 (m, 1H), O.O(TMS),
581		A	390.42	3	1H NMR (300,0 MHz, MeOD) d 8.80 (d, 1H), 8.54 (s, 1H), 8.41 (s, 1H), 8.27 (s, 1H), 4.43 (d, 1H), 2.17-1.75 (m, 8H), 1.74 (m,2H), 1.65 (s, 3H), O.OO(TMS)
582		A	404.43	3.21	1H NMR (300,0 MHz, DMSO) d 12.46 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.32-8.28 (m, 3H), 7.10 (d, J = 7.1 Hz, 1H), 4.27-4.20 (m, 1H), 2.26 (d, J = 10.1 Hz, 1H), 1.93 (m, 1H), 1.83 (m, 1H), 1.68 - 1.59 (m, 3H), 1.36 (m, 2H) and 1.24 (s, 3H)ppm
583		A	418,45	1.65	1H NMR (300.0 MHz, MeOD) d 8.72 (d, 1H), 8.6 (d, 1H), 8.3(m, 2H),4.1(m, 1H), 3.9-3.8 (m, 1H), 3.75-3.50(dd, 1H), 2.45-2.35(m, 1H), 2.35-2.15(m, 2H), 1.95-1,85(m 1H), (1.65(dd, 3H), 0.00(TMS) ppm
584		A	483.44	2.52	1H NMR (300.0 MHz, DMSO) d 12.45 (m, 1H), 8.71 (d, J = 8.5 Hz, 1H), 8.31 (m, 2H), 8.01 (m, 1H), 5.33 (s, 1H), 4.62 4.43 (m, 2H), 4.39 - 3.72 (m, 5H), 3.68 (s, 2H), 3.43 - 3.40 (m, 1H), 3.15 (s, 1H), 3.07 (s, 1H), 2.33 (s, 2H) and 2.08 (s, 2H)ppm
585		A	418.41	3.21	1H NMR (300 MHz, MeOD) ? 8.80 ? 8.76 (m, 1H), 8.37 (s,

-385WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

					1H), 8.35 (d, J = 2.3, 1H), 8.27 ? 8.23 (m, 1H), 4.49 ? 4.42 (m, 1H), 2.43 ? 2.34 (m, 1H), 2.09 (d, J = 6.2, 1H), 1.98 ? 1.36 (m, 12H), 0.94 (dd, J = 11.3. 3.8, 3H).
586	A	A	418.38	2.95	1H NMR (300 MHz, MeOD) ? 8.93 ? 8.85 (m, 2H), 8.93 ? 8.87 (m, 1H), 8.31 (dd, J = 4.5,1.2, 2H), 8.31 (dd, J = 4.5, 1.2, 2H), 8.30 (d, J = 2.3, 1H), 8.19 (d, J = 5.0, 1H), 5.26 ? 5.20 (m, 1H), 3.37 (dd, J = 3.3, 1.6, 2H), 3.33 (ddt, J = 6.6, 3.3,1.6, 118H), 2.11 (dd, J = 8.0, 5.8, 2H), 1.80 (tdd, J = 21.2, 18.9, 11.6, 8H), 1.63 ? 1.54 (m, 3H), 0.86 (q, J = 7.4, 4H)
587	A	A	421.4	1.56
588	A	A	421.4	1.56
589		A	427.42	1.56	H NMR (300.0 MHz, DMSO) d 12.32 (s, 1H), 11.99 (m, 1H), 8.70 (d, J =2.3 Hz, 1H), 8.28 (d, J =2.4 Hz, 1H), 8,16 (d, J = 4.0 Hz, 1H), 8.11 (d, J = 2.8 Hz, 1H), 7.32 (d, J =7.3 Hz, 1H), 6.93 (s, 2H), 4.31 (s, 1H), 4.19 (m, 1H), 3.66 (d, J = 14.0 Hz, 1H), 3.55 (d, J = 14.0 Hz, 1H), 3.01 (m, 1H), 2.77 (m, 1H), 2.15 -1.90 (m, 3H), 1.75 -1.68 (m, 1H) and 1.49 1.37 (m, 1H) ppm
590		C	433.37	2.09	H NMR (300.0 MHz, MeOD) d 8.81 (d, 1H), 8.19 (d, 2H), 7.98 (d, 1H), 4.48 (s, 1H), 2.92 - 2.86 (m, 1H), 2.80 2.56(m, 3 H), 1.94-1.83 (m, 3H), 1.72-1.65 (m, 1H), 1.25(d, 6H), 0.00 (s, H) ppm
591	A	A	433.41	2.6	H NMR (300.0 MHz, MeOD) d 8.82 (d, J = 2.4 Hz, 1H), 8.21 (d, J = 2.3 Hz, 1H), 8.16 (s, 1H), 7.99 (d, J =4.1 Hz, 1H), 4.29 - 4.21 (m, 1H), 4.04 - 3.96 (m, 1H), 3.87 (s, 2H), 3.40 (s, 3H), 2.34 (d, J — 11.6 Hz, 1H), 2.21 (d, J = 12.5 Hz, 1H), 2.02-1.93 (m, 2H), 1.74-1.62 (m, 1H) and 1.54-1.28 (m, 3H)ppm
592		A	463.42	2.52	1H NMR (300 MHz, METHANOL-d4) Shift 8.84 (s, 1H), 8.21 (s, 1H), 8.16 (s, 1H), 7.99 (d, J = 3.97 Hz, 1H), 4.18 - 4.34 (m, 1H), 4.14 (br. s„ 2H), 3.49 - 3.74 (m, 3H), 3.3 (s, 3H) 2.38 (d, J = 9.06 Hz, 1H), 2.19 (d, J = 13.41 Hz, 1H), 1.84 2.11 (m, 2H), 1.51-1.78 (m, 1H), 1.12 -1.47 (m, 3H)
593		A	418.21	1.47	H NMR (300.0 MHz, MeOD) d 8.85 (d, J = 2.3 Hz, 1H), 8.22 (d, J = 2.2 Hz, 1H), 8.15 (s, 1H), 7.99 (d, J = 4.1 Hz, 1H), 4.28 - 4.20 (m, 1H), 2.82 - 2.73 (m, 1H), 2.65 (s, 2H), 2.40 (d, J = 10.2 Hz, 1H), 2.15 (d, J = 8.5 Hz, 1H), 2.05 -1.92 (m, 2H), 1.64-1.55 (m, 1H) and 1.44-1.12 (m, 3H) ppm
594	A	A	427.37	1.61	H NMR (300.0 MHz, DMSO) d 12.31 (s, 1H), 11.86 - 11.77 (m, 1H), 8.70 (d, J = 2.2 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.15 (d, J = 3.9 Hz, 1H), 8.10 (d, J =2.5 Hz, 1H), 7.54 (s, 1H), 7.31 (d, J = 7.6 Hz, 1H), 6.87 (s, 1H), 4.19 (m, 1H), 3.57 (d, J = 13.8 Hz, 1H), 3.48 (d, J = 13.8 Hz, 1H), 3.04 (d, J = 8.3 Hz, 1H), 2.80 (d, J = 10.4 Hz, 1H), 2.10 -1.90 (m, 3H), 1.72 -1.62 (m, 2H) and 1.51 -1.35 (m, 1H) ppm
595	A	A	405.37	1.65	H NMR (300.0 MHz, DMSO)d 12.32 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.18-8.15 (m, 2H), 7.32 (d, J = 7.1 Hz, 1H), 4.20 (d, J = 7.1 Hz, 1H), 3.46 (t, J = 5.8 Hz, 2H), 3.19 (s, 3H), 3.10 - 3.06 (m, 1H), 2.82 - 2.78 (m, 1H), 2.57 - 2.50 (m, 2H), 2.11 -1.95 (m, 3H), 1.71 -1.63 (m, 2H) and 1.48 -1.35 (m, 1H) ppm
596	A	A	402.34	2.99	H NMR (300.0 MHz, MeOD) d 8.86 (d, J = 2.3 Hz, 1H), 8.38 (s, 1H), 8.35 (d, J = 2.3 Hz, 1H), 8.25 (d, J = 5.1 Hz, 1H), 4.59 (d, J = 8.1 Hz, 1H), 3.00 (d, J = 8.0 Hz, 1H), 2.62 (m, 1H), 2.55 (m, 1H), 2.11 (d, J = 10.4 Hz, 1H), 1.85 -1.59 (m, 3H) and 1.51 -1.36 (m, 2H) ppm
597	C	A			H NMR (300.0 MHz, MeOD) d 8.78 (d, J = 2.3 Hz, 1H), 8.37 (s, 1H), 8.34 (d, J = 2.3 Hz, 1H), 8.23 (d, J = 4.9 Hz, 1H), 4.71 - 4.67 (m, 1H), 3.25 - 3.22 (m, 1H), 2.94 (m, 1H), 2.77 (m, 1H), 1.86 (d, J = 11.0 Hz, 1H) and 1.70 -1.58 (m, 5H)

-386WO 2010/148197

PCT7US2010/038988

					ppm
598	A	A	432.41	1.83	H NMR (300.0 MHz, MeOD) d 8.86 (d, J = 2.4 Hz, 1H), 8.22 (d, J = 2.3 Hz, 1H), 8.17 (s, 1H), 8.02 - 7.97 (m, 1H), 4.45 (m, 1H), 3.14 (d, J = 10.8 Hz, 1H), 2.75 (d, J = 10.3 Hz, 1H), 2.38 - 2.26 (m, 2H), 2.12 - 2.08 (m, 1H), 1.92 -1.70 (m, 2H), 1.66 -1.55 (m, 1H), 1.20 (d, J = 7.5 Hz, 6H), 0.00 (TMS) PPm .............................
599	A	A	446.46	2.28	H NMR (300.0 MHz, MeOD) d 8.86 (d, J = 2.4 Hz, H), 8.23 (d, J = 2.3 Hz, H), 8.17 (s, H), 8.03 (d, J = 4.1 Hz, H), 4.46 (m, 1H), 3.05 (d, J = 12.8 Hz, 1H), 2.66 (s, 3H), 2.34 (dd, J = 11.3, 20.6 Hz, 2H), 2.08 (d, J = 12.3 Hz, 1H), 1.89-1.71 (m, 2H), 1.66-1.54 (m, 1H), 1.10 (d, J = 6.4 Hz, 6H), and -0.00 (TMS) ppm
600	A	A	460.46	2.31	H NMR (300.0 MHz, MeOD) d 8.81 (d, J = 2.4 Hz, H), 8.22 (d, J = 2.4 Hz, H), 8.14 (s, H), 8.02 (d, J = 4.0 Hz, H), 4.45 4.37 (m, 1H), 3.61 (s, H), 2.97 (d, J = 8.8 Hz, 1H), 2.80 (s, 3H), 2,80-2.75(m, 1H), 2.39-2.32 (m, 2H), 2.32 (s, H), 2.15 (dd, J = 3.6,12.7 Hz, 1H), 1.91 -1.79 (m, 2H), 1.53 -1.47 (m, 1H), 1.10 (d, J = 6.8 Hz, 6H), and -0.00 (TMS) ppm
601	A	A	490.47	2	H NMR (300.0 MHz, MeOD) 8.88 (d, J = 2.3 Hz, H), 8.23 (d, J = 2.3 Hz, H), 8.17 (s, H), 8.02 (d, J = 4.1 Hz, H), 4.47 4.41 (m, 1H), 3.38 (m, H), 3.32 - 3.23 (m, 4H), 3.24(s, 3H), 3.12-3.07 (m, 1H), 2.73 (d, J = 10.8 Hz, 1H), 2.35-2.29 (m, 2H), 2.19-2.15 (m, 1H), 1.91 -1.8O(m, 2H), 1.47-1.42 (m, 1H), 1.10 (d, J = 6.5 Hz, 6H), and -0.00 (s, H) ppm
602	A	A	472.42	2.31	H NMR (300.0 MHz, MeOD) d 8.82 (d, J = 2.4 Hz, H), 8.22 (d, J = 2.3 Hz, H), 8.15 (s, H), 8.01 (d, J = 4.0 Hz, H), 4.41 (m, 1H), 3.02 (d, J = 10.0 Hz, 1H), 2.59 - 2.47 (m, 2H), 2.40 - 2.30 (m, 2H), 2.09 - 2.01 (m, 1H), 1.89 -1.85 (m, 1H), 1.78 -1.66 (m, 1H), 1,61 -1.55(m, 1H), 1.10 (d, J = 6.6 Hz, 6H), 0.68 - 0.63 (m, 2H). 00.44 - 0.40 (m, 2H) and 0.00 (s, H) ppm
603	A	A	434.2	1.54	H NMR (300.0 MHz, DMSO) d 12.31 (s, 1H), 8.71 (d, J = 1.6 Hz, 1H), 8.28 (d, J = 1.5 Hz, 1H), 8.20-8.16 (m, 2H), 7.32 (s, 1H), 7.19-7.11 (m, 1H), 5.20 (s, 1H), 4.24 (s, 1H), 3.99 (s, 1H), 3.01 (d, J = 9.0 Hz, 1H), 2.70 - 2.64 (m, 2H), 2.36 2.27 (m, 3H), 1.94 (s, 1H), 1.71 (s, 2H) and 1.48 (s, 1H) ppm
604	A	A	461.2	1.79	H NMR (300,0 MHz, DMSO) d 8.68 (d, J = 2.2 Hz, 1H), 8.25 (d, J = 2.2 Hz, 1H), 8.19-8.14 (m, 2H), 7.33 (d, J = 7.5 Hz, 1H), 4.21 (t, J = 5.9 Hz, 2H), 4.00 - 3.96 (m, 1H), 3.54 (t, J = 7.6 Hz, 1H), 3.15 (d, J = 8.9 Hz, 1H), 3.03 - 2.91 (m, 1H), 2.78 (d, J = 10.5 Hz, 1H), 2.11 -1.92 (m, 3H), 1.71 (s, 2H), 1.43 -1.35 (m, 1H), 1.27 (s, 3H), 1.22 (s, 1H) and 1.14 (s, 3H)ppm
605	C	C	391.07	1.425	H NMR (300.0 MHz, DMSO) d 12.51 (s, 1H), 8.72-8.57 (m, 3H), 8.35 - 8.32 (m, 3H), 7.94 (d, J = 7.9 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.11 (d, J = 7.9 Hz, 1H), 5.02 (m, 1H), 3.69 (m, 1H), 3.33 - 3.24 (m, 4H), 2.29 (s, 1H) and 2.12 - 2.06 (m, 2H)ppm
606	A	A	432.15	1.62
607	C	C	433.18	1.87	H NMR (300.0 MHz, DMSO) d 12.48 (s, 1H), 8.68 (s, 1H), 8.32 - 8.29 (m, 3H), 7.68 (d, J = 2.5 Hz, 1H), 4.77 - 4.73 (m, 1H), 4.27 - 4.10 (m, 2H), 3.76 - 3.40 (m, 2H), 3.19 - 3.04 (m, 2H) and 2.15-1.83 (m, 6H) ppm. 2.05 and 2.03 (acetyl rotamers, two burried s, 3H)
608	A	A	433.36	2.88	H NMR ¢300.0 MHz, DMSO) d 9.03 (s, 1H), 8.65 (s, 1H), 8.48 (d, J = 5.1 Hz, 1H), 8.41 (s, 1H), 4.64 (s, 1H), 4.27 (s, 1H), 2.97 (m, 2H), 2.30 (d, J = 10.5 Hz, 1H), 2.06 (s, 2H), 1.91 (d, J = 11.2 Hz, 2H), 1.64 -1.23 (m, 5H), 0.99 (t, J = 6.9 Hz, 3H), and 0.00 (TMS), ppm
609	A	A	433.32	2.79	H NMR (300.0 MHz, MeOD) d 8.68(s, 1H), 8.64 (s, 1 H),

-387WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

					8.37 (d, J = 1.8 Hz, 1H), 8.29 (d, J = 5.4 Hz, 1H), 5.15 (s, 1H), , 4.71 - 4.63 (m, 1H), 3.33 (d, J = 11.6 Hz, 1H), 3.10 (m, 2H), 2.26 (m, 2H), 2.04 (m, 3H), 1.83 (m, 1H), 1.70 1.50 (m, 2H). 1.03 (m,3H), and 0.00 (TMS) ppm
610	A	C	449.42	1.52	H NMR (300.0 MHz, MeOD) d 8.85 (d, J = 2.3 Hz, 1H), 8.22 (d, J = 2.2 Hz, 1H), 8.15 (s, 1H), 7.98 (d, J =4.1 Hz, 1H), 4.20 (m, 1H), 3.82 (dd, J = 3.9, 8.2 Hz, 1H), 3.55 - 3.45 (m, 1H), 3.30 (s, 3H), 3.23 - 3.07 (m, 1H), 2.86 - 2.77 (m, 2H), 2.68 - 2.59 (m, 1H), 2.44 (d, J = 10.9 Hz, 1H), 2.15 (d, J = 9.8 Hz, 1H), 2.07 - 1.94 (m, 2H), 1.65 -1.56 (m, 1H) and 1.42-1.17 (m, 3H)ppm
611	A	A	447.4	1.95	H NMR ¢300.0 MHz, MeOD) d 8.78 (d, J = 2.3 Hz, 1H), 8.19 (d, J = 2.2 Hz, 1H), 8.14 (s, 1H), 7.96 (d, J = 4.0 Hz, 1H), 4.25 - 4.18 (m, 1H), 3.96 - 3.88 (m, 1H), 3.61 (t, J = 6.2 Hz, 2H), 3.31 (s, 3H), 2.39 (t, J = 6.2 Hz, 2H), 2.37 (d, J = 17.1 Hz, 1H), 2.18 (d, J = 12.0 Hz, 1H), 2.03 -1.91 (m, 2H), 1.67 (q. J = 13.4 Hz, 1H) and 1.45 -1.22 (m, 3H) ppm
612	A	A	418.37	4.59	H NMR (300.0 MHz, MeOD) d 8.77 (s, 1H), 8.37 (d, J = 2.7 Hz, 2H), 8.26 (d, J = 4.7 Hz, 1H), 4.46 (m, 1H), 2.39 (m, 1H), 2.10 (m, 1H), 1.92 -1.35 (m, 8H) and 0.93 (t, J = 7.7 Hz, 3H) ppm
613	A	A	388.13	1.82
614	A	A	459.35	3.06	H NMR (300.0 MHz, DMSO) d 12.32 (s, 1H), 8.72 (s, 1H), 8.29 (s, 1H), 8.18 (s, 2H), 7.31 (d, J = 6.2 Hz, 1H), 6.10 (d, J = 5.3 Hz, 1H), 4.16 (s, 2H), 3.04 (s, 1H), 2.79 (d, J = 8.6 Hz, 1H), 2.59 (d, J = 9.9 Hz, 2H), 2.26 (t, J = 9.5 Hz, 2H), 1.94 (s, 1H), 1.72 (s, 2H) and 1.48 (s, 1H) ppm
615	A	A	378.3	3.59
616	C	C	378.3	3.74
617 (diasteromer 1)	A	A	386.35	3.58	H NMR (300.0 MHz, DMSO) d 13.15 (s, H), 9.58 (s, 1H), 9.49 (d, J = 6.4 Hz, 111H), 9.23 (s, H), 8.59 (s, H), 8.52 (d, J = 5.0 Hz, 1H), 8.42(s, 1H), 4.52 (s, 1H), 3.34 (s, 1H), 3.17 (s, 1H), 2.11 (s, 2H), 1.96 -1.85 (m, 4H), 1.5-1.2 (m, 2H), and -0.00 (s, H) ppm
618 (diasteromer 2)	A	A	386.34	3.16	H NMR (300.0 MHz, DMSO) d 13.13 (s, 1H), 9.45 (s, 1H), 9.28 (s, 1H), 8.66 (s, 1H), 8.51 (d, J = 5.1 Hz, 1H), 8.42 (s, 1H), 4.61 (s, 1H), 3.33 (s, 1H), 3.17 (s, 1H), 2.16 (d, J = 12.5 Hz, H), 2.06 (s, 1H), 2.02-1.78 (m, 4H), 1.66-1.60 (m, 2H), 1.46 (m, 1H), and 0.00 (s, H) ppm
619	A	A	446.23	2.23	H NMR (300.0 MHz, DMSO) d 12.30 (s, 1H), 8.71 (s, 1H), 8.28 (s, 1H), 8.17 (d, J = 6.9 Hz, 2H), 7.42 (s, 1H), 7.35 (d, J = 7.6 Hz, 1H), 4.73 (d, J = 7.4 Hz, 1H), 4.23 (s, 1H), 3.51 (d, J =5.8 Hz, 1H), 3.17 (dd, J = 9.2,17.9 Hz, 1H), 3.04 (d, J = 10.9 Hz, 2H), 2.89 (s, 1H), 2.63 (d, J = 5.6 Hz, 1H), 2.25 (d, J = 11.4 Hz, 1H), 2.18 - 2.07 (m, 2H), 1.70 (d, J = 11.3 Hz, 2H) and 1.43 -1.35 (m, 1H) ppm
620	B	A	400.41	1.92
621	A	A	445.45	2.39
622	A	A	431.42	2.46
623	A	A	435.4	3.62	H NMR (300.0 MHz, DMSO) d 12.32 (s, 1H), 8.69 (s, 1H), 8.35 - 8.25 (m, 1H), 8.27 (d, J = 2.4 Hz, 1H), 8.21 (d, J = 3.9 Hz, 1H), 7.51 (d, J = 6.7 Hz, 1H), 5.02 - 4.60 (m, 3H), 4.37 4.20 (m, 3H), 3.62 - 3.40 (m, 2H), 3.17-2.62 (m, 2H), 2.10 (s, 1H) and 1.85 -1.60 (m, 3H) ppm
624	A	B	378.15	2.49	MeOH d4 8.8 (d, 1H); 8.2 (d, 1H); 8.1 (s, 1H); 7.9 (d, 1H); 4.2 (dd, 1HJ; 3.6 (dt, 1H); 3.4 (dd, 1H); 2.2 (bd, 1H); 2.05 (bd, 1H); 1.8 (dr, 1H); 1.6 (m, 1H); 1.4 (m, 2H).
625	A	A	378.34	2.42	MeOH d4 8.8 (d, 1H); 8.2 (d, 1H); 8.1 (s, 1H); 7.9 (d, 1H); 4.2 (dd, 1HJ; 3.6 (dt, 1H); 3.4 (dd, 1H); 2.2 (bd, 1H); 2.05 (bd, 1H); 1.8 (dr, 1H); 1.6 (m, 1H); 1.4 (m, 2H).

-388WO 2010/148197

PCT7US2010/038988

2018200219 11 Jan 2018

626	A	A	390.39	4.05	H NMR (300.0 MHz, CDCI3) d 8.87 (d, J = 2.3 Hz, 1H), 8.31 (d, J = 2.3 Hz,1 H), 8.17 (d, J = 2.7 Hz, 1H), 8.03 (d, J = 3.5 Hz, 1H), 7.28(CDCI3), 6.8 (s, 1H), 4.67 (m, 1H), 2.1-1.88 (m, 4H), 1.8-1.50 (m, 7H), 0.99 (t, J = 7.5 Hz, 3H) ppm
627 (diasteromer 1)	A	A	388.36	4.01	H NMR (300.0 MHz, CDCI3) d 9.65 (s,1 H), 8.97 (s, 1H), 8.31 (d, J = 2.3 Hz, 1H), 8.15 (d, J = 2.7 Hz, 1H), 8.05 (d, J = 3.4 Hz, 1H), 7.28(s, CDCI3), 6.75 (s, 1H), 6.06 (dd, J = 10.7, 17.3 Hz, 1H), 5.32 (d, J = 3.9 Hz, 1H), 5.18 (d, J = 10.8 Hz, 1H), 4.66 (qn, J = 4.0 Hz, 1H),2.08 -1.86 (m, 4H), 1.79-1.61 (m, 6H), 1pp
628 (diasteromer 2)	A	A	388.37	3.65	H NMR (300.0 MHz, CDC!3)d 9.62 (s, 1H), 8.95 (s, 1H), 8.34 (3, 1H), 8.20 (s, 1H), 8.10(s, 1H), 7.28(s, CDCI3), 6.03 (dd, J = 10.7,17.3 Hz, 1H), 5.39-5.30 (m, 1H), 5.10 (d, J = 10.7 Hz, 1H), 4.87-4.81 (m, 1H), 4.76 - 4.64 (m, 1H), 2.292.24 (m, 2H), 2.19 - 2.02 (m, 2H), 1.84 -1.78 (m, 3H), 1.62 -1.21 (m, 3H), ppm
629	A	A	446.23	4.45
630	A	A	390.36	3.95	H NMR (300.0 MHz, MeOD) d 8.72 (s, 1H), 8.53 (s, 1H), 8.39 (s, 1H), 8.30 (s, 1H), 4.65 - 4.60 (m, 1H), 2.66 (t, J = 11.3 Hz, 1H), 2.46 (d, J = 10.2 Hz, 1H), 2.17 - 2.04 (m, 3H) and 1.57 -1.44 (m, 4H) ppm
631	A	A	378.15	3.1
632	A	A	378.15	2.97
633	A	A	473.42	3.25	H NMR (300.0 MHz, MeOD) d 8.64 (d, J = 2.2 Hz, 1H), 8.51 (s, 1H), 8.36 (d, J = 2.2 Hz, 1H), 8.29 (d, J = 5.5 Hz, 1H), 4.39 (t, J = 11.9 Hz, 1H), 3.93 - 3.82 (m, 3H), 3.54 - 3.30 (m, 2H), 2.52 - 2.43 (m, 1H), 2.37 - 2.33 (m, 1H), 2.20 (d, J = 11.6 Hz, 1H), 2.01 (d, J = 11.3 Hz, 2H), 1.90 -1.88 (m, 1H), 1.83 -1.63 (m, 4H) and 1.59-1.26 (m, 3H) ppm
634	A	A	433.21	3.47	H NMR (300.0 MHz, MeOD) d 8.61 (d, J = 2.1 Hz, 1H), 8.53 (s, 1H), 8.35 <d, J = 2.0 Hz, 1H), 8.29 (d, J = 5.5 Hz, 1H), 4.37 (t, J = 11.2 Hz, 1H), 3.95 (s, 1H), 3.80 (s, 2H), 2.42 (t, J = 5.5 Hz, 3H), 2.20 (d, J = 11.5 Hz, 1H), 2.03 (d, J = 11.0 Hz, 2H) and 1.76-1.29 (m, 4H) ppm
635	A	A	459.38	3.12	H NMR (300.0 MHz, MeOD) d 8.48 - 8.45 (m, 2H), 8.29 8.23 (m, 2H), 4.84 (d, J = 6.0 Hz, 1H), 4.38 (d, J = 6.0 Hz, 1H), 4.26 - 4.23 (m, 1H), 3.96 (s, 1H), 3.77 - 3.62 (m, 2H), 2.36 (s, 1H), 2.18 (d, J = 11.5 Hz, 1H), 2.02 (d, J = 12.3 Hz, 2H), 1.70 -1.25 (m, 4H) and 1.59 (s, 3H) ppm
636	A	A	473.4	3.12	H NMR (300.0 MHz, MeOD) d 8.64 (d, J = 2.3 Hz, 1H), 8.51 (s, 1H), 8.36 (d, J = 2.3 Hz, 1H), 8.29 (d, J = 5.6 Hz, 1H), 4.44 - 4.36 (m, 1H), 3.96 - 3.87 (m, 3H), 3.47 - 3.37 (m, 2H), 2.49 - 2.35 (m, 2H), 2.21 (d, J = 12.4 Hz, 1H), 2.02 (d, J = 11.9 Hz, 2H) and 1.83 - 1.23 (m, 8H) ppm
637	A	A	474.43	2.39	H NMR (300.0 MHz, MeOD) d 8.68 (s, 1H), 8.62 (s, 1H), 8.40 (s, 1H), 8.33 (d, J = 4.7 Hz, 1H), 4.44 - 4.35 (m, 2H), 4.21 (d, J = 12.2 Hz, 1H), 4.04 - 3.92 (m, 2H), 3.58 (d, J = 12.3 Hz, 1H), 3.23 - 3.08 (m, 2H), 2.37 (d, J = 8.1 Hz, 1H), 2.23 (d, J = 11.1 Hz, 1H), 2.05 (d, J = 9.7 Hz, 2H), 1.72 (m, 2H) and 1.59-1.44 (m, 2H) ppm
638	A	A	459.37	3.77	H NMR (300.0 MHz, MeOD) d 8.55 (d, J = 1.0 Hz, 1H), 8.46 - 8.45 (m, 1H), 8.29 - 8.27 (m, 2H), 4.28 (d, J = 6.1 Hz, 2H), 4.00 - 3.87 (m, 3H), 2.36 - 2.16 (m, 3H), 2.00 -1.91 (m, 5H) and 1.75 -1.41 (m, 4H) ppm
639	C	C	472.46	2.39	H NMR (300.0 MHz, MeOD) d 8.66 (s, 1H), 8.60 (s, 1H), 8.38 (s, 1H), 8.31 (d, J = 4.7 Hz, 1H), 4.43 - 4.36 (m, 1H), 3.98 - 3.91 (m, 1H), 3.43 (d, J = 10.3 Hz, 2H), 3.03 (t, J = 10.6 Hz, 2H), 2.60 (s, 1H), 2.38 (d, J = 10.2 Hz, 1H), 2.21 (d, J = 10.6 Hz, 1H), 2.07 -1.92 (m, 6H) and 1.74-1.30 (m, 4H) ppm
640	A	A	447.41	3.37	H NMR (300.0 MHz, MeOD) d 8.69 (d, J = 2.3 Hz, 1H), 8.51

-389WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

(diasteromer 1)					(s, 1H), 8.37 (d, J = 2.2 Hz, 1H), 8.29 (d, J = 5.6 Hz, 1H), 4.43 (t, J = 11.9 Hz, 1H), 4.14 (q, J = 6.1 Hz, 1H), 3.94 (t, J = 11.9 Hz, 1H), 2.40 - 2.19 (m, 4H), 2.03 (d, J = 8.2 Hz, 2H), 1.78 -1.69 (m, 1H), 1.59 -1.44 (m, 3H) and 1.18 (d, J = 6.1 Hz, 3H) ppm
641 (diasteromer 2)	A	A	447.41	3.47	H NMR (300.0 MHz, MeOD) d 8.69 (d, J = 2.3 Hz, 1H), 8.51 (s, 1H), 8.37 (d, J = 2.2 Hz, 1H), 8.29 (d, J = 5.6 Hz, 1H), 4.43 (t, J = 11.9 Hz, 1H), 4.14 (q, J = 6.1 Hz, 1H), 3.94 (t, J = 11.9 Hz, 1H), 2.40 - 2.19 (m, 4H), 2.03 (d, J = 8.2 Hz, 2H), 1.78 -1.69 (m, 1H), 1.59-1.44 (m, 3H) and 1.18 (d, J = 6.1 Hz, 3H) ppm
642	A	A	433.38	3.52	H NMR (300.0 MHz, MeOD) d 8.68 (s, 1H), 8.56 (s, 1H), 8.39 (d, J = 1.5 Hz, 1H), 8.31 (d, J = 5.3 Hz, 1H), 4.47 - 4.40 (m, 1H), 4.15 (s, 1H), 3.98 (m, 1H), 2.41 (s, 1H), 2.23 (d, J = 10.6 Hz, 1H), 2.04 (d, J = 11.0 Hz, 2H) and 1.77 - 1.36 (m, 7H)ppm
643	A	A	404.36	3.3	H NMR (300.0 MHz, MeOD) d 8.98 (d, J = 2.3 Hz, 1H), 8.45 (s, 1H), 8.38 (d, J = 2.3 Hz, 1H), 8.30 (d, J = 5.7 Hz, 1H), 5.26 - 5.22 (m, 1H), 2.17 - 2.10 (m, 1H), 1.87 -1.82 (m, 4H), 1.68-1.59 (m, 3H)and 1.36 (s, 3H) ppm
644	C	C	418.4	3.37	H NMR (300.0 MHz, MeOD) d 8.87 (d, J = 2.3 Hz, 1H), 8.45 (s, 1H), 8.38 (d, J = 2.3 Hz, 1H), 8.31 (d, J = 5.6 Hz, 1H), 5.26 - 5.23 (m, 1H), 2.14 - 2.09 (m, 1H), 1.96 -1.72 (m, 6H), 1.59 (s, 3H) and 0.87 (t, J = 7.4 Hz, 3H) ppm
645	A	A	418.41	3.37	H NMR (300.0 MHz, MeOD) d 8.87 (d, J = 2.3 Hz, 1H), 8.46 (s, 1H), 8.37 (d, J = 2.3 Hz, 1H), 8.30 (d, J = 5.6 Hz, 1H), 5.25 - 5.23 (m, 1H), 2.17 - 2.09 (m, 1H), 1.98 -1.74 (m, 6H), 1.58 (m, 3H) and 0,87 (t, J = 7.4 Hz, 3H) ppm
646	A	A	392.35	3.35	H NMR (300.0 MHz, DMSO)d 12.30 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.20 - 8.15 (m, 2H), 4.57 4.54 (m, 1H), 4.4-4.3(5, 1H), 4.08-4.01 (m, 1H), 3.37-3.29 (m, 2H), 3.17 (d, J = 5.3 Hz, H), 2.50(qn, J = 1,7Hz DMSO), 1.99 (s, 1H), 1.91 (d, J = 3.6 Hz, H), 1.77 -1.65 (m, 6H), 1.59 (d, J = 7.5 Hz, 1H).
647	A	A	474.4	3.59	H NMR (300.0 MHz, MeOD) d 8.56 (s, 1H), 8.50 (d, J = 2.2 Hz, 1H), 8.30 (t, J = 5.6 Hz, 1H), 8.31 (s, 1H), 4.26 (t, J = 11.2 Hz, 1H), 3.82 (t, J = 11.1 Hz, 1H), 3.65-3.61 (m, 4H), 3.39 - 3.36 (m, 4H), 2.36 (d, J = 10.0 Hz, 1H), 2.17 (d, J = 12.0 Hz, 1H), 2.02 (d, J = 10.2 Hz, 2H)and 1.70-1.32 (m, 4H)ppm
648	A	A	489.38	3.67	H NMR (300.0 MHz, MeOD) d 8,65 (s, 1H), 8.52 (d, J = 1.6 Hz, 1H), 8,37 (d, J = 2.0 Hz, 1H), 8.28 (dd, J = 2.9, 5.5 Hz, 1H), 4.39 (s, 1H), 4.06 - 3.54 (m, 7H), 2.55 - 2.38 (m, 2H), 2.19 (d, J = 10.7 Hz, 1H), 2.03 -1.99 (m, 3H) and 1.69 -1.24 (m, 5H)ppm
649	A	A	475.37	3.32	H NMR (300.0 MHz, MeOD) d 8.79 (d, J = 2.3 Hz, 1H), 8.51 (s, 1H), 8.44 (d, J = 2.2 Hz, 1H), 8.32 (d, J = 5.6 Hz, 1H), 5.22 (dd, J = 4.4, 6.0 Hz, 1H), 4.53 - 4.45 (m, 1H), 4.21 3.50 (m, 5H), 2.52 - 2.43 (m, 1H), 2.27 - 2.04 (m, 5H) and 1.72 -1.27 (m, 4H) ppm
650	A	A	461.38	3.79	H NMR (300.0 MHz, MeOD) d 8.56 - 8.54 (m, 2H), 8.34 (s, 1H), 8.30 (t, J = 5.4 Hz, 1H), 4.29 (t, J = 11.4 Hz, 1H), 3.93 (t, J = 11.6 Hz, 1H), 3.54 (s, 2H), 2.34 (d, J = 10.8 Hz, 1H), 2.18 (d, J = 11.4 Hz, 1H), 2.01 (d, J = 11.3 Hz, 2H), 1.731.37 (m, 4H) and 1.15 (s, 6H) ppm
651	A	A	473.41	4.1	H NMR (300.0 MHz, MeOD) d 8.56 - 8.51 (m, 2H), 8.33 8.29 (m, 2H), 4.30 (d, J = 3.0 Hz, 1H), 3.98 (dd, J = 11.5, 23.4 Hz, 2H), 3.83 - 3.79 (m, 1H), 3.55 (t, J = 8.9 Hz, 1H), 2.35 (d, J = 11.1 Hz, 1H), 2.19 (d, J = 11.2 Hz, 1H), 2.031.90 (m, 4H) and 1.73 - 1.37 (m, 8H) ppm
652	A	A	459.41	3.86	H NMR (300.0 MHz, MeOD) d 8.72 (d, J = 2.3 Hz, 1H), 8.56

-390WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

					(s, 1H), 8.42 (d, J = 2.2 Hz, 1H), 8.34 (d, J = 5.6 Hz, 1H), 4.51 - 4.43 (m, 1H), 4.02 - 3.88 (m, 3H), 3.86 - 3.78 (m, 2H), 3.07 - 3.02 (m, 1H), 2.42 (d, J = 7.5 Hz, 1H), 2.25 (d, J = 12.0 Hz, 1H), 2.19 - 2.06 (m, 4H) and 1.79 -1.35 (m, 4H) ppm
653	A	A	418.4	3.37	H NMR (300.0 MHz, MeOD) d 8.87 (d, J = 2.0 Hz, 1H), 8.28 (s, 1H), 8.19 (d, J = 1.8 Hz, 1H), 8.01 (d, J = 3.7 Hz, 1H), 4.90 (m, 1H), 2.12 (m, 2H), 1.76 -1.58 (m, 7H) and 0.86 (t, J = 7.3 Hz, 3H) ppm
654	B	B	411.37	2.87
655 (diasteromer 1)	A	A	376.39	3.93	H NMR (300.0 MHz, CDCI3) d 10.63 (s, 1H), 8.85-8.82 (m, 1H), 8.27 (dd, J = 2.4,12.5 Hz, 1H), 8.17 - 8.14 (m, 1H), 8.03 (d, J = 3.4 Hz, 1H), 7.28 (s, H), 4.84 (d, J = 6.3 Hz, 1H), 4.58 (dq, J = 3.9,15.7 Hz, 1H), 2.26 (d, J = 12.0 Hz, 2H), 2.09 -1.95 (m, 2H), 1.84-1.75 (m, 3H), 1.47 -1.32 (m, 5H) and 1.22 (td, J = 12.4, 5.2 Hz, 1H) ppm
656 (diasteromer 2)	A	A	376.38	4.01	H NMR (300.0 MHz, CDCI3) d 9.54 (s, 1H), 8.86 (d, J = 2.3 Hz, 1H), 8.31 (d, J = 2.4 Hz, 1H), 8.15 (d, J = 2.7 Hz, 1H), 8.04 (d, J = 3.5 Hz, 1H), 7.28 (s, H), 6.66 (s, 1H), 4.62 - 4.59 (m, 1H), 1.96 -1.88 (m, 4H), 1.81 (dd, J = 4.5, 14.9 Hz, 2H) and 1.68 -1.57 (m, 5H) ppm
657	C	C	394.41	2.97	H NMR (300.0 MHz, DMSO) d 12.41 (s, 1H), 8.80 (d, J = 2.3 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.25 (s, 1H), 8.17 (d, J = 4.0 Hz, 1H), 7.64 (s, 1H), 4.80 - 4.50 (m, 3H), 4.47 (dd, J = 7.5, 14.8 Hz, 1H), 3.89 (dd, J = 5.3, 6.3 Hz, 1H), 3.77 (dd, J = 5.1,5.0 Hz, 1H), 3.50-3.37 (m, 2H), 2.36 - 2.24 (m, 1H), 2.04 (dd, J = 8.3,13.5 Hz, 1H), 1.99 (s, 1H), 1.27 (td, J = 8.4, 4.4 Hz, 1H) and 1.21 (s, 1H) ppm
658	A	A	459.29	3.5
659	A	A	445.21	3.41
660	A	A	445.21	3.35
661	A	A	395,17	2.13
662	A	A			H NMR (300.0 MHz, DMSO) d 12.26 (s, 1H), 8.42 (dd, J = 2.8, 9.8 Hz, 1H), 8.27 (q, J = 1.3 Hz, 1H), 8.21 (d, J = 2.7 Hz, 1H), 8.16 (d, J = 4.0 Hz, 1H), 7.35 (d, J =7.4 Hz, 1H), 4.49 (m, 1H), 4.39 (d, J = 4.0 Hz, 1H), 4.24-4.21 (m, 1H), 3.64 - 3.61 (m, 1H), 3.05 - 3.02 (m, 1H), 2.77 (t, J = 9.7 Hz, 1H), 2.36 (ddd, J = 4.8,12.7, 12.7 Hz, 2H), 2.18 - 2.12 (m, 2H), 1.95 -1.91 (m, 1H), 1.76 -1.72 (m, 1H) and 1.66 -1.41 (m, 2H)ppm
663	A	A	445.34	2.64
664	A	A	431.26	2.48
665	A	A	431.26	2.53
666	D		428.3	2.6
667	D		414.5	1.4
668		A	429.3	3.51	H NMR (300.0 MHz, DMSO)d 12.32 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.18 - 8.16 (m, 2H), 7.38 (d, J = 7.7 Hz, 1H), 4.22 -4.17 (m, 1H), 3.31 -3.16(m, 3H), 2.90 (m, 1H), 2.40 (t, J = 10.2 Hz, 2H), 2.00 -1.95 (m, 1H), 1.77 -1.60 (m, 2H) and 1.50 -1.38 (m, 1H) ppm
669	A	A	386.08	2.26	H NMR: (300.0 MHz, DMSO) d 12.31 (s, 1H), 8.69 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.19-8.17 (m, 2H), 7.47 (d, J = 7.7 Hz, 1H), 4.30 - 4.20 (m, 1H), 3.80 (s, 2H), 3.07 3.03 (m, 1H), 2.82 - 2.73 (m, 1H), 2.29 - 2.10 (m, 2H), 2.05 1.96 (m, 1H), 1.87 -1.65 (m, 2H) and 1.49 -1.40 (m, 1H) ppm
670	C	C	559.42	3.57	H NMR (300.0 MHz, MeOD) d 8.64 (d, J = 2.3 Hz, 1H), 8,40 (s, 1H), 8.32 (d, J = 2.3 Hz, 1H), 8.29 (d, J = 5.0 Hz, 1H), 6.96 (m, 1H), 4.84-4.80 (m, 1H), 4.34 (m, 1H), 4.29-4.19 (m, 3H), 3.54 - 3.47 (m, 1H), 3.15-3.07 (m, 1H), 2.68-2.58

-391WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

					(m, 1H), 1.92 (s, 3H), 1.59-1.51 (m, 4H), 1.26 (t, J = 7.1 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H) and 0.89 (t, J = 7.4 Hz, 3H) ppm
671	C	C	531.4	3.14	H NMR (300.0 MHz, MeOD) d 8.66 (d, J = 2.3 Hz, 1H), 8.39 (s, 1H), 8.32 (d, J = 2.3 Hz, 1H), 8.29 (d, J = 5.0 Hz, 1H), 6.97 (m, 1H), 4.82 - 4.79 (m, 1H), 4.34 (m, 1H), 4.25 (dd, J = 7.6, 10.1 Hz, 1H), 3.54 - 3.47 (m, 2H), 3.11 -3.04 (m, 1H), 2.65 - 2.57 (m, 1H), 1.91 (s, 3H), 1.59 (m, 4H), 0.95 (t, J = 7.4 Hz, 3H) and 0.89 (t, J = 7.4 Hz, 3H) ppm

Table 2: IC50, EC50, NMR and LCMS Data of Compounds of FIGs. 4 and 5:

Compound Nos.	ICso	ec_m	LCMS_ Plus	1_CMS_ RT	NMR
672	A	A	432.28	3.83
673	A	A	448.28	3.81
674	A	A	405.15	3.16
675	C	C	428.32	2.2
676	A	A	445.34	2.45
677	A	A	404.38	3.32	H NMR (300.0 MHz, MeOD) d 8.93 (d, J = 2.4 Hz, 1H), 8.21 - 8.19 (m, 2H), 7.97 (d, J = 4.0 Hz, 1H), 4.81 (dd, J = 2.8, 9.4 Hz, 1H), 2.24 - 2.16 (m, 1H), 2.11 2.05 (m, 1H), 1.74 (m, 2H), 1.63 -1.52 (m, 4H) and 1.26 (s, 3H) ppm
678	A	A	388.44	3.13	H NMR (300.0 MHz, MeOD) d 8.67 (dd, J = 2.4, 9.1 Hz, 1H), 8.47(s, 1H), 8.34-8.31 (m, 2H), 5.27-5.23 (m, 1H), 2.12-2.04 (m, 1H), 1.88-1.80 (m, 4H), 1.66 -1.56 (m, 3H) and 1.35 (s, 3H) ppm
679	A	A	471.06	3.28
680	A	A	471.19	3.31
681	A	A	447.5	3.65	H NMR (300.0 MHz, MeOD) d 8.69 (d, J = 2.3 Hz, 1H), 8.49 (s, 1H), 8.36 (t, J = 2.2 Hz, 1H), 8.27 (d, J = 5.6 Hz, 1H), 4.42 (t, J = 3.8 Hz, 1H), 3.89 (t, J = 3.5 Hz, 1H), 2.33 (d, J = 6.0 Hz, 1H), 2.22 (d, J = 11.4 Hz, 1H), 2.00 (d, J = 11.8 Hz, 2H), 1.78 -1.39 (m, 4H) and 1.34 (d, J = 8.3 Hz, 6H) ppm
682	A	A	473.49	3.96	H NMR (300.0 MHz, MeOD) d 8.68 (d, J = 1.7 Hz, 1H), 8.49 (d, J = 0.8 Hz, 1H), 8.36 (d, J = 2.3 Hz, 1H), 8.27 (d, J = 5.6 Hz, 1H), 4.47-4.38 (m, 1H), 3.94 3.87 (m, 3H), 2.33 - 2.19 (m, 3H), 2.04 -1.88 (m, 3H), 1.90 -1.73 (m, 2H), 1.73 -1.41 (m, 4H) and 1.36 (d, J = 8.6 Hz, 3H) ppm
683	A	A	417.49	3.85	H NMR (300.0 MHz, MeOD) d 8.67 (d, J = 2.3 Hz, 1H), 8.51 (s, 1H), 8.37 (d, J = 2.3 Hz, 1H), 8.28 (d, J = 5.6 Hz, 1H), 4.46 - 4.36 (m, 1H), 3.95 - 3.87 (m, 1H), 2.35 (d, J = 11.7 Hz, 1H), 2.23 - 2.16 (m, 3H), 2.02 (d, J = 10.5 Hz, 2H), 1.77-1.64 (m, 1H), 1.58-1.43 (m, 2H), 1.40 -1.23 (m, 1H) and 1.11 (t, J = 7.6 Hz, 3H) ppm
684	A	A	429.49	3.86	H NMR (300.0 MHz, MeOD) d 8.61 (d, J = 2.3 Hz, 1H), 8.51 (s, 1H), 8.35 (d, J = 2.3 Hz, 1H), 8.29 (d, J = 5.6 Hz, 1H), 4.42 - 4.32 (m, 1H), 3.96 - 3.88 (m, 1H), 2.35 (d, J = 11.7 Hz, 1H), 2.19 (d, J = 12.0 Hz, 1H), 2.04 - 2.00 (m, 2H), 1.72 -1.27 (m, 5H) and 0.88 0.70 (m, 4H) ppm

-392WO 2010/148197

PCT/US2010/038988

685	A	A	431.49	3.87	H NMR (300.0 MHz, MeOD) d 8.60 (d, J = 2.3 Hz, 1H), 8.56 - 8.52 (m, 1H), 8.33 (dd, J = 2.3, 5.7 Hz, 1H), 8.28 (d, J = 5.6 Hz, 1H), 4.39 - 4.30 (m, 1H), 3.94 - 3.86 (m, 1H), 2.48 - 2.34 (m, 2H), 2,17 (d, J = 11.8 Hz, 1H), 1.99 (d, J = 11.8 Hz, 2H), 1.71 -1.67 (m, 1H), 1.62-1.27 (m, 3H)and 1.10 (d, J =6.1 Hz, 6H) ppm
686	A	A	443.49	3.99	H NMR (300.0 MHz, MeOD) d 8.62 (d, J = 2.3 Hz, 1H), 8.51 (s, 1H), 8.35 (d, J = 2.3 Hz, 1H), 8.28 (d, J = 5.6 Hz, 1H), 4.43 - 4.32 (m, 1H), 4.00 - 3.92 (m, 1H), 2.31 (d, J= 11.8 Hz, 1H), 2.21 (d, J = 12.1 Hz, 1H), 2.04 -1.97 (m, 2H), 1.76-1.58 (m, 2H), 1.53-1.33 (m, 2H), 1.32 (s, 3H), 1.18 -1.03 (m, 2H) and 0.63 0.55 (m, 2H) ppm
687	A	C	450.2	3.43
688	A	A	475.41	4.65
689	A	A	445.47	3.7	H NMR (300.0 MHz, MeOD) d 8.69 (d, J = 2.3 Hz, 1H), 8.49 (s, 1H), 8.37 (d, J = 2.2 Hz, 1H), 8.27 (d, J = 5.6 Hz, 1H), 4.48 - 4.41 (m, 1H), 4.00 - 3.93 (m, 1H), 2.35 (d, J = 6.0 Hz, 1H), 2.22 (d, J = 11.3 Hz, 1H), 2.03 (d, J = 13.0 Hz, 2H), 1.74-1.35 (m, 4H), 1.18 1.14 (m, 2H) and 0.99 - 0.86 (m, 2H) ppm
690	A	A	469.47	3.34·	H NMR (300.0 MHz, DMSO) d 12.33 (s, 1H), 8.70 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.20 (d, J = 2.6 Hz, 1H), 8.17 (d, J = 4.0 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 4,27 - 4.17 (m, 1H), 3.67 (s, 3H), 3.64 (s, 3H), 3.21 -3.16(m, 1H), 2.96-2.90 (m, 3H), 2.332.20 (m, 2H), 1.99 -1.94 (m, 1H), 1.80 -1.60 (m, 2H) and 1.47-1.35 (m, 1H) ppm
691	A	A
692	A	A	420.3	3.13
693	A	A	448.32	3.51
694	A	A	420.3	2.94
695	A	A	448.32	3.3
696	A	A	390.42	3.29	1H NMR (300 MHz, DMSO) d 12.55 (bs, 1H), 8.73 (d, J =2.4 Hz, 1H), 8.26 (d, J =2.4 Hz, 1H), 8.16 (s, 1H), 8.10 (d, J = 4.0 Hz, 1H), 7.94 (bs, 1H),4.11 (bs, 1H), 2.26 - 2.02 (m, J = 10.7 Hz, 3H), 2.00 -1.69 (m, J = 32.8, 20.4 Hz, 4H), 1.68 -1.21 (m, 5H).
697	A	A	447.49	3.91	H NMR (300.0 MHz, MeOD) d 8.71 (s, 1H), 8.51 (s, 1H), 8.39 (s, 1H), 8.28 (d, J = 5.5 Hz, 1H), 4.46-4.38 (m, 1H), 3.69-3.61 (m, 1H), 2.37 (d, J = 11.7 Hz, 1H), 2.18 (d, J = 10.6 Hz, 1H), 2.07 - 1.98 (m, 2H), 1.74 1.62 (m, 1H), 1.57-1.39 (m, 2H), 1.39 - 1.25 (m, 1H) and 1.19 (d, J = 6.1 Hz, 6H) ppm
698	A	A	447.48	3.6	H NMR (300.0 MHz, MeOD) d 8.71 (s, 1H), 8.50 (s, 1H), 8.38 (d, J = 1.6 Hz, 1H), 8.28 (d, J = 5.3 Hz, 1H), 4.46 - 4.39 (m, 1H), 3.93 (t, J = 6.4 Hz, 2H), 3.62 (t, J = 11.5 Hz, 1H), 2.38 (d, J = 11.1 Hz, 1H), 2.18 (d, J = 11.0 Hz, 1H), 2.07 -1.99 (m, 2H), 1.71 -1.49 (m, 4H), 1.35 -1.22 (m, 2H) and 0.93 (s, 3H) ppm
699	A	A	461.51	4.18	H NMR (300.0 MHz, MeOD) d 8.70 (s, 1H), 8.51 (s, 1H), 8.39 (s, 1H), 8.28 (d, J = 5.3 Hz, 1H), 4.46 - 4.39 (m, 1H), 3.77 (d, J = 6.5 Hz, 2H), 3.70 - 3.62 (m, 1H), 2.38 (d, J = 11.8 Hz, 1H), 2.18 (d, J = 10.6 Hz, 1H), 2.07 -1.99 (m, 2H), 1.88 - 1.84 (m, 1H), 1.71-1.28 (m, 4H) and 0.91 (d, J = 4.5 Hz, 6H) ppm

-393WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

700	A	A	433.49	4	H NMR ¢300.0 MHz, MeOD) d 8.70 (s, 1H), 8.50 (s, 1H), 8.38 (d, J = 1.9 Hz, 1H), 8.28 (d, J = 5.5 Hz, 1H), 4.46 - 4,38 (m, 1H), 4.01 (q, J = 7.0 Hz, 2H), 3.66 (t, J = 11.7 Hz, 1H), 2.38 (d, J = 11.3 Hz, 1H), 2.18 (d, J = 11.0 Hz, 1H), 2.07 -1.99 (m, 2H), 1.75 -1.62 (m, 1H), 1.57-1.39 (m, 2H) and 1.36 -1.19 (m, 4H) ppm
701	A	A	457.48	4.03	H NMR (300.0 MHz, MeOD) d 8.69 (s, 1H), 8.49 (s, 1H), 8.37 (d, J = 1.6 Hz, 1H), 8.27 (d, J = 5.4 Hz, 1H), 4.55 (s, 2H), 4.37 (t, J = 11.6 Hz, 1H), 3.70 - 3.57 (m, 1H), 2.37 (d, J = 10.7 Hz, 1H), 2.17 (d, J = 11.2 Hz, 1H), 2.07 -1.98 (m, 2H), 1.78 (s, 3H) and 1.70 -1.22 (m, 4H) ppm
702	A	A	443.46	3.84	H NMR (300.0 MHz, MeOD) d 8.69 (s, 1H), 8.49 (s, 1H), 8.38 (s, 1H), 8.27 (d, J = 5.4 Hz, 1H), 4.61 (s, 1H), 4.41 (t, J = 11.7 Hz, 1H), 3.65 - 3.53 (m, 3H), 2.37 (d, J = 8.2 Hz, 1H), 2.17 (d, J = 10.9 Hz, 1H), 2.02 (t, J = 13.2 Hz, 2H) and 1.70 -1.27 (m, 4H) ppm
703	A	A	417.52	3.66	H NMR (300.0 MHz, MeOD) d 8.54 (s, 1H), 8.39 (dd, J = 2.7, 9.1 Hz, 1H), 8.34 (s, 1H), 8.29 (d, J = 5.5 Hz, 1H), 4.49 - 4.41 (m, 1H), 4.04 - 3.97 (m, 1H), 3.88 (s, 2H), 3.41 (s, 3H), 2.35 (d, J = 11.8 Hz, 1H), 2.21 (d, J = 11.2 Hz, 1H), 2.02 (d, J = 11.7 Hz, 2H) and 1.73 1.36 (m, 4H) ppm
704	A	A	457.56	3.77	H NMR (300.0 MHz, MeOD) d 8.51 (s, 1H), 8.39 (d, J = 9.1 Hz, 1H), 8.34 (s, 1H), 8.27 (d, J = 5.4 Hz, 1H), 4.41 (t, J = 11.3 Hz, 1H), 4.03 (d, J = 10.5 Hz, 1H), 3.91 (t, J = 11.3 Hz, 1H), 3.79 - 3.76 (m, 1H), 3.51 (d, J = 7.5 Hz, 1H), 2.31 (d, J = 11.2 Hz, 1H), 2.20 (d, J = 12.4 Hz, 1H), 2.00 -1.89 (m, 4H) and 1.67-1.33 (m, 8H)ppm
705	A	A	403.49	3.47	H NMR (300.0 MHz, MeOD) d 8.54 (s, 1H), 8.40 (dd, J = 2.6, 9.1 Hz, 1H), 8.36 (s, 1H), 8.28 (d, J = 5.5 Hz, 1H), 4.43 (t, J = 11.7 Hz, 1H), 3.68 - 3.61 (m, 4H), 2.39 (d, J = 11.1 Hz, 1H), 2.19 (d, J = 11.2 Hz, 1H), 2.03 - 1.99 (m, 2H)and 1.65-1.25 (m, 4H) ppm
706	A	A	458.53	3.42	H NMR (300.0 MHz, MeOD) d 8.52 (s, 1H), 8.37 (dd, J = 2.7, 9.1 Hz, 1H), 8.34 (s, 1H), 8.27 (d, J = 5.6 Hz, 1H), 4.43 (t, J = 11.8 Hz, 1H), 3.81 (t, J = 11.6 Hz, 1H), 3.65 - 3.62 (m, 4H), 3.37 - 3.34 (m, 4H), 2.35 (d, J = 11.7 Hz, 1H), 2.22 (d, J = 11.8 Hz, 1H), 2.01 (d, J = 11.0 Hz, 2H) and 1.66 - 1.29 (m, 4H) ppm
707
708	A	A	432.5	3.49	H NMR (300.0 MHz, MeOD) d 8.86 (d, J = 2.2 Hz, 1H), 8.47 (s, 1H), 8.38 (d, J = 2.2 Hz, 1H), 8.31 (d, J = 5.6 Hz, 1H), 5.22 - 5.19 (m, 1H), 2.15-2.10 (m, 1H), 2.01 -1.72(m, 6H), 1.64-1.53 (m, 3H), 1.40-1.13 (m, 2H) and 0.90 (t, J = 7.2 Hz, 3H) ppm
70S (enantiomer 1, see 710)	A	A	390.46	4.11	H NMR (300.0 MHz, CDCI3) d 9.89 (s, 1H), 8.86 (d, J = 2.1 Hz, 1H), 8.30 (s, 1H), 8.16 (d, J = 2.2 Hz, 1H), 8.02 (d, J = 3.4 Hz, 1H), 7.28 (s, H), 6.81 (d, J = 5.6 Hz, 1H), 4.65-4.61 (m, 1H), 2.04 (d, J = 12.8 Hz, 1H), 1.87-1.84 (m, 3H), 1.77 - 1.71 (m, 3H), 1.65 - 1.55 (m, 2H), 1.38 - 1.22 (m, 3H) and 0.92 - 0.85 (m, 3H) ppm
710 (enantiomer 2, see 709)	A	A	390.47	4.02	H NMR ¢300.0 MHz, CDCI3) d 10.15 (s, 1H), 8.90 (d, J = 2.3 Hz, 1H), 8.29 (dd, J = 2.4, 7.3 Hz, 1H), 8.16 (d, J = 2.7 Hz, 1H), 8.05 - 8.02 (m, 1H), 7.30 (d, J = 11.4 Hz, H), 4.85 (d, J = 8.2 Hz, 1H), 4.68 - 4.55 (m, 1H), 2.30 - 2.24 (m,2H), 2.10-1.95 (m, 1H), 1.81 -1.72 (m, 5H), 1.66- 1.49 (m, 2H), 1.45-1.16 (m, 3H)and 1.01 -0.90(m, 3H) ppm

-394WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

711	C	C	503.52	2.91	1H NMR (300 MHz, MeOD) d 8.94 (d, J = 2.2 Hz, 1H), 8.53 (s, 1H), 8.45 - 8.31 (m, 2H), 5.25 (d, J = 9.4 Hz, 1H), 4.15 - 3.95 (m, 2H), 3.84 (t, J = 10.8 Hz, 2H), 3.52 (t, J = 14.1 Hz, 3H), 3.26 - 3.03 (m, 3H), 2.66 (s, 2H), 2.40 - 2.13 (m, 3H), 2.02 (d, J = 32.7 Hz, 4H), 1.82-1.46 (m, 3H).
712	A	A	402.47	3.98	H NMR ¢300.0 MHz, DMSO) d 12.28 (s, 1H), 8.77 (d, J = 2.4 Hz, 1H), 8,27 (d, J = 2.4 Hz, 1H), 8.18 (s. 1H), 8.11 (d, J = 4.0 Hz, 1H), 7.34 (d, J = 7.7 Hz, 1H), 5.98 - 5.84 (m, 1H), 5.06 (s, 1H), 5.02 (d, J = 2.8 Hz, 1H), 4.52 - 4.42 (m, 1H), 4.20 (s, 1H), 2.19 (d, J = 7.3 Hz, 2H), 2.06 (d, J = 11.8 Hz, 1H), 1.95 -1.77 (m, 2H), 1.57 (d, J = 12.0 Hz, 2H), 1.44 (t, J = 12.3 Hz, 1H) and 1.28- 1.16 (m, 2H) ppm
713	A	A	402.49	4.13	H NMR (300.0 MHz, DMSO) d 12.31 (s, 1H), 8.72 (d, J =2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.19 (s, 1H), 8.14 (d, J = 4.0 Hz, 1H), 7.51 (d, J = 7.4 Hz, 1H), 6.00 - 5.86 (m, 1H), 5.09 - 5.03 (m, 2H), 4.67 (s, 1H), 4.36 4.33 (m, 1H), 2.33 (d, J = 7.0 Hz, 2H), 1.86 -1.70 (m, 3H) and 1.65 -1.35 (m, 5H) ppm
714	A	A	435.34	3.3
715	A	A	491.39	3.68
716	A	A	477.37	3.75
717	A	A	436.48	3.71	H NMR (300.0 MHz, DMSO) d 12.28 (d, J = 2.0 Hz, 1H), 8.79 (dd, J = 2.4, 5.4 Hz, 1H), 8.26 (d, J = 2.4 Hz, 1H), 8.17 (d, J = 2.7 Hz, 1H), 8.12 (dd, J = 1.5, 4.0 Hz, 1H), 7.35 (d, J = 7.9 Hz, 1H), 4.73 (t, J = 3.9 Hz, 1H), 4.55 - 4.51 (m, 2H), 3.85 - 3.82 (m, 1H), 2.02 -1.87 (m, 3H), 1.72-1.41 (m, 5H) and 1.31 -1.19 (m, 2H) PPm
718	A	A	436.49	3.6	H NMR (300.0 MHz, DMSO) d 12.29 (s, 1H), 8.71 (t, J = 2.3 Hz, 1H), 8.27 (d, J = 2.4 Hz, 1H), 8.19 (dd, J = 2.8, 4.5 Hz, 1H), 8.15 (t, J = 3.7 Hz, 1H), 7.52 (t, J = 7.7 Hz, 1H), 4.97 (d, J = 16.0 Hz, 1H), 4.77 (dd, J = 3.8, 10.5 Hz, 1H), 4.54 (t, J = 5.6 Hz, 1H), 4.32 (m, 1H), 3.86 (m, 1H), 2.00 -1.97 (m, 2H), 1.82 -1.63 (m, 4H) and 1.59-1.45 (m, 4H) ppm
719	A	A	443.5	4.07	H NMR (300.0 MHz, DMSO) d 12.58 (s, 1H), 8,68 (d, J = 2.2 Hz, 1H), 8.36 - 8.23 (m, 4H), 7.81 (t, J = 5.5 Hz, 1H), 4.17 (d, J = 7.5 Hz, 1H), 2.94 (t, J = 6.0 Hz, 2H), 2.43-2.35 (m, 1H), 2.14 -1.22 (m, 8H), 0.91 0.80 (m, 1H), 0.40 - 0.31 (m, 2H) and 0.20 - 0.10 (m, 2H)ppm
720	A	A	459.5	3.99	H NMR (300.0 MHz, DMSO) d 12.72 (s, 1H), 8.65 (s, 1H), 8.54 (s, 1H), 8.45 (d, J = 2.7 Hz, 1H), 8.39 - 8.37 (m, 2H), 4.42 - 4.08 (m, 3H), 4.02 - 3.88 (m, 2H), 3.64 -3.57(m, 1H), 3.18- 3.12 (m, 3H) and 2,12 -1.19 (m, 9H)ppm
721	A	A	417.5	3.93	H NMR (300.0 MHz, DMSO) d 12.31 (s, 1H), 8.72 (d, J =2.4 Hz, 1H), 8.29 (d,J=2.4 Hz, 1H), 8,19 (s, 1H), 8.14 (d, J =4.0 Hz, 1H), 7.71 (s, 1H), 7.53 (d, 1H), 4.19 - 4.06 (m, 1H), 3.05 (dd, J = 5.6, 7.1 Hz, 2H), 2.33 (m, 1H), 2.13 -1.20 (m, 8H) and 0.98 (t, 3H) ppm
722	A	A	447.52	4.11	H NMR (300.0 MHz, DMSO) d 13.14 (s, 1H), 9.50 9.45 (m, 1H), 9.26 (s, 1H), 8.58 (d, J = 5.1 Hz, 1H), 8.49 (d, J = 5.1 Hz, 1H), 8.40 (s, 1H), 8.01 (s, 1H), 5.60 (s, H), 5.50 (s, 1H), 4.39 (s, 1H), 2.94 (d, J = 7.3 Hz, 1H), 2.81 (qn, J = 6.3 Hz, 1H), 2.51 (s, H), 2.32 (d, J = 7.0 Hz, 2H), 2.08 (s, 2H), 1.87 - 1.64 (m, 4H), 1.17 (t, J = 7.2 Hz. 3H) and -0.00 (s, H) ppm

-395WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

723	A	A	445.5	4.03	1H NMR (300 MHz, MeOD) d 8.66 (d, J = 2.2 Hz, 1H), 8.51 (s, 1H), 8.37 (d, J = 2.2 Hz, 1H), 8.29 (d, J = 5.6 Hz, 1H), 4.51 -4.28(m, 1H), 4.01 -3.80(m, 1H), 2.40 -2.15(m, 2H), 2.11 -1.86 (m, 2H), 1.84- 1.26 (m, 4H), 1.18 (s, 9H)
724	A	A	428.45	3.69	1H NMR (300 MHz, MeOD) d 8.69 (d, J = 1.9 Hz, 1H), 8.53 (s, 1H), 8.38 (d, J = 1.7 Hz, 1H), 8.29 (d, J = 5.3 Hz, 1H), 4.52 - 4.34 (m, 1H), 4.02 - 3.84 (m, J = 11.5 Hz, 1H), 3.52 (s, 2H), 2.40 (d, J = 12.0 Hz, 1H), 2.22 (d, J =10,9 Hz, 1H), 2.14-1.97 (m, 2H), 1.81 -1.23 (m,4H).
725	A	A	446.48	2.47	1H NMR (300 MHz, MeOD) d 8.73 (d, J = 1.6 Hz, 1H), 8.56 (s, 1H), 8.47 (s, 1H), 8.37 (t, J = 7.8 Hz, 1H), 8.31 (d, J = 5.2 Hz, 1H), 4.56 - 4.37 (m, 1H), 4.133.98 (m, 1H), 3.93 (s, 2H), 2.92 (d, J = 3.6 Hz, 6H), 2.43 (d, J = 12.4 Hz, 1H), 2.22 (d, J = 12.4 Hz, 1H), 2.07 (t, J = 13.1 Hz. 2H), 1.83 -1.24 (m. 4H).
726	A	A	443.53	3.92	1H NMR (300 MHz, MeOD) d 8.61 (d, J = 2.3 Hz, 1H), 8.53 (s, 1H), 8.35 (d, J = 2.2 Hz, 1H), 8.29 (d, J = 5.6 Hz, 1H), 4.47 - 4.24 (m, 1H), 4.01 -3.77(m, 1H), 3.14 -2.98(m, 1H), 2.41 -1.01 (m, 14H).
727	A	A	457.51	4.04	1H NMR (300 MHz, MeOD) d 8.68 (d, J = 2.3 Hz, 1H), 8.52 (s, 1H), 8.36 (d, J = 2.3 Hz, 1H), 8.28 (d, J = 5.6 Hz, 1H), 4.51 -4.30 (m, 1H), 4.04 - 3.80 (m, 1H), 3.25 - 3.04 (m, 1H), 2.39 (d, J = 20.1 Hz, 1H), 2.22 (d, J = 12.3 Hz, 1H), 2.02 (d, J = 12.9 Hz, 2H), 1.94 -1.24 (m, 4H), 1.12 (dd, J = 10.1, 3.0 Hz, 6H), 1.04 - 0.94 (m, J = 9.4, 4.3 Hz, 1H), 0.75 - 0.62 (m, 1H).
728	A	A	459.56	4.17	1H NMR ¢300 MHz, MeOD) d 8.68 (d, J = 2.3 Hz, 1H), 8.49 (d, J = 22.9 Hz, 1H), 8.36 (t, J = 5.8 Hz, 1H), 8.28 (d, J = 5.6 Hz, 1H), 4.53 - 4.27 (m, J = 11.6, 8.2, 3.7 Hz, 1H), 4.02 - 3.83 (m, J = 15.7, 7.7 Hz, 1H), 2.37 (d, J = 12.0 Hz, 1H), 2.22 (d, J = 12.1 Hz, 1H), 2.06 (d, J = 14.0 Hz, 2H), 2.06 (s, 2H), 1.82 -1.15 (m, 4H), 1.01 (s, 9H).
729	A	A	486.54	2.78
730	A	A	488.52	3.82
731	C	C			(400MHz, DMS0-d6): 12.33 (br s, exchanged with D2O, 2H), 8.72 (d, J=1.6Hz , 1H), 8.27(d, J=2.4Hz, 1H), 8.20 (s, 1H), 8.13 (d, J=3.6Hz, 1H), 7.47(d, J=7.2H z,exchanged with D2O, 1H), 4.04-4.02 (m, 1H), 2.17-2.00 (m, 5H), 1.63-1.39 (m, 4 H).
732	A	A			(400MHz, CDCI3):12.33(s, 1H), 8.75(d, J=2.4Hz,1H), 8.28(d,J=2.4Hz,1H), 8.18(s,1 H), 8.12(d, J=4Hz,1H), 7.49(d,J=8Hz,1H),4.3(t,J=5.2Hz,1H),4.04-3.97(m,1H), 3.48-3,43(m,1H),3.38-3.34(m,2H), 2.09- 2.0(m,1 H), 1.95-1,93(m,1 H), 1.81-1,25(m,7H).
733	A	A			(400MHz, DMSO-d6): 12.33(brs, exchanged with D2O, 1H), 8.27(d, J=2Hz, 1 H), 8.19(s,1H), 8.11(d, J=3.6Hz,1H), 7.39(d, J=6.4Hz, Exchanged with D2O.1H), 4. 05(brs, 1H), 2.39(s,1H), 2.142.12(m,2H), 1.77-1,61(m,6H).
734	A	A	443.4	3.39	1H NMR (300 MHz, MeOD) d 8.71 (d, J = 2.3 Hz, 1H), 8.49 (s, 1H), 8.38 (d, J = 2.3 Hz, 1H), 8.29 (d, J = 5.6 Hz, 1H), 4.45 (s, 1H), 3.91 (s, 1H), 3.77-3.50 (m, 2H), 2.35 (d, J = 10.0 Hz, 1H), 2.22 (d, J = 11.9 Hz, 1H), 2.02 (d, J = 11.7 Hz, 2H), 1.71 (d, J = 14.0 Hz, 1H), 1.38 (tdd, J = 16.2, 11.9, 4.6 Hz, 6H), 1.08 (t, J = 5.5 Hz, 3H), 1.04 - 0.94 (m, 1H), 0.61 - 0.49 (m, 1H).
735	A	A	529.46	4.62

-396WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

736	A	A	489.4	4.56
737	A	A	485.44	4.57
738	A	A	439.37	3.31	1H NMR (300 MHz, MeOD) d 8.60 (d, J = 37.9 Hz, 1H), 8.33 (d, J = 23.9 Hz, 1H), 7.64 (d, J = 8.1 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 6.00 (t, J = 54.0 Hz, 1H), 4.42 (s, 1H), 4.01 (s, 1H), 2.47 - 2.31 (m, 2H), 2.23 (d, J = 10.9 Hz, 1H), 2.12-1.97 (m, 2H), 1.77-1.17 (m, 5H), 0.95-0.83 (m, 1H).
739	A	C	486.52	2.16	1H NMR (300 MHz, MeOD) d 8.65 (d, J = 45.0 Hz, 1H), 8.34 (d, J = 23.5 Hz, 1H), 7.70 (d, J = 7.7 Hz, 1H), 7.22 (d, J = 7.6 Hz, 1H), 4.45 (s, 1H), 4.01 (s, 1H), 3.72 (s, 1H), 3.45 (s, 1H), 3.10 (d, J = 11.3 Hz, 1H), 2.82 (d, J = 12.1 Hz, 3H), 2.36 (s, 1H), 2.28 1.25 (m, 16H).
740	A		447.53	3.98	H NMR (300 MHz, MeCD) d 8.73(s, 1H), 8.45(s, 1H), 8.37(d, J = 2.1 Hz, 1H), 7.25(d, J = 5.5 Hz, 1H), 4.89 4.8 (m, 1H), 3.02 - 2.95(m, 2H), 2.86(d, J = 0.5 Hz, 1H), 2.65(d, J = 12.0 Hz, 1H), 2.46(d, J = 12.2 Hz, 1H), 2.03 -1,98(m, 1H), 1.9 -1,8(m, 1H), 1.78 - 1,68(m, 1H), 1.5 -1.3(m, 2H), 0.95(t, J = 7.3 Hz, 3H) and 0.0(s, TMS)
741	A		470.46	3.82	1H NMR (300 MHz, DMSO) d 12.32 (s, 1H), 8.70 (d, J = 2.4 Hz, 1H), 8.27 (d, J = 2.4 Hz, 1H), 8.26 (d, J = 2.8 Hz, 1H), 8.18 (d, J = 3.9 Hz, 1H), 7.34 (d, J = 7.1 Hz, 1H), 5.77 (d, J - 2.9 Hz, 1H), 4.60 (s, 1H), 3.73 (dd, J = 10.1,6.3 Hz, 6H), 2.30 - 2.15 (m, 1H), 2.04 - 1.86 (m, 1H), 1.85-1.50 (m, 6H).
742	A		470.49	3.7	1H NMR (300 MHz, DMSO) d 12.30 (s, 1H), 8.75 (d, J = 2.4 Hz, 1H), 8.27 (d, J = 2.4 Hz, 1H), 8,18 (d, J = 2.8 Hz, 1H), 8.14 (d, J =4.0 Hz, 1H), 7.44 (d, J = 7.7 Hz, 1H), 5.38 (s, 1H), 4.55-4.36 (m, 1H), 3.71 (d, J = 3.1 Hz, 3H), 3.68 (d, J = 3.2 Hz, 3H), 2.16 - 2.01 (m, 2H), 2.00 -1.72 (m, 3H), 1.71-1.41 (m, 2H), 1.39 -1.18 (m, 1H).
743	A	A	419.34	2.86
744	A	A	419.34	2.61
745	A	A	447.5	3.8	1H NMR (300 MHz, MeOD) d 8.70 (d, J = 18.1 Hz, 1H), 8.50 (s, 1H), 8.38 (d, J = 10.4 Hz, 1H), 8.30 (s, 1H), 4.54 (s, 2H), 4.19 (s, 2H), 3.42 (s, 3H), 2.95 (d, J = 15.2 Hz, 3H), 2.25 (d, J = 11.8 Hz, 1H), 2.09 (s, 2H), 1.98-1.39 (m, J = 62.5 Hz, 5H).
746 (racemic mixture of diastereomer 1 with respect 1 OH of the cyclohexyl ring, see 755)	A	A	422.48	3.6
747	A	A	448.48	3.42
748	A		448.5	3.51
749	A	A	422.47	3.6
750	A	A	447.36	3.07
751	A	A	433.35	2.88
752	A	A	447.36	2.78
753	A	A	454.4	3.32

-397WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

754	A	C	406.35	3.16	1H NMR (300 MHz, MeOD) d 8.70 (d, J = 2.2 Hz, 1H), 8.47 (s, 1H), 8.37 (d, J = 2.2 Hz, 1H), 8.28 (d, J = 5.5 Hz, 1H), 5.37 - 4.57 (m, 49H), 2.42 (dd, J = 13.3, 4.2 Hz, 2H), 2.15 (d, J = 10.4 Hz, 1H), 2.07 - 1.87 (m, 3H), 1.77 (dd. J = 18.1, 8.6 Hz, 3H).
755 (racemic mixture of diastereomer 2 with respect 1OHofthe cyciohexyl ring, see 746)	A	C	406.35	3.03
756	A	A	472.45	2.24
757	A	A	399.52	3.29	1H NMR (300 MHz, MeOD) d 9.00 (d, J = 7.7 Hz, 1H), 8.59 (s, 1H), 8.52 (d, J = 4.8 Hz, 1H), 8.33 (d, J = 5.3 Hz, 1H), 7.69 (d, J = 5.3 Hz, 1H), 4.54 - 4.32 (m, 1H), 4.18 - 3.99 (m, 1H), 3.88 (s, 2H), 3.40 (s, 3H), 2.44 (d, J = 11.6 Hz, 1H), 2.13 (d, J = 10.9 Hz, 1H), 1.97 (t, J = 13.6 Hz, 2H), 1.77-1.28 (m, 4H).
758	A	A	427.4	3.26	1H NMR (300 MHz, MeOD) d 8.71 (dd, J = 14.6, 2.9 Hz, 1H), 8.49 (s, 1H), 8.38 (s, 1H), 8.29 (d, J = 5.6 Hz, 1H), 4.42 (t, J = 11.9 Hz, 1H), 3.95 (t, J = 11.6 Hz, 1H), 2.39 (d, J = 12.1 Hz, 1H), 2.27-2.12 (m, 1H), 2.03 (d, J = 10.0 Hz, 2H), 1.95 (s, 1H), 1.70 (d, J = 13.1 Hz, 1H), 1.61 -1.18(m, 8H).
759	A	A	460.48	2.15	1H NMR (300 MHz, MeOD) d 8.72 (d, J = 1.8 Hz, 1H). 8.57 - 8.44 (m, 1H), 8.38 (d, J = 1.4 Hz, 1H), 8.29 (d, J = 5.0 Hz, 1H), 4.45 (s, 1H), 4.00 (s, 1H), 3.86 (d, J = 8.5 Hz, 1H), 2.97 - 2.80 (m, 7H), 2.47 (s, 1H), 2.22 (d, J = 11.5 Hz, 1H), 2.06 (d, J = 11.1 Hz, 2H), 1.84-1.19 (m, 9H).
760	A	A			(400MHz, DMSO-d6): 12.35 (brs, 1H), 8.75 (d, J=2.4Hz,1H), 8.29(d,J=2Hz,1 H), 8.2-8.17(m,2H), 6.97(d,J=6.8Hz, 1H), 4.6-4.54(m,1H),4.5(brs, 1H),3.58-3.48( m,2H),2.57(s,1 H),2.332.227(m,2H), 1.76-1,69(m,2H),1.61-1,59(m,1H),1.431.32(m,2H )
761	A	A			(400MHz, DMSO-d6): 12.35(brs, 1H), 8.75(d,J=2.4Hz,1H), 8.29(d,J=2Hz,1H), 8.28.17(m,2H), 6.97(d,J=6.8Hz, 1H), 4.64.55(m,1 H),4.5(br s, 1 H),3.58-3.5(m,2 H),2.56(s,1 H),2.33-2.227(m,2H),1.76- 1.69(m,2H),1.61-1.59(m,1 H),1.43-1,32(m,2H)
762	A	A	406.35	3.23
763	A	A	406.35	3.06	1H NMR (300 MHz, MeOD) d 8.70 (d, J = 2.2 Hz, 1H), 8.47 (s, 1H), 8.37 (d, J = 2.2 Hz, 1H), 8.28 (d, J = 5.5 Hz, 1H), 5.37 - 4.57 (m, 49H), 3.38 - 3.26 (m, 26H), 2,42 (dd, J = 13.3, 4.2 Hz, 2H), 2.15 (d, J = 10.4 Hz, 1H), 2.07 -1.87 (m, 3H), 1.77 (dd, J = 18.1,8.6 Hz, 3H).
764	A	A	420.36	3.2	1H NMR (300 MHz, MeOD) d 8.70 (d, J = 2.3 Hz, 1H), 8.50 (s, 1H), 8.39 (d, J = 2.3 Hz, 1H), 8.30 (d, J = 5.5 Hz, 1H), 4.91 - 4.77 (m, 27H), 3.77 (s, 3H), 3.38 - 3.26 (m, 39H), 2.45 (dd, J = 13.2, 3.8 Hz, 2H), 2.20 (d, J = 9.8 Hz, 1H), 2.06 (s, 1H), 2.00 - 1.82 (m, 3H), 1.82 1.23 (m, 5H).
765	A	A	453.38	3.34
766	A	A	449.41	3.4
767	A	A	487.42	3.56

-398WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

768	A	A	486.46	2.24
769	A	C	415.5	2.75	1H NMR (300 MHz, MeOD) d 8.84 (s, 1H), 8.31 (s, 2H), 6.99 (s, 1H), 4.42 (s, 1H), 4.08 (s, 1H), 3.90 (s, 2H), 3.42 (s, 3H), 2.40 (s, J = 20.9 Hz, 1H), 2.26 - 1.85 (m, J = 27.0 Hz, 3H), 1.79 - 1.20 (m. 4H).
770	A	A	469.44	3.22	NMR 1H (MeOH-d4): 9.0 (s, 1H), 8.6 (m, 2H), 8.3 (m, 2H), 8.1 (s, 1H), 4.5 (m, 1H), 4.1 (m, 1H), 3.9 (s, 3H), 1.3-2.6 (m, 10H).
771	A	A	472.45	2.21
772	A	A	455.43	2.97
773	A	A	451.4	3.31	NMR 1H (MeOH-d4): 8.7 (s, 1H), 8.5 (s, 1H), 8.3 (s, 1H), 8.2 (d, 1H), 4.7 (s, 1H), 4.15-4.5 (m, 4H), 3.7 (t, 1H), 2.4 (m, 1H), 2.2 (m, 1H), 2.0 (t, 2H), 1.2-1.8 (m, 4H).
774	A	C	472.45	2.21	NMR 1H (MeOH-d4): 8.7 (d, 2H), 8.3 (d, 2H), 4.4 (m, 1H), 3.6-4.0 (m, 3H), 3.3 (s, 3H), 2.9 (m, 3H), 2.0-2.5 (m. 6H), 1.2-1.8 (m,4H).
775	A	A	435.34	3.21	1H NMR (300 MHz, MeOD) d 7.40 (d, J = 2.1 Hz, 1H), 7.21 (s, 1H), 7.10 (d, J = 2.2 Hz, 1H), 7.03 (d, J = 5.6 Hz, 1H), 2.71 (dt, J = 13.2, 6.7 Hz, 1H), 2.55 (dt, J = 18.3, 9.2 Hz, 1H), 2.26 (s, 3H), 0.90 - 0.67 (m, 2H), 0,58 (d, J = 13.5 Hz, 1H), 0.53 - 0.37 (m, 2H), 0.37 0.18 (m, 1H).
776	A	A	392.34	2.9	1H NMR (300 MHz, MeOD) d 7.40 (d, J = 2.1 Hz, 1H), 7.21 (s, 1H), 7.10 (d, J = 2.2 Hz, 1H), 7.03 (d, J = 5.6 Hz, 1H), 2.71 (dt, J = 13.2, 6.7 Hz, 1H), 2.55 (dt, J = 18.3, 9.2 Hz, 1H), 2.26 (s, 3H), 0.90-0.67 (m, 2H), 0,58 (d, J = 13.5 Hz, 1H), 0.53 - 0.37 (m, 2H), 0.37 0.18 (m, 1H).
777	C	C	410.32	2.37
778	A	A	507.53	3.54	1H NMR (300 MHz, DMSO) d 12.32 (s, 1H), 8.72 (dd, J = 4.9, 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.22 8.09 (m, 2H), 7.45 (dd, J = 16.1, 8.1 Hz, 1H), 6.85 (d, J = 11.9 Hz, 1H), 4.51 -4.41 (m, 1H), 4.32 - 4.16 (m, 2H), 3.84 - 3.71 (m, 2H), 3.60 (s, 1H), 3.26 (d, J = 2.6 Hz, 3H), 2.70 - 2.56 (m, J = 22.6 Hz, 1H), 2.45 (s, 1H), 2.17 -1.92 (m,2H), 1.77-1.41 (m, 4H), 1.33 -1.11 (m, 2H).
779	A	A	433.42	3.22	1H NMR (300 MHz, MeOD) d 8.72 (d, J = 2.2 Hz, 2H), 8.48 (s, 2H), 8.34 (dd, J = 23.7, 3.9 Hz, 3H), 4.99 (d, J = 5.4 Hz, 3H), 4.88 (s, 1H), 4.85 - 4.67 (m, 32H), 3.44 - 2.95 (m, 44H), 2.29 (dd, J = 13.5, 4.1 Hz, 3H), 2.11 (d, J = 9.5 Hz, 2H), 2.04 -1.80 (m, 7H), 1.76 (s, 3H), 1.13 (t, J = 7.2 Hz, 4H).
780	A	A	487.36	3.57
781	A	A	394.32	2.81
782	A	A	424.5	3.96
783	A	A	456.39	2.9
784	A	A	473.41	3.29
785	A	A	461.44	3.59
786	A	A	419.34	3.01
787	A	A	382.399	2.47	(400MHz, DMSO-d6): 12.36 (s, exchanged with D2O, 1H), 8.71 (d, J=2.4Hz, 1 H), 8.29 (d, J=1.6Hz, 1H), 8.25 (s,1 H), 8.18 (d,J=4Hz,1 H),7.58 (d,J=7.2Hz, excha nged with D2O,1H), 4.27 (br s,1 H), 2.15-2.06 (m,6H), 1.75-1.69 (m,2H).

-399WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

788	A	A	362.399	2.68	(400MHz, DMSO-d6): 12.34 (s,exchanged with D2O.1H), 8.72 (d,J=2.4Hz,1H),. 8.28 (d,J=2.4Hz,1 H), 8.20 (d,J=2.4Hz,1H), 8.13 (d,J=4.4Hz,1H), 7.5 (d,J=6Hz, exc hanged with D2O.1H), 4.42 (br s, exchanged with D2O.1H), 4.04 (t,J=3.6Hz,1H), 3.88 (S,1H), 1.89-1.6(
789	A	A			H NMR (300.0 MHz, DMSO) d 12.90 (s, 1H), 8.96 (s, 1H), 8.84 (s, 1H), 8.64 (s, 1H), 8.42 (d, J = 5.1 Hz, 2H), 7.85 (t, J = 5.4 Hz, 1H), 4.22 (d, J = 7.8 Hz, 1H), 3.34 - 3.17 (m, 7H) and 2.09 -1.26 (m, 9H) ppm
790	A	A	406.49	3.87	H NMR (300.0 MHz, CDCI3) d 14.46 (s, 1H), 8.81 (s, 1H), 8.22 (s, 1H), 8.12 (s, 1H), 7.96 (t, J = 1.6 Hz, 1H), 7.34 (d, J = 11.5 Hz, H), 4.59 (d, J = 3.1 Hz, 1H), 3.94 (s, 2H), 2.04-1.70 (m, 8H), 1.68 (m, 2H), and 0.00 (s, H) ppm
791	A	A	434.38	3.26
792	A	A	434.38	2.9
793	A	A	406.5	3.69	H NMR (300.0 MHz, CDCI3) d 9.47 (s, 1H), 8.93 (d, J = 2.3 Hz, 1H), 8.27 (d, J = 2.3 Hz, 1H), 8.16 (d, J = 2.7 Hz, 1H), 8.06 (d, J = 3.4 Hz, 1H), 7.28 (s, H), 4.85 (s, 1H), 4.75 (m, 1H), 4.01 - 3.97 (m, 2H), 3.07 (s, 1H), 2.50 (m,2H), 2.30 (m, 1H), 2.10 (m, 1H), 1.89 -1.79 (m, 4H), 1.36 (m, 3H) and 0.99 (s, 1H) ppm
794	B	A	449.48	3.9
795	A	A	432.39	3.86	1H NMR (300 MHz, CDCI3) d 8.80 (1 H, s), 8.25 (1 H, s), 8.0 (1 H, s), 7.95 (1 H, s), 5.2 (1 H, m), 4.25 (2 H, q), 1.95-1.45 (8 H, m), 1.25 (3 H,s), 1.15(3 H, t) ppm.
796	A	A	446.45	3.12	H NMR (300.0 MHz, MeOD) d 8.73 (s, 1H), 8.52 (s, 1H), 8.38 (s, 1H), 8.31 (br s, 1H), 4.34 (m, 1H), 2.60 2.56 (m, 1H), 2.27 (m, 1H), 2.08 (m, 3H)and 1.891.78 (m, 3H) ppm
797	A	A	450.5	3.86	1H NMR (300 MHz, DMSO) d 12.30 (s, 1H), 8.73 (t, J = 2.7 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.18 (d, J =2.8 Hz, 1H), 8.14 (d, J = 3.9 Hz, 1H), 7.53 (d, J = 7.6 Hz, 1H), 5.29 (d, J = 5.0 Hz, 1H), 4.79 - 4.65 (m, 2H), 4.37 (s, 1H), 3.23 - 3.14 (m, 2H), 2.02 (dd, J = 40.1, 10.3 Hz, 1H), 1.91 -1.64 (m, 7H), 1.59-1.44 (m, 3H), 1.19 (d, J =10.6 Hz, 3H).
798	A	A	446.34	3.37	H NMR (300.0 MHz, MeOD) d 8.67 (s, 1H), 8.56 (s, 1H), 8.38 (s, 1H), 8.31 (brs, 1H), 4.47 (m, 1H), 4.21 (m, 1H), 2.41 (m, 1H), 2.22 (m, 1H), 2.10-1.90 (m, 3H), 1.72 (m, 2H) and 1.50 (m, 1H) ppm
799	A	A	433.43	3.01
800	A	A	433.42	2.66
801 (racemic mixture of diastereomer 1, see 802)	A	A	461.44	3.35
802 (racemic mixture of diastereomer 2, see 801)	A	A	461.44	2.81
803	A	A	461.44	2.94
804	A	A	404.3	3.45	H NMR (300.0 MHz, MeOD) d 8.84 (s, H), 8.61 (s, H), 8.36 (s, H), 8.30 (d, J = 5,1 Hz, H), 5.57 (s, H), 3.5 (1 Η, M), 1.97 -1.3 (m, 8 H), 0.93 (s, 3H),, ppm

-400WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

805	A	A	403.34	2.98	H NMR (300.0 MHz, MeOD) d 8.85 (d, J = 2.4 Hz, H), 8.22 (d, J = 2.3 Hz, H), 8.16 (s, H), 7.99 (d, J = 4.1 Hz, H), 7.86 (s, H), 3.48 (d, J = 7.0 Hz, H), 2.80 (s, H), 2.15 (s, H), 2.0 (s, H), 1.86 (qn, J = 3.3 Hz, H), 1.80 (s, H), 1.74(s, H), 1.44(3, H).
806	A	A	417.36	3.1	H NMR (300.0 MHz, CDCI3) d 9.01 (s, H), 8.77 (d, J = 2.4 Hz, H), 8.21 (d, J = 2.4 Hz, H), 8.06 - 7.96 (m, H), 3.44 (s, H), 3.42 (d, J = 4.0 Hz, H), 3.41 (t, J = 4.0 Hz, H), 2.19-1.66 (m, H), 1.97 (s, H) and 1.56 (s, H) ppm
807	A	A	431.37	3.24
808	C	A	392.34	2.9
809	A	A	392.34	2.9	1H NMR (300 MHz, DMSO) d 13.10 (s, 1H), 9.20 (d, J = 2.7 Hz, 1H), 8.93 - 8.67 (m, 2H), 8.49 (d, J = 5.6 Hz, 1H), 8.39 - 8.30 (m, OH), 4,78 (s, 1H), 3.54 (s, 1H), 3.17 (s, 2H), 2.51 (s, 4H), 2.02-1.63 (m, 3H), 1.46 (dd, J = 41.3,11.6 Hz, 3H), 1.18 (s, 3H).
810	A	A			H NMR (300.0 MHz, DMSO) d 8.69 (d, J = 2,4 Hz, 1H), 8.21 - 8.18 (m, 2H), 8.10 (d, J = 4.0 Hz, 1H), 7.29 (d, J = 7.6 Hz, 1H), 6.83 (s, 1H), 5.84 - 5.70 (m, 1H), 5.07 - 5.00 (m, 2H), 4.27 (t, J = 4.0 Hz, 1H), 3.50 (d, J = 7.2 Hz, 3H), 2.39 (d, J = 8.3 Hz, 3H), 2.32 - 2.07 (m, 2H) and 1.82 -1.08 (m, 5H) ppm
811	A	A	447.36	3.18
812	A	A	447.36	2.7
813	A	A	447.36	2.79
814	A	A			H NMR (300.0 MHz, DMSO) d 12.92 (s, 1H), 9.02 8.88 (m, 2H), 8.64 (s, 1H), 8.41 (s, 2H), 4.29 (s, br 1H), 4.00 - 3.35 (m, 8H) and 2.17-1.27 (m, 10H) ppm
815	A	A	433.35	2.92
816	A	A	406.29	3.24
817	A	A	439.3	1.48
818	A	A	465.34	1.73
819	A	A	505.3	1.47
820	A	A	493.3	2
821	A	A			(400MHz, DMSO-d6): 12.34 (s, exchanged with D2O,1H),8.76(s,1H),8.28 (s,1H ),8.19 (s,1H), 8.14 (d,J=4Hz,1H),7.54 (d,J=6.8Hz, exchanged withD2O,1H), 4.71-4. 66 (m,1H),4.59(d,J=3.2Hz, exchanged withD2O,1H),4.27 (br s,1H), 2.232.20(m,1H), 1.98-1,57(m, 10H)
822	A	A			(400MHz,DMSO-d6):12.34 (s, exchanged withD2O,1H), 8.73 (d,J=1,6Hz, 1 H),8.2 8d,J=2Hz,1 H),8.21 (s, 1 H),8.15(d,J=3.6Hz, 1 H),7.49 (d,J=7.2Hz, exchanged with D2O, 1H),4.75(d,J=3.6Hz,exchanged withD2O,1H), 4.494.44 (m,1H), 4.22-4.21 (m,1H), 2. 34-1.50 ( m, 8H)
823	A	A	448.39	3.67
824	A	A	448.39	3.05
825	A	A	404,3	3.38
826	A	A	404.3	3.38	H NMR (300.0 MHz, DMSO) d 12.34 (s, H), 8.74 (d, J = 2.3 Hz, H), 8.33 (d, J = 2.3 Hz, H), 8.28 (d, J = 1.6 Hz, H), 8.17 - 8.12 (m, H), 4.34 (s, H), 4.29 (s, H), 3.89 (s, H), 3.55 (d, J = 6.3 Hz, H), 3.32 (s, H), 2.50 (s, H), 2.29 (s, H), 1.95 -1.90 (m, H), 1.82 (d, J = 6.6 Hz, H), 1.76 (s, H), 1.67 (s, H), 1.55 (s, H), 1.44 -1.42 (m, H), 1.31 (s, H), 1.23 (s, H), 1.17 (s, H), 1.07 (s, H), 0.84 (d, J = 6.9 Hz, H) and -0.00 (d, J = 1.0 Hz, H) PP^m

-401WO 2010/148197

PCI7US2010/038988

2018200219 11 Jan 2018

827	A	A	404.37	2.72
828	A	A	377.37	1.9
829	A	A	470.4	2.95
830	A	B	392.34	2.98	MeOD d4: 8.8 (d, 1H); 8.5 (s, 1H); 8.4 (d,1H); 8.3 (d, 1H); 4.5 (dd,1 H); 3.6 (dd, 1H); 3.3 (dd, 1H); 2.3 (m, 2H); 2.1 (m, 1H); 1.9 (m, 1H); 1.6 (app t, 2H); 1.3 (m, 1H).
831	A	A	392.34	2.98	MeOD d4: 8.8 (d, 1H); 8.5 (s, 1H); 8.4 (d,1 H); 8,3 (d, 1H); 4.5 (dd, 1H); 3.6 (dd, 1H); 3.3 (dd, 1H); 2.3 (m, 2H); 2.1 (m, 1H); 1.9 (m, 1H); 1.6 (app t, 2H); 1.3 (m, 1H).
832	A	A	376.34	2.94	MeOD d4: 8.8 (d, 1H); 8.65 (s, 1H); 8.45 (d, 1H); 8.35 (d, 1H);4.2 (dd,1 H); 3.4 (dd, 1H); 2.2 (m, 2H); 2.0 (m, 1H);1.6 (m, 4H); 1.2 (d, 3H).
833	B	A	376,34	2.94	MeOD d4: 8.8 (d, 1H); 8.65 (s, 1H); 8.45 (d,1 H); 8.35 (d, 1H); 4.2 (dd, 1H); 3.4 (dd, 1H); 2.2 (m, 2H); 2.0 (m, 1H); 1.6 (m, 4H); 1.2 (d, 3H).
834	A	A	442.37	3.25	H NMR ¢300.0 MHz, DMSO) d 12.32 (s, 1H), 8.70 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.19 - 8.18 (m, 2H), 7.31 (d, J = 7.1 Hz, 1H), 5.76 (s, 1H), 5.26 (t, J = 6.4 Hz, 1H), 4.58 (s, 1H), 3.87 - 3.74 (m, 2H), 2.50 (qn, J = 1.8 Hz, H), 2.01 -1.80 (m, 3H), 1.74 -1.50 (m, H) and -0.00 (TMS) ppm
835	A	A	442.37	2.84	H NMR (300.0 MHz, DMSO) d 12.30 (s, 1H), 8.76 (d, J = 2.2 Hz, 1H), 8.28 (d, J = 2.3 Hz, 1H), 8.19-8.13 (m, H), 7.44 (d, J = 7.6 Hz, H), 5.22 - 5.17 (m, 2H), 4.48.4.45 (m, 1H), 3.80 (td, J = 15.9, 7.4 Hz, H), 3.18 (d, J = 5.2 Hz, 2H), 2.51 (s, H), 2.09 (d, J = 11.4 Hz, 1H), 2.03 (s, 1H), 1.92 -1.80 (m, 1H), 1.70 (t, J = 12.3 Hz, H), 1.70 -1.60 (m, 3H), 1.42 (dd, J = 9.9, 12.9 Hz, 1H), 1.26 (dd, J = 11.5, 22.0 Hz, 1H) and -0.00 (s, H) ppm
836	A	A	483.39	3.37
837	A	A	483.39	2.93
838	A	C	388.37	4.02
839	A		433.4	3.69	1H NMR (300 MHz, MeOD) d 8.83 (d, J = 2.1 Hz, 1H), 8.49 (s, 1H), 8.38 (d, J = 1.9 Hz, 1H), 8.26 (d, J = 5.6 Hz, 1H), 3.49 - 3.14 (m, 3H), 2.68 (s, OH), 2.19 (d, J = 14.2 Hz, 1H), 2.09 (d, J = 13.0 Hz, 1H), 1.96 (s, 4H), 1.76 (S, 2H), 1.49 (d, J = 41.9 Hz, 3H).
840	A		438.32	3.68	H NMR (300.0 MHz, DMSO) d 12.29 (s, 1H), 8.78 (dd, J = 2.4, 6.6 Hz, 1H), 8.27 (d, J = 2.4 Hz, 1H), 8.18 (d, J = 1.9 Hz, 1H), 8.13 (dd, J = 0.8, 4.0 Hz, 1H), 7.44 (d, J =8.1 Hz, 1H), 4.83-4.78 (m, 1H), 4.52 (t, J = 3.6 Hz, 1H), 2.97 - 2.82 (m, 2H), 2.58 (d, J = 1.4 Hz, 3H), 2.19-1.81 (m, 3H), 1.72 -1.57 (m, 2H), 1.54-1.32 (m, 1H) and 1.31 -1.12 (m, 2H) ppm
841	A	A	390.5	2.97	(400 MHz, DMSO-d6): 12.8 (br.s, exchanged with D2O, 1H), 8.68 (br.s, 1H), 8.40-8.38 (m, 2H), 4.594.57 (m, 1H), 2.36-2.11 (m,4H), 2.11-2.06 (m, 1H), 1. 92-1.79 (m, 2H), 1.46-1.44 (m, 2H).
842	A		454.37	3.47	H NMR (300.0 MHz, DMSO) d 13.06 (s, 1H), 9.35 (d, J =6.4 Hz, 1H), 9.10 (d, J =2.5 Hz, 1H),8.74(s, 1H), 8.48 (d, J = 5.6 Hz, 1H), 8.41 (s, 1H), 4.67 (d, J = 7.7 Hz, 1H), 3.41 - 3.25 (m, 2H), 3.02 (s, 3H), 2.29 (d, J = 11.8 Hz, 1H) and 2.08 -1.35 (m, 8H) ppm
843	A	A	525.43	3.58
844	A	A	525.43	3.09

-402WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

845	A		449.41	3.36	1H NMR (300 MHz, MeOD) d 8.36 (s, 1H), 8.22 (s, 1H), 8.13 (s, 1H), 4.25 (br s, 1H), 4.14 - 3.79 (m, 3H), 3.44 (s, 3H), 2.38 (br s, 1H), 2.17 (br s, 1H), 2.09 - 1.92 (m, 2H), 1.79 -1.29 (m, J = 62.8 Hz, 4H).
846		A	390.399	2.91	¢400 MHz, DMS0-d6): 12.61 (br.s, exchanged with D20, 1H), 8.69 (s, 1H), 8.41-8.30 (m, 3H), 3.54-3.43 (m, 2H), 2.74-2.68 (m, 1H), 2.46-2.42 (1H), 2.15-2. 08 (m, 2H), 1.82 (br.s, 3H), 1.57-1.47 (m, 2H).
847		A	389.35	3.79
848		A	376.399	2.79	(400 MHz, DMS0-d6): 12.6 (br.s, exchanged with D20, 1H), 8.70 (s, 1H), 8 .40-8.30 (m, 3H), 4.65A.60 (m, 1H), 3.01-2.93 (m, 1H), 2.28-1.95 (m, 4H), 1.861.72 (m, 2H).
849		A	390.399	2.89	(400 MHz, DMS0-d6): 12.90 (br.s, exchanged with D20, 1H), 9.20 (br.s, ex changed with D20, 1H), 8.65 (s, 1H), 8.44 (d, J=4.8 Hz, 1H), 8.39 (d, J=2Hz, 1H), 3.56-3.49 (m, 3H), 2.85-2.80 (m, 1H), 2.01-1.89 (m, 3H), 1.77-1.67 (m, 2H), 1.44-1.39 (m, 1H).
850		A			(400MHz, DMSO-d6): 12.32 (br s, exchanged with D2O, 1H), 8.75 (s, 1H), 8. 28 (s, 1H), 8.20 (s, 1H), 8.14 (d, J=3.6Hz, 1H), 7.6 (d, J=6.4Hz, exchanged with D20, 1H), 4.58-4.53 (m, 1H), 2.27 (d, J=7.2Hz, 2H), 2.19-1.67 (m, 5H), 1.36-1.2 9(m,1H).
851	A	A	483.39	3.6
852	A	A	483.39	3.05
853		A	438.36	3.58	H NMR ¢300.0 MHz, DMSO) d 12.29 (s, 1H), 8.78 (s, 1H), 8.26-8.18 (m, 3H), 7.44 (s, 1H), 5.05-4.30 (m, 2H), 3.08-2.74 (Μ, 1H) and 2.26 - 0.92 (m, 12H) ppm
854	A	A	454.27	2.64	H NMR (300,0 MHz, DMSO) d 12.30 (s, 1H), 8.79 (d, J = 2.3 Hz, 1H). 8.27 (d, J = 2.3 Hz, 1H), 8.19 (d, J = 2.7 Hz, 1H), 8.13 (d, J =4.0 Hz, 1H), 7.47 (d, J = 7.7 Hz, 1H), 4.90 (s, 1H), 4.51 (t, J = 3.9 Hz, 1H), 3.01 (s, 3H), 2.24 (d, J = 12.3 Hz, 1H), 2.09 -1.79 (m, 4H), 1.71-1.41 (m, 3H) and 1.36 -1.05 (m, 2H) ppm
855	A	A	414.35	3	1H NMR (300 MHz, DMSO) d 12.33 (s, 1H), 8.74 (d, J = 2.4 Hz, 1H), 8.41 - 8.04 (m, 3H), 7.62 (d, J = 7.4 Hz, 1H), 4.30 (s, 1H), 3.54 - 3.06 (m, 3H), 2.67 - 2.31 (m, 1H), 2.23-1.33 (m, 6H)
856	A	A	424.34	3.63	H NMR (300.0 MHz, CDCI3) d 8.85 (q, J = 2.3 Hz, H), 8.17 (dd, J = 2.3, 21.3 Hz, 2H), 8.00 (d, J = 3.5 Hz, 1H), 5.03 (s, H), 4.64 - 4.55 (m, 1H), 4.38 (dd, J = 4.0, 8.3 Hz, 1H), 4.01 - 3.88 (m, 2H), 2.45 - 1.90 (m, 4H), 1,51-1.25 (m, 3H) and 0.00 (s, H) ppm
857	A	A	433.37	3.47	1H NMR (300 MHz, DMSO) d 13.02 (s, 1H), 9.22 (s, 1H), 9.03 (d, J = 2.4 Hz, 1H), 8.71 (d, J = 2.1 Hz, 1H), 8.46 (d, J = 5.5 Hz, 1H), 8.41 (d, J = 2.1 Hz, 1H), 7.81 (t, J = 5.8 Hz, 1H), 4.64 (d, J = 8.0 Hz, 1H), 3.16 2.99 (m, 2H), 2.09 -1.73 (m, 3H), 1.85 (s, 3H), 1.73 1.42 (m, 3H), 1.28 (dd, J = 27.5,10.6 Hz, 2H).
858	A	A	490,36	2.78
859	A	A	424.41	3.8	H NMR (300.0 MHz, MeOD) d 8.73 (s, 1H), 8.17 (d, J = 1.8 Hz, 1H), 8.11 (d, J = 2.0 Hz, 1H), 7.96 (d, J = 3.7 Hz, 1H), 4.57 (s, 1H), 4.50 (d, 1H), 4.10 - 3.80 (m, 2H), 2.21 -1.60 (m, 8H) and 0.00 (s, H) ppm
860	A	A	392.34	2.82	MeOD4: 8.75 (d, 1H); 8.5 (s, 1H); 8.4 (d, 1H); 8.25 (d, 1H); 7.7 (d, 1H); 7.2 (d, 1H); 4.5 (ddd, 1H); 3.65 (d, 1H);2.35(s, 1H); 2.1 (m, 1H); 1.85 (m, 2H); 1.6 (m, 3H); 1.35 (s, 3H).

-403WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

861	A	A	362.33	2.43	MeOD4 8.55 (dd, 1H); 8.2 (d, 2H); 8.0 (d, 1H); 7.7 (d, 1H); 7.2 (d, 1H); 4.2 (ddd, 1H); 3.6, (ddd, 1H); 3.4 (dd, 1H); 2.4 (s, 2H); 2.2 (m, 1H); 2.1 (m, 2H); 1.8 (m, 1H); 1.4 (m, 3H).
862	A	A	442.44	3.77	1H NMR (300 MHz, DMSO) d 12.28 (s, 1H), 8.75 (d, J = 2.4 Hz, 1H), 8.27 (d, J = 2.4 Hz, 1H), 8.15 (s, 1H), 8.11 (d, J = 4.0 Hz, 1H), 7.69 (d, J = 2.2 Hz, 1H), 7.41 (d, J = 1.7 Hz, 1H), 7.38 (s, 1H), 6.22 (t, J = 2.0 Hz, 1H), 4.67 (s, 1H, OH), 4.49-4.38 (m, 1H), 4.10 (s, 2H), 2.05-1.80 (m, 2H), 1.72-1.55 (m, 2H), 1.52-1.40 (m, 2H), 1.35-1.14 (m, 2H).
863	A	A	503.42	3.36
864	A	A	503.42	3.46
865	A	A	517.43	3.57
866	A	A	416.33	2.75	1H NMR (300 MHz, MeOD) d 8.53 (s, 1H), 8.38 - 8.30 (m, 2H), 8.28 (d, J = 5.6 Hz, 1H), 4.40 (ddd, J = 11.9, 8.2, 3.9 Hz, 1H), 3.78 (ddd, J = 11.9, 8.2, 3.8 Hz, 1H), 2.89 (s, 6H), 2.33 (d, J = 11.6 Hz, 1H), 2.21 (d, J = 11.4 Hz, 1H), 2.05-1.96 (m, J = 6.8, 4.1 Hz, 3H), 1.67 -1.33 (m, 4H).
867	A	A	503.35	2.79
868	A	A	503.35	2.93
869	A	A	376.28	2.6	1H NMR (300 MHz, MeOD) d 8.65 (dd, J = 9.6, 2.8 Hz, 1H), 8.20 (s, 1H), 8.17 -8.09 (m, 1H), 8.01 (d, J = 4.0 Hz, 1H), 4.53 (s, 1H), 3.60 (s, 2H), 1.89 (dd, J = 28.7,12.9 Hz, 3H), 1.74-1.41 (m, 5H), 1.28 (s, 3H).
870	A	A	457	2.84	1H NMR (300 MHz, DMSO) d 12.23 (s, 1H), 8.41 (dd, J = 9.9, 2.8 Hz, 1H), 8.24 (d, J = 13.1 Hz, 2H), 8.14 (d, J =4.0 Hz, 1H), 7.79 (d, J = 7.6 Hz, 1H), 7.48 (d, J = 7.6 Hz, 1H), 4.12 (s, 1H), 3.76 (d, J = 11.2 Hz, 2H), 3.38 - 3.15 (m, 3H), 2.35 (dd, J = 12.6, 8.6 Hz, 1H), 2.04 (dd, J = 25.4, 9.8 Hz, 2H), 1.89 - 0.99 (m, 10H).
871	A	A	438.34	2.89
872	A	A	376.28	2.57
873	A	A	486.46	2.98	1H NMR (300 MHz, MeOD) d 8.49 (s, 1H), 8.41 (dd, J = 9.0, 2.6 Hz, 1H), 8.35 (s, 1H), 8.28 (d, J = 5.6 Hz, 1H), 4.55 - 4.37 (m, 1H), 3.83 (d, J = 12.8 Hz, 2H), 3.59 - 3.43 (m, 2H), 2.50 - 2.28 (m, 3H), 2.22 (d, J = 10.6 Hz, 1H), 2.01 (d, J = 11.6 Hz, 2H), 1.74 -1.25 (m, 5H), 1.15 (d, J = 6.2 Hz, 6H).
874	A	A	486.46	2.9	1H NMR (300 MHz, MeOD) d 8.51 (s, 1H), 8.42 (d, J = 9.0 Hz, 1H), 8.35 (s, 1H), 8.28 (d, J = 5.3 Hz, 1H), 4.46 (s, 1H), 3.95 - 3.76 (m, J = 11.0 Hz, 2H), 3.76 3.61 (m, 2H), 3.61 - 3.51 (m, 1H), 3.50 - 3.39 (m, 2H), 2.43-2.28 (m, 1H), 2.22 (d, J = 12.0 Hz, 1H), 2.01 (d, J = 11.0 Hz, 2H), 1.53 (ddd, J =44.1, 27.8, 15.6 Hz, 4H), 1.32-1.10 (m,6H).
875	A	A	401.3	3.01	H NMR (300.0 MHz, DMSO) d 12.32 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.29 - 8.26 (m, 2H), 8.17 (d, J = 3.9 Hz, 1H), 7.44 (d, J = 7.7 Hz, 1H), 4.31 (s, 1H), 2.85 (d, J = 5.9 Hz, 2H), 2.51 (t, J = 1.7 Hz, H), 2.08 - 1.98 (m, 1H), 1.77 -1.64 (m, 4H), 1.50 (d, J = 6.3 Hz, 3H) and 0.00 (s, H) ppm
876	A	A	489.34	2.99
877	A	A	489.34	2.75
878	A	A	374.21	1.64
879	A	A	483.45	2.35
880	A	A	427.4	2.97

-404WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

881	C	C	389.27	2.03	1H NMR (300 MHz, DMSO) d 12.79 (s, 1H), 8.77 (s, 1H), 8.60 (d, J = 2.3 Hz, 1H), 8.43 (d, J = 4.8 Hz, 1H), 8.37 (d, J = 2.3 Hz, 1H), 7.52 (s, 3H), 4.29 (s, 1H), 4.08 (d, J = 12.6 Hz, 1H), 3.90 (d, J = 13.7 Hz, 1H), 3.16 - 2.95 (m, 2H), 2.17 (d, J = 9.7 Hz, 1H), 1.92 (d, J = 8.5 Hz, 1H), 1.81 -1,57 (m, 2H).
882	A	A	401.3	2.73	H NMR (300.0 MHz, MeOD) d 8.86 (d, J = 2.4 Hz, 1H), 8.19 - 8.16 (m, 2H), 7.97 (d, J = 4.0 Hz, 1H), 4.69 - 4.58 (m, 1H), 2.65 (s, 2H), 2.26 - 1.98 (m, 3H), 1.84 (d, 1H), 1.79 -1.73 (m, 1H), 1.67 -1.47 (m, 2H), 1.36 1.21 (m, 1H) and 0.00 (TMS) ppm
883	A	A	457.38	3.55	1H NMR (300 MHz, DMSO) d 12.25 (s, 1H), 8.638.02 (m, 4H), 7.62 (dd, J = 62.6, 7.2 Hz, 2H), 3.90 (t, J = 60.4 Hz, 4H), 2.47 - 0.73 (m, 15H).
884	E	A	471.39	3.74
885	A	A	420.24	3.09
886	A	A	454.26	3.62	H NMR (300.0 MHz, DMSO) d 12.32 (s, 1H), 8.72 (d, J = 2.2 Hz, 1H), 8.28 - 8.24 (m, 2H), 8.17 (d, J = 3.8 Hz, 1H), 7.44 (d, J = 7.2 Hz, 1H), 5.34 (s, 1H), 4.32 (s, 1H), 3.41 (s, 2H), 3.04 (s, 3H), 2.22 (d, J = 11.7 Hz, 1H), 2.12-1.69 (m, 4H) and 1.52 (d, J = 8.7 Hz, 3H) ppm
887	A	C	420.24	3.09
888 (diastereomer 1, see 889)	A	A	420.36	3.93	H NMR (300.0 MHz, MeOD) d 8.81 (d, J = 2.4 Hz, 1H), 8.21 (d, J =2.4 Hz, 1H), 8.13 (s, 1H), 7.97 (d, J = 4.0 Hz, 1H), 4.50 (s, 1H), 4.28-4.18 (m, 1H), 3.72 (dd, J = 4.2, 9,1 Hz, 2H), 2.02 (d, J = 6.3 Hz, 1H), 1.89 -1.81 (m, 4H), 1.69 - 1.55 (m, 3H), 1.26 -1.20 (m, 4H) and -0.00 (s, H) ppm
889 (diastereomer 2, see 888)	A	A	420.37	3.94	H NMR (300.0 MHz, MeOD) d 8.79 (d, J = 2.4 Hz, 1H), 8.21 (d, J = 2.4 Hz, 1H), 8.12 (s, 1H), 7.99 (d, J = 4.0 Hz, 1H), 4.47 (dd, J = 3.6, 7.6 Hz, 1H), 4.25-4.17 (m, 1H), 2.10 (dd, J = 3.7, 13.4 Hz, 1H), 1.91 -1.77 (m, 3H), 1.69 -1.50 (m, 4H), 1.20 (d, J = 9.4 Hz, 2H) and -0.00 (TMS) ppm
890	A	A	472.42	3.6
891	A	A	456.4	3.82
892	A	A	472.41	3.69
893	A	A	486.42	3.6
894	A	A	486.44	3.6
895	A	A	442.42	3.7
896	A	A	500.42	3.77
897	A	A	458.42	3.48
898	A	A	472.42	3.51
899	A	A	401	3.6	1H NMR (300 MHz, DMSO) d 12.30 (s, 1H), 8.41 (dd, J = 9.8, 2.9 Hz, 1H), 8.24 (d, J = 9.7 Hz, 2H), 8.13 (d, J =4.0 Hz, 1 H>, 7.71 (d, J = 7.6 Hz, 1H), 7.48 (d, J = 7.4 Hz, 1H), 4.15(3, 1H), 3.73 (s, 1H), 2.22-1.91 (m, 4H), 1.82 (d, J = 11.1 Hz, 2H), 1.29 (ddd, J = 54.3, 34.3,10.3 Hz, 4H), 0,97 (t, J = 7.6 Hz, 3H).
900	A	A	413	3.56	1H NMR (300 MHz, DMSO) d 12.23 (s, 1H), 8.40 (dd, J =9.9, 2.9 Hz, 1H), 8.25 (s, 1H), 8.22 (s, 1H),8.13 (d, J = 4.0 Hz, 1H), 8.02 (d, J = 7.7 Hz, 1H), 7.48 (d, J = 7.5 Hz, 1H), 4.15 (s, 1H), 3.72 (s, 1H), 2.22 -1.73 (m, 4H), 1.62 -1.04 (m, 5H), 0.75 - 0.53 (m, 4H).
901	A	A	442.37	2.97
902	A	A	472.43	3.41
903	A	A	472.48	3.65
904	A	A	472.38	2.72

-405WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

905	A	A	472.38	2.61
906	A	A	472.38	2.67
907	A	A	486.4	2.88
908	A	A	457.35	2.53
909	A	A	499.38	2.62
910	A	A	486.4	3.02
911	A	A	506.29	2.57
912	A	A	460.35	2.79
913	A	A	456.39	2.98
914	A	A	486,4	2.79
915	A	A	456.39	2.98
916	A	A	500.41	3.1
917		A	454.34	2.54
918		A	508.34	3.38
919		A	470.4	1.59
920		A	384.34	1.74
921		A	488.38	1.92
922		A	481.4	1.79	H NMR (300.0 MHz, MeOD) d 8.44 - 8.41 (m, 2H), 8.32 (dd, J = 1.6, 2.7 Hz, 1H), 8.24 (d, J = 5.5 Hz, 1H), 4.42 (t, J = 11.8 Hz, 1H), 3.79 (t, J = 11.6 Hz, 1H), 3.65 (td, J = 10.2, 4.7 Hz, 2H), 3.54 (qn, J = 1.6 Hz, 1H), 2.97 (dt, J = 12.5, 4.2 Hz, 1H), 2.34 (d, J = 10.7 Hz, 1H), 2.21 (d, J = 12.1 Hz, 1H), 2.03 - 1.87 (m, 4H) and 1.79-1.23 (m, 7H) ppm
923		A	499.38	1.57	H NMR (300.0 MHz, MeOD) d 8.53 (dd, J = 2.8, 9.6 Hz, 1H), 8.18 - 8.08 (m, 2H), 7.99 (d, J = 4.1 Hz, 1H), 4.25 (dt, J = 15.2, 4.8 Hz, 1H), 4.04 (d, 2H), 3.83 3.68 (m, 1H), 2.80 (dd, J = 2.5, 25.7 Hz, 2H), 2.46 2.35 (m, 2H), 2.21 (d, J = 10.7 Hz, 1H), 1.97 (s, 1H), 1.80 - 1.75 (m, 2H), 1.63 -1.29 (m, 3H) and 1.22 (d, J = 4.8 Hz, 4H) ppm
924		A	403.34	1.77
925		C	398.35	1.75
926		A	472.38	2.08	H NMR (300.0 MHz, MeOD) d 8.76 (d, J = 2.4 Hz, H), 8.44 - 8.38 (m, H), 8.27 (d, J = 5.6 Hz, H), 4.87 (d, J = 5.1 Hz, H), 4.64 -4.56 (m, H), 3.38-3.19 (m, H), 2.65 (s, H), 2.46 (s, H), 2.42 (s, H), 2.16 (s, H), 2.07 (t, J = 12.0 Hz, H), 2.00 (s, H), 1.88 (q, J = 6.6 Hz, H), 1.88 (s, H), 1.70 (s, H) and 1.61 (d, J = 12.8 Hz, H) ppm
927		C	420.36	1.8
928		A	420.36	1.79
929			431.19	1.82	H NMR (300.0 MHz, MeOD) d 8.85 (d, J = 2.4 Hz, H), 8.22 (d, J = 2.3 Hz, H), 8.15 (s, H), 7.99 (d, J = 4.1 Hz, H), 7.70 (d, J = 8.0 Hz, H), 7.64 (s, H), 5.49 (s, H), 5.01 (s, H), 4.95 (s, H), 4.88 (s, H), 4.56 - 4.47 (m, H), 3.53 (d, J = 1.7 Hz, H), 3.35 - 3.17 (m, H), 3.07 (s, H), 2.66 (s, H), 2.36 (s, H), 2.13 (d, J = 9.6 Hz, H), 2.02 1.98 (m, H), 1.89 (s, H), 1.83 -1.77 (m, H), 1.73 -1.68 (m, H), 1.63 (s, H), 1.49 -1.42 (m, H), 1.36 (s, H), 1.28 (s, H), 1.20 -1.07 (m, H) and 0.01 (d, J = 3.3 Hz, H) ppm

-406WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

930			417.19	1.84	H NMR (300.0 MHz, MeOD) d 8.86 (d, J = 2.4 Hz, H), 8,26 - 8.22 (m, H), 8.15 (s, H), 8.03 - 7.98 (m, H), 7.67 (s, H), 7.62 (s, H), 5.47 (d, J = 10.7 Hz, H), 5.09 (d, J = 6.6 Hz, H), 5.01 (s, H), 4.88 (s, H), 4.61 (s, H), 4.52 (dd, J = 7.1, 15.2 Hz, H), 4.52 (s, H), 3.72 (s, H), 3.66 (s, H), 3.60 (d, J = 7.1 Hz, H), 3.54 - 3.43 (m, H), 3.34 (s, H), 3.31 (qn, J = 1.6 Hz, H), 3.08 (t, J = 1.7 Hz, H), 2.76 - 2.71 (m, H), 2.13 (d, J = 12.7 Hz, H), 2.01 (d, J = 8,5 Hz, H), 1.83 -1.76 (m, H), 1.72-1.67 (m, H), 1.63 (s, H), 1.42 (s, H), 1.37 (d, J = 6.5 Hz, H), 1.29 1.15 (m, H), 0.98 (s, H), 0.83 (s, H), 0.20 (s, H), 0.07 (s, H), 0.00 (TMS) and -0.20 (s, H) ppm
931			494.39	2.04
932	A	A	416.44	2.93
933	A	A	453.4	1.5
934	A	A	476,09	1.92
935	A	A	478.08	1.89
936	A	A	460,1	1.76
937	A	A	474.6	2.02
938	A	A	388.11	1.87
939	A	A	392.41	2.42
940			490.1	2.04
941			472.13	1.79	H NMR (300.0 MHz, MeOD) d 8.70 (d, J = 2.2 Hz, H), 8.51 -8.43 (m, H), 8.33 (s, H), 8.10 (d, J = 5.6 Hz, H), 4.77 (s, H), 4.63 - 4.53 (m, H), 4.15 (d, J - 4.5 Hz, H), 3.98 - 3.90 (m, H), 3.84 (t, J = 5.0 Hz, H), 3.63 - 3.53 (m, H), 3.48 - 3.41 (m, H), 3.21 (s, H), 3.16 (s, H), 3.11 (s, H), 2.82 (s, H), 2.65 (s, H), 2.49 (d, J = 9,8 Hz, H), 2.13-1.90 (m, H), 1.86- 1.72 (m, H), 1.67 (s, H), 1.62 -1.51 (m, H), 1.33 (dd, J = 6.5, 17.5 Hz, H) and -0.00 (TMS) ppm
942			466.2	1.66
943			456.13	1.92	H NMR ¢300.0 MHz, MeOD) d 12.44 (s, H), 8.49 8.46 (m, H), 8.33 (s, H), 8.23 (d, J = 5.6 Hz, H), 7.31 7.25 (m, H), 7.19 (d, J = 7.9 Hz, H), 7.12 (s, H), 7.07 (t, J = 7.2 Hz, H), 4.90 (d, J = 12.9 Hz, H), 4.81 (d, J = 6.3 Hz, H), 4.75 (s, H), 4.69 (s, H). 4.60 (t, J = 11.1 Hz, H), 4.58 (s, H), 4.23 (s, H), 4.06 (d, J = 8.5 Hz, H), 3.72 (s, H), 3.54 (s, H), 3.44 - 3.39 (m, H), 3.32 - 3.25 (m, H), 3.18 (t, J = 1.7 Hz, H), 3.15 (s, H), 3.08 - 3.07 (m, H), 2.98 (s, H), 2.65 (s, H), 2.47 (d, J = 12.5 Hz, H), 2.05 (q, J = 11.9 Hz, H), 2.00 (s, H), 1.91-1.83 (m, H), 1.73 (d, J = 9.7 Hz, H), 1.64 (s, H), 1.56 (d, J = 12.6 Hz, H), 1.45 (s, H), 1.37 (d, J = 6.9 Hz, H), 0.20 (s, H), 0.07 (s, H), 0.01 - -0.02 (m, H), -0.20 (s, H), 2.49 (s, H) and -2.71 (s, H) ppm
944			482.1	1.93
945	A	A	402.399	2.23	(400MHz, DMSO-d6): 12.35 (br s, exchanged with D2O.1H), 9.18 (brs, excha nged with D20,1H), 8.75 (s,1H), 8.28 (s,1H), 8.19 (s,1H), 8.15 (d, J=3.2Hz,1H), 4.38 (brs,1H), 3.01 (d, J=1OHz,1H), 2.8 (s,1H), 2.58 (s,1H), 1.68 (d, J=9.2Hz, 1H), 1.56-1.22 (m,5H)
946	A	A	402.399	1.88	(400MHz, DMSO-d6): 12.15 (br s, exchanged with D2O, 3H), 8.77 (d, J=2.4Hz, 1H), 8,28 (d, J=2Hz, 1H), 8.20 (s, 1H), 8.17 (d, J=4Hz,1H), 7.78 (d, J=6Hz,1 H), 4.66-4.65 (m,1 H), 2.7-2.65 (m,2H), 1.72 (d, J=9.6Hz, 1H), 1.58-1.32 (m, 5H)

-407WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

947	A	A	402.32	3.42	H NMR (300.0 MHz, MeOD) d 8.87 (d, J = 2.1 Hz, 1H), 8.48 (s, 1H), 8.39 (d, J = 1.9 Hz, 1H), 8.30 (d, J = 5.7 Hz, 1H), 4.73 (d, J = 3.3 Hz, 1H), 3.12 (m, 1H), 2.76 (brs, 1H), 2.56 <d, J = 4.2 Hz, 1H), 1.86 (d, J = 9.5 Hz, 2H), 1.79-1.49 (complex m, 2H) and 1.51 (embedded d, J = 10.4 Hz, 2H) ppm
948	A	A	417.36	3.11
949	A	A	417.29	2.99
950		A	430.41	3
951	A	A	431.37	2.98	NMR 1H (MeOH-d6): 8.7 (s, 1H), 8.5 (s, 1H), 8.35 (s, 1H), 8.3 (s, 1H), 4.5 (m, 1H), 4.3 (m, 2H), 3.9 (m, 1H), 3.7 (m, 2H), 2.2 (m, 2H), 1.3-2.1 (m, 6H).
952	A	A	430.83	2.83
953	A	A	430.43	3.17
954	A	A	444.36	3.33
955	A	A	458.37	3.58
956	A	A	429.53	3.15	H NMR (300.0 MHz, MeOD) d 8.72 (d, J = 2.2 Hz, 1H), 8.49 (s, 1H), 8.39 (d, J = 2.1 Hz, 1H), 8.29 (d, J = 5.5 Hz, 1H), 4.54- 4.47 (m, 1H), 4.13 (t, J = 11.8 Hz, 1H), 3.57 - 3.45 (m, 2H), 2.42 - 2.36 (m, 2H), 2.25 (m, 1H), 2.15 - 2.00 (m, 4H), 1.90 -1.59 (m, 4H) and 1.53 -1.43 (m, 1H) ppm
957	A	A	544.4	3.62
958	A	A	444.4	3.21	NMR 1H (MeOH-d4): conclusive with structure.
959	A	A	431.37	3.21
960	A	A	431.37	3.24
961	A	A	431.37	3.05
962	A	A	431.37	3.09
963	A	A	445.38	3.39
964	A	A	445.38	3.16
965	A	A	415.37	2.9
966	A	A	415.37	2.9
967	A	A	415.37	2.64
968	A	A	415.37	2.72
969	A	A	415.31	2.94
970	A	A	431.3	3.16
971	A	A	431.3	3.01
972	A	A	415.31	2.94
973	A	A	415.31	2.95
974	A	A	416.33	1.79
975	A	A	415.37	1.82
976	A	A	415.37	1.72
977	A	A	399.53	2.17

Table 3: IC50, EC50, NMR and LCMS Data of Compounds of FIG, 6

Comp. Nos.

Cell Flu, MDCK protect! o n, ATP (All: IC50: uM)(Mea n (All))

Cell Influenza HA(-) 30 hr A/PR/8 bDNA:bDN AEC50 uM(Mean (All))

LCMS_Plus

LCMS_RT

NMR

-408WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

979	A	A	385.48	2.31	H NMR (300.0 MHz, MeOD) d 8.65 (dd, J = 2.8, 9.6 Hz, 1H), 8.19 (s, 1H), 8.14 (dd, J = 2.0, 2.5 Hz, 1H), 7.98 (d, J =4.1 Hz, 1H), 4.75 - 4.65 (m, 1H), 2.64 (s, 2H), 2.20 (d, J = 12.6 Hz, 2H), 2.01 (dd, J = 3.4, 9.8 Hz, 2H), 1.84 1.75 (m, 1H), 1.63 -1.47 (m, 2H), 1.33 (dd, J = 3.6,12.4 Hz, 1H) and 0.00 (TMS) ppm
980	A	A	432.26	2.46	DMSO d6:12.5 (bs, 1H); 8.75 (d, 1H); 8.65 (d, 1H); 8.3 (m, 4H); 7.7 (m, 2H); 7.2 (bs, 1H); 4.5 (bs, 1H); 2.7 (s, 3H); 2.3 9dd, 1H); 2.0 (m, 2H); 1.8-1,2 (m, 8H); 0.8 (t, 3H).
981	A	A	399.25	1.65	1H NMR (300 MHz, MeOD) d 8.52 (s, 1H), 8.46 - 8.23 (m, 3H), 4.51 (t, J = 11.9 Hz, 1H), 3.23 (s, 1H), 3.04 (d, J = 7.3 Hz, 3H), 2.44 (s, 2H), 2.25 (d, J = 11.9 Hz, 1H), 2.11 (d, J = 12.7 Hz, 1H), 2,01 -1.80 (m, 2H), 1,72 (d, J = 12.4 Hz, 2H), 1.47 (s, 2H), 1.30 (t, J = 7.3 Hz, 5H).
982	A	A	399.25	1.64	1H NMR (300 MHz, MeOD) d 8.52 (s, 1H), 8.30 (d, J = 5.6 Hz, 3H), 4.50 (t, J = 12.1 Hz, 1H), 3.48 (s, 2H), 3.35 (s, 2H), 3.04 (q, J = 7.3 Hz, 5H), 2.25 (d, J = 3.5 Hz, 4H), 2.02 - 1.82 (m, 2H), 1.70 (t, J = 12.5 Hz, 2H), 1.58-1.35 (m, 3H), 1.30 (t, J = 7.3 Hz, 8H).
983	A	A	486.2	1.83
984	A	A	376.28	1.58
985	A	A	439.24	1.94
986	A	A	458.24	1.66
987	A	A	401.83	2.12
988	A	A	401.9	1.99
989	B	A	474.3	1.45	NMR 1H (MeOH-d4):8.3 (m, 2H), 8.1 (s, 1H), 4.4 (t, 1H), 3.8 (t, 1H), 3.6 (m, 4H), 3.4 (m, 4H), 2.3 (m, 1H), 2,2 (m, 1H), 2.0 (m, 2H), 1.31.7 (m, 4H).
990	A	A	429.26	1.92
991	C	C	429.26	1.96
992	A	A	526.3	1.99	in MeOH-d4
993	A	A	438.21	1.83
994	A	A	512.3	1.83	NMR 1H (MeOH-d4): 8.6 (d. 1H), 8.4 (s, 1H), 8.3 (d, 1H), 8.2 (m, 1H), 4.3 (t, 1H), 3.8 (t, 1H), 3.5-3.6 (m, 3H), 3.1 (m, 2H), 2.8 (t, 1H), 2.3 (m, 3H), 2.2 (m, 2H), 2.0 (m, 2H), 1.85 (m, 1H), 1.3-1.75 (m, 4H).
995	A	A	470.5	2.04	1H NMR (300 MHz, DMSO) d 8.41 (dd, J = 9.8, 2.9 Hz, 1H), 8.33 - 8,04 (m, 2H), 7.49 (d, J = 7.4 Hz, 1H), 6.21 (d, J = 8.0 Hz, 1H), 4.61 (s, 3H), 4.11 (d, J = 7.9 Hz, 1H), 3.90 (s, 3H), 3.66 - 3.42 (m, 1H), 2.18-1.90 (m, 2H), 1.87 1.69 (m, 2H), 1.58 - 0.68 (m, 8H)

-409WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

996	A	A	470.49	2.23	1H NMR (300 MHz, DMSO) d 8.41 (dd, J = 9.8, 2.9 Hz, 1H), 8.32 - 8.04 (m, 2H), 7.49 (d, J = 7.6 Hz, 1H), 6.22 (d, J = 8.0 Hz, 1H), 4.61 (s, 3H), 4.09 (s, 1H), 3.90 (s, 3H), 3.66 - 3.41 (m, 1H), 2.17 -1.89 (m, 2H), 1.78 (dd, J = 10.3, 7.1 Hz, 2H), 1.65-0.69 (m,8H).
997	A	A	526.3	2
998	C	C	526.3	2
999	A	A	508.28	2.09
1000	A	A	476.22	1.86
1001	A	A	467.27	1.94
1002	A	A	481.28	2.2
1003	A	A	526.39	2.29
1004	A	A	543.41	1.45
1005	A	A	541.49	1.57
1006	A	A	526.39	2.25
1007	A	A	526.39	2.25
1008	A	A	429.45	2.64	CDCI3: 9.6 (m, 1H); 8.5 (dd, 1H); 8.25 (m, 2H); 8.1 (d, 1H); 4.8 (appt, 1H); 4.5 (m, 1H); 3.4 (m, 1H); 2.8 (s, 3H); 2.6 (m, 1H); 2.25 (m, 1H); 1.9 (m, 3H); 1.5-1.0 (m, 5H)
1009	A	A	443.7	2.81	CDCI3: 9.4 (m, 1H); 8.6 (dd, 1H); 8.25 (bs, 2H); 8.1 (d, 1H); 4.8 (appt, 1H); 4.6 (m, 1H); 3.5 (m, 2H); 3.1 (m, 1H); 2.6 (m, 1H); 2.25 (m, 1H);1.9 (m, 3H); 1.5-1.0 (m, 6H)
1010	A	A	487.29	1.93	CDCI3: 9.6 (m, 1H); 8.5 (dd, 1H); 8.25 (bs, 2H); 8.0 (d, 1H); 4.75 (app t, 1H); 4.5 (m, 1H); 4.25 (m, 1H); 3.6 (m, 1H); 3.55 (s, 3H); 3.5 (m, 2H); 2.7 (m, 1H); 2.26 (app t, 1H); 2.0 (m, 3H); 1.9 (m, 3H); 1.5-1.0 (m, 7H)
1011	A	A	473.28	1.79
1012	A	C	504.06	2.09
1013	A	A	486.47	2.52	1H NMR(d6-DMSO) 12.10 (s, 1H), 8.48-8.45 (m, 1H), 8.40-8.32 (m, 3H), 6.12 (d, J =7.8 Hz, 1H), 4.27-4.09 (m, 2H), 3.72-3.47 (m, 1H), 3.41-3.11 (m, 2H), 2.17-1.98 (m, 3H), 1.90- 1.72 (m, 4H), 1.60-1.37 (m, 2H), 1.32-1.20 (m, 1H)
1014	A	A	441.45	2.07	1H NMR (300 MHz, DMSO) d 12.26 (s, 1H), 8.53 - 8.01 (m, 3H), 7.89 (s, 1H), 7.60 (d, J = 7.4 Hz, 1H), 4.33 - 3.68 (m, 4H), 2.74 (s, 2H), 2.23 (d, J = 13.1 Hz, 1H), 2.08 -1.73 (m, 3H), 1.70 -1.08 (m, 3H).
1015	A	A	527.47	1.38	1H NMR (300 MHz, DMSO) d 12.61 (s, 1H), 8.38 (ddd, J = 9.6, 8.6, 2.9 Hz, 4H), 6.17 (d, J = 7.5 Hz, 1H), 4.20 (d, J = 10.5 Hz, 1H), 3.91 (d, J = 30.8 Hz, 4H), 3.72 - 2.96 (m, 11H), 2.37 -1.68(m, 6H), 1.52-1.10 (m, 4H).

-410WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1016	A	A	468.42	1.68	1H NMR (300 MHz, DMSO) d 12.67 (s, 1H), 9.15 (s, 1H), 8.49 (dd, J = 9.3, 3.8 Hz, 3H), 8.28 (d, J = 2.0 Hz, 1H), 6.41 (d, J = 7.5 Hz, 1H), 4.32 (s, 1H), 3.67 (s, 1H). 3.57 - 3.46 (m, 3H), 3.25 - 3.19 (m, 3H), 2.91 - 2.61 (m, 2H), 2.51 (dt, J = 3.6, 1.8 Hz, 4H), 2.23 -1.81 (m, 4H), 1.54-1.37 (m, 2H), 1.32- 1.23 (m, 3H).
1017	A	A	429.26	1.84
1018	A	A	429.26	1.83
1019	A	A	500.41	1.78
1020	A	A	514.42	1.91
1021	A	A	514.42	1.85
1022	A	A	460.48	1.76	1H NMR (300 MHz, DMSO) d 12.26 (s, 1H), 8.42 (dd, J = 9.8, 2.8 Hz, 1H), 8.29 - 8.20 (m, 2H), 8.14 (d, J = 4.0 Hz, 1H), 7,54 (d, J = 7.3 Hz, 1H), 6.04 (d, J = 7.9 Hz, 1H), 5.37 (s, 1H), 5.19 (s, 1H), 4.11 (d, J =4.5 Hz, 1H), 3.63 (d, J = 7.6 Hz, 1H), 3.57 - 3.40 (m, 2H), 3.23 (ddd, J = 18.1, 10.3, 5.4 Hz, 2H), 2.17-2.01 (m, 3H), 1.90 -1.74 (m, 2H), 1.52-1.20 (m, 4H).
1023	A	A	499.45	2.15	H NMR (300.0 MHz, MeOD) d 8.51 (dd, J = 2.8, 9.6 Hz, 1H), 8.18 - 8.15 (m, 2H), 7.99 (d, J = 4.1 Hz, 1H), 4.75 (s, H), 4.31 -4.19 (m, H), 3.82 - 3.73 (m, 2H), 3.76 (dd, J = 3.6, 11.9 Hz, 1H), 3.54 - 3.45 (m, 1H), 2.68 (s, 3H), 2.36 (d, J = 11.8 Hz, 1H), 2.22 -1.90 (m, 6H), 1.62 (s, H), 1.52-1.24 (m, 4H) and -0.00 (TMS) ppm
1024	A	A	427.27	2,07
1025	A	A	427.27	2.04
1026	A	A	413.26	1.94
1027	B	A	413.26	1.9
1028	A	A	414.34	2.36	1H NMR (300 MHz, MeOD) d 8.56 (dd, J = 9.2, 2.8 Hz, 1H), 8.47 (s, 1H), 8.37 - 8.32(m, 1H), 8.30 (d, J = 5.6 Hz, 1H), 5.17 (d, J = 6.9 Hz, 1H), 3.69 (s, 3H), 2.96 (d, J =6.8 Hz, 1H), 2.19-2.11 (m, 1H), 2.09-2.02 (m, 1H), 1.74 (complex m, 9H).
1029	A	A	443.27	1.97	CDCI3: 9.75 (bs,1 H); 8.6 (dd, 1H); 8.25 (d, 1H); 8.23 (s, 1H); 8.15 (d, 1H); 4.8 (d, 1H); 4.6 (m, 1H); 3.5 (m, 3H); 3.1 (m, 1H); 2,75 (bd, 1H); 2.25 (bd, 1H); 2.0 (m, 2H); 1.4 (d, 3H); 1.25 (t, 3H).
1030	A	A	443.27	1.99	CDCI3: 9.75(bs,1H); 8.5 (dd, 1H); 8.25 (d, 1H); 8.23 (s, 1H); 8.0 (d, 1H); 4.8 (d, 1H); 4.5 (m, 1H); 3.5 (m, 2H); 3.4 (m, 1H); 2.5 (bd, 1H); 2.1 (bd, 1H); 1.7 (m, 3H); 1.4 (ddd, 1H); 1.2 (m, 6H).
1031	A	A	416.46	1.69
1032	A	A	510.52	2.1

-411WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1033	A	A	479.39	2.08	1H NMR (300 MHz, DMSO) d 12.23 (s, 1H), 8.50 - 8.46 (m, 1H), 8.42 (dd, J = 9.8, 2.8 Hz, 1H), 8.26 (dd, J = 2.7,1.5 Hz, 1H), 8.22 (d, J = 2.7 Hz, 1H), 8.14 (d, J = 4.0 Hz, 1H), 7.73 (td, J = 7.7, 1.8 Hz, 1H), 7.47 (d, J = 7.3 Hz, 1H), 7.31 - 7.15 (m, 2H), 6.32 (t, J = 5.8 Hz, 1H), 6.14 (d, J = 7.8 Hz, 1H), 4.29 (d, J = 5.8 Hz, 2H), 4.22 - 3.97 (m, 1H), 3.57 (d, J = 7.7 Hz, 1H), 2.21 - 2.10 (m, J = 11.0 Hz, 1H), 2.07- 1.98 (m, 1H), 1.95 -1.72 (m, 2H), 1.59 - 0.88 (m, 4H).
1034	A	A	400.37	2.15	1H NMR (300 MHz, MeOD) d 8.58 (dd, J = 9.3, 2.8 Hz, 1H), 8.41 (s, 1H), 8.29 (dd, J = 2.7, 1.7 Hz, 1H), 8.22 (d, J = 5.3 Hz, 1H), 5.10 (d, J = 6.9 Hz, 1H), 2.89 (d, J = 7.0 Hz, 1H), 2.17 (brs, 1H), 2.03 (brs, 1H), 1.99-1.49 (m, 7H).
1035	A	A	444.42	1.81
1036	A	A	472.5	1.67	NMR 1H (MeOH-d4): 8.4 (m, 2H), 8.25 (m, 2H), 4.4 (m, 1H), 3.8 (m, 2H), 3.6 (m, 2H), 3.4 (m, 2H), 2.35 (m, 1H), 2.2 (m, 1H), 2.0 (m, 2H), 1.8 (m, 2H), 1.15-1.46 (6H).
1037	C	C	470.4	1.72
1038	A	A	470.4	1.73
1039	A	A	458.43	1.61	H NMR (300.0 MHz, CDCI3) d 7.70 (s, H), 7.28 (s, H), 7.11 (s, H), 5.31 (s, H), 4.17-4.02 (m, H), 3.78 (s, H), 3.73 (q, J = 7.0 Hz, H), 3.49 (s, H), 2.97 (s, H), 2.90 (s, H), 2.65 (s, H), 2.03 (d, J = 11.7 Hz, H), 1.87 (s, H), 1.29 - 1.21 (m, H) and 0.93 (d, J = 6.7 Hz, H) ppm
1040	A	A	428.43	1.67	H NMR (300.0 MHz, CDCI3) d 10.54 (s, H), 8.53 (dd, J = 2.8, 9.4 Hz, H), 8.50 (s, H), 8.25 8.06 (m, H), 7.30 (d, J = 10.7 Hz, H), 5.96 (s, H), 5.32 (s, H), 4.95 (d, J = 8.0 Hz, H), 4.87 (d, J = 6.6 Hz, H), 4.27 - 4.11 (m, H), 4.02 - 3.92 (m, H), 3.77 (t, J = 6.2 Hz, H), 3.51 (s, H), 2.92 (s, H), 2.73 - 2.67 (m, H), 2.45 - 2.37 (m, H), 2.26 (d, J = 10.3 Hz, H), 2.18 (d, J = 3.9 Hz, H), 2.12 (s, H), 2.06 -1.95 (m, H), 1.89 (s, H), 1.87 (q, J = 3.4 Hz, H), 1.73 (d, J = 8.6 Hz, H), 1.67 (s, H), 1.63 -1.58 (m, H), 1.33 -1.26 (m, H), 1.17 (t, J = 11.6 Hz, H), 0.94 (d, J = 6.6 Hz, H), 0.85 - 0.68 (m, H), 0.61 (t, J = 7.0 Hz, H), 0.62 (s, H) and 0.53 (d, J = 7.2 Hz, H) ppm
1041	A	A	486.46	1.95	1H NMR ¢300 MHz, MeOD) d 8.42 (dd, J = 9.2, 2.8 Hz, 1H), 8.40 (d, J = 2.8 Hz, 1H), 8.34 - 8.29 (m, 1H), 8.26 (d, J = 5.5 Hz, 1H), 4.43 (dd, J = 14.0,10.0 Hz, 1H), 3.99 - 3.90 (m, 1H), 3.75 (ddd, J = 15.3, 7.6, 3.6 Hz, 2H), 3.40 (d, J = 5.3 Hz, 3H), 3.35 (s, 3H), 2.36 (d, 3 = 11.9 Hz, 1H), 2.22 (d, J = 12.9 Hz, 1H), 2.041.75 (m, 7H), 1.68-1.19 (m, 6H).
1042	A	C	457.5	1.31
1043	A	A
1044	A	A	454.53	1.91

-412WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1045	A .	A	454.4	1.9
1046	C	C	479.41	2.08	1H NMR (300 MHz, DMSO) d 12.23 (d, J = 2.3 Hz, 1H), 8.51 - 8.35 (m, J = 8.5, 4.9,1.7 Hz, 3H), 8.32 - 8.19 (m, 2H), 8.14 (d, J = 4.0 Hz, 1H), 7.63 (dt, J = 7.8, 1.9 Hz, 1H), 7.47 (d, J = 7.5 Hz, 1H), 7.36 - 7.25 (m, 1H), 6.27 (t, J = 6.0 Hz, 1H), 6.00 (d, J = 7.9 Hz, 1H), 4.22 (d, J = 6.0 Hz, 2H), 4.17 - 3.98 (m, J = 10.5, 6.4 Hz, 1H), 3.67 - 3.44 (m, J = 7.8 Hz, 1H), 2.16 (d, J = 11.3 Hz, 1H), 2.03 (d, J = 11.7 Hz, 1H), 1.95 -1.70 (m, J = 25.5, 11.7 Hz, 2H), 1.53 - 0.93 (m, J = 33.7, 28.1, 12.8 Hz, 4H).
1047	A	A	501.5	1.65
1048	A	A	396.41	2.17	1H NMR (300 MHz, MeOD) d 9.07 (d, J = 6.8 Hz, 1H), 8.56 - 8.50 (m, 2H), 8.37 (d, J = 5.6 Hz, 1H), 7.55 (dd, J = 8.1, 5.1 Hz, 1H), 5.21 (d, J = 6.8 Hz, 1H), 3.73 (s, 3H), 3.00 (d, J = 6.6 Hz, 1H), 2.21 -2.15 (m, 1H), 2.10-2.05 (m, J = 5.8 Hz, 1H), 1.99 -1.52 (m, 9H).
1049	A	A	440.62	2	1H NMR (300 MHz, MeOD) d 9.08 (d, J = 7.2 Hz, 1H), 8.58 (s, 1H), 8.55 (dd, J = 5.3, 0.8 Hz, OH), 8.34 (d, J = 5.6 Hz, 1H), 7.74 (dd, J = 8.0, 5.4 Hz, 1H), 4.49 - 4.37 (m, 1H), 3.93 - 3.81 (m, 1H), 3.67 - 3.56 (m, 4H), 3.39 - 3.31 (m, 4H), 2.42 (d, J = 11.1 Hz, 1H), 2.17 - 2.05 (m, J = 11.4 Hz, 1H), 1.99 (burried m, 3H), 1.67 1.26 (m, 5H).
1050	A	A	456.57	2.71	1H NMR (300 MHz, DMSO) d 12.23 (s, 1H), 8.42 (dd, J = 9.8, 2.8 Hz, 1H), 8.22 (ddd, J = 28.3, 14.1,2.7 Hz, 3H), 7.49 (d, J = 7.7 Hz, 1H), 5.79 (d, J = 7.9 Hz, 1H), 4.20 - 4.00 (m, 1H), 3.61 (d, J = 8.0 Hz, 1H), 3.49 - 3.36 (m, 1H), 3.17 (d, J = 5.2 Hz, 1H), 2.84 - 2.65 (m, 1H), 2.22 -1.72 (m, 5H), 1.48 -1.10 (m, 5H), 0.98 (dd, J = 6.6,1.8 Hz, 3H).
1051	A	A	456.44	2.6	1H NMR (300 MHz, DMSO) d 12.23 (d, J = 2.3 Hz, 1H), 8.42 (dd, J = 9.9, 2.9 Hz, 1H), 8.22 (ddd, J = 28.6,14.3, 2.8 Hz, 3H), 7.49 (d, J = 7.4 Hz, 1H), 5.79 (d, J = 7.9 Hz, 1H), 4.21 3.99 (m, 1H), 3.61 (d, J = 7.9 Hz, 1H), 3.40 (dd, J = 9.7, 7.3 Hz, 1H), 3.14 (dd, J = 17.0, 7.6 Hz, 1H), 2.71 (dd, J = 9.7, 8.0 Hz, 1H), 2.20 - 1.73 (m, 5H), 1.54 - 1.11 (m, 5H), 0.98 (d, J = 6.6 Hz, 3H).
1052	A	A	456.67	2.75	1H NMR (300 MHz, DMSO) d 12.23 (d, J = 2.1 Hz, 1H), 8.42 (dd, J = 9,9, 2.9 Hz, 1H), 8.22 (ddd, J = 30.6, 15.3, 2.8 Hz, 3H), 7.49 (d, J = 7.5 Hz, 1H), 5.74 (d, J = 7.9 Hz, 1H), 4.07 (d, J = 5.2 Hz, 1H), 3.88 (dd, J = 8.7, 4.5 Hz, 1H), 3.69 - 3.50 (m, 1H), 3.27 - 3.24 (m, 1H), 3.17 (t, J = 3.7 Hz, 1H), 2.21 -1.66 (m, 5H), 1.38 (dd, J = 41.1, 29.2 Hz, 5H), 1,04 (d, J = 6.2 Hz, 3H).

-413WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1053	A	A	456.27	2.65	1H NMR (300 MHz, DMSO) d 12.23 (d, J = 2.1 Hz, 1H), 8.42 (dd, J = 9.9, 2.9 Hz, 1H), 8.22 (ddd, J = 27.2,13.6, 2.8 Hz, 3H), 7.49 (d, J = 7.5 Hz, 1H), 5.75 (d, J = 8.0 Hz, 1H), 4.26 4.02 (m, 1H), 3.97 - 3.83 (m, 1H), 3.72 - 3.53 (m, 1H), 3.31 (s, 1H), 3.16 (s, 1H), 2.15-1.64 (m, 5H), 1.44 (s, 5H), 1.04 (d, J = 6.2 Hz, 3H).
1054	A	A	472.42	2.34	1H NMR (300 MHz, DMSO) d 12.27 (s, 1H), 8.42 (dd, J = 9.9, 2.8 Hz, 1H), 8.27 (dd, J = 2.7, 1.4 Hz, 1H), 8.23 (d, J = 2.8 Hz, 1H), 8.14 (d, J = 4.0 Hz, 1H), 7.53 (d, J = 7.5 Hz, 1H), 7.29 (s, 1H), 6.70 (s, 1H), 5.91 (d, J = 8.0 Hz, 1H), 4.11 (s, 1H), 3.90 (d, J = 3.0 Hz, 1H), 3.62 (d, J = 8.1 Hz, 1H), 3.27 (d, J = 4.2 Hz, 2H), 2.11 (d, J = 10.4 Hz, 1H), 1.99 (s, 2H), 1.93 -1.77 (m, 4H), 1.75 (s, 1H), 1.54 -1.21 (m, 5H).
1055	A	A	472.41	2.34
1056	A	A	486.33	1.89
1057	A	C	486.4	1.89
1058	A	A	472.43	2.67	1H NMR (300 MHz, MeOD) d 8.46 (dd, J = 10.0, 2.8 Hz, 1H), 8.17 - 7.91 (m, 2H), 4.28 4.08 (m, 1H), 3.88 - 3.71 (m, 1H), 3.62 (d, J = 5.1 Hz, 3H), 3.46 - 3.32 (m, 4H), 2.87 (s, 3H), 2.32 (d, J = 11.9 Hz, 1H), 2.15 (d, J = 12.9 Hz, 1H), 2.03 -1.85 (m, 2H), 1.67-1.20 (m, 4H).
1059	A	A	495	2.03
1060	A	A	508	1.42
1061	A	A	474	1.89	NMR 1H (MeOH-d4): 8.5 (s, 1H), 8,15-8.34 (m, 3H), 4.4 (m, 1H), 3.8 (m, 1H), 3.5 (m, 2H), 3.5 (m, 2H), 3.3 (m, 2H), 2.9 (s, 1H), 2.4 (m, 1H), 2.2 (m, 1H), 2.0 (m, 2H), 1.2-1.5 (m, 4H), 1.1 (t, 3H).
1062	A	A	458	1.68
1063	A	A	444	1.91
1064	A	A	504.5	1.91	H NMR (300.0 MHz, MeOD) d 8.44 (dd, J = 2.8, 9.6 Hz, H), 8.14 (t, J =4.5 Hz, H), 8.13 (s, H), 7.98 - 7.94 (m, H), 7.70 (s, H), 7.06 (s, H), 6.28 (d, J = 7.3 Hz, H), 5.49 (s, H), 4.83 (s, H), 4.52 (s, H), 4.22 - 4.09 (m, H), 3.75 (dd, J = 3.8, 11.4 Hz, H), 3.69 (s, H), 3.57 - 3.30 (m, H), 3.26 (s, H), 3.10 (s, H), 2.99 (s, H), 2.87 (d, J = 8.6 Hz, H), 2.36 - 2.33 (m, H), 2.19 (d, J = 12.2 Hz, H), 2.03 (d, J = 10.6 Hz, H), 1.95- 1.89 (m, H), 1.65 (s, H), 1.61 -1.52 (m, H), 1.43-1.13 (m, H)and -0.00 (s, H) ppm
1065	A	A	486	1.96
1066	A	A	474	1.82
1067	A	A	474	1.89	in MeOH-4
1068	A	A	474	1.86	in MeOH-d4
1069	A	A	484	1.99
1070	A	A	400.39	2.15	1H NMR (300 MHz, MeOD) d 8.66 (dd, J = 9.6, 2.8 Hz, 1H), 8.19 (s, 2H), 7.98 (d, J =4.1 Hz, 1H), 4.91 (d, J = 6.8 Hz, 1H), 2.75 - 2.63 (m, 1H), 2.18-1.41 (m, 10H).

-414WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1071	A	A	400.56	2.15	1H NMR (300 MHz, MeOD) d 8.66 (dd, J = 9,6, 2.8 Hz, 1H), 8.19 (s, 2H), 4.90 (d, J = 6.9 Hz, 1H), 2.75 - 2.64 (m, 1H), 2.15 -1.42 (m, 10H).
1072	A	A	537	2.09	1H NMR (300 MHz, DMSO)d 12.55 (s, 1H), 8.40 (t, J = 3.1 Hz, 1H), 8.36 (d, J = 2.8 Hz, 1H), 8.33 (t, J = 3.7 Hz, 2H), 6.43 (d, J = 7.7 Hz, 1H), 4.19 (d, J = 7.2 Hz, 1H), 3.66 (d, J = 7.4 Hz, 1H), 3.48 (dd, J = 13.1, 5.9 Hz, 4H), 3.35 - 3.25 (m, 1H), 2.67 (d, J = 7.0 Hz, 2H), 2,21 -1.80 (m, 6H), 1.56-1.22 (m, 4H).
1073	A	A	490	1.99
1074	A	A	490	2.01
1075	A	A	458	2.04	NMR 1H (MeOH-d4):8.44 (s, 1H), 8.4 (d, 1H), 8.3 (m, 1H), 8.2 (d, 1H), 4.3-4.4 (m, 2H), 3.8 (m, 1H), 3.2 (q, 2H), 2.2-2.34 (m, 2H), 2.0 (m, 2H), 1.3-1.6 (m,4H), 1.1 (m, 8H).
1076	A	A	473	1.33	NMR 1H (MeOH-d4): 8.5 (s, 1H), 8.4 (dd, 1H), 8.3 (m, 1H), 8.26 (d, 1H), 4,4-4.45 (m, 1H), 3.8 (m, 1H), 3.5-3.7 (m, 2H), 3.3 (m, 2H), 2.95 (m, 9H), 2.35 (m, 1H), 2.2 (m, 2H), 1.95 (m, 2H), 1.25-1.55 (m,5H).
1077	A	A	474.43	1.68	H NMR (300.0 MHz, MeOD) d 8.47 - 8.25 (m, H), 7.98 (s, H), 4.95 (s, H), 4.89 (s, H), 4.82 (s, H), 4.49 - 4.40 (m, H), 4.21 - 4.10 (m, H), 4.01 (s, H), 3.92 (s, H), 3.54 (t, J = 1.7 Hz, H), 3.44 - 3.30 (m, H), 3.07 (t, J = 1.6 Hz, H), 2.99 (s, H), 2.87 (d, J = 6.6 Hz, H), 2.65 (s, H), 2.51 (q, J = 12.1 Hz, H), 2.36 - 2.31 (m, H), 2.24 - 2.04 (m, H), 1.99 (s, H), 1.81 (d, J = 11.6 Hz, H), 1.71-1.66 (m, H), 1.61-1,45 (m, H), 1.40 1.37 (m, H), 1.18-1.08 (m, H), 0.19 (s, H), 0.00 (TMS) and -0.20 (s, H) ppm
1078	A	A	481	1.91	NMR 1H (MeOH-d4): 8.5 (s, 1H), 8.17-8.33 (m, 3H), 4.4 (m, 1H), 3.75 (m, 1H), 3.6 (m, 2H), 2.7-2.9 (m, 3H), 2.4 (m, 1H), 2.2 (m, 1H), 2.05 (m, 2H), 1.2-1.7 (m, 4H), 0.9 (m, 2H), 0.75 (m, 2H).
1079	A	A	472.37	2.11	1H NMR (300 MHz, DMSO) d 12.23 (s, 1H), 8.42 (dd, J = 9.9, 2.9 Hz, 1H), 8.30 - 8.19 (m, 2H), 8.13 (d, J = 4.0 Hz, 1H), 7.49 (d, J = 7.5 Hz, 1H). 5.77 (t, J = 6.3 Hz, 1H), 4.66 (s, 1H), 4.20 - 4.04 (m, 1H), 3.71 - 3.50 (m, J = 7.7 Hz, 1H), 3.30 (q, J = 5,3 Hz, 1H), 3.18 (dd, J = 7.8, 4.8 Hz, 2H), 3.04 (d, J = 10.5 Hz, 1H), 2.11 (d, J = 11.6 Hz, 1H), 2.00 (d, J = 9.5 Hz, 1H), 1.88 -1.59 (m, 4H), 1.52-1.32 (m, 2H), 1.35-1.18 (m, 5H).
1080	A	A	500	2.01	NMR 1H (MeOH-d4): 8.5 (s, 1H), 8.26-8.33 (m, 3H), 4.36 (m, 1H), 4.05 (m, 1H), 3.9 (m, 1H), 3.75 (m, 2H), 3.3 (m, 2H), 3.2 (m, 2H), 2.4 (m, 1H), 2.2 (m, 2H), 1,8-2.0 (m, 5H), 1.2-1.6 (m, 5H), 1.1 (t, 3H).

-415WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1081	A	A	512	1.84	NMR 1H (MeOH-d4): 8.4 (s, 1H), 8.25-8.35 (m, 3H), 4.7 (s, 2H), 4.35 (m, 1H), 3.8 (m, 1H), 3.35 (q, 2H), 2.2-2.3 (m, 5H), 2.0 (m, 2H), 1.31.8 (m, 4H), 1.1 (t, 3H).
1082	B	A	498.35	2.69	1H NMR (300 MHz, CDCI3) d 10.71 (s, 1H), 8.53 (d, J = 9.9 Hz, 1H), 8.20 (s, 1H), 8.11 (d, J = 2.9 Hz, 1H), 4.87 (d, J = 6.9 Hz, 1H), 4.29 (d, J = 6.9 Hz, 1H), 4.14 (m. 1H), 3.82 (m, 4H), 3.34 (m, 4H), 2.56 (s, 1H), 2.30 (m, 1H), 2.05 (m, 1H)„ 1.91 (m1H), 1.81 -1.42(m, 2H), 1.41 -0.87 (m, 7H).
1083	A	A	456.2	2.74	1H NMR (300 MHz, MeOD) d 8.33 - 8.21 (m, 2H), 8.11 (dd, J = 9.3, 2.3 Hz, 1H), 4.38 (m, 1H), 3.51(4 H), 3.72 (m, 1H), 2.85 (s, 3H), 2.30 (m, 1H), 2.10 (m, 1H), 2.02-1.88 (m, 6H), 1.57-1.30 (m,4H).
1084	A	A	486.46	1.76
1085	A	A	458.5	2.05
1086	A	A	444.61	1.87
1087	A	A	458.56	2.04
1088	C	C	482.46	2.87	1H NMR (300 MHz, MeOD) d 8.40 (d, J = 10.0 Hz, 1H), 8.01 (dd, J = 17.7, 2.5 Hz, 2H), 4.14 (s, 1H), 3.84 - 3.53 (m. 2H), 3.28 (s, 3H), 2.28 (d, J = 11.9 Hz, 1H), 2.11 (s, IH), 2.05-1.76 (m, 6H), 1.61 - 1.00 (m,9H).
1089	A	A	424.69	1.77	1H NMR (300 MHz, MeOD) d 9.32 - 9.10 (m, 1H), 8.67 (s, 1H), 8.65 - 8.59 (m, 1H), 8.39 (d, J = 5.6 Hz, 1H), 7.87 (dd, J = 8,1,5.6 Hz, 1H), 4.53 - 4.34 (m, 1H), 3.97 - 3.79 (m, 1H), 2.42 (d, J = 11.5 Hz, 1H), 2.11 (d, J = 10.5 Hz, 1H), 2.05 - 1.83 (m, 5H), 1.70 - 1.33 (m, 4H).
1090	A	A	382.61	1.96	1H NMR (300 MHz, MeOD) d 9.00 (dd, J = 8,1, 1.5 Hz, 1H), 8.46 (dd, J = 5.0, 1.4 Hz, 1H), 8.32 (d, J = 5.6 Hz, 1H), 7.47 (dd, J = 8.1, 5.0 Hz, 1H). 5.21 - 5.10 (m, J = 6.8 Hz, 1H), 3.01 - 2.87 (m, J = 6.8 Hz, 1H), 2.23 - 2.12 (m, 1H), 2.06 -1.98 (m, 1H), 1.98 -1.47 (m, 7H).
1091	A	A	472.25	1.77
1092	A	A	472.25	1.77
1093	A	A	488.19	1.9
1094	A	A	488.19	1.9
1095	A	A	514.41	2.33	1H NMR (300 MHz, DMSO) d 12.27 (s, 1H), 8.42 (dd, J = 9.8, 2.8 Hz, 1H), 8.29 - 8.25 (m, J = 1.4 Hz, 1H), 8.23 (d, J = 2.8 Hz, 1H), 8.14 (d, J = 4.0 Hz, 1H), 7.52 (d, J = 7.4 Hz, 1H), 6.23 (d, J = 7.7 Hz, 1H), 4.21 - 3.92 (m, 3H), 3.60 (s, 1H), 3.17 (d, J = 5.2 Hz, 2H), 2.11 (d, J = 12.4 Hz, 1H), 2.00 (d, J = 7.9 Hz, 1H), 1.81 (d, J = 10.7 Hz, 2H), 1.62 (d, J = 11.8 Hz, 2H), 1.52 - 1.17 (m, 6H), 1.02 (d, J = 9.4 Hz, 8H).
1096	A	A	456.45	2.01
1097	A	A	488	1.56

-416WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1098	A	A	460.39	2.38	1H NMR (300 MHz, DMSO) d 12.27 (s, 1H), 8.42 (dd, J = 9.9, 2.8 Hz, 1H), 8.29 - 8.01 (m, 3H), 7.50 (d, J = 7.1 Hz, 1H), 5.84 (d, J = 7.8 Hz, 1H), 5.60 (d, J = 8.2 Hz, 1H), 4.29 - 3.99 (m, 1H), 3.72 (dd, J = 12.8, 6.6 Hz, 1H), 3.52 (d, J = 8.1 Hz, 1H), 3.25 - 3.05 (m, 4H), 2.19 1.68 (m, 3H), 1.52 -1.11 (m, 3H), 1.00 (d, J = 6.7 Hz, 3H).
1099	A	A	470.35	2.2	1H NMR (300 MHz, DMSO) d 12.26 (d, J = 2.4 Hz, 1H), 8.42 (dd, J = 9.8, 2.9 Hz, 1H), 8.23 (ddd, J = 30.4,15.2, 2.7 Hz, 2H), 7.54 (d, J = 7.5 Hz, 1H), 6,14 (d, J = 8.0 Hz, 1H), 4.50 (d, J = 10.5 Hz, 2H), 4.25-3.95 (m, 1H), 3.62 (dd, J = 12.4, 6,7 Hz, 2H), 3.25 - 3.03 (m, 2H), 2.19 0.90 (m, 10H).
1100			474	1.55
1101	A	A	502.5	1.76
1102	A	A	571.14	1.65	1H NMR (300 MHz, DMSO) d 12.26 (s, 1H), 8.42 (dd, J = 9.8, 2.9 Hz, 1H), 8.29 - 8.25 (m, J = 2.8, 1.5 Hz, 1H), 8.23 (s, 1H), 8.14 (d, J = 4.0 Hz, 1H), 7.54 (d, J = 7.7 Hz, 1H), 5.97 (d, J = 7.8 Hz, 1H), 4.20 - 4.08 (m, J = 5.2 Hz, 1H), 4.08 - 3.98 (m, 2H), 3.97 - 3.86 (m, J = 11.5, 8.4 Hz, 1H), 3.30 - 3.23 (m, 1H), 3.17 (d, J = 5.2 Hz, 1H), 3.07 (d, J = 5.4 Hz, 1H), 2.182.07 (m, J = 11.8 Hz, 1H), 2.06 -1.93 (m, J = 10.5 Hz, 1H), 1.92-1.74 (m, 6H). 1.76-1.63 (m, 2H), 1.42 (dd, J = 23.4, 11.6 Hz, 2H), 1.35 -1.15 (m, 3H), 0.81 (dd, J = 13.3, 6,8 Hz, 6H).
1103	A	A	486	1.72	1H NMR (300 MHz, DMSO) d 8.36 (d, J = 8.1 Hz, 1H), 8.23 (d, J = 1.5 Hz, 1H), 8.20 (s, 1H), 8.11 (d, J = 3.8 Hz, 1H), 7.43 (s, 1H), 6.13 (d, J = 7.5 Hz, 1H), 5.76 (s, 1H), 4.13 (s, 2H), 3.24 - 2.98 (m, 4H), 2.27 - 2.20 (m, 1H), 2.01 (d, J = 11.5 Hz, 3H), 1.81 (d, J = 11.6 Hz, 2H), 1.63 0.93 (m, 11H).
1104	A	A	490.43	1.59	1H NMR (300 MHz, d6-DMSO) 12.70 (s, 1H), 8.42 (s, 1H), 8.34 (s, 1H), 8.26 (d, J = 17.1 Hz, 1H), 6.02 (d, J= 7.2 Hz, 1H), 5.37 (s, 1H), 5.19 (s, 1H), 4.33 (s, 1H), 4.13 (s, 3H), 2.27 (s,1H), 2.10(s, 3H), 1.77 (s, 5H), 1.481.14 (m, 6H)
1105	A	A	474.4	1.5	NMR 1H (MeOH-d4): 8.5 (s, 1H), 8.25-8.33 (m, 3H), 4.4 (m, 1H), 4.1 (d, 2H), 3.8 (m, 1H), 3.5 (dd, 2H), 2.3-2.4 (m, 2H), 2.0 (d, 2H), 1.31.6 (m, 4H).
1106	A	A	502.43	2.35	1H NMR (300 MHz, DMSO) d 12.26 (s, 1H), 8.42 (dd, J = 9.8, 2.8 Hz, 1H), 8.30 - 8.05 (m, 3H), 7.54 (d, J = 7.5 Hz, 1H), 5.96 (d, J = 7.8 Hz, 1H), 4.26 - 3.93 (m, 1H), 3.80 (s, 2H), 3.59 (s, 1H), 3.33 - 3.16 (m, 8H), 1.93 (dd, J = 67.2, 22.0 Hz, 4H), 1.60 - 0.89 (m, 5H).

-417WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1107	A	A	502.02	2.38	1H NMR (300 MHz, DMSO) d 12.26 (s, 1H), 8.42 (dd, J = 9.9, 2.8 Hz, 1H), 8.35 - 8.01 (m, 3H), 7.54 (d, J = 7.5 Hz, 1H), 5.96 (d, J = 7.8 Hz, 1H), 4.13 (s, 1H), 3.80 (s, 2H), 3.69 - 3.44 (m, 1H), 3.28 (d, J = 9.4 Hz, 7H), 2.04 (d, J = 32.3 Hz, 2H), 1.83 (d, J = 8.8 Hz, 2H), 1.33 (dt, J = 25.0, 12.2 Hz, 5H).
1108	A	A	516.71	2.2	1HNMR (300 MHz, DMSO) d 12.26 (s, 1H), 8.65 - 7.90 (m, 4H), 7.53 (d, J = 6.6 Hz, 1H), 6.29 (d, J = 6.9 Hz, 1H), 4.12 (s, 1H), 3.72 - 2.94 (m, 11H), 2.04 (d, J = 30.8 Hz, 2H), 1.72 (d, J = 44.2 Hz, 3H), 1.32 (d, J = 56.3 Hz, 5H).
1109	A	A	516.41	2.39	1H NMR (300 MHz, DMSO) d 12.27 (s, 1H), 8.27 (dd, J = 48.0, 38.1 Hz, 4H), 7.55 (s, 1H), 6.36 (s, 1H), 4.12 (s, 1H), 3.81 -2.81 (m, 11H), 2.21 -1.68 (m, 5H), 1.32 (d, J = 53.8 Hz, 6H).
1110	A	A	458.5	2,02
1111	A	A	472.51	1.72
1112	A	A	472.45	1.73
1113	A	A	472.45	1.73
1114	A	A	487.48	1.64
1115	A	A	521.5	1.5	NMR 1H (MeOH-d4): 8.5 (s, 1H), 8.3-8.35 (m, 3H), 6.37-6.7 (tt, 1H), 4.4 (m, 1H), 3.8 (m, 1H), 3.5-3.75 (m, 5H), 2.18-2.4 (m, 2H), 2.0 (d, 2H), 1.3-1.7 (m,4H).
1116	B	C	445.45	1.64
1117	A	A	501.56	2.16
1118	A	A	486.5	1.68	NMR 1H (MeOH-d4): 8.27-8.32 (m, 4H), 4.4 (m, 1H), 3.35 (m, 1H), 2.4-2.64 (m, 2H), 1.82.2 (m,4H), 1.4-1.75 (m, 4H).
1119	A	A	474.24	1.89
1120	A	A	490.23	2.01
1121	A	A	490.23	2.01
1122	A	A	456.26	1.93
1123	A	A	456.26	1.93
1124	A	A	472.25	2.06
1125	A	A	472.19	2.06
1126	A	A	474.24	1.89
1127	A	A	492.08	2.82	1H NMR (300 MHz, DMSO) d 12.25 (s, 1H), 8.41 (dd, J = 9.8, 2.7 Hz, 1H), 8.30 - 8.05 (m, 2H), 7.50 (s, 1H), 7.23 (td, J = 6.1, 2.9 Hz, 5H), 6.17 (d, J = 8.3 Hz, 1H), 5.80 (d, J = 7.9 Hz, 1H), 4.73 (s, 1H), 4.11 (d, J = 5.3 Hz, 1H), 3.50 (s, 1H), 2.21 -1.66 (m, 4H), 1.28 (dd, J = 14.7, 9.7 Hz, 7H).
1128	A	A	458.41	2.87	1H NMR (300 MHz, DMSO) d 12.26 (s, 1H), 8.42 (dd, J = 9.9, 2.9 Hz, 1H), 8.23 (ddd, J = 29.2, 15.1, 2.7 Hz, 3H), 7.53 (d, J = 7.4 Hz, 1H), 5.97 (d, J = 7.8 Hz. 1H), 4.11 (d, J = 5.2 Hz, 1H), 3.62 (d, J = 7.8 Hz, 1H), 3.15 (dd, J = 9.6, 6.3 Hz, 2H), 2.74 (s, 2H), 2.05 (dd, J = 27.0, 11.4 Hz, 2H), 1.81 (d, J = 11.2 Hz, 2H), 1.55-1.06 (m, 7H), 0.86 (t, J = 7.2 Hz, 3H).

-418WO 2010/148197

PCT/US2010/038988

1129	A	A	444.41	2.59	1H NMR (300 MHz, DMSO) d 12.26 (d, J = 2.1 Hz, 1H), 8.42 (dd, J = 9.8, 2.8 Hz, 1H), 8.23 (ddd, J = 30.0, 15.0, 2.7 Hz, 3H), 7.53 (d, J = 7.5 Hz, 1H), 5.98 (d, J = 7.9 Hz, 1H), 4.35 3.94 (m, 1H), 3.63 (d, J = 8.8 Hz, 1H), 3.22 3.02 (m, 2H), 2.75 (s, 2H), 2.05 (dd, J = 26.7, 11.8 Hz, 2H), 1.81 (d, J = 10.5 Hz, 2H), 1.37 (ddd, J =41.6, 24.7, 8.1 Hz, 6H), 0.79 (t, J = 7.4 Hz, 3H).
1130	A	A	444.1	2.6
1131	A	A	430.07	2.47	1H NMR (300 MHz, DMSO) d 12.26 (s, 1H), 8.42 (dd, J = 9.8, 2.9 Hz, 1H), 8,23 (ddd, J = 29.8,15.3, 2.7 Hz, 2H), 7.53 (d, J = 7.5 Hz, 1H), 6.00 (d, J = 7.9 Hz, 1H), 4.11 (d, J = 5.2 Hz, 1H), 3.62 (d, J = 9.3 Hz, 1H), 3.25 - 3.06 (m, 2H), 2.74 (s, 2H), 2.05 (dd, J = 28,7,11.2 Hz, 2H), 1.81 (d, J = 10.5 Hz, 1H), 1.55-1.09 (m, 4H), 0.96 (t. J = 7.0 Hz, 2H).
1132	A	A	486.1	2.46	1H NMR (300 MHz, DMSO) d 12.26 (s, 1H), 8.42 (dd, J = 9.8, 2.8 Hz, 1H), 8.20 (dd, J = 32.6, 8.6 Hz, 2H), 7.53 (d, J = 7,7 Hz, 1H), 5.90 (d, J = 7.9 Hz, 1H), 4.28 - 3.92 (m, 2H), 3.62 (d, J = 7.1 Hz, 1H), 3.45 - 3.08 (m, 9H), 2.21 -1.68 (m, 5H), 1.53 - 0.89 (m, 6H).
1133	A	A	488.19	1.88	1H NMR (300 MHz, MeOD) d 8.36 (dd, J = 9.4, 2.6 Hz, 1H), 8.28 (m, 2H), 5.13 (s, 2H), 4.35 (m, 1H), 3.79 (s, 1H), 3.67 - 3.56 (m, 4H), 3.39 - 3.32 (m, 4H), 2.33 (m, 1H), 2.16 (m, 1H), 1.98 (m, 2H), 1.69-1.20 (m, 4H).
1134	A	A	442	2.3	NMR 1H (MeOH-d4): 8.5 (s, 1H), 8.3 (m, 3H), 4.4 (m, 1H), 3.6 (m, 4H), 2.6 (m, 1H), 1.5-2.3 (m, 12H).
1135	A	A	484.42	2.32	1H NMR (300 MHz, DMSO) d 12.23 (s, 1H), 8.42 (dd, J = 9.8, 2.7 Hz, 1H), 8.33 - 8.06 (m, 3H), 7.49 (d, J = 7.7 Hz, 1H), 6.15 (d, J = 7.7 Hz, 1H), 4.24 (s, 3H), 3.55 (d, J = 12.5 Hz, 3H), 2.83 (d, J = 12.5 Hz, 2H), 1.99 (s, 2H), 1.72 (ddd, J = 33.2, 19.4, 9.2 Hz, 5H), 1.46 1.02 (m, 4H).
1136	A	A	417.48	1.99
1137	A	A	459.52	2
1138	A	A	345,16	0.55	1H NMR (300 MHz, DMSO) d 12.40 (s, 1H), 8,56 - 8.13 (m, 2H), 7.89 (s, 2H), 4.37 (s, 6H), 3.21 (d, J = 22.3 Hz, 1H), 2.27 (s, 1H), 2.01 (s. 1H), 1.63-1.14 (m, 2H).
1139	A	A	472.32	2.06	1H NMR (300 MHz, MeOD) d 8.55 (dd, J = 9.8, 2,7 Hz, 1H), 8.08 (m, 2H), 5.12 (m, 2H), 4.19 (m, 1H), 3.80 (m, 1H), 2.33 (m, 1H), 2.17 (m, 1H), 2.06 -1.77 (m, 8H), 1.69-1.21 (m, 4H).
1140	A	A	443.53	2.29	1H NMR (300 MHz, CDCI₃) δ 9.91 (s, 1H), 8.51 (dd, J= 9.4, 2.8 Hz, 1H), 8.26 (dd, J = 2.6, 1.7 Hz, 1H), 8.22 (d, J = 2.8 Hz, 1H), 8.07 (d, J = 3.5 Hz, 1H), 5.42 (d, J = 6.2 Hz, 1H), 5.10-4.92 (m, J= 7.8, 3.9 Hz, 1H), 4.48 -

-419WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

					4.30 (m, 1H), 3.42 (q, J = 11.8, 6.1 Hz, 4H), 2.44 (dt, J = 12.9 Hz, 1H), 2.11 - 1.81 (m, 7H), 1.75-1.46 (m, 3H)
1141	A	A	467.52	1.78
1142	A	A	403.15	1.7	H NMR (300.0 MHz, MeOD) d 8.67 (d, J = 2.3 Hz, 1H), 8.61 (s, 1H), 8.39 (d, J = 2.3 Hz, 1H), 8.32 (d, J = 5.5 Hz, 1H), 4.50 - 4.43 (m, 1H), 3.70 - 3.63 (m, 1H), 3.31 (qn, J = 1.6 Hz, H), 2.47 - 2.39 (m, 1H), 2.30 (d, J = 12.1 Hz, 1H), 2.15 - 2.08 (m, 2H), 1.70 (q, J = 11.9 Hz, 2H), 1.50-1.14 (m, 2H) and -0.00 (TMS) ppm
1143	A	A	387.06	1.45
1144	A	A	456.07	1.78	1H NMR (300 MHz, MeOD) d 8.83 (s, 1H), 8.67 - 8.09 (m, 4H), 2.67 (s, 3H), 2.18 (dd, J = 101.0, 49.9 Hz, 5H), 1.34 (d, J = 29.6 Hz, 3H).
1145	A	A			1H NMR (300 MHz, DMSO) d 12.24 (d, J = 2.3 Hz, 1H), 8.43 (dd, J = 9.8, 2.9 Hz, 1H), 8.26 (dd, J = 2.7, 1.5 Hz, 1H), 8.16 (d, J = 3.8 Hz, 1H), 7.78 (s, 1H), 7.50 (d, J = 7.3 Hz, 1H), 4.58-4.18 (m, 1H), 3.42-3.32 (m, 1H), 2.11 (d, J = 13.1 Hz, 2H), 1.98 -1.69 (m, 4H), 1.68 1.14 (m, 4H), 0.92 (t, J = 7.4 Hz, 3H).
1146	A	A			1H NMR (300 MHz, DMSO) d 12.25 (d, J = 2.1 Hz, 1H), 8.43 (dd, J = 9.8, 2.9 Hz, 1H), 8.26 (dd, J = 2.8, 1.5 Hz, 1H), 8.21 -8.10 (m, 2H), 7.80 (s, 1H), 7.48 (d, J = 7.4 Hz, 1H), 4.59 4.22 (m, 1H), 3.33 - 3.20 (m, 4H), 2.31-1.96 (m, 2H), 1.94 - 1.16 (m, 7H), 0.92 (t, J = 7.4 Hz, 3H).
1147	A	A			1H NMR (300 MHz, DMSO)d 12.24 (s, 1H), 8.39 (dd, J = 9.8, 2.8 Hz, 1H), 8.32-8.26 (m, 1H), 8.20 (dd, J = 9.7, 3.2 Hz, 1H), 7.89 (s, 1H), 7.24 (t, J = 22.3 Hz, 1H), 4.37 (s, 1H), 3.47 (d, J = 7.8 Hz, 1H), 2.18 (d, J = 10.5 Hz, 1H), 2.03 -1.14 (m, 9H), 0.96 (t, J = 7.3 Hz, 3H).
1148	A	A			1H NMR (300 MHz, DMSO) d 12.30 (s, 1H), 8.39 (dd, J = 9.8, 2.9 Hz, 1H), 8.28 (dd, J = 2.7, 1.5 Hz, 1H), 8.18 (dd, J = 4.9, 3.0 Hz, 1H), 7.92 (s, 1H), 7.40 (d, J = 8.1 Hz, 1H), 4.32 (s, 1H), 3.40 (d, J = 8.5 Hz, 1H), 2.14 (d, J = 12.7 Hz, 1H), 1.97-1.17 (m,9H), 1.10-0.80 (m, 3H).
1149	A	A	445.51	2.37
1150	A	A	457.47	2.47
1151	A	A	461.51	2.15
1152	A	A	493.5	2.39
1153	A	A	443.21	1.99
1154	A	A			1H NMR (300 MHz, MeOD) d 8.63 - 8.40 (m, 1H), 8.31 - 8.03 (m, 2H), 7.99 (dd, J = 3.9,1.1 Hz, 1H), 4.49 (t, J = 11.5 Hz, 1H), 3.44 - 3.25 (m, 3H), 3.22 - 3.08 (m, 1H), 2.29 (dd, J = 40.0,12.5 Hz, 2H), 2.13 -1.16 (m, 8H), 1.00 (q, J = 7.0 Hz, 3H).
1155	A	A	457.28	2.16

-420WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1156	A	A	457.28	2.13
1157	A	A	443.21	2.11
1158	A	A	443.41	2.09	1H NMR (300 MHz, MeOD) d 8.63 - 8.40 (m, 1H), 8.23 - 8.12 (m, 2H), 8.04 (t, J = 4.4 Hz, 1H), 4.56 (dd, J = 7.7, 3.8 Hz, 1H), 3.64 - 3.47 (m, 1H), 2.28 (dd, J = 13.6, 4.0 Hz, 1H), 2.19 1.46 (m, 9H), 1.01 - 0.73 (m, 3H).
1159	A	A	457.22	2.25
1160	A	A	457.22	2.21
1161	A	A	360.47	1.68
1162	A	A	430.14	2.5	1H NMR (300 MHz, DMSO) d 12.32 (s, 1H), 8.78 (d, J = 2.3 Hz, 1H), 8.29 (d, J = 2.4 Hz, 1H), 8.17 (dd, J = 4.8, 3.4 Hz, 2H), 7.60 (d, J = 6.9 Hz, 1H), 4.74 (t, J = 6.4 Hz, 1H), 3.64 (d, J = 17.5 Hz, 3H), 2.95 (d, J = 6.9 Hz, 1H), 2.03 1.30 (m, 11H).
1163	C	C	470.46	1.58
1164	A	A	470.46	1.65
1165	A	A	441.64	2.75	1H NMR (300 MHz, DMSO) d 12.27 (s, 1H), 8.70 - 8.02 (m, 3H), 7.63 (dd, J = 63.2, 7.4 Hz, 2H), 4.13 (s, 1H), 3.70 (s, 1H), 2.23 - 0.92 (m, 18H).
1166	A	A	455.65	2.96	1H NMR (300 MHz, DMSO) d 12.27 (s, 1H), 8.62 - 7.97 (m, 3H), 7.59 (dd, J = 41.7, 7.6 Hz, 2H), 4.13 (s, 1H), 3.71 (s, 1H), 2.21 -0,92 (m, 20H).
1167	C	C	543.6	2.55
1168	A	C	444.49	1.78
1169	A	A	486.52	1.74
1170	A	A	531.57	2.02
1171	C	A	577.51	2.57
1172	A	A	501.5	2.16
1173	A	A	442.29	2.94	1H NMR (300 MHz, DMSO) d 12.33 (d, J = 2.4 Hz, 1H), 8.78 (dd, J = 19.9, 2.5 Hz, 1H), 8.29 (d, J = 2.4 Hz, 1H), 8.20 (d, J = 2.8 Hz, 1H), 8.13 (d, J = 4.1 Hz, 1H), 7.26 (d, J = 8.8 Hz, 1H), 4.47-4.21 (m, 2H), 2.12 (s, 2H), 1.761.33 (in, J = 25.6, 14.7 Hz, 11H), 1.19 (d, J = 9.9 Hz, 3H), 1.08 (d, J = 7.0 Hz, 1H).
1174	C	C	583.52	1.77	1H NMR (300 MHz, MeOD) d 8.49 (d, J = 6.1 Hz, 1H), 8.42 (d, J = 2.6 Hz, OH), 8.39 (s, 1H), 8.35 (s, 1H), 8.29 (d, J = 5.6 Hz, 1H), 8.19 (d, J = 4.1 Hz, OH), 4.74 - 4.58 (m, 1H), 4.38 (dt, J = 42.8, 21.3 Hz, 2H), 3.84 (dd, J = 16.3, 6.7 Hz, 1H), 3.70 - 3.58 (m, 1H), 3.48 (s, 1H), 3.31 (dt, J = 3.2, 1.6 Hz, 6H), 3.02 (s, 1H), 2.61 (t, J = 11.7 Hz, 1H), 2.21 (d, J = 6.0 Hz, 3H), 2.111.86 (m, 5H), 1.86 -1.27 (m, 7H), 0.92 (d, J = 6.1 Hz, 6H).

-421WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1175	A	A	456.35	2.98	1H NMR (300 MHz, DMSO) d 12.33 (s, 1H), 8.83 (d, J = 2.4 Hz, 1H), 8.29 (d, J = 2.4 Hz, 1H), 8.19 (d, J = 2.8 Hz, 1H), 8.13 (d, J =4.1 Hz, 1H), 7.18 (d, J = 9.2 Hz, 1H), 4.33 (s, 1H), 4.23 - 3.97 (m, J = 25.1, 15,2 Hz, 1H), 2.05 (bd s, J = 34.2 Hz, 2H), 1.91 -1.31 (m, 14H), 0.83 (t, J = 7.0 Hz, 3H).
1176	A	A	401.17	1.72
1177	A	A	417.16	1.95	1H NMR (300 MHz, d6-DMS0) 5 12.39 ¢3, 1H), 8.74 (d, /=2.4 Hz, 1H), 8.55 (s, 1H), 8.31 (d, J = 2.6 Hz, 1H), 8.27 (d, J = 2.4 Hz, 1H), 8.18 (d, J = 4.0 Hz, 1H), 7.44 (d, J = 7.2 Hz, 1H), 4.51 -4.31 (m, 1H), 4.13-3.93 (m, 3H), 3.17 (d, J = 5.3 Hz, 1H), 2.11 -1.89 (m, 1H), 1.88 - 1.49 (m, 2H), 1.48 -1.13 (m, 2H)
1178	A	A	430.22	2.5	1H NMR (300 MHz, DMSO) d 12.32 (s, 1H), 8.78 (d, J = 2.4 Hz, 1H), 8.29 (d, J = 2.4 Hz, 1H), 8.17 (dd, J = 4.9, 3.2 Hz, 2H), 7.60 (d, J = 6.9 Hz, 1H), 4.73 (t, J = 6.3 Hz, 1H), 4.07 (q, J = 5.3 Hz, 2H), 3.61 (s, 3H), 3.17 (d, J = 5.3 Hz, 4H), 2.95 (d, J = 6.7 Hz, 1H), 2.02 -1.35 (m, 10H).
1179	A	A			1H NMR (300 MHz, DMSO) d 12.32 (s, 1H), 8.78 (d, J = 2.4 Hz, 1H), 8.29 (d, J = 2.4 Hz, 1H), 8.24 - 8.11 (m, 2H), 7.60 (d, J = 6.9 Hz, 1H), 4.74 (t, J = 6.8 Hz, 1H), 4.07 (q, J = 5.3 Hz, 2H), 3.63 (s, 3H). 2.95 (d, J = 6.6 Hz, 1H), 2.06- 1.33 (m, 10H).
1180	A	A	467.46	1.8
1181	A	A	459.09	2.26	1H NMR (300 MHz, CDCI3) d 8.24 (s, 1H), 8.02 (d, J = 3.6 Hz, 1H), 4.36 (d, J = 6.8 Hz, 1H), 3.91 (s, 2H), 3.74 - 3.64 (m, 3H), 3.49 3.30 (m, 3H), 2.68 (s, 1H), 2.23 (s, 1H), 2.09 (s, 1H), 1.91 (S, 1H), 1.58 (d, J = 13.4 Hz, 2H). 1.22 (dd, J = 21.2, 9.9 Hz, 3H).
1182	A	A	486.65	2.05	1H NMR ¢300 MHz, DMSO) d 8.30 - 8.05 (m, 1H), 7.60 (dd, J = 7.3, 2.4 Hz, 1H), 7.31 (dd, J = 5.0, 2.1 Hz, 1H), 4.09 (m, 1H), 3.57 (m, 1H), 3.17 (m, 4H), 1.99 (m, 2H), 1.77 (m, Hz, 4H), 1.56-1.10 (m, 3H).
1183	A	A	416.31	3.04	1H NMR (300 MHz, MeOD) d 8.94 (d, J = 2.3 Hz, 1H), 8,21 (d, J = 2.2 Hz, 1H), 8.16 (s, 1H), 8.00 (d, J = 4.1 Hz, 1H), 4.92 (d, J = 6.8 Hz, 1H), 2.76 (d, J = 6.8 Hz, 1H), 2.07 (d, J = 23.8 Hz, 2H), 1,89-1.46 (m, 7H).
1184	A	A	416.13	2.26	1H NMR (300 MHz, MeOD) d 8.92 (d, 1H), 8.22 (d, J = 2.3 Hz, 1H), 8.19 (s, 1H), 8.02 (d, J = 4.2 Hz, 1H), 4.94 (d, J = 6.9 Hz, 1H), 2.78 (d, J = 6.7 Hz, 1H), 2.13-2.02 (m, 3H), 1.931.45 (m, 7H).

-422WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1185	A	A	360.15	1.71
1186	A	A	570.68	1.56
1187	A	A	444.01	2.61	1H NMR (300 MHz, DMSO) d 12.74 (s, 1H), 8.76 (d, J = 2.3 Hz, 1H), 8.58 (s, 1H), 8.43 8.34 (m, 2H), 4.94 - 4.84 (m, 1H), 4.08 (ddd, J = 7.1, 2.3 Hz, 2H), 3.01 (d, J = 6.8 Hz, 1H), 2.05-1.99 (m, 1H), 1.98 -1.84 (m, 2H), 1.65 (complex m, J = 79.2 Hz, 8H), 1.13 (t, J = 7.1 Hz, 3H).
1188	A	A	396.24	1.97	1H NMR (300 MHz, MeOD) d 8.49 (ddd, J = 27.3, 9.7, 2.9 Hz, 1H), 8.25 - 8.08 (m, 2H), 8.01 (dd, J = 9.2,4.1 Hz, 1H), 7.73 (dd, J = 23.6, 2.3 Hz, 1H), 7.56 - 7.43 (m, 1H), 6.28 (dt, J = 7.3, 2.4 Hz, 1H), 4.73-4.27 (m, 2H), 2.60 1.58 (m, 9H).
1189	C	A	461	4.64	(400 MHz, DMSO-d6): 12.01 (b s, exchanged with D2O; 1H), 8.73 (d, J=2 Hz; 1H), 8.23 (d, J=2Hz; 1H), 8.10 (dd, J=13.6,4.4Hz; 2H), 7,29 (bs, exchanged with D2O; 1H), 3.87-3.86 (m, 1H), 3.58-3.52 (m, 2H), 3.35-3.19 (m, 2H), 2.07-1.95 (m, 2H), 1.88-1.70
1190			474.2	2.03
1191			476.15	2.34
1192			432.11	2.27
1193	A	A	500.22	2.04	1H NMR (300 MHz, MeOD) d 8.45 (dd, J = 9.6, 2.7 Hz, 1H), 8.36-8.18 (m, 2H), 5.17 (t, J = 7.1 Hz, 1H), 4.42 (m, 1H),3.77(m, 1H), 3.29 (m,4H), 2.34 - 2.19 (m, 2H), 2.08 -1.84 (m, 4H), 1.74-1.28 (m, 4H), 0.98 (t, J = 7.4 Hz, 3H).
1194	B	A	500.28	2.23
1195			563.24	2.47	in DMSO-d6 and D20 exchange
1196	A	A	388.43	1.84
1197	A	A	415.18	1.96	1H NMR (300 MHz, MeOD) d 8.91 (d, J = 2.3 Hz, 1H), 8.44 (s, 1H), 8.38 (d, J = 2.3 Hz, 1H), 8,27 (d, J = 5.6 Hz, 1H), 5.30 (d, J = 6.9 Hz, 1H), 2.86 (d, J = 6.8 Hz, 1H), 2.12 - 2.03 (m, 2H), 1,98 -1.64 (m, 6H), 1.63-1.52 (m, 2H).
1198			486.27	1.99
1199			486.43	2.14
1200			485.1	2.34
1201			458.98	2.18

-423WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1202	406.43	1.79	1H NMR (300 MHz, DMSO) d 12.08 (s, 1H), 8.73 (ddd, J = 7.9, 4.4, 1.5 Hz, 1H), 8.41 - 7.98 (m, 3H), 7.47 (dd, J =41.7, 7.0 Hz, 1H), 7.19 (ddd, J = 14.2, 7.9, 4.7 Hz, 1H), 5.82 - 5.63 (m, 2H), 4.71 (d, J = 73.1 Hz, 1H), 4.31 (d, J = 11.2 Hz, 1H), 2.36-1.55 (m, 13H).
1203	490.23	1.99	1H NMR (300 MHz, CDCI3) d 11.09 (s, 1H), 8.11 (s, 1H), 8.05 (m, 1H), 7.86 (d, J = 3.5 Hz, 1H), 5.32 - 4.78 (m, 4H), 4.14 (d, J = 8.0 Hz, 1H), 3.84 (s, 1H), 3.74 - 3.18 (m, 6H), 2.67 (d, J = 11.7 Hz, 1H), 2.33 -1.75 (m, 7H), 1.48 - 1.27 (m, 2H), 1.26 - 0.95 (m, 4H).
1204	457.06	2.04
1205	417.16	1.77
1206	429.58	1.94
1207	431.5	1.94
1208	429.5	1.85
1209	456.42	1.88
1210	472.47	1.75
1211	486.42	1.88
1212	396.44	1.94	1H NMR (300 MHz, DMSO) d 12.28 (s, 1H), 8.59 - 8.07 (m, 4H), 7.90 - 7.36 (m, 3H), 6.25 (dt, J = 16.0, 2.0 Hz, 1H), 4.79 - 4.15 (m, 2H), 2.36 (d, J = 8.8 Hz, 1H), 2.19 -1.55 (m, 6H), 1.50-1.10 (m, 1H).
1213	480.65	2.16
1214	411.49	1.74
1215	460,23	1.91
1216	444.23	2.15
1217	430.39	2.26	1H NMR (300 MHz, DMSO) d 12.38 (s, 1H), 8.75 (d, J = 2.4 Hz, 1H), 8.55 (s, 1H), 8.29 (d, J = 2.4 Hz, 1H), 8.25 (d, J = 3.8 Hz, 1H), 8.22 8.16 (m, J = 4.8 Hz, 2H), 7.47 (d, J = 31.1 Hz, 2H), 5.23 (t, J = 8.1 Hz, 1H), 4.11 (q, J = 5.1 Hz, 1H), 3.17 (d, J = 5.2 Hz, 2H), 1.09 (d, J = 6.0 Hz, 3H), 0.94 (d, J = 6.7 Hz, 3H).
1218	406.18	1.8
1219	406.44	1.79	1H NMR (300 MHz, DMSO) d 12.08 (s, 1H), 8.86 - 8.63 (m, 1H), 8.39 - 7.90 (m, 3H), 7.53 (d, J = 7.5 Hz, 1H), 7.21 (dd, J = 7.9, 4.7 Hz, 1H), 5.74 (s, 1H), 4.27 (d, J = 10.5 Hz, 2H), 2.89 (s, 1H), 2.79-2.66 (m, 1H), 2.15 (d, J = 48.2 Hz, 6H), 1.93-1.17 (m, 4H)

-424WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1220			424.44	2.1	1H NMR (300 MHz, DMSO) d 12.27 (s, 1H), 8.45 (dd, J = 9.8, 2.8 Hz, 1H), 8.30 - 8.08 (m, 3H), 7.45 (d, J = 6.9 Hz, 1H), 4.86 (s, 1H), 4.59 (s, 1H), 2.35 -1.94 (m, 7H), 1.81 (d, J = 5.5 Hz, 5H).
1221			424.45	2.02
1222			440.46	2.22
1223			440.5	2.34	1H NMR (300 MHz, DMSO) d 12.35 (s, 1H), 8.74 (d, J = 2.4 Hz, 1H), 8.40 - 8.01 (m, 3H), 7.48 (d, J = 6.7 Hz, 1H), 4.84 (s, 1H), 4.59 (s, 1H), 2.35-1.56 (m, 13H).
1224			461.19	2.46	1H NMR (300 MHz, DMSO) d 12.56 (s, 1H), 8.72 (t, J = 8.2 Hz, 1H), 8.54 (t, J = 5.7 Hz, 1H), 8.40 (t, J = 7.9 Hz, 1H), 8.33 (t, J = 3.4 Hz, 2H), 7.79 (d, J = 7.3 Hz, 1H), 4.66 (t, J = 8.0 Hz, 1H), 3.81 (qd, J = 17.5, 5.8 Hz, 2H), 1.78 (td, J = 28.9, 16.0 Hz, 6H), 1.18 (s, 5H).
1225			517.24	2.99	1H NMR (300 MHz, DMSO) d 12.44 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.58 (d, J = 2.8 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.23 (d, J = 4.0 Hz, 1H), 8.20 (s, 1H), 7.55 (s, 1H), 4.72 (t, J = 8.4 Hz, 1H), 4.17 (d, J = 9.2 Hz, 1H), 1.90 (s, 2H), 1.68 (d, J = 21.4 Hz, 4H), 1.32 - 0.95 (m, 5H), 0.84 (s, 9H).
1226			388.5	1.8
1227			510.23	2.12
1228			411.67	1.79	MeOD4; 8.5 (dd, 1H); 8.26 (s, 1H); 8.25 (dd, 1H); 7.95 (d, 1H); 4.6 (app d, 1H), 4.25 (m, 1H); 4.25 (m, 1H); 3.3 (m, 4H); 2.75 (m, 2H); 2.5 (app d, 1H); 2.2 (m, 4H); 1.7 (m, 2H).
1229			416.42	2.29	H NMR (300.0 MHz, MeOD) d 8.72 - 8.64 (m, 1H), 8.39 (s, 1H), 8.32 (d, J = 2.3 Hz, 1H), 8.21 (d, J = 5.2 Hz, 1H), 4.71 (d, J = 6.3 Hz, 1H), 3.67 - 3.57 (m, 2H), 2.33 - 2.26 (m, 1H), 2.10 (m, 1H), 1.78-1.70 (m, 1H), 1.28-1,25 (m, 7H)and 1.19 (s, 3H)ppm
1230	A	A	443.04	2.48	1H NMR (300 MHz, CDCI3) d 8.15 (d, J = 1.2 Hz, 1H), 8.08 (d, J = 6.3 Hz, 1H), 7.88 (d, J = 3.3 Hz, 1H), 3.80 (d, J = 11.2 Hz, 1H), 3.68 (s, 1H), 3.26 (d, J = 6.4 Hz, 4H), 2.56 (d, J = 11.8 Hz, 1H), 2.14 (d, J = 12.8 Hz, 1H), 1.99 (d, J = 10.3 Hz, 1H), 1.9
1231	A	A	422.5	1.68	NMR 1H (MeOH-d4):8.5 (dd, 1H), 8.15 (m, 2H), 8.0 (d, 1H), 4.2 (m, 1H), 3.75 (m, 1H), 2.3 (d, 1H), 2.2 (d, 1H), 1.9 (m, 2H), 1.2-1.6 (m, 4H).

-425WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1232

A

450.5

1.8

NMR 1H (MeOH-d4): 8.2 (m, 4H), 4.5 (m, 1H), 3.9 (m, 1H), 2.2 (m, 4H), 1.3-1.6 (m, 4H).

Table 4: IC50, EC50, NMR and LCMS Data of Compounds of FIG. 7

Comp. Nos	Cell Flu, MDCK protection, ATP (All: IC50: uM)(Mean (AH))	Cell Influenza HA(-) 30 hr A/PR/8 bDNA (All: EC50: uM)(Mean (AH))	LCMS Plus	LCMS RT	NMR
1300	D		334	1.8
1301					(400 MHz, CDCI3): 9.97 (br. s, exchanged with D2O, 1H), 8.95 (d, 3=2.0 Hz, 1H), 8.28 (S, 1H), 8.18 (s, 1H), 8.15 (d, 3=6.0 Hz, 1H), 6.21 (d, 3=4.8 Hz, 1H), 6.16 (br. s, exchanged with D2O, 1H), 3.45-3.35 (br. hump, 1H), 2.95-2.85 (br. hump, 1H), 2.6-2.4 (br. hump, 3H), 1.981.7 (m, 4H), 1.59 (s, 3H), 1.57 (s, 3H), 1.16 (d, 3=5.6 Hz, 3H)
1302	B				(400 MHz, CDCI3): 9.95 (br. hump, exchanged with D2O, 1H), 8.95 (s, 1H), 8.28 (d, 3=1.6 Hz, 1H), 8.18 (s, 1H), 8.14 (d, 3=6.0 Hz, 1H), 6.19 (d, 3=6.0 Hz, 1H), 5.72 (s, exchanged with D2O, 1H), 3.6- 3.4 (m, 4H), 2.90-2.80 (m, 2H), 2.1-2.05 (m, 2H), 1.52 (s, 6H)
1303	D		360	2.6	500MHz, CDCI3: 10.8(br ex,1 H), 9.12(d,1H), 8.75(s,1H), 8.45(d,1H), 8.35(d,1H), 7.5(dd,1H), 7.31(d,1 H), 7.29(d,1H), 7.24(m,2H), 6.3(d,1H) 5.62(dt,1H), 2.9(m,2H), 2.23(dm,2H), 2.0(m,2H)
1304			360	2.6	500MHz, CDCI3: 10.8(br ex,1H), 9.12(d,1 H), 8.75(3,1 H), 8.45(d,1H), 8.35(d,1H), 7.5(dd,1H), 7.31(d,1 H), 7.29(d,1H), 7.24(m,2H), 6.3(d,1H) 5.62(dt,1H), 2.9(m,2H), 2.23(dm,2H), 2.0(m,2H)
1305			342	2.3
1306			342	2.3	500MHz MeOD-d4: 8.65(d,1H), 8.42(3.1H), 7.9(d,1H), 7.24(dd,2H), 7.13(m,4H), 6.5(d,1H), 5.65(m,1H), 2.8(m,3H), 2.2(m,1H), 2,08(m,1H)1,9(m,3H)
1307	A	A	380.2	3.52	DMSO d6 12.2 (s, 1H); 8.7 (s, 1H); 8.3 (s, 1H); 8.15 (m, 2H); 7,0 (d, 1H); 5.4 (d, 1H); 4.8 (d, 1H); 4.4 (bs, 1H); 4.1 (bs, 1H); 1.9-1.6 (m, 6H)
1308			370	2.1	500MHz : MeOD-d4: 8.9(d,1H), 8.4(s,2H), 8.3(d,1H), 7.4(m,1H), 2.1 (m,1H), 1.9(m,2H), 1.8(m,2H), 1.75(m,2H), 1.3(m,6H)
1309			326	2.1

-426WO 2010/148197

PCT7US2010/038988

2018200219 11 Jan 2018

1310			327	0.4	500MHz, MeOD-d4: 8.75(dd,1H), 8.42(s,1H), 8.39(dd,1H), 8.25(d,1H),7.69(d,2H), 7.35(dd,1H), 7.2(d,2H), 4.36(111,1 H), 3.40(6,1 H), 3.2(m,1 H),2.3(m,5H), 2.00(qin,1 H), 1.7(m,4H)
1311			328.3	2
1312	A	A	328.3	2
1313	D		330,1	2.25	(300 MHz, CDCI3) 10.68 (brs, 1H), 8.56 (dd, 1H), 8.25 (d, 1H), 8.04 (d, 1H), 4.95 (d, 1H), 4.14 (m, 1 H), 2.20 (m, 2 H), 1.89-1.31 (m,7H)
1314	D		362	2.3
1315	B		360.2	3.05	(CDCI3, 300 MHz) 8.76 (d, 1H), 8.28 (d, 1H), 7.99 (d, 1H), 7.98 (s, 1H), 4,92 (d, 1H), 4.11 (m, 1H), 3.89 (s, 3H), 2.21 (m, 2H), 1.89-1.23 (m, 8H)
1316	D				¢400 M Hz, CDC!3): 9.16 (s, exchanged with D2O, 1H), 9.07 (d, J = 2.0Hz, 1H), 8.30 (d, J=2.4 Hz, 1H), 8.17 (d, J=2.4 Hz, addition of D2O changhed to s, 1H), 8.07 (d, J=3.6 Hz, 1H), 5.28 (s, excha nged with D20,1H), 2.98-2.95 (m, 1H), 1.051.00 (q, 2H), 0.75-0.71 (m, 2H).
1317	B				(400 MHz, CDCI3): 8.98 (s, exchanged with D20,1H), 8.92 (s, 1H), 8.28 (br. s, 1H), 8.17 ( br. s, 1H), 7.98 (s, 1H), 4.42 (d, J= 6.4 Hz, addition of D2O changed to s, 1H), 4.20 -4.15 (m, 1H), 2.25 (b r. d, J=11.2 Hz, 2H), 2.03 (s, 3H), 1.88 (br. d, J=12.4 Hz, 2H), 1.78-1.75 (m, J=13.2 Hz, 1H), 1.61-1.50 (m, 2H), 1.33-1.27 (m, 3H).
1318	A	A	312.1	1.96	H NMR (300 MHz, CDCI3) 10.72 (s, 1 H), 8.85 (dd, J = 1.3, 7.9 Hz, 1 H), 8.38 (d, J = 3.9 Hz, 1 H), 8.25 (s, 1 H), 8.05 (d, J = 3.5 Hz, 1 H), 7.23 (dd, J = 4.8, 8.0 Hz, 1 H), 4.97 (d, J = 6.5 Hz, 1 H), 4.23-4.13 (m, 1 H),, 2.22 - 2.18 (m, 2 H), 1.91-1.26 (m, 8 H)
1319	B		327.1	1.5	H NMR (300 MHz, d4 methanol) 8,24 (d, 1H), 7.99 (s, 1 H),l 7.92 (d, 1H), 7.88 (d, 1H), 4.15 (m, 1H), 2.15 (m, 2 H), 1.91- 1.26 (m, 8 H)
1320	D		360.2	2.3
1321	D		360.2	2.3
1322	D		374.2	2.4
1323	D		362.2	1.5
1324	D		328.2	2.07	H NMR (300 MHz, CDCI3) 10.84 (s, 1 H), 8.91 (d, J = 2.2 Hz, 1 H ), 8.29 - 8.14 (m, 3H), 6.13 (d, J = 5.9 Hz, 1 H), 4.96 (s, 1 H), 3.86 (s, 1 H), 2.15-1.48 (m, 10 H)

-427WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1325	D				(400 MHz, DMS0-d6): 12.35 (br. s, exchanged with D20, 1H), 8.76 (d, J=2.4 Hz, 1H), 8.28 (d, J=2.4 Hz, additon of D2O changed to s, 1H), 8.20 (d, J=2.4 Hz, 1H), 8.16 (d, J=3.6 Hz, 1H), 7.84 (br. d, j=6.4 Hz, exchanged with D2O, 1H), 4.64 (sextet, J=8.0 Hz, addition of D2O changed to quintet, J=8.0 Hz, 1H), 2.492.19 (m, 2H), 2.17-2.10 (m, 2H), 1.801.72 (m, 2H).
1326	B				(400 MHz, DMSO - d6): 12.31 (br. s, exchanged with D20,1H), 8.75 (br. d, J=2.4 Hz, 1H), 8.27 (d, J=2.4 Hz, 1H). 8.19 (d, J=2.4 Hz, 1H), 8.13 (d, J=3.6 Hz, 1H), 7.55-7.50 (m, exchanged with D2O, 1H),4.47-4.40 (m, 1H), 2.06-2.0 (m, 2H), 1.80-1.50 (m, 6H).
1327	D				(400 MHz, DMSO-d6): 12.87 (d, J=2.4 Hz, exchanged with D2O, 1H), 8.73 (d, J=2.4 Hz, 1H), 8.28 (d, J=2.4 Hz, 1H), 8.16 (d, J=4.0 Hz, 1H), 8.11 (d, J=2.4 Hz, addition of D2O changed to s, 1H), 6.70 (s, 1H), 4.90 ( br. s, exchanged with d2O, 1H), 3.79 (s, 2H), 2.25-2.20 (m, 2H), 1.95-1.85 (m, 2H), 1.80-1.62 (m, 4H).
1328	A	A			(400 MHz, DMSO-d6): 12.49 (s, exchanged with D2O, 1H), 10.1 (s, exchanged with D2O, 1H), 8.72 (br. s, 1H), 8.29 (br. s, 1H), 8.23-8.20 (m, 2H), 4.70-4.50 ( m, 1H), 3.94 (br. s, 2H), 2.69 (s, 3H), 2.32 (s, 2H>, 2.19-2.00 (m, 6H).
1329	D		361.2	1.4
1330	D		361.2	1.4
1331	D				(400 MHz, DMSO-d6): 12.30 (s, exchanged with D2O, 1H), 8.66 (d, J=2.4 Hz, 1H), 8.40 (s, exchanged with D2O, 1H), 8.27 (d, J=2.4 Hz, 1H), 8.24 (d, J=3.6 Hz, 1H), 8.03 (d, J=2.8 Hz, 1H), 3.57 (s, 3H),2.79-2.73 (m, 2H), 2.45-2.38 (m, 2H), 2.05-1.96 (m, 2H).
1332	D				(400 MHz, DMSO-d6): 13.11 (s, exchanged with D2O, 1H), 9.22 (s, exchanged with D2O, 1H), 8.62 (d, J=2.4 Hz, 1H), 8.43 (d, J=2.0 Hz, 1H), 8.32 (s, exchanged with D2O, 2H), 8.07 (s, 1H), 4.20-4.17 (m,1H), 3.15-3.10 (m, 1H), 2.16-2.10 (m, 7H), 1.70-1.59 (m, 4H).
1333	D		342	0.25	(d4-methanol, 300 MHz) 8.88 (d, 1H), 8.63 (s, 1H), 8.48 (d, 1H), 8.36 (d, 1H), 3.89 (dd, 2H), 3.73-3.59 ( m, 2H), 3.02 (dd, 2H), 2.44 (m, 1H), 2.02 ( br dd, 2H), 1.80 (m, 1H), 1.59 (m, 1H)
1334	D		377.1	3.863	(400 MHz, DMSO-d6 + D2O): 8.64 (d, J = 2.4Hz, 1H), 8.51 (s, 1H), 8.39 (d, J=2.4 Hz, 1H), 8.36 (s, 1H), 4.13-4.10 (m, 1H), 3.10-3.0 (m. 1H), 2.10 (br. d, J=10 Hz, 4H), 1.66-1.42 (m, 4H).

-428WO 2010/148197

PCT/US2010/038988

1335	D		406.1	3.217	(400 MHz, DMS0-d6): 12.39 (s, exchanged with D20, 1H), 8.74 (d, J=2.0 Hz, 1H), 8.34 (s, 1H), 8.27 (d, J=2.4 Hz, 1H), 8.15 (d, J=2.8 Hz, 1H), 6.60 (s, exchanged with D20, 1H), 2.25 (d, J=13.2 Hz, 2H),1.95 (br. t, J=11.6 Hz, 2H), 1.59-1.40 (m,6H).
1336	D		396.1	5.16	(400 MHz, DMS0-d6): 8.66 (d, J=1.6 Hz, 1H), 8.40 (s, 1H), 8,38 (s, 1H), 8.26 (d, J=2.0 Hz, 1H), 6.59 (d, J=6.8 Hz, exchanged with D20.1H), 4.27-4.20 (m, 1H), 1.95 (br. s, 2H), 1.81 (br. s, 2H), 1.68(br. d, J=11.2 Hz, 2H), 1.54-1.42 (m. 4H).
1337	A	A	411.2	1.166	¢400 MHz, DMS0-d6 + D20): 8.67 (d, J=2.4 Hz, 1H), 8.50 (s, 1H), 8.36 (d, J = 2.4Hz, 1H), 8.06 (s, 1H), 4.27-4.20 (br.s, 1H), 3.50-3.40 (m, 1H), 2.10-1.50 (m, 8H).
1338	D		376.2	2.13	NMR 1H DMS0-d6:12.6 (s, 1H), 8.9 (s, 1H), 8.4 (m, 3H), 8.0 (m, 1H), 4.8 (bs, 1H), 3.7 (s, 2H), 1.1-1.6 (m, 10H).
1339	D		386.25	2.85	NMR 1H DMSO-d6: 12.7 (s,1H), 8.7 (m, 1H), 8.4 (οι, 4H), 7.6 (m, 2H), 5.5 (bs, 1H), 4.1 (m, 1H), 1.0-2.3 (m, 14H).
1340	A	A	400.3	3.22
1341	B		355.4	3.1
1342	A	A	428.2	2.84
1343	D		375.3	1.39	(d4-methanol, 300 MHz) 8.83 (d, 1H), 8.44 and 8.29 (2s, 1H), 8.24 (d, 1H), 8.18 (s, 1H), 8.05 (d, 1H), 3.72 (dd, 1H), 3.51 (m, 2 H), 2.84-2.64 (m, 3 H), 2.77 (s, 3 H), 2.44 (m, 1 H), 2.15-1.99 (m, 2 H), 1.79 (m, 1 H), 1.36 (m, 1 H)
1344	A	A	413.3	2.9
1345	A	A	361.2	1.5
1346	D		361.2	0.7
1347	B		358.1	2.1
1348	D		313.2	2.15
1349	D		313.2	2
1350	D		313.2	2.08
1351	B		327.2	2.15
1352	D		327.2	2.15
1353	A	A	327.2	2.19
1354	B	B	342.2	1.6
1355	D		313.6	1.04
1356	B		375.15	1.61
1357	A		347	1.3
1358	A	A	363.3	1.3
1359	B		347.3	1.3
1360	D		367.3	1.4
1361	A		369.5	1.53
1362	C	C	361.3	2.1

-429WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1363	A	A	481.37	3.56	H NMR (300.0 MHz, MeOD) d 8.77 (d, J = 2.3 Hz, 1H), 8.30 (s, 1H), 8.27 (d, J = 2.2 Hz, 1H), 8.22 (d, J = 4.4 Hz, 1H), 7.58 - 7.54 (m, 5H), 4.94 - 4.87 (m, 1H), 4.45 (dd, J = 13.1,30.3 Hz, 2H), 3.78 3.54 (m, 2H), 3.47 - 3.37 (m, 1H), 2.46 2.40 (m, 1H) and 2.09 (m, 1H) ppm
1364	A	C	348.11	3.46
1365	A	A	362.33	3.29	H NMR (300.0 MHz, MeOD) d 8.71 (d, J = 2.1 Hz, 1H), 8.45 (s, 1H), 8.35 (d, J = 2.2 Hz, 1H), 8.29 (d, J = 5.5 Hz, 1H), 4.07 (s, 2H), 2.13 (qn, J = 1.5 Hz. H), 1.37-1.33 (m, 2H)and 1.17-1.11 (m, 2H)ppm
1366	A	A	362.15	3.6	Methanol d4 8.7 (d, 1H); 8.2 (d, 1H); 8.1 (s, 1H); 8.0 (d, 1H); 7.65 (m, 1 H);4.2 (m, 2H); 2.0-1.6 (m, 6H)
1367	A	A			1HNMR (400MHz, DMSO-d6): 12.30 (s, exchanged with D2O, 1H), 9.17 (d, J=2.4Hz, 1H), 8.26(d, J=2.4Hz, 1H), 8.22(d, J=4Hz, 1H), 8.17(3,1 H), 7.32(s. exchanged with D2O, 1H), 3.32 (s,1H), 1 .77-1.61(m,8H), 1.30-1.28 (m,2H)
1368	A	A			1HNMR (400MHz, DMSO-d6): 12.33(s, exchanged withD2O, 1H), 8.74 (d, J-2.4HZ, 1H), 8.29(d, J=2.4Hz, 1H), 8 .17(d, J=4Hz, 1H), 8.10(d, J=2Hz, 1H), 6.74(3,1 H, partially exchanged with D2O), 4.60 (s, exchanged with D2O, 1H), 2.25(br s,2H), 2.12(br s, 5H), 1.
1369	A	A			1HNMR (400MHz, DMSO-d6): 12.33(s, exchanged with D2O, 1H), 8.70 (s, 1H), 8.28 (s, 1H), 8.17(d, J=4.4Hz, 1 H), 6.99(s,1H), 4.3(s,1H), 2.20-1,75(m,13H), 1.55(d, J=12.8Hz, 2H)
1370	A	A	360.42	3.78	H NMR (300.0 MHz, DMSO) d 12.35 (s, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.23 - 8.20 (m, 2H), 7.75 (d, J = 7.5 Hz, 1H), 4.45 (d, J = 9.4 Hz, 1H), 2.65 - 2.62 (m, 2H), 2.50 (t, J = 1.8 Hz, H), 2.36 (dd, J = 12.2, 17.4 Hz, 1H), 2.26 - 2.20 (m, 3H), 2.07 - 2.04 (m, 1H), 1.84 1.74 (m, 2H) and -0.00 (s, H) ppm
1371	A	A			(400MHz, DMSO-d6): 12.32(s, 1H), 8.78(brs, 1H), 8.28(brs,1H), 8.17(brs ,1H), 8.13(d, J=3.6Hz,1H), 7.40(d, J=8Hz, exchanged with D2O.1H), 4.85(br s, 1H),2.31-2.25(m,1H), 1.87- 1,82(m,1 H), 1.68 (br S,2H),1.47(br s,1 H), 1.29-1,16(m,5H), 0.89-0.81 (m,1H).
1372	A	A			(400MHz, DMSO-d6): 12.33(s, 1H), 8.77(d, J=2Hz,1H), 8.27(d,J=2.4Hz,1H),8.18(d, J=2Hz,1H), 8.13(d, J=4Hz,1H),7.65(d, J=8,4Hz, 1H),4.85-4.77(m,1H), 2.64-2. 60(m,1H),2.36-2.34(m,1H), 2.22- 2.19(m,1H),1.97(brs, 1H),1.85- 1.84(m,1H),1.72-0. 83 (m, 13H)

-430WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018


1373	A	A			(400MHz, DMS0-d6): 12.51 (s, exchanged with D20,1H), 8.69 (s,1 H), 8.32(d , J=2Hz,1H), 8.29(d, J=3.6Hz,1H), 8.23(s, 1H), 6.96(s, exchanged with D20, 1H), 3.03 (s, 2H), 2.47 (d, J=12.8Hz,2H), 1.75-1.74(m,2H), 1.51(br s,5H). 1.351.33(m ,1H).
1374	A	A			(400MHz, DMS0-d6): 12.33(s, 1H), 8.77(d, J=2Hz, 1H), 8.27(d, J=2.4Hz, 1H) , 8.18(d, J=3.2Hz,1H),8.13(d, J=4Hz,1H), 7.65(d, J=8.4Hz, 1H), 4.834.79(m,1H), 2.64-2.19(m,3H), 1.97(br S,1H), 1.85-1.83(m,1H), 1 _72(dd, J1=11,6,6.4Hz,1 H),1.28 (s,9H),1.1(d, J=7,3H)
1375	B	C	360.4	3.82	H NMR (300.0 MHz, DMSO) d 12.53 (s, 1H), 8.63 (d, J = 2.4 Hz, 1H), 8.33 (dd, J = 2.7, 9.8 Hz, 1H), 8.32 (s, 1H), 8.21 (d, J = 3.2 Hz, 1H), 2.65 (d, J = 10,3 Hz, 1H), 2.43 - 2.37 (m, 4H), 2.24 (t, J = 9.1 Hz, 1H), 1.82 (t, J = 11.6 Hz, 2H) and -0.00 (s, H) ppm
1376	C	c			(400MHz, DMSO-d6): 12.32 (s, exchanged with D2O, 1H), 8.76 (s, 1H), 8.29- 8.11 (m, 3H), 6.64 (s, exchanged with D2O, 1H), 2.25-2.14 (m, 9H), 1.801.70 (m,6H).
1377	C	c			(400MHz, DMSO-d6):12.35(brs, 1H), 8.71 (d,J=2.4Hz,1 H).8.29(d,J=2.4Hz.1 H), 8.19-8.17(m,2H), 6.79(d,J=9.6Hz, partially exchanged with D2O.1 H),5.014.99(m, 1H), 1.82-1.79(m,3H), 1.661.27(m,6H), 0.88(s,9H).
1378	A	A			400MHz, DMSO-d6): 12.32(s, 1 H),,8.74(d, J=2Hz,1 H),8.28(d,J=2Hz,1 H), 8.18(d ,J=2.8Hz, 1H), 8.11 (d, J=3.6Hz, 1 H),7.46(d,J=8.8Hz, 1H),4.19-4.16(m,1H), 1.99-1.91 (m,2H), 1.78-1,48(m,5H), 1.15-1.07(m,2H), 0.91 (d,J=6.8Hz,3H), 0.88(d,J=7.2Hz,3H) , 0.71(d,J=6.8Hz,3H).
1379	A	A	358.3	2.91	(400MHz, DMSO-d6): 12.33 (br s,1H), 8.76 (d, J=2Hz,1H), 8.28 (d,J=2Hz,1H), 8.18 (d, J=2Hz,1H), 8.14 (d, J=3.6Hz,1H), 7.6 (d, J=5.6Hz,1H) 4.37- 4.36 (br m, 1H), 3.16 (d, J=5.6Hz,1 H), 2.69 (br s, 1H), 2.24 (br s, 1H), 1.99 (t, J=12,1 H),1 .6-1,2(m, 8H)

-43 1WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1380	A	C	403.34	3.1
1381	A	c	388.37	4.04
1382	A	A	388.37	4.02
1383		A	371.34	3.99
1384		C	388.37	4.26
1385	A	A	388.37	4.26
1386	C	C	401.23	3.89
1387			424.54	3.53	1H NMR ¢300 MHz, DMSO) d 12.30 (s, 1H), 8.68 (d, J = 2.4 Hz, 1H), 8.25 (d, J = 2.4 Hz, 1H), 8.32 - 8.09 (m, J = 19.6, 9.0 Hz, 2H), 7.62 (d, J = 7.1 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.77 - 6.59 (m, 2H), 4.57 - 4.33 (m, 1H), 3.71 (s, 3H), 3.21 - 2.77 (m, 4H), 2.29 - 2.11 (m, J = 14.7 Hz, 1H), 1.87 -1.66 (m, J = 23.9,12.0, 5.7 Hz, 1H).

Table 5: IC50, EC50, NMR and LCMS Data of Compounds of FIG. 8

Nos	Cel! Flu, MDCK protection, ATP (IC50: IC50: uM)(Mean (All))	Cell Influenza HA(-) 30 hr A/PR/8 bDNA:bDNA EC50 uM(Mean (AH))	LCMS Plus	LCMS„RT	NMR
1400	B		361.44	3.7	1H NMR (DMSO-d6): 1.53 (3H, m), 1.81 (2H, m), 1.98 (1H, m), 2.90 (1H, m), 3.31 (1H, m), 3.43 (1H, m), 3.58 (2H, m), 7.85 (1H, s), 8.30 (2H, d), 8.36 (1H, s), 8.68 (1H, d), 8.84 (1H, s), 12.52 (1H,s)
1401	B		361.44	3.59	1H NMR (DMSO-d6): 1.34 (1H, m), 1.60 (1H, m), 1.92 (2H, m), 2.20 (1H, m), 2.78 (2H, m), 3.24 (3H, m), 3.54 (1H, m), 7.99 (1H, s), 8.23 (1H, m), 8.30 (2H, d), 8.60 (1H, d), 8.70 (1H, s), 12.45 (1H,s)
1402	D		361.44	3.57	1H NMR (DMSO-d6): 1.41 (2H, m), 1.92 (2H, m), 2.08 (1H, m), 2.83 (2H, m), 3.29 (2H, m), 3.44 (2H, m), 7.97 (1H, s), 8.20 (1H, s), 8.25 (1H, s), 8.30 (1H,s), 8.48 (1H, d), 8.71 (1H, s), 12.43 (1H,s)
1403	B		347.4	3.67	1H NMR (DMSO-d6): 1.94(1H, m), 1.96 (2H, m), 2.14 (1H, m), 3.20 (2H, m), 3.71 (2H, m), 3.83 (1H, m), 7.89 (1H, s), 8.30 (4H, m), 8.69 (1H, s), 8.91 (1H, s), 12.58 (1H, s)
1404			347.4	3.54	1H NMR (DMSO-d6): 1.77 (1H,m), 2.12 (1H, m), 2.77 (1H, m), 3.00 (1H, m), 3.17 (1H, m), 3.34 (2H, m), 3.60 (2H, m), 7.98 (1H, s), 8.23 (1H, d), 8.31 (2H, m), 8.71 (3H, m), 12.53 (1H, s)

-432WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1405	D	394,45	5.28	1H NMR (DMS0-d6): 2.04 (4H, m), 2.84 (2H, m), 3.33 (1H, s), 5.61 (1H, m), 7.18 (3H, m), 7.27 (1H, d), 8.00 (1H, d), 8.21 (1H, t), 8.23 (1H, s), 8.26 (1H, s), 8.68 (1H, s), 12.34 (1H, s)
1406		333	3.54	1H NMR (CD30D): 2.40-2.50 (2H, m), 2.6-2.7 (2H, m), 3.50-3.60 (3H, m), 3.73.8 (1H, m), 5.2-5.3 (1H, m), 8.40 (1H, s), 8.50 (1H, m), 8.55 (1H, s), 8.75 (1H, s)
1407		347	3.5	1H NMR (DMS0-d6): 1.80-1.90 (2H, m), 2.1-2.2 (2H, m), 3.05-3.15 (2H, m), 3.4-3.5 (2H, m), 4.30-4.40 (1H, m), 7.657.70 (1H, m), 8.30-8.35 (2H, m), 8.408.50 (1H, s), 8.60-8.70 (1H, s), 8.758.80 (1H, m), 12.0 (1H, s)
1408	A	347.47	3.68	1H NMR (DMS0-d6): 1.66 (1H, m), 1.85 (1H, m), 1.98 (1H, m), 2.11 (1H, m), 2.90 (2H, m), 3.32 ¢1H, m), 3.47 (1H, m), 4.46 (1H, m), 7.57 (1H, d), 8.31 (3H, m), 8.66 (3H, m), 12.47 (1H, s)
1409	D	348.44	4.42	1H NMR (DMS0-d6): 1.67 (2H, m), 1.96 (2H, d), 3.49 (2H, t), 3.96 (2H, d), 4.30 (1H, m), 7.62 (1H, d), 8.18 (1H, s), 8.22 (1H, s), 8.29 (1H, s), 8.72 (1H, s),12.36 (1H, s)
1410	A	360.46	5.39	1H NMR (DMS0-d6): 1.17 (5H, m), 1.70 (6H, m), 2.67 (2H, d), 8.27 (1H, s), 8.42 (2H, s), 8.72 (1H, s), 12.57 (1H, s)
1411		374.5	5.47	1H NMR (DMS0-d6): 1.15 (8H, m), 1.28 (2H, m), 1.72 (2H, m), 1.84 (2H, m), 4.23 (1H, m), 7.43 (1H, d), 8.12 (1H, s), 8.18 (1H, s), 8.27 (1H, s), 8.73 (1H, s),12.32 (1H, s)
1412	A	346.43	5.25	1H NMR (DMS0-d6): 0.85 (1H, m), 1.48 (4H, m), 1.68 (1H, d), 1.81 (2H, m), 2.04 (2H, m), 4.03 (1H, m), 7.49 (1H, d), 8.13 (1H, s), 8.19 (1H, s), 8.29 (1H, s), 8.73 (1H, s), 12.21 (1H,s)
1413		362	4.5	(d6-DMS0,400MHz) 1.23 - 1.33 (2H, m), 1.72 (2H, d), 1.99 - 2.04 (1H, m), 3.27 (2H, t), 3.41 (2H, t), 3.85-3.89 (2H, m), 7.80 (1H, t), 8.14 (1H, d), 8.21 (1H, s), 8.28 (1H, d), 8.74 (1H, d), 12.35 (1H, brs)
1414		375	3.95	(d6-DMS0, 400MHz) 1.14 - 1.24 (2H, m), 1.75 - 1.80 (5H, m), 2.11 (3H, s), 2.75 (2H, d), 3.40 (2H, t), 7.80 (1H, t), 8.13 (1H, d), 8.20 (1H, s), 8.28 (1H, d), 8.73 (1H, d), 12.35 (1H, s)

-433WO 2010/148197

PCT/US2010/038988

2018200219 11 Jan 2018

1415	D	348	3.27	(d6-DMSO, 400MHz) 1.66 -1.74 (1H, m), 1.99 - 2.08 (1H, m), 2.67 - 2.74 (1H, m), 3.49 - 3.51 (2H, m), 3.58 - 3.67 (2H, m), 3.73 (1H, t), 3.79 - 3.84 (1H, m), 7.88 (1H, t), 8.16 (1H, d), 8.22 (1H, s), 8.29 (1H, d), 8.74 (1H, d), 12.36 (1H, brs)
1416	B	347.47	3.54	1H NMR (CDCI3 / MeOD): 0.83 (2H, m), 1.94 (1H, m), 2.32 (1H, m), 3.00 (1H, m), 3.30 (1H, m), 3.36 (2H, m), 3.46 (1H, m), 3.60 (1H, m), 3.87 (1H, m), 8.15 (1H, s), 8.24 (1H, s),8.29(1H, s), 8.68 (1H, s)
1417	D	333.51	5	1H NMR (DMSO-d6): 2.15 (1H, mj, 2.30 (2H, m), 3.35 (2H, m), 3.58 (1H, m), 4.77 (1H, m), 7.87 (1H, s), 8.29 (3H, m), 8.81 (1H, s), 8.94 (2H, brs), 12.45 (1H, s)
1418	D	333.4	5	1H NMR (DMSO-d6): 2.17 (1H, m), 2.34 (1H, m), 3.34 (3H, m), 3.58 (1H, m). 4.79 (1H, m), 7.87 (1H, d), 8.27 (3H, m), 8.68 (1H, s), 8.81 (2H, br s), 12.45 (1H, s)
1419	B	403.48	3.18	1H NMR (DMSO-d6): 0.82 (2H, m), 1.11 (1H, m), 1.22 (1H, m), 1.85 (2H, t), 1.98 (3H, s), 2.07 (1H, br s), 3.00 (1H, t), 3.51 (1H, s), 3.83 (1H, m), 4.40 (1H, d), 8.40 (1H, s), 8.44 (1H, d), 8.65 (1H, s), 8.88 (1H, s), 9.20 ¢1H, br s), 12.91 (1H, s)

In Vivo Assay [001175] For efficacy studies, Balb/c mice (4-5 weeks of age) were challenged with 5xlO³TCIDso in a total volume of 50 μΐ by intranasal by intranasal instillation (25 μΐ/nostril) under general anesthesia (Ketamine/Xylazine). Uninfected controls were challenged with tissue culture media (DMEM, 50 μΐ total volume). For the prophylaxis study (FIG. 1), the initial dose of Compound 514 (100 mg/kg) or vehicle only (0.5% Methylcellulose/0.5% Tween 80) were administered 2 hours prior to infection by oral gavage (10 mL/kg) and continued twice daily for 5 days. For the treatment study (FIG. 2), Compound 588 (200 mg/kg) or vehicle only (0.5% Methylcellulose/0.5% Tween 80) were administered by oral gavage 24 hours post infection and continued twice daily for 10 days. Animals were monitored for survival for 21 days and Kaplan Meier plots. As shown in FIGs. 1 and 2, Compound 514 and Compound 588 provided complete survival that was statistically significant from vehicle treated controls (P<0.0001).

Table 6. Influneza Therapeutic Mouse Model (Dosing @ 48 hours post infection with 30 mg/kg BIDX 10 days)

-434WO 2010/148197

PCI7US2010/038988

2018200219 11 Jan 2018

Compounds	Percent Survival	Percent Weight Loss (Day 8)
895	100	12.8
936	100	20.9
933	100	28.0
706	75	27.0
967	75	30.9
866	62.5	29.5
968	37.5	32.7

[001176] All references provided herein are incorporated herein in its entirety by reference. As used herein, all abbreviations, symbols and conventions are consistent with those used in the contemporary scientific literature. See, e.g., Janet S. Dodd, ed., The ACS Style Guide: A Manual for Authors and Editors, 2nd Ed., Washington, D.C.: American Chemical Society, 1997.

1001177] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

2018200219 25 Mar 2019

The claims defining the invention are as follows:

1. A compound represented by the following Structural Formula (IA):

R¹ (IA), or a pharmaceutically acceptable salt thereof, wherein:

Z¹ is -R*, -F, -Cl, -CN, -OR*, -CO₂R*, -NO2, or -CON(R*)₂;

Z² is -R*, -OR*, -CO2R*, -NR*2, or -CON(R*)₂;

Z³ is -H, -OH, halogen, -NH2; -NH(Ci-C4 alkyl); -N(Ci-C4 alkyl)₂,-O(Ci-C4 alkyl), or CiCe alkyl that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C4 alkyl);

R¹ is -H or Ci-Ce alkyl;

R² is -H, -F, -NH2, -NH(Ci-C4 alkyl),-N(Ci-C4 alkyl)2,-C=N-OH, cyclopropyl that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, -OCH3, and -CH3, or C1-C4 alkyl that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C4 alkyl);

R³ is -H, -Cl, -F, -OH, -O(Ci-C₄ alkyl), -NH2, -NH(Ci-C ₄ alkyl), -N(Ci-C₄alkyl)2, -Br, -CN, or C1-C4 aliphatic that is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO2H, -CO2(Ci-C4 alkyl), and C1-C4 alkoxy;

R⁴ is:

436

2018200219 29 Aug 2019

rings G3 and G4 are each independently a 5-10 membered non-aromatic bridged ring optionally further substituted with one or more instances of J^A;

ring G5 is a 5-10 membered non-aromatic bridged ring optionally further substituted with one or more instances of J^B;

X is -O-, -S-, or -NR^g-;

Q² is independently a bond, -O-, -S-, -NR-, -C(O)-, -C(=NR)-, -CO2-, -OC(O)-, -C(O)NR-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O- -NRC(O)-, -NRC(O)NR-, -NRCO2-, -OC(O)NR-, -S(O)-, -SO2-,-N(R)SO2- -SO2NR’-, -NRSO2NR’-, or-('CR⁶R⁷)p-Y¹-;

each of J^A and J^B is independently selected from the group consisting of halogen, cyano, oxo, -NCO, and Q*-R⁵; or optionally two J^A and two J^B, respectively, together with the atom(s) to which they are attached, independently form a 4-8 membered ring that is optionally substituted with one or more instances of J^E1;

Q¹ is independently a bond, -0-, -S-, -NR’-, -C(O)-, -C(=NR)-, -C(=NR)NR-, -NRC(=NR)NR-, -CO2-, -OC(O)-, -C(O)NR’-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O-NRC(O)-, -NRC(O)NR’-, -NRCO2-, -OC(O)NR’-, -S(O)-, -SO2--SO2NR’-, -NRSO2-, or-NRSO2NR’-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)2O-, -CO2SO2-, or-(CR⁶R⁷)P-Y¹-;

Y¹ is independently a bond, -0-, -S-, -NR’-, -C(O)-, -C(=NR)-, -C(=NR)NR-, -NRC(=NR)NR-, -CO2-, -OC(O)-, -C(O)NR’-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O-NRC(O)-, -NRC(O)NR’-, -NRCO2-, -OC(O)NR’-, -S(O)-, -SO2--SO2NR’-, -NRSO2--NRSO2NR’-, -P(O)(OR)O-, -OP(O)(OR^a)O-, -P(O)₂O-, or-CO₂SO₂-;

R⁵ is: i) -H; ii) a Ci-Ce aliphatic group optionally substituted with one or more instances of J^C1; iii) a C3-C10 non-aromatic carbocycle, or a 6-10 membered aryl group, each optionally and independently substituted with one or more instances of J^C1; or iv) a 4-10 membered nonaromatic heterocycle, or a 5-10 membered heteroaryl group, each optionally and independently substituted with one or more instances of J^D1; or

437

2018200219 29 Aug 2019

R⁵, together with Q¹, optionally forms a 4-8 membered, non-aromatic ring optionally substituted with one or more instances of J^E1; and

R⁶ and R⁷ are each independently -H or Ci-Ce alkyl optionally substituted with one or more substitutents selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ce aminoalkoxy, Ci-Ce cyanoalkoxy, Ci-Ce hydroxyalkoxy and C2-C6 alkoxyalkoxy, or optionally R⁶ and R⁷, together with the carbon atom to which they are attached, form a cyclopropane ring optionally substituted with one or more instances of methyl;

R⁸ and R⁹ are each independently-H, halogen, cyano, hydroxy, amino, carboxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 cyanoalkyl, C2-C6 alkoxyalkyl, C1-C6 aminoalkyl, C1-C6 hydroxyalkyl, C1-C6 carboxyalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 aminoalkoxy, C1-C6 cyanoalkoxy, C1-C6 hydroxyalkoxy, or C2-C6 alkoxyalkoxy;

R¹³ and R¹⁴are each independently -H, halogen, or C1-C6 alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 aminoalkoxy, CiCe cyanoalkoxy, C1-C6 hydroxyalkoxy, and C2-C6 alkoxyalkoxy;

Optionally, R¹³ and R¹⁴, together with the carbon atom to which they are attached, form a cyclopropane ring, optionally substituted with one or more instances of methyl;

R²¹, R²², R²³, R²⁴, and R²⁵ are each independently -H, halogen, -OH, C1-C6 alkoxy, or CiΟό alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 aminoalkoxy, C1-C6 cyanoalkoxy, C1-C6 hydroxyalkoxy, and C2-C6 alkoxyalkoxy;

R^g is -H or C1-C6 alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 aminoalkoxy, C1-C6 cyanoalkoxy, C1-C6 hydroxyalkoxy, and C2-C6 alkoxyalkoxy;

R and R’ are each independently -H or C1-C6 alkyl optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 aminoalkoxy, C1-C6 cyanoalkoxy, C1-C6 hydroxyalkoxy and C2-C6 alkoxyalkoxy; or optionally

438

2018200219 25 Mar 2019

R’, together with R⁵ and the nitrogen atom to which they are attached, forms a 5-7 membered non-aromatic heterocycle optionally substituted with one or more instances of J^D1;

R* is independently: i)-H; ii) a Ci-Cg alkyl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, C3-C8 non-aromatic carbocycle, 5-6 membered non-aromatic heterocycle, phenyl, 5-6 membered heteroaryl, -O(Ci-C6 alkyl), and -C(O)(Ci-C6-alkyl); wherein each of said alkyl groups in -O(Ci-C6 alkyl), and -C(O)(Ci-C6-alkyl) is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo,-NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy; and wherein each of said carbocycle, heterocycle, phenyl, and heteroaryl is independently and optionally substituted with one or more instances of J^E1; or iii) a C3-C8 non-aromatic carbocycle, or a 4-8 membered nonaromatic heterocycle, each of which is independently and optionally substituted with one or more instances of J^E1; and each of J^C1 and J^D1 is independently selected from the group consisting of halogen, cyano, oxo, R^a, -OR^b, -SR^b, -S(O)R^a, -SO2R^a, -NR^bR^c, -C(O)R^b, -C(=NR)R^C, -C(=NR)NR^bR^c, -NRC(=NR)NR^bR^c, -C(O)OR^b, -OC(O)R^b, -NRC(O)R^b, -C(O)NR^bR^c, -NRC(O)NR^bR^c, -NRC(O)OR^b, -OCONR^bR^c, -C(O)NRCO2R^b, -NRC(O)NRC(O)OR^b, -C(O)NR(OR^b), -SO2NR^cR^b, -NRSO2R^b, -NRSO2NR^cR^b, -P(O)(OR^a)2, -OP(O)(OR^a)2, -P(O)2OR^a and -CO2SO₂R^b, or optionally, two J^C1 and two J^D1, respectively, together with the atom(s) to which they are attached, independently form a 4-8 membered ring that is optionally substituted with one or more instances of J^E1;

each J^E1 is independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, amido, Ci-Cg alkyl, -O(Ci-C6 alkyl), and -C(O)(Ci-C6-alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy;

R^a is independently:

i) a Ci-Cg aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino,

439

2018200219 25 Mar 2019 carboxy, amido, -O(Ci-C6 alkyl), -C(O)(Ci-C6-alkyl), C3-C8 non-aromatic carbocycle, 4-8 membered non-aromatic heterocycle, 5-10 membered heteroaryl group, and 6-10 membered carbocyclic aryl group; wherein each of said alkyl groups for the substituents of the Ci-Ce aliphatic group represented by R^a is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CC>2(Ci-C₄ alkyl), and Ci-C₄ alkoxy; and wherein each of said carbocycle, heterocycle, heteroaryl and carbocyclic aryl groups for the substituents of the Ci-Ce aliphatic group represented by R^a is optionally and independently substituted with one or more instances ofJ^E1;

ii) a C3-C8 non-aromatic carbocycle, or a 4-8 membered non-aromatic heterocycle, each of which is optionally and independently substituted with one or more instances of J^E1; or iii) a 5-10 membered heteroaryl, or 6-10 membered carbocyclic aryl group, each of which is optionally and independently substituted with one or more instances of J^E1; and

R^b and R^c are each independently R^a or -H; or optionally, R^b and R^c, together with the nitrogen atom(s) to which they are attached, form a 5-7 membered non-aromatic heterocycle optionally substituted with one or more instances of J^E1;

p is independently 1, 2, 3 or 4;

q is 0, 1 or 2;

x is 0, 1 or 2; and r is 1 or 2;

provided that if Q² is a bond, then R⁵ is an optionally substituted C3-C8 non-aromatic carbocycle; an optionally substituted 6-10 membered carbocyclic aryl group; an optionally substituted, 4-8 membered non-aromatic heterocycle; or an optionally substituted 5-10 membered heteroary group.
2. The compound of claim 1, wherein Q² is independently -O-, -CO2-, -OC(O)-, -C(O)NR-, -NRC(O)-, -NRC(O)NR-, -NRCO2-, -OC(O)NR- -SO2-, or -(CR⁶R⁷)_P-Y¹-.
3. The compound of claim 2, wherein Q² is independently -O- or -CO2-.

440

2018200219 25 Mar 2019
4. The compound of claim 1, wherein R¹ is -H.
5. The compound of claim 1, wherein R² is -H, -F, -CH3, -CH2OH, or -NH2.
6. The compound of claim 5, wherein R² is -H or -CH3.
7. The compound of claim 1, wherein R³ is -H, -Cl, -F, -Br, -CN, -CF3, -O(Ci-C4 alkyl),

-OH, -NH2, -NH(Ci-C₄ alkyl), or -N(Ci-C₄ alkyl)₂.
8. The compound of claim 1, wherein:

Z¹ is -H, -F, -Cl, -CF3, -CH3, or -CN; and

Z² is -H or an optionally substituted Ci-Ce alkyl.
9. The compound of claim 1, wherein:

R² is -H; and

R³ is -H, -F, -Cl, -CF3, -CH3, -C2H5, -NH2, -NH(CH₃), or-N(CH₃)2.
10. The compound of claim 1, wherein:

Z¹ is -H, -F, -Cl, -CF3, -CH3, or -CN;

Z² is -H or C1-C6 alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C4 alkyl);

Z³ is -H or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C4 alkyl);

R¹ is -H;

R² is -H;

R³ is independently -H, -Cl or -F;

R⁶ and R⁷ are each independently -H or -CH3, or together with the carbon atoms to which they are attached they form a cyclopropane ring;

each R⁸ is independently -H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, CiC4 hydroxyalkyl, C2-C4 alkoxyalkyl, -O(Ci-C4 alkyl), -NH2, -NH(Ci-C4 alkyl), or-N(Ci-C4

441

2018200219 25 Mar 2019 alkyl)2;

each R⁹ is independently -H or -CH3; and

R¹³ and R¹⁴ are each independently -H or -CH3, or together with the carbon atoms to which they are attached form a cyclopropane ring.
11. The compound of claim 1, wherein each of rings G3-G5 is independently and optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, Ci-Ce alkyl, -NH2, -NH(Ci-C6 alkyl), -N(Ci-C6 alkyl )₂, -O(Ci-C6 alkyl), -C(O)NH2, -C(O)NH(Ci-C₆ alkyl), -C(O)N(Ci-C₆ alkyl)₂, -C(O)(Ci-C₆-alkyl), -OC(O)(Ci-C₆ alkyl), -NHC(O)(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)C(O)(Ci-C₆ alkyl), and -CO₂R^b; wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄alkyl), and C1-C4 alkoxy.
12. The compound of claim 11, wherein each of rings G3-G5 is independently and optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO2H, -CC>2(Ci-C₄ alkyl), C1-C4 alkoxy, and C1-C4 alkyl wherein each of said alkyl groups is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, and -O(Ci-C₄ alkyl).
13. A pharmaceutical composition, comprising a compound according to any one of claims 1-12, or a pharmaceutically acceptable salt of the same, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
14. Use of a compound, or pharmaceutically acceptable salt thereof, according to any one of claims 1-12 in the manufacture of medicament for reducing influenza viruses in a patient.
15. Use of any compound, or pharmaceutically acceptable salt thereof, according to any one of claims 1-12 in the manufacture of medicament for treating influenza in a patient.

442

2018200219 25 Mar 2019
16. Use of any compound, or pharmaceutically acceptable salt thereof, according to any one of claims 1-12 in the manufacture of medicament for inhibiting the replication of influenza viruses in a patient.
17. A compound represented by Structural Formula (II):

or a pharmaceutically acceptable salt thereof, wherein:

Z¹ is -F;

Z² is -H or Ci-C₆ alkyl;

R³ is -H, -F, -Cl, -CF₃, -NH₂, -NH(CH₃), or-N(CH₃)₂;

the group -[C(R¹³R¹⁴)]_x-ringA-Q²-R⁵ is independently selected from:

R⁵ is independently:

i)-H;

ii) a Ci-C6-aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄

443

2018200219 29 Aug 2019 alkyl), -OC(O)(Ci-C4 alkyl), -C(O)O(Ci-C4 alkyl), -CO2H, C3-C8 non-aromatic carbocycle, phenyl, 4-8 membered non-aromatic heterocycle, and 5-6 membered heteroaryl;

iii) a C3-C7 non-aromatic carbocycle, a 4-7 membered non-aromatic heterocycle, a phenyl group, or a 5-6 membered heteroaryl, each of which is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), and -CO₂H;

wherein each of said alkyl groups for the substituents of R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy; and wherein each of said carbocycle, phenyl, heterocycle, and heteroaryl for the substituents of the Ci-Ce aliphatic group represented by R⁵ is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)2, -OCO(Ci-C₄alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy; and ring A is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄alkyl), -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄alkyl), -CO2H, and -CO2(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO2H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy;

provided that rings A21, and A26 are further substituted with one or more substituents other than -H.
18. The compound of claim 17, wherein Z² is -H; and R³ is -H, -F, or -Cl.
19. The compound of claim 17, wherein the compound is represented by Structural Formula

444

2018200219 25 Mar 2019 (XIA) or (XIB):

H or H (XIA) (XIB) or a pharmaceutically acceptable salt thereof, wherein ring A is optionally further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C2 alkyl), -N(Ci-C2 alkyl)2, C1-C2 alkyl, C1-C2 haloalkyl, C1-C2 hydroxyalkyl, C2-C4 alkoxyalkyl, C1-C2 alkoxy, C1-C2 hydroxyalkoxy, C1-C2 haloalkoxy, C2-C4 alkoxyalkoxy, -CO2H, and -CO2(Ci-C₄ alkyl).
20. The compound of claim 17, wherein x is 0.
21. A pharmaceutical composition, comprising a compound according to any one of claims

17-20, or a pharmaceutically acceptable salt of the same, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
22. Use of any compound according to any one of claims 17-20 in the manufacture of medicament for reducing influenza viruses in a patient.
23. Use of any compound according to any one of claims 17-20 in the manufacture of medicament for treating influenza in a patient.
24. Use of any compound according to any one of claims 17-20 in the manufacture of medicament for inhibiting the replication of influenza viruses in a patient.
25. A compound represented by Structural Formula (III):

445

2018200219 25 Mar 2019

or a pharmaceutically acceptable salt, wherein:

ring B is independently selected from:

wherein ring B is optionally and independently substituted;

each Q³ is independently -C(O)-, -CO2-, -C(O)NR’-, -SO2--SO2NR’-, -C(O)NRC(O)O- or -(CR⁶R⁷)_p-Y'-;

Z¹ is -H, -F, -Cl, C1-C4 haloalkyl, C1-C4 alkyl, -O(Ci-C₄ alkyl), or -CN;

Z² is -H, Ci-C₆ alkyl, -O(Ci-C₆ alkyl), -NH₂, -NH(Ci-C₆ alkyl), or -N(Ci-C₆ alkyl)₂, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy;

R³ is -H, -Cl, -F, -Br, -CN, -CF3, -O(Ci-C₄ alkyl), -OH, -NH₂, -NH(Ci-C₄ alkyl), or -N(Ci-C₄ alkyl )₂;

R⁵ is independently:

i) -H;

ii) a Ci-Ce aliphatic group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄

446

2018200219 29 Aug 2019 alkyl), -OC(O)(Ci-C4 alkyl), -C(O)O(Ci-C4 alkyl), -CO2H, C3-C8 non-aromatic carbocycle, phenyl, 4-8 membered non-aromatic heterocycle, and 5-6 membered heteroaryl; or iii) a C3-C7 non-aromatic carbocycle, a 4-7 membered non-aromatic heterocycle, a phenyl group, or a 5-6 membered heteroaryl ring, each of which is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C4 alkyl), -NH2, -NH(Ci-C4 alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -OC(O)(Ci-C₄ alkyl), -C(O)O(Ci-C₄ alkyl), and -CO₂H;

wherein each of said alkyl groups for the substituents of R⁵is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy;

R⁶ and R⁷ are each independently -H or Ci-Ce alkyl optionally substituted with one or more substitutents selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ce aminoalkoxy, Ci-Ce cyanoalkoxy, Ci-Ce hydroxyalkoxy, and C2-C6 alkoxyalkoxy, or optionally R⁶ and R⁷, together with the carbon atom to which they are attached, form a cyclopropane ring optionally substituted with one or more instances of methyl;

R¹³ and R¹⁴are each independently -H, halogen, or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-C7 aminoalkoxy, CiCe cyanoalkoxy, Ci-Ce hydroxyalkoxy, and C2-C6 alkoxyalkoxy, or, optionally, R¹³ and R¹⁴, together with the carbon atom to which they are attached, form a cyclopropane ring, optionally substituted with one or more instances of methyl;

each R and R’ is independently -H or Ci-C ealkyl;

Y¹ is independently a bond, -0-, -S-, -NR’-, -C(O)-, -C(=NR)-, -CO2-, -OC(O)-, -C(O)NR'-, -C(O)NRC(O)O-, -NRC(O)NRC(O)O-, -NRC(O)-, -NRC(O)NR’-, -NRCO2-, -OC(O)NR’-, -S(O)-, -SO2--SO2NR’-, -NRSO2-, or-NRSO2NR’-;

p is 1, 2, 3, or 4; and y is 0 or 1;

provided that if Q³ is -C(O)-, then R⁵ is a substituted Ci-Ce aliphatic group; an optionally substituted C3-C7 non-aromatic carbocycle; a phenyl group; optionally substituted 4-7 membered

447

2018200219 29 Aug 2019 non-aromatic heterocycle; or an optionally substituted 5-6 membered heteroaryl group;

provided that if Y¹ is a bond, then R⁵ is a substituted Ci-Ce aliphatic group; an optionally substituted C3-C7 non-aromatic carbocycle; a phenyl group; an optionally substituted 4-7 membered non-aromatic heterocycle; or an optionally substituted, 5-6 membered heteroaryl group; and provided that the ring B-Q³-R⁵ moiety is not .V-mcthyl-3-pyrrolidinyl ( ).
26. The compound of claim 25, wherein R³ is -H, -F, -Cl, -CF3, -NH2, -NHJCFF), or -N(CH₃)₂.
27. The compound of claim 26, wherein R³ is-H, -Cl, or -F.
28. The compound of claim 25, wherein

Z¹ is -H, -F, -Cl, -CF3, -CH3, or -CN; and

Z² is -H or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO2H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy.
29. The compound of claim 28, wherein

Z¹ is -H, -F, or -CN; and

Z² is -H or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄alkyl, -NH2, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO2H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy.
30. The compound of claim 25, wherein R¹³ and R¹⁴are each independently -H, halogen, or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and Ci-Ce alkoxy.

448

2018200219 29 Aug 2019
31. The compound of claim 30, wherein R¹³ and R¹⁴are each independently -H or C1-C4 alkyl.
32. The compound of claim 25, wherein R⁶and R⁷ are each independently -H or -CH3, or, together with the carbon atoms to which they are attached, they form a cyclopropane ring.
33. The compound of claim 25, wherein the compound is represented by Structural Formula (XIIA) or (XIIB)

(XII A) (XIIB).
34. The compound of claim 25, wherein y is 0.
35. The compound of claim 25, wherein the group -[C(R¹³R¹⁴)]_y-ringB-Q³-R⁵ has the structure:

wherein ring B2 is optionally and independently further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, 449

2018200219 29 Aug 2019

NH₂, -NH(Ci-C₂ alkyl), -NH(Ci-C₂ alkyl)₂, Ci-C₂ alkyl, Ci-C₂ haloalkyl, Ci-C₂ hydroxyalkyl, C2-C4 alkoxyalkyl, Ci-C₂ alkoxy, Ci-C₂ hydroxyalkoxy, Ci-C₂ haloalkoxy, C₂-C₄ alkoxyalkoxy, -CO₂H, and -CO₂(Ci-C₄ alkyl).
36. A pharmaceutical composition, comprising a compound according to any one of claims 25-35, or a pharmaceutically acceptable salt of the same, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
37. Use of any compound, or pharmaceutically acceptable salt thereof, according to any one of claims 25-35 in the manufacture of medicament for reducing influenza viruses in a patient.
38. Use of any compound, or pharmaceutically acceptable salt thereof, according to any one of claims 25-35 in the manufacture of medicament for treating influenza in a patient.
39. Use of any compound, or pharmaceutically acceptable salt thereof, according to any one of claims 25-35 in the manufacture of medicament for inhibiting the replication of influenza viruses in a patient.
40. A compound represented by Structural Formula (IV):

(IV)

450

2018200219 25 Mar 2019 or a pharmaceutically acceptable salt, wherein:

ring C is independently selected from:

wherein each of rings C1-C5 is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄ alkyl), -CO₂H, and -CO2(Ci-C₄ alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more independently substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-Ce alkyl), -N(Ci-C6 alkyl)2, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy.

Z¹ is -H, -F, -Cl, Ci-C₄ haloalkyl, Ci-C₄ alkyl, -O(Ci-C₄ alkyl), or-CN;

Z² is -H, Ci-C₆ alkyl, -O(Ci-C₆ alkyl), -NH₂, -NH(Ci-C₆ alkyl), or -N(Ci-C₆ alkyl)₂, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄ alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO2H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy;

R³ is -H, -Cl, -F, -Br, -CN, -CF₃, -O(Ci-C₄ alkyl), -OH, -NH₂, -NH(Ci-C₄ alkyl), or -N(Ci-C₄ alkyl)2; and

R¹⁰ is independently -H; or a Ci-Ce alkyl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, Ci-Ce alkoxy, Ci-CY haloalkoxy, Ci-Ce aminoalkoxy, Ci-GV cyanoalkoxy, C1-C6 hydroxyalkoxy, C2-C6 alkoxyalkoxy, C3-C8 non-aromatic carbocycle, phenyl, a 4-8 membered non-aromatic heterocycle, and a 5-6 membered heteroaryl group; wherein each of said carbocycle, phenyl, heterocycle, and heteroaryl group for the substituents of the Ci-Ce alkyl group represented by R¹⁰ is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, amino, carboxy, C1-C6 alkyl, Ci-Ce haloalkyl, C1-C6 cyanoalkyl, C2-C6 alkoxyalkyl, Ci-Ce aminoalkyl, Ci-Ce hydroxyalkyl, Ci-G, alkoxy, C1-C6 haloalkoxy, Ci-Ce aminoalkoxy, Ci-Ce cyanoalkoxy, Ci-Ce hydroxyalkoxy, and C2-C6 alkoxyalkoxy.

451

2018200219 29 Aug 2019
41. The compound of claim 40, wherein R³ is -H, -F, -Cl, -CF3, -NH2, -NH(CH3), or -N(CH₃)₂.
42. The compound of claim 41, wherein R³ is-H, -Cl, or -F.
43. The compound of claim 40, wherein

Z¹ is -H, -F, -Cl, -CF3, -CH3, or -CN; and

Z² is -H or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH2, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO2H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy.
44. The compound of claim 43, wherein

Z¹ is -H, -F, or -CN; and

Z² is -H or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, Ci-C₄alkyl, -NH2, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO2H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy.
45. The compound of claim 40, wherein R¹⁰ is independently -H, Ci-Ce alkyl, Ci-Ce haloalkyl, C2-C6-alkoxyalkyl, Ci-Ce hydroxyalkyl, Ci-Ce aminoalkyl, or Ci-Ce cyanoalkyl.
46. The compound of claim 40, wherein R¹⁰ is -H or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)2, -OCO(Ci-C₄ alkyl), -CO2H, -CO2(CiC₄ alkyl), and Ci-C₄ alkoxy.
47. The compound of claim 46, wherein R¹⁰ is -H or Ci-Ce alkyl.
48. The compound of claim 40, wherein each of rings C1-C5 is optionally and independently further substituted with one or more substituents independently selected from the group

452

2018200219 25 Mar 2019 consisting of halogen, cyano, hydroxy, -NH2, -NH(Ci-C2 alkyl), -N(Ci-C2 alkyl)2, C1-C2 alkyl,

C1-C2 haloalkyl, C1-C2 hydroxyalkyl, C2-C4 alkoxyalkyl, C1-C2 alkoxy, C1-C2 hydroxyalkoxy, C1-C2 haloalkoxy, C2-C4 alkoxyalkoxy, -CO2H, and -CO2(Ci-C₄ alkyl).
49. The compound of claim 40, wherein the compound is represented by Structural Formula (XIII)

(XIII).
50. A pharmaceutical composition, comprising a compound according to any one of claims 40-49, or a pharmaceutically acceptable salt of the same, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
51. Use of any compound, or pharmaceutically acceptable salt thereof, according to any one of claims 40-49 in the manufacture of medicament for reducing influenza viruses in a patient.
52. Use of any compound, or pharmaceutically acceptable salt thereof, according to any one of claims 40-49 in the manufacture of medicament for treating influenza in a patient.
53. Use of any compound, or pharmaceutically acceptable salt thereof, according to any one of claims 40-49 in the manufacture of medicament for inhibiting the replication of influenza viruses in a patient.
54. A compound represented by Structural Formula (V):

453

2018200219 25 Mar 2019

or a pharmaceutically acceptable salt, wherein: ring D is independently selected from one of the structures depicted below:

wherein each of rings D1-D7 is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -O(Ci-C₄ alkyl), -NH₂, -NH(Ci-C₄ alkyl), -N(Ci-C₄ alkyl)₂, -C(O)(Ci-C₄alkyl), -CO₂H and -CO₂(Ci-C4 alkyl), wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-Ce alkyl), -N(Ci-C6 alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and Ci-C₄ alkoxy;

each R^d is independently -H, Ci-Ce alkyl or - C(O)(Ci-Ce alkyl), wherein each of said alkyl moiety is optionally and independently substituted with one or more groups selected from halogen, cyano, hydroxy, oxo, -NH₂, -NH(Ci-C6 alkyl), -N(Ci-Ce alkyl)₂, -OCO(Ci-C₄alkyl), -CO(Ci-C₄ alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy;

Z¹ is -H, -F, -Cl, C1-C4 haloalkyl, C1-C4 alkyl, -O(Ci-C₄ alkyl), or -CN;

Z² is -H, C1-C6 alkyl, -O(Ci-C6 alkyl), -NH₂, -NH(Ci-C6 alkyl), or -N(Ci-Ce alkyl)₂, wherein each of said alkyl groups is optionally and independently substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO₂H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy;

R³ is -H, -Cl, -F, -Br, -CN, -CF₃, -O(Ci-C₄ alkyl), -OH, -NH₂, -NH(Ci-C₄ alkyl), or -N(Ci-C₄ alkyl)₂;

R¹³ and R¹⁴ are each independently -H, halogen, or Ci-Ce alkyl optionally substituted

454

2018200219 29 Aug 2019 with one or more substituents independently selected from the group consisting of halogen, cyano, oxo, hydroxy, amino, carboxy, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-C7 aminoalkoxy, CiCe cyanoalkoxy, Ci-Ce hydroxyalkoxy, and C2-C6 alkoxyalkoxy, or, optionally, R¹³ and R¹⁴, together with the carbon atom to which they are attached, form a cyclopropane ring, optionally substituted with one or more instances of methyl; and z is 1 or 2.
55. The compound of claim 54, wherein R³ is -H, -F, -Cl, -CF3, -NH2, -NH(CH₃), or -N(CH₃)₂.
56. The compound of claim 55, wherein R³ is-H, -Cl, or -F.
57. The compound of claim 54, wherein

Z¹ is -H, -F, -Cl, -CF3, -CH3, or -CN; and

Z² is -H or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH2, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO2H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy.
58. The compound of claim 57, wherein

Z¹ is -H, -F, or -CN; and

Z² is -H or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, C1-C4 alkyl, -NH₂, -NH(Ci-C₆ alkyl), -N(Ci-C₆ alkyl)₂, -OCO(Ci-C₄ alkyl), -CO(Ci-C₄alkyl), -CO2H, -CO₂(Ci-C₄ alkyl), and C1-C4 alkoxy.
59. The compound of claim 54, wherein R¹³ and R¹⁴ are each independently -H, halogen, or Ci-Ce alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, and Ci-Ce alkoxy.
60. The compound of claim 59, wherein R¹³ and R¹⁴ are each independently -H or C1-C4

455

2018200219 25 Mar 2019 alkyl.
61. The compound of claim 54, wherein R⁶ and R⁷ are each independently -H or -CH3, or, together with the carbon atoms to which they are attached, they form a cyclopropane ring.
62. The compound of claim 54, wherein the compound is represented by Structural Formula (XIV)

F

(xiv).
63. The compound of claim 62, wherein z is 1.
64. The compound of claim 54, wherein each of rings D1-D7 is optionally and independently further substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH2, -N(Ci-C2 alkyl), -NH(Ci-C2 alkyl)2, C1-C2 alkyl, C1-C2 haloalkyl, C1-C2 hydroxyalkyl, C2-C4 alkoxyalkyl, C1-C2 alkoxy, C1-C2 hydroxyalkoxy, C1-C2 haloalkoxy, C2-C4 alkoxyalkoxy, -CO2H, and -CC>2(Ci-C4 alkyl).
65. A pharmaceutical composition, comprising a compound according to any one of claims 54-64, or a pharmaceutically acceptable salt of the same, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
66. Use of any compound, or pharmaceutically acceptable salt thereof, according to any one of claims 54-64 in the manufacture of medicament for reducing influenza viruses in a patient.
67. Use of any compound, or pharmaceutically acceptable salt thereof, according to any one of claims 54-64 in the manufacture of medicament for treating influenza in a patient.

456

2018200219 25 Mar 2019
68. Use of any compound, or pharmaceutically acceptable salt thereof, according to any one of claims 54-64 in the manufacture of medicament for inhibiting the replication of influenza viruses in a patient.

69. A compound selected from any one of the following compounds

1 2 3 F H F N Γ VsiN / X n, H a —-Z Η n /VW y=N / n—\ 'Un r H / F W ^N Η O Ci J ( ) /7 rl ^N Η O 4 5 6 F --/ H ^H-_n_h CIn o // / \ ⁷ / \ ^^0 H-\ H\ y=w /Λ y=N II I / H a / ^Cl J H 7 8 9 C-h ^^0 8 F £ H-N ___ HN _ ^HN\—-v N / yrN y^N Ci / ci I ^Cl II -I / H Li Λ. H U V H 10 11 12 ά F ,^-L F O-H F _X Η --χ fj VN^HJ ^N ! vVA / ) n Γ V-L / \^3N / \ y^N h\W Pi Γ 4^H P) ysN w Cl f νΤΛ ^N H

457

2018200219 25 Mar 2019

13 14 15 F ί¹ O-H If xy—-N / N' / < \c=N / J XX/ H /''X 0—ζ J 1 F h-J'Q / n( // V^-N H F d-XQ ₀ Cl 'h'⁰^/ ϊ 1Λ ° Si^N ^H H 16 17 18 F <z4y-N Cl Γ ΊΓίΛ ⁰ ί-Ό <\ ^Ny=N ^HX-N 1TX5 ° F rO U\ ^NXiN ''Hx-N “rd 19 20 21 F ^οιγγί Xvu F /rC^hi¹ ΛΝ a^X VV Ό5 ^{0 Λ} ^N H F rvL-O r Y ην> o f ” H 22 23 24 F i-Aiii¹ Γ~\ Vn ^vhVn .η a Γ )τχ__. νβ ⁰ O F ,__l Η --X //Xy-N / > Vn ^X,hX-\ a ν°\ T Ίν ⁰ H F AAn ci^vT ^X⁰'— Fn ⁰ o-

458

2018200219 25 Mar 2019

25 26 27 Λ ο F \=N ^νϊΚ-Ν B ^cl—-ϊ-Χ Λ·⁰ YY5 ° θ F / \ \=N HXJ H ci--.( ^^rNv- η © Γ χΓ 28 29 30 F φ<^Η rx F —-Z H —· ΛλΟ \=N ΗΧ-N h ci^-/ )r\ Τ ιΛ ⁰ ^N H dr%Q₀ CI^-4 >°v-C5C- Ίι ίΧ ^ο ^kN^ 31 32 33 F F^/ T^F J H ^H _n.H // Ny—N HH F ViXN I \ ^ΟΙ>-^^Λχ_-Ζ N—- H F —-Z H v ci —. Γ )rA Y Ίν ⁰ F —-Ζ η —X ΙΓΧ—Ν / > ^NyrT ^VhO ci —/ ?r χ_ Υ Ιν ⁰ ^ν^“ΝΙ ^Ν Η 34 35 36 F —-Z H —-K Γχ-Ν Γ\ ^Ny=N ^vh\-n / ci J h\ ip ⁰ F /r4y-.N f~\ ^Vh\-N ci Γ V s— ΥίΛ ⁰ / F __Ζ ^Η r-X ΝτΥ”^ΝΧ.·χ J \ΰΣΝ HΝ—Ν ,Ο ^α Ji ΥίΛ ⁰ ' ^Ν Η

459

2018200219 25 Mar 2019

37 38 39 F F F Z H x jPv-N ΓΛ /rZy-N ΛΝ r\ N f \»—4. J. ysN η VN V ^S^vn \s:N ^VHVN 6 ct Λ ci _Λ J rV ^ci>^x )r Υηρ» o ΊιΤΛ ⁰ Ti T V ox. H ^M H 40 41 42 F F F H X Ar-^N ΛΑ ^V^N f) jf%-n / \ ^NV=N ''Ά-Ν ή W ^χ”ηχ_νh ^x,hN-\ Cl J ci λ. f /TN/ YYn ° o Ίί ° ^H ΥΥλ ⁰ A Ψίι W ^'Nⁱ^N re _H ιί H 43 44 45 F F F J H r-i Jt¹ r-X /ΓΧ-Ν ff Xv-N / \ ^Txv-n f^\ N d V.i J ^N ' X”.K J N / \p-< J SfsH HX-N VSN HVN y=N HVN Cl .A «‘isf Cl^-T )r\z CI^^Z A'o- ΤΡΠ> ° ^A Ίί Ύ y ° TprS ° ^<NA1 46 47 48 F F F d H H — \sN ''HX-N ⁿ-LfT ^vhVn y^N- Cl _Λ J n\-^ «'n.n Ίίηη> ° / *-ν^ν_η 1 Ύ\> o r < sUn x< 11 ΥΎλ ⁰ H

460

2018200219 25 Mar 2019

49 50 51 F ''iLk Cl tvs ⁰ μ F /X y ^v'iU ^clrtC F H //\_N O ’VsN 'HV-N Η/Μ' Cl ~ j y\x ΊΠΟ ⁰ N 52 53 54 F ^rx_csC^M F dAn ci_^/ yv, iM ° ir^ 0 F -dAo ^clTpn> ° °Ίτ9ι 55 56 57 'CQ F dAQ ci J )r\^ tp ⁰ O F A H ____ N^/rV\jA y=N ^ΉΝ-ν ci λ Y )r^V- γγ% o 58 59 60 F tfV'Lo Vx y-N nK-N cs^jf Vx5 ^kN^ F N H .--x AV2 y:N ^Wx-N H ci J yA— Τ ίΛ ^{0 H} o ί ^ltNv-< O ci^/

461

2018200219 25 Mar 2019

61 62 63 F Go F ^hNvX N, « Y N Cl ! &° °«iO r^Nni\ ^H,U, f«. « 3-fi ci / K1A F 0AC_yO W ° o ^-yo o ^s 64 65 66 F °G N πΚ ^HNy-f v Cl Λ. J C^^F°io r*^N nN Q ci V CG °io _-N nN Gn Cl 67 68 69 GN-Br ^Ojsre λ^ν nN Ur G J F A-tO CIsx^G ^V°yΐΠη ⁰ O F Γ\ GF 'Gn ci )r°v— ΌΟ °οΌ 70 71 72 F Y JJ r-\ r/VVO Cl -S. / V-x ip °&Ό CI-V/ Ago ci __/ «'V^ VT% ⁰ Π) H F Ago ^Ny=N Cl 1 ΛΓ^υν__K Π Ί+ ⁰ yr ^{H F}G F

462

2018200219 25 Mar 2019

73 74 75 ci / zr v- fp O px \=\ F dr-n ίΓτΑ ° Γ ⁿ⁵/1 F hfV'VO \SN ΠΗ\-Ν H T|M> ° Fy^F 76 77 78 F dAQ W “ m F ά<β, _oιΠπ> ° m F d^OQ _# TfqA ⁰ 79 80 81 F d^Q _{tf F}c's^-Γ y v Lf Τι ίΛ ⁰ V^F F /-MLo “τίνΓ iEXJ V-< o ^AjO y:O λ^νV-Ax ^HtvT N. ΐ,Ν Cl J KO> 82 83 84 F 0AQn TjA °o=< OH F V°^h Π5 ⁰ F ΑΛ-ΟΛλ ci J ir\^J 1ΓΪ3 ⁰

463

2018200219 25 Mar 2019

85 86 87 F F _α -dsG^ π in ° ^F ^N H o °io r^N ^HNy-Z N. +Λ4 Cl J 88 89 90 '0 J I Οτ^ϋ°ϊο Q _Fhnj Q CI-^J V-i| Vs °5sC ’?=O ^HV\ Ό Cl J ip o °X>^Fλ^ν 'hX V Cl J ίΠρ> 91 92 93 h NS_N O-cf =5:0 r-N HN J v Cl λ J F J H ,—. ^ίτ'^Νχ^Ζ / Cl· ζχ _1 ci WA ⁰ H F Cr^-flQ C! M ZTx Η Ίν ° H 94 95 96 F όΑΏ ~ ^k»'Sl F /γ4-ι5^! y=N +HN-N f) Cl J /r'VJ VX? ⁰ ^N lii F /^ ci _C1 > ^ vO Χϊ?> °a

464

2018200219 25 Mar 2019

97 98 99 F ALo „ ci /r'S-* iPtA ⁰ kw^—N ^M H F dAn YA Av W_p F -MO ci I ir\A ίΠο> ° 100 101 102 F z-\ ^Νγ=Ν ''’ΪΓ\_Ν Cl \_ ϊΑ ⁰ O -^¾ V/ F =, vx? ° F TjA ° 103 104 105 F N^r^^N\_FfZ2j \sN H\^N Jb-O yw ΤιΥΛ ° ⁰ A<o ysN A~N Cl J «\__s ΓΧ5 ° O F A Η --χ N⁷V'^N\-J? V=N LFN^4\ C! / /TV lllv ° k_N^_H 106 107 108 diAn ^CIFT% F dAn^n ^αΏ5 F Alov. ysN ^TA-N JT+s ci ___{

465

2018200219 25 Mar 2019

109 110 111 ^Clrt< dAci , w ° F AvQ ysN HX—N Cl Ji o' Τϊ5 ⁰ 112 113 114 F Aj· V A-< ci,^7 #V VX5 ^h\ *ⁿh x F __l Η —— ¹ /Γ\_-νCJ o ^Ny=N '’’iTUi JA ci J n\^J tn ° F A<n JUT ΊΡΤλ ⁰ ^N H 115 116 117 H J ] n-A / h y-^ ^HV< Νχ R V_-N H J ) W-A / h H-N / Nx R Ci J Τς5 ^νΆ cS' Α2) h ci Γ /τ·^Νν-χ TVS 0 Π 118 119 120 F dAQ_# ^c,nS r-w ‘'Ά O F Aj ^Ny=N '^>ik-N Cl J Α5 ° F _nA<O ^Nv=N ^ΊΪΧ,Μ JI Uz ci^A k^Nv_AF VM* ° C°

466

2018200219 25 Mar 2019

121 122 123 F άΛΩ Ci ° / 4<ω_ο ci - .( k°v_c5C^H Ti% ⁰ F A-^sLo 7=N hV-N ^Clrr( “ 124 125 126 F VSN ΊΚ-Ν „ Ίίΐν \=2 ^N H F ^Νύτ^*ΐΟ o ci_^s_T y”·^ Ίί £v θ θΛ ^N ΐι dACr ci - )r^o^ ίΓΤλ ° ^f 127 128 129 -d^o Cl ____Γ fp o F J H ,___ /VvO \=N '’hM H ci^^r y-y YV^ ⁰ zx F H --x /VvO vsN H\--N H ci y-v. 130 131 132 F -Mcg W »u F YM> 0 V X ^kN^ F /ΓΝ_-ν / \ ^Ny*l ^χίΓ^-Ν P w

467

2018200219 25 Mar 2019

133 134 135 F 7 Η N f \i.( J y^N ^vhV-N_v OH yys F J H x AXN f\ Kim ^VK' /Λ Cl Λ. I KO F rLi? r\ V kC<h? ^c'-zO KO XOn 136 137 138 F rLtf Kn 'hKn Cl ^XssZ KO ^F F rU rx ⁿx=n 'tLni _rx ci J KO SKig, F r> An ''-hVn h o r If AA h θ' « % 139 140 141 F -,ί H .—. /ΓΜ r> ⁿ\=n SLn UN CI^^Z OO Γη ' 'Λ F w F H --. d*'-kQjv w N ^,^_| 142 143 144 *VO° LI j Q° V ^f-X k L 'Ί'^Τ'νΗ CⁿCl F «Kt^Ud η AX ° X_nA-n ” H w ^SA</=x °'-m O r^F

468

2018200219 25 Mar 2019

145 146 147 F AUo \=N ⁰ Ο F /tX—1? J \ ysN nK-N /β) VrC Q F ^F F J u β-Ν γγ Cl y=N rtk-N jYN-CI ci J vTa ⁰ 148 149 150 F .Z'-Ab Τι ίΛ ° F rix^Ji U\ o ^Ny=N ^V’hN~n Jpx . Cl / fl\=/ YM> 0 ^kN^ J Γβ 9. y:N tLh ci f Ir'NsJ Η Ίν ° 151 152 153 F /τΑΐϊ* Γ\ F \=:N 'ΤΚν JpS Cl J nx-J Η ΎΛ ⁰ '^F ^N' H F /VOA 'xsn ^tK-n JTW ΊίΧΤΛ ⁰ F Η Ίν ⁰ 154 155 156 F CI^^/ tr-Nsd pp> ⁰ F v2r F dArru Π5 °

469

2018200219 25 Mar 2019

157 158 159 F ng iM ⁰ F Ago o y=N TM JTT Cl J n\sd ϊ y, o F H IT 'N—N / \ ν' Γ X..-Z / H jy—*'oX || |A '^N>H H 160 161 162 H IT Xv-N Γ X y=N H'n— C'x-x'+jsG 0=4 Yn ? ^k H F < H ,--\ ft 'M-n Γ \ N Γ \..< / y^N H^XN—⁷ ^c,yG <G A JO /° 0 X F ___1 H ,___ N / \.-A / y=N o=4 y 1? ^νΉ Cl 163 164 165 F -7 ^H r— TV Γ ) y=N ^H N-⁷ Cl F __( H N Γ X..A / X^N °=4 TX? /° F -7 H ,___ N Γ \.-i / y=N h'm—' C's^sG 0=4 ΪΤ» o Gy-N N Z> H >> 166 167 168 F __7 H ,. N Γ \.-< I y=N Hn-'-⁷ VG 0=4 O. / F ___/ H rv\ / ) ν' Γ X..-χ / y=N h\_j ^os4 T 1? ^nH ^H A F __1 H rt y-N Γ X N Γ / y=N h^x _h—' CL J n-d ^<N H ^X

470

2018200219 25 Mar 2019

471

2018200219 25 Mar 2019

181 182 183 F -/ H . N / NA / V=N Η N—¹ 0=4 Ύ P) /° SA--N ( ^H c. H F __/ Η --χ ii Ά- N / \ ν' Γ A. / H N-·' o=Z Y n r^H <_na_Nh ς F -/ Η --χ 0 N-A / > N^f / A / XiSN H^xh—^! ^ClyxU 0=4 W /° S-A ς 184 185 186 F __J H --x ana / \ y=N hV ^cw °P ^<N h F _l Η --χ AA\ / Λ N / A / XsiN H^x _w—' o=4 < X' /° ⁰\ Λγ ysN AA ^ciyaa o=4 _cIX^ XT N jy H 187 188 189 F -J H n Γ A / \s=n hA ^av%4 o=4 1 ίΓ / ^{N H} N'P ( H \ Cl F __/ H --x ff Vn Γ \ n Γ NA / 'ySiN H^xn— ^ανΑ oX Hix o An 1 F -J H _____ N / A / Vi=N H>A θ’-χ,ΑχΑ 0=4 Ji 1 N n-h H ^=0 °7 190 191 192 F ΛνΟ y=N hN—¹ ^ayXA o=4. I X? A'Al ₀—C 7 H ,Ά F H ,___ Γχ-Α Γ > N Γ / H\—J ^C!X^rA 0=4 y qA N-h 4An / H \ F -/ H ---_x iTA Γ 7 n' i A I °ά4 °a A? /

472

2018200219 25 Mar 2019

193 194 195 F ___/ H χ fT Xy—N / \ N / / νγζ ή F .__J. H W n' / X—-x k^n / X ^C!x^vf \> lX/ °=< ^KN H J} °^nh XisN Η N—' YYv <_n^-n 196 197 198 F H [Γ N Γ \--- v^n / X ^C’yWC ^0S^n-h H F / ^H if Vs—N N Γ \—-x V^=N Γ ι ^clYVus ^_NJ-N °=^_νΉ H IT V-x N / V—X y^N Γ \ ^C,V^Y-4 B 17 ^O;V. VW 7^° Η χ 199 200 201 F !T W n' / \—χ \-=^N / \ H Tv °=sZ. X. xiU./ 7^0 H S. F —-A ^H v w ν' Γ X—-χ X=SN ! \ ΐ 1 z °^sX ^H X F rC-N /v <r VJ a V Yn ^h° /Y) ^<n^^Nh W 202 203 204 Αλο X=iN HX-J ^C,’x^x^s-n OsX. ]| W N-H ^<N H S \ F A<O \==N Cl J ς F H _-x W- N Γ \ N Γ \^k / ysN h\_j ^Ο==^ν-η o \

473

2018200219 25 Mar 2019

474

2018200219 25 Mar 2019

5Π —( H _ v K/i CO H F Λλχν·· ⁰ wA ° ί 23 ^hAh· H 220 221 “222 _z<sJ 0 (i x3 'ViF'-’N H A-<bq^j3 i ,T ) ^N M f 1 «ALjq^O o ( E? 223 224 2^5 al h ΟΟ Hj \ A AJ fT> H F A Η x ^<K H of Ξ26 227 228 ¢4 f J H -r—. fVv °O F ό^-Ο ' ιί^Γν °^x H

475

2018200219 25 Mar 2019

476

2018200219 25 Mar 2019

241 242 243 Λου i iPyA ^ΰίν\ H J ν ί if S/Sl G JJ —/ H Ji V^N XUiX LJv J J TM' μ ^XX C/χΏ CO ° 7 H 244 245 246 H __ a/ ⁰ in Ή F (Γχ5 H A Ji , . ο ί ΤΓΛ 247 248 2+9 F m H •&\o [OrS °^f^yⁱ M F •d-xo Cd X 2£ΰ 251 252 r—X ^H ’V'xQ Co °5 1 F ___/ H / Λ \iSN FlSp Co °tr 0 F ΛΑϊΟ-Λ XX—f ** (X?

477

2018200219 25 Mar 2019

253 254 255 F i 'X+ F όΛϊζχιι,^ ο ί Σ + Cx 25fi 257 F κΆ ^Η /Ν Ο\γ) I JZ? ⁿn F ό<-Ό ¢0 Ώ F &\Q Οί ί 258 260 261 F VszH Co ^9fi$^ C /7 H N-Jf H x JV'x / > ViW CO 3o —2 ^H jj xy-\ Γ N N. J χι-’Ά. / X^w W r H 262 263 264 F _J N —-n. iZV\^riZ^ Vⁿ Co ⁰ u F 0¾ ° © F (CXy ⁶ J^,’^H Xj^-n^z 7 H

478

2018200219 25 Mar 2019

265 266 I 267 n Γ X-.-A / Cq F H IC 7 \ k / 7 CO ° ^h H H ___ y'-O lOn> ^ΰ^$* “ 0 268 2&g 270 F QAsC^ cvy ^q H F /V^NCx> Cd> ° <n^n_h F ycH '^X-N ιΠο ° Si^N H 271 272 273 7 H r-x Α^Μ '/rO Ort & N^l OAsQ F w v ex? ^{n N}h 274 27& 276 F A H ,'-χ hrV^’Jlf 7 \5^1 H ίΐΊΑ ° C_hA-_n ^H H r-Λ J* ry» ht> m « H F * r-X tfvAjVi

479

480

2018200219 25 Mar 2019

289 290 291 ,__/ H x ) ΥΎΛ f _j! m »r γ^-**v-/ / =Ac A 7 oi’Cz vf 292 293 294 QA ^aXX? 5’ y—ZjJ* r^X yA H n-2 ^Gl J-%^ J Λ -=£ ΥΪ? ? ^N H A rA H A^vT) ^c w °i ^H jA) 295 296 297 F —A H AV\A? ''y=PN AjJ “ή F A. ^M □ Γν’Μ vA A ^N H F A j ° QA c· / ί/ γχ> I ^H 29« 299 d06 F •AC YtS ^v\ Α*ι^-Ν| Ί1 _H Aw “Ar hc w A ” Η O F A j o _b<v*m / ^r--\ a / / 7 ΊΓΪ5

481

2018200219 25 Mar 2019

482

483

2018200219 25 Mar 2019

484

2018200219 25 Mar 2019

485

2018200219 25 Mar 2019

486

2018200219 25 Mar 2019

487

2018200219 25 Mar 2019

488

2018200219 25 Mar 2019

[FOLLOWED BY PAGE 490]

489

2018200219 25 Mar 2019

490

2018200219 25 Mar 2019

4-45 446 447 pt Ή T TTy hi F _ayr^vv 05 ⁰ ' 44B 449 450 dto, ‘V H AMj ci _j v\ w H ifVA J} ys 1* Cl / }r^ TfzO ^d H

F

491

2018200219 25 Mar 2019

492

2018200219 25 Mar 2019

493

2018200219 25 Mar 2019

494

2018200219 25 Mar 2019

4M 494 495 JJ/A XV' ήυ-Ν 0 f £1.^/ __ f^CZw ιζΎ^ >A <_N O ¥13 ^{H n} _h 496 497 49B f ^H F H fj CI V ,^HV 03 T F Ά °+ H 499 600 S6i F H •Y °x H ί /^N* ZV* «LA^ [ J*-H H Xi^H f / XX H see 503 504 f <A ^rt Τχχρί¹ F -J¹ HI __ _ΝΧγ^Ν·^Π \sSH G* ^rt Ώ3 Xvji-^N H ^H? \ rf 03 H

495

2018200219 25 Mar 2019

496

2018200219 25 Mar 2019

497

2018200219 25 Mar 2019

498

555 557 573 ip ^h ^{N K} cKq 7-^N Hp Υτλ H K'O H F r-ί t¹ XX? flJN H F —A H rVv ^N ' /λ ^c w P ^H i 0 H

499

2018200219 25 Mar 2019

500

2018200219 25 Mar 2019

501

2018200219 25 Mar 2019

502

2018200219 25 Mar 2019

503

2018200219 25 Mar 2019

504

2018200219 25 Mar 2019

505

711 712 713 0 ιΉ dr^^OH0 H JL z __Z H «A 11 ''N N /ΓΤχ-νΙΓ V* oh ^H V T) Tn ^N H F __/ H rVv Αζ F H YNy-N H ’όΓ 715 716 720 V HN. ci Y ΊΠ0> > ^H|V-X <51 ιθ-γ^ y_N ' Tx5 H JFVJtH ,, 0 .j+m, M-Y 722 731 —H fMOl o?S H H _NfV\y XcT Y H H 733 740 %O Γη f hA^// Vj? Yz5 F H Γν\^Ηtof Y' H Λ H M

506

2018200219 25 Mar 2019

-------------7B1-------------- Αν—Z> /K H H H 0 Γ7 h §/V G Η_χ /? a F Tn ^{n N}h 7έι H 0 L hVp η_λ_/ 9 Ή a f Yr? H 787 /Vo f \ ci 7 x 1 --------7®-------- /4-y. Or Q w H ^hJJ< * X^O < H H \ Jf ΓΌ ^F*^Z ( 7 ΧΧ> «= XX? ^w“* H IL .sJL·/ o=A. 7M F 798 r-4 j // y-χ h \s=n 7\ έΐό HuG w ^vo ^cLxx_A \__' [| ^'x-N - x? o Ct KD * fl 821 G .1* _u r⁵ / Vlo^H 822 <-—4 ^μ rVML· V* / H a P έίΑ YXS \On H ΥΎ5 H XX? H

507

2018200219 25 Mar 2019 w

508

2018200219 25 Mar 2019

J ^H A° ^N _rN vx> ^N H 948 J Η P n j z^nh ysN / /%/ CK/--V.A KO N N 949 _F OOa^H N >-NH >=N ΎΎ5 ^N H 950 0 / ρΆ rArNH >=N ci-s^s^A XjO ^N H 951

509

2 H F F f N Xx. H -N, A IT N. A H Vk P iT N. H -rt χ -N -N Γ Yxz^NH =N Clx CA Clx / - Il Ϊ CH 3 Il i ch₃ rxs CH_a ⁿ' E 959 ⁿ a 960 961

[FOLLOWED BY PAGE 511]

510

2018200219 25 Mar 2019

511

2018200219 25 Mar 2019

512

2018200219 25 Mar 2019

513

2018200219 25 Mar 2019

514

2018200219 25 Mar 2019

515

2018200219 25 Mar 2019

516

2018200219 25 Mar 2019

517

2018200219 25 Mar 2019

518

2018200219 25 Mar 2019

1324 1325 1326 XfiSN Cl λ J To LA/ Η OAn Cl / H X< 1327 1328 1329 F Or UQ H __( H ΓΜν / > N f f ^Cl /X —1 03 H 1330 1331 1332 dXQ. ¢1 J Τ Ί7 H or ¥jo ^N H όο Cl J \O ll Ίζ O 133J 1334 1335 Ο H z--X H \sw HX-»^ _μΝ_κ Λ J XX? ^w _H Cl Ο ^μ a / \__/ lX> nr ii Oy

519

2018200219 25 Mar 2019

520

2018200219 25 Mar 2019

1343 1340 1350 Η ΓγΑ Π J ^H w H •Q-MO« iOz F 0ΑΚλ Crj ^N7< 1351 1352 1353 H -_-v y ''•• M \,C^N H __J H ,___ (Πθ ^f' H Η if ΤΑ.-/ ) XssK h\—⁷ 7 H Co _H 1354 1355 1356 F &Φ y^· o __ J H QQ H F 0A|O \=SH H ^xhK / ^H Jj A<iO Cl / Yt3 1357 1358 1359 F _/ H /yAj d+ci H F __( fi jF yAi* X—;n Γχ„_η d J \__I Υχ>

521

2018200219 25 Mar 2019

522

2018200219 25 Mar 2019

1574 Cl \ / ττλ F O.H _wrUA ci J \ J m ν·η rU- ysn h/ \_Hci —. J »·* Ά ψ_ y ΊΠΓ5 1375 1376 1W __1 μ a a J \^J w> h ^hn_/a nj™ «Λ» JL F C w γ—^Hd Γ Yx5 1378 1379 1380 yO* .P¹ F ^H y / Q Cl / XX? H Cl Γ 1Q3 H vt JkT A J lAf H IT H || 1381 1382 1383 X-/~ if'VA /h ^N H __/ H .fV-'lH vxtLcgN Cl Γ \^J Tjl>* ^<N H

523

2018200219 25 Mar 2019

1337

[FOLLOWED BY PAGE 525]

524

2018200219 25 Mar 2019

uoo p-o a —. ^H YXS H 1401 a -- / Tn H H ___- fV'l / VH yw N—^f Cl -- J XXn H 1403 __1 H __ jfV-N /~A \s=m Cl a J ^H Ίι Ί\\ 1404 0A-O, ^'jA' 1405 F A ^N_uίί/Γ Ν-χΝ H H 1 f H 1406 A-c olAT A· IX? 1407 ^H OyA-x ci /X -J V—N Tl5 ^h 1408 1 H TtV AjssN ΓΝν-η a J v_,J i4uy F -A p tTVy-v ^ciY\a F —H ,x \-sN J ci J 05 Χ_Μί>^~Η H dr>O a -- Γ Υχ$

525

1412 1413 1414 _2 ^h \sSiN ci J \^2 Cl Λ J 03 _2 ^H r—X # / p· Cl -A jT m H 141S 1416 14i? F H __ ci J h ___ N Γ X-A -N.H Cl· I 03 H Z H •Xr A X» 141 δ 14iS _a A m h d Γ Ττχ

or a pharmaceutically acceptable salt thereof.

70. A pharmaceutical composition, comprising an effective amount of a compound according to claim 69, or a pharmaceutically acceptable salt of the same, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
71. Use of any compound, or pharmaceutically acceptable salt thereof, according to claim 69 in the manufacture of medicament for reducing influenza viruses in a patient.
72. Use of any compound, or pharmaceutically acceptable salt thereof, according to claim 69 in the manufacture of medicament for treating influenza in a patient.

526

2018200219 25 Mar 2019
73. Use of any compound, or pharmaceutically acceptable salt thereof, according to claim 69 in the manufacture of medicament for inhibiting the replication of influenza viruses in a patient.